<SEC-DOCUMENT>0001213900-23-039902.txt : 20230515
<SEC-HEADER>0001213900-23-039902.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515170058
ACCESSION NUMBER:		0001213900-23-039902
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		23923954

	BUSINESS ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(646) 677-3870

	MAIL ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0323_actiniumphar.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 15 19:02:04 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:atnm="http://actiniumpharmaceuticals.com/20230331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric><b>&#160;&#160;&#160;&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the quarterly period ended <b><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">March 31, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric><b>&#160;&#160;&#160;&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from __________ to __________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber"><b>001-36374</b></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: hidden-fact-0">ACTINIUM
PHARMACEUTICALS, INC.</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>74-2963609</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<br/> Incorporation or Organization)</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/> Identification No.)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100 Park Ave., 23<sup>rd</sup> Floor</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New York, NY </b></span></p></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10017</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(646)</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">677-3870</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
Telephone Number, Including Area Code)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">275 Madison Avenue, 7<sup>th</sup>&#160;Fl</ix:nonNumeric>.<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">10016</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Address)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section&#160;12(b) of the Act:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol</b>&#160;</span></td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock, par value $0.001</b></span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATNM</b></span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NYSE</ix:nonNumeric> American</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#160;No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). &#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#160;No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric>&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards, provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744;&#160;Yes <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric>&#160;No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate the number of shares
outstanding of each of the issuer&#8217;s classes of common stock, as of May 15, 2023: <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">26,409,826</ix:nonFraction></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top; width: 81%"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II &#8211; OTHER INFORMATION</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">71</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior Securities</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">71</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">71</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: top"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">71</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">72</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I - FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. &#160;FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (which include
only normal recurring adjustments) necessary to present fairly the financial position at March 31, 2023 and December 31, 2022, and the
results of operations and cash flows for the three months ended March 31, 2023 and 2022, respectively, have been made. Certain information
and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction
with the financial statements and notes thereto included in the Company&#8217;s audited financial statements for the year ended December
31, 2022 in the Company&#8217;s Annual Report on Form 10-K. The results of operations for the three months ended March 31, 2023 are not
necessarily indicative of the operating results for the full year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">94,522</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">108,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">3,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">98,546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">110,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment, net of accumulated depreciation of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">536</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">487</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">604</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Restricted cash &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">2,544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">2,341</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Finance leases right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">102,026</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">114,192</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: center; text-indent: -9pt; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">7,358</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">10,130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating leases current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">494</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Finance leases current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">7,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">10,628</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">&#160;&#160;&#160;&#160;Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;&#160;&#160;&#160;Long-term operating lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="atnm:LongtermOperatingLeaseObligationsNoncurrent" scale="3" unitRef="usd">1,954</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="atnm:LongtermOperatingLeaseObligationsNoncurrent" scale="3" unitRef="usd">2,083</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">44,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">47,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">25,729,370</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">25,674,823</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">356,984</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">355,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">299,802</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">288,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">57,208</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">66,481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">102,026</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">114,192</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Three Months&#160;Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">940</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">940</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">7,849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">4,369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">1,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">11,584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">6,104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">11,584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">5,164</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income - net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">547</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">547</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">11,037</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,129</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9">Net loss per share of common stock&#160;&#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.23</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11">Weighted average shares of common stock outstanding&#160;&#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">25,696,623</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">22,143,974</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2023 to March
31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 50%; font-weight: bold">Balance, January 1, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">25,674,823</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">355,220</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">288,765</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">66,481</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">993</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">993</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">54,414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">11,037</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">11,037</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance, March 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">25,729,370</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">356,984</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">299,802</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">57,208</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2022 to March
31, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-weight: bold">Balance, January 1, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">329,271</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">255,748</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">73,545</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance, March 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">329,692</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">260,877</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">68,837</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
the<br/>
Three Months Ended<br/>
March 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash Flows Used In Operating Activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">11,037</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,129</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">993</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Depreciation &amp; amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd">182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd">137</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">1,989</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">114</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd">2,770</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd">275</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Other liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">731</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" sign="-" unitRef="usd">336</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" sign="-" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" sign="-" unitRef="usd">90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Used In Operating Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">15,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">5,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows Used In Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Used In Investing Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows Provided By / Used In Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Sales of shares of common stock, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:SalesOfSharesOfCommonStockNetOfCosts" scale="3" unitRef="usd">770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Proceeds from the exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Provided By / Used In Financing Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">770</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" sign="-" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net change in cash, cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">14,383</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">5,810</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">109,608</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">78,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at end of period</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">95,225</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">72,411</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Condensed Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:NatureOfBusinessPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b>
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with
cellular level precision to treat patients with high unmet medical needs.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2023 and December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd">94,522</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd">108,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssetsCurrent" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssetsCurrent" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="3" unitRef="usd">95,225</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="3" unitRef="usd">109,608</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases of corporate office
spaces.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>
</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_14" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_15" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_16" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_17" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:GrantRevenuePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_18" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="atnm_LicenseRevenueTextBlock-c0_cont_1" escape="true" name="atnm:LicenseRevenueTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_19" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="atnm_LicenseRevenueTextBlock-c0_cont_2" id="atnm_LicenseRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_20" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="atnm_LicenseRevenueTextBlock-c0_cont_3" id="atnm_LicenseRevenueTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_21" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation continuedAt="atnm_LicenseRevenueTextBlock-c0_cont_4" id="atnm_LicenseRevenueTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_22" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation id="atnm_LicenseRevenueTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_23" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_24" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_25" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
March 31, 2023 and 2022, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_26" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">3,324</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">1,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">1,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,052</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">5,092</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">3,385</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_27" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance</i>, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_28" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, FASB issued
ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers</i>,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, FASB issued ASU
2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock
Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#8217;s financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $<ix:nonFraction contextRef="c31" decimals="-6" format="ixt:num-dot-decimal" name="atnm:MilestonePayment" scale="6" unitRef="usd">1</ix:nonFraction> million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of <ix:nonFraction contextRef="c32" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNetAssetsPercentage" scale="-2" unitRef="pure">2</ix:nonFraction>% of net sales will be due to FHCRC.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_LeasesTextBlock-c0_cont_1" escape="true" name="atnm:LeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_2" id="atnm_LeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_3" id="atnm_LeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_4" id="atnm_LeasesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_5" id="atnm_LeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a
lease for corporate office space effective June 1, 2022. The lease has a term of <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseDescription">5 years 2 months</ix:nonNumeric>, with an expiration date on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1">July 30,
2027</ix:nonNumeric> and current annual rent of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="6" unitRef="usd">0.6</ix:nonFraction> million. The Company is also responsible for certain other costs, such as insurance, utilities and
maintenance. At March 31, 2023, for capitalization purposes under ASC842, the Company has this operating lease and a finance lease for
office equipment. During the three months ended March 31, 2023, the Company spent $<ix:nonFraction contextRef="c33" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LandImprovements" scale="6" unitRef="usd">0.3</ix:nonFraction> million in improvements at its corporate office
space, which has been included in the value of the operating right-to-use asset as of March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_6" id="atnm_LeasesTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_7" id="atnm_LeasesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">162</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">93</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_8" id="atnm_LeasesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_9" id="atnm_LeasesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Cash flow information:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">150</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">94</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_10" id="atnm_LeasesTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_11" id="atnm_LeasesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOrDescriptionOfWeightedAverageTerm"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.3</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">0.8</ix:nonNumeric> year</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_12" id="atnm_LeasesTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_13" id="atnm_LeasesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOfWeightedAverageDiscountRate"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">4.8</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">8</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_14" id="atnm_LeasesTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><ix:continuation id="atnm_LeasesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/>
Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/>
Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%">2023 (excluding three months ended March 31, 2023)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" unitRef="usd">456</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="3" unitRef="usd">618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="3" unitRef="usd">631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="3" unitRef="usd">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" scale="3" unitRef="usd">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">2,728</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="atnm:PaymentWithImputedInterestPremium" scale="3" sign="-" unitRef="usd">271</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="atnm:MaturitiesOfLeaseLiabilities" scale="3" unitRef="usd">2,457</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="atnm:MaturitiesOfLeaseLiabilities" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_OtherRevenueTextBlock-c0_cont_1" escape="true" name="atnm:OtherRevenueTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 &#8211; Other revenue </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="atnm_OtherRevenueTextBlock-c0_cont_2" id="atnm_OtherRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#8217;s ability to terminate
the module. The consideration is recognized as revenue over each module and revenue of $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RevenueRecognized" scale="6" unitRef="usd">0.8</ix:nonFraction> million was recognized during the three months
ended March 31, 2022. There was no other revenue recognized from a collaboration during the three months ended March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_OtherRevenueTextBlock-c0_cont_3" id="atnm_OtherRevenueTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had a grant
from a government-sponsored entity for research and development related activities that provides payments for reimbursed costs,
which included overhead and general and administrative costs, as well as an administrative fee. The Company recognized revenue from
grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and development
expense. Other revenue recognized from this grant for the three months ended March 31, 2022 was $<ix:nonFraction contextRef="c24" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="6" unitRef="usd">0.1</ix:nonFraction> million. There was no
corresponding revenue for the three months ended March 31,
2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="atnm_OtherRevenueTextBlock-c0_cont_4" id="atnm_OtherRevenueTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $<ix:nonFraction contextRef="c36" decimals="-6" format="ixt:num-dot-decimal" name="atnm:UpfrontPayment" scale="6" unitRef="usd">35</ix:nonFraction> million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="atnm_OtherRevenueTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#8217;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#8211; current liability at March
31, 2023 and December 31, 2022. Long-term license revenue deferred was $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="atnm:LongtermLicenseRevenueDeferred" scale="6" unitRef="usd"><ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="atnm:LongtermLicenseRevenueDeferred" scale="6" unitRef="usd">35.0</ix:nonFraction></ix:nonFraction> million at March 31, 2023 and December 31, 2022; this deferred
revenue will be recognized upon European Union regulatory approval of Iomab-B.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5  - Equity&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company
entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which
the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $<ix:nonFraction contextRef="c37" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd">200</ix:nonFraction> million of its common stock. Shares of
common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. On June 28, 2022,
the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales Agreement&#8221;)
with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley Securities&#8221;). The A&amp;R Sales Agreement modifies the original
Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three months ended
March 31, 2023, the Company sold <ix:nonFraction contextRef="c38" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares">0.1</ix:nonFraction> million shares of common stock, resulting in gross proceeds and net proceeds of $<ix:nonFraction contextRef="c38" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">0.8</ix:nonFraction> million. For
the three months ended March 31, 2022, there were no sales of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the three months ended March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; vertical-align: bottom">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares">3,396</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.85</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd">15,204</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: bottom">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" unitRef="shares">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: bottom">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="3" unitRef="shares">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" unitRef="shares">82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares">3,324</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.07</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">8.50</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd">11,114</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: bottom">Exercisable, March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares">975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">13.66</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted">7.21</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" unitRef="usd">2,304</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
March 31, 2023, the Company granted new employees options to purchase <ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="atnm:GrantOfStockOptionsToEmployees" scale="3" unitRef="shares">11</ix:nonFraction> thousand shares of common stock with an exercise price ranging
from <ix:nonNumeric contextRef="c39" name="atnm:DescriptionOfExercisePriceRange">$10.20 to $11.60</ix:nonNumeric> per share, a term of <ix:nonNumeric contextRef="c39" format="ixt-sec:duryear" name="atnm:StockOptionTerm">10</ix:nonNumeric> years, and a vesting period of <ix:nonNumeric contextRef="c39" format="ixt-sec:duryear" name="atnm:VestingPeriodOfStockOption">4</ix:nonNumeric> years.&#160;The options have an aggregated fair value of
$<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="atnm:AggregateFairValue" scale="3" unitRef="usd">82</ix:nonFraction> thousand that was calculated using the Black-Scholes option-pricing model. <ix:nonNumeric contextRef="c39" name="atnm:StockOptionDescription">Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 3.59% to 4.21% (2) expected life of 6 years, (3) expected volatility range from 81.3% to 81.4%,
and (4) zero expected dividends.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2023
was $<ix:nonFraction contextRef="c39" decimals="-5" format="ixt:num-dot-decimal" name="atnm:UnrecognizedCompensationExpense" scale="6" unitRef="usd">9.0</ix:nonFraction> million related to unvested options, which is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c39" format="ixt-sec:duryear" name="atnm:WeightedAverageTerm">3.1</ix:nonNumeric> years. During the three
months ended March 31, 2023 and 2022, the Company recorded compensation expense related to stock options of $<ix:nonFraction contextRef="c39" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToStockOptions" scale="6" unitRef="usd">0.8</ix:nonFraction> million and $<ix:nonFraction contextRef="c40" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToStockOptions" scale="6" unitRef="usd">0.4</ix:nonFraction> million,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit activity for the three months ended March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%; vertical-align: bottom">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="atnm:RSUsOutstandingBeginningBalance" scale="0" unitRef="shares">325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt; vertical-align: bottom">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; vertical-align: bottom">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="atnm:RSUsOutstandingEndingBalance" scale="0" unitRef="shares">325</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.96</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $<ix:nonFraction contextRef="c41" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedInvestmentsAtFairValue" scale="6" unitRef="usd">1.9</ix:nonFraction> million, was determined based on the stock
prices on the dates of the grants and is being recognized over <ix:nonNumeric contextRef="c42" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">three years</ix:nonNumeric>. The unrecognized compensation expense at December 31, 2022
of $<ix:nonFraction contextRef="c43" decimals="-5" format="ixt:num-dot-decimal" name="atnm:UnrecognizedCompensationExpense" scale="6" unitRef="usd">1.6</ix:nonFraction> million is expected to be expensed over <ix:nonNumeric contextRef="c43" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">2.4</ix:nonNumeric> years. During the three months ended March 31, 2023, the Company recorded compensation
expense related to RSUs of $<ix:nonFraction contextRef="c42" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" unitRef="usd">0.2</ix:nonFraction> million. There was no compensation expense related to RSUs for the three months ended March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the three months ended March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="3" unitRef="shares">1,443</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">16.58</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c45" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.33</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="3" unitRef="shares">1,443</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">16.58</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c45" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">1.08</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares">1,440</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">15.94</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c45" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.08</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6  - Subsequent Event</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since March 31, 2023, the
Company has sold <ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="atnm:SharesOfCommonStockValue" scale="6" unitRef="shares">0.6</ix:nonFraction> million shares of common stock under its A&amp;R Capital on Demand Sales Agreement, resulting in net proceeds of
$<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="atnm:NetProceeds" scale="6" unitRef="usd">5.6</ix:nonFraction> million.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. &#160;MANAGEMENT&#8217;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>FORWARD-LOOKING STATEMENT NOTICE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Form 10-Q contains certain
forward-looking statements. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may
be deemed to be forward-looking statements. &#160;Without limiting the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221; or comparable
terminology are intended to identify forward-looking statements. &#160;These statements by their nature involve substantial risks and
uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. &#160;These
factors include but are not limited to economic conditions generally and in the industries in which we may participate; competition within
our chosen industry, including competition from much larger competitors; technological advances and failure to successfully develop business
relationships.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium
Pharmaceuticals, Inc. (&#8220;Actinium&#8221;) is a biopharmaceutical company developing targeted radiotherapies to deliver
cancer-killing radiation with cellular level precision to treat patients with high unmet medical needs. Our vision is to build a
specialty, hospital focused, radiotherapeutics company that develops and markets medicines for relapsed or refractory cancer
patients who are treated primarily in large quaternary care hospitals and their catchment areas. We intend to leverage the clinical
data of our lead product candidates, Iomab-B and Actimab-A, to improve outcomes in patients with relapsed or refractory acute
myeloid leukemia (&#8220;r/r AML&#8221;) by launching two radiotherapy drugs over the next several years to address the significant
need for better outcomes from treatment with therapeutics or from undergoing a bone marrow transplant (&#8220;BMT&#8221;).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also intend to further
advance Iomab-B outside of acute myeloid leukemia (&#8220;AML&#8221;) based on promising data as a disease control and conditioning agent
for various other blood cancers. Based on early promising clinical trial results, we are also working on a lower dose, next generation
conditioning program, Iomab-ACT, for rapidly growing cell and gene therapies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Our Clinical Pipeline</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AML is an aggressive, heterogeneous
disease that is difficult-to-treat. Most AML patients develop relapsed or refractory disease within one year of being afflicted and have
an extremely poor prognosis and dismal survival. Currently, a BMT is the only curative regimen available for AML patients, however, access
is limited to AML patients who are fit enough to withstand the challenges associated with this treatment. The majority of AML patients
are considered not transplantable in routine clinical practice as they are not fit enough to withstand the rigors of the patient journey
which includes therapy to attain a remission, conditioning regimens to destroy diseased marrow, challenge of the transplant itself or
post-transplant complications.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Iomab-B and Actimab-A
product candidates potentially fill the major unmet medical needs in r/r AML in a complementary fashion as they are directed at different
parts of the patient journey. Iomab-B is being developed as a targeted bridging therapy candidate that we believe could provide both disease
control and conditioning in one agent. We believe results from a Phase 3 trial demonstrate the possibility for unprecedented access to
a BMT and improved survival in unfit patients who are currently not considered transplantable in routine clinical practice. We are developing
Actimab-A as a targeted therapy candidate for fit patients that has demonstrated an extension in survival in a proof-of-concept study
and is poised for advanced development in collaboration with the NCI, or National Cancer Institute. Together, we believe these two product
candidates could provide us the opportunity to transform the treatment of AML, especially in the relapsed and refractory segment which
represents over 50% of AML patients.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We announced in October 2022
that Iomab-B met the primary endpoint of durable Complete Remission (&#8220;dCR&#8221;) with a high degree of statistical significance
(p&lt;0.0001) in the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractor AML, or &#8220;SIERRA trial.&#8221; In February
2023, we announced full trial results, demonstrating unprecedented transplant access and improved outcomes in patients with relapsed/refractory
AML, with double 1-year and median overall survival (&#8220;OS&#8221;) compared to control arm patients. These data were presented at
the 2023 Tandem Meetings aka the Transplantation &amp; Cellular Therapy Meetings of the American Society for Transplantation and Cellular
Therapy (&#8220;ASTCT&#8221;) and the Center for International Blood &amp; Marrow Transplant Research (&#8220;CIBMTR&#8221;). We believe
these results from the SIERRA trial may provide the opportunity, if we are able to obtain FDA approval, to establish Iomab-B as a new
standard of care.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results from the SIERRA
trial were recently presented and discussed at major oncology medical and nursing congresses, which is helping to broaden the awareness
of Iomab-B among members of the relevant medical and scientific communities as we prepare for potential commercialization if we achieve
FDA approval. On April 27, 2023, the results from the SIERRA trial were also showcased at the European Society for Blood and Marrow Transplantation
(&#8220;EBMT&#8221;) 49<sup>th</sup> Annual Meeting, which is well-attended by the European transplant community. On April 28, 2023, we
announced that two posters that detailed clinical findings from the SIERRA trial sites were presented at the 48<sup>th</sup> Annual Oncology
Nursing Society (&#8220;ONS&#8221;) Congress. We believe that the scientific community present at such events took note of the successful
administration of Iomab-B infusions at various BMT centers, which was done without increasing radiation exposure risks to treating nursing
staff. On May 11, 2023, we announced that these results were also accepted for oral presentation at the European Hematology Association
(&#8220;EHA&#8221;) 2023 Hybrid Congress to be held in Frankfurt, Germany on June 8-11, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are working towards completing
and submitting our Biologics License Application (&#8220;BLA&#8221;) for Iomab-B to the U.S. Food and Drug Administration (&#8220;FDA&#8221;)
in the second half of 2023 and if approved, we intend to commercialize Iomab-B in the U.S.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are committed to bringing
Iomab-B to patients globally and are working with Immedica AB (&#8220;Immedica&#8221;), our European, Middle East and North Africa (&#8220;EUMENA&#8221;)
partner, for the subsequent marketing authorization application (&#8220;MAA&#8221;) of Iomab-B with the European Medicines Agency (&#8220;EMA&#8221;).
Europe represents a large commercial market opportunity with approximately twice as many transplants performed in Europe compared to the
U.S.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A is being developed
under what we believe to be the current industry-leading clinical-study program utilizing the potent alpha radiation emitting isotope
Actinium-225 (&#8220;Ac-225&#8221;) with clinical data in approximately 150 patients treated over 6 clinical trials. The potent linear
energy transfer emitted by Ac-225 has no known resistance mechanism. Actimab-A is being developed in combination with other regimens to
exploit mechanistic synergies and leverage the mutation-agnostic mechanism of action of Ac-225 with the objective of establishing it as
a backbone therapy in AML, an extremely heterogenous disease.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our Actimab-A +
CLAG-M therapeutic combination trial results in r/r AML provide validation of this approach, which such results were presented at the
American Society of Hematology (&#8220;ASH&#8221;) 2022 Annual Meeting &amp; Exposition in December 2022. Phase 1 results from the Actimab-A
+ CLAG-M combination trial showed high response rates and minimal residual disease (&#8220;MRD&#8221;) negativity, translating to a survival
benefit of 53% and 32% at one and two years in patients who are typically expected to live two to four months. At the same meeting, we
shared Phase 1 data showing that the combination of Actimab-A + venetoclax was well-tolerated with responses, including a Complete Remission
(&#8220;CR&#8221;) and a partial response in early dose escalation cohorts. We believe the promise of these results may pave the way for
the NCI Cooperative Research and Development Agreement (&#8220;CRADA&#8221;), announced on February 6, 2023, to develop Actimab-A for
the treatment of patients with AML and other hematologic malignancies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To explore the potential for
a broader development opportunity with our Actimab-A program, we are studying the potential use of Actimab-A in solid tumor indications
through our R&amp;D efforts. CD33-expressing myeloid derived suppressor cells (&#8220;MDSCs") are present within the tumor microenvironment
and exert immunosuppressive effects. On April 18, 2023, we presented preclinical data at the Association for Cancer Research (&#8220;AACR&#8221;)
Annual Meeting that depicted Actimab-A&#8217;s role in the tumor microenvironment to overcome immunosuppression driven by MDSCs. We believe
that our findings thus far show Actimab-A&#8217;s potential to selectively deplete MDSCs in lung and colorectal cancer. Actimab-A also
demonstrated superior depletion of human MDSCs compared to Mylotarg, a CD33-targeted antibody-drug conjugate (&#8220;ADC&#8221;) in colorectal
cancer (p&lt;0.01), highlighting the powerful cytotoxicity and potential therapeutic benefit of radiotherapy compared to naked antibodies
or ADCs. We believe that the data we have gathered to-date continues to support our objective to demonstrate the potential for Actimab-A
to be a backbone therapy to broadly improve antitumor activity of immunotherapies and other therapeutic modalities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our differentiated R&amp;D
efforts are further exemplified by our next-generation Iomab-ACT conditioning program for rapidly growing cell and gene therapies, as
well as our solid tumor and immunotherapy collaborations with Astellas Pharma Inc. (&#8220;Astellas&#8221;), AVEO Oncology/LG Chem (&#8220;LG
Chem&#8221;) and EpicentRx, Inc. (&#8220;EpicentRx&#8221;). We have several ongoing programs in solid tumors at the pre-clinical stage
with investigational new drug (&#8220;IND&#8221;) enabling studies underway.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our platform has been used
to develop a pipeline of novel radiotherapeutic assets to drive company growth. Preclinical pharmacology studies with our targeted radiotherapeutics
such as HER3-ARC, HER2-ARC or CD33-ARC have shown strong improvement in tumor growth inhibition in various preclinical tumor models as
single agents or in combination with immunotherapy such as magrolimab, an anti-CD47 monoclonal antibody. These results have prompted the
team to spearhead efforts in multiple solid tumor programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium&#8217;s lead solid
tumor program is a targeted radiotherapy against HER3, a pan-cancer target that is overexpressed in several solid tumor indications with
high unmet need. We have aligned our R&amp;D strategy of advancing solid tumors into the clinic with our Actimab-A program. We recently
presented pre-clinical data at the AACR 2023 Annual Meeting, highlighting this opportunity. We believe the results support further testing
to evaluate the anti-tumor effects of HER3-targeted radiotherapy. HER3 conjugated to either alpha-emitting Ac-225 or beta-emitting Lutetium-177
(&#8220;Lu-177&#8221;) displayed anticancer activity in ovarian and colorectal cancer preclinical models. The consistent overexpression
of HER3 in multiple solid tumor types, including ovarian, renal, prostate, urothelial, breast, and lung cancers suggests broad utility
of a HER3-targeted agent in a clinical setting, which we intend to explore further. In addition, our intellectual property (&#8220;IP&#8221;)
portfolio includes over 200 issued patents and pending patent applications worldwide</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are actively working on
launching an early access program (&#8220;EAP&#8221;) for Iomab-B and intend to file a BLA by year-end while preparing for a U.S. commercial
launch, if such BLA is approved by FDA, and working with our partner Immedica to support the Marketing Authorization Application (&#8220;MAA&#8221;)
and, if approved by EMA, commercialization in the EU. Late-stage Actimab-A development is expected to begin in the second half of 2023
under the NCI CRADA. With the approximately $94.5 million cash on hand as of March 31, 2023, we expect to fund operations through 2025
as we continue to drive ahead with realizing our five-year plan.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market opportunity for
Iomab-B and Actimab-A, as depicted in the diagram below, exists in AML and for cellular therapy conditioning in various blood cancers.
We believe that Iomab-B and Actimab-A can fill the major unmet medical needs in r/r AML in a complementary fashion as they are utilized
in different parts of the patient treatment journey. The incidence of AML is approximately 21,000 patients per year, with a prevalence
of approximately 70,000 in the U.S., (approximately 27,500 new patients per year in Europe) and the disease has an outsized economic impact
relative to its population size. Over 50% of patients diagnosed with AML will develop relapsed or refractory disease, with a median age
of 68 years at diagnosis. Despite 10 new approved therapies since 2017, no significant advancements have been made toward a cure and there
is an important unmet medical need for better therapeutics, which provide the opportunity for Actimab-A. Actimab-A is a targeted radiotherapy
for fit patients that has demonstrated an impressive improvement in survival in a proof-of-concept study and is poised for advanced development
in collaboration with the NCI. Using Actimab-A in combination with chemotherapy or a targeted therapy, we have the potential opportunity
to treat both newly diagnosed or r/r AML patients, with the potential addressable population comparable to the prevalence of patients
with AML.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Today, less than 20% of AML
patients are able to access a BMT, currently the only potentially curative option. These patients are usually younger, fit, and able to
withstand the challenges associated with this treatment, leaving the large majority of AML patients ineligible for transplant. This provides
an opportunity for Iomab-B, which has demonstrated the ability to enable unfit patients to benefit from a BMT. Thus Iomab-B can potentially
expand the market from the approximately 400 r/r AML patients who are transplanted currently to approximately 8,000 unfit patients that
could be eligible for transplant. Iomab-B has demonstrated the ability to improve BMT access with extended survival and potentially curative
outcomes in several other hematological diseases outside of AML. Several clinical trials in over 300 patients with myelodysplastic syndromes
(&#8220;MDS&#8221;), acute lymphocytic leukemia (&#8220;ALL&#8221;), Hodgkin&#8217;s lymphoma (&#8220;HL&#8221;), Non-Hodgkin lymphoma
(&#8220;NHL&#8221;) and multiple myeloma (&#8220;MM&#8221;) have demonstrated the same value proposition as in AML. This data provides
a potential opportunity to expand the market for Iomab-B beyond AML via label expansion. In the U.S., there are approximately 185,000
patients diagnosed annually with blood cancers (e.g., leukemia, lymphoma, and myeloma) that are treatable with BMT, of which, approximately
20,000 are transplanted, leaving greater than 165,000 patients who could potentially benefit from transplant. These patients do not receive
a BMT today primarily because they are unfit with active disease and are not considered eligible, as they cannot tolerate the rigors of
therapy required to induce a remission and the conditioning agents required to ablate the marrow prior to a BMT.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beyond BMT, the opportunity
exists for better conditioning in other areas of cellular therapy such as CAR-T as well as gene therapies. The pipeline of CAR-T and gene
therapies has rapidly expanded, with the addressable patient population expected to nearly double in the next one to five years and reach
approximately 93,000 patients in the U.S. by 2030 based on the current pipeline of cellular therapies. The CAR-T market size in terms
of dollars is estimated to grow at a CAGR of approximately 11% over the next 5 plus years. The addressable market for Iomab-ACT is in
line with the patient population for cellular therapy as all patients receive conditioning of some type prior to these treatments. We
will continue to develop Iomab-ACT, our lower dose, next generation conditioning program for rapidly growing cell and gene therapies based
on early promising results, ultimately with the value proposition of improving overall access and outcomes for patients who need cellular
or gene therapies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium&#8217;s strategy
is to build a fully integrated, specialty radiotherapeutics company focused on the top 100 cancer hospitals using the power of our platform
to deliver new treatment options for patient populations living with high unmet medical needs in hematology and oncology. We believe our
focus on relapsed and refractory disease in cancer indications with high unmet medical need, with limited or no competition, and where
the primary delivery of care occurs in large comprehensive cancer care centers, is the appropriate strategy for our company. The cell
killing power of linear energy transfer delivered via radiotherapeutics is unmatched by other technologies and we believe relapsed, refractory
disease is an area where radiotherapeutics can succeed over other approaches. However, radiotherapeutics must be delivered on a just-in-time
basis, and commercial and supply chain barriers are higher than with other types of medicines. The validity of our approach is demonstrated
by our product development strategy as well as the commercial and operating model that we are building for our lead product candidates,
Iomab-B and Actimab-A.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to transform the
treatment of AML with our Iomab-B and Actimab-A product candidates, each of which has demonstrated extension of survival in the most difficult-to-treat
patients who are typically expected to survive for two to four months. The r/r AML segment comprises over 50% of all AML patients. Actimab-A,
a therapeutic agent, and Iomab-B for induction and conditioning, can be used in a complementary fashion as depicted in the diagram below.
Based on solid clinical evidence with these product candidates, we intend to develop and commercialize these two radiotherapy drugs, starting
with Iomab-B in 2024 and Actimab-A in 2027, if approved, to improve survival in patients with r/r AML.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Iomab-B and Actimab-A have the potential
to significantly improve r/r AML outcomes in a complementary manner</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operating model required to achieve our vision
is attractive for several reasons, including the concentrated point of care; the top 50 transplant centers account for approximately 75%
of BMTs and the top 100 hospitals treat over 50 percent of r/r AML patients. Further, there is significant overlap in the healthcare providers
and ecosystem required to diagnose, treat and care for r/r AML patients within these hospitals, which will enable us to deploy a relatively
small commercial organization and operate a supply chain without the need for large investments. Our product pipeline is targeting a broader
opportunity in conditioning via label expansion of Iomab-B into BMT for other blood cancers and with Iomab-ACT, our next generation conditioning
program for rapidly growing cell and gene therapies. Further, our solid tumor programs are initially directed at relapsed or refractory
cancers, a stage of disease where treatment is again concentrated in large hospitals, which account for a significant portion of patients.
We believe our strategy will enable us to build a successful company with high operating efficiencies and is feasible to achieve without
requiring a commercial partner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our strategic priorities are to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Establish Iomab-B as the standard of care to improve BMT access and survival outcomes in r/r AML patients who are currently not considered transplantable in routine clinical practice: </i></b>We intend to file a BLA in the second half of 2023 based on the positive results from the Pivotal Phase 3 SIERRA trial and leverage our operating track record at key cancer centers to build an organization that can effectively commercialize Iomab-B. By virtue of the SIERRA trial, we have established operations at 24 leading BMT centers that represent about 30% of transplant volume in the U.S. and have strong working partnership with Key Opinion Leaders and their teams. The SIERRA results demonstrating unprecedented access to BMT and outcomes along with our commitment to operational excellence provides a strong foundation for our commercial team in the U.S. We will also work with our partner Immedica to file the MAA for the EU and support Iomab-B&#8217;s potential approval and launch with our expertise, as well as supply drug product for commercialization.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance Actimab-A in combinations as a backbone therapy for r/r AML:</i></b> We intend to progress late-stage development of Actimab-A to leverage its mutation-agnostic mechanism of action and exploit synergies in combination with other treatments to develop it as an AML backbone therapy. This approach is validated by proof-of-concept data from our Actimab-A + CLAG-M combination trial in r/r AML, which included 57% of patients who had failed venetoclax and are expected to live two to four months on average. The results demonstrated high response rates overall and in these venetoclax failed patients&#8217; median OS was 59% at one year and thirty-two percent at two years. Our collaboration with the NCI under the CRADA could provide broad support for late-stage development of Actimab-A + CLAG-M and also other clinical trials to broaden use of Actimab-A. Actimab-A, if approved, would enable us to launch a second product that is complementary to Iomab-B and fulfill our ambition of transforming the treatment outcomes of r/r AML and expand our commercial footprint into the remaining top 100 cancer care centers outside of the leading BMT hospitals.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expand the Iomab-B label and revenue stream via life cycle management:</i></b> We intend to leverage data from several clinical trials that demonstrate the ability of Iomab-B to improve BMT access and outcomes in five additional hematologic indications. These data in MDS, ALL, HL, NHL and MM provide the foundation to expand the label for Iomab-B and increase its market potential. In AML, we would seek label expansion into haploidentical transplants, earlier lines of treatment and younger patients below the age of 55, the cutoff in the SIERRA trial. As much as possible, we would seek to use investigator sponsored trials as the primary strategy for label expansion in order to maximize capital utilization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Further expand our conditioning franchise by developing Iomab-ACT for cell and gene therapies:</i></b> We plan to develop Iomab-ACT to be used for either lymphodepletion or reduced intensity conditioning prior to CAR-T and gene therapies. Similar to BMT, access and outcomes of patients who might benefit from these therapies is limited by sub-optimal chemotherapy-based conditioning agents. The number of patients potentially eligible for Iomab-ACT is growing with increased availability of commercial cell and gene therapy products, as well as the expanding number of indications. We are studying Iomab-ACT in conditioning prior to CAR-T cellular therapy via a National Institutes of Health (&#8220;NIH&#8221;) funded clinical trial with Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;). We expect to present proof-of-concept data from this study in the second half of 2023 and announce further development of this program in the CAR-T space.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leverage our R&amp;D capabilities and technological prowess to advance our solid tumor programs and partnerships: </i></b>We intend to continue to direct our R&amp;D effort to advance our solid tumor programs into the clinic and support life cycle management for Iomab-B and Actimab-A. Our solid tumor programs and technological capabilities are validated by our partnerships with Astellas, LG Chem, and EpicentRx, which are focused on solid tumors and immunotherapies. Our R&amp;D capability is demonstrated by our patent portfolio with over 200 issued and pending patent applications worldwide which include protection for Iomab-B into 2037. Our IP portfolio also includes several patent families to manufacture Ac-225 in a cyclotron and includes valuable know-how.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In keeping with our strategic vision over the
next five years, we plan to first focus on ensuring an Iomab-B approval and successful launch into core BMT centers to support commercial
success. We intend to expand the Iomab-B label and revenue stream while progressing the development of Actimab-A by leveraging the NCI
CRADA. We will progress the development of Iomab-ACT to proof-of-concept and explore potential partnerships as a means to achieve commercialization.
Our solid tumor programs will progress toward the clinic as we continue to build out our commercial footprint into the top 100 hospitals
leaving us positioned to develop them in line with our vision. With commercial dynamics aligning favorably for a successful Iomab-B launch
and with late-stage development of Actimab-A in collaboration with the NCI, we plan to deliver on our mission to transform the treatment
of AML and patient outcomes, and create a highly differentiated, specialty radiotherapeutics company focused on the top 100 large hospitals.</span></td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Product Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have strategically focused our development
efforts in areas where there is a significant unmet medical need. We are developing a portfolio of novel radiotherapeutics that has the
potential to positively impact the outcomes of people living with hard-to-treat diseases such as r/r AML via both a therapeutic and induction/conditioning
agent. Outside of AML, our pipeline development offers the opportunity to enhance the value proposition of cell and gene therapies with
our targeted conditioning programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">AML Focused Programs &#8211; Iomab-B
and Actimab-A</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Iomab-B and Actimab-A product candidates are
focused on addressing the major unmet medical needs in r/r AML in a complementary manner and are directed at different parts of the patient
journey.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-B &#8211; Targeted Radiotherapeutic
for Induction and Conditioning. A potential new standard of care enabling a curative BMT in currently non-transplantable r/r AML patients
with poor survival prognosis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Opportunity to Change the Current Paradigm
for Accessing a BMT and Improving Outcomes </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current approach in preparing patients for
a BMT is to first induce a remission with therapeutic agents to reduce the disease burden and then suppress or destroy the patient&#8217;s
immune system, including the diseased bone marrow, with conditioning regimens prior to transplanting the healthy donor hematopoietic stem
cells, which are expected to restore normal bone marrow function following engraftment. As this approach requires patients to withstand
multiple challenges from non-targeted therapies, which include chemotherapy agents and/or total body irradiation that are highly toxic,
BMT is typically limited to FIT patients. Iomab-B is a targeted therapy that provides both disease control and conditioning in one agent
and is well-tolerated even by UNFIT patients who typically are not transplanted in routine practice today. The SIERRA trial was designed
to demonstrate that UNFIT patients with active disease could be administered Iomab-B and proceed directly to a BMT without the need for
inducing a remission and that this approach could result in improved survival and curative outcomes. As seen by the positive results of
the SIERRA trial detailed below, Iomab-B represents an exciting new paradigm in the management of AML patients and establishes a potential
new standard of care especially for UNFIT patients in the relapsed or refractory setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A similar approach has also been tried in the
Phase 3 ASAP trial but with FIT patients. However, to avoid confusion between the potential of the approaches used in the ASAP and SIERRA
trials, important distinctions between these trials are depicted in the graphic below. The ASAP trial sought to demonstrate non-inferiority
between two non-novel approaches and found that outcomes similar to those of current practice could be achieved without first getting
a patient into remission before taking them to BMT by giving them sequential conditioning or treating them twice with non-targeted chemotherapy
agents that are typically used in this setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ASAP approach is limited to only FIT patients
as the UNFIT patients treated in SIERRA could not tolerate ASAP&#8217;s highly toxic sequential conditioning approach. Sequential conditioning
is not novel as a similar trial to ASAP was conducted by the UK National Cancer Research Institute in 2019, which did not show any benefit
from this approach in high-risk AML and MDS patients (Craddock et al. Augmented Reduced Intensity Regimen Does Not Improve Postallogeneic
Transplant Outcomes in Acute Myeloid Leukemia. J Clin Oncol. 2021). &#160;The SIERRA trial results therefore can change the paradigm in
transplant because non-transplantable patients in routine clinical practice can benefit from a transplant with Iomab-B and have superior
outcomes. While both approaches in these trials support increased access to BMT, only Iomab-B is applicable to the unfit patients who
comprise approximately 80%of r/r AML patients and can potentially expand the market for transplant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Schetelig et al. Results from the Randomized
Phase III ASAP Trial. ASH 2022</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Pivotal Phase 3 SIERRA Trial for Iomab-B (<sup>131</sup>Iodine-apamistamab)
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SIERRA trial was designed to demonstrate the
ability of Iomab-B to overcome challenges related to patient access to curative BMT. Unfortunately, approximately 30% of patients with
AML have primary refractory disease while 50% relapse quickly after achieving initial remission. Getting these patients with primary r/r
AML into remission is very challenging due to characteristics such as age, comorbidities, and disease features such as high-risk mutations
that contribute to lack of response to salvage therapies and limit treatment options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patients must be able to overcome several challenges
related to curative BMT. The first access challenge is that the patient needs to be in complete remission prior to BMT. The current clinical
practice is not to transplant patients with active AML as outcomes are poor due to high relapse rates. The National Comprehensive Cancer
Network (&#8220;NCCN&#8221;) guidelines also recommend treatment to achieve remission prior to transplant in patients with relapsed AML.
The second challenge to access is tolerance to current conditioning regimens. For older patients, myeloablative regimens are not an option
due to intense toxicity and mortality. The third challenge is the ability to achieve post-BMT remission and successful engraftment. Inadequate
conditioning can lead to graft failure, which is associated with very high mortality. Patients who fail to achieve a CR post-transplant
have extremely poor outcomes and a survival of a few weeks. The fourth challenge relates to BMT tolerability and post-BMT complications.
The conditioning and immunosuppressive regimens given to these patients put them at high risk for infectious complications and toxicity.
In the SIERRA trial, Iomab-B addresses all four of these challenges. Access to BMT is improved as CR is not needed pre-BMT given effective
disease control and targeted myeloablation. With better post-BMT engraftment, CR and lower complications, the SIERRA trial also addressed
the challenges related to improved outcomes through Iomab-B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SIERRA results, presented in the late-breaker
session at the 2023 Tandem Meetings: Transplantation &amp; Cellular Therapy Meetings of the ASTCT and the CIBMTR, support Iomab-B&#8217;s
value proposition of enabling both improved access and outcomes of a BMT, thereby providing a significant curative option for r/r patients,
a segment that represents approximately 50% of all AML patients and the majority not transplanted today. The design of the SIERRA trial
is provided in the figure below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>SIERRA: A Novel, Pivotal Phase 3 Study of
Iomab-B in r/r AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><img alt="" src="img_006.jpg"/></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pivotal Phase 3 SIERRA trial is a 153-patient,
randomized, multi-center, controlled trial of Iomab-B in patients aged 55 and above with active r/r AML, who were heavily pre-treated
and had high-risk characteristics. Patients enrolled had blast counts of 5% or greater in the marrow or circulating blasts suggestive
of active AML. In this study, Iomab-B was compared to the control arm that allowed physician&#8217;s choice of over 20 available agents,
including chemotherapies and/or targeted therapies such as venetoclax (BCL-2 inhibitor), FLT3 inhibitors, IDH inhibitors and Mylotarg,
reflecting current best treatment practices attempting to get patients to CR. The control arm included recently approved AML therapies
that were added to the SIERRA protocol as they became available. The crossover arm was designed in SIERRA for an equipoise that offered
Iomab-B to patients failing to achieve a CR on the control arm with an intent to rescue them by taking them to transplant. Of note, SIERRA
had highly restrictive optionality for post-transplant maintenance. Patients with active, r/r AML are not considered eligible for BMT
with current approaches and the SIERRA trial was the only randomized Phase 3 trial to offer BMT as a treatment option for this patient
population. These patients would not be offered BMT in standard practice and therefore have dismal survival outcomes of two to three months.
The primary endpoint of the SIERRA trial was dCR of 180 days and the secondary endpoints are OS and Event-Free Survival (&#8220;EFS&#8221;).
The comparison of OS in subjects randomized to the control arm who crossed over to receive Iomab-B versus all others in the control group
was an exploratory efficacy endpoint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As seen in the graphic below,
the primary endpoint of 6-month dCR was met with a high degree of statistical significance (p&lt;0.0001). 75% of patients (44/59) receiving
Iomab-B achieved an initial remission 30 days after their BMT compared to 6.3% of patients (4/64) in the control arm. 22% of the patients
receiving Iomab-B maintained dCR lasting 180 days or more despite limited optionality for post-transplant maintenance, while none of the
patients on the control arm achieved dCR. The current standard practice is to administer post-transplant maintenance therapy to reduce
chances of relapse. The results presented below are on a per protocol basis, which means that only data that was in strict adherence to
the protocol without any deviations was considered for the analysis. It is important to note that the p-value of the primary endpoint
in the Intent-to-Treat (&#8220;ITT&#8221;) analysis was &lt;0.0001, the same as the per protocol analysis.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>SIERRA Results: Iomab-B Meets Primary Endpoint
with High Significance (p&lt;0.0001)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As demonstrated in the OS graph below, patients
who achieved 6-month dCR had 92.3% 1-year survival and 59.9% 2-year survival. Median OS had not been reached in these patients. It is
worth noting that two years in CR is a significant milestone in this patient population, highly indicative of long-term survival and a
possible curative outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Overall Survival for Patients who Achieved
6-month dCR with Iomab-B</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OS was one of the secondary
endpoints of the study. The Kaplan-Meier plot in the inset of the graph below shows ITT OS results between the Iomab-B arm and the control
arm. Due to the crossover design, ITT analysis of OS was confounded by the early crossover of patients (within 28 days) from the control
arm to the Iomab-B arm (57.1%). The effective rescue of these crossover patients by Iomab-B led to an outsized contribution of the Iomab-B
effect on control arm patients. As a result, median OS in the Iomab-B arm was similar to that in the control arm and this secondary endpoint
was not met in the ITT analysis.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to isolate the true impact of Iomab-B
on OS, one of the exploratory efficacy endpoints was the comparison of OS in subjects randomized to the control arm who crossed over to
receive Iomab-B versus all others in the control arm, as well as the control arm patients who did not crossover versus the Iomab-B arm.
The Kaplan-Meier plot of OS in the graphic below shows that this exploratory analysis demonstrated the clear benefit of Iomab-B over the
control arm. The median OS for the Iomab-B group was 6.4 months which was double the 3.2 months for the non-crossover patients in the
control arm. Patients who crossed over from the control arm to receive Iomab-B had a median OS of 7.1 months demonstrating further the
ability of Iomab-B to treat patients who are non-treatable by conventional means.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A similar pattern favoring the Iomab-B group was
seen across the pre-defined subgroups, where 1-year OS for Iomab-B was 26.1% compared with 13.1% for the non-crossover control arm. The
1-year OS for patients in the crossover arm was 35.8%. This clearly demonstrates the OS benefit of Iomab-B over the control arm and two
to three-fold improvement in survival outcomes possible with its use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Kaplan-Meier Plot of Overall Survival &#8210;
Iomab-B, Crossover, and Non-Crossover Control Arm </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_009.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-B produced a significant and clinically
meaningful improvement in the secondary endpoint of EFS, with a 78% reduction in the probability of an event (Hazard Ratio=0.22, p&lt;0.0001
for both per protocol and ITT basis). EFS at 180 days for the Iomab-B arm was 28% compared to 0.2% for the control arm. In the SIERRA
trial, an event is defined as one of the following: a patient not achieving CR/CRp or crossing over, patient not receiving BMT, a patient
relapsing or death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the figure below comparing EFS with Iomab-B
versus the control arm, the initial vertical drop in the curve in the Iomab-B arm represents those patients who did not achieve a remission
after Iomab-B or those who did not proceed to transplant, while the initial vertical drop in the curve in the control arm mainly represents
patients who did not achieve a remission with salvage therapy and either crossed over to Iomab-B or went onto best supportive care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Event-Free Survival with Iomab-B Versus Control
Arm</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_010.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below shows relevant adverse events
in transplanted Iomab-B patients. In these patients, incidence of sepsis was four times lower in the Iomab-B arm than the control arm
(6.1% vs. 28.6%). In addition, rates of other treatment related adverse events were lower in favor of Iomab-B, including febrile neutropenia
(43.9% vs. 50.0%), mucositis (15.2% vs. 21.4%) and acute graft versus host disease (&#8220;GVHD&#8221;) (26.1% vs. 35.7%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Grade &#8805;3 Treatment-Emergent Adverse Events
in Transplanted Patients Through Day 100 Post-HCT</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_011.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With current treatment practice, patients who
have r/r AML with active disease, utilizing current conditioning agents have poor outcomes and very low survival rates. Using an Iomab-B
led regimen, an unprecedented number of patients were able to access transplant and were able to do so with active disease, eliminating
need for achieving a CR in order to transplant the patient. Thus, patients are also able to access BMT faster with Iomab-B, in less than
half the time compared to conventional care. Iomab-B represents an exciting new paradigm with the potential to establish a new standard
of care in r/r AML setting, making it possible for most patients to get to a successful transplant with Iomab-B with a portion of these
patients having a long-term survival benefit. As shown below, with an Iomab-B led regimen, the majority of patients who are non-transplantable
in routine clinical practice can be successfully transplanted, administering myeloablative radiation with reduced intensity conditioning
tolerability to ultimately achieve transformative survival outcome, changing the treatment paradigm for r/r AML patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Iomab-B &#8211; New Paradigm to Upend BMT
Access and Improve r/r AML Outcomes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_012.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Future Development and Life Cycle Management
for Iomab-B</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The results of the Pivotal Phase 3 SIERRA trial
validate the value proposition of Iomab-B, and we believe it could establish unprecedented access to transplant (currently the only curative
option) with better safety and tolerability and improved outcomes, all of which could potentially make Iomab-B the new standard of care
for patients with r/r AML. We are actively working to launch an EAP and successfully file a BLA in the second half of 2023, and if approved,
we anticipate the commercial launch for Iomab-B in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We intend to commercialize Iomab-B in the U.S.
The commercial opportunity is supported by favorable dynamics, summarized by the &#8220;Three Ps and Two Cs&#8221;:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patients</i>: With its promising profile, Iomab-B provides the opportunity for unprecedented BMT access and better outcomes for patients, with favorable safety and tolerability</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Physicians</i>: Our goal is to help physicians make BMT an option for a vast majority of r/r AML patients who currently are unable to access transplant without disruption to current practice. Patients are able to return to their referring physicians for post-BMT follow-up, long-term care</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Payers</i>: Iomab-B potentially unlocks value through getting patients safely to effective, potentially curative transplants, with improved outcomes and a manageable safety and tolerability profile</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Competition</i>: While there have been multiple new product approvals in AML over the last several years, they primarily focus on addressing genetic mutations, with limited competition in conditioning to increase access to BMT. We do not see direct or indirect visible competition for Iomab-B in the 5-to-10-year horizon to impair the commercial success of Iomab-B</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentrated Call Points</i>: The commercialization for Iomab-B will benefit from a concentrated market. The top 50 centers perform 75% of BMTs and tend to be concentrated in metropolitan areas. These factors allow for commercialization delivered by a focused 35&#8211;50-person commercial organization. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The favorable commercial dynamics for Iomab-B
in the U.S. are further supported by the strong foundation of core competencies developed during the successful execution of the SIERRA
trial at leading high-volume BMT centers. We established and actively managed end-to-end supply chain, never missing a patient dose, and
were able to treat 60% more patients than expected due to the high number of crossover patients. We focused on operational excellence
at the point of care, working in partnership with leading Key Opinion Leaders and their teams to successfully execute SIERRA at a wide
array of centers. As a result, we have broad reach across leading BMT centers that account for 30% of BMT volume, which speaks to the
concentration of the BMT market. The positive SIERRA results of unprecedented access and outcomes along with our commitment to operational
excellence provide a strong foundation for our commercial team.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">In April 2022, Actinium licensed the EUMENA commercial
rights for Iomab-B to Immedica, an independent pharmaceutical company headquartered in Sweden. Immedica has significant know-how and experience
in commercializing niche and specialty care products across Europe and the Middle East, with extensive regulatory and commercial expertise
and capabilities. Actinium will continue to be responsible for certain clinical development activities and Iomab-B manufacturing and will
retain commercialization rights in the U.S. and rest of the world. Currently, there an estimated ~7,200 BMTs for AML in EUMENA, two times
that of the U.S., performed in a concentrated of number of centers. The incidence rate of AML in Europe is 3.7 per 100,000, or ~27,500
new patients per year. Actinium received an upfront payment of $35 million USD with the potential for an additional $417 million USD in
regulatory and sales milestones and mid-twenty percent royalties. Iomab-B has been granted Orphan Drug Designation by the EMA and has
received positive Scientific Advice from EMA that the SIERRA trial can support a marketing authorization with filing expected in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Background on Iomab-B </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-B is a first-in-class targeted radiotherapy consisting of apamistamab,
an anti-CD45 mouse antibody conjugated to radioactive iodine 131 (&#8220;I-131&#8221;) designed to deliver targeted myeloablative radiation
to malignant and hematopoietic cells prior to allogeneic BMT. CD45 is uniquely expressed on blood cancer, immune and bone marrow stem
cells at high levels. Targeting CD45 enables delivery of high radiation doses directly to the bone marrow, with a median of 16 gray and
as high as 44.6 gray in the SIERRA trial, while minimizing radiation exposure to vital organs such as lungs, heart and gastrointestinal
tract, thereby producing myeloablative outcomes with an overall better safety profile and the tolerability of a reduced intensity regimen.
I-131 is a beta- and gamma-emitting radioisotope that works on the cell surface and does not need to be internalized. Developed at the
Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;), Iomab-B has been studied in multiple disease indications including leukemias,
lymphomas, MDS, and MM. Over 300 patients received Iomab-B through prior studies, demonstrating the potential for unprecedented access
to BMT, improved survival and tolerability, and we intend to leverage these data as we plan for label expansion of Iomab-B. Iomab-B has
been granted Orphan Drug Designation from the FDA and has patent protection into 2037.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Actimab-A &#8211; CD33 targeting radiotherapeutic
&#8211; mutation agnostic mechanism of action has potential as combination backbone therapy in highly radiosensitive, mutation rich AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Our Actimab-A <i>(<sup>225</sup>Ac-lintuzumab
satetraxetan) </i>program is focused on developing combinations with other AML treatment regimens with mechanistic synergies to establish
Actimab-A as a backbone therapy, leveraging the mutation-agnostic mechanism of action of Actimab-A. There is no known resistance mechanism
to targeted radiotherapies, making Actimab-A an attractive candidate for a variety of combinations. The scientific rationale is to use
CLAG-M, a powerful chemotherapy regimen routinely used to treat patients with r/r AML, and then use Actimab-A for its precision targeting
ability that produces double-strand-DNA breaks that lead to cancer cell death to clear out residual disease. Actimab-A has demonstrated
clinically significant survival benefit in a proof-of-concept study and is poised for advanced development in collaboration with the NCI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Actimab-A + CLAG-M Phase 1 Study Results </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">In collaboration with the Medical College of Wisconsin,
the Actimab-A + CLAG-M Phase 1 trial was conducted in r/r AML patients. These patients had a median age of 63, failed two or more lines
of therapy, which includes 57% having received prior treatment with venetoclax, a BCL-2 inhibitor. 67% of these patients had adverse cytogenetics,
52% had a TP53 mutation, and 57% had a prior BMT. Median OS is typically two to four months for this patient population, with a median
OS of less than 3 months for patients who relapsed following venetoclax and a median OS less than 2 months for those with a TP53 mutation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These trial results were presented
as an oral presentation at the ASH Annual Meeting in December 2022. In this difficult-to-treat r/r AML population, the results demonstrate
its high potential. We reported 1-year survival of 53% and 2-year survival of 32%, which are as much as double what can be expected with
currently available therapies. The trial showed an Overall Response Rate (&#8220;ORR&#8221;) of 65% across all dose cohorts, 52% complete
remission rate, and a 75% MRD negativity rate. As highlighted in the figure below, the results are highly encouraging and show that the
high rates of responses and MRD negativity are translating to a meaningful survival benefit in these difficult-to-treat patients, who
would otherwise have dismal outcomes.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Actimab-A + CLAG-M &#8211; Impressive Response
and Survival Benefit in r/r AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><b><img alt="" src="img_013.jpg"/></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Actimab-A + CLAG-M Compared to CLAG-M Alone
in r/r AML</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Efficacy of CLAG-M has been reported in older
studies (Halpern and Walter. CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia. Oncotarget 2018 and Mushtaq
et al. Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. ASH 2018) in patients with r/r AML,
however, almost all of these studies were conducted in the pre-targeted therapy era where no patients enrolled had prior venetoclax-based
therapy, thus efficacy data of CLAG-M in the current era, in patients exposed to prior venetoclax, or with other high-risk features, is
limited. When combined with Actimab-A, the combination has demonstrated a clinically significant survival benefit in a proof-of-concept
study irrespective of prior targeted treatment. Relapsed or refractory AML after failing venetoclax-based therapy is associated with dismal
survival outcomes, with a median OS of less than 3 months. In comparison, the combination trial of Actimab-A + CLAG-M led to 1-year survival
of 59% and 2-year survival of 32% in patients who failed prior venetoclax-based therapy, which compares very favorably to the traditional
outcomes in these patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Actimab-A + venetoclax Phase 1/2 Study Results</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are conducting a
Phase 1/2 multi-center trial combining Actimab-A + venetoclax in both fit and unfit patients 18 years and older with r/r AML led by
UCLA Medical Center. Data from our Actimab-A + venetoclax combination trial was presented at the 2022 ASH Annual Meeting. We have
demonstrated preclinically that combinations of Actimab-A and venetoclax have mechanistic synergies. Overexpression of MCL-1, an
anti-apoptotic protein, is associated with resistance to venetoclax in AML. Actimab-A kills tumors cells with DNA double-strand
breaks and downregulates MCL-1, which can (re-)sensitize AML cells or reduce tumor resistance to venetoclax. The Actimab-A +
venetoclax combination has been well-tolerated with responses, including a CR and a partial response in early dose escalation
cohorts. In our ongoing clinical trial, we are exploring the optimal dose of Actimab-A, as well as the dosing regimen of the
combination. We expect to present proof-of-concept of this study in the second half of 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Further Development for Actimab-A</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">On February 6, 2023, we announced that we entered
into a CRADA with the NCI, part of the NIH, to develop Actimab-A for the treatment of patients with AML and other hematologic malignancies.
The NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A, and the CRADA
will provide extensive support for and accelerate the development of Actimab-A alone or in combination with chemotherapy, immunotherapy,
targeted agents and other novel combinations. The CRADA studies will be overseen by the NCI in collaboration with Actinium&#8217;s clinical
development team, where Actinium has the right to review and approval all protocols and has full right to all data. This broad collaboration
may accelerate our Actimab-A development efforts with access to NCI&#8217;s vast network of over 2,000 clinical trial sites and its Myelomatch
program. Later this year, we will provide updates on our progress as we move into late-stage development with Actimab-A + CLAG-M, as well
as other developments with our venetoclax combination trial as part of our backbone development strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exploring the broader
opportunity with our Actimab-A program and the potential use of Actimab-A in solid tumor indications through our R&amp;D efforts. CD33-expressing
MDSCs are present within the tumor microenvironment and exert immunosuppressive effects, and we believe that Actimab-A can play an important
role in the tumor microenvironment by depleting MDSCs in a targeted manner. On April 19, 2023, we presented data at the AACR Annual Meeting,
that we believe support the potential role of Actimab-A to overcome immunosuppression by MDSCs in the tumor microenvironment. We believe
our preclinical findings show promise with regard to Actimab-A&#8217;s ability to selectively deplete CD33-expressing MDSCs in both lung
and colorectal cancer, which we intend to explore further via clinical development. Actimab-A also demonstrated superior depletion of
human MDSCs compared to Mylotarg, a CD33-targeted ADC in colorectal cancer (p&lt;0.01), highlighting the powerful cytotoxicity and potential
therapeutic benefit of radiotherapy compared to naked antibodies or ADCs. MDSCs are ubiquitous across multiple cancer indications and
with the substantial number of immunotherapies in development or currently in clinical use, we believe our data may support the potential
for Actimab-A, if ultimately approved for commercialization for such indication, to be a backbone therapy that could broadly improve antitumor
activity of immunotherapies such as checkpoint inhibitors and T and NK cell therapies and other therapeutic modalities in multiple solid
tumor indications.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Background on Actimab-A</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A is an anti-CD33
antibody linked to the potent alpha-emitting radioisotope Ac-225. Actimab-A targets CD33, which is expressed in virtually all malignant
cells in patients with AML regardless of cytogenetics or mutations and enables potent alpha radiation to be directed against radiosensitive
AML cells. These cells have no known resistance or repair mechanisms when hit with the alpha particles from the Ac-225 isotope payload
that cause double stranded DNA breaks. We believe Actimab-A is the first radiotherapeutic for r/r AML and has the unique value proposition
of broad applicability, a differentiated mechanism of action, and targeted precision that is well-tolerated with minimal toxicity. Our
CD33 development program is driven by data obtained from approximately 150 AML patients in 6 trials and demonstrated single agent activity
with high response rates, but was also associated with prolonged neutropenia. A combination strategy was considered appropriate given
the changing treatment landscape of AML; hence, based on presumed mechanistic synergies, an investigator-initiated trial of Actimab-A
+ CLAG-M and a company-sponsored Actimab-A + venetoclax were developed and patients were enrolled into these studies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Conditioning Focused Programs</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-B</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We will further expand the Iomab-B franchise by
focusing on lifecycle management for label enhancement and indication expansion. Iomab-B data in five additional hematologic indications
(i.e., MDS, ALL, HL, NHL, and MM) provide the foundation to explore indication expansion opportunities to increase the total addressable
market for Iomab-B. Across early trials at the FHCRC, Iomab-B demonstrated similar improved access to BMT and outcomes. We will leverage
these data with strong results from the pivotal Phase 3 SIERRA trial to execute a comprehensive life cycle management strategy to further
expand Iomab-B&#8217;s role in a variety of malignant and non-malignant hematological disorders. We will continue to develop the Iomab-B
franchise to potentially address a broader market opportunity to address the over 165,000 patients diagnosed with cancers (e.g., leukemia,
lymphoma, and myeloma), who could potentially benefit from transplant, but are unable to access one today.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-ACT</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Iomab-ACT is comprised of apamistamab, the same
anti-CD45 antibody as Iomab-B, but utilizes lower, nonmyeloablative levels of I-131 to achieve lymphodepletion for cellular therapies
such as CAR-T or reduced intensity conditioning for gene therapies. We intend to continue to develop the Iomab-ACT program designed specifically
for use prior to CAR-T and gene therapies, ultimately with a value proposition of improving overall access and outcomes for patients who
need cellular or gene therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Preclinical data showed a single, low-dose of
Iomab-ACT demonstrated lymphodepletion and as CD45 positive immune cells are implicated in major CAR-T side effects, i.e., cytokine release
syndrome ("CRS") and immune effector cell&#8211;associated neurotoxicity syndrome (&#8220;ICANS"), Iomab-ACT has the potential
to be developed as a conditioning agent for CAR-T therapies. CRS and ICANS remain two most common toxicities of CAR-T therapies with severe
cases (&gt;Grade 3) seen in &gt;20% of patients and fatality rates between 0-10%. Due to its effect on host monocytes/macrophages, we
believe conditioning with Iomab-ACT will potentially reduce the incidence of CRS and ICANS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Unlike chemotherapy, Iomab-ACT is targeted in
nature, and we expect it to potentially promote improved CAR-T cell expansion, resulting in responses that are higher and more durable.
We believe our Iomab-ACT program is highly differentiated when compared to fludarabine and cyclophosphamide (&#8220;Flu/Cy&#8221;) or
other chemotherapy-based regimens that are used as standard practice today for lymphodepletion prior to cell therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We are studying
Iomab-ACT in collaboration with MSKCC, for conditioning prior to CAR-T therapy for patients with relapsed or refractory B-cell acute
lymphoblastic leukemia (&#8220;B-ALL&#8221;) or diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;). This study funded by a NIH
grant is the first-of-its-kind study to use a radiotherapeutic-based conditioning regimen with CAR-T therapy. We have completed
treatment of an initial cohort of three patients and will expand to a second cohort. This study was presented at the ASH Annual
Meeting in December 2022 as a trial-in-progress. We expect to present proof-of-concept data from this study in the second half of
2023 and look forward to sharing more on our Iomab-ACT trial with MSKCC, along with future development plans in the CAR-T space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">R&amp;D and Preclinical Programs</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our R&amp;D efforts yield
differentiated, high-value programs that demonstrate our experience across multiple validated cancer targets and isotopes and cover broad
areas of focus leveraging our clinical development experience across hematology, targeted conditioning, solid tumors, and next generation
radiotherapies. Our programs also inform the advancement of our Iomab-B, Actimab-A, and Iomab-ACT programs. We have utilized our technology
platform to develop our clinical portfolio in hematology &#8211; Iomab-B and Actimab-A, in conditioning for transplant and as a therapeutic,
respectively. Our research collaborations with Astellas, LG Chem (formerly AVEO Oncology), and EpicentRx establish our work with immunotherapies
and in solid tumors. We are working on several preclinical programs which include novel approaches to established targets such as HER2
and HER3, as well as novel targets that show immense potential for radiotherapeutic approaches. Underpinning our development programs
is our expanded patent portfolio of over 200 issued patents and pending patent applications worldwide.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our platform has been used to develop a pipeline of novel radiotherapeutic
assets to drive company growth. Preclinical pharmacology studies with our targeted radiotherapeutics such as HER3-ARC, HER2-ARC or CD33-ARC
have shown strong improvement in tumor growth inhibition in various preclinical tumor models as single agents or in combination with immunotherapy
such as magrolimab, an anti-CD47 monoclonal antibody. These results have prompted the team to spearhead efforts in multiple solid tumor
programs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium&#8217;s lead solid
tumor program is a targeted radiotherapy against HER3, a pan-cancer target that is overexpressed in several solid tumor indications with
high unmet need. The HER3-targeted radiotherapeutic agent showed potent tumor cell cytotoxicity, enhanced antitumor effects and significantly
improved survival with an Ac-225 radiolabeled HER3 antibody compared to a naked HER3 antibody in a preclinical non-small cell lung cancer
(&#8220;NSCLC&#8221;) model. We have also demonstrated the direct impact of targeted radiotherapy in modulating immune signals such as
calreticulin upregulation to enhance tumor cell killing. Further, we have leveraged the immunomodulatory effect(s) of targeted radiotherapy
in combination with CD47 targeting agents such as magrolimab for sustained tumor growth inhibition in mouse models of AML and NSCLC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also aligned our R&amp;D
strategy of advancing solid tumors with HER3 into the clinic with our Actimab-A program. On April 19, 2023, we announced encouraging preclinical
proof-of-concept data at the AACR 2023 Annual Meeting showcasing the anti-tumor effects of HER3-targted radiotherapy using multiple
therapeutic radionuclides in preclinical models of high unmet need malignancies. Actinium&#8217;s HER3-ARC conjugated to either Ac-225
or Lu-177 showed highly significant tumor growth suppression (p&lt;0.0001) in an ovarian cancer model compared to bevacizumab, an anti-VEGF
monoclonal antibody indicated in ovarian cancer. Data presented also showed promising antitumor activity in a preclinical model of colorectal
cancer, a highly aggressive malignancy, including a significant reduction in tumor growth (p&lt;0.0001), when dosed with 225Ac-HER3-ARC.
Actinium's HER3-targeted radiotherapy displayed strong anticancer activity when conjugated to either alpha-emitting Actinium-225 or beta-emitting
Lutetium-177 in models of two high unmet need cancers, highlighting its therapeutic potential for HER3+ malignancies. The consistent overexpression
of HER3 in multiple solid tumor types, including ovarian, renal, prostate, urothelial, breast, and lung cancers suggests broad utility
of a HER3-targeted agent in a clinical setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to expand on capabilities and technologies across therapeutic
modalities, linker technologies and in vivo cancer models, and build visibility through presentations at key conferences and publications
in journals of high impact. Our R&amp;D efforts are centered on the advancement of our key programs with a robust &#8220;fast-to-clinic&#8221;
approach in niche indications. Underpinning our development programs is our expanded patent portfolio of over 200 issued patents and pending
patent applications worldwide.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Platform Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary technology
platform is built on the core competency to produce targeted radiotherapeutics, and coupled with our know-how and IP, establishes our
company in the development of isotope-agnostic, multi-targeted products that may address the treatment of hard-to-treat diseases. In our
clinical and preclinical programs, we have utilized multiple isotopes including Ac-225, I-131 and Lu-177 directed at multiple targets
in oncology and hematology such as CD45, CD33, HER3, among others. Our targeted radiotherapies combine the cell-killing ability of radiation
via a radioisotope payload with a targeting agent, such as a monoclonal antibody.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In addition to developing targeted radiotherapies,
we also own patents related to the manufacturing of Ac-225 in a cyclotron. We have expertise in utilizing the alpha emitting isotope Ac-225
including clinical experience in treating approximately 150 patients with our alpha-emitter-based therapies, &#8220;gold standard&#8221;
linker technology and five issued patents in the U.S. and 49 patents internationally related to the manufacturing or Ac-225 in a cyclotron,
which we believe has the potential to produce higher quantities of highly pure Ac-225 than current methods. When appropriate, we are well-positioned
to leverage this technology to produce Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our proprietary technology platform is supported
by IP, know-how and trade secrets that cover the generation, development, methods of use and manufacture of targeted radiotherapies and
their select components. Our IP covers various methods of use in multiple diseases, including indication, dose and scheduling, radionuclide
warhead, and therapeutic combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As of March 2023, we have expanded our patent
portfolio to over 200 issued patents and pending patent applications worldwide, which we believe constitutes a valuable business asset.
Our IP includes 45 patent families, including key patents that relate primarily to our radiotherapeutic candidates. Our patent portfolio
includes 12 issued patents and 39 pending patent applications in the U.S., and 151 that are issued or pending internationally. The effective
lives of the issued patents in our portfolio, or patents that may issue from the pending applications in our portfolio, ranges from expirations
between 2024 and 2043.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">For our Iomab-B product candidate, we have four
issued patents in the U.S. and issued patents in Canada, Europe and Japan that relate to the composition. The basic patent terms of these
patents expire in 2036 and 2037. Related patent applications are also currently pending in the U.S. and internationally. In addition,
we own both U.S. and international pending patent applications that relate to the use of Iomab-B or Iomab-ACT in the treatment of cancers
and non-malignant conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our patents also cover key areas of our business
such as manufacturing key components of our product candidate, Actimab-A, including Ac-225 in a cyclotron. We have expertise in utilizing
the alpha emitting isotope Ac-225 including clinical experience in treating approximately 150 patients with our alpha-emitter-based therapies,
&#8220;gold standard&#8221; linker technology and five issued patents in the U.S. and 49 patents internationally related to the manufacturing
or Ac-225 in a cyclotron, which we believe has the potential to produce higher quantities of Ac-225 than currently utilized methods. These
patents will expire in the years 2024 through 2027. In addition, we also own U.S. and international patents and pending patent applications
that relate to the manufacturing of Actimab-A and its use in the treatment of cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><b>Results of Operations &#8211;
Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For&#160;the</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Three&#160;Months&#160;Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">940</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">940</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,849</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">547</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">547</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,037</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,129</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the three months ended March 31, 2023 and March 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We determined that certain
collaborations with a third-party are within the scope of Topic ASC 606, <i>Revenue Recognition from Contracts with Customers, </i>or
ASC 606. The collaboration agreement is made up of multiple modules related to various research activities. While the third party has
the option to terminate the agreement at the conclusion of any module, we identified a single performance obligation to provide research
services within each module for which we receive monetary consideration. The consideration is recognized to revenue over each module and
revenue of $0.8 million was recognized during the three months ended March 31, 2022. There was no other revenue recognized from a collaboration
during the three months ended March 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Institutes of
Health awarded us a Small Business Technology Transfer cost reimbursable grant to support a clinical collaboration with Memorial Sloan
Kettering Cancer Center, or MSK, to study Iomab-ACT, our CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve
lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. We recognized other revenue from this
grant for the three months ended March 31, 2022 of $0.1 million. There was no other revenue recognized from a grant from a government-sponsored
entity for the three months ended March 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;On April 7, 2022, we
entered into a license and supply agreement with Immedica Pharma AB, or Immedica, pursuant to which Immedica licensed the exclusive product
rights for commercialization of Iomab-B in the European Economic Area, Middle East and North Africa (EUMENA) including Algeria, Andorra,
Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi
Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, we
were entitled to an upfront payment of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement,
we are eligible to receive regulatory and commercial milestone payments and are entitled to receive royalties in the mid-20 percent range
on net sales of the product in certain countries that may result from the License Agreement. We will continue to be responsible for certain
clinical development activities and the manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the
world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract liabilities are
recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in our condensed consolidated balance
sheets depending on the short-term or long-term nature of the payments to be recognized. Our contract liabilities primarily consist of
advanced payments from licensees. There was no Other revenue deferred-current liability at March 31, 2023 and December 31, 2022. Long-term
license revenue deferred was $35.0 million at March 31, 2023 and December 31, 2022, resulting from the receipt from Immedica; this deferred
revenue will be recognized upon European Union regulatory approval of Iomab-B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
of $7.8 million for the three months ended March 31, 2023 increased $3.4 million from $4.4 million for the three months ended March 31,
2022. Higher research and development expenses were primarily due to increased CMC activity related to the planned BLA filing for Iomab-B
in the second half of 2023, as well as increased compensation of $1.1 million resulting from higher headcount. The CMC expenses associated
with the planned BLA filing are expected to be one-time in nature and incurred in the first half of 2023, with a decrease in CMC expenses
expected in the second half of 2023 with submission of the BLA for Iomab-B.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and administrative expense</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative expenses of $3.7 million for the three months
ended March 31, 2023 increased by $2.0 million from $1.7 million for the three months ended March 31, 2022. Higher expenses were primarily
due to higher professional and consulting fees, as well as legal fees, which as we detail in our subsequent risk factors herein, were
related to obtaining a permanent injunction against a former employee who violated the non-compete provision of their employment agreement,
increased compensation of $0.3 million and non-cash equity compensation of $0.5 million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the three months ended March 31, 2023 of $0.5 million increased from
$35 thousand for the three months ended March 31, 2022 due to a higher average interest rate, as well as a higher average cash balance.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss of $11.0 million
for the three months ended March 31, 2023 increased by $5.9 million from $5.1 million for the three months ended March 31, 2022 primarily
due to higher research and development expenses, of which certain CMC expenses are expected to be one-time in nature and incurred in the
first half of 2023, as well as general and administrative expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have financed
our operations primarily through sales of shares of our stock. The following table sets forth selected cash flow information for the
periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For&#160;the<br/> Three&#160;Months&#160;Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(15,077</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,781</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash provided by / used in&#160;&#160;financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">770</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14,383</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,810</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the three months ended March 31, 2023 of $15.1 million increased by $9.3 million from $5.8 million in the prior-year period,
primarily as a result of a higher net loss of $5.9 million, and compared to the prior-year period, a reduction in accounts payable and
accrued expenses of $2.5 million and an increase in prepaid expenses of $1.9 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $76 thousand and $7 thousand for the three months ended March 31, 2023 and 2022, respectively, due to the purchase of equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities for the three months ended March 31, 2023 was $0.8 million from the sale of common stock. During the three months ended March
31, 2022, net cash used in financing activities was $22 thousand of payments of finance leases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020 we entered
into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which we
may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of our common stock. On June 28, 2022, we
entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement, or the Amended Sales Agreement, with JonesTrading and
B. Riley Securities, Inc. The Amended Sales Agreement modifies the original Capital on Demand&#8482; Sales Agreement to include B. Riley
as an additional sales agent thereunder. Shares of common stock are offered pursuant to our shelf registration statement on Form S-3 filed
with the SEC on August 7, 2020. For the three months ended March 31, 2023, we sold 0.1 million shares of common stock, resulting in gross
proceeds and net proceeds of $0.8 million. For the three months ended March 31, 2022, there were no sales of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following
the date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Use of Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management&#8217;s discussion
and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States, (&#8220;GAAP&#8221;). The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure
of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored
and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base
our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known.
Actual results may differ materially from these estimates under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our significant accounting
policies are described in detail in the notes to our consolidated financial statements appearing in our Annual Report filed on Form 10-K
for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value Measurement </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value is defined as the
price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants.
A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for
identical assets or liabilities and the lowest priority to unobservable inputs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize revenue in accordance
with ASC 606. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects
the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements
within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue as we satisfy a performance obligation. We only apply
the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the
goods or services we transfer to the customer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, we assess whether the promised goods or services promised within each contract
are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not to be distinct
are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods or services are
distinct, we evaluate certain criteria, including whether (i)&#160;the customer can benefit from the good or service either on its own
or together with other resources that are readily available to the customer (capable of being distinct) and (ii)&#160;the good or service
is separately identifiable from other goods or services in the contract (distinct in the context of the contract).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires us to allocate
the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction
price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling
price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer.
We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation as each performance
obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input
method.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Arrangements </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We follow the accounting guidance
for collaboration agreements, which requires that certain transactions between us and collaborators be recorded in our consolidated statements
of operations on either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced
disclosure of collaborative relationships. We evaluate our collaboration agreements for proper classification in our consolidated statements
of operations based on the nature of the underlying activity. When we conclude that we have a customer relationship with one of our collaborators,
we follow the guidance of ASC 606<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Grant Revenue </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had a grant from a government-sponsored
entity for research and development related activities that provided for payments for reimbursed costs, which included overhead and general
and administrative costs as well as an administrative fee. We recognized revenue from the grant as we performed services under this arrangement.
Associated expenses were recognized when incurred as research and development expense. Revenue and related expenses are presented gross
in the consolidated statements of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Revenue </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a product
licensing agreement whereby we allowed a third party to commercialize a certain product in specified territories using our trademarks.
The terms of this arrangement includes payment to us for a combination of one or more of the following: upfront license fees; development,
regulatory and sales-based milestone payments; and royalties on net sales of licensed products. We use judgment to determine whether milestones
or other variable consideration should be included in the transaction price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement,
we will recognize revenue from upfront license fees allocated to the license when the license is transferred to the licensee and the licensee
is able to use and benefit from the license. For licenses that are bundled with other promises, we determine whether the combined performance
obligation is satisfied over time or at a point in time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, we evaluate whether the milestones are considered probable of being achieved
and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant
revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not
within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until regulatory
approval is received. At the end of each subsequent reporting period, we will re-evaluate the probability of achieving such development
and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such
adjustments are recorded on a cumulative catch-up basis and recorded as part of license revenues during the period of adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, we
will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and if
such is the case, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation
to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements or when it is
probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with
any variable consideration is subsequently resolved. Amounts payable to us are recorded as accounts receivable when our right to consideration
is unconditional.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development Costs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are expensed as incurred. These costs include the costs of manufacturing drug components and final drug product, the costs of clinical
trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and equipment. Research
and development reimbursements are recorded by us as a reduction of research and development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-Based Payments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate the fair value
of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the
cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the
award. We account for forfeitures of stock options as they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounting Standards Recently Adopted </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB
issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides
guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted
for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related
to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification
and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line
items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments
of ASU 2021-10 are effective January 1, 2022, including interim periods. We adopted this standard effective January 1, 2022 and the standard
did not have a material impact on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, FASB issued
ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers</i>,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance ASC
606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue contracts.
Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent
with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are effective January
1, 2023, including interim periods. We will evaluate the impact of ASU 2021-08 on any future business combinations that we may enter in
the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, the Financial
Accounting Standards Board, or FASB, issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments
(Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s
Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option
that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share
(EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January
1, 2022, including interim periods. We adopted this standard effective January 1, 2022 and the standard did not have a material effect
on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Subsequent Event</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since March 31, 2023, we have
sold 0.6 million shares of common stock under our A&amp;R Sales Agreement, resulting in net proceeds of $5.6 million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="clear: both; display: block;"><br/></span>
</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not currently exposed
to significant market risk related to changes in interest rates. As of March&#160;31, 2023, our cash equivalents consisted primarily of
short-term money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general
level of U.S. interest rates. Due to the short-term nature of the cash equivalents in our portfolio and the low risk profile of our cash
equivalents, an immediate 10% change in interest rates would not have a material effect on the fair market value of our financial position
or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not currently exposed
to significant market risk related to changes in foreign currency exchange rates. Our operations may be subject to fluctuations in foreign
currency exchange rates in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation generally affects
us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial
condition or results of operations during the three months ended March 31, 2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Evaluation of Disclosure
Controls and Procedures</i>. &#160;Under the supervision and with the participation of our management, including our principal executive
officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of March 31, 2023, of our
disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended,
or the Exchange Act. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded
that, as of March 31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that the information
we are required to disclose in our filings with the Securities and Exchange Commission, or SEC, under the Exchange Act (i) is recorded,
processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated
to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely
decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Changes in Internal Control
over Financial Reporting</i>. There were no changes in our system of internal controls over financial reporting during the period covered
by this report that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8211; OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>In analyzing our company,
you should consider carefully the following risk factors, together with all of the other information included in this Quarterly Report
on Form&#160;10-Q. Factors that could cause or contribute to differences in our actual results include those discussed in the following
subsection, as well as those discussed above in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; and in our Annual Report filed on Form 10-K for the year ended December 31, 2022. Each of the following risk factors,
either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affect
the value of an investment in our company. The risks and uncertainties described below are not the only ones we face. Additional risks
not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair
our business operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are providing the following
summary of the risk factors contained in this Report on Form 10-Q to enhance the readability and accessibility of our risk factor disclosures.
We encourage you to carefully review the full risk factors contained in our Annual Report on Form 10-K for the year ended December 31,
2022 in their entirety for additional information regarding the material factors that make an investment in our securities speculative
or risky. These risks and uncertainties include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a clinical-stage company and have generated no revenue from commercial sales to date;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to obtain additional financing, we will be unable to continue or complete our product development or product commercialization and you will likely lose your entire investment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on the success of Iomab-B and the SIERRA trial and we may not be able to complete the necessary clinical development or our development efforts may not result in the data necessary to receive regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not demonstrated that any of our products are safe and effective for any indication and will continue to expend substantial time and resources on clinical development before any of our current or future product candidates will be eligible for FDA approval, if ever;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary, Interim, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations;&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently depend on a single third-party manufacturer to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party manufacturer, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent position is highly uncertain and involves complex legal and factual questions.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on our key personnel, and the demand for&#160;talent in the biotechnology industry is highly competitive; if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement or execute our business strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in our stockholders&#8217; interest; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a clinical-stage company and have
generated no revenue from commercial sales to date. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product
sales to date. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If
we do not address these risks successfully, our business will suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred net losses in every year
since our inception and anticipate that we will continue to incur net losses in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not profitable and
have incurred losses in each period since our inception. As of March 31, 2023 and December 31, 2022, we had an accumulated deficit of
$299.8 million and $288.8 million, respectively. We reported a net loss of $11.0 million and $5.1 million for the three months ended March
31, 2023 and 2022, respectively. We expect to continue to operate at a net loss as we continue our research and development efforts, continue
to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that the
products under development by us will be approved for sale in the United States or elsewhere. Furthermore, there can be no assurance that
if such products are approved, they will be successfully commercialized, which would have an adverse effect on our business prospects,
financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain additional financing,
we will be unable to continue or complete our product development and you will likely lose your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following the
date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required
to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or
otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred
cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms or indeed on any terms.
In addition, from time to time, we may not be able to secure enough capital in a timely enough manner which may cause the generation of
a going-concern opinion from our auditors which can and may impair our stock market valuation and also our ability to finance on favorable
terms or indeed on any terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To raise additional capital,
we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock.
We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal
to or greater than the price per share paid by investors, and investors purchasing shares or other securities in the future could have
rights superior to existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities, clinical
studies or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may
require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights
to future product candidates or certain major geographic markets. We may further have to license our technology to others. This could
result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of funding we will
need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope
of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary
to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative,
licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited access to the capital markets
and even if we can raise additional funding, we may be required to do so on unfavorable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited access to
the capital markets to raise funds. The capital markets have been unpredictable in the recent past for radioisotope and other oncology
companies and unprofitable companies such as ours. In addition, it is generally difficult for development-stage companies to raise capital
under current market conditions. The amount of capital that a company such as ours is able to raise often depends on variables that are
beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at all. If we are able to consummate
a financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate funds are not available on acceptable
terms, or at all, our business, including our technology licenses, results of operations, financial condition and our continued viability
will be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the success of
Iomab-B and the SIERRA trial and we may not be able to complete the necessary clinical development or our development efforts may not
result in the data necessary to receive regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have completed patient
enrollment in the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory AML), a 153-patient multi-center randomized
trial that will compare outcomes of patients who receive Iomab-B and a BMT to those patients receiving physician&#8217;s choice of salvage
chemotherapy, defined as conventional care, as no standard of care exists for this patient population. We have announced that Iomab-B
met the primary endpoint of dCR in the SIERRA trial with statistical significance (p&lt;0.0001). The SIERRA trial may be unsuccessful
and fail to demonstrate a safety and efficacy profile that is necessary to receive favorable regulatory approval. Even if Iomab-B receives
favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations.
Any or all of these factors could have a material adverse impact on our business and ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to establish sales, marketing
and commercial supply capabilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates become approved, we would have to
build and establish these capabilities in order to commercialize our approved product candidates. The process of establishing commercial
capabilities will be expensive and time consuming. Even if we are successful in building sales and marketing capabilities, we may not
be successful in commercializing any of our product candidates. Any delays in commercialization or failure to successfully commercialize
any product candidate may have material adverse impacts on our business and ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business could be adversely affected
by the effects of health epidemics, including the global COVID-19 pandemic.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global health crisis caused
by the novel coronavirus COVID-19 pandemic and its resurgences has had and may in the future negatively impact global economic activity.
Although the Public Health Emergency for COVID-19 declared by the U.S. federal government has ended, there remains a risk that new variants
of COVID 19, or other infectious diseases, may still emerge. The full impact of such an event cannot be predicted at this time, and could
depend on numerous factors, including vaccination rates among the population, the effectiveness of COVID-19 vaccines and boosters against
the COVID-19 variants and the response by governmental bodies and regulators. Given the ongoing and dynamic nature of the circumstances,
it is difficult to predict the impact of a future pandemic on our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many countries around the
world imposed quarantines and restrictions on travel and mass gatherings in response to the COVID-19 pandemic and could reinstitute such
policies in response to future infectious disease outbreaks. In such a scenario, our ability to continue to operate our business may also
be limited. Such events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations,
any of which could materially affect our business, financial condition and results of operations. In response to COVID-19, we implemented
hybrid working for our office-based staff, while our research staff has been actively working in our laboratory throughout the pandemic
and thus far have not experienced a significant disruption or delay in our operations as it relates to the clinical development, preclinical
development of manufacturing of our drug candidates. Although we are adhering to health and safety protocols, an outbreak of infectious
disease at our facilities could nonetheless cause shutdowns of facilities and a reduction in our workforce, which could cause a disruption
or delay in such operations. New outbreaks may further divert the attention and efforts of the medical community to coping with such outbreaks
and may disrupt the marketplace in which we operate and may have a material adverse effect on our operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market disruption and volatility
following a new outbreak of infectious disease could have an adverse effect on our ability to access capital, which could in turn negatively
affect our liquidity. In addition, a recession or market correction resulting from the spread of such disease could materially affect
our business and the value of our common stock.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A future pandemic could adversely
affect our clinical trial operations, including our ability to conduct the trials on the expected timelines and recruit and retain patients
and principal investigators and site staff who, as healthcare providers, may have heightened exposure to a future pandemic if their geography
is impacted by the pandemic. Further, future pandemic could result in delays in our clinical trials due to prioritization of hospital
resources toward the pandemic, restrictions in travel, potential unwillingness of patients to enroll in trials at this time, or the inability
of patients to comply with clinical trial protocols if quarantines or travel restrictions are reinstated that impede patient movement
or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other
third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials,
and the pandemic may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work
for us, which may result in delays or hinder our ability to collect data from our clinical trials.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a future pandemic
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB&#8217;s
or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to monitor the
impacts of COVID-19 on the global economy and on our business operations. However, the ultimate impact from COVID-19 or any future pandemic
on our business operations and financial results during 2023 will depend on, among other things, the ultimate severity and scope of the
pandemic, including the new variants of the virus, and whether governmental and private travel restrictions and public concerns about
public gatherings are reinstated. We are not able to fully quantify the impact that these factors had on our financial results during
2022 and will have in 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to cybersecurity
risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are increasingly
dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks and
cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks, utility
outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systems are maintained,
repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">theft or misappropriation of funds;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss, corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical data or employee data);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption or impairment of our and our business operations and safety procedures;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage to our reputation with our potential partners, patients and the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased costs to prevent, respond to or mitigate cybersecurity events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we utilize various
procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.
Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers, and
others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed for a period
time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have cybersecurity insurance
coverage in the event we become subject to various cybersecurity attacks, however, we cannot ensure that it will be sufficient to cover
any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Regulation&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of seeking regulatory
approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the effort and expense
incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products from the FDA, we may never
be able to generate significant revenue and may be forced to cease operations. In particular, the FDA permits commercial distribution
of a new antibody radiation-conjugate product only after a BLA for the product has received FDA approval. The BLA process is costly, lengthy
and inherently uncertain. Any BLA filed by us will have to be supported by extensive data, including, but not limited to, technical, preclinical,
clinical trial, chemistry, manufacturing and controls (&#8220;CMC&#8221;) and labeling data, to demonstrate to the FDA&#8217;s satisfaction
the safety and efficacy of the product for its intended use. The lengthy approval process as well as the unpredictability of future clinical
trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm
our business, results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve
any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for
our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate
with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate.
Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2012, we acquired
rights to apamistamab, a clinical stage anti-CD45 monoclonal antibody with safety and efficacy data in more than 300 patients in need
of a BMT. Iomab-B is our product candidate that links I-131 to apamistamab that is being studied in the pivotal Phase 3 SIERRA trial.
Product candidates utilizing apamistamab would require BLA approval before they can be marketed in the United States. We are also evaluating
Iomab-ACT, which uses a lower dose I-131 for lymphodepletion prior to CAR-T or adoptive cell therapy. We are currently evaluating clinical
trials that would use our construct for lymphodepletion. Our CD33 Alpha program studying Actimab-A (lintuzumab-Ac-225) product candidate
is also being studied in several Phase 1 trials under our sponsorship and investigator-initiated trials in patients with r/r AML. Product
candidates utilizing the lintuzumab antibody would require BLA approval before they can be marketed in the United States. We are in the
early stages of evaluating other product candidates consisting of conjugates of Ac-225 with human or humanized antibodies for pre-clinical
and clinical development in other types of cancer. The FDA may not approve these products for the indications that are necessary or desirable
for successful commercialization. The FDA may fail to approve any BLA we submit for new product candidates or for new intended uses or
indications for approved products or future product candidates. Failure to obtain FDA approval for our products in the proposed indications
would have a material adverse effect on our business prospects, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval process in the
United States and in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other
resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical data, conduct
additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In addition, even if we
obtain approval to market our products in the United States or in other countries, the approval could be revoked, or other restrictions
imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA
or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and cash
flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited. Additionally, even
if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications that we
request. The Company&#8217;s products may not be approved for the specific indications that are most necessary or desirable for successful
commercialization or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not demonstrated that any of our
products are safe and effective for any indication and will continue to expend substantial time and resources on clinical development
before any of our current or future product candidates will be eligible for FDA approval, if ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplated biological
product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval, and commercialization
of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approval is received. The research,
testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product candidates are, and will remain,
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, as applicable. We
are currently not permitted to market any of our current or future product candidates in the United States until we receive FDA approval
(of each) via the BLA process. To date, we have two product candidates in clinical development and have not-yet submitted a BLA for any
of our candidates and, for many such candidates, do not expect to be in a position to do so for the foreseeable future, as there are numerous
developmental steps that must be completed before we can prepare and submit a BLA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceutical and biological product candidates under the FDCA and the Public Health Service Act (&#8220;PHSA&#8221;),
as well as their respective implementing regulations. Such products and product candidates are also subject to other federal, state, and
local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal,
state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. The process required
by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical laboratory tests and animal studies in accordance with FDA&#8217;s good laboratory practices (&#8220;GLPs&#8221;) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;), which must become effective before human clinical trials in the United States may begin;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s IND regulations, GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with cGMPs and assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval, or denial, of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before testing any biological
product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate.
The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND
is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding
the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological
product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical
hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure
that submission of an IND will result in the FDA allowing clinical trials to begin or that, for those that have already commenced under
an active IND, that issues will not arise that suspend or terminate such trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events
should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be
conducted and monitored in accordance with the FDA&#8217;s regulations composing the GCP requirements, including the requirement that
all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional
review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting
the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed
consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until
completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in subjects.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the completion of clinical
trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA
must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition
of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial
waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept
the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Before approving a BLA, the FDA
will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical
trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant
must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the submission
of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and
deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret
the same data. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our product candidates
or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in
part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our proposed endpoints for
any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trial process is also lengthy and
requires substantial time and effort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2015, the FDA
cleared our IND filing for Iomab-B and we have completed patient enrollment of a randomized, controlled, pivotal Phase 3 clinical trial
under such IND to study Iomab-B in patients 55 years of age or older with relapsed or refractory AML. The Phase 3 SIERRA trial met its
primary endpoint with high statistical significance with positive results for secondary endpoints and exploratory endpoints and it is
expected to form the basis for a BLA for Iomab-B for use in preparing and conditioning AML patients for a BMT. Additionally, there are
physician IND trials at the FHCRC that have been conducted or are currently ongoing at FHCRC with Iomab-B (for other target indications)
and the apamistamab antibody (formerly known as BC8) we licensed. We have other clinical trials ongoing and others that we have planned
but not-yet commenced, for our other drug candidate Actimab-A under our own sponsorship and investigator-initiated trials ongoing. Except
for Iomab-B (for patients with AML), we expect that the clinical trials we need to conduct to be in a position to submit BLAs for our
product candidates currently in-development will take, at least, several years to complete. Moreover, failure can occur at any stage of
the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Also, the results of early preclinical
and clinical testing may not be predictive of the results of subsequent clinical trials. A number of companies in the biopharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier studies. And, preclinical and clinical data are often susceptible to multiple interpretations and analyses.
Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have, nonetheless,
failed to obtain marketing approval of their products. Success in preclinical testing and early clinical trials does not ensure that later
clinical trials, which involve many more subjects, and the results of later clinical trials may not replicate the results of prior clinical
trials and preclinical testing. Any failure or substantial delay in our product development plans may have a material adverse effect on
our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay, suspend,
or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could delay or disrupt
the clinical development of our product candidates and potentially cause our product candidates to fail to receive regulatory approval:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving, or the inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling patients into clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may suspend, or the FDA
or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if we or they
believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs based on similar technologies,
are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimal factors related to toxicity, clinical
efficacy, imbalances in safety and efficacy profiles or for other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result in
perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation of the
study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in the analysis of clinical
data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for
and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials may also be
delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated
by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB (Data Safety Monitoring
Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection
of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical
hold;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
interpretation of data by the FDA or similar foreign regulatory authorities;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
to achieve primary or secondary endpoints or other failure to demonstrate efficacy;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
safety issues; or</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
of adequate funding to continue the clinical trial.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Modifications to our product candidates
may require federal approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The BLA application is the
vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United
States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products may require
additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket approvals before
we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for a particular use or indication,
we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results.
If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conducting clinical trials
and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect our ability
to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects, financial
condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials necessary to support approval
of our product candidates are time-consuming and expensive. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initiating and completing
clinical trials necessary to support FDA approval of a BLA for Iomab-B, Actimab-A, and other product candidates, is a time-consuming and
expensive process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not necessarily predictive
of future results, and any product candidate we advance into clinical trials may not have favorable results in later clinical trials.
We worked with the FDA to develop the SIERRA clinical trial to test the safety and efficacy of Iomab-B in patients with relapsed or refractory
AML who are age 55 and above prior to a BMT. This trial is designed to support a BLA filing for marketing approval by the FDA. In addition
to clinical data, a BLA filing encompasses preclinical, CMC, labeling and other information. Even if the clinical data from the SIERRA
trial is positive, there can be no assurances that the BLA filing we produce will meet all of the FDA&#8217;s requirements or that they
will not request additional information or studies, which may delay the FDA&#8217;s review or we may not be able to produce. We have also
worked with the FDA to develop a regulatory pathway for lintuzumab-Ac-225 in patients with high-risk MDS that consists of a dose-confirming
Phase 1 trial that can be followed by a randomized, controlled pivotal trial that could support a BLA filing. To date, we have not initiated
this clinical trial and we may never elect or be able to do so. There can be no assurance that the data generated during the trial, or
any trial, will meet our chosen safety and effectiveness endpoints or otherwise produce results that will eventually support the filing
or approval of a BLA. Even if the data from this trial are favorable, the data may not be predictive of the results of any future clinical
trials.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preliminary, Interim, and &#8220;top-line&#8221;
data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject
to audit and verification procedures that could result in material changes in the final data.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;From time to time,
we may publicly disclose preliminary, interim, and top-line data from our clinical trials, which is based on a preliminary analysis
of then-available data, and the results and related findings and conclusions are subject to change as more patient data become
available or following a more comprehensive review of the data related to the particular study or trial. For example, in February
2023 we announced that Iomab-B met the primary endpoint of dCR in the SIERRA trial with statistical significance (p&lt;0.0001). We
also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or
had the opportunity to fully and carefully evaluate all data. Our clinical trials may be open label studies and certain of our
clinical development and or operations staff may review interim or preliminary safety or efficacy data during routine data
collection, cleaning and analysis from time to time. Interim or preliminary results that we report may differ from future results of
the same studies, or different conclusions or considerations may qualify such results once additional data have been received and
fully evaluated. Preliminary, interim or top-line data also remain subject to audit and verification procedures that may result in
the final data being materially different from the top-line, interim or preliminary data we previously published. As a result,
top-line, interim and preliminary data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are
subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data
become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure
of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or
weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the interim, top-line or
preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating
results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our clinical trials may fail to demonstrate
adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our clinical trials
are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign
authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure
that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials
and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the
proposed indicated uses. If FDA concludes that the clinical trials for Iomab-B, Actimab-A, or any other product candidate for which we
might seek approval, have failed to demonstrate safety and effectiveness, we would not receive FDA approval to market that product candidate
in the United States for the indications sought. In addition, such an outcome could cause us to abandon the product candidate and might
delay development of others. Any delay or termination of our clinical trials will delay or preclude the filing of any submissions with
the FDA and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients
enrolled in clinical trials will experience adverse side effects that are not currently part of a product candidate&#8217;s profile.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intellectual property related to antibodies
we have licensed has expired or likely expired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The key patents related to
the humanized antibody, lintuzumab, which we use in our Actimab-A product candidate have expired. It is generally possible that others
may be eventually able to use an antibody with the same sequence, and we will then need to rely on additional patent protection covering
alpha particle drug products comprising Ac-225. Our final drug construct, Actimab A, consists of the lintuzumab antibody labeled with
the isotope Ac-225. We currently own issued and pending patents relating to methods of manufacturing Actimab-A, methods of treatment using
Actimab-A and production of the Ac-225 isotope. In addition, we possess trade secrets and know how related to the manufacturing and use
of isotopes. Any competing product based on the lintuzumab antibody is likely to require several years of development before achieving
our product candidate&#8217;s current status and may be subject to significant regulatory hurdles but such development by others is nevertheless
a possibility that could negatively impact our business in the future. We own 4 issued U.S. patents, 1 issued Canadian patent, 1 issued
European patent (validated as a national patent in several countries) and 1 issued Japanese patent that relate to the composition of our
Iomab-B product candidate. Patent applications relating to Iomab-B are also pending in the U.S. and internationally. We have and may continue
to file patents related to Iomab-B that can provide barriers to entry but there is no certainty that these patents will be granted or
such granting thereof will adequately prevent others from seeking to replicate and use the apamistamab antibody or the construct. Our
patent portfolio includes pending applications related to radioimmunoconjugate composition, formulation administration, and methods of
use in treating solid or liquid cancers. This subject matter includes composition, administration, and methods of treatment for our product
candidates Actimab-A and Iomab-B. Any competing product based on the antibody used in Iomab-B is likely to require several years of development
before achieving our product candidate&#8217;s current status and may be subject to significant regulatory hurdles but such development
by others is nevertheless a possibility that could negatively impact our business in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our CD33 program clinical trials are testing
the same drug construct. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CD33 program is comprised
of several clinical trials including investigator-initiated trials in AML that are studying the same drug construct consisting of lintuzumab-Ac-225.
Negative results from any of these trials could negatively impact our ability to enroll or complete our other trials studying lintzumab-Ac-225.
Additionally, negative outcomes including safety concerns, may result in the FDA discontinuing other trials utilizing lintuzumab-Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iodine-131 is a key component
of our Iomab-B drug candidate. We currently source medical grade I-131 from three suppliers including two leading global manufacturers.
Currently, there is sufficient supply of I-131 to support additional trials we may undertake utilizing I-131 and for commercialization
of Iomab-B. We continually evaluate I-131 manufacturers and suppliers and intend to have multiple qualified suppliers prior to the commercial
launch of Iomab-B. While we consider I-131 to be commoditized and obtainable through several suppliers, there can be no guarantee that
we will be able to secure I-131 or obtain I-131 on terms that are acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium-225 is a key component
of our Actimab-A product candidate, technology platform, preclinical R&amp;D programs and other drug candidates that we might consider
for development with the Ac-225 payload. There are adequate quantities of Ac-225 available today to meet our current needs via our present
supplier, the Department of Energy (&#8220;DOE&#8221;). The Ac-225 currently supplied to Actinium&#8217;s clinical trials from the DOE
is derived from the natural decay of thorium-229 from so-called &#8216;thorium-cows&#8217; and is able to produce sufficient quantities
that are several multiples of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase.
The DOE is also producing Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that is currently
being evaluated by Actinium. Initial preclinical and modelling results have indicated that the linear accelerator sourced Ac-225 does
not impact labelling efficiency and expected distribution. In accordance with representations made by the DOE, the capacity of Ac-225
from this route is expected to be sufficient to supply all of Actinium&#8217;s pipeline and commercial Ac-225 needs and support new program
expansion by not just Actinium but also other companies that are developing Ac-225 based products. Additional routes of Ac-225 production
are being pursued by the DOE including the generation of new thorium cows and production via a cyclotron. The cyclotron production method
for Ac-225 production leverages Actinium&#8217;s proprietary technology and know-how and presents an additional path towards production
of high-quality Ac-225 at a scale that would be able to satisfy commercial needs. In addition, we are aware of at least ten other government
and non-government entities globally including the U.S., Canada, Russia, Belgium, France and Japan that have, or expect to have ability
to supply Ac-225 or equipment for its production within the timeframes relevant to the potential first commercial approval of our Ac-225-based
drug candidate.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract for supply of
this isotope from the DOE must be renewed yearly, and we renewed our contract to extend through the end of 2023. While we expect this
contract will continue to be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the
contract or that change its policies that allow for the sale of isotope to us. Failure to acquire sufficient quantities of medical grade
Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates that we
may develop and would materially harm our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to conduct clinical
trials to advance our drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other isotopes we may
choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our isotopes. These suppliers
may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers are subject to regulations
and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217; compliance to these
standards. Failure to comply with regulations and standards may result in their inability to supply isotopes and could result in delays
in our clinical trials, which could have a negative impact on our business. We have developed intellectual property, know-how and trade
secrets related to the manufacturing process of Ac-225. While we have manufactured medical grade Ac-225 of a purity compared to the cyclotron
sourced material in the past, this activity was terminated due to operating cost reasons and we currently do not have experience in manufacturing
medical grade Ac-225 and may not obtain the resources necessary to establish our own manufacturing capabilities in future. Our inability
to build out and establish our own manufacturing facilities would require us to continue to rely on third party suppliers as we currently
do. However, based on our current third-party suppliers and potential future suppliers of Ac-225 we expect to have adequate isotope supply
to support our current ongoing clinical trials, current and planned preclinical R&amp;D activities and commercialization should our drug
candidates receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of clinical
trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain in the trial until
its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
size and nature of the patient population;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
patient eligibility criteria defined in the protocol;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
proximity of patients to trial sites;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
design of the trial;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to recruit clinical trial investigators with the appropriate competencies and expertise;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
clinical trials for similar or alternate therapeutic treatments;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&#8217;s
and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to
other available therapies;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to obtain and maintain patient consents; and</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
risk that patients enrolled in clinical trials will not complete a clinical trial.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, refractory patients,
which several of our trials are enrolling, participating in clinical trials are seriously and often terminally ill and therefore may not
complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events related or unrelated
to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in our clinical trials, delays
in patient enrollment will result in increased costs or affect the timing of our planned trials, which could adversely affect our ability
to advance the development of our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our product
candidates on a timely basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during the course of the
clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification is evaluated.
In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or all of the data generated
by the clinical trial is not usable because the same protocol was not used throughout the trial. This might require the enrollment of
additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval of a product candidate. If
the FDA believes that its prior approval is required for a particular modification, it can delay or halt a clinical trial while it evaluates
additional information regarding the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any delay or termination of
our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required
approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays
or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in
costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product candidates or
result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays
in the completion of our Iomab-B clinical trials would adversely affect our business and prospects and could cause us to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have obtained orphan drug designation
from FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in the future,
but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations we have received
or may receive in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received orphan drug
designation for Iomab-B and Actimab-A for treatment of AML in both the United States and the EU. Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects
fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will
be recovered from sales in the United States for that drug or biologic. Similarly, the EMA grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation neither
shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory
review or approval process. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities
for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition, if a product candidate receives
the first FDA approval for the indication for which it has orphan designation, such product is entitled, upon approval, to seven years
of orphan-drug exclusivity, during which the FDA may not approve any other application to market the same drug for the same indication,
unless a subsequently approved product is clinically superior to orphan drug or where the manufacturer is unable to assure sufficient
product quantity in the applicable patient population. In the EU, orphan drug designation entitles a party to financial incentives such
as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may
be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain (or have
obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for such candidates
for the applicable indications due to the uncertainties inherent in the development of novel biologic products. And, an orphan drug candidate
may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is broader than the indication for
which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product
to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, even if we successfully
obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the product from
competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) the FDA or EMA
can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphan drug if the later-approved
drug if deemed clinically superior to the orphan drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval of
our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may
also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our
product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials
that we conduct post-approval. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker
information. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result
in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product
recalls;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
warning letters or holds on clinical trials;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license
approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
or the imposition of civil or criminal penalties.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage and reimbursement may be limited
or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage and
reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement for newly
approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products
are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed all or part of the
product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as
a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement approval generally
does not occur prior to the filing of a BLA for that product and may not be granted until many months after BLA approval. In order to
obtain coverage and reimbursement for these products, we or our commercialization partners may have to agree to a net sales price lower
than the net sales price we might charge in other sales channels. The continuing efforts of government and third-party payors to contain
or reduce the costs of healthcare may limit our revenue. Initial dependence on the commercial success of our products may make our revenues
particularly susceptible to any cost containment or reduction efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures intended
to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of
the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The Affordable Care Act, for
example, substantially changed the way healthcare is financed by both governmental and private insurers. The Affordable Care Act contains
a number of provisions that could impact our business and operations, primarily, once we obtain FDA approval to commercialize one of our
product candidates in the United States, if ever, and may also affect our operations in ways we cannot currently predict. Affordable Care
Act provisions that may affect our business include, among others, those governing enrollment in federal healthcare programs, reimbursement
changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion of state
Medicaid programs, fees and increased discount and rebate obligations, transparency and reporting requirements, and fraud and abuse enforcement.
Such changes may impact existing government healthcare programs, industry competition, formulary composition, and may result in the development
of new programs, including Medicare payment for performance initiatives, health technology assessments, and improvements to the physician
quality reporting system and feedback program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been significant
judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable Care Act since its
enactment. For example, former President Trump issued several Executive Orders and other directives designed to delay the implementation
of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the
Affordable Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part of the Affordable Care Act.
While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation the Affordable Care Act have
been passed. For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision requiring individuals to purchase
and maintain health coverage, or the &#8220;individual mandate,&#8221; by reducing the associated penalty to zero, beginning in 2019.
In December 2018, a district court in Texas held that the individual mandate is unconstitutional and that the rest of the Affordable Care
Act is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded
the case back to the lower court to reassess whether and how such holding affects the validity of the rest of the Affordable Care Act.
The Fifth Circuit&#8217;s decision on the individual mandate was appealed to the U.S. Supreme Court. On June 17, 2021, the Supreme Court
held that the plaintiffs (comprised of the state of Texas, as well as numerous other states and certain individuals) did not have standing
to challenge the constitutionality of the Affordable Care Act&#8217;s individual mandate and, accordingly, vacated the Fifth Circuit&#8217;s
decision and instructed the district court to dismiss the case. As a result, the Affordable Care Act will remain in-effect in its current
form for the foreseeable future; however, we cannot predict what additional challenges may arise in the future, the outcome thereof, or
the impact any such actions may have on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Affordable
Care Act, there have been numerous other Congressional initiatives and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drug products. Pharmaceutical product prices have been the focus of increased
scrutiny by the government, including certain state attorneys general, members of Congress and the United States Department of Justice.
State or federal healthcare reform measures or other social or political pressure to lower the cost of pharmaceutical products could have
a material adverse impact on our business, results of operations and financial condition.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Biden administration also
introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative
front, the American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid
drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, beginning January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting Competition
in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, HHS released
a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and sets out a variety
of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these
principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most recently, on August 16,
2022, President Biden signed into law the&#160;Inflation&#160;Reduction&#160;Act&#160;of 2022 (the &#8220;IRA&#8221;), which, among other
provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. Specifically, the
IRA authorizes and directs the Department of Health and Human Services (the &#8220;DHHS&#8221;) to set drug price caps for certain high-cost
Medicare Part B and Part D qualified drugs, with the initial list of drugs to be selected by September 1, 2023, and the first year of
maximum price applicability to begin in 2026. The IRA further authorizes the DHHS to penalize pharmaceutical manufacturers that increase
the price of certain Medicare Part B and Part D drugs faster than the rate of inflation. Finally, the IRA creates significant changes
to the Medicare Part D benefit design by capping Part D beneficiaries&#8217; annual out-of-pocket spending at $2,000 beginning in 2025.
We cannot be sure whether additional or related legislation or rulemaking will be issued or enacted, or what impact, if any, such changes
will have on the profitability of any of our drug candidates, if approved for commercial use, in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our relationships with customers, health
care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including
administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs
such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and
earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare professionals and
third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing
approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we conduct research, market, sell and distribute any products for which we obtain marketing approval. Federal and state
healthcare laws and regulations that may affect our operations, directly or indirectly, include the following, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Anti-Kickback Statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual
for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal
and state healthcare programs such as Medicare and Medicaid;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal false claims laws, including civil whistleblower or qui tam actions under the federal False Claims Act, which impose criminal
and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the
federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation
to pay money to the federal government;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to
defraud any healthcare benefit program or making false statements relating to healthcare matters and also imposes obligations, including
mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses,
and their respective business associates that create, receive, maintain or transmit individually identifiable health information for
or on behalf of the covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission
of individually identifiable health information;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or
state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of
a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception
applies;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Physician Payments Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which requires certain
manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s
Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value
provided to physicians and any ownership and investment interests held by physicians or their immediate family members. Beginning in
2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value to physician
assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and
certified nurse midwives during the previous year; and</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
state laws and regulations, including (among others) state anti-kickback and false claims laws, which may apply to our business practices,
including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services
reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the
pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States
federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state
laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking
gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require
the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in
certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating
compliance efforts.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to comply with applicable
healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance under these laws and regulations
are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight (if we become subject to
a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws), and the curtailment or restructuring
of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities
with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party payors may not adequately reimburse
customers for any product candidates that we may commercialize or promote, and may impose coverage restrictions or limitations such as
prior authorizations and step edits that affect their use.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products
and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other
third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend
in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring
that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage
and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement
may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate
for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may
not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining reimbursement approval
for any product candidate for which we obtain marketing approval from any government or other third-party payor is a time-consuming and
costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products. Moreover,
eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Even when a payor determines that a product that we may commercialize
or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitations that preclude payment for some
uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements, or may simply deny coverage altogether.
Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be
based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other
services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Furthermore, the Centers for Medicare and Medicaid Services frequently change product descriptors, coverage
policies, product and service codes, payment methodologies and reimbursement values. Commercial third-party payors often rely upon Medicare
coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain and maintain coverage
and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our
overall financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties to conduct our
clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with
regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the ability
to independently conduct our clinical trials for our product candidates and we must rely on third parties, such as contract research organizations,
medical institutions, clinical investigators and contract laboratories to conduct such trials. Our reliance on these third parties for
clinical development activities results in reduced control over these activities. Moreover, the FDA requires us to comply with regulations
and standards, commonly referred to as GCPs (good clinical practices), for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our
reliance on third parties does not relieve us of these responsibilities and requirements. If we or any of our third-party contractors
fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable
foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing
practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our consultants, contract
research organizations and other similar entities with which we are working do not successfully carry out their contractual duties, meet
expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there are a number
of other third-party contractors we could engage to continue these activities, we may not be able to enter into arrangements with alternative
third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our planned clinical trials and delayed
development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors, we
cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry
out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data they obtain
is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical
development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory
approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results
and prospects would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The antibodies we use in our targeted radiotherapy
product candidates may be subject to generic competition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any existing
or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our targeted radiotherapy product
candidates. Our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these products pursuant
to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval
of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review
and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity
to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after
the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As
a result, its ultimate impact, implementation, and meaning are subject to uncertainty. Even if a biosimilar gets approved for one of the
antibodies that we use, the final constructs of our drug candidates consist of an antibody, radioisotope and in some cases a linker. Therefore,
we do not believe that the final drug product of our candidates can be subject to competition from a biosimilar as outlined in BPCIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may never achieve
market acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-B, Actimab-A product
and future product candidates that we may develop may never gain market acceptance among physicians, patients and the medical community.
The degree of market acceptance of any of our products will depend on a number of factors, including the actual and perceived effectiveness
and reliability of the product; the results of any long-term clinical trials relating to use of the product; the availability, relative
cost and perceived advantages and disadvantages of alternative technologies; the degree to which treatments using the product are approved
for reimbursement by public and private insurers; the strength of our marketing and distribution infrastructure; and the level of education
and awareness among physicians and hospitals concerning the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating specific
cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide patients with
sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the use of each product candidate
from influential physicians will be essential for widespread market acceptance. Our product candidates are still in the development stage
and it is premature to attempt to gain support from physicians at this time. We can provide no assurance that such support will ever be
obtained. If our product candidates do not receive such support from these physicians and from long-term data, physicians may not use
or continue to use, and hospitals may not purchase or continue to purchase, them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure of Iomab-B, Actimab-A
or any of our other product candidates to significantly penetrate current or new markets would negatively impact our business financial
condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our third-party
service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial
cost and be a distraction to our management and employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently depend on single third-party
manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party
manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently operate
manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturers
to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonal
antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect to continue
to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing or future manufacturers
could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory approval of our product
candidates or commercialization of any approved products. Further avenues of disruption to our clinical or eventual commercial supply
may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen circumstances that might occur
at any of our suppliers or contract manufacturing partners including an inability to come to terms on renewal of existing contracts or
new contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on single
manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuity we are
evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing partners,
however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we would be able
to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity and support
our growth plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates require
precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers we may engage in
the future to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls or withdrawals,
delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our business. Contract manufacturers
may encounter difficulties involving production yields, quality control, and quality assurance. These manufacturers are subject to ongoing
periodic and unannounced inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and
other applicable government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&#8217;
compliance with these regulations and standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may elect to build or purchase
a manufacturing facility or facilities in the future to operate for the purposes of manufacturing our own products. We have never built,
owned or operated a manufacturing facility. There can be no assurances that we will be able to successfully accomplish this and in doing
so we may experience delays, cost overruns, or other problems that could seriously hurt our business. Even if we successfully build or
purchase a manufacturing facility, we may not realize the expected benefits of these efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on vendors with
specialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered into manufacturing
and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be the exclusive manufacturer and
supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail to comply with required regulations
or breach their contractual obligations it may be difficult, or we may be unable to identify suitable alternative third-party manufacturers.
While we identify and evaluate third-party manufacturers from time to time, even if we do identify suitable alternative third-parties,
we may fail to reach agreement on contractual terms, it may be prohibitively expensive and there can be no assurance that we can successfully
complete technology transfer and development work necessary or complete the necessary work in a timely manner. Any of which could prevent
us from commencing manufacturing with third-parties which could cause delays or suspension of our clinical trials and pre-clinical work
that may have a negative impact on our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, these third-party
contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shutdowns, employee strikes, or
any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct (either
ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-party manufacturers
to consistently supply quality product when required would have a material adverse effect on our ability to develop or commercialize our
products. We have faced delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such
delays and risks in the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company,
including delays in clinical trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are successful in obtaining marketing
approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party
manufacturers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our product candidates
have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or other regulatory
agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party
specialized manufacturers to produce commercial quantities of approved products. These manufacturers may not be able to successfully increase
the manufacturing capacity for any approved product in a timely or economic manner, or at all. Significant scale-up of manufacturing may
require additional validation studies, which the FDA must review and approve. Scale-up for commercial product may require financial commitment
or investment by us, which we may not have sufficient capital for or may elect not to undertake. If third party manufacturers are unable
to successfully increase the manufacturing capacity for a product candidate, or we are unable to establish our own manufacturing capabilities,
the commercial launch of any approved products may be delayed or there may be a shortage in supply, which in turn could have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will
be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure
and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for
or market our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have conflicts with
our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation
of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during
our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner that is adverse to our best interests.
Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization
of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a partner to pay us milestone
payments or royalties we believe are due under a collaboration; uncertainty regarding ownership of intellectual property rights arising
from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the partner to
cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the
part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure
of the results of those activities; initiating litigation or alternative dispute resolution options by either party to resolve the dispute;
or attempts by either party to terminate the agreement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If in the future we are unable to establish
U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates,
we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive regulatory approval.
In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution,
managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with
technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming
and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the commercialization
of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with
third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution
systems or in lieu of our own sales force and distribution systems. In particular, we have and expect to continue to partner with third
parties to commercialize Iomab-B outside the United States. In April&#160;2022, we entered into a licensing agreement with Immedica, in
which Immedica acquired the product rights for commercialization of Iomab-B for certain territories outside the U.S. If we are unable
to enter into or maintain such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize
any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If
we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties,
our future product revenue will suffer and we may incur significant additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face significant competition from other
biotechnology and pharmaceutical companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates face,
and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academic and research
institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii)
emerging competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with
our product candidates and technologies and may develop and commercialize additional products and technologies that will compete with
our product candidates and technologies. Because several competing companies and institutions have greater financial resources than us,
they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development, or R&amp;D,
and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we do and have substantially
greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory approvals, and manufacturing
and marketing pharmaceutical products. They also have greater name recognition and better access to customers than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The drug-related side
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even if any of our product candidates
receives marketing approval, as greater numbers of patients use a product following its approval, an increase in the incidence of side
effects or the incidence of other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result
in a number of potentially significant negative consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
authorities may withdraw their approval of the product;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
authorities may require the addition of labeling statements, such as warnings or contraindications;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may elect, or we may be required, to recall or withdraw product from the market;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
could be sued and held liable for harm caused to patients; and</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
reputation may suffer.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or could harm or
prevent sales of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon securing and protecting critical
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are dependent on obtaining
and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages of
development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether the commercial
versions of these product candidates will incorporate proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our patent position is highly uncertain
and involves complex legal and factual questions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, we cannot predict
the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our licensors might
not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors
might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative
technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications
of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially
viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and,
we may not develop additional proprietary technologies that are patentable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, our owned and
licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protection for the
full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or our licensors have applied
for and will continue to apply for patents for certain products and methods. Such applications may not result in the issuance of any patents,
and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible
that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because
of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain a preferred position, we
could become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration of our
patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we license from third parties, or subsequent
related filings, would adversely affect our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents issued or licensed
to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if such enforcement
is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further, such litigation
can go on for years and the time demands could interfere with our normal operations. There has been substantial litigation and other proceedings
regarding patent and other intellectual property rights in the pharmaceutical industry. We may become a party to patent litigation and
other proceedings. The cost to us of any patent litigation, even if resolved in our favor, could be substantial. Some of our competitors
may be able to sustain the costs of such litigation more effectively than we can because of their substantially greater financial resources.
Litigation may also absorb significant management time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although
we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of
confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means, these measures may
not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access
to, the same or similar information. In addition, we cannot guarantee that we have executed these agreements with each party that may
have or have had access to our trade secrets. Furthermore, if the employees and consultants who are parties to these agreements breach
or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade
secrets through such breaches or violations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our patent rights
are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents may
be terminated, and we may be unable to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are found to be infringing on patents
or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the
development or sale of our products, and/or pay damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others,
or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases
that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other
persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the
affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required
to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process.
Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved
in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to infringement
or other intellectual property claims against us, we may become a party to other patent litigation or proceedings before regulatory agencies,
including post-grant review, inter parties review, interference or re-examination proceedings filed with the U.S. Patent and Trademark
Office (or similar proceedings before corresponding tribunals in other jurisdictions) that challenge our patent rights or the patent rights
of our licensors. The costs and efforts of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings
can be substantial and the outcome can be uncertain. An adverse determination in these proceedings could weaken or invalidate the patent
claims that cover our technology, which adverse determination could harm our business significantly and dissuade companies from collaborating
with us or permit third parties to directly compete with the same technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to protect and enforce our patents
does not guarantee that we will secure the right to commercialize our patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent is a limited monopoly
right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention.
This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or using its invention.
While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention where other permissions
may be required for commercialization to occur. For example, a drug cannot be marketed without the appropriate authorization from the
FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented itself, cannot be commercialized
if it infringes the valid patent rights of another party.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on confidentiality agreements to
protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our
competitors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on trade secrets that
we seek to protect through numerous measures, including non-compete and confidentiality agreements with our employees and other parties.
If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. Any remedies
that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we
may have to expend resources to protect our interests from possible infringement by others. For instance, we learned that a former employee,
Qing Liang, Ph.D., who was employed by Actinium in the position of Vice President, Head of Radiation Sciences, violated the non-compete
provision of her employment agreement by working for a direct competitor. Additionally, while working for the direct competitor, Dr. Liang
continued to provide consulting services to Actinium. We also learned that Dr. Liang was providing consulting services to another company,
which was in violation of certain provisions of her post-employment consulting agreement with Actinium. Dr. Liang, who had access to materials
containing proprietary information and trade secrets, pursuant to actions taken by Actinium, is no longer employed by the direct competitor.
With the assistance of outside counsel and a forensic investigator, we identified that Dr. Liang downloaded confidential information prior
to her employment at Actinium ending. To aid in arbitration proceedings, we petitioned and were granted a Stipulated Preliminary Injunction
by the Supreme Court of the State of New York, New York County (Index No. 656841/2022) on June 28, 2022 that ordered that Dr. Liang is
enjoined from destroying or deleting any Actinium documents or information, is enjoined from using, transmitting or transferring any Actinium
Information other than to her counsel or Actinium&#8217;s counsel, ordered to return Actinium information within 5 days of Stipulated
Preliminary Injunction, ordered to disclose to Actinium under oath, all persons and devices she transferred or disclosed Actinium Information,
and ordered to allow a qualified forensic examiner selected by Actinium to remove and permanently delete all Actinium Information from
any electronic devices, systems, email accounts, or other electronic or physical storage sites belonging to Dr. Liang. We are currently
in arbitration with Dr. Liang and intend to enforce the terms of her employment agreement, especially the non-compete and confidentiality
provisions, to the fullest extent of our ability. On April 25, 2023, a Final Award and Permanent Injunction was granted by the Supreme
Court of the State of New York, New York County (Case No. 01-22-0003-2375_ that ordered that Ms. Liang is permanently enjoined from using,
possessing, transmitting or transferring any Actinium property, documents of business information. Further, until April 1, 2024, Dr. Liang
shall not, either directly or indirectly, engage in any business that directly or indirectly is developing, or plans to develop, radioimmunotherapies
for cancer or any targeted conditioning therapy or agent for adoptive cell therapy including bone marrow transplant and CAR-T.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to expand our development and
regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and, as a result, we may encounter difficulties
in managing our growth, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to experience significant
growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory
affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that are potentially able to obtain
regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales,
distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we
may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales or
marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be
expensive and time consuming and will require significant attention of our executive officers to manage. We will also have to compete
with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of
any of our product candidates that we obtain approval to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To manage our anticipated
future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and
continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our
management team in managing a public company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may
divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans
or disrupt our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us
to liability for claims arising from the use or misuse of these materials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials,
such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations governing, among
other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely eliminate the
risk of contamination or injury from these materials and we could be held liable for any damages that result, which could exceed our financial
resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future claims
may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the costs
of complying with such federal, state, local and foreign environmental regulations are not significant, and consist primarily of waste
disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our research,
development, production and commercialization efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not have any
international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant
opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries involves
inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected changes in
regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating
intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to experience any
of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition
may suffer and cause us to reduce or discontinue our international development and registration efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future operations and
successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon
to manage our business. If any member of our current senior management terminates his or her employment with us and we are unable to find
a suitable replacement quickly, the departure could have a material adverse effect on our business. An overall tightening and increasingly
competitive labor market has been observed in the U.S. employment market generally, especially in response to the COVID-19 pandemic. Specific
to the biotechnology industry in which we operate, there is significant demand and competition for highly specialized talent that we require.
A sustained labor shortage or increased turnover rates within our employee base, caused by the COVID-19 pandemic, as a result of general
macroeconomic factors, or due to dynamics within our industry, could lead to increased costs, such as increased wage rates to attract
and retain employees, and could negatively affect our ability to efficiently conduct our clinical development, R&amp;D, business development
and potential regulatory and commercial activities. If we are unable to hire and retain employees capable of performing at a high-level,
or if mitigation measures we may take to respond to a decrease in labor availability, have unintended negative effects, our business could
be adversely affected. An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, caused by the COVID-19
pandemic, general macroeconomic factors or as a result of biotechnology industry dynamics could have a material adverse impact on our
operations, results of operations, liquidity or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical and regulatory
personnel. This activity is likely to create additional demands on the time and attention of our senior management personnel as they identify,
hire, and train external and internal candidates to fill the sizable number of positions required to execute our business plans, including
submitting a BLA and building a commercial organization. The market for talent in our industry is very competitive. Many of the other
biopharmaceutical companies we compete against for qualified personnel have greater financial and other resources, more favorable risk
profiles and a longer operating history in the biopharmaceutical industry than we do. They also may provide more diverse opportunities
and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates than what we have
to offer. There can be no assurance that such professionals will be available in the market, or that we will be able to retain existing
professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base in relation to such compensation,
which may include equity compensation, may increase significantly, which could have a material adverse effect on us. Failure to establish
and maintain an effective management team and workforce could adversely affect our ability to operate, grow and manage our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Managing our growth as we expand operations
may strain our resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to need to grow
rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates as well
as potential commercial operations, which will place a significant strain on our financial, managerial and operational resources. In order
to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities.
Moreover, we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase our
expenses and may require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm
our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may expand our business through the acquisition
of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217;
ownership interests in our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so. Acquisitions
involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt
and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating
acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business
concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key
employees of the acquired companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
product, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated
with some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired products,
businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business
or companies may require a substantial capital investment by us. We may not have these necessary funds, or they might not be available
to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute
each current stockholder&#8217;s ownership interest in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Ownership of Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The sale of securities by us in any equity
or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additional capital
through the sales of stock and warrants in order to expand our level of operations to continue our research and development efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any sale of common stock by
us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional shares
of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing strategic relationships
with targeted customers and vendors. In order to do so, or to finance the cost of our other activities, we may issue additional equity
securities that could dilute our stockholders&#8217; stock ownership. We may also assume additional debt and incur impairment losses related
to goodwill and other tangible assets if we acquire another company and this could negatively impact our earnings and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>Our common stock is subject to price volatility which could
lead to losses by stockholders and potential costly security litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading volume of our
common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock to fluctuate
substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating
results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and
the financial markets or other developments affecting our competitors or us. This volatility has had a significant effect on the market
price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of our common
stock may be highly volatile and could fluctuate in response to factors such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
or anticipated variations in our operating results;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
of developments by us or our competitors;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
actions regarding our products;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption
of new accounting standards affecting our industry;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
or departures of key personnel;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
of new products by us or our competitors;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
of our common stock or other securities in the open market;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inaccurate
or unfavorable reports from securities or industry analysts; and</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
events or factors, many of which are beyond our control.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market is subject
to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&#8217;s securities,
securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful,
could result in substantial costs and diversion of our management&#8217;s attention and our resources, which could harm our business and
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends on our
common stock, so any returns will be determined by the value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations
will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. As a result, the
success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common
stock will appreciate in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>Certain provisions of our Certificate of Incorporation
and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even
if such a transaction were in our stockholders&#8217; interest.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our
management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our
stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock.
Among other things, the certificate of incorporation and bylaws:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
that the authorized number of directors may be changed by resolution of the board of directors;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote
of a majority of directors then in office, even if less than a quorum;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide
the board of directors into three classes;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at
a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content
of a stockholder&#8217;s notice;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are governed
by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging
in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own,
15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing
a change in our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with the reporting requirements
of federal securities laws can be expensive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission
and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with the
preparation of registration statements and related documents with respect any offerings of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to utilize our
federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, or the Code.&#160;The limitations apply if we experience an &#8220;ownership change&#8221;, generally defined as a greater
than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period.&#160;Similar
provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously occurred.&#160;If we
have experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability to utilize
our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in our stock ownership,
which may be outside of our control, may trigger an ownership change and, consequently, the limitations under Sections 382 and 383 of
the Code.&#160;As a result, if or when we earn net taxable income, our ability to use our pre-change net operating loss carryforwards
and other tax attributes to offset such taxable income may be subject to limitations, which could adversely affect our future cash flows.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to establish and maintain adequate
finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal
controls requirements for publicly traded companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, we operate
in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporate oversight
and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary
for us to produce reliable financial reports and are important to help prevent financial fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts. We complied
with Section 404 at December 31, 2022 and 2021 and while our testing did not reveal any material weaknesses in our internal controls,
any material weaknesses in our internal controls in the future would be required us to remediate in a timely manner so as to be able to
comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section 404 in a timely manner
each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory authorities which would require
additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot
provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose
confidence in our reported financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Multiple
securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publish inaccurate or
unfavorable research about our business, the price of our common stock would likely decline. If one or more of these analysts cease coverage
of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could cause the price of our common
stock and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated&#160;bylaws, as
amended,&#160;designate the U.S.&#160;federal&#160;district courts as the&#160;exclusive forum&#160;for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated&#160;bylaws,
as amended,&#160;provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities
Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasing or otherwise acquiring
any interest in our security shall be deemed to have notice of and to have consented to such provision. Such choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees, which may discourage such lawsuits, if successful, might benefit our stockholders. Stockholders who do bring
a claim in the federal district courts of the United States of America could face additional litigation costs in pursuing any such claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. EXHIBITS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copies of the following documents
are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed with the SEC on April 17, 2013).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>


<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022322/ea125571ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</span></a></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="f10q0323ex31-1_actiniumphar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10q0323ex31-2_actiniumphar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10q0323ex32-1_actiniumphar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10q0323ex32-2_actiniumphar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Label Linkbase Document </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
herewith.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
herewith.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
a management contract or compensatory plan or arrangement.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 15, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Sandesh Seth</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer<br/>
(Duly Authorized Officer and<br/>
Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Steve O&#8217;Loughlin</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer and<br/>
Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">73</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:EntityRegistrantName">Actinium Pharmaceuticals, Inc.</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-7" name="us-gaap:SubleaseIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-8" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-9" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.23</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-10" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.43</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="0" id="hidden-fact-11" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">22143974</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-12" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">25696623</ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-13" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-14" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-16" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-19" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-20" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-21" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-22" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-23" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-24" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-25" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-26" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-27" name="atnm:SalesOfSharesOfCommonStockNetOfCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-28" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-29" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-30" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-31" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-32" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-33" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-34" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-35" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-36" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-37" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-38" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-39" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-40" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-41" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-42" name="atnm:PaymentWithImputedInterestPremium" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-45" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-48" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-49" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-50" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001388320</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnm-20230331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9caiv6eidgRXaZ9zAXdjNfZ+isHx1VzVZ87eyhOzogc2PX2d1XZ8wl+DFVBBOlP2XOCV7m8TrbAw3/cxmmUnzGizHRtYmp9Bx4mrmawKhgHfR6SGOMJ2SDIxoGajoho/mYq9u3FnIN53VBQ==] CSR-->
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2012-05-16</xbrli:startDate>
    <xbrli:endDate>2012-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2012-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-03</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0323ex31-1_actiniumphar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATION OF PRINCIPAL
EXECUTIVE OFFICER&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PURSUANT TO&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>18 U.S.C. SECTION 1350,&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AS ADOPTED PURSUANT TO
SECTION 302 OF&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>THE SARBANES-OXLEY ACT
OF 2002&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Dated&nbsp;&nbsp;May 15, 2023</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)&#8239;</TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10q0323ex31-2_actiniumphar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATION OF PRINCIPAL
FINANCIAL AND ACCOUNTING OFFICER</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PURSUANT TO</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AS ADOPTED PURSUANT TO
SECTION 302 OF</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Steve O&rsquo;Loughlin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Dated: May 15, 2023</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0323ex32-1_actiniumphar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATION OF PRINCIPAL
EXECUTIVE OFFICER</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PURSUANT TO</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2023 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Sandesh Seth, Chairman &amp; CEO of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Dated: May 15, 2023</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>f10q0323ex32-2_actiniumphar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATION OF PRINCIPAL
FINANCIAL AND ACCOUNTING OFFICER</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PURSUANT TO</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2023 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Steve O&rsquo;Loughlin, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Dated: May 15, 2023</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>atnm-20230331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 15 19:02:03 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://actiniumpharmaceuticals.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:atnm="http://actiniumpharmaceuticals.com/20230331" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20230331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20230331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20230331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20230331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet" id="atnm_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals" id="atnm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement" id="atnm_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals" id="atnm_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3" id="atnm_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow" id="atnm_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies" id="atnm_r_CommitmentsandContingencies">
        <link:definition>008 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Leases" id="atnm_r_Leases">
        <link:definition>009 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue" id="atnm_r_OtherRevenue">
        <link:definition>010 - Disclosure - Other Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="atnm_r_Equity">
        <link:definition>011 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent" id="atnm_r_SubsequentEvent">
        <link:definition>012 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy" id="atnm_r_AccountingPoliciesByPolicy">
        <link:definition>013 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" id="atnm_r_LeasesTables">
        <link:definition>015 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="atnm_r_EquityTables">
        <link:definition>016 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable" id="atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable">
        <link:definition>017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable" id="atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable">
        <link:definition>018 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails" id="atnm_r_CommitmentsandContingenciesDetails">
        <link:definition>019 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" id="atnm_r_LeasesDetails">
        <link:definition>020 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable" id="atnm_r_ScheduleofcomponentsofleaseexpenseTable">
        <link:definition>021 - Disclosure - Leases (Details) - Schedule of components of lease expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" id="atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
        <link:definition>022 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable" id="atnm_r_ScheduleofweightedaverageremainingleasetermsTable">
        <link:definition>023 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable" id="atnm_r_ScheduleofweightedaveragediscountratesTable">
        <link:definition>024 - Disclosure - Leases (Details) - Schedule of weighted average discount rates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9caiv6eidgRXaZ9zAXdjNfZ+isHx1VzVZ87eyhOzogc2PX2d1XZ8wl+DFVBBOlP2XOCV7m8TrbAw3/cxmmUnzGizHRtYmp9Bx4mrmawKhgHfR6SaqjHKKP+Z6Xy/eUHNylQHZ9ag5/7SznA==] CSR-->
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable" id="atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable">
        <link:definition>025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails" id="atnm_r_OtherRevenueDetails">
        <link:definition>026 - Disclosure - Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="atnm_r_EquityDetails">
        <link:definition>027 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable" id="atnm_r_ScheduleofsummaryofstockoptionactivityTable">
        <link:definition>028 - Disclosure - Equity  (Details) - Schedule of summary of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable" id="atnm_r_ScheduleofsummaryofrestrictedstockunitactivityTable">
        <link:definition>029 - Disclosure - Equity  (Details) - Schedule of summary of restricted stock unit activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable" id="atnm_r_ScheduleofwarrantactivitiesTable">
        <link:definition>030 - Disclosure - Equity  (Details) - Schedule of warrant activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" id="atnm_r_SubsequentEventDetails">
        <link:definition>031 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
  <xs:element name="ScheduleOfComponentsOfLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="OtherRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueAbstract"/>
  <xs:element name="ScheduleOfSummaryOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfWarrantActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWarrantActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract16"/>
  <xs:element name="FinanceLeaseCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeaseCostAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract17"/>
  <xs:element name="NonCashActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonCashActivityAbstract"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract18"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageDiscountRatesAbstract"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract20"/>
  <xs:element name="LongtermOperatingLeaseObligationsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
  <xs:element name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
  <xs:element name="SalesOfSharesOfCommonStockNetOfCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems"/>
  <xs:element name="LeasesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesTextBlock"/>
  <xs:element name="OtherRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueTextBlock"/>
  <xs:element name="OtherRevenueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_OtherRevenueTable"/>
  <xs:element name="OtherRevenueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueLineItems"/>
  <xs:element name="NatureOfBusinessPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NatureOfBusinessPolicyTextBlock"/>
  <xs:element name="GrantRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_GrantRevenuePolicyTextBlock"/>
  <xs:element name="LicenseRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LicenseRevenueTextBlock"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems"/>
  <xs:element name="ScheduleOrDescriptionOfWeightedAverageTerm" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
  <xs:element name="ScheduleOfWeightedAverageDiscountRate" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageDiscountRate"/>
  <xs:element name="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems"/>
  <xs:element name="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable"/>
  <xs:element name="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems"/>
  <xs:element name="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <xs:element name="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems"/>
  <xs:element name="LeaseDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeaseDomain"/>
  <xs:element name="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
  <xs:element name="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
  <xs:element name="PaymentWithImputedInterestPremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_PaymentWithImputedInterestPremium"/>
  <xs:element name="MaturitiesOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MaturitiesOfLeaseLiabilities"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
  <xs:element name="RSUsOutstandingBeginningBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_RSUsOutstandingBeginningBalance"/>
  <xs:element name="RSUsOutstandingEndingBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_RSUsOutstandingEndingBalance"/>
  <xs:element name="NumberOfWarrantsOutstandings" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_NumberOfWarrantsOutstandings"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MilestonePayment"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsLineItems"/>
  <xs:element name="RevenueRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RevenueRecognized"/>
  <xs:element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_UpfrontPayment"/>
  <xs:element name="LongtermLicenseRevenueDeferred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_LongtermLicenseRevenueDeferred"/>
  <xs:element name="AgreementDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_AgreementDomain"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EquityDetailsLineItems"/>
  <xs:element name="GrantOfStockOptionsToEmployees" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_GrantOfStockOptionsToEmployees"/>
  <xs:element name="DescriptionOfExercisePriceRange" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DescriptionOfExercisePriceRange"/>
  <xs:element name="StockOptionTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StockOptionTerm"/>
  <xs:element name="VestingPeriodOfStockOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_VestingPeriodOfStockOption"/>
  <xs:element name="AggregateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_AggregateFairValue"/>
  <xs:element name="StockOptionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StockOptionDescription"/>
  <xs:element name="UnrecognizedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnrecognizedCompensationExpense"/>
  <xs:element name="WeightedAverageTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageTerm"/>
  <xs:element name="CompensationExpenseRelatedToStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_CompensationExpenseRelatedToStockOptions"/>
  <xs:element name="SharesOfCommonStockValue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharesOfCommonStockValue"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetProceeds"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="atnm_AgreementAxis"/>
  <xs:element name="LeaseAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="atnm_LeaseAxis"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="FinanceLeaseLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeaseLiabilitiesMember"/>
  <xs:element name="OperatingLeaseLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingLeaseLiabilitiesMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>atnm-20230331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 15 19:02:03 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20230331.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9caiv6eidgRXaZ9zAXdjNfZ+isHx1VzVZ87eyhOzogc2PX2d1XZ8wl+DFVBBOlP2XOCV7m8TrbAw3/cxmmUnzGizHRtYmp9Bx4mrmawKhgHfR6cfgOdVzlXuxyEtElXVnCPrbzyFhL7h6Mw==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_SubleaseIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20230331.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20230331.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>atnm-20230331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 15 19:02:03 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_Leases" roleURI="http://actiniumpharmaceuticals.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_OtherRevenue" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_SubsequentEvent" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_LeasesTables" roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofcomponentsofleaseexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofweightedaverageremainingleasetermsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofweightedaveragediscountratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofsummaryofstockoptionactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofsummaryofrestrictedstockunitactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofwarrantactivitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_LeasesDetails" roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_OtherRevenueDetails" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_SubsequentEventDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20230331.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20230331.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20230331.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20230331.xsd#atnm_LeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_LeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenue">
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueLineItems" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTable" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_OtherRevenueLineItems" xlink:to="atnm_OtherRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueLineItems" xlink:to="atnm_OtherRevenueTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20230331.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_NatureOfBusinessPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenuePolicyTextBlock" xlink:href="atnm-20230331.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_GrantRevenuePolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenueTextBlock" xlink:href="atnm-20230331.xsd#atnm_LicenseRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_LicenseRevenueTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20230331.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20230331.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9caiv6eidgRXaZ9zAXdjNfZ+isHx1VzVZ87eyhOzogc2PX2d1XZ8wl+DFVBBOlP2XOCV7m8TrbAw3/cxmmUnzGizHRtYmp9Bx4mrmawKhgHfR6Rf4oZiaNx/GpGFGSWfnC4WwKFJGiCS3qw==] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseCostAbstract" xlink:href="atnm-20230331.xsd#atnm_FinanceLeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="atnm_FinanceLeaseCostAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_LeaseCostAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseAxis" xlink:href="atnm-20230331.xsd#atnm_LeaseAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="atnm_LeaseAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain" xlink:href="atnm-20230331.xsd#atnm_LeaseDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain_0" xlink:href="atnm-20230331.xsd#atnm_LeaseDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeaseLiabilitiesMember" xlink:href="atnm-20230331.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeaseDomain" xlink:to="atnm_OperatingLeaseLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseLiabilitiesMember" xlink:href="atnm-20230331.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeaseDomain" xlink:to="atnm_FinanceLeaseLiabilitiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentWithImputedInterestPremium" xlink:href="atnm-20230331.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="atnm_PaymentWithImputedInterestPremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_MaturitiesOfLeaseLiabilities" xlink:href="atnm-20230331.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_MaturitiesOfLeaseLiabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfSummaryOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230331.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230331.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingBeginningBalance" xlink:href="atnm-20230331.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_RSUsOutstandingBeginningBalance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingEndingBalance" xlink:href="atnm-20230331.xsd#atnm_RSUsOutstandingEndingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_RSUsOutstandingEndingBalance" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfWarrantsOutstandings" xlink:href="atnm-20230331.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_NumberOfWarrantsOutstandings" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230331.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20230331.xsd#atnm_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_MilestonePayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DerivativeNetAssetsPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="atnm_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateAndOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_CorporateAndOtherMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="us-gaap_LeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="us-gaap_LandImprovements" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails">
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueAbstract" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueRecognized" xlink:href="atnm-20230331.xsd#atnm_RevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_RevenueRecognized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UpfrontPayment" xlink:href="atnm-20230331.xsd#atnm_UpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_UpfrontPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermLicenseRevenueDeferred" xlink:href="atnm-20230331.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_LongtermLicenseRevenueDeferred" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsLineItems" xlink:href="atnm-20230331.xsd#atnm_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20230331.xsd#atnm_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementAxis" xlink:href="atnm-20230331.xsd#atnm_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_AgreementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain" xlink:href="atnm-20230331.xsd#atnm_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain_0" xlink:href="atnm-20230331.xsd#atnm_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20230331.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_AgreementDomain" xlink:to="atnm_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantOfStockOptionsToEmployees" xlink:href="atnm-20230331.xsd#atnm_GrantOfStockOptionsToEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_GrantOfStockOptionsToEmployees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionOfExercisePriceRange" xlink:href="atnm-20230331.xsd#atnm_DescriptionOfExercisePriceRange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_DescriptionOfExercisePriceRange" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionTerm" xlink:href="atnm-20230331.xsd#atnm_StockOptionTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_StockOptionTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_VestingPeriodOfStockOption" xlink:href="atnm-20230331.xsd#atnm_VestingPeriodOfStockOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_VestingPeriodOfStockOption" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateFairValue" xlink:href="atnm-20230331.xsd#atnm_AggregateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_AggregateFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionDescription" xlink:href="atnm-20230331.xsd#atnm_StockOptionDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_StockOptionDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UnrecognizedCompensationExpense" xlink:href="atnm-20230331.xsd#atnm_UnrecognizedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_UnrecognizedCompensationExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageTerm" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_WeightedAverageTerm" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20230331.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_CompensationExpenseRelatedToStockOptions" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_SharesOfCommonStockValue" xlink:href="atnm-20230331.xsd#atnm_SharesOfCommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="atnm_SharesOfCommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceeds" xlink:href="atnm-20230331.xsd#atnm_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="atnm_NetProceeds" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="29" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>atnm-20230331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 15 19:02:03 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By / Used In Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseAxis" xlink:href="atnm-20230331.xsd#atnm_LeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeaseAxis_lbl" xml:lang="en-US">Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueAbstract" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueAbstract_lbl" xml:lang="en-US">Other revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_OtherRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfSummaryOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of Summary of Stock Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Shares Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule of Summary of Restricted Stock Unit Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfWarrantsOutstandings" xlink:href="atnm-20230331.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl" xml:lang="en-US">Number of Shares, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl0" xml:lang="en-US">Number of Shares, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price,Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share Outstanding, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value,Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $536 and $487</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0" xlink:to="atnm_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract1" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract1" xlink:to="atnm_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract2" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract2" xlink:to="atnm_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20230331.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract3" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract3" xlink:to="atnm_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract4" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract4" xlink:to="atnm_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 25,729,370 and 25,674,823 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract5" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract5" xlink:to="atnm_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract6" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract6" xlink:to="atnm_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract7" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract7" xlink:to="atnm_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract8" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract8" xlink:to="atnm_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract9" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract9" xlink:to="atnm_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract10" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract10" xlink:to="atnm_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share of common stock &#8211; basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract11" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract11" xlink:to="atnm_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract12" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract12" xlink:to="atnm_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Used In Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation &amp; amortization expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Other liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20230331.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract13" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract13" xlink:to="atnm_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Used In Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract14" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract14" xlink:to="atnm_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Provided By / Used In Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20230331.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl" xml:lang="en-US">Sales of shares of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract15" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract15" xlink:to="atnm_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract16" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract16" xlink:to="atnm_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of diluted net loss per share anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20230331.xsd#atnm_LeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseCostAbstract" xlink:href="atnm-20230331.xsd#atnm_FinanceLeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="atnm_FinanceLeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20230331.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract17" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract17" xlink:to="atnm_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20230331.xsd#atnm_NonCashActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonCashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract18" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract18" xlink:to="atnm_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20230331.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl" xml:lang="en-US">Schedule of weighted average discount rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20230331.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentWithImputedInterestPremium" xlink:href="atnm-20230331.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MaturitiesOfLeaseLiabilities" xlink:href="atnm-20230331.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueTextBlock_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summary of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted average remaining contractual term (in years), Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Cancelled/Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230331.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term (in years), Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract19" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract19" xlink:to="atnm_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Number of Shares, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230331.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summary of restricted stock unit activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingBeginningBalance" xlink:href="atnm-20230331.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl" xml:lang="en-US">RSUs Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">RSUs, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">RSUs, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingEndingBalance" xlink:href="atnm-20230331.xsd#atnm_RSUsOutstandingEndingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RSUsOutstandingEndingBalance_lbl" xml:lang="en-US">RSUs Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingEndingBalance" xlink:to="atnm_RSUsOutstandingEndingBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled/Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Shares, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract20" xlink:href="atnm-20230331.xsd#atnm_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract20" xlink:to="atnm_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeaseLiabilitiesMember" xlink:href="atnm-20230331.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseLiabilitiesMember" xlink:href="atnm-20230331.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl" xml:lang="en-US">Finance Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementAxis" xlink:href="atnm-20230331.xsd#atnm_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20230331.xsd#atnm_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeNetAssetsPercentage_lbl" xml:lang="en-US">Net sales percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNetAssetsPercentage" xlink:to="us-gaap_DerivativeNetAssetsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Current annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandImprovements_lbl" xml:lang="en-US">Landlord assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovements" xlink:to="us-gaap_LandImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueRecognized" xlink:href="atnm-20230331.xsd#atnm_RevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UpfrontPayment" xlink:href="atnm-20230331.xsd#atnm_UpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermLicenseRevenueDeferred" xlink:href="atnm-20230331.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate value of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of common stock, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantOfStockOptionsToEmployees" xlink:href="atnm-20230331.xsd#atnm_GrantOfStockOptionsToEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_GrantOfStockOptionsToEmployees_lbl" xml:lang="en-US">Grant of stock options to employees (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsToEmployees" xlink:to="atnm_GrantOfStockOptionsToEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionOfExercisePriceRange" xlink:href="atnm-20230331.xsd#atnm_DescriptionOfExercisePriceRange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_DescriptionOfExercisePriceRange_lbl" xml:lang="en-US">Exercise price ranging, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfExercisePriceRange" xlink:to="atnm_DescriptionOfExercisePriceRange_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionTerm" xlink:href="atnm-20230331.xsd#atnm_StockOptionTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StockOptionTerm_lbl" xml:lang="en-US">Stock option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_VestingPeriodOfStockOption" xlink:href="atnm-20230331.xsd#atnm_VestingPeriodOfStockOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_VestingPeriodOfStockOption_lbl" xml:lang="en-US">Vesting period of stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateFairValue" xlink:href="atnm-20230331.xsd#atnm_AggregateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AggregateFairValue_lbl" xml:lang="en-US">Aggregate fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionDescription" xlink:href="atnm-20230331.xsd#atnm_StockOptionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StockOptionDescription_lbl" xml:lang="en-US">Stock option, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionDescription" xlink:to="atnm_StockOptionDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnrecognizedCompensationExpense" xlink:href="atnm-20230331.xsd#atnm_UnrecognizedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnrecognizedCompensationExpense_lbl" xml:lang="en-US">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageTerm" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageTerm_lbl" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20230331.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl" xml:lang="en-US">Compensation expense related to stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9caiv6eidgRXaZ9zAXdjNfZ+isHx1VzVZ87eyhOzogc2PX2d1XZ8wl+DFVBBOlP2XOCV7m8TrbAw3/cxmmUnzGizHRtYmp9Bx4mrmawKhgHfR6U2PWacIAWX6c+p/vIlwAArN6I3ruDvHWg==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xml:lang="en-US">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Grant year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Expected term year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SharesOfCommonStockValue" xlink:href="atnm-20230331.xsd#atnm_SharesOfCommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharesOfCommonStockValue_lbl" xml:lang="en-US">Shares of common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharesOfCommonStockValue" xlink:to="atnm_SharesOfCommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceeds" xlink:href="atnm-20230331.xsd#atnm_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetProceeds_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceeds" xlink:to="atnm_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20230331.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenuePolicyTextBlock" xlink:href="atnm-20230331.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl" xml:lang="en-US">Grant Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenueTextBlock" xlink:href="atnm-20230331.xsd#atnm_LicenseRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LicenseRevenueTextBlock_lbl" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenueTextBlock" xlink:to="atnm_LicenseRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateAndOtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateAndOtherMember_lbl" xml:lang="en-US">Corporate Office Space [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateAndOtherMember" xlink:to="us-gaap_CorporateAndOtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20230331.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Capital on Demand Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTable" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTable_lbl" xml:lang="en-US">Other Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTable" xlink:to="atnm_OtherRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueLineItems" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueLineItems_lbl" xml:lang="en-US">Other Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueLineItems" xlink:to="atnm_OtherRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:to="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable_lbl" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:to="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems_lbl" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain" xlink:href="atnm-20230331.xsd#atnm_LeaseDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseDomain_lbl" xml:lang="en-US">Lease [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseDomain" xlink:to="atnm_LeaseDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of maturities of lease liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsTable" xlink:to="atnm_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="atnm_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain" xlink:href="atnm-20230331.xsd#atnm_AgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementDomain_lbl" xml:lang="en-US">Agreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementDomain" xlink:to="atnm_AgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20230331.xsd#atnm_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsLineItems" xlink:href="atnm-20230331.xsd#atnm_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_EquityDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AggregateFairValue_lbl0" xml:lang="en-US">The amount of aggregate fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl0" xml:lang="en-US">The amount of compensation expense related to stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DescriptionOfExercisePriceRange_lbl0" xml:lang="en-US">Description of exercise price range.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfExercisePriceRange" xlink:to="atnm_DescriptionOfExercisePriceRange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_GrantOfStockOptionsToEmployees_lbl0" xml:lang="en-US">Grant of stock options to employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsToEmployees" xlink:to="atnm_GrantOfStockOptionsToEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl0" xml:lang="en-US">The amount of operating lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl0" xml:lang="en-US">The amount of long-term license revenue deferred.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl0" xml:lang="en-US">Long-term operating lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl0" xml:lang="en-US">The amount of present value of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MilestonePayment_lbl0" xml:lang="en-US">The amount of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl0" xml:lang="en-US">Nature of Business policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetProceeds_lbl0" xml:lang="en-US">Amount of net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceeds" xlink:to="atnm_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl1" xml:lang="en-US">The number of shares, outstanding beginning.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of maturities of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl0" xml:lang="en-US">The amount of payment with imputed interest premium.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl0" xml:lang="en-US">RSUs Outstanding, Beginning balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RSUsOutstandingEndingBalance_lbl0" xml:lang="en-US">RSUs Outstanding, Ending balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingEndingBalance" xlink:to="atnm_RSUsOutstandingEndingBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RevenueRecognized_lbl0" xml:lang="en-US">The amount of revenue recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl0" xml:lang="en-US">The amount of sales of shares of common stock, net of costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharesOfCommonStockValue_lbl0" xml:lang="en-US">Shares of common stock value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharesOfCommonStockValue" xlink:to="atnm_SharesOfCommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockOptionDescription_lbl0" xml:lang="en-US">Stock option, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionDescription" xlink:to="atnm_StockOptionDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockOptionTerm_lbl0" xml:lang="en-US">Stock option term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UnrecognizedCompensationExpense_lbl0" xml:lang="en-US">Unrecognized compensation expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UpfrontPayment_lbl0" xml:lang="en-US">Upfront payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_VestingPeriodOfStockOption_lbl0" xml:lang="en-US">Vesting period of stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WeightedAverageTerm_lbl0" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AgreementAxis_lbl0" xml:lang="en-US">Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Anti Dilutive Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:to="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnrecognizedCompensationExpense_lbl1" xml:lang="en-US">Unrecognized Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl1" xml:lang="en-US">RSUs Outstanding Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl1" xml:lang="en-US">Payment With Imputed Interest Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl0" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateFairValue_lbl1" xml:lang="en-US">Aggregate Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl2" xml:lang="en-US">Number Of Warrants Outstandings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandImprovements_lbl0" xml:lang="en-US">Land Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovements" xlink:to="us-gaap_LandImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseAxis_lbl0" xml:lang="en-US">Lease Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Grant Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseRevenueTextBlock_lbl0" xml:lang="en-US">License Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenueTextBlock" xlink:to="atnm_LicenseRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateAndOtherMember_lbl0" xml:lang="en-US">Corporate and Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateAndOtherMember" xlink:to="us-gaap_CorporateAndOtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems_lbl0" xml:lang="en-US">Descriptionof Businessand Summaryof Significant Accounting Policies Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract18" xlink:to="atnm_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract19" xlink:to="atnm_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract16" xlink:to="atnm_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract17" xlink:to="atnm_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl0" xml:lang="en-US">Finance Lease Liabilities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract20" xlink:to="atnm_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrantOfStockOptionsToEmployees_lbl1" xml:lang="en-US">Grant Of Stock Options To Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsToEmployees" xlink:to="atnm_GrantOfStockOptionsToEmployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl0" xml:lang="en-US">Other Restricted Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonCashActivityAbstract_lbl0" xml:lang="en-US">Non Cash Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWarrantActivitiesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWarrantActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWarrantActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWarrantActivitiesAbstract" xlink:to="atnm_ScheduleOfWarrantActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageTerm_lbl1" xml:lang="en-US">Weighted Average Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl1" xml:lang="en-US">Compensation Expense Related To Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract10" xlink:to="atnm_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract11" xlink:to="atnm_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract14" xlink:to="atnm_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract15" xlink:to="atnm_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract12" xlink:to="atnm_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract13" xlink:to="atnm_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockOptionDescription_lbl1" xml:lang="en-US">Stock Option Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionDescription" xlink:to="atnm_StockOptionDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RevenueRecognized_lbl1" xml:lang="en-US">Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl0" xml:lang="en-US">Schedule Of Weighted Average Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract2" xlink:to="atnm_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract1" xlink:to="atnm_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract4" xlink:to="atnm_UnlabeledAbstract4_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract3" xlink:to="atnm_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0" xlink:to="atnm_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_VestingPeriodOfStockOption_lbl1" xml:lang="en-US">Vesting Period Of Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract9" xlink:to="atnm_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract6" xlink:to="atnm_UnlabeledAbstract6_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract5" xlink:to="atnm_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract8" xlink:to="atnm_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract7" xlink:to="atnm_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTextBlock_lbl0" xml:lang="en-US">Other Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl3" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharesOfCommonStockValue_lbl1" xml:lang="en-US">Shares Of Common Stock Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharesOfCommonStockValue" xlink:to="atnm_SharesOfCommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesTextBlock_lbl0" xml:lang="en-US">Leases Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockOptionTerm_lbl1" xml:lang="en-US">Stock Option Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl1" xml:lang="en-US">Maturities Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseCostAbstract_lbl0" xml:lang="en-US">Finance Lease Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="atnm_FinanceLeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeNetAssetsPercentage_lbl0" xml:lang="en-US">Derivative, Net Assets, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNetAssetsPercentage" xlink:to="us-gaap_DerivativeNetAssetsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Restricted Cash Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl0" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfExercisePriceRange_lbl1" xml:lang="en-US">Description Of Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfExercisePriceRange" xlink:to="atnm_DescriptionOfExercisePriceRange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl0" xml:lang="en-US">Restricted Investments, at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl1" xml:lang="en-US">Sales Of Shares Of Common Stock Net Of Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl0" xml:lang="en-US">Schedule Or Description Of Weighted Average Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems_lbl0" xml:lang="en-US">Leases Details Scheduleofsupplementalcashflowinformationrelatedtoleases Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl1" xml:lang="en-US">Longterm Operating Lease Obligations Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementAxis_lbl1" xml:lang="en-US">Agreement Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl1" xml:lang="en-US">Nature Of Business Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UpfrontPayment_lbl1" xml:lang="en-US">Upfront Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems_lbl0" xml:lang="en-US">Leases Details Scheduleofcomponentsofleaseexpense Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0" xml:lang="en-US">Finance Lease, Interest Payment on Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl0" xml:lang="en-US">Operating Lease Liabilities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RSUsOutstandingEndingBalance_lbl1" xml:lang="en-US">RSUs Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingEndingBalance" xlink:to="atnm_RSUsOutstandingEndingBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetProceeds_lbl1" xml:lang="en-US">Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceeds" xlink:to="atnm_NetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl0" xml:lang="en-US">Sublease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl1" xml:lang="en-US">Longterm License Revenue Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl2" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US">Operating And Finance Lease Liability Maturity Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>atnm-20230331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 15 19:02:03 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_Leases" roleURI="http://actiniumpharmaceuticals.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_OtherRevenue" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_SubsequentEvent" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_LeasesTables" roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofcomponentsofleaseexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofweightedaverageremainingleasetermsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofweightedaveragediscountratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofsummaryofstockoptionactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofsummaryofrestrictedstockunitactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_ScheduleofwarrantactivitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_LeasesDetails" roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_OtherRevenueDetails" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#atnm_r_SubsequentEventDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230331.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20230331.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="LongtermOperatingLeaseObligationsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20230331.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20230331.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="SalesOfSharesOfCommonStockNetOfCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTextBlock" xlink:href="atnm-20230331.xsd#atnm_LeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenue">
    <loc xlink:type="locator" xlink:label="OtherRevenueAbstract" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTable" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueTable"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueLineItems" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="OtherRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueTable" xlink:to="OtherRevenueLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTextBlock" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueLineItems" xlink:to="OtherRevenueTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20230331.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureOfBusinessPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantRevenuePolicyTextBlock" xlink:href="atnm-20230331.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GrantRevenuePolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenueTextBlock" xlink:href="atnm-20230331.xsd#atnm_LicenseRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicenseRevenueTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20230331.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOrDescriptionOfWeightedAverageTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfWeightedAverageDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20230331.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:href="atnm-20230331.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9caiv6eidgRXaZ9zAXdjNfZ+isHx1VzVZ87eyhOzogc2PX2d1XZ8wl+DFVBBOlP2XOCV7m8TrbAw3/cxmmUnzGizHRtYmp9Bx4mrmawKhgHfR6YtaNBbOZbkha98s5lz3yKzqDkK36UA7Yg==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:to="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseCostAbstract" xlink:href="atnm-20230331.xsd#atnm_FinanceLeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="FinanceLeaseCostAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:to="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_LeaseCostAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="WeightedAverageDiscountRatesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LeaseAxis" xlink:href="atnm-20230331.xsd#atnm_LeaseAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="LeaseAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitiesMember" xlink:href="atnm-20230331.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAxis" xlink:to="OperatingLeaseLiabilitiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilitiesMember" xlink:href="atnm-20230331.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAxis" xlink:to="FinanceLeaseLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentWithImputedInterestPremium" xlink:href="atnm-20230331.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="PaymentWithImputedInterestPremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturitiesOfLeaseLiabilities" xlink:href="atnm-20230331.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentWithImputedInterestPremium" xlink:to="MaturitiesOfLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfSummaryOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230331.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230331.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="RSUsOutstandingBeginningBalance" xlink:href="atnm-20230331.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="RSUsOutstandingBeginningBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RSUsOutstandingEndingBalance" xlink:href="atnm-20230331.xsd#atnm_RSUsOutstandingEndingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="RSUsOutstandingEndingBalance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivitiesAbstract" xlink:href="atnm-20230331.xsd#atnm_ScheduleOfWarrantActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivitiesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsOutstandings" xlink:href="atnm-20230331.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantsOutstandings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsOutstandings_0" xlink:href="atnm-20230331.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantsOutstandings_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230331.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="atnm-20230331.xsd#atnm_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="MilestonePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DerivativeNetAssetsPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="atnm-20230331.xsd#atnm_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateAndOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_CorporateAndOtherMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LandImprovements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails">
    <loc xlink:type="locator" xlink:label="OtherRevenueAbstract" xlink:href="atnm-20230331.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenueRecognized" xlink:href="atnm-20230331.xsd#atnm_RevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="RevenueRecognized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontPayment" xlink:href="atnm-20230331.xsd#atnm_UpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="UpfrontPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermLicenseRevenueDeferred" xlink:href="atnm-20230331.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="LongtermLicenseRevenueDeferred" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="atnm-20230331.xsd#atnm_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="atnm-20230331.xsd#atnm_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="atnm-20230331.xsd#atnm_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="AgreementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomain" xlink:href="atnm-20230331.xsd#atnm_AgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20230331.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantOfStockOptionsToEmployees" xlink:href="atnm-20230331.xsd#atnm_GrantOfStockOptionsToEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="GrantOfStockOptionsToEmployees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfExercisePriceRange" xlink:href="atnm-20230331.xsd#atnm_DescriptionOfExercisePriceRange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DescriptionOfExercisePriceRange" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionTerm" xlink:href="atnm-20230331.xsd#atnm_StockOptionTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockOptionTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriodOfStockOption" xlink:href="atnm-20230331.xsd#atnm_VestingPeriodOfStockOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="VestingPeriodOfStockOption" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateFairValue" xlink:href="atnm-20230331.xsd#atnm_AggregateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionDescription" xlink:href="atnm-20230331.xsd#atnm_StockOptionDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockOptionDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedCompensationExpense" xlink:href="atnm-20230331.xsd#atnm_UnrecognizedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnrecognizedCompensationExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageTerm" xlink:href="atnm-20230331.xsd#atnm_WeightedAverageTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WeightedAverageTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20230331.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CompensationExpenseRelatedToStockOptions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharesOfCommonStockValue" xlink:href="atnm-20230331.xsd#atnm_SharesOfCommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SharesOfCommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="atnm-20230331.xsd#atnm_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="NetProceeds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="atnm-20230331.xsd#atnm_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $3 G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#C?^"F_P"W
M'^WOJ_\ P4]^/OP5^&?[5?QE^'VB:9\<O#'P0^%W@KP1\0+_ .'W@K1H]8;P
MMH&@B\MM%\J(2WNNZ^MWK_B*^CO+V199)W9H+:&V3S?4O%/_  4QU;Q/JGAO
MX/?\%'OVD/B;_P (WXFUWX<>)M7\5^,?BW\!M)3XP:/X]N?AMI/PL\%WOQ$N
MKC3OB-XB\?>*K6ZL_ HT#48;MGM)[;QQI?@FZ:TBNOZ!/VS?^#;[PM^U=^T]
M\7/VDM"_:Y\6_"YOC#XCMO&.L>#;CX5:-XT&B^)3IUA8ZC/HWB-/&?A6[33;
MF;3H+VPM)]/>[TR1G1=2NE6&2/$U'_@WM_:5UG5AK^L?\%@OVA]3UQ?"%S\/
MUU6]^'4D]XO@N\F2ZN_#P=OB\%6WNKV./4+B_5!K4VIQQZI)J;:DBW8_>\/Q
M9P?1RS)*>#Q&282KALIPU#'8?'<,SQ+EC84J$*LZE2GEM:59\T*W+..)BN>:
MKRE74U3I_G-;*<YEB\=.K3QM6%3%U:E">'S.%)>P<ZKC!1GB8\EXRIMKV3LH
MJ"4+.3_#;PEHG_!8WQ)XD\%:1JG[>'Q3\*:#XGU;P7H_B/QEJ'[4^MWFF?#'
M4?'FJ_"O2?#>A^-].@GM[^W\8ZU/\9O ']B^$[0S3:E/JSVDFI6#VD\R6;ZT
M_P""J8TG1KGP]_P45^/?BKQ9XGT:74O"_P ,].^+GC*U\<:Q*WA+X+>+--!M
M[KQ!_9%CIFK1_&_PW8Q7USJHO]/, OM1T:&'4?(T_P#:[0?^#=7X_>%=0LM7
M\,_\%:?C?H&JZ< MA?Z3\)+*TN+0+IGAC1HC&R?%0J9+?2_!'@VSM)I4DFLT
M\*Z#-:207>GP7"Y4G_!MO\8YM/N=*E_X*J?&%M-NK33;">S_ .%.V"(;/1M+
MT;0]*MX9(OBI'<6::?HOASP[I=JUA-;2"RT#187D<:79&&9<79'*HI+-^%84
MXN%X4^#*B4[592GS<^65)QO3<::<9W:3=HS;F"RC'J%GA,V<VI6D\ZI^ZVE&
M#5L2E9.[:<6KWNVN5+\0O#Y_X+!^(BMWIG[>'Q,U3PY<74*Z/XDT#]K'5-:L
M/&^E6\5W=>)]6^&L8N+(^+U\'6>D>)CX@L9)]%GAU#POK.EQL9ELY;LOC_P6
M(LH!J@_;H^*J^' ;F\O=<U7]J[5-%_X170'LM?U/P[X@\>Z=/<7%QX7MO&%A
MX;U$>'[:.369)M45=+>4,R7,O[H7G_!NE\>[_6;KQ!>?\%9_C;<ZY>W!N[K5
M9OA'9/=2W!T(>%C("?BIY,*MX;!T5X+>*&W:QDN \+2W-S--U?PT_P"#?KXW
M?#+QOI/CJU_X*7^,?&ESI%O-:Q^'_'GP+.I^&;N-M%U?P]:O>66C?&K0=0-Q
MI.D:_K=GI4MOJ=N+:'5;^)XYH[AE!6XQR*,9SH8[A&I-4URT)\'UX0G433:]
MJ\ ^1NZ2G)2BMO9^SN*&2Y@Y*-2CFRCS64XYQ3=HO17B\1>R6KC%7=KJ2=[_
M ,_O[)?[;G_!17X:?\%%?@=\&OB/^UQ\=/$5[HW[5/A7X'_%3P9XI^)=_P#$
M'P1K,4GQ!MO _CC0;BRU<W6F:M9.&ODT[5K>*&YMIX[74]/G@FBC:O\ 1P5%
MYR <,0,\X'' SG_/X5_,=\)?^#<:W\'_ +7/A']K7XG?MI>)OB;KVA_&]?C]
MXC\-:-\$_#G@!/%WCF/Q++XSCA_M6W\;^((="T:;Q(T5Q>6ECHT\LNF1/IEK
M/923?;8OZ<T/'3!(W$9SRW/Z=..!TS7POB'F_#^<XW**N1PPL94,M]EF$\)E
M_P#9]&>+G5C4:A!4<.ZD8?O5&3I^[!PCS/5+Z+AK!YA@J&,ACY5)*>*YL,JN
M(^L5%14&KR:J5.1R]QM<VK3=EU-B?W5_[Y'^%&Q/[J_]\C_"G45^?V7]-_YG
MTHW8G]U?^^1_A1L3^ZO_ 'R/\*=119=OQ?\ F W8G]U?^^1_A1L7!&T#/H #
M^8]*=119?TW_ )AN,$:#C&1[_A_A_7K1Y:?W13Z*++LON#[_ +VOR:&>6G]T
M4>6G]T4^BBR[+[D'W_>_\QGEI_=%'EI_=%/HHLNR^Y!]_P![_P QGEI_=%'E
MI_=%/HHLNR^Y!]_WO_,9Y:?W11Y:?W13Z*++LON0??\ >_\ ,9Y:?W11Y:?W
M13Z*++LON0??][_S&>6G]T4>6G]T4^BBR[+[D'S?WO\ S&>6G]T4>6G]T4^B
MBR[+[D'W_>_\QGEI_=%'EI_=%/HHLNR^Y!]_WO\ S&>6G]T4>6G]T4^BBR[+
M[D'W_>_\QGEI_=%'EI_=%/HHLNR^Y!]_WO\ S&>6G]T4>6G]T4^BBR[+[D'W
M_>_\QGEI_=%'EI_=%/HHLNR^Y!]_WO\ S&>6G]T4>6G]T4^BBR[+[D'W_>_\
MQGEI_=%'EI_=%/HHLNR^Y!]_WO\ S&>6G]T4>6G]T4^BBR[+[D'W_>_\QGEI
M_=%'EI_=%/HHLNR^Y!]_WO\ S&>6G]T4>6G]T4^BBR[+[D'W_>_\QGEI_=%'
MEI_=%/HHLNR^Y!]_WO\ S&>6G]T4>6G]T4^BBR[+[D'W_>_\QGEI_=%'EI_=
M%/HHLNR^Y!]_WO\ S&>6G]T4>6G]T4^BCE79?<@^_P"]_P"8SRQG()7_ '3@
M?4@Y!/7GT/XT;#_??\Q_\33Z*++LON0#-A_OO^8_^)HV'^^_YC_XFGT4679?
M<@&;#_??\Q_\31L/]]_S'_Q-/HHLNR^Y ,V'^^_YC_XFC8?[[_F/_B:?119=
ME]R 9L/]]_S'_P 31L/]]_S'_P 33Z*++LON0#-A_OO^8_\ B:-A_OO^8_\
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MPDZ552E+%)TI*J[.#2E*SE*S21KT5F?VSI?_ $$M._\  ^U_^._X4?VSI?\
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MS3HK+_MG2_\ H):;_P"!UKU_[^_I^M']L:7G_D)Z=CGC[=:_A_RU[4>PK_\
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M2'U_!?\ 0;@O_"W!_P#S6:=%9G]LZ7_T$M._\#[7_P".T?VSI?\ T$M._P#
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M'L:__/BM_P"":O\ \I#Z_@O^@S!_^%F#_P#FLU**S?[7TS_H(Z?_ .!UM_\
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M;@Y5)P=3F?#&43]UR<7.<E@9M7E[MWS:M<S5TW^B'_#O;]CSK_PI73,=,_\
M"4>-QTX_Z&>C_AWM^Q[_ -$4TS_PJ/''_P TXKQ[7/\ @JM^SGX2N/$>K>-/
M#OQ;\)?";P_KGQ+\#P?'S5/!MI/\(?$WQ4^#FB^(=;^)'PL\+:SI>N7^NZGX
MIT4^$O%>@Z/>OX>MO"_C#Q;X7\1>&O"NO:KJ5A''<XUU_P %6_A;IEQ_PC^N
M_L__ +4GASXDM\4?@?\ !^#X2Z[\//#EEX_NO&?[0WA;QQXU^&Z6UL/'$N@R
M:/-X;\!ZK?>(=5.OK#X:N&DTK58X=5TS5[*PT6<\?R2:SOBAIW:;SK')-*W-
MJ\?%?N^:*JZ_N7.FJWLG4@I0^ /"Y6OP5P2K[?\ &,Y-KVM_PG._-KR?SVER
M.7+*WO7_  [V_8\_Z(IIG_A4>./_ )IZ/^'>W['O_1%-+_\ "H\<9_\ 4GQ^
MGXUX+XT_X*U_L]?#WQE\7/!'BWP+\;=-U?X4>%?$OC:**+PIX<O[OQ_X>\&?
M$GPA\*O%,_A'1;'QC<:[97EIXK\=>'3HNF>.--\'WGBK1KL:SX?2]L0LK>A?
M S_@HS\+OCC\7M,^"=O\+?CG\-_&6JZC\6O"\$_Q)\':)I6@'XA_ J;0V^*W
MP\CUC1/%7B"*[U[POIGB;0=8&I645SX5U.UOIK*PU^;6=-U+3+6'GG'T:3K3
MSSBB-*--5G-YSC[*DX>TYU_MUY1Y+RO&,DDG?6+2:\/_  OE)0CP3P2YN3@H
MKAG)F^;FY;/_ (3O==]%=K?2ZU.W;_@GO^QX%)_X4GI1P._B?QST]\>)_P!<
M?6L'_A@C]D3_ (2D:7_PI;2?L9\/-J)7_A)/' <W(U)+8,7'B<?+Y1*A<<D9
M[XK[M8Y5C@\ GGC. ?SY^F#7(?\ ,]+U/_%(M@=N=9CSQ]017)#C#BQ\]^*.
M(7>E4<?^%G,OLJ#7_,4]>O3Y,VJ>&OATO9I<!<&K]Y#_ )IG)MGSIWM@;6T6
MCNKO;:WS!_P[V_8\_P"B)Z6,>GB?QP!QQW\4'T_K0?\ @GM^QY_T1/3/H/$_
MC@G\CXH]_6OM C@]3U_7\/RZU^<7[1O[>MG^S)^T!X@\">.O!FJZ]\,/#W[.
M7@'XMO=> M+O?$7Q/U7QS\1?VD=%_9]\/>$]%\.MJ%AIFHZ;/>^(--O=HDCU
M(W32A9&A58FNAQ/QIBJGL<-Q)Q'6J\DIJFLZS'FE&#III)XM<TFZD4HIIN[L
MURMA5\.?#6C%5*O G!D(N48\SX8R:R<KVO; -I>Z[NSMIW1Z2W_!/K]CI1D_
M!33<9(R/$_C@CCKR/$Q_#U]J4?\ !/K]CH\_\*3TSH#C_A)_'6!GIG/B?/.#
MT';IWKY*^*G_  5U^'VB?"'XF:Y\,/@O\;/%'QP^'WPZ_:;\8>)_@_JW@O34
MOOA%<_LU-)X=\4ZW\9;G3_&"V$7@=?']WH6B?:_ &N>*]=UG2;O4=7T+3[BV
MTB_FM^D\)_\ !3G33J&I>%=7^&'C_P"*7Q0N]9\/V/A/X4? 'P-<:SXJGTJW
M_9P^#WQX^)6N7=[XN\7:5H%]HOA/_A:EEIVG:A%J&CW.M7FI>'O"NE:/JWB.
M>:67L>;^(2I2J_VYQ(HPDXRYL[QO-%*,9^T<?K_NTN6<9*M*4*3@U*,Y1?,<
M_P#J%X7<RC_J1P4VTFK<,9.U+5QY4UEVLW.+CR13DI+E:4M#Z4/_  3V_8\Q
M_P D3TSI_P!#1XXR?_+G_I3?^'?'['><?\*4TW/_ &,_CC'.<$'_ (2?D''!
MZ>]>#?%/_@JI\*_AQXJU[X=CX1_&NX\=+\*?''C[P3I7B+PYHO@Z+Q=XE\#?
M!:;XZ:M\/+K2M:\1)XZ\(ZI9^$(KFWU+6_%'@W3O#D'B#2-?\.V6IW^LZ6;.
M?S'X._\ !6&'QG/8Z'XE^#GCS5/BMXR\(_L[:W\.?V>_AKX:M+_XE:AJ_P 6
M?@+J7QS\;+>>)?$?C?3OA_=^%O"GA[3GUB#7I]4\,?8=(O=%TG4HK_Q1JT%B
MLK.?$"5)5UGW$?LG9IRSO&Q<HM.7/!/'I^SBHR<ZK:IPY6ISCU?^H'A?SNG_
M *D<%<Z6J_U8R=\KVY7_ ,)R_>-Z1@KRENHO8^R?^'>W['G_ $133/Q\4>.,
MC_RY\?S]J/\ AWM^QYT_X4II?'_4S^.<_P#J3X_(>GX^#0?\%;OV;M2U3PO!
MX=\'?'/Q-X7UNR^"NH>)OB#H_P /(AX2^%B_'GXC>(_@[X-TSXF'4M>L->T'
MQ'IWQ9\,:EX$\7^'++1-5U3P[J,4NH7,+Z1#+?+^HRN2Q4C!&>I&."!QP" 3
MTX_4USXKB3C?!\BQ7$'$^'=53=-5<XS&+?);F7*L7)IQYD^62B[-.SC)2>M+
MPZ\,Z_/['@?@FKR64^3AK)&DY7:_YEZWLU=76C5[IGPGXD_8(_9&TVP@N+7X
M+:0DDNKZ%:,Q\2^.''D7VM6-I<H!_P )./\ 66\\B!NJ[LCG%;__  [W_8].
M?^+):4.2!_Q5'CDYP2!G_BJ!CGJ.>O!KZB\:KG2;;D_\C!X7[]O^$CTL?S.?
MK77CH*R_UOXM=*F_]9^(4^>M=K.<Q3:_=65_K-]-7ZM]QQ\-?#MUJL7P'P:T
MH4FD^&<E:5U4Z/ VU_'2]['Q?_P[V_8]_P"B)Z5_X4_CG\?^9H__ %>]'_#O
M;]CS_HB>E_\ A4>.?P_YFC_]?M7VA14_ZW\6?]%1Q%_X>LR_^:37_B&?AS_T
M07!G_B,9)_\ ,)\7?\.]OV/?^B)Z5_X4_CG\?^9I_P#U>]'_  [V_8]_Z(GI
M7_A3^.>O_A4_I^M?:-%'^M_%G_14<1?^'K,O_FD/^(9^'/\ T07!G_B,9)_\
MPGQ?_P .]OV//^B)Z7_X5'CG_P":BD_X=[?L>_\ 1$]*_P#"G\<__-37VC11
M_K?Q9_T5'$7_ (>LR_\ FD/^(9^'/_1!<&?^(QDG_P PGQ?_ ,.]OV//^B)Z
M7_X5'CGI_P"%1^OZ4?\ #O;]CW_HB>E?^%/XY_\ FHK[0HH_UOXL_P"BHXB_
M\/69?_-(?\0S\.?^B"X,_P#$8R3_ .83XN_X=[?L>_\ 1$]*Q_V-'CD<<_\
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MRJ2IPA&I.K3C(7 7A:W9<%<$-W<;+AK)GJE%M:9=T4DV_ABE-RE%0FX_6_\
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M[?\ D9O'.,Y(P3_PE'?J>1D8Y/9/^'?/['?_ $133.N/E\3^.3P1G)_XJ<]
M>3^E<+_P4"_:<^-W[+'@73/B)\+_  Q\%=9\/VB:F^M1_%CQ=XKTWQ-\0?&C
M7>CV7P\_9_\ @AX+\$:/JNO>*?BQ\7KR[U:Q\/ZM<^9HOA>;2XKS4]&UBRGO
M)--^6],_X*2_M">)/B9!X?\ #7P)^&5QX?\ BWXK_:O^#_[./A[Q)\0M:\)^
M,(/B]^R'I?VWQO<_'3Q.=+UGPEX=\":_-HWCE+-_"^FZCJV@KX9T\3SZR/$8
METGKH9YQU7PZQ4.)L[]B^=<TN(,="2E3NY1DI8A6ERQG/E3DE3A-N49)4IY5
M/#_PRA4]E+@/@]U%RZ+A7)Y)J348R36!?NW:@WI:32MRMRC]O#_@GU^QU_T1
M33"<X /B?QQSQD'/_"3].O3T[]*</^"?'['AZ?!32CUS_P 51XYY(QD#_BJ.
M/QZ'\:_/?4?^"D7[6%O^R-XF_:C\/?"7X$^/?"WP@^+GQ"\&^/?'7@^]^,.H
M_#GXU>"?!NK>%M&TCQQ^S_%IV@ZIJVA>#-:U;7?$FF^*/B]\1-4N?AE\/[/X
M;^(_%DMYXE\-7UK=6O[CZ/?0ZII>FZI;R6\L&I6-IJ$,EI=P7]H\5];Q743V
MU]:EK:]MVCE5H+NW+07,16:)BCKG+$\1<;8-)U^)\]2=:K0_=Y_CZCC5HQIS
MG":6)4HRY*U.:4E%M/6,90G"%4O#OPTKMJGP%P?=0A4][A;)HJ4)N48RBW@+
M27-"2?*W9K>2<6_C]O\ @GS^QV.3\$]-'.,?\)/XXZ^@QXG.3QW(_&@?\$^?
MV.^?^+)Z9SG /B?QSDXZGCQ/UXQQV'?-<!^UQ^V9K_[,7Q__ &4_!%SH'A6X
M^#_Q?O\ XACXU>.=<OM3L];^&_A[08/#>B>%_$>@I;%=)DL7\<^,/#NG^*GU
ME"EIHUY)>6LD<L#N/S^M_P#@KQ\;;?X$>&_B'XD^%'PY\/?$WQ+X9_; \467
MPVDM/'%UIRV'[/OQ"^"&A^$;?4?$O]M6CZ-JT_A3XR6MQXSTNXTZ[-_XCMOL
M^@7.FV5A<_:^BCG''^)I4:]'B//I4\0KTO\ A?QO,_?JTVG#ZYS0<'1G*?-;
MEA*G4?N3A?.IP#X84IRI3X%X-4X-*2_U6R?=J#6OU"VOM(I-;RO%:QDE^H _
MX)]?L=$X'P3TSZ_\)/XY /T/_"4?C[T[_AWM^QX?^:*:9_X5'CCCV_Y&>OG3
M7?\ @L+^R=X<\0_%W1-1L_BG/:?"G3?B]?6OB#1_"NEZWIOQ*O?@)JMKH?Q7
MT;P+I^D^(KKQ'#>^&]5NW@MKSQKHGA#1->LM,U[6="U6^T;0]1U"'BO$O_!7
MWX>:$O[./C;_ (5/XXM?@=\8M _:/\3^/?B'>:IX%UNX^'FD_L^:+I5W=RZ5
M9>!?&7BO3O'">(]1UC3HM,/AK5=2O-2MM1TJVT?3[[5]0:RLQ9MXB.U\YXHC
M=I)SS?,8)OV;K<JYL:FYNG%N,%:4G>'+SIQ4K@/PL=W'@K@AV3;4>&LFE9*:
M@W=9<]%)I-ZI;WMJ?8'_  [V_8\[?!33/_"H\;__ #3T?\.]OV//^B*:9_X5
M'CC_ .:>O%M0_P""H_PPT74-/\#ZU\"OVEM*^.FJ>._#G@#3OV=KWP/X6'Q9
MNKSQQ\//'/Q,\ >(DA@\<R^#O^$.\5^'OAQXRLQK[>+0F@>)/#VKZ!XCM],O
M[&1:YJV_X+)?LA7^K_#"QLE^)MQH_P 1O"WP@\3:EXF'A2PALOAG)\>-0NM*
M^&'AOQ[HTOB!?%I\1:MJ5E/;:Y;>#O#WBVR\'17&EZAXHOM,TO5;2^<CG/B!
M./-#.>*IQM*5Z>;X^:<8I-R3IXZ=X.]H32Y:DKQIRJ23BK? 'A<GKP5P2M4K
M/AG)DTY/E2:>6III[Q=I16LHQ6I]'?\ #O;]CSO\$]+]#CQ/XYYR?0^*.WU'
M?M6%H/[ O[(6H6=S+<?!726>/6=9LXROB7QPH^SV6I7%M "/^$H(W+"BJ2,;
MF&X]36M^QG^W9\*?VXM"\:>(_A5X?\;:%I?@K5=,T^Y_X3>/PE9ZA?)JR7\E
MK(VD>'/%OB35?#VIVATZX@UWPOXRLO#GB?0+LP6VIZ1#+(57ZL\)'_B77IQD
M_P#"0>(R!U./[9N^V>OH<]O?CEK\4\9X:5:CB.(^(Z-:G.E&=.IG&8J<.92G
M9KZW*SE%QDE?9KYW#PX\-JSI3I<"\%SIRC5<9PX:R7EE;ECI_L*NE)2UMH[[
M'RS_ ,.]OV/ /^2*:8  3_R,_CC  Z_\S-7Q[^T#X9_X)H?LV>,HO GC_P"
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MN)Q&)EEF,PN*PN&KQP&(HX?#?85%%%?.GZ&%-)&2,@8!Z]N!S^ SGG]*=2$
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M  N#]JS_ *-!;_P^_@3_ .5=)_PN']JS_HT$_P#A]_ G_P JZ?\ J]F/_/\
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M]IEK+X1^(^H^$-4\36[I9212"_>]\#^'Y=.U2.2*]TT0W M)4-S*Q\C\<_\
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M^+=!TWP]#<Z=;QZ7;V%UX6\.ZAI8LKW3A-+ZN/C'^U8/^;0"?K\>/ 1Z]/\
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M5^TTWC#X]7+6K7'["GAJ=[&/4(K$S?%KX5S-91:K/]JU6*T\SP^QM8M3NO\
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MEB,7BJK]G1I<\X4X>[4JU:LX4</0Q%:I"D?19WGV7Y!AZ-?'.O.IBL1'!8#
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MSE*;BG)Z22C%)7;;;26O^D__ ,/'/^"?V3C]M/\ 9=!ZD_\ "\/AZ>0".^O
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M''X*^.M2^*.O_M>6Q\9W5U\(/$6D>/=/\&-HUU+IOPNUFS\;ZE=^ M"T;7-
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MS\%_B'K7CC2M9M[)O 'A;Q/H'B%YG_$$_"3XN'_FC7QAZ<#_ (5!\2\?B?\
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MK7AW3FF@U31-3LKJU\^VGM7CE./B+QY_P1^^ GQST[P9I'[3WQ0^._[1.E>
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M_P#*^NRQGN1CI@G]<^^:;@ X+D'TW<UXG-37_+J?_@R__MB/K%&K_P _(_\
M@K_[H<?_ ,)YX:_Y[:G_ ."/7?\ Y7T?\)YX:_Y[:G_X(]=_^5]=A\O]\\_[
M0H( _B/4#[WKC_'-'/3_ .?4_P#P9_\ :!RU?^?D?_!?_P!T./\ ^$\\-?\
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M/^>E_P"%<?\ YF#ZU5_Y\X[_ ,-W_P!^GMO_  G?AT?\O.I'_N :U_33J/\
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M/^>C_P"%<?\ YF#ZS5_Y\X[_ ,-W_P!^GMW_  G?AT?\O.I'_N :U_33J/\
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M+]FMIIE.:G_SZG_X,_\ M Y:O_/R/_@O_P"Z'OW_  GGAK_GMJ?_ ((]=_\
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M:3ERI_EK:?L@?%W7_#]IXL^'EWX"^+_AC5O"7C#Q9H&L?"C7]8\4KXC;X?\
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MO+?4-1FUBX:V2*W:"SE?*N[+^K_Y_P"0O=VT]-/\C\G?'W[%G_!1/6+SQ?\
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MPOD+1117/==U]Z_S/4"N,\;?\@ZP_P"QE\,_^GBUKLZXSQM_R#K#_L9?#/\
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MX[:)O%\NMZYXMU2>R;[/HT+K+_@B5^SCXE^-NJ_%KP]^T-;^(K_QU\1OBO\
MM ZKX./A;P3XIT@^$_C1\;_%/QY\ 7'P_L;'Q!#;>'+3P3XX\1ZA%X?^(<FF
M>(8/$%A902:1:Z#KMLNM1^@_L:? G]H3QQXP_P""B6E_$/QY\7KGX*:9+\3_
M -DG]CZ7XM7GQ&6W\0> /%VH^+?BAXS^(VL^&?&US%>^+8_!?C/XG67P#\%_
M$"YM);_7? ?P8 TO6+W2=4CGF_,_QO\ L;?\%$OA!\/_ -FC49OA#<>'-<\
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MQA1U=K]EXFIQQ+JY!&4VH1Q#>31<Y3DZ2@JWLDI.I*]*,%-N<DX13DK&?MO
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MQ?\ ZVPE@UQ1]6FO88MX-T%A90WH?6(R^KJ'O:4G[Z>CTZGZ3X:/P\J+-/\
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M1^USXX_:^)R?@!\&\_\ 9PNMC^7P<KZJP?1/R-&#Z)^1H^L4_P#H#POW5_\
MYI#ZE7_Z&>8K_M[!_P#S"?*G_";_ +7O_1 /@W_XD+KG_P YRC_A-_VO?^B
M?!O_ ,2%US_YSG^>:^J\'T3\C1A_4#_/TH^L4_\ H#POW5__ )I%]1K_ /0S
MS'_P+!_I@3X;_P"$"_:,^)7QM^$OQ+^(_ACX3_#[PO\ !&W\;ZIX?\/>'/'W
MB/QQK_C#QCXX\/-X1:?5-4F\$>'+#P_X8\/Z!<ZG<+:6]KJFJ:WK-U8DSZ59
MZ?,E]]9B;QOC_CQ\*'C.?[6UG!]P#HN<#C//J2>:[(+@DYSGMZ#\<GGJ??/M
MAV/\?QZ?RK*I7E5=.]&A3A3@X4X0@^6$7*4W\52<FY3G*;<IMMM;))+7#X*.
M']LU7Q-2I7J*K6JU:D7.<XTX4H_!2A",84J<(1C"$8I)O64I2?%^=XX_Y\/"
MG_@UUCMU_P"8+^7]:/.\<_\ /AX4_P#!KK'?I_S!>W?^E=I14<W]RE_X+7_R
M1T^S_P"GE7_P/_[0XSS?'''^@^$_?_B:ZU_30_\ '/8US?BJ3Q>=/LOM=EX9
M2+^W_#S1M;ZGJSR&X&K6OD!EDTB,+$TH597#,Z1[RJ.P"GU?_/\ C7&>-<C3
M; #C_BI/# /T_MBTSC/KT_\ KU=*7[V'N4_B_D_NSUTE\OF95Z?[JHO:5=8_
MSWZPZ. &?QP,_P"@>$L9/75]:(!ZG&-%Y!/H!SGV%)YOCC_GP\)]AG^U=9ZC
MD==$!P#ZC\:[!.IZ?>DS],C_ .M4E9*6W[NE_P" :]/[QI[._P#R\JZ?W[+[
MN7S.+$WC@<BP\*CITU;6<X'K_P 27KG\QU&.:/-\<'/^@>%,G@YU76/Q_P"8
M+T_3/<UVE%5S?W*7_@M?_)#]G_T\J_\ @?\ ]H<7YOCCK]@\*<?]176,X/\
MW!>OK_(4GF^.,$'3_"F#P1_:NL8/KQ_8G0C@?UZ5VM%'-_<I?^"U_P#)![/_
M *>5?_!G_P!H<7YWCG_GQ\*=,<ZMK)..P.=%['D_TZT>=XY_Y\?"G/\ U%=8
M_'/_ !)>_;^M=I11S?W*?_@'_P!N'L_^GE7_ ,#_ /M#B_-\<?\ /AX4]/\
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M#1/'VE>%[SP[J6@^(/!&KVFM67B;^SUOQ<:7_P (W<ZU+?PQ'P_X%?&?Q!\
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MDWD#M\LQP_Y7W\_4_1VBBBOPH_KT**** "BBB@ HHHH **** "BBB@ HHHH
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M;\7L@-^TO\+45B \@^%?Q6F* L-T@B#0^84'S>698A)C8)(\[Q_2[^RW\/O
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MK=O^TWYCM^'_ .OO2X_VC^G?\/\ ]7:CFI?\^:G_ (/C_P#*0Y,1_P _H?\
M@C_[L<C_ ,)UX<_Y[:G_ .$]XA_^5='_  G7AS_GMJ?_ (3WB'_Y5UUV/]IO
MT_PI-O\ M-Z=1_A^O6CFI?\ /FI_X/C_ /*0Y,1_S^A_X(_^[G)?\)UX<_Y[
M:G_X3WB'_P"5='_"=>'/^>VI_P#A/>(?_E7778_VC^G^%)M_VF_/_P"M1S4O
M^?-3_P 'Q_\ E(<F(_Y_0_\ !'_W8Y+_ (3KPY_SVU/_ ,)[Q#_\JZ/^$Z\.
M?\]M3_\ ">\0_P#RKKKL?[1]>W^'Z=*,?[1_3M^'_P"OO1S4O^?-3_PHC_\
M*0Y,1_S^A_X(_P#NQR/_  G7AS_GMJ?_ (3WB'_Y5T?\)UX<_P">VI_^$]XA
M_P#E776[?]IOS'?\/_U=J7'^TWZ=OP_/U[T<U+_GS4_\'Q_^4AR8C_G]#_P1
M_P#=SD?^$Z\.?\]M3_\ ">\0_P#RKKE?%GB[0;O3[)()[\O'KWAZX;S=#UR)
M=D&K6TCX:;3HU=MBL5C4F20C;&K.RJ?5]O\ M-^?_P!:N.\:$C3+##-C_A)?
M#'?G']LVA'Z@?CCO6E*5/VD+4Y_%I>LGTEO^Z5_R,ZL:WLZG-5BUR_\ /E)[
MQV?MG;[A!XZ\.YR9]2 R<'_A'_$(S\W(Q_9>>@R>V3UJ4>.O#9Y$^I_^$]XA
M_P#E775@DDC)ZMC'& "1Z>@X]^^22'X_VFZY[?X=/;\ZR4J5OX4__!Z7;I[%
M^IKRU];58*S?_+F_GK^]1R/_  G7AS_GMJ?_ (3WB'_Y5T?\)UX<_P">VI_^
M$]XA_P#E776[?]IOS_\ K4N/]H^O;_#].E/FI?\ /FI_X/C_ /*1<F(_Y_0_
M\$?_ '<Y'_A.O#G_ #VU/_PGO$/_ ,JZ/^$Z\.?\]M3_ /">\0__ "KKKL?[
M3?I_A2;?]IOS'?\ #_\ 5VHYJ7_/FI_X/C_\I#DQ'_/Z'_@C_P"[G)?\)UX<
M_P">VI_^$]XA_P#E71_PG7AS_GMJ?_A/>(?_ )5UUV/]H_IV_#_]?>C'^TW?
MT[_A_P#J[4<U+_GS4_\ !\?_ )2')B/^?T/_  1_]V.1_P"$Z\.?\]M3_P#"
M>\0__*NC_A.O#G_/;4__  GO$/\ \JZZW;_M-^?_ -:C;_M-^=/FI?\ /JI_
MX.3_ /<(<F(_Y_1_\$?_ '<Y ^.O#AQ^_P!2^\#_ ,B]XAZ9R,?\2P<GC\,\
M&N>\-^,-"M;.[CEFO\OKFO3+LT/79@8YM6NI(R3%IKJI9&7<A(>)BR2*'! ]
M/QCN>OKG@].,>O;![]>W+^$R3I]]ECQX@\1\D]<ZU>#D]\ _@>IST.:CR5+T
MY[TUK5\Y_P#3I>=^Y+C7YZ=ZL=JFOL4ND;_\O7?==>A$/'7AO_GOJ9]/^*>\
M0G_W%TO_  G7AS_GMJ?_ (3WB'_Y5UUI7W;\\<?D?\]Z-O\ M-Z=1_A^O6ES
M4O\ GU4_\'I?^X65RXC_ )_0_P#!"_\ EQR7_"=>'/\ GMJ?_A/>(?\ Y5T?
M\)UX<_Y[:G_X3WB'_P"5===C_:;]/\*,?[1_3M^'_P"OO1S4O^?-3_P?'_Y2
M')B/^?T/_!'_ -V.1_X3KPY_SVU/_P )[Q#_ /*NC_A.O#G_ #VU/_PGO$/_
M ,JZZW;_ +3?F._X?_J[4N/]IOT[?A^?KWHYJ7_/FI_X/C_\I#DQ'_/Z'_@C
M_P"[G(_\)UX<_P">VI_^$]XA_P#E70?'7AP?\M]3'U\/>(?_ )5UUV/]IOT_
MPI-ONWY__6H<J=OX51?]QT_G_!!1Q&G[Z#UU_<=.NOMG^0D;^8JN!\CJ&4\@
MLK#()4@,I(Y*L R]",Y ?30N"3D\D\9R.?;''X?B33JS5];VMT_X+Z_+S.@3
M/^<']?3\:A=FW<$C  *X/).['S <\#(Y/X<FFS,%(8OL 4EB6" #K\YSP%QN
M)QT4@DYPWY]Z6OCS]LS6_$&LKXT\5_#3]EOP_K^I^&_"UGX"U>X\-^./CMJ6
M@7MQI>N^*=3\86++J_AOX:0ZI;W.G>'-.\.W%EJGB/[++JUWJ45@]K;2^IEN
M6?7XXK$U\52R_+L!&E+&X^M3J5N25>4X8;#8;"TFJ^,QF*G3JJAAZ4J:4*-;
M$5Z^'P]&=67S6?\ $/\ 8]3 8#!Y?7SG/,WGB(Y7E.&K4<,ZM/"4Z=7'8['8
MW$J6&RW*\!3K4'BL;6A6E[7$8;"83"XO&XBE0C]_K="0E$<%QDX!4D '!SAL
MCIN!(X!YR.EQ6!4'H,9Y/;KU/L17Q7<_L+_ :*W\SPG:^/OASXAA4-IWC3P1
M\4/'^F>)]/NXBKQW7VF\\07]EJ2"55GGM-8L;_3K^1 ;VTG0LAO?!7XB?$3P
MI\1M6_9M^..KP>)O&&G>''\9?"WXHVUBFDQ_%CX>VMW'INIG7-.@86%C\1/!
M=]-96_BJ#3=MEJ5EJ6FZY;6UM'<S0KT/*L%B<)B<5DV95,=4P-*>(Q> Q>!>
M QL<'3E"-3&X90Q>-PV+H4.>G+%4X5:6*PU*:Q$J5;#QK5*/FT>)LVP.8X#
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MUJW;_@'_ .OO29\8_P!WPW_WUJ_?_@'_ .KM1;^_2_\  _\ [0/:2_Y]U/\
MP!__ "9U%%<QGQC_ '?#7_?6K]O^ ?GZ]Z,^,?[OAK_OK5N__ /_ -7:BW]^
ME_X'_P#:![27_/NI_P" /_Y,Z>BN7SXQ_N^&_P#OK5^W_ /_ -?>C/C'^[X;
M]/O:O_\ $?KUHM_?I?\ @7_V@>TE_P ^ZG_@#_\ DSJ**YC/C'^[X:]?O:M_
M\1^G2DSXQ_N^&_\ OK5_7_<_7^E%O[]+_P #_P#M YY?\^ZG_@#_ /DSJ**Y
M?=XPS@CPUZ]=6/\ [)C'MGWH#>,".GAK.!WU?&/KMR#U]_6GRO\ GI?^!_\
MV@<\O^?<_P#P'_[<ZBBN6W>,/^I9[_Q:MW]]O]/ICK1N\8?]2SV_BU;M_P !
M[_\ Z\TK?]/*/_@Q?_(![1_R3_\  ?\ [<ZFBN6W^,/^I9[_ ,6K=_\ @'^>
MV*-WC#_J6>W\6K]O^ _Y[YHM_P!/*/\ X,7_ ,@'M'_S[G_X#_\ ;G4T5RV[
MQA_U+/0_Q:MW_P" _P!<^A%&_P 8?]2SUS][5O\ XC_ZWM1;_IY1_P#!B_\
MD ]H_P#GW/\ \!_^W.IHKEMWC#_J6>G][5_7/]W_ .O[XXI=_C#_ *EGK_>U
M;TQ_<_\ K>V>:+?]/*/_ (,7_P @'M'_ ,^Y_P#@/_VYU%%<MN\8?]2STQ][
M5_\ XG_Z_O1N\8?]2SW_ (M7[_\  ?\ /;%%E_S\H_\ @Q?_ " >T?\ )/\
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M1:G^6)8?Z^-?\RU::O\ VEZ+O?V27XZ[)'^O_P#\)1X9_P"ABT+_ ,&^G_\
MR11_PE'AG_H8M"_\&^G_ /R17^0 [/&-SWEZJYQE]4U!5SZ FY&>/?/Y4!G<
M!EO+YE(."NJ7^"<]F6?GJ.X&.!ZD_P"(&WVXD7:ZRQ-7ZJ_UAI-=;VMZZ#_U
M\VMEJ>W_ #$M[];*DW:W7;I<_P!@NVU33=129M-U"QO_ "=HF-E=P77D^8&9
M/--N\GE[PC%=Y7<%8@\&N<!!\<J5&<^$7(]#_P 3J,G!'8\$]Z_R=/@9\>/B
M]^S;\4/!_P 7?@O\0/%?@;QMX3\0:-J5M>Z1XAU>"SU:UMM1M9+SP[XDTW[5
M]BU_PWK=H)=,UC1]3@N+2YLKF4!%E$<B?ZN_A[4)=5US0=6GCCAFU3X<Z?J,
ML,._R8I;Z\M+F2.(.2WE))*PCW,S[1\Q).:_/^,^!Z_!E?"*6/IYA0S##8MT
MJD:,L/4A/#NA&I"I2E.I&6E6$H5(32EK%Q35W[^39[3SN%1K#RP]7#5\.IP=
M158RC5]JX3C)1@U9Q:E%IM/5-ZV](JM=WMG80_:+^[MK*WWQQ^?=SQ6T/F3.
ML44?FS.B;Y9'6.--VYW944%B ;-?G#_P5-_99\6_ME_LNV_P%\(V,M[+XB^,
M_P $M9\0RP:_!X;N='\)^%?B!I6O:YXCM=2GD0&Y\/16<6L0V4*W%U?-9_9[
M>TNI'$$GP:_JY](?H)<^)/#UG.;:\UW1K2Y%U%8FWNM4L;><7D\<4T%IY4LZ
MR"ZFBG@EBMRHFDCFB=4*R(6T&OK)+M=/>\M5OWMI+U+$SQ"\>SADCAFNTM=_
MGM;1331123K&8DDEC1G#.H/\>^L?\$R_VR'_ &@U^/7Q^_8KT;]KD?%W1/B;
MXR^.GPWM_BU\*O\ A&[;X]?%_P"".C>$+>[\/W'Q#\2:5:Z5X9^&^MZ+I?A3
M1O%.@6MOK?A[3=,M?$?ANQ>9-A^@_P!GK_@GO^V_\ OVK/V4?B1XT^'VG_&?
M7O ?@;]GW2_VA?VCO&7Q(\->-M#N](^$7[+U_P#"_P 6W?P@GN7\(_M#_"WQ
M[>^*[QM D^$VF_\ "P?V>_C';$_%GQI8:#XWNKV.U8']0US>6EDB27EU;VD<
ML\%M')<SQ0(]S=2K!;6Z/*R*T]Q.Z0P1*3)-*ZQQJS$"F?VCIX6\<WUH$TX$
MZBQN80NG[8%N6^W,7Q:;;=EG;[08\0L)3\A#5^!/_!1_X!?MM_\ !2_X1?LK
MZ-\'/A=IGP/T&'X=>//VC_&NC_';Q]J7A+Q%\/OVBH?!=AH?[-WA&*3X77&J
MZX_C[X8^*O%?B#XF_;)H#X$_M'PCIECK&HP7<UM%7.:)\,/V[=2\-_\ !2WP
M%XP_9 \86GB#]OKX83:[H7CS2/BU\&Y? 7@+XC:I^PGX/^%VL^#-4LY?'J>+
MK4)\9/#^L:#I^JZ3HUYI4MI?:;KDMY;V9N[N, _HC1TD1)(W62-U5T=&#(Z,
M 59&4E65@058$@@@@XIU?GO^R;\9_CJFE_ ?X(_%+]CGXP?!R2Q^%=WHFM^-
M/$GC'X3^+_#>A7WPK\+_  \TJT_M2Z^'OC#Q0R1^/;[6M7M_"[RR0W<DOA36
M'O;*WADMI7_0<\ X[#_]5 '(^,\'2+4G _XJ#PN23C(_XJ+2\#Z'MTY_$5Y;
M^T5^U%^SY^R=X'C^(O[1?Q9\'_"3P==:A'H^G:IXJOVBEUC6)(I)TTGP_H]I
M'=:SK^J-!')<-8Z/87MPEO')<2HD*,Z^H^-,#2;8') U[PJ.F<Y\1Z;C_P!!
MY_SC^#?_ (.;/&'B?6_^"A?A+P?JFLWMYX6\!?L^>#[CPEH+S2C3-$O?%NO>
M)[SQ)J-K9JQ@&J:T]AIL-]J1C^V3V6G:=8O*UK9P1I]9P9PW#BK.,'E%3$SP
MN'E#'8FM5IQC.JZ6'C0DZ=%2]Q5*DIPBIS3C&/-+EDTHGA9SF;RG#8G&1I*K
M47U:E3A)M0<ZOM4I3L[\L5&3M'5M):*[/ZAO^'Z7_!*0 9_;"\'CK_S)_P 3
M1GCH ?!)('3'ZFD_X?I_\$H_^CP_"'_A(?$S_P"8BO\ -:^8G&T\?[WZG;R>
M?K1A_P"[_/\ ^)K]J_X@GPVO^9EG.R?Q8#M_V#GQ#XXS&[_V7!/IM7_^6:>A
M_I2_\/T_^"4?_1X?A#_PD/B9_P#,11_P_3_X)1_]'A^$/_"0^)G_ ,Q%?YK6
M'_N_S_\ B:,/_=_G_P#$T?\ $%.&O^AEG/WX#_YF#_7?,?\ H$P7W5__ )8?
MZ4O_  _3_P""4?\ T>'X0_\ "0^)G_S$4?\ #]/_ ()1_P#1X?A#_P )#XF?
M_,17^:UA_P"[_/\ ^)HP_P#=_G_\31_Q!3AK_H99S_X%@/\ YF#_ %WS'_H$
MP7W5_P#Y8?Z4O_#]/_@E'_T>'X0_\)#XF?\ S$4?\/T_^"4?_1X?A#_PD/B9
M_P#,17^:UA_[O\__ (FC#_W?Y_\ Q-'_ !!3AK_H99S_ .!8#_YF#_7?,?\
MH$P7W5__ )8?Z4O_  _3_P""4?\ T>'X0_\ "0^)G_S$4?\ #]/_ ()1_P#1
MX?A#_P )#XF?_,17^:UA_P"[_/\ ^)HP_P#=_G_\31_Q!3AM[9EG-_\ %@/_
M )F#_7?,?^@3!?=7_P#EA_I2_P##]/\ X)1_]'A^$/\ PD/B9_\ ,11_P_3_
M ."4?_1X?A#_ ,)#XF?_ #$5_FM?-D @#J!G(Z?\!&?<\\9/.*[?2?AA\4O$
M'A74_'?A[X7_ !(\0^!M%^V?VQXU\/\ @3Q5KGA'2?[.5'U'^TO$>EZ3=Z38
M_P!G(Z2:A]INHOL,;"2Z\J,[JSJ>#/"U%*5;-\THQ<HP4JM;+:47.>D(J52E
M3C*4GHHQDY-Z1BWH5'C3,YOEA@L)-I.5HPQ$GRQ6LK1G)J*NKR:45?62/]&[
M_A^G_P $H_\ H\/PA_X2'Q,_^8BC_A^G_P $H_\ H\/PA_X2'Q,_^8BO\V?4
M=,U31YK>VU?3;[2;F\TVPUFTM]3L[FPFNM&U6W6[TK6+6*ZABDN-+U2T9;O3
MM0A5[2^M62XM9I8F#5G>:FT,'C*DD*PD&"PSD [>>QXR<'IWK2/@IPU)*4<S
MSB46KJ498"2:ULTXX:47L]F_A?9V3XVS).SPF"4M?=:KIV7DZE^VC2>J=K--
M_P"E3_P_3_X)1_\ 1X?A#_PD/B9_\Q%'_#]/_@E'_P!'A^$/_"0^)G_S$5_F
ML;@6*94NH!*A@6 /.6 &1^(_*M2#1=<NK*VU*UT/6KK3+W7!X7L-3M=)U"?3
M;_Q.T4%POAFQU"&U>TO?$1M[JUG_ +#MI9M46&[M)&M52Z@,BEX+<,P2<\TS
M>*;23<\OC=M-I+FP\;OW962;;46TFDVA<;9FW[N#P<FE>T8UVTGUTFW:^FMM
M7Z7_ -),_P#!=3_@E$ 3_P -A>$#@$_\B?\ $TDX&<8'@G)Z8 ')S@<XK]#/
M@1^T%\%?VF?A]IOQ4^ ?Q-\(_%;X>ZG=7=A:^)O!^IIJ%G%J5@=E_I&I0$)>
MZ1K-B9(C>:/JUM9ZC:I+%)-;(DL3/_DZZMX&\=Z#HUMXE\0>!/'&@>&[W6-1
M\.V'B37/"'B+1O#=[XAT>22+5M#L]>U#3+;2+O6--FM[B&\T^WO)+F":UNXF
MC\RUNEB_IE_X-6_%_B2S_:B_:C\ 6NLWL?@S6_@;X9\:ZIX;$TC:9<^+="\<
MVN@:7X@%LS"./5(=%UF_TR6Z1!+<V;P13NZ6MN$^6XL\+<HR;(,=G649KB\1
M/+U"=6G7EA*U"I3]O"C6@IX6SIU:<JL9)OF6DJ<X0;37K91Q9C,9F.'P6+PE
M*$<0W"$J:JPG!\DYQFU5DU.$N7ET5_>4HR<8L_N,HH'045^)+9>B/O0HHHI@
M%%%% !1110 4444 %%%% !7%^-?^0;8?]C+X9_\ 3Q:]O\GUKM*XSQM_R#K#
M_L9?#/\ Z>+6KI_Q(?XO_;9F-?\ A37]V_XP.O7()'J78_0M@?C4E1IU/^])
M_P"A"I,_X_Y_.LHK3^O+8U77^NP57:ZMEN!:&X@^UF$W(M?-3[2UNKB)IU@W
M>:81(PC,H3RQ(0A8,0*L5^6'QUT#]H?X>_\ !1KX:_M(_#K]G+QM\>OA=>?L
MC>(O@%XBN?!'CWX8>&+KP7XOUKXZ>$?&L.KZOHGQ%\8>%IM4TF'PSIM_</=:
M!'J%\KPFT6&22:.)J&?IW!K>C7,MK!;ZOIEQ/>B^-E#!?VLTMV-,F6WU(VL<
M<K/<#3[AT@OC$K_9)G6.X\MV"FS>7]CI]M+>W]Y:6-G %:>[O+F&VMH5D=8X
MS-/.T<40>1TC3>PW.RJN20*_DAUO_@GQ_P %6]*^)NI?'3P+-K7A?QYI_P *
MYOAQ<:OX=\?_  ]A\2W7PQUC_@H1\<?BM\0/!'PITC3M<\(:1X6^('B;X ZO
M\+-5A\41^)_ ]YJP35_#VH>-K'Q)(SV_Z1_M!_LQ_M.?$'X*?\$]];^-GPG;
M]N.Z^!&@^+&_:F_9M\2>(_AYX+O_ (Q>.?&7P@F\$>#_ (B:KINI>(3\%/%7
MB7X7^(;G49-5T[4O$$VCP7/BK5_'/@N6XU[0=&MY #]Q2<=??CV! SZ\=_KW
MXJ$W5L+@69N(?M9A-P+3S8_M)MU=(FG$&[S3 DDB(TH4QJ[*I8,0#_,5XL\'
M?\%,4^)UE^RO^RMXY7X+'P=^PSX:^,NO?"+0?B%K?Q \ ?L\?&OPI\/?'/PC
M^'7[,GAKXX?$3P--=^(-!^*-_P"+?"7Q+L]=\0:C?W5CXE^#-[K.HZ*/!UY'
M#J%;XM?LH_\ !4#6=8\+?%?]GR#X]_#_ ,3Z?\#M2^&?B35?CK\>?A/\3?VC
M9_AK??MA?#;XC^-?AWX<\8^$-7\+>&[?QMXG^$GAW6;GP#?7'B>QU'P_8QW/
MA?4?BKI.NZG8WUB ?U!A@3@$''O_ )]_R]#FG5\Z?LD:'\9?#?[-?P5T/]H;
MQ!JWBGXV:5X T.R^)'B#Q!!X;M_$&I>(H86$KZ^O@_4M9\+2ZW#;&VM]7O-"
MU;4;"^U*&YO(;RX$YD;Z+!!Z4 -('''4Y_+G]<8-<MX3)&GWIP/^1@\1YZ=M
M9N_UP,=_Y5U)."/J/U! KE/"O_(.O?\ L8?$G_IYO*3^"IZTG^,S*7\2'DJG
M_I,3K:**#T/...OI[TS4J7DRV\$LSAV2%7E98XWDD98XRQ6-(U9Y)& VI&@9
MY&8*H)P*^3(?VDO ?Q@\8?$;X"?"#QUJNC?&/P'\/_#'C[Q-K-[\.M<U'PQX
M!L_$6L/#I^@>)-7U>TLO"%OX[N[*QNIKWP-=ZTGB;1='NX-?OM-AM1&S?47B
M)G31=7>&.:>==-OI(K>WOH]-GFE2TF,44.HRE8M.EE<+'%?RL([*1UNI"J1,
M:_GI_8;^/OB_PGX)\0>%/C9JO[-'[/WPSTCX@_&3XH?'0:?>?\)E93> 6M[Q
M]5\#>(?B;XEU":7XL7VD6\%W/\7OVF[FWT_P1?>*+U/AOX)?4)-*2)NW!X6A
M'#YCG6-S'#8/!Y<LNPT*>-AAZ6#>8YEF5'#8'VV*K.M5KU\;5=+*<MR7#8.=
M3,<?F%&I.O1I8>HCP\YS?"X)4\KJY7G68XS-W"A@8Y#4C/%TDZ\:6.Q.*P\*
MN&Q6"RO 8%U\QQO$$<5A\-E<,*Z564\1B<#1Q/;_  5_X*4?%3]IW]ISX4?#
M3X>^-? GA#X<:7\:?%?ASXHZ]HO@G4/BSI7QJN?#'AC4H-6^#O[/OC/2A:6M
M]X-^&VOQVUW\8/VC[_3;7PCIOB62#P=X7U#4FCN(;C]](<!0<8Y;OD=CG.3D
M<<9Z]>O7\V/V)-=_9Y_:>^$WPZ^+GP'^"%]\ /A9\,=9N?"GP&M-)T72OA7K
M7B'X2:2)I=(_M#P-HEM9ZOX9^%/C2YOV\6^'O 7B1;-=?L9M%\:W6EH]]:.?
MTIC5E7#,"1GGZXQG  R !]>3WHQV$R[ 0P.78'#XW#RP-"O2QJS''3S+%U<7
M6QN*QLJM7&S<IU6J>-A2C2E)_5(4:>"A&%+"4XOT<-B_KSK8N-#$THXBK*MS
M5HTL-0YI?NI4,MRQ8/"XK+\LPD<'3I87Z_5QV-S%UZ^:U,7.EC*$5+03@$GH
M.3144\L<,3R2MM11\S<\#IQM!.<D<8]3T!KAMTBM7LDNNR_R.IM)7>B6K?;]
M+=[CF8!0P( [$GCDC@?7IVQ6<Z7GVUI/.C^Q>7M6,#Y_-)'?&2"<Y.[;@[=O
M))@O7LG>RDENC%OE#6^UN)BVP@<Y^7.U2V!]\C@GF#_0?[:>3[:XU#[,5:TW
M901[<AR .?EPXC!R =Y W5HHM1DVI:TJC:]FY6<6HNTKJR6MZEDHO<YJE52D
MHKELJU*/,J\8.TXR:O&S<NB5.S=1.\=%=XOQ2X^&OQ"[X\">+_J?^*?U"OG3
MX7>"=5^(7['/P%\,Z/\ $3QQ\++Y_AE\!]:_X3'X=2Z-#XHBMO"]MX1\2W^@
M1/KNBZ_8-I/C"RTF?PKXDB_LYKV?P_K&IPZ7=:?J4EKJ%M]%_%+_ ))K\0O^
MQ%\7_P#J/ZA7FO[+K%?V9_@ 55G9/@I\-6$:;3)(R>#-).V/<53S&QA-Y5 S
M*2<"O9@W'AJ;6ZXHP[7PO7^P*^EI)QU5_B32W>R/DJJOXBX1/KP!F*MK_P!%
MC@-?=:>EKZ-/[V?C%^P5X@_:J^*WQ\^&GQEBN/\ @IEK_P"RWXKUGXDZGI'B
M?]H#XM_L5-\*+_PZ-/\ &&EZ%-XN^$_@3PCIGQPTR!==M[6UT#0$O(->T#5X
MM)?Q4&M++5HF_5GXZ_\ )P_[&/7_ )*%\3\DX&3_ ,*F\0_3/7T[5_.W_P $
MW;[X$2_MR_ #QGX3^#W[)=GXP^,_B#]I*^3X2_!;XD?M!ZQ^U!^Q5J'A?1?%
MS:IK?[2OAWQI\3-<\&78\2+-?>"?'LFL^ _";:5\3/&F@?\ "&KK%C-+?1?T
M2_'8$?M$?L8@\D?$+XGY/J?^%2^(N?RZ^^17T->#I\103I0I1_L'.8PC",(O
MEADN<0M4<(4U4J0G&5.=94U3KN/M:,JE&<*D_+XH<9<+0<9.;_UIX0<I7;C>
M7%O#L[Q3;Y8R34E!RE.G?DJ*,XN*^Q(?NGZ^W]U?\C]>:_R)?BMD_%KXOX _
MY*]\4QGOC_A/_$7L?P[=,CC%?Z[$) 0Y_O?T4_D.N?09K_)F_:Y^&OBSX#_M
M1_M"?"GXFZ>?#?C#PM\8OB(;JSU)9+%+_2]8\6:MK6A>(-)-ZL#:AH.OZ-J-
MEJ>D:G;A[6]M+A&BE+*Z+]AX'U(+,>(:;G&-2I@L#*G3;7-.-+&U_:2C&]Y*
M'/#F:7N\\7*R=UV\=1E]5RV2C)QC7K1E)1;47.E!QNTG;F496O:_*[7>AZ3^
MPYX;\)>*/B_\1-.\;:1X;UG1[/\ 9)_:^\16L7BNRL]1TG3?$GAWX%^*-3\-
M>(X;2\4AM8\.:O#!J^BRV@&IPZA:Q/IA%X(S7Z*:-_P3>_9JG^)G@CP)XCE^
M+G@WP7%\6_!'P^\-_%W5?BEX.OM(_;F\#>*/@GX\^)'B3XI? >RB\-6EK\,;
M7P#J?AK0;ZXVWWC7P\?#NOVWAKQ3=V?CPS6*_@V-3TT'*ZG8H1G#1ZC!&V#U
M!9)U8JPP&3)5ER&!7BF)?Z7&8ECU&QC6)'C@\O4H46VBDD,LD=JJ3J+1))"7
ME2V$2NQ+.&))/[5F62YEB\;4Q6#SS$9;&M1HTIT:,6W>E&JG4C+VG*ISA4<)
M<\'"$?WE-/$PHU(?$8;%X>C1]E6P4,3.,Y3C.;=K2E!\KBXMM1Y>:T?B?N/]
MW*2?[4:9^Q#^S'\8?!?PYU+X.Z1\4O!WC3Q]X#_X)]?&4:#XU_:"^'VKZ3!H
M7[8_Q*\?_#?QA\'+/7-<\ ^%;32]8\ 6GP\G\6:;\3/$"W5[<:CXBM?#NH>#
M$L+?3EU'Z.D_8#^!WA3P-\2;+P]^SC\5_BOJWQ!^'7[-'C&V^".G?%*QT?XS
M_#?68?VG/B;\,/'5SX2^(_Q!^%VB^/K'1I_"=AHOC/QMX<O?AKHVJ/IEHJZI
M)8^#-^IV'\Y<FHZ7*I1]1L61@J^6VIQ,FV-@T2[//"A(7"O;J!MMW&^ 1OS1
M_:6GY+?VM;[Q*\_F#6!YGGS*Z33^9]IW^;*KR":7)DE#R;V;S'+>37X6SZM[
M.#XMQCIPG[3EJQK.<IJM&M34ZM'%4JC5-TXJ#CRRB^:-YTZE6$^NEF>"@IMY
M12YYZ.46K1BX2A)*,H5(WM4DW?1VC>SA!K]I/V4?V>?A9X(_:C_:K\+>&_&O
MPZ_::T[X>_!;]K'2_A5X=\._#[P]\:?BN=>\ >(O#6D>"O&MC\*?B)X=L/@[
MXM\87$0O8?#UII?BW6;+4IY+N\M4M+.<+%\V?\%'O!OAWPI\7/A%?Z#X)L/A
MU?\ C?\ 9D^%?BSQUX-G\$>&/A1\0+#XA?:_%&@^)M4^+7P<\#7=]X#^%'C7
MQ"='LM4M/"WA"6#2KWPE+X>\27-K%J^M:DS_ )W)JFG1A1!J=C;"-0L;6NIP
MVS(HX"1O!/&Z(% 78I"X !' H.J:;ODD;4[)WD)>66;48)II6 5 \LTDSRRL
M$0(ID=B$14&%4*/3PG#^,H9W3S>OFT\7RX*.%J4I451E6Y</&BG*-"JL*HJ:
M==/V3JRJMN33DY'+5QL)X2>%AA8TN:JZD9<[J*'[R4M'./M=8M4^5S4(P6C=
MN4OK_K+<@ 9NK3(X'6ZA/IU_+C\A_K@^"_\ 7>#_ /LE.@_^C+&O\E?P3X<U
MWXD^-O!WP\^'^F7/C+QSXW\4Z#X7\)^%O#J'5-:UO7=7U.UM;*RM+*S$\Q!E
ME62YN"GV>QM(Y[V\DBMH)77_ %LO"]E<Z=JOAO3;U!%=V'PUTJQNHU=)%CN;
M.ZL[>YC61"5D"31NHD7*.!N4D$5^4>-U6#J</TU.+J0H9M4E!23J*$IX)*4H
M7YE%N+BI245*46E=IV^LX'C)?7Y\KY'6P45.WN2DOK,I14MI.-TW9]5U9Z=^
MM?S%_$_]K;_@HMI/Q^\0^'-$U"[L_@-;?\%/OVB_@UI'C:QN&O/B'+X&\+_L
M&_$+XD^%?AE-\.Y?A V@P?"C2?B+IFE>)=&^)"_$&[\1:GXLMK+0;F.73;J2
MPE_ITINT=P.W0>F,9SG/0#)[<5^!'Z0?S>^)_P#@H'X]^./_  3N^":_LW?M
M$>(KW]H_3/V6O%'Q)_:2^)'@OP?'J/CCP+XM^&W[)&M>*M7BUO0=<\#2>'+3
MQ'K/QRUGP)I[Z'%I%JUW?FZT[3+1[*'48(O(?"?[9W_!32X^/GP\^#D,EQXH
M^+OPO_:L^#G[,OQB\&^,;:X^&GP4^)U]H/['O[2OC'QI\0+/Q_I'PJ\<:SHO
M@/XO7_AOX3_&K2[C1].ODL/$6I:=X(BO-.MGN[&?^J#8F<[5Z8^Z,D=P?4<#
M@\< ]AA2H(Q@'ZC/]<_3GB@#^:'_ ()H?\%(/B$WQ#\,>%?VZOCWK&DZI\1?
MV,OV;?%O@;PWX[\+G2TU[XQ^(/C;^UAX?^)EQH%UHO@/0Y=3U4Z!X3^'.E7M
MG<K:1QZ;8:%J$.BZ?/JMU+=?2G_!23]LSXK?#Z/]@CX__LK>-?&'B?X(ZOJW
MQ/\ CK\6=&^&_A >*[;XW_ 'X=_#+3_'6J>&OLUSX:U+7;&[U+P[-JNJ^&4T
MI]#UV?6[*"T7[0RO9G]P[JUM[VVN+.Z@BN+6[@EMKF"9 \4]O/&T4T,J,,-'
M+$[QNIX*,5/!JKI&CZ5H&EZ?HFB:=8Z1HVDV=MI^E:5IEK!8:=INGV<2P6EC
M8V=JD5O:VEM"BPP00QI''$JHJ[10!_*59_M-?\%/_ =AX0TW7OBM\1OB%XUB
M\/\ [3OP@\:V&F_#/09K5_B_\:OVB1\'OV=_'=FEAX006UA^SYXNUKPOHNGG
M<VC:KX);4-9\6"_BBEU1?WG_ .";7C3XG_$7]A7]F+QG\:/$^O>-/BIKGPOT
MR3QYXM\3Z5::%K_B7Q%:WM_I][KFJ:/8Z9HUGIUUJ7V1;M[6UTJP@C651%;J
MI&?MX(H.0H!YY P>>3DCDY/)]3R>>:4\ XXX_ETH X_QF#_95MD\?V_X5SSC
M&/$.F\_F3T[_ %&?X$_^#E<?\;,.,$G]G?X6$<=<:KXPZ'!XQG/Y=S7]]_C3
M']DVN?\ H/\ A?Z_\C'I>/\ /UQS7\EO_!Q%_P $QOVE?C5\9_!W[8/[.W@+
MQ%\:-)_X5QIGPY^)OP_\%VCZUX]\,WGA?4]7U'0O%F@>&;=5U#Q+X=U/3M7F
ML-8L]&2]U?2-1TV&\%G=VFI-]A_1O"[,<'EO%&"K8[$4L+2K87,\+3JXB<:5
M%5ZL,.Z4*E6<HPIJ;IRBI3E&//RQ<ES)GRG%.&KXG+<7##TIUJD)X.K*G!.4
MW3A[?G<8KWFTIJ344W:[L]3^.4@Y.57/7GC_ -EHQ_LK_G_@-?4H_89_;@8
MC]C+]JH X/\ R;_\4^A&3U\+@_3/XXIW_##'[<'_ $9E^U7_ .(__%'_ .9C
MO_\ KQ7]2?VGECM;,LNV5[YA@%K_ .%GH?E/U7%=<+B?_">M^E/_ #/EC'^R
MO^?^ T8_V5_S_P !KZF_X88_;@_Z,R_:L_\ $?\ XH__ #,]O_U9H_X88_;@
M_P"C,OVK/_$?_BC^7_(L_P#UO>G_ &GEO_0RRW_PXX#_ .; ^JXK_H%Q/_A/
M6_\ E1\LX_V5_P _\!HQ_LK_ )_X#7U/_P ,,?MO_P#1F?[5?_B/_P 4O_F8
MI/\ AAC]N#_HS+]JS_Q'_P"*/_S,T?VGEO\ T,LM_P##C@/_ )L#ZKBO^@7$
M_P#A/6_^5'RSC_97_/\ P&C'^RO^?^ U]3_\,,?MP?\ 1F7[5?\ XC_\4?S_
M .18_P#K^U)_PPQ^W!_T9E^U9_XC_P#%'_YF:/[3RW_H99;_ .'' ?\ S8'U
M7%?] N)_\)ZW_P J/EG'^RO^?^ T8_V5_P _\!KZF_X88_;@_P"C,OVK/_$?
M_BC_ /,SW_\ UXH_X88_;@_Z,S_:K_']G_XI?EQX8_S[TO[3RW_H99;_ .''
M ?IC+A]5Q7_0+B?_  GK?_*CY9 (Y ''7!'(_P"^?7'H.>>P/ZI?"#]NCPY^
MS?\ LI_LO:?X#T6+QW^T%\+/BW^U[XJM]'U#XA_%3PEX1^'UI\5-$\ ^'?"^
ML>-O GA2;1?"'QATWQ/I\7B.6R\/Z_K-W:6$^C&'5K-+*^DMKWY2/["_[<)'
M_)F?[50Z_P#-O_Q2.?3_ )EC\^#GZ<4[_AA?]N G_DS/]JKD#G_A0'Q1XQN
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MHH *XSQM_P @ZP_[&7PS_P"GBUKLZXSQM_R#K#_L9?#/_IXM:NG_ !(?XO\
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MI;CSY8UA01@&S)"D;@ >0,$)D A"V<J!0)[?^W9K8Z9)]J2UW_VAL_=%2O\
MJRV.<@[ XRQ8-$0HVFI;IM;QIAMEMF;S$_M3?PBI\JOY63G'W^4)8$+@%<T'
M^V?[8D %M_8WV?*-SY_VC"GME@=V>#\A3:<AN*:4>5^]#^#7=OK,T[JHERVY
M;.35^6#TJ).4MFC-N3J13C5M[?"IOZI2<4G1=WSWO&,7;GJKWJ$G&$+IMF+\
M4O\ DFOQ"_[$7Q?_ .H_J%?(NF1^*3^P/\+-1\%Z[\6?#VO^'/@S\%/&$;_
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M?^&&OV6\\?LQ_LK#V_X9[\"__(U'_##7[+9Z_LQ_LKG_ +M[\"?UM37\I_\
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MLG;_ +B7_P"OM748'H*3 ]!^0KY?FG_T[_\ !5/_ "/8]DOYZG_@VI_F<O\
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MW_X)I_Y![)?S5/\ P;4/T+^R>+/^@WI?_@ED_P#EEVSR>GO1]D\6?]!O2_\
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MSVSTK^*W_A]Q_P %#_\ HH_PX_\ #1>'O_DFC_A]Q_P4/_Z*/\./_#1>'O\
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M='?U_P"PB.>WZXK^*_\ X?;_ /!1#K_PL?X<=<?\DB\._7_GY]*!_P %N/\
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M]!O2_P#P2R?_ "RKJ**.:7_3O_P33_R#V2_FJ?\ @VH<M]D\6?\ 0;TSU_Y
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M_7=/O2Z[K[U_F%GV?W,_>/\ :%_:H_9Z_90\#67Q,_:-^+/A'X0?#[4M8M=
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M3;BN>34;I7=[7NWRQ\1S'_F6?$X_[A]MSW_Y_P#_ #T[4G_"13?]"UXG_P#
M"U]<_P#/_P#Y%=5M/8C_ +Y%&T_WA_WR.W3\J\FZZ4E_X%+]4SKY9K:K)?\
M;M/_ #.5_P"$BF_Z%KQ/_P" %K_\GT?\)'-_T+7B?_P7VO\ \GUU>T_WO_'1
MWZ_G1M/]X?\ ?(HYO^G2_P# I?\ R(<M3_G[/_P&G_F<I_PD<W_0M>)__!?:
M_P#R?1_PD<W_ $+7B?\ \%]K_P#)]=5M/]X>GW1T]*7#?WO_ !T4<W_3I?\
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M">OQ9_:4/ S_ ,23X>X)P,G'V#UYQV/3UIO_  X&_9__ .BL?M*_^"/X??\
MR!7]'&W\/J%_H*-A]1_WR*^A_P!>.*5MFV+?SH__ #(>?_8.6?\ 0+3_ / 7
M_P#+C^<?_AP-^S__ -%8_:5_\$?P^_\ D"C_ (<#?L__ /16/VE?_!'\/O\
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M3ZC_ +Y%+M/][W^Z.OK2YO\ ITO_  *7_P B'+4_Y^S_ / :?^9RG_"13?\
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MZ^)-QG://%/FQ5DZ+2B[\*G@'X,Z+=^&=7L? 7AG2=2GNH+K1M2TOPUIMAJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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=+/&Y)%KVD[.-3+Y2J)KFLU.7O36TY>]+F>I__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $\ C,# 2(  A$! Q$!_\0
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MSW#1VR2*WZ0ZI'>WNF7UOI=ZNG:A<6E];6EY]G^VBQOR&"RLN0&$;@G8VT'
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M/BK^T#\5_P!I3X\>._ J0FZ7P*OQ1\?^/]*AC\*^&4A7PCX4\!>&K0W7B87
MNA\\>#/^"*!\._$?4?B7KW[3FM^)_$/B#XV:3\<_$5[;_#C2-,OM0\4Z)\9?
MCW\>QF5/$,N%/QC^*/PM\4ERN ?@/X3CQND(0 _6R\_:8_9UTS2=3\1ZC\??
M@[:>'],T,^,KW6;OXE^$8--T_P )GQ=-X%&N-JXUSRWT%?B%I&K^#)&,C1-X
MQA;P?NCNHEM'\P/[?7[&T/Q+M_A*_P"TG\)?^$MN_@W8_M LR^-]&B\+P?!S
M6?$>A^#/#GC4>-Q<GPHF@>*=?UU(O"TH\2E[MR9(@D'E8_+70?\ @B#J^F_
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M^").D>*=(\<GQ;^T-K7C7QM\6?@S\>/A]\0?B;XO^%GA#6/$>N?$[]JSXB^
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MF1ZC\Z7(SC(SZ=Z!A102!U('UI,CU'YT!_P_R[^@M%)N4=2!^(HR/4?G1?\
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M9:M\2#\"? /Q+N/AIX#\,M=33JLVM?%.$^'/"SM+X)D\.S%2Y\P_G3\,[_\
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MXV_#CX'^ ?'/Q(^(&OPZ1X7^'>B?VWXCEMO]-O;'3%5=S_V9%NE);.(QL^8
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M)/7H>8U-?$II^:DO)[I=FOD&Q!T11_P$?X4"-!T1!]% _I3J*7-_>_\ )O\
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M^E6&P^%VP^'2_NX?#I6Z64:"LNV_*FDMAWF_]=/^^(O_ (FE^;^\_P#WPO\
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M(ZD9*2:E"=2G.$D])0G"<)Q:>J<9)^JNBHRE!WBVFM=&UMKT:['XZZC^P?\
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MTW2-,L_L=GI-I9_V=IMAV_EQUK1K[JMFWU/#?V5P['^P\KT3FGS5N(VG*_\
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MAH^AG((92H9/#/BD@J^"NTC-?<E?GM^W[^VE_P ,N^%_#_@#X96-MXM_:?\
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M:34VH5:?+7A)TI>YRYA@%AFL7A=<KGS<DFEHVXRY&TY)32E?3=+F7VD=Z#D
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ME?\ !3[26\57VJZS\"O$>A_LW6O[0WC_ /9RM?V@CXZT;4=3U'Q)X&^"NO\
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M/COK&$3_ +%SE.=*6KY+64Z5_LRIWCRIM2=*2=FX-GV_ /$>)S7"9GDV;?\
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M7QV\?_M>Z)^TPWQ*_P""3/AKP(?A]J_C'PU\(="\">.S^S)_PO3P7\<=$\/
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MD:9H.DZ'HYU[QQK6N'Z?VX..1UZ<U^D<-4/[,X6S7-XQG&><UO\ 5R$TTO\
MA I<E;B"2FOWB;J3RJC>#C=0J1YDG-3_ !GB5_ZP>)>59*_>R3@F"XHJTV^9
M2XCS^^1\.QE%IJ2A%9MG=IQDH-PDK7C;UJBB'_3+"WU6#_2=/NK/[;9W>?\
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MQIX3\4>()9I/'\R6T<$WSO\ M)?MY?&#XC)^UM\+8/BS_:'PJ^(W[+7_  5
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M;YKU;]N[XQ^*/A1K_C?Q%X]_9RNK;Q[XBTN]\)?LZ:7I7Q+T[XO?!C2O O\
MP4%^$W[->NKXWUK0/$S-X@;_ (1[Q!GQLOBI/!:+\92/ H\$^,? *>,(JXSP
M]_P4U_;*\3^#_B!\4-)\"_!G1M \4>#OCSK'PYTCXN:W\,OA1I7PG\4?"CXI
M:%X%\/Z+KNMM^T:?$_Q ?Q1&VO6_C:7Q7X/^#DOA'XPMX7%S)X4\#^*H9(\0
M_P!JZV?W=SZ9_9W_ ."7.K_!+XX:/\9+WXH_#G_1OC5X3^--UX"^&GP@U?P1
MX6LM2T3]F3X@?LTS:+H6MZ]\1_&7BO7G\31^-AXK;Q3XR\4^+?%K/HL,2R%G
M<1_L17P[^PO^T9K_ .T#\-?&,?CO6HKGXH?#+XI>*/AIXXTF\^&0^$VO^']6
MT/2- US1M&USP5'\2/BSX:'B1/#NOZ'/)XD^%WC+Q?X,GW9MG9XY533\"?$_
M4-3_ &S?VI_AE=0Z/;:+X$^"G[*'B;1[V&;71XBO-1\?:[^T!C1[B!O$DGAV
M1T/@=4\)+X7\*6S2$SR2OXI;*)O<PQ"OVU?^?^1]GT5^,'[ '[>?[1W[3/CC
MP?K/Q0\$>"_#GPJ^,OPJ^)7Q,THR7WPX\&^)/A-J'@+QSH.AZ+X-2)?CAXL^
M)?Q>T,IX@E\+^-O%OBCX.?!QO!WC30(U=)4\4Q1K^S_G03?:/L]Q;7/V7_C\
M_P _EGIGVXKHOW5OZ[DXC#[:KIU\D^C_ %"BBBF86OIWT^_3]3\\OVU9U\3_
M !4_92^%@/[B_P#'FJ>/-9]CX'6.4_7*-K'ZGCC'!_MI^#_%7Q(_9#_:F\ ^
M!]#U+Q)XX\=_L]_%'PQX/\/:3G^T]>\4:]X+U\:%HNA]L].?7.,UU7QLD74?
MVXOA=:+_ ,RY\&M5URU_WM:U;6X#^($*^OW?Q/L]?K.-4,-PSPKA(Q253AR=
M:22MSU,_X@S>+FUUE;#TU?5QC",6THJWXCPG_M?%_BGG*;?_ !DT>&5?I_J[
MD.3R5K[6E.5FK6;;33;;_%[4?@W^T&?CS<ZI;_#KXV?\+@'[2'A?Q-X;_:"M
M?$9'P/T']@\_!G0?#^N?L_8/B0>&?^$@/B1=>\+K\+AX.'C)O&>O>&?'8) S
M7SO#^PK\8M-^"(^P_#K]H#_A:%K_ ,$L/ >M6@_X7!\2]2U,_P#!1C0O&?\
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MO&WQ1_X2\^#?&849\%2-X09V^H[/_@H1\#Y_'&L>'-5T/XM>&_!^E_%3XG_
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M^#]6\/>)-9\-_P!A?%#QU_P@.O>!=$US7/#_ (D\(^)_A_\ \)7X<T/QP/\
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M\.'XU#P./'/A?Q7XN;_A,O&?_",^.@K'@_/&FZ;\8_'EU\+_  Y^SU/\4?\
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M1=6OQ4\&.U]J?C?/]@:3HN79F_X2W:&7&_P@2P)4,& ^,M2_X)\_&J7Q#?\
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MACX*\+^*?BMX\^$WAK5OB;K6B>"=1UKQY\*/&&N> ==0#7\$JWS2#Q2X8?\
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ME\>];_L'Q-&WB%O#7P]UP^&8_%'BT/\ &;XTOKKK\0/!D?\ PB,",?/^G?\
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M/^"<OA:'Q'X?\1^,/VA/C]\2+CP;X/\ @-\/O EIXM/PU \)> OV;OC3X?\
MCQ\*=%SX>\->$O\ A(/$?_"1:)HGA?QOXH\6#_A-/&O@S R,Y'Z(U\G?MO\
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M^T7X'\<^%S_Q6(_XHO\ X1< '-<O\=_C]XC_ &BI?CC^U1_;GB3PEX7\4_\
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M (47HNOZ#H7]AY[G^W.WYFO6**%A=4[>FGFO[OI?7_,PU?S\_P#@^8?\M?\
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M./\ A$-'T4L?#>A8\0:U'XDW;2WC  ;F,8)3DFWH_-Z=V]D_+7L[]NJ['O\
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M7PHC> !X=U[1/#'C,>+9/!;^$?%[.RK)X&\%RRCYC\4_\%3/C3\1] UKP_\
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MW#QS,HEE5OV2\,^((/%GAOP_XK@L=;TR#Q/X<TSQ-9Z3X@L_[.\36']MZ/\
MVZ=%US1./^$?\1#HP'W3E<G!KY?\2_L+?LL^*I#/??#K4--U"[\3?$_6KS5_
M!/Q'^)?@CQ-KH^.GC7_A._BKHFNZY\/_ !/X1\4:_P##SQ9XA \2^-OA=XJ/
M_"&;CG;C(/UE9V<%E:V]A806UMI^EV?V&SM+3_EPTO''<C_/'M2WTNN]_P /
MZ_I=!8HHHKI **** "BBB@ HHHH;MKVU^[7] >S]'^3)K;_C^LCV^U/GU[_X
M5^5W_!&2&:_\._MO^-, VGC']NOXS:CIUX>EY8*FA*KX/3&X@=^1^'Z0^._%
MUC\/O GCKQ[?S"WT[P)X/\3^,[S/(*Z)HFO:Z> .>G\AQG-?"7_!%+PEJOA_
M]@[P)XBU@!]7^*GC/XD?$S4@_'_(;\7W6DVP'3)&C:):D;>,D  YQ7OTI?5.
M!^)\39<M?$\-X?6Z<FY9SF]11TM)J,8W2<K*5VE='L-\N09FGHYOA^$-;7:]
MI-V_FLE>26R^+8_7\< #THH'0=J*_/T[I/ND_O2?ZGRX4444P/S<NE'PK_;S
M)(M[;P]^T5\/Q@']V+OQKX)C62->3R+>RTU$.2-TFML#R,U]PG" L>W).?4]
M^WT%?*G[<_@?6=9^&&D_$_PLJ-XR^!_B33?B3I(D52KZ9I.[^VX'7[OEPQ[=
M>;<N))-&CC')Y]R\ >-]%^)'@GPQXZT!S_9/B_1=.UNS4$-]D1W_ .)QIAP!
MM(*.I7LY?&5VFOT#.W/->'^&N(:34IPHKAGB"4K2]G7R%2EAI2LW)1Q&15**
MIR:7-+"U+2;39^%\)?\ &/\ &_'?!L].:H_$GA9/W8SX=X@:7$<(1?*I3R+/
MHU)N,;\L<WB[6U.[HHZ5\C?L9>&OVQO"7PEOM+_;D^*7PH^+'QJ'Q&\=W=KX
MK^$'@F;P1X=;X:R:O')X#T?^QI!$(]<BCW[PT3EI9!!YOBV:VD\7S_+-I;;=
M-]%TZ/I;?R[GZ8O>5T[K1W]==]NJZ]3Z-\8^/_ WPWT)O$_Q#\<^$? /AM;I
M+0Z]XV\2Z)X*\-C49&94TA]9\0.FU69),9(W;'"9*LH6Y\:^#=/T;1?$.J^*
M?#.F:%X@N_#5KX<UV\\3:/8:;KVH:_,(]#_L+7&*Q^(6\394^$40N?%9Q$JL
M)8RWYG_M06WAKX??MR_!WXW?M)>#M0\7?LP:=^S+\4/ '@G7[GX=:Q\6? OP
MC_:'UKXC>&M:UW6O&?A[P]X9\4?\(YXA^*_P_4>%O!/Q-/A8@C0_%'@K[3'_
M ,)DL'B[X6^,GP>\5?MH:+\-OV8/V8?V2]3^$W[/7PP\'_'G]H*R\._&[Q)X
MQ^ >F:!\4?BSXU^('@;]E+XE^!-OPT^++:#XA\(^(O\ A:G[3W@?X7%/!K>#
M8]:^%[./!SAO!AYO;Z[^7_#:_GI^;Z?JZ\OZ^6Q^^'CCXZ_ _P"%NI6VB?%;
MXT?"7X;:U<VGVNUTCX@?$CP?X+U"]TX!=^KIHWB+Q!&9$#9 DV#.#NVD%5Z?
MQ/\ $#P+X.\+_P#";>,?'7A/PCX)*::__":^*_$>D>'/#>S664:,5UK7B/#A
M8[E"D$\E"JMR&_GJTS3/VS/VJ?B5K?QH\!^ ?A#X/_:&M_\ @FW\&/!?CGP1
M^U%^SCK_ (S\":]^TEX'^-'[3F@^-_A?HVNZWXE\'IX=B?Q)H6N+_P )++_P
MF$4_A#Q#X5\:%9/!<T:R?HG^P#X?F/[-'[,OPGT+X.RW?[+>A?!72M,35?VC
M=5NM$_: T'QYHVH2V^M>!_'G[/\ K'PT/A70SX3\1V_B'PT[>%?&,W@^V.AV
MQ\!1+X&-BS'MWW]?UZ_G_E8^KJ_]?Y'W#X$^,WPB^*8U?_A5?Q3^&/Q0.A-I
MXUC_ (5]XX\(^-6T$:P2-$_MD>'_ ! ?[!+;=T2#F:+,D6Y037IU?G/_ ,$J
M_A]I_P /OV%?@'9OX"T_P+XLD\.^*$\3:?-X37P5JMVS?$OQS)H::_&= 3Q$
M)#$T<J";!19 Z_+)AOS.\(_&+]J*\^$6MZA?_$K]NZ3XHW>H?!N7_@H&+OX:
MM%X:_9HT[6OCZOA_XX#]EUU\-2^)M"\1^$_AVLC#PY\)T\7^"HO@KH,7QO6)
M_B @D\:-8BW7^OO#ZNC^DFN?FF\-^#--B$TWA_PKH;ZDEG:*7T?P_IBZKX@U
MA%7255Y%2/6_%'B'6"2JB,.^M2,H>Y<M)_/?X<?]JCXP^)8_"NG_ !U_;)T'
MX!^'/A=^W[XU^ _Q!M;G7/"/Q)^*GACP+K/[,*?LYZO\3];U_P .0^*==/A3
M7->^+$7@67Q6J>,OC+X+T03?$&+QJGF1/Y'\0_'/Q_\ C/:_!V/]HOQ!^U/;
M_&?7/C1_P2=\9?"SX0>%?AQXR_X4EXJ^#C:Y^R_X_P#CI\2_&NA^'_#/_",?
MV_X7^-"?%5O'?BGQ9XS\&^-?@PWASPB OA#P&<^+QXB_7^OO-_JR[?E_D?TK
M3^./ %]I@O9O&'@JXT"Z<V37A\2:+J.FWPUC7/\ A! ,[74B3Q&R^&%1MK?\
M)@[>"E(9<5VT4/DQ>1! +:WM<_Z):=N_!^N#Z9Q7\KO@W_A?.D>/8_BIJVH?
MM#6_QG^(OP6_9*\+Z+9ZKHOC(>&M<TGP+_P5I^+6@_%?0WT3_A'F\,:"WA3X
M,:[X)8-MCQX)\0IXWV';YDFUXH^+W[;4WPH\7Q_#[XH?MC1_M ZO\(_'[_ME
M:3JG@[6CX:_9O^/?_"_OA%H7PMTK]G@Z[X;/AG0 /#>N?%)/!?AOX7GQCX+\
M;?!S0$\<>/OG,/C9Q5[=;^O_  ^^H?5_ZN?TX7NO:/INHZ1I-[J>G6&H:Y>Z
MA8>'-+GNQ8:GKVIZ1I3:P1HG.=>$>@(QFX(1(V+$D%5V*_G0_:#U[]L7X2^*
M?C]\-?AKX]_:7\9:'\,O'G[1=]\)/&WB"QUGXB^.6T[7?^"5FO?%?0FT3QL?
M#CC7_#_A7]HM5'@D;Y<>- / 2S3*J^#VV?%VO_M*?![Q!>?#K5_CM^U?J_[/
MOB"T_8 \7_&_XKZK>:OXE^+G@;3OBGI'Q_A^/47POUWP]X9;Q/H'_"5>)_ O
MP2B\=^%?A2K'X+>#=>\5>./ B^#3D$5=J_F_ZZF#P_\ 5S^A:BOS>_X)<?$'
MQ=\2/V?OB1K/B;XB_$WXHQZ#^UW^U?X!\$>+?C99?V=\1]2^&O@?XT>(- \"
MZ1KB'PSX0D(B\/0J(\^% 2C$-AD0U^D-=":WLK)W>BZ6;Z=OU.=W6[;[J[_S
MZGPM^W_X=O7^#?A_XDZ1!-/JWP?^(OAGQE:BU^\; 2/HW&>H8R:4S#.>^,9K
MI]+U.RUG3].UVRG^TV&O6>F:S:=_^)9KA()'MD'&,\'M7TUXX\):7X]\(^(_
M!.M<Z1XK\/:KX>NT[L-;C>,@>_[P8Y'/?H#^:O[+>M:G'X+U;X7>*"(/%WP4
M\1ZGX U:V!X;26&=!/'!!&"#WY..#7Z?D&)_M/@SV2DW4X>XA4Y1WYN&N(DH
MN2^U%4L]I7E9<L?;W?+S7?XSFG_&/^+$9O\ Y$O'7#7+S.T8_P"M7#C=E=VB
MYO(\VNM7-_V3:WNW7TU1117$]W;:[MZ7=C[5;::KOO\ B%5YH8)OL_GP6US]
MEO/MMG]KL_\ CPU0#\??_ U8HI 9\VFZ5-=6]]/I6FW.H6N/L=W=V>C?VE8'
M\1_AC\B%FT;0YHO(GT/1+FW^QZI9?9+O1]&_Y!>N_P#(=[\\^OICH:OT4N6/
M\J^Y?Y#N^[^]_P"9S^@^%?"OA;[0/"GA7PCX2^U?\?G_  B?AO1O#?V__P )
M_/Z=O;-=!113$%%%%'KMU].OX!Z[=?3K^%PK\/O^"KGAO_A7OQO_ &/_ -IJ
M"#[-H]SJ_BC]G[QY=_\ 4*UTG7="_P#0==Q^5?N#7RK^VS^SU_PTY^S!\5OA
M+! /^$HU/1SXF\!W?)^P^._ W_$^T(>O4+X8)Z :\17O<+YC0ROB#*\5B5?*
M9N,)J[NU-N#OWY93C-*5T^62MS69]!PYB,-A\VE'&?\ (IG%Q\W*2M%/NN=K
M1W5W??4_*FBO%_V>_B1/\3OA5X7UR^/V7Q3I?_%+^/+.[S_:=AXHT+_B0Z[_
M /7_ #XKVBOT+%T%AL7+"XK:?,X>:DI2BE;=V<=%=^1Y.8Y?BLKQV:83%:1<
M[PZ:2ES12OUY91VL_(^'_"O_ "D)^,'_ $]?L]^ OR_MK0/TQ]?P-?<%?#_A
MS_E(9\3_ /LV_P +_P#IYT"ON"O2SM)2RNR2_P",:X>>UM==7HM7U>[ZMGRO
M#+NLSYFVO]9>(4[MOW4HZ:O9*]ELNB05]3?LD>"O^$N^+OA"&>'[3;VVL?VS
M=G_J&:'_ ,3T8_$C&?YG%?+/^N_<0?U'?H!ZGO7Z^_L$_#D:/I/B#QY>P@LJ
M_P#"-Z2O< DZ[K9..@8KHHSWVD'@5\QG&)>5Y)FV:\W)*M>A3?7GJQE32A9I
M\R3E)<NJY4[:7'C\-+-<WX6X<2;EG/$_/.VMN&N'&L[?/HTHN:4&YI1?PMN_
M*?HG1117\^MW;?=M_>V_U/Z'24;);1TCZ+16[:);!1112 **** /SZ_X*,_"
M"[^+7PS^ ,L?P[\4_%"+X3_MI_LH_%K7_#O@Q-<U+Q)9>"O GQ-#>-M:T31?
M#K#Q/KZ^$O#FM.70*SNI+(5\M@WY<Z=^R/\ MB_"GX->$=6_9F\._&WP!^T)
M\4/ G_!4S0_B*ESXW\;'PY8:MX@^*'B'QQ^S@S:-KWB5O"W@+7SF,_!+Q1X1
M3P9Y UUY)9#&Z^7_ $ET5S_5GV_!_P"0'\]/P1_9F^+GBOQW\#]"U^Q_:@;]
MG:7]J71O$?C?X>^*?!WQC_9P\.>$-,T+]DGXO2ZSJC:/X@_:0^+7Q-\0?#[Q
M7\99?A9+XVB\6>,AX,\8?&31DE\"+XO2?Q@[_%'Q8TK]LWP%X'_::^+/B_P!
M^U+\&-%\5?LH_&33_B5:Z/KWQ,\//I'QU_X:L^ 4O@;1]&^-OQ"^,_BH>//B
M2/AZ/'X\$?'7P?X1^$W@KR-93P=X$E5I)(8?Z[:Y[Q7X4\*^-] U#PIXP\.Z
M+XK\+Z^I&KZ!X@T<:GX;OLC^W<ZWH;!AD<8# C@9!Y%+ZLUT_#_@?TSG/YX_
MC'X?_:/^$'A+X@?'G]FCPE^T#\-/ &D?M _"SX=_LR_ GXV>,O'>D^-O$+_M
M4_#5OV</C=JJ>#?'/B+Q9XGD\.^&/C5XQ^%?QS\&>$?%9,;^,?A-\2_&W@\"
MV\:,7_6'X^?"WX@^#_V?/V;OA7\'[_X@>+=0^&/[0/[$^C>)-7TG5]8O_$FN
M_##P/\3_   /BGK'CG6F)EU_03X;T77/$OC8 ;3M?<$8HM?7&O>#/!OBC4_"
M^M^*/"OAOQ)K'@76O^$H\"ZOXBTC1]4U3PGXG.CMHO\ ;.AE]W]@>(!X>8A?
M$N0L2MMC"@**Z2A8=OY>O^739^9N?BK^P+^SU\=?@UXR_8_\2>*=,^/.GW'C
MO]F#]HFU_:ZN/B9X\\6^-=,_X6_%\2OAWX@^!T/C/1-=\4>*_#&@>(/#&@ZQ
MX\7P2?#;J5\(2.K VZQAO-?#WP9_;AM?CEX4_P""BL_PW\)6WB#7/VN]3\3^
M+_@I;^&_&#?M36?[''CLZ'^S1HGPOUP#Q-_PC1_X1'X=:#X'_:?D\*LH4^,M
M#\2A68[U7]]**/JK_I/S\O,+?U]_^9_*=>_L7?M9_P##)7C_ /9@A^ /CX>
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M_"7>#?&+[+D>,XG=#[A\2/V6?VAOC?\ LU_%?X:?%SXW>%M:^(WQ4^)?PO\
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MXV:O3EGO_(W=E%V2B]-&M%%%?GNO7?KZ]?QN?JX4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1111OIU>RZOT6[^28:->3T
M;Z6>CUV$*@D$]5.1S7R-^V[^U#I/[(_[/OB_XJSPV^H>-[AH_"'PE\*\#4_%
MOQ)UQG.AZ$FBM$Z2#PX8SX@D4%6%OHDK!T<1EOJ77-;TKPQHNK>(_$6JZ;HV
M@:%I.J:QXAUW5+U=,T[1M-T,,VN:OK.XJH.T,Q)(VJI8D!21^/'[-.@ZU_P4
MH_:NM_VT/'.A7FF?LE?L]ZIJWAK]DKP=K%J4?QOXZ_M4IK?QIU?1SET8LI\A
MBJ1!E\-#S5N?"_BN.?W<AR_"J4LXS9?\(V2M5*BY7^^FTG1R"$TK2GG-2G'F
MO*].C&K4E:*@Y^M@*&&?^UXN_P#9.3)<NMN>4D^6";W<YV6TK1YGW/MK_@FA
M^RIJW[,/[/-N/B!>-J7QR^+^MWGQ9^..O7!3^TKOQWXQS<3Z5*[0K)&N@(RV
M\T>^6-_$A\07,3*+IQ7Z1_P[O[PX_,=?UIIV *"#@8  Z #@#WX[8'>I@ 5'
M7^HYYKXS.,PQ6>9IF.:XV7-/-)*32NHTXKGY*4$_AITJ?)3I1224*4=$[W\#
M%XFOC,3+%XAJ\FVET2V23\HI+9#Z***Y5HK=C **** $P/0?E2%1@\+GGD@=
M<=3Q3J#T.>G>C:[6]K:6OILK^72]TNU@>N^J^\^ OVCO@GXPT?Q1I_[2'P$C
M%M\5/#=FR^*_"<8\K3OBMX87<QT74@J*$U> *#:7 ;<"%&=RH7]?^#/QF\'?
M''P;;>+/#-Q/;7%NJV/B/PK=D+JOA?5E!+:-K:#&UE*ACMW#!!&.0/I#E"QV
MK@JH#%N<]U8<D8).#@!@.ISQ\%_'#]GSQCX5\8S_ +07[-YMK#XAX,GCGP$P
M,?A[XJ:<#(S"55C2.#7XE $-P2%; #%6"/-^B93C\!Q7E^!X<XAQ\<JS;*HS
MCPOQ/4C%PG&2;?#?$CY6GA9<SCDV<S]I+)*E14ZG_"9*]#\2X@R#-N!,US+B
M_A#+GG&39Q9\6<)IV5&R?-Q-PS&R4,Z@DYYSDT53CG<*?M(6S%?[7]@* !P,
M>V<T[K7@?P+_ &@?"GQNTJY2QAN/#GC30R%\5>!/$!5/$GA75&"@12QE\_V,
MS!BC1IY3+C;L8E#[YC'X\U\YC<!BLKQ4L'FM-T\SA)P2E'ENEK&4&OW<H2C:
M4:D)2A44E*$G%^[]?DV<97GV599FV4YHLZRN+:JPM:=&=DI0JP:4Z<Z<[PE3
MJ1A*$HN,HIK4HHHKFZ7Z=^GW[?B>M=:O9?EV3[:=[!1110 4444 %%%% !11
M10 4444 %%%%&]U9.ZLT]5)?RM=4]K.ZLWIJ%VM5>ZVLVGNGH]U=I/U2;NTF
MOG3]HK]G[0_CSX7CLIKYO#GCOPW<KK/P]\9V./[2\*ZM$K@21KL!?174QQ$%
M\,B(HP44'Y/^%/Q6UJXUR^^#_P 7[(>%?C9X: M+JWNF#:3X]TDC<-<T(@X*
ME>A&>H(ZYK].2-PX..>N#R.XQQUZ9[5\_P#Q[_9Y\&_'K0+>TU43Z-XOT)EO
M?"GCW2ML?B/PGJ?S%Y(F6/+:,Q* K(ZQ,  6C(WG[7AOB/"4\(N'>(>:ID\I
M*5.K"TZV0U)M>\FO>JY-4:YJ^4N2<G)U:;56_/\ E7%O!>;8;-O]>^!7&.;I
M/_6GA:5E#B>$4WK9)1X@5O\ A#SS5[95FK_L^TEQ-%?+-M\4_'?P0U^R^&_[
M3MF+>&8+9>$OC1I.%\$^*2RY4:^F0T7B)@"5#+ANH/4U].P3V]]:07UC/;7.
MGW7^FVEU:7G]I:;?=_U'/N,8]*]W%Y9B,%"%6E.%3)*BYJ=6D_:4:JU:=*K%
M.+5K-PDX5(:QG33A)J<@XKRKB=J.'_=YUDW_ "4_"M6T.)>&^SM)P52+=FY0
M52+5W%V:+-%%%><U;6S2\TTK=-TNA]/=/57L]K[V>U_.V_G<****E-/9I^C3
M_)L'IOIZZ?G8****86?9_<_\@HHHH[VL-)MVY6[;JSVZWTTT[VW"OSN_;\_8
MFF_:;\.>'_B/\)+ZV\)?M/\ PE_TWX5^+.-,_P"$MTOG/PRUT]_#I/7KCK@<
MU^B->._%OXV^"?@_8#_A(;T:GX@N_P#D$^"M*_Y&77>XX'.@_@0#S\P/%>YD
M+S6.9Y9/AZ,IYHM)J"<HRB[IPG;W5"46U)U)1A%/FDX\L6N7$\6X+@V2S_'Y
MK')LHRM<CH2:<L3?1P5-OGK<[;CRJG5?O:1V/Y0?@9XP\1_$C]O#Q1/KG@[4
MO!/CC0?V>_\ A"O'GA35K/\ LT:#XHT+6O\ B>U_2_\ LE_LO?VQ'IWC[QQ8
M$^%[7-[I&E7? \6ZH/\ F->_AXDCCT))["OQH^(?P)_:4_:(_P""I^L^(/!K
M^'/A!\?-*_90\,_'SP+X7U'2#-X8\=:=H/CD^&7\%>.1'DC_ (2C0PT<O_"5
M[O+8,&5 C$?OA^QQ^W/X<_:2FU3X4>._"MQ\#OVK/AF%TCXB?L_ZZR6&H%=%
M4?\ $Z\#$ +X@\,LI$BR*S'P>20"!Y?C"7]#\1LYQ.'RJE'AF<*M6?#-%<4^
MRY:CX=52;BG24%+VE.<XSC_;U+VD8MN-Z<MLN"N%,-XCX?\ UQYI+A-<4\13
M7"UI0K.=XRC/B&%HU%D;DU.*4$^9Q69;H^^  . ,#T%%%%?S1J[.[;E:7-J^
M;1>]?KZW>^ZV/W51C%1IQ48Q@E"$(VY81BE&,816BC&*48J,4N5*RL%%%%%^
M_P"(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M**';9NU^_;NK[_*X:==NOIU_"XUBP/ R/\_C^5#LL$,\US/;6]O;G[7=W5WU
ML<<X&".,#D\#'4UF:YKNA>%=$U?Q%XCU/3O#VA:'9G6=3UO7;Q=,L-&TU4+G
M5]7UN1T0':I(WNBJ 2S* 37XK^+/'WQI_P""L?BW6O@U^SC?^(/A3^PSH.KR
M:-\9OVBQ:G2O$7QT4LRZSX*^%1(;&@,I1)I\$??_ .$Y54SX)\9>KE.4_P!J
M3>(QB>49/E$J:K<1U+^RITW!N<$E&]2M6@I1I8:+G.K*7,U"E&4Y=^!P/MVY
M3DH9/!7E)Z-;/5R:=[WLM6[K1W5U^(OBOQA_P5B^,VH?LV?!/5M5T3]ACX4^
M(M,C_:,^-6C>98_\+S\2Z(RD_##P-JR,5;0 Q4S2JN<8\;;Q$G@P^,?WE\!^
M!/"WPT\(Z#X"\&:/IWA[PCX6TFPT?P_H6F6PL=/TO3=*1(H8($C4(J*JKQU8
M@NQ=G=JY#X)_!#X9_L^_#KPS\+/A9X;T_P +^#O"5BEEI6EV4&U1L%MOU#49
M6/F:KJ\TD(>XUFX:2XEE9MTA (/LGRY= 2" #G& .X(//7&#R.V2!7E<0<1X
M;,K95E7/2R?*Y+V=.5HU*]6:;EGF)YFXSQ%>UU%<RHP4</2=H2<^;,<?]97U
M/")K*X.3C%ZN334>>5DO>:3W6EVK%G /. ??'6EH P /08HKY];'DA1110 4
M444 %%%% !@=,<>E(0,'('0CIT&/\\4M(W0_0_RHVU^>BU^7=]%WV"U]+7OT
MT_X;_@GQE\>?V7]&^)-_:_$/P!K5W\-?C-HNZ;2/&V@Q_99-1 7!TC6XT$GG
MVTBGYB$W(2"RN'.WS+P'^U)K/A+Q!;_"C]J/0H/AM\1/FM-(\9Y"?#KQUMCR
MNK1:TX0:"S, ICN'B92[;I!M"C] )&8O;()70.#N6.)5+ L>K#E%(Z!3SC)]
MN"^(GPQ\$?%;P]=^%_&_ARPU[2IE8>5>Q&0V[;402:??(%GTR1-JXD@EC<C(
M5@"<_9Y9Q-@\5@X91Q30J9OE-.,50Q5-Q_U@X>32Y5AJDF_K.&CHWDN(O1GH
MJ4Z,Y*:_'^(/#O&X/-L=Q;X=9G+(LWG_ ,E!PO\ #PMQ6K73SJERWPN>/:GG
MF4*G--K^U*681A8U ZG R'![C!_ @9_SQUZJ>X3&01D8[XXY/'N?Y@]?@<?"
MO]HO]EQ3<_!G4[CXV?""S($WPJ\4W8'B70=.3/R>#M:;<1\H^8,TT"[]EOX4
MF;]X?:OA+^U!\)_B]<?V#9:K<^$_'MJ0M]\/O&H_X1SQ/97X4@ILPBZV . 4
M+X"\X+<:X_A?%?59YMD-6.>90HM>UP_-ST::?_,]R)^UQ62SY>62FZ=2C)\S
MC7G&$U'BR/Q%PCS-</\ %N5O@CBR":?#W$:?L.([-+GX<XCC;(,[B_BA%U*6
M<17+&>60D?2-% (/(.1ZBBOG];V:M+^5=/1;V7339(_1%)22::L]DFFO1--I
MVVT[!1110.SVL[^C"BBB@5TW9--]DU?[KW_ ****!A1110 4444 %%%%&][I
M.^C3VDNTNZ>SO?1L$VG=/E?\UKV?1VNKV>MFU>UKJ[9R?BCPCX7\>Z)?^'?&
M6@:?XAT740T=WIFJV;7UB8R1E'! 8J67*A@1D$C //P7KW[)7Q6^#=W-K?[+
MOC;[5H!47E[\&/'UR=2T@D#)&B:T7>2+)!*H2XZ#S"QQ7Z.[3G!)V^AY_'<?
MF!]N1VSVIP&.G^?\_P#ZS7NY/Q)G&0WPV#JRGEL_9RJY#B(JMD%5PNKU(2:2
MGR.252DZ-6'NN,G**9\3Q5P)P_Q1S8S$Q=+./A_UGX8;X>XC7+9Q4W'D=:$9
M?%&I_:N4S2FFH<[/RMT_]IK1]%U,>&/C9X0\5_!?Q<<XMM?M=8U3POJ&#@C0
M]=!.<=QUSVKZ"T'7]"\26']J>'-=TSQ)8?\ /WI5Y_:/KT]N#D\^_6OK/Q%X
M6\->,=+N-%\5:+HWB#2;K&=-UW1TU#3B.>"75\CID8)&..N*^/O%O[!/P/U>
M_GU;P0WC'X0:_@?\37P#XD?2RS<?-_9&N;@ <@X$/4\-P!7V.%S[@O,],?#B
M+(*S:?+1MQ%PW)2>K]E-TL\IVDVFHSK0BENXI)_'_P!B>*_#ZO@I<-<<9)JO
M?G_J]Q0DM(J55_VMD52=DES?\)/---M14M.F /<Y]L8_J:6O(9OV5/VG?#+@
M^"?VH8-<L2,VND>/?"*LHQT']O.?%#L>PQ'Z\=,YY^&_[>FFR?ZW]G[Q';^T
MVN:<?3GY"/3H/3TS74LMR3$>[@N+>&G+XHQFZV03:;=KNKDLVMEI*;L[^KYW
MQGG."=LY\*O$V-MW%Y#Q!%-=5_86;PERW5XOE3Y4F>W45X5_P@_[>DO^IT/]
MGVV^FI:Z?PR(C^?8]ZNQ_ []N+7?W&M?%3X1^#,GG_A$O#,=_J8XZDS>'XAC
MW!.,8^M/*\!%?[;Q5PREVCG]2LWY6H9%-O\ \ENVDG<2X\Q>+5\#X?\ B;KL
MO]7Z<%=[+FSW.8QCK9<U[1W5TE?V@'/3I7COC;]H#X2_#TFWUOQAI]UK(_YE
M[P^#XB\2'D]-$T <]^@/T[UY+\5/A!\./AY;6K_M,?M4_$;X@>(6C+V7PR\'
M.NEW^NO\N(GT>%I?F(/^LA7PK$-I^<\!K'PW_9;\8?$](3X4^'6G_LN?":<;
M#JEU;-K_ ,9O%.GR*1Y;Z]KRMXFT(EHAN!3PQ-;&17D'BJWEWU]!EV3\(X;#
M/-<US.M+)8*#E5ITED%&LJC<>3"UL[G4SOB&HI*__")D:@M+UXP?M%\1G7B%
MXAXS'_V%PAPQ3AQ4T^3()\0_ZPYY!;>UXDGD2?#O#]-<RG)9OGLG:+A'+)3M
M%^$ZW^U5\9_C'XG;X:_L_> ]1TK5=24VCZO?6@U#Q&%4$LS,<>&/#P R6R=H
M /3K7W_^S%^PMHGPPOX/B3\7]0E^('Q<N0E^U[JL_P#:%CH5\PC;S TFY-9\
M0*&9)/$DT2W#A6\I$RKM]9_"3X&?#;X(Z(VA^ /#]OIYN(PVJZM<E;OQ#K$R
M D2:MJ[AIYI QZNYCP!L4-\U>MQ1*(@@Y1R"27)*L">"< N/4@'&>V.?B^,/
M$W!5,'/A_@?*EP[D24U4K)Q?$?$45&\I8K$.:E2I-7_V:E.+DF_:S2;B_NN
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MQDDMDEI;9;+9;;>3. ****8!1110 4444 %%%% !1110 F!QP..G X^GI1@
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M44B*+NYTBT4ZA>-'DJ=5U2;S-9UF4N=XDN99)&.$W!5 'J,B;E"Q[!@]&4$
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MMD'WO]REY[?Y#_UEQ_\ SZX>_P##!A[_ 'VW\^^I^*,?[$'_  50U*3.M_\
M!4T:? ?X?#W[/7@I'.3Z2M'[G[WH3VJS)_P3'_:K\2P-%X__ ."IO[3FH)<#
M%Q;^"]/B\"QN#QA6MO$5T5'U09]*_:,''4$_]M *7(_NG_OZ/\*R?B%Q$[?5
M8<-P:=^:'#/#D9)=XMY14::M>+3332=TU<A\29INGA5K?W<DPZVULI>S=O6V
MF_0_%VW_ .")/P.UA"?BQ^T)^UU\9KDY^T#QU\9WN+!AUSY$'AZ-AWSB4XR"
M2._M_@3_ ()$_P#!/3X<I;_V5^SGX=UVXLU+B[\<ZEXH\;[QP0&@\3:_>Z+N
M'3Y;9><Y'4C]-C^7U_R*> 3C)'7IDYZ]A_+ZUY^*XXXQQ6D^)<]C'3W*<U1@
MK75HJE3I)1MHHJ2CRV25DK8XC/\ -<3\68RUW2Y8KTY81C;?OZWMIYWX(^%/
MPW^&]G]@\ ?#KP5X$T_!'V+PEX4T/P\A_P!Y=$MX(V_[Y)]^*]%P@ & I&,X
M 'Z@8[_YYJ2D*@G)'ZFOGL17J8EN6)JU:DI:.56K4J2?K.=2I)ZM[RMJU:V_
MFN<Y:RE)OS;^?7OJ+28'H/RI:*SLK6LK=K+_ ")# ].O6BBBF%@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-J_W
M1^0I:*!63W2?JD_S0F!Z#\J6BB@+);)+T27Y)"8'H/R%+110-Z[Z^NOYW"BB
MB@5EV7W+_(*3 ]!^0I:*!A1110 4F!Z#\A2T4 ?.W[3WP>D_:!^ 7Q7^"]OX
MIN/ FH_$3P=JN@Z%XQLM(B\0ZGX5UG _X1[Q;;:'-(B:S)X8\1KH_B***62.
M)I(HTDDCR7;\Y+__ ()(Z/<^'?'6A:#\;M3L?^$F\8_%/Q+X>_M+P+%JB^#]
M-\<?#/6O >@>"I)#XH5-=T#PSK?Q ^-?C+QDC8?QOXL^+WBB1/\ A$/ES^TE
M?)O[7/B#XS^'O@OX@TO]FWPU_;7QU\>7&E_#/X;ZS<6+3^&OAKK?CJX_LB3X
MR>.4C+A? _PJT&35_%UPABDFU&?0[;P?;[I_$@:( \W^#W['FC>!OB?X-^,5
MYXRL?$VLZ%K'[5OC*[6T\/-I5EKOQ._:7^)'AO7];\:,?[?N]\O@_P"'_@V/
MX3^#@?,1/!F]VE+ *WCOBS_@G'H_B[0O'?@C6?B];./B-_POC6-6M8O!.DQK
MJ/BO]I'XS'QU\;_&6M:'_;TG_"0>(I/@Y_8/P&\%RMQX,\$R>)&5YCXM\F/X
M?^'7PD_:S^"/A[X??LT:CX5_:2\$_#+PU\5_CA'X:U/]C/Q#%K":[X]\8>(O
MA/\ $'X7ZQXT^*?Q<\.Q2_\ "H67QI\6O$OC;Q5XN\+2>!_%?CJW\2^#?'=N
MQA\)^!_'%7X6?"#]KV'Q7!9P2_M=>"]"\9?$GQ[XR^,/C*Y(?Q[I_P#;?Q/_
M &E?BQX]\%_"W6-=W/X>\-^*/#GPR_9M^%_@Y_"B_P#"$Q)XD23P.51PU 'Z
MN_M*?L7^%OVJ/&/PWF^)GC3QM9?"[X4:)XGO/#/PU^&WB?QK\,[\?$OQ'HL_
M@B'XCZIXX^'WB;PWXB,OA+X=:QXQ\*>%/#,!2.1/'GB6YD=A%%"OR5/_ ,$K
MK34)-)BU/X]WFJ:KI?P\\*?#G5F/@F$OX@\#>!O@QX"\ _"[1-< \4.%\.1_
M$OX6#XV^- 7SXVNM_@21;>S07C?(NM:/_P %'_A[\(!876N?MA_$O4/&G@']
MEZU^(_B1;TZGXDT7XG'X9?%SQY\4]+\#Z%\/_#G_  DNA^'#XBC^%7P(\8S>
M$QX/QXQSXZ\;^.RC>-"VS\!?#G[?=Y\>_ 7C_P 0:/\ M":%\?T\!_LW^&?B
MMJGQ#TC1O!?[*WCSX8>"_P!F?7];\:)XWUGP]_PE[^(?B--^TC\5-<\)P1^$
M5/C;PA)H \:0JW@8^,EH _2CX!?LI_%G]FWXGZS>^%_CA\,-0^#/C#_A5^D7
M?@;Q!\']?'Q+_LKX4?L_^!?A%X>T;1/BHGQLC\,OG_A!#XJ:/_A3Y"MK_B8\
M_NW/B6N?\$M+#6_BW\0?BQ;?'76X-3\8>,/VA/&6EZ,O@+2_[+\.O\7="T*7
MP/H+LVNA=;T#X2_&3_A-OCVJS&)_&OC7Q'")DMU\,0/+Y!^T!X%_;Q^-/QR^
M"?Q3\1?!KP$/!/['OQ2^#%Y)H.@>+_B/'JOBSXH^(/&7@23XY_&GX*:*GAQ(
M_B!\/_"OP;U[7?A?X)3XHCP@_G3?'201[&\'2#<_:/\ %W[=I_;[\$M\'_!/
MQS_X5+X%\2^%;>\TO18F7X2?$7X:3?"[X@>-_&>LG59/)^&\'B#Q5\0FT/X4
MPP^+1XL\;^#/%^@>&?&H;P;X%\8.S 'KFI_\$X+_ ,/>+= ^(7P4^-6G?#GQ
MQX,T?PQX&\ 3^(_@WHOQ(\.>!/A?X<^ <'P*31]#\/R^)?"./$T$TOC/Q3X,
M\7*6AM'\>>(_!5UX-\4>!V$:>E>+/V)KY?"'[+.@?L__ !@;X/ZQ^R?X(\3?
M#+P9KGC'X9Z+\5L^&_%W@KP[X#\0:VF@2:]X-\/:'\2H="T4?\(?XI43^$;6
M36?$MK/X%\5>$?$SV47QO\&]?_;:\*?L5?M2:[>I^UAXT^*5UXQ\.Z%\.->^
M)NCMX;^)3Z;KP\/:1X\^)G@CX4Z]X>\6>(O#\WA ZYKDW_"KO"\?C3PAXS\8
M> IF^ .WP#XQ\(L8]"\(_M4_$;_@GQX0^'_QVM/VD[C7_&?[8N@VNM2:"?&6
MF?''P?\ LO\ AG]I^VUO2&UIO[?'Q+>/Q7\.?!B+</XNN?%WC2+P=XXCC\=H
MQ$S1 'IWC'_@EYK'C;1?'GA&T_: T*T\ -J_QU\4_"?3+;X'Z(NK:)XW^.VL
M3K\3=2^*6N:-XJMI_BSH3Z%)K7PQ3PMX8A^$4*^#M?GM3ME\*^#IX=.?_@F7
MXVF\7W/Q@N_VE+#Q!\=$^*&D_%W2/%NN_!6'4_ ^G^._^$Z_MB1=<\ GXF"7
M7_#UM\.= ^%_PR\(*WBU/&W@H?#[PQXSM_&T\^^%/AR[^&__  41^$'PLBLO
M &L?M VN@_$72/@WX^^/-K9^']6\;^*/"?CKXY>-OC_\5_CGHGP3T3X??\7.
M\.MX2FUGX9_"WQMXF\*%O&8;6Y/'.1('\8KZ_P"*-#_X*)Z/\+]>\1>+O$/[
M2OB7Q-H'A7]F?X&VUMX+\KPYL37-&A\=?';]H ^"/ ,GB[Q5X_\ $#)KVA_
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M"]EJ[76J6FFR:4OB#Q#KFM:QXCUWQ!)HD^O>)983XH\0ZSKGB.XC/B6<Q27
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &; D,# 2(  A$! Q$!_\0
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M"D <\D\ $$\$&AM)<ST7?I]XKZVZ]NNG_!)**C61'. 3G+#[K8.P@-R1C@G
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M** "BBB@ HHHH **** "BBB@"*0E0IYQDYQCK@D>YR>!CDDBOS6^,?[?=_X
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MZ_%<B4<;]3P_UN*]G[FF)]LO<]W2T=+"T445B>@%%%% !1110 4444 %%%%
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MKYA6=[6M=JR5K:O1I_\ #=CVNLNUW;M;R"BBBF 4444 %%%% !1110 4444
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MW?2[MH@HHHJAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $$W*HASAVVE@2-H"DDDCD#C&<Y!.
M0<@5_/9_P5K_ &??&_PJ^-'@#_@I%^SO^V!\"OV4/C/I?PYU3]G+Q]I/[3WB
MBR\/_"GXZ?#15U_XBZ;X T*2_P!,UNYOO&LNIZ9>O)X2TC2#J'B*QM;'Q)I6
MO>%M8\!N_B;^A2?&P9W8W<[,[L;6S@@@@XSR"#Z'-?RQ_P#!0W3/V9_$'_!;
M/]GZP_X*-^)-!L_V2-&_8]U;6O@QH_Q+\0:7I/P1D^/*_$:ZM?$5I\3$OI5T
M^T\.W_A=['5=9?Q!+8:7J6J>&OAU%KU[>^%[6YTJ]^GX2C5>:U:M%U&L+E^+
MQ>(PU+"PQU7'8?#^PJU,'#!U6J5=U>6$GS/]TJ4JT4ZE*$7XF?.FL%RU(Q7M
M:U&C"K.JZ,*-2;ERUY55K3C22E=JW-S<KT9YA_P1[_9<\9?'#XH?LL>,?C!^
MW!^RI\=/AC_P3@\#>(='_9W_ &;/V:_&.E>-=3\,:UXLTF^\#GQ]\6X]4\+:
M#XICMOL2VFK>'=8U);Z>7Q;HFC/X:N?#&EZ=XEL?&_\ 7&A9 03D!25^[\HS
M@+\J( I R1MR&W#<0!G^0/XD^*?^"7OP<_X*H_L$>/OV!_C?^RI\#K#PQ:?%
M'6?VL/'G@3XR?#KP9^S'=?!?4?#@TG1_!VM^(9=:N/A9K7Q0\0Z@-9M=-\#>
M&'E\3.UUI'C7Q/!I']@>%_&7A[^JGX/?'3X)?M >'M0\7? CXP_"_P"-?A32
MM=N_"VJ^)OA)X^\*_$;PYIGB:UL-+UJZ\.WVM^$=6UG3K37+72==T74[G2KJ
MZCOH[#5M,OY+>.WU*V>7KXS5>OBL'F+PN*P^$QF"AB*&'K98L L%&IB:W/2E
M&E#V4G7K*I7A7E.-?$QDYU*47"#EEDDJ4(5<,JU.K6HXB#E5AB/;K$4U2BXS
MA.3YFH1DHN*3C!JR>K/74.>HY*@^O! X/Z=O6I*C4C.!GD'KP3C XR <#\N>
MV,5)D9 ]>GX5\8OU?XMM?@?0;Z]&[K2V@4444P"D)QU_K@<$\G' X/)P,\=2
M!2TQS@;B0H7+$GC 4'G<1A1_>8C 4GUS0 I=1U8#C/)QQD#KZ9(SZ9&>HRNX
M<_7'0^N/QY[].OH:_"7Q'_P5_P#$MA_P6\\%_P#!*3PS\&=#\2?#?4O#46E?
M$SXZR>(=<T/Q%\./C#J7[-GQ3_:GT+PA!X>O-$.D^+=*UCX:^!=&FAU'2M2A
ML[&Z\3ZB)]8&J>&[OP]/]-?\%6O^"A;?\$Y?V8IOBGX4^'=K\9?C3XNUVX\,
M?![X2W6N3>'-,U^3POX4\1_%;XK^._%^OVFG:E=^&_AI\&?@GX#^(OQ4\?>)
M3IQT>"P\,66C7VJ^'F\20ZM9 'Z?JZM]UE;C/RD$8R1G()'4$#U*MCH<!8;=
MV0 !DD\8 ZDYQ@#N3TZFOD+]C+]I6[_:)_9I_9<^+/Q&L?!GPY^+/[1'[/7@
M3X^3_"32?&.GZS=Z=HWC#P[H&OS7FA)-<KJ>L:!ID'B31(+O58;3[/8W.H6U
MI?21W4R1#Z,U7X@^!-%O]:TK6O&GA+1M4\,^$W\?^(]-U7Q)HEAJ'A[P+'/J
M=H_C;6[&\O(KG2O"4=WHVKV[^([Z.VT=9]*U*(WOF6-TD8!V6020.H_ ] >,
MCD<C)&1G@\@BE)QZ_D3_ "KX$_X)S_MV>!/^"A'[/6G_ +0O@>VT+0--\3>*
M/'Z^'O!=MXTT+Q5XPT[X8:1\3/'?@SX3>,_'VE:/(+GP-KGQ2\)^#!XW?P=J
MUI!<^&;B_P!0\--=ZM=:#?:K=_66@_%[X5>,/$VN^!_"?Q+^'WBCQIX9?4T\
M1^$?#OC3PWK7BCP])H>IP:+K2ZUX?T[4;O5=*DT76;FWTK4UU"RA&G:M-!87
MH@NI$CH ]'WH0"&!!( *_-DDXXQG(X.2.  Q) 4D*"#P/Y'CIP?0\]#@^U?G
M9H__  4 \ ^)_P#@HGXX_81T*;P-(OPJ^ _A?XB?$CQ]JGQ*\.:-K%M\8_B?
MXRN])^&7P$\'_#S4;FVU_P 9ZT_@'P9X]\?>._$'A]=2TWPD'\#:!J$5KK6N
MRP6_T-^SCX^^*?Q&\/>/O%?Q&M/@DOAR[^+WC_3_ (%:I\#?B1J?Q0TOQ/\
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MQ(^,^D^'M(\<Z-X3\;ZI\%O@]\0_C-</9Q>)_@WX?^,_Q=\-:XFDZ)J?A?\
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MA?5="T/3M.U%;_4/S6_;(\>_#+XFZQ_P<M_M;_%;2/AI\0?A=^S/^R9\)/\
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MFN_V)I][8^&;"RTR  _$7_@FY_P2Y_9'_:P_8YN/V]/^"CWPT^&?[6W[3/\
MP4:\&VG[2/QN^*/QBL9-7TGX/?#WQSX>O[_X=?"+]G^[U^2/6?V?_ WPA^%6
ML:;H]OJGA'7X/%L&KV33_P#">2^$?"'PPTSP5^='@Z#XB_M@?\$P/^"*7[ 7
MAOX[_%*'3/VH/V_OBC/X'^.S^*=/T[XY)^P/^P=\0_C?\0/"7BOPEXGNO"%[
MXE\'_$WP]X&\*?!J#X;>+Y?A[HUKX9\0Z5X3T3QC9^'=*UO[%>?LS9?\$ ?@
MGHWA?Q'^S[X>_:Y_;CT#]@3Q5XRUWQ7K'[ &C_&+2+'X%C1_$VLQ>(_$7PGT
M3QC#X2'QU\,_!;7=;6XO=3\ ^'_B?8+=7&K>([Y]576?$FN:SJ/Z(#]A+X20
M?M$_LJ_'K3&U7P_HO[%GP ^(_P  OV</@EX<M-'T'X8_#G3/B=:_#SP_KWB2
MQ@TBTL]?U"^M?AY\,O#OPYT7POKNLZSX T31D_M72O#5IXF2/78P#\9?&7[$
MO[$'[&__  5Z_P"".G@S]DWX._"[X#^)O!?P_P#V_P#XG_&+5]"NY[;QEXU^
M#5C\!_\ A!M*N/BYXLU?7-:\>_$S6F^)?CNSU_P_XK^+MYKDK6/A?QY=Z=XR
M6^T>?2M1_/\ _:/_ &8?!_PLTG]LO]JO]J+]@GX!_P#!77_@G]^V5\7/BE^T
M7)_P4?\ V</'-GXU_;:_99_9T\<Z7:067V#1_B#IWB;5?$/@#]GSPUI>A^'?
MAEJ/P ^*^@^ OAK\-_A[K'C7Q9I^CZ?>:IX<M?ZNK3]CCP&/VY-;_;UU'7O$
MVJ_%.[_9=TS]DK0/#MU_9,'A#PI\,A\39?BUXH?3X;33+?4M9U?Q?XLBT*6_
MN_$UYJ?]EV^@K;>'DTFWU;5UO?SGE_X(0_"JSTGQ?\%O"?[8?[<O@?\ 87^(
M'B+4]9\7_L#^%/B]H6F_ E_#OB/5CKGB[X/^#?$H\)-\:?AM\"O%VH&2'Q)\
M-/ OQ,T&VO-)UKQGIUKJMJGBR_EH _5']D[2O ^A_LM_L[Z7\,_B7XV^,GPT
MT_X(?"^V^''Q9^)=Y%J7Q ^(GP^'@K16\%>,_&^HQ^&_!C7_ (F\1>&&TO5-
M:O;OPQH-]=7US-=:GIUOJ$MR#_-[\2?#GPS_ &T?VPOVJ/VGOA7_ ,$AOB9_
MP5>O/#?B*[_9D^'WQ0_;#^.W[.'@3]BWPM)\ =>T+P=\6?!7[+WA#XFZ1XBU
M.S\)K\14\5ZM>?%-OA7\2KKQY\1[3QUI_ACQMHOAG4O$%O9?U2>$_"7ASP)X
M4\.>"/!?A[1O"7A#P9X?T?PKX1\*^&]-LM&\.^&O#7AW3H-)T'P_H.D:?';6
M&EZ/HVEVEIIVEZ?:6UM8V-G:VL%K:6\,"1K^+VL?\$//!=EXD^-5C\%?VY_V
M_P#]F+X!?M#>/?$/Q2^*7[-GP%^,_AKPOX(E^('B_49]:\::KX!\8ZUX"\3?
M$_X7Z-XXUM+._P#%7A[PCXPMK/5K:35/#[-;>&-2CT/3P#\-?V4_@-XD_:Y_
MX)S_ +8?[*GP8U?X"_L5ZO\ 'O\ X*@_$'3OV3_V(/BE^T%\1OB3^SCX\\*_
MLHZ;\+O$G[3OP#\"?$3X?OX6\4_$C]GGQ]XK\*_%#QAXVU+X$>';WP\U@-<@
MLXM/667Q#I'W1_P3Z^&7P/\ "W_!3#X;:;\6O^"<.K_\$B/V[_AY\#OBU8^&
M-$_96U3X?WG[$/\ P4"^!L\7AJR^(EY>ZQX*^&NFZ#J6I?##QQK7A3XEZ7X-
M>3PW\2/"!N/AW;^._&OB^RT:R\+Z9^B.C_\ !$G]FCP[^P9\*OV#?#'Q%_:#
M\!Z%^S[\4_'WQB_9Q^/OPQ^)5W\._P!HKX$>._''C3XD^)QJW@7Q_P"'(HDE
M33="^*WBWX>7-IXBTS6K?7_"MZ;C5TG\3VFE>(;#V+]EW_@F7X0^!'QXO_VK
M?BU^T%^T3^V3^T\WP^O?A/X2^+?[2'B3PK/'\+?AEK.JV&M>(/"/PM^'WPV\
M*>!?AYX2E\2ZKI=E>^)/%*>';[Q=?JMQIMKKUGHNJZWI5^ >\_MV?'KP)^S)
M^R#\?/C+\1?$7Q,\+:#X;\ :CH]KJ?P2L-,U3XTR>,O'\UM\/?AUI'P:TOQ!
MI>O>'[OXM>(O'OBGPUH/PRMO$FD:EX:7QEJ&BIXC@E\/QZBI_C(_;H_9I\)_
MLU?\$U?BA>P?\&].D?#ZWL? ;:-:?ME_M ?MG_ ;4_VYM"_:.\?>([;PE\//
MC'I^I?"G2?B7\5_BSXRE^+GB+P_XZ_X0[2?B#X$T?Q5=)?\ A>S\&Z-X(GCL
MU_M9_; _9*^#W[<?[.'Q._9:^/>FZ[J?PP^*NEZ79:S)X7\07OA3Q5HVK^'/
M$&D>,/!_B_PSK^F,K:=XB\'^--!T'Q7I2WEKJN@7VH:-#8>(M U[P]>ZKH>H
M_DUXS_X((:#\9X?A<W[3/_!1;_@HA^TQ=_ OQS\*?'WP;L/BO\5/ $O@GP=X
ME^%/B?2-:TWQ9J/@CPW\.-#TWQ]\1-6T.T\1^"=2^(OQ"G\2^*#X9\;:X(+R
M#6)O[3C /V[^$?AWQ+X0^&/PY\)^,_$\WC7Q=X7\ ^#O#GBKQA<2WD\_BOQ'
MHGA_3]-UKQ+/-J-Q<W\UQKVI6UUJLTU[--<R_:T\ZXN)DDFD]&J*.(1EBN?F
M/.3TP<C&#SDEF);+$M@D(J(LM !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% $,P&T%CA023D$C 4GISSD#:> #SR>#_-G_ ,%!?$__  4>
M^!O_  4W^'_[0W[(?[._[0O[2'PHLOV>O#O@WXE?#:+Q_K-A^SQXMOY?$_C>
MZMQI'A[2-5MK32_B/X;LM4O)3XF\2^&O&-KIK:UIEUINF -?6Y_I,E&57J2"
M3D<'H0W0'JI(QC)Z#DU_-E_P4(A^(G[;O_!2_P -?\$UKS]HGXD?L^?L[Z#^
MQGK'[1_Q$T;X1^)]*\+^-/CGKMUX\G\,0> Q>WVD:@+R&UTFQ74U\-ZK:>)?
M#MSH6G>+-6U/PSJDT%K/IOTO"48SS6LZE+"UL+3P&+^O1QU'$8C#T\+-4*52
MI&CA9PKSKWK4H8?V4Z;A4G[252G",YQ\;.Y<N%A>I6I*6)H*G*C*,9RK7FX0
MDYJ452DHMU.:-G:.^B/<_P!GO_@HG_P4Z^)_QN^&'P]^+/\ P21\8?!CX9^+
M?%5MHOC3XMWWQ;GURR\!:+);7\LVOW.D?\*_TUM0@@G@L[81MJ=LLOVDW3R1
M B!?W5AY8N ,MT8*$#C"_,0&;?T&&/(^95)^:OY#/V6?BE\8OAEJ'_!N3XD\
M#?&#7WTW]HCX$_$+X,?%?X#7?V'6?#7B+P1%I.G>--2^(36L4$'C&ZU+0[ZX
MTNY3Q-JNI:C8^%W\*Z"VDGP]HNO?%72/B5_7E;DE<L"KE3G(4.,!5)X9@< *
MI"D@  AF!!,\5X2CA\3@YX7!8+ 4JU#%1C#+UB[U?JN.Q&&G]:^O5J\X5.:B
MG!J;IRA47)=PG)WE-2M.G4C5E5G9Q?-4E2F[3A3G%.5*%.&G-MR\RU3;NBTH
M[YZYR.V>/U_GVXIU,7&00<Y!_$\9(^OMZ4^OFHWMK?776UU=+1VWMW/6VT"B
MBBJ **** "BBB@ HHHH *"< GTHKQ7]I+XOZ/^SW^SO\>?CYXACOY= ^!_P9
M^*/Q@UR/2K"/5M3?2/AIX&UWQIJ2Z=I4U[IT.J7S6>B3"STZ;4+&*\N#'!)>
M6JN9XP#VC>G'SKR,CYAR..1SR/F7GW'J*-ZY(R,@ D#G )(!..@R& )P"5;^
MZ<?QQ?"OX+_\%2M$_P""*NA?\%+OB+_P5>_:5OOVH/A3^S!X]_;I^%?PWLW^
M&&J?LW:U\([W0/\ AHF'X=_M :#?_#_6O&O[0?BCQ9\,EUS2])\0:MX\\.^'
MOA8_B?PCX*\'^%K'2_AQ>Z[XY^V='^/'[77_  5R_:-M?A'\!?C[XW_80_8U
M^#O[+G[,_P 4?VK_ !)\%8_"%_\ M/>/_CU^V'\'M+^/GPZ^"OP>^,?CGP)X
MNT'P=X.^%7PYUCP%KWBWXE:!X4\.>*=7U+7+[PF-"OM*\56VH^" #^D+>A P
MP'?L"O!SD-C:0,DAAG"MQD''B?[/G[0OPG_:?^&EK\8?@AXJMO''PRO_ !7\
M2O!FC^,;"">'1M?U7X4?$7Q1\+/%][X?N)X8AJOAR'QEX,\1:?HWB"W7^S=?
MT^QM];T>XU#1]1L-0N/YP?BQ\5?VOOV//"'_  5L_86^(W[97QX^+^A? O\
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M=1Z5XH\0>']8;0-<OM7 /['HI/.02[6&Y598I4V21[XTD,4RG8T<C @RQRY
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MJ_,?_@E>O[1OC_\ 9ZOOVJOVI?$WCB/XF?ME>+;[]H30/@CXAUK[;X5_9?\
M@KXEC$/P%^!G@W1HM(T"#2-0T3X20>$]:^)]W>:)8>(M8^*.N>+)?$1NM1M6
MN9/TXH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR2<Y/3L3Z_\ U^>M/KY:.W3_ +=T6RZ/8]SN^^OELMO(****H HHHH ****
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M[(44 ?C9\*?V<?\ @J=\4_VEO!'[2W[9_P"T+\)_A=X$^!?AKQE:_"[]AO\
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M/Y?@]XC\87WV'QK:V%II&OV-KJ<OA;3]-U7^BRB@#\5_!?[./_!6O]H;XY?
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ME^%QJEU=:]XAFMH+)M4US7/$&HZSXAU>>&SMH+.Q&IZO>)IUE$EI8K;VP$0
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M%%% !1110!%(&(3!Z$[OESGY&P1R,8.#GGC(QS7QS^WSXY\7_#;]DWXO^-?
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MW_?!_P#B?K_D<F\?WF_[X/\ \3]?\CDYH_S+[U_F%UY_<_\ (DHJ/>/[S?\
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M>?W/_(DHJ/>/[S?]\'_XGZ_Y')O']YO^^#_\3]?\CDYH_P R^]?YA=>?W/\
MR)**CWC^\W_?!_\ B?K_ )')O']YO^^#_P#$_7_(Y.:/\R^]?YA=>?W/_(DH
MJ/>/[S?]\'_XGZ_Y')O']YO^^#_\3]?\CDYH_P R^]?YA=>?W/\ R)**CWC^
M\W_?!_\ B?K_ )')O']YO^^#_P#$_7_(Y.:/\R^]?YA=>?W/_(DHJ/>/[S?]
M\'_XGZ_Y')O']YO^^#_\3]?\CDYH_P R^]?YA=>?W/\ R)**CWC^\W_?!_\
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M3=O^ULGU;:Y<GQ=K/O\ \*._>UEY'Y._\/P/^":7_1<O&W_B+G[6?_SBZ/\
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M_P""_P#G('U7BG_H;Y/_ .&?%_\ SQ/R=_X?@?\ !-+_ *+EXV_\1<_:S_\
MG%T?\/P/^":7_1<O&W_B+G[6?_SBZ_6+[$O]W]8__C='V)?[OZQ__&Z/K/#/
M_0HS[_P_X+_YR!]5XI_Z&^3_ /AGQ?\ \\3\G?\ A^!_P32_Z+EXV_\ $7/V
ML_\ YQ='_#\#_@FE_P!%R\;?^(N?M9__ #BZ_6+[$O\ =_6/_P"-T?8E_N_K
M'_\ &Z/K/#/_ $*,^_\ #_@O_G('U7BG_H;Y/_X9\7_\\3\G?^'X'_!-+_HN
M7C;_ ,1<_:S_ /G%T?\ #\#_ ()I?]%R\;?^(N?M9_\ SBZ_6+[$O]W]8_\
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MO&W_ (BY^UG_ /.+H_X?@?\ !-+_ *+EXV_\1<_:S_\ G%U^L7V)?[OZQ_\
MQNC[$O\ =_6/_P"-T?6>&?\ H49]_P"'_!?_ #D#ZKQ3_P!#?)__  SXO_YX
MGY._\/P/^":7_1<O&W_B+G[6?_SBZ/\ A^!_P32_Z+EXV_\ $7/VL_\ YQ=?
MK%]B7^[^L?\ \;H^Q+_=_6/_ .-T?6>&?^A1GW_A_P %_P#.0/JO%/\ T-\G
M_P##/B__ )XGY._\/P/^":7_ $7+QM_XBY^UG_\ .+H_X?@?\$TO^BY>-O\
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M<90E*$D]'S1;C*ZZ----=&FNANI*23333V:U37=/JNS"BBB@H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BE^Z#G&
MTDY()7H1S@$C!YR.00.1G->,?'WX0^'/CY\*?%_PD\6ZEKNC^'?&5I8VFIZC
MX:DTZWUV"&QU;3]6B.GRZMIFM:8I>?3X8Y_M>EWT;V;W,:Q+*\<T7L\HSLXS
MAP>^<;6'9ER.1D'<#T*G.1\"_P#!3+R&_8B^/2S)&8AHWAI7:>-3#@^.?"[
MR"8")U614*Y.-P4!@V#7HY/1GB,WRNC0Q+P6)J8[#0P^+2O]6JRK0C"NHW2?
MLI24]6KN.FQ\[Q7B</@N&\]Q6,P:S'#4<JQU2OE[;4<?1AA:LZF%E-4ZCIQK
M13IRDHU&E+X=#ZR^$OP^T;X4?#WP'\,]!O-3U#1/A[X(\,>"-&OM:>UFU:[T
MKPIHMEH=C=ZG-86.FV$FHW=M9K-J#V>GV5G)>><UI:VT(%O%Z;SD\_0>E?*W
M[%3#_ADS]F)48F,?L]_!PQ\$C8WP^\/%0IP5^12A(1F!5T&<8"_4_4D#@C'.
M/J?\_C7+BXRAC,9"=1UJE/&8RG4K-6=6K3Q5>%2K;_IY4C.IU^/=G9D=6G6R
M;*:U+#1P=&KE>75:.$BU*.%HU,#A9TL,I6CS+#TYPHJ3C%R5--Q3T'4445@>
ML%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !1110 4444 %-)7/)Y' ]<D=!G@D@<#FAB ,G./8$DX!;&
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MD D/I]_)V?KI_F)-/5.Z_P FT_Q04444#"BBB@ HHHH **** "BBB@ HHHH
MAEPR@$'&<D ]<JPQ_M @DX&.1GD\5\[?M6?&C4OV>?@%\0_C!H^@V7B/4O!=
MCI-W;:+J5Y/I]E?&_P!>TK1W6YO;6&XG@2&'4I)_,BB9O,@16 1F-?0]PNX)
MDM@,<A0#N!1EVG)&!SNSR01P.,CY_P#VH?@I/^T-\"_'_P '+;Q+#X0D\;6&
MEV*>(KC0V\20Z6NGZ[I.M/*VBKK7AYKUI4TPVR*=8L3!+.ESFX\DVL_9E?U/
M^T\ LQ47E_US#?7(VJR;PGMH+$KEI+GM[)S_ (=V^BYK'B\1+,GD.<_V,W#-
MEE>.EELX^RYHX]8>I]4:^L-4+JKR-.HU!;3]V[.E^ WQ)N_BU\'/A3\3=0TN
M'1;_ .(GPW\$>.;_ $BUN);JVTJ[\5^&M-URXTZ"YGCBEN(K*6]>WAEEC21X
M8HY)4#RD#V.O'_@9\-6^$7PF^&'PPDUL>(I/AQ\.O!O@.775TX:3'K+^%/#F
MF:$=4CTO[=J?]F+?FQ^UKIW]HZC]C\[R#>W6P7$OK_&3] #^I_K6.)]E]:Q7
MU=6PWUK%?5EK98;ZS7^K)<RYDOJ_LM)6DK6DN:YT9.\:\JRS^T6WCWEV >.<
MO9W>->"PSQ;?LFZ=WB?;M^S;@V[P;ARBT445B>D%%%% !1110 4444 12[=J
MELCD@8/.2K# _.J37,2RI&)8\@'"$_O79!C*C.64="P!XZ9QBI[J0+$#D8W
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M9V_A)/ [:'9-X33PQ#ID*:=%X;&ABP&B1V,4=G'I9@6UC2..-*_E/L?VC?\
M@U.FT>SEO? _PQTN6;2K:2ZTW5?V5?VJ;[5=-S:XN;35;_3_ (7ZQ97][9J9
MK?5+ZRUG5[.\D@N)HM4U&"-;N3^ICX-WOPYO_A%\+M0^$26T/PHU#X>^"KWX
M7QV6G:AI%I#\/;CPUI\_@I+/2-6M;'5M.M8O#)TX6^G:K:VNJ6=LBP7]O;W<
M,T*>IQA5Q52E@OK"XHJ+V]>-%<0T:.'I**I1E+ZK[&G34J[G&]1OG7LN2TK/
M7CR)8>$JRH_V4IN$93C@)UJE2SLE.52K*5X-^[&+M-6Y6C\)/^#B#P!\-/C+
M\.OV'_@7X[TOP[I&K_&_]L;P7\+_  Q\;/%<VN76C? 2T\5Z?<V'B7QQ#X;L
M/%_A+P[XIUB\L)+31K32_&\^H>&QIEQK4T0TK5AIWB#2/RT_X*N?\$(_V'_V
M&/V/=9_:=^&/BWXB2:Y\-?&GPWAUCP/\3-<\$ZO;?&'P]XF\6:1X2UCP9X<O
M-,\'>%KOPMXT,.J2>+++7K"#Q)96^D:%XATZ;P@UMJ%GJWAC^LO]L;]F#]GC
M]L'X'>)/@S^TSX<TO7/AI?3VFLC4;S4H_#VJ>"O$VG))%HGC+PIXLS#>>%_$
MFFF^N+%=1AG6VU+1=7U3PMK]AK/A?Q#K>C:A_(SXR\&?\$$_V//B_P"&M6F^
M.O[6?_!3#Q[X$UG3O$GPX_9T\(^(/#?QZ^&3:E'!/>Z3IEIK?AKPAX!^&GC>
MUL;6UM[_ %7P<_Q+\42-I7A<:=XI\*ZKI-Q)H6K^UPCF6*CA,%2P>(SFE+*J
MV+Q.*P&$RV.,PN9QJR<XNMC*CIT,'&,.6A65>;HTH7Q,$ZMHOCSG#TOK%6I6
MI8"JJSH0HUJV(G2JX>4.55(2H1<I8CG?O05.+;M[.5HZGZ5_\$H_ MI^QK_P
M4P_:,_8/^"7Q(\:>)_V5+S]D+X7?M-Z)\-?'NL0>(-5^#/Q/\1ZSX0M-3\/1
M2Z5=PZ'H>K^)M-\8ZCXQ\5QVGAKPO=>(;/6O!$EUIEXOAN'Q-XE_IM(!X-?%
MW[+7[(_P6^!7B[XU_'GP/X2\1:5\7/VM/%-M\4_C5KWC37]5U[Q+)J5_)JFM
M:3X+M;?48+"R\,^%O +>)-3\/Z!H.DZ-I4ZV=O&/$,FJZG9I/;?:/X?_ %Z^
M+S['4\QS'ZS34T_JV%HXB=14E.OBZ-*4,37DZ24).=1J"G\56-"-6;<JNGOY
M9A9X3#>SG.,U*K6JTU!2Y:=.I/FA3CSI3M%7:4E>*ER[104445XYZ 4444 %
M%%% !12$@=32T %%(6&0,\GM@G]1P/QI"ZCJ<<XZ'K@G'3L 2?0#)P*3:2;;
MLEOY ,DZ*2< $G!/'0_>/88SGKZ#D@UQWBWQ?HG@_3&U#5IV7>[QVMK%%YUU
M>SHCOY4$9PF5"_/+*T=O"[1+/+&9$#Y_Q ^(6B>"]/9[B6.[U:0?\2[1HY56
MZO)6#HKL"#]GM$(9I;R1?*1D$2%[AXH9/B37O$FK^+-3DU;6K@W$^3%#;("E
MI8195O)M(2[+&DHY9E>5YY%::X='94'V'#7"F(SJ3Q.)52AEE-_O)J#57$O1
M>RH-I:2;2G55X0BWJY-<OYCQSX@8+AR$L#@G#%YU5IS5"$:D71P,FI?O<2XM
MKG6LH46U.I))-1A>_P!:?";QAJWC.[\5:GJ1,:1W5A%I]@KGR-/LC%.R0HK*
MI>X<G=>7+C?<S8*"*WCM[2U]MR,D>G7\:^:?V=,_9/%#$DL;G3MQ8\[O)N<C
MTP6#.,< -CM7TH&'0L"?7H/\*\OB3#4,'G6.PN'@J='#SITZ<(W:A&-*FK-O
M5M/XFVVW=MN]SZ#@3&8G,.%<IQV+K2Q&)Q=*I7K5I[U)SK5+NW1*W*DK))))
M)6'44F0>A!_&EKP[KJTGZGUP44A('4TF]?7]#_A3 =13=P/0Y_ _X4N1[_D?
M\*!V?86BDSGU_(C^8I:!!12$@<FC<#TR?P/^% "T4F<^OY$?S%+0)M+=C'.
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MW:TUN?08?$2KM\R2]+6_ OT445SG4MOF_P V%,?. %QDL!R<=>I^ZQ)4?,
M,E1EE7)#Z\>_:%^,.B?L\_ /XW?'[Q+$EQX;^!OPB^)/QA\0P2SWUK%/H?PR
M\&:WXUU:*6YTO2-?U*WCDL=#G22;3]"UJ]B1B]II&J3K'87 ,\W_ &4/VN?A
ME^V'X>^+/BWX3:1\0++PK\)/C]\5/V=;CQ!XX\(R>%=+\?>*?@]JMIH'C'QA
M\,+DWE[#XS^&9\3RZGX9TSQE;?9(KKQ)X;\5:+-I]E?:%>QGZF\Q, [AM) #
M<X.[IST^;^'GYLKC.Y<_DY_P0X^$6N_!O_@E/^QEH_C/5]6\0^/_ !]\*8_C
M_P#$;Q#XET6_T'Q;J_CO]I+7-7^._B5O'$>J:KK.JZSXMTJ\^(/_  CVL>)M
M:O6U7Q++HZ^(+S3]#;5%T'3ORC_;N_X*+?\ "X_VX?VD_P!C/Q!^TQ^V_P#L
MA?LL?LNZ3\*O"GBWQG_P3^_9E^)GQ$_:#^/?QZ\<^'I/B9XGTN']HWPA\+_C
M!IWP%\!_!31W^'.C7_A/2O!>B^,OB7K'B?Q0LWBK4O!G^@V@!_5\TL:C)=0,
MD9!S@@E6SC.-I5MV>%".S85&(?N7U'4#KW.,#\<C'J2!U(K^:S_@FE^VSXVT
M&']O;X>WWQW^/WQL_97_ &7_ (+?#[XV? 3]JS_@I;\-O'?P ^(/AZ\U;POX
MXMOB/\*_C?\ %#Q%\+/ %]\4O ?@KQ+X$TWQS_PMI_AW:^-]$T;QMKGAB\MO
M&$>@>&;J'\??C-^VKX!L_P!FWQY^V3X-_P""\?\ P4]^-7[7O@SX5^./&7AO
M4?V>OV=/B+X7_P"":4'QH\+:->7WA/X6^)_A#K7[(TWPQMO!VJ^)-4TWP!<:
MU\1?'<VI9O=)\6^/1I+Q66G$ _O29E((STSN/W2HR5+9.-N!DANI4$J3UKY=
M^+?[6/PQ^#?[0?[*_P"S)XFL/&VK?%#]KN_^,%O\,H?"GAA]9T'0])^!O@FT
M\<?$#Q9\0-8-Y:)X6\*Z;#JOACPW:7D<6HSW_B3Q9H5B;'[%<:AJ.F_D1X^\
M<?MI_P#!0[]H/P)^P7H'QP\8?L/:'\%_V0/V??VBO^"E7Q1_9E32-&^.MA\?
M_P!H"#4#X'_9-^#OC'Q3?^,_^%0:,EKX/\<?$O7?B?X8/Q1O9]'TKPYX!F\0
M"VU#7O[:X']G']GOXI^!_P#@NGX1^$?Q7_:,^*/[6/PX_8M_X)AZIXU_9[\:
M_M":KI4WQU\':]^TU\8?"?PNU:+Q5KO@/2/!OA'XOZVGAWX$?$:+6?BMX@\)
M:!XRU+1/&O@OPUXNMO&^O>"+/XAZD ?TJ1D*,LR %5*A22/FZ  YR"P(B*XW
M*0@0^6K&4NH(!9020 ">3DX&!U.3QZ=?0BORG_X*Y_M2VW[+W[-/AO5G_;6^
M%G[ MQ\0_B_X*\%7_P"T#X\\$7/Q6\9:!X*+7^O^-+7X)?">+PAXTT[QG\4-
M3M-(M/#P;Q3X<N/"?A/POK7B#Q;J&H6^N:/H"3?AO^SQ^TE9?"C_ (* ?L0_
M"K]C'_@HQ_P5-_;!7]J7XX^*O!/QI^%O_!1GX?\ CF[^$7BSX&^#?@W\2_BA
MXR^*OP \=?%3X"?L_'PSK_PUOK#1M46Q^'>K7L_B?3;_ $2"^TO6_#&DZ7H&
MN@']D&]?7MG.#C'.<GH-N/FS]W(SC<,F]<$[@ ,\DX'"[LY. 1M^;(.,9.>#
MC^,']M7X]_$C2?VROVDO#G_!2/\ ;R_X*A_\$L="MOC7KW@__@G;\9_V;_#V
MF^&_^":GB'X8W/A'PC?_  DF^+/B/PMX(\;>(OBY\7=0\3VWB+QK\9?#GQ%\
M=>&?#]CH1U?PI9>)_AEH;7.@^&OT'_X*&^,?^"F7PK_8 _8RM9_%WQS^,>J7
M_B#1O"?_  44^.__  2T\!^%?$7[3?B7X3?\(%XDM;+XH?LV:-XHT&#2/"E]
MXVU\>&_$7CKQ3X-\%V+>#+BXN+WP-<^#?"XD2< _HV+J 26P P4]<AB1M4C&
M06RH4'EBZJN2RY7<N<9R1C( )/) !( ) SWZ  DG"DC^1;]FO]NGP_\ LG?L
MJ?MZ?MQ? /\ X*>?$?\ X*1_L2_!'X,72Z+\*OVU6\7:O^V/\(/VW+_Q+X?\
M$_##P+XL\2W?P[\ >,6^"7QFU_7;;P]Y'B#PAI5KX>U6WAG\#+<-9^/M?O?C
M_P 7_M<?%"#X8:K^U%!_P4Q_X+!>(?\ @HSX3^'&K^-/!_P)\-_L"?'#P;_P
M3H\1?$G2M#U34M/_ &?=2_9FO/V8[;3-:\':U]LO_A&/BWXM^)%GXKM-4N-%
M^,VJZA;ZWX8LK&W /[+?C%^TE\)O@?XL^!7@+Q[K]S;^-OVDOB@GPD^#GA+1
MM.O-9UWQ9XIB\-Z[XQUVZ2UL01IGAGPAX/\ #>M>)/%GBC4Y+32-'L[6TL/M
M,OB'7?#NEZK[NC*.2RA2"VX/D88@[F(!50S^9M!D('(4MN*I_(U\4?V=O$O_
M  5:_P""L7[$GBKX@?&']O#]DVY\%_\ !(3P?^VG=Z%\"?C%;?#27]G;XA?M
M-^,K7X7S_"7X=^(#\&+7Q-X1\2^*M&T3XM:1\:/$7B6?3?B/X[TC0/"6E>'+
MGPGH7P_N]"T_^C+]N^T\5O\ L0?MAQ^!?'GB+X8>,T_9:^/O_"(_$OPI>ZGI
M_B[P!XDB^%GB:31/&?AS5-%UG0M9L_$/AV^@MM9TR_L-;TS48M2M;2XM-2T^
M:)9E /KC>F,[@!@G)..!G+<X^7@G=T(Y!(YJ*9R%&S:7+84,2!]TMG 21F4\
M*^U<JC,VY=I(_C&_X*M?MW?M:_$+_@E9^R&G[('Q9^*_PM^/<'_!/KX#_P#!
M3[]J+Q=\+O%'C2]^+&E?!![3X)_#;1_!>L^,_"FB:;<Q0_$SQC\8O'GQ:\0>
M++B]T!9_!7[*/Q;OM0TB\T*?4].N/T>_;#_;;\0_\-0?M"?%GX;>-/'8_9B_
MX)'?L&?%3X]_&:+P-\4-=\$_#S]I7]K#]IKX16WB+]FCX,:U)I/@SQ#H_C;P
MOX'^"%OJ/Q2M_%%A>>,]&\(^-?C/\'_$Y\++J?ANTEN@#]0KS]O'X1>&? 7@
MGQ_\3/"GQD^"^G?%+]K'0/V./A'X9^,7PRU+P!\0/BE\2_%?Q4E^%'@[Q#X6
M\ :I<CQ1;_#SQ<]EJOQ$T/7/$^E^&=5?X3Z%J7CV\T"RTPVEM==CX\_:Y^&G
MP^_:K^ /['%_HWC_ %_XO?M#^"?BQ\2-";PAX3GU_P )> ? OP=M=&DU_P 6
M?%SQ!#>V\G@GP]X@UG7M+\'^#=9N+#4+'Q!XRN[/PQ=3:??ZCI)U3^7'Q-^Q
ME^TA^V%\3O\ @@!\ ?C?^V?^WS\.O%MC^P3\0/VJ_P!H?5?"GQ,N? /Q'\*_
M$OP'X"\#Z+X?\:Z;J_B7PE\1/%NE_M'Z=XU_:9_X59\1_'GQ2U'5]/C^'.A7
MNA^#=)\%^+?&OB:35_ISQ%^SM^T%^V3_ ,%D_P!HOX<_!K]I_P")W[.'P2_8
M4_8,_9P_8K^*_P <M"N];\=_M3^,M=^.5SK7Q[URS^!?Q,^)7AB_\#_"SXH^
M+/!+^"'^.?QXM+?XD_$ZQB\)?#";2&36_&U_J/PS /ZFXQ@Y!!7!"D'<""0R
MX[ 8;Y0N!@A "L:,9J_$/_@BUX\^+&H_\/#/@7XL_:#^,7[5/PD_9 _;L\;_
M +,WP5^.'[1-SIFK?'34/^$(^'?PZU3XK> ?'OBNST[P]?\ CU?A[\1_$.JV
M.A>.]8\,VDGB*PU-IM&U2Z\,P:+H7A?]O* "BBB@ HHHH **** "BBB@ HHH
MH AE4'@GJ3A?7,;*>_IG!/ (S7\PW[</_!#K_@DK\/(_VA_VV?VH?B3\<O >
MB^+?B)X[^+_Q#U>T\8>"'M)?&?Q9\<ZOXIOM \':"/A/JVNZE>ZWXJ\32Z1X
M6\/0SZOJUV\UA:R7%TZ3WI_IZE!(4#.-PSCN,'()[#OGVQQW_GF_X./]8\ ^
M%?V0/V<?&_Q'ET#6O"_@']OCX >,=6^$?B.VUMM/_:"T?1_#'Q6?Q9\&6U'3
MM-U'1M$&O^!Y?$_B*]U+QBUAX<?2?"FHZ7;75QXKU'PSI.I?0<*U\='/<!@\
M'C,;@XYCB:.$Q4L"Z4*TZ#]K55.,JU*I3<YU:4(P<N6-.<U.<N6%CRLXIT98
M*M5K4:=>-&G.JE4YW"#]R#FU"4;KE=Y=XQ<5K(_G6^%WPG_X-P_B9\2[#X=Z
MUK'_  4$^#>C>(=;B\-^&?BW\8%^#6@_"G6;F^U:+3=#U&37M!T'Q=KGA+P_
MJ=M(_B2V\0^/O#'A'0?#^@Q7>J>+;SP[);7$4/\ ?[\*_ &@?"CX;?#[X6>%
M)+Z7PS\,_!/A/X>^')-2N+>ZU,Z!X-T'3_#FDRZC<VUO:P3W\EAI<'VR6"UM
M;:6Z1S%:6ZXB7^0+_@I=_P %RO\ @GK^U?\ L*>+/V9_A1X,\8ZAK_Q-M_ N
M@:3I_C;P/HOA70/@=9Z7J>E:JOC*W;3->U33]8UKX?1Z6FFZ)X8\$WUS::OJ
M4L=BFM0>&I[B[?\ 9W_@F?\ \%5?V,/VH;OX??L>? +QW\2_'WQ"^$WP#TJ\
MOO$7C7X=WWA2'Q)X?^%MEX$\":MXBN;B]UK5VMM8U?4?$&C:C_9<MS=2(M[-
M(UY,+;?-]/Q9@<\QV687&XC"9_2AAZ^8?6,+F>*I8_V%"E3HP6/5>E1PSHNL
MW&C4HSC*,G#VE)N&K\7(\5@:&)GAZ=; R]M"+IRPU*I0]HVYS=*?.YPJR@TZ
MD9TVG%?NZB3,'_@MY\7?VC/AG\,OV9_#O[)7QU\:?"7]H;XT?M%>'_A!\,O!
MOA#PQX U.Q^+NM^*K">WCT?QQXR^(]TFD?#KPEX<5?[5FUO3-*\3:QJ>N7&A
MZ&-'M]'O-:\1>'?RS_;@^'/_  7+_87^ B?M)>-?^"FTGQ"^&7AWQ%X.TSXR
M2^"/A]\/;77OAEX=\7ZWH_A>#QII.E>*_"6F1?$G2[#Q)KEMH]SH=E=>&]:G
M>_T6^BL[72YM>U'PK^[O_!4O]D#P'^UI^SWI5[XE^.5O^S!XS_9Z\;:5\>/A
M3^T;?7>DZ?HOPE\:^$;6\2#6_%UUK.J:!:Q^%);>\,NHO'X@T&XT_5K+1-86
M_GCTJ72[[\#M:^&WQO\ VM6T_P"%'_!1W_@N[^P1XU_9+TWQ5X>\2^)O 7P:
M^*7[/VC^,/B;I7AC4CJECI.NZU8^#_A/%X<$\UAI5U)?W>J>/K"SFN[V>#2&
MU#2M-UBX.%\90HY5@^1Y1[/"UL7+-\/F7#[Q^*Q5.4W.E3RVO3RW$I2=)*$8
M5L50E3Q$N=S=#W!9M2J/&8KF>+4ZD<+' RPV8?5J,:B3=2>(INK!1ES6YIN$
MHSI-147+WC]-O^"9O[0W[8WA/]L?XU_\$_/VO_B[H'[35WX8^ ?@K]J'X0_M
M"Z1X;TGPAJNL>"O&&J:#I.M^'O$6B:9!8N]L/$'B=4\*C5-/@UVPMO#^M37M
MY=Z+KOAC3M!_?(Y[''OUK\S/V3OV$YOA%^U;^TY^V?X[^*EK\7/''[0%MI'@
MCX2V^DZ-?:3X6^!_[-/A>]^T>"/A9X3:[\3Z_#J,.I:?:^%M;\3ZAIMKH6BZ
MEXITN^U[2](M9==U)[G],Z^2XAKX/$YE*M@50C2GAL)[?ZOA_JE)XM4G]:E#
M#JT*3YW"-2-.,*7MJ=9TX*G*-_>RN&(AA?W_ #IRJU)4U5K?6*BI-QY.:I=W
M3:FXIMM0E&^MPHHHKQ3T@HHHH C? *GDD-@ >I!/)]/;OT%,) '7"@YS[CT'
MKQP.O4\=I'*@?-T/'3/)X''?K_\ 6]*<\T4:;F90BCS,Y(4JO);<" 1P"%SA
M^$/RL6H5]>6+<KQ45WE)V5M&VVWLK]WL1.48+GDXQ45*TIM1A!).4YRDVDDD
MKMMI*VHLS@;20PR2 S$!<;6)+!E("X4[CR53<>U?+'Q8^-)LGG\-^"[N-[QU
M U/78#')%IZO&)/LNF. \-UJD@E5KJ^4_9[*-EM[60W_ )T]GROQ8^-YUDWO
MAKP=<,-,+B"_\0V\J'^TT9Y([JSTIP 5L3L!&I ^5>H$^S+<6!2:Y^<(5 0J
M N$^0A5VAB"Q\P@LWSOGYF)+-M7>Q58TC_6^#N!)5)4,TSNBU27+4H8&I%I5
MM%*%2M&5G974H4Y)1DE>KT@_YO\ $GQ;L\1P_P +XMQFI2P^-SBG"TXZRA5H
M8&47R\J?-3EB$VW>U)QUF[T9>61II2S2R&65WD<S.\DKAI'\YR)&D=LO<-(I
M>9V1B[LC226D&"H](R/R857CZI_US/\ Z$*LK]Y?]QO_ $,5^MRA&"<8I0AK
MRQCHK+2,59)*R25DDE9)+37\ A.=2?/4NYRDW.3;E*I+FO*I-N]YS<FY:[LN
M $[  2=T?MCYEZ^@Z<GCMU(JY'USZF/'_?;=1U'3J<#\Q51?X!ZE..<L 02!
MCD\ D]@ 2> :X[PQ\4/AWXO\;?$GX<^%_&6AZ_X[^#]QX-L_BGX5TN:2?5?
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MA'()'-)N&2,\], $X)QC..G4'G'&3T!( /YR+[_@BU\:_P!KKPY_P4(\:_\
M!0SXL_ G0?CG^WE\%_@[\%=,T+]CWP!XHT_X6?L^VO[/7C6_^)7PN\=R>+?&
MFH>$/B1^T)XNN/B39>"/&?BB;QM:^"+B2Q\.W7PYM-6D\$7'A^T\*>C:U^R=
M_P %O/VH-.\)?!;]J;]LK]F3]F;X&^&?%OAG7?B#\6/^"=I_:#\*_M7_ +1G
MAOP?K=E<0>"9_$_C"[\'Z1^R_;^-K*R35O&WB#X3ZYXSU,ZMM\+6,,G@*Y\0
MZ1XA_>*?6-*M;K3[&ZU*QM;W5IKFWTJSN;J&WNM3GL[:6]NH=.MYG2:^EM[*
M&:]F2U25DLXI+I@($:07C(@ 8DX.,<'G(!&!C))R. ">O'!P ?E!X/\ V3OV
MMOA9_P %7OC-^U7X#U#]G#6?V1_VI?A!\!?!'QKLO%NM_%&R_:3\&>(_V=/"
M/QKT_P 'R?#/1]+\,:A\-O%&E^(O$_C_ ,-W'B?6?&_C+3]5BT%=6M],TJ&_
MT2TD\3_IKXW\%>'?B-X*\8_#SQCI_P#:_A'Q]X:\0>#?%.D"]O\ 3/[2\->*
M=*NM$UW3AJ&DW5EJMB;W2[VZ@-WIM]9W\,DK3VEW;3".6*\WBKPPEC=ZF_B+
M0TTVPU-M&OM0?5;!;&RU=-0CTIM*O+MIQ;VNH#5)H=,^Q3R1W)OYH;,1FYEC
MC:[#K.DW.HWNCV^IV$^K:;#97&I:7#=P2:EIUOJ7VDZ=/?V*2&YLX;\65Z;*
M6YBC2[%G=&!I!;3; #^:/]D__@C5^V-\,/\ @E7^VK^RY^T/\<?A1\6/VR?V
MEOV;K']DOX?>/+#Q7X^D^"'PQ_9V^#WP>U/X6?LM_"&UGN/AGX?UK3/#OPZN
M?%OQ'\4^(=5TCX7W&MZSK'C[6M3U:?Q;KLMWJ]][+KO_  2;_:(U?_@DOXL_
M87@^)?PKTK]I3]JOXR^%OB;^VC\=])UWXE6'@V2'Q7\=/!GC[XT6?P^TF71]
M0\6?$SP[X=^!?@K0?V5_AE\,_%^H?"K0/%OPDT#0M%\7>(_">E0W>E7'] -M
M=6UY#%<VEQ#=6\\4,\$]O(DT,T%Q&LL$\,L99)89HG62.5&:-T(96(R:E#*<
MX8-CK@Y X# $@8!*LK 'D@@C(YH _'OQ_P#L4?M4Z+_P5\^$/[>GP'O?V:W^
M !_8F\/_ +$WQN\ _$75/B/X?^).@>#M$^.WBGXRCQ-\%]*\&>#M5\$:MJ21
MZGX?T+3M.\8:[X=T^SM]/U--D@NK.XL_;_V"?V1OB;^SAXC_ &X_B9\;?$/@
M[QI\3OVO_P!M;XE_M!VNJ^'-1USQ5J'A;X+_ /"->"/AY\"/A#K7CKQ;X?\
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M?2:=*FURV<(OW8\L4K+1*T;);)-)VM?5,****DT"BBB@"O<G$9'.6RH]R5;
M.>"&.%P2,[L AB*^)/VA?&WB]=8/A5K6]T3PP8T/VR-C#'XH#VR?;H3>!/):
MQM5EEM9]':2*>656GU+-K-:Q5]OR<C Y(.>1T.#M/) ZD?XC&1R/BSPCI/C3
M2;K1-;MC+;3 /'(C+'<V=VF?L][9W'SO;W,#'*.JE&5GAGCN())4/N<.9E@\
MIS;#8['8&&.H4I+FIS=W!R:BJ\*;3A.K0^."FG%V:^+E:^.XYR+,N(N'\9EF
M59G5RS%U8.49035/%Q@G*6"Q%2-JE&A7MRRG3<97:YFX\T7^7" !L9+,&C3?
M][=M1 0C83:JA51XG42))&49G"*QN0])/]\?R:NZ^(GPVU7X=ZG%!<N;[1;V
M;;I.L^6L*3&-)&:QO@K&&/4H LC\$1W<(:ZM@I^U6UIPD1P6!X+,2 >&P.IV
MG# 9(YQ@Y4@X8$_TU@<PP6982EBL!6C7P]6\XR3LTU;FC*FM:;@WRR@U%Q:V
MLT?POF>3YCDF-JY?FF'JX7%TJC52%12M[S;C*E*5U.E-1YH3C*49+523;2T(
M^J?]<S_Z$*LK]Y?]QO\ T,56CZJ/2,@_7<*LK]Y?]QO_ $,4ZNL4UM=N_=79
MI1WCZ+\T:-M$US-:V\8W/<SV\,8P"6>2>.-  8Y&W,Y"KY:[PS!CF,.#^7W_
M  2@,OC#X8_M5?M*>?<2Z1^UC_P4 _:S^,7@J*[$5C>VWPS\(>.8_@)X!M=8
MT&"T,'ASQ#;6'P>O5UJV%WK,ET$CU.XO[N6]&G6?Z0^(K/6=0\,>(=.\.:GI
M.B^)-1\.:]IOA[6-?T2\\2Z!I'B#4-+O+31=5UWPYINO>%M1\0Z+IFHSVU_J
MN@Z=XH\,WVLV-O/I=IXBT*>[35;/\?\ X!_\$\?^"BW[-GP8^'WP!^$G_!5O
MP)HWPX^&'A\^%_!]GJG_  3<^%NOZM9Z2=0O=2 N]:UKX^ZE?W]W]IO[JY%Q
M>RW;;I!&'0(CCY'-WB8YC@Z]+!U\70PU'$2G&@Z2;KUXQIP5JU6G&=J:<DXJ
M\7UV/O,DCE]3)<VPE;-\+EV)QN)RY<N+HXN=\+A'5Q,I4IX?#U5>I6E3A*,I
M)/EU3M8[/Q[^T3\8;OXZ?\%?[;0?B]!\'? _[#?[(_P5E\)>+1\(_AMX[O?
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M&WT$YPI_+H3_ "[^GJ< <D5^%O\ P<0ZAXG\1?\ !.>]_9L^'OANY\7?$_\
M;;_:1_9A_9)^&WAPI;0:%K&O^/?BYX>\8:S8>+]>GD%QX/\ "5]X"^'WC&SU
M/QOI=I?W_A::XM-4B33X[:XUO20#P6#_ (+*_MU>!_V<OV>?V\_VB/\ @G-X
M.^#W["_Q$E^ UI\9_%]S^T7?:G\>?@]X9^,%_I/A_4OVBM2^#\/PG>PC^"NC
M>)-=TF;1?#DOC"]^)>I>$]5\/^(];TWPY+J^KZ=X1^D/B?\ \%-/VEM?_;O_
M &H/V OV-?V2]'^.GQ+_ &<?AQ^S]XK\0^./B3\1+KX3_"GPYJ_Q?T?Q)X\U
MA_'7C%- \43KHT7@I/ VB^!]#\):+KGCOQ1XZ\6:XW_"*V_PY^'GCKQOH?QY
M^V!^U+J/_!:'X=>#/^";_P"S9^S!^UWX+TCXT^._@GK_ .WCX]_::_9S\>_
M#PM^RY^SOX&\?Z;X_P#B1\.->U[QK/IL6M?M*^*-:\%Z-X'\%^$?AO)XST/6
MH+KQAJUEX_TRQ\*77B'3OLW_ ((Z^%O$.NZQ_P %+/VI?%OP^U#P3K'[4?\
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M&^&OQ0^'TUWKVBV&HZ./&/AO^P]:TWQ!HMOJ=I DGY,?!G]M*S_8]_X*9_\
M!7;]I'X\_LY?M67?[//Q7\7?!O\ 9A_94\=_!_\ 9U^*'Q7\-77B?]@?X6R>
M%?B-\"?#6@:%HG_"2?#A_B!XD^)?_"2?";5;OPSX>_9^^)>L>$_BYJ.A_$OS
M/!6H:MJW-?&OX/\ [4FM_P#!.7_@JG^U)XK^#/C[X<?M9?\ !:CX[? OX0?"
MW]GN72O$%I\5?A]^S+XDU;X:?LH_ GP=\7?"_AOQ)/X<\#_%RV_9[U#X@_$;
MXJZ9K?B;2=$LKS6X? GQ3U+2]1T[6/"ND@'=?%*?P+^TC^S'_P $&/@'X?\
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MUS6_#[>(/"VM>&_%VDZSX7LKCPGK TG2K^^7Q7)XK\'^!OU(K\2_^"</A/\
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M\Z=2+DZ=51DJ->G%M*I1J.*C4A9)NSNKZI/:Z!D+_P !Q]> *NQ]6'J5Q^/
M_453'\ [Y3([CD<$=C['!JVAPQ^L?8G^(^E;5VDTKMW3DEY);^BZ]//J84=8
MIK52LHOHWKHK^7Y-EA>Y'MCMG)4_R(_/V-7HP2_(Z[?S _QJBAR <_W.ONL1
MQVY[D=1W%:$9&]>O!]#_ (5P5=VNMEIUV7ETW]&CU,/JHM7=VUIKJE9_=U+,
M0QN]SG\\U;3HOU]O?U_SZ\9JK'W_  _K5N/HOU_K7%4:25^_9]CU,.G=:/?]
M46H2RR!@2'0!U885D965@P(R<@CD JP7<5)8!'T)9Y[HF6XFEGE:-':29WEE
M=B@)W3RNTTA14CC)D;;\NV%(XT!EST_UC>\3#\3P*N)]W_MF%]>=I&..G)')
MXKS*T:=O:\D74I_"VO>UW2TO96Z:;;V/:P_.IQA[2:A4A/GIW?LG*/P5):VY
MXW]R^O8LQ@$QCMCGO_"67.>>2/PSZ<U;B.=^>,(".HY=#D8Z9R!GW/'%5(^"
MF>,!1^.UA@'OR1TS5N+^,=\*,9'8$']>_3ZUQU9)\LFDFTFTD[7:ZV6CTU^_
M0].BI>ZFFVM&UO*WVY.U[OK?R+2Y#@@9.]E_[Y=R3P>QX]\\9XK03J?I_450
M4C<#U DD;\&=F4_B.?;OBKR$ \D#([D =1W/^?I7#-JTGTU_,]JBG>*];Z_\
M'4N1$!%)SC';K5E/]8!\W!/4@C[I].,^_?FJT>-@&X9 P0"#W![$_7/X#KS9
M0CS <@C/H>!M([@=S_7WKAJ:W:U5NG3U^9ZD$W":MJ[65]=^U_Q+$?4_6/\
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MLZ[XK\*>"/AE;S^*/BEXUN+'2/"?@1&TW2-7UE/$.O\ A;3-8X3U3]8Y&!&
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ME&5 R02<C')^4$_Y_KTK\G?^"NO[,WQX_:%^!/P8\4_LR:)X?\9?&_\ 9/\
MVM/@I^U]X"^''B;5K3P_H_Q0U7X0KXJM%\#W6OWVJZ%9:.MXGBQ]5:>XUS1%
MO(]'DTB/6-*GU**^@_6*4C: <_>'('3.<=>F<8]<G Y(K\7_ /@N!\*OVGOB
MU^RW\+K#]CWPE\8_%7QO\(?M-^!?&^BM\&_B?8?##4/#VCZ5X#^*6F:]K'C6
MYGU#0-3\6^ K_3];?PE=^$O#?B[P?K#>)?$_A;Q-<:O?:#X9UOPQX@]+(G+^
MV\NY*F&HM8JG'VN,O'"TW.%>F_K,U.GRX>5.K4A4DJD)153F4TXI/AS%)X.O
MSPE4A&C-RIP3=26L'%0BDW)^TC"5K.W)I;F/RU_X*5^!?VU-#U+]LGX;>"OV
M"OB#\=]$_P""N/PZ_99U9[SP/>WGQ/\ "7[-?[1'PS\)>"_A?XZ\/>,KO2_!
M46CZ!H6E6WAKX9Z_X7^(OQ M_AOX;?6[#6?'-WXYBTK2-5\/_#3^H_X&>%?%
M/@'X+_"3P-XXUP^*?&W@OX9> /"OC+Q(VIZEKDOB#Q7X>\*Z3I6OZV^KZTD6
ML:M)JVJ6=WJ U36(HM2OUN/M]^BW4UP!^!EA_P % _\ @O#;Z38Q:I_P1Z\-
MZEK$.GVL6JWVG?&/0]$TO4]72VB2_O[#19O&FMW&BZ=?7RSW5MI%UK&O7%C:
MSQ6MSK.I3027EQ_0;\,-;\7^)/AO\/\ Q'X_\+GP5XYU_P #^%-:\9>#5OHK
MY?"GBS5-#T^_\1>%UOHGDBOO["U:XO-*^UQ2RPW2VOG":02"O:XBEC*6!R["
MXFED\:='$5'[3+LSIYA6Q%58>G0C.NHXC$.E"EAJ="A12Y(5734N7VJDSSLK
M5%XBO4HU,5.]"*C3Q&"EA84(N7--PG*G#VLY57.3BFVDVMC\(?\ @X/TNQLO
MAU^P_P#$_P")G@3QO\0_V7O@]^V7X/\ 'G[3>C^#AJM[!9^ +7P[KD#ZQKUA
MI6L:,;:TCM#J^BV/B/4;[3M/L;K6QX=?6]*N?%=C!J/\]GQ$@\/?&O\ 8M_;
ML_:[\:?!KQMXQ^.?_!3W]OOPQ\*OV M>F^%1\6^(/#^G^#_B%/XZM5\ ?$Z#
M2DUK0!K?@J+Q%\#K+2/"_E^(O&E[\-$T31-+\2Z5H'CN_P#!_P#6%_P5K_:J
M^/O[/_@+]G7X6?LK2^%M(_:$_:\_:.\'_L[^!?&7C;1;77/#O@2R\2V=_/KG
MBR;3]0,^F7.IV,B:/;VEGK.DZYIRZ=>:O?2Z/JE[96.G77XV>(_C=^WM^R#^
MQA^W9\2+_P#:?M_VBOBY_P $^O\ @HG\(KC6/''QB\(WFK6?C7X;>)_A1\']
M-\6?#KP+X>/B.YM?AWIWB#7?CK/IFKW=K?3BV\ 3^+QX03P9XHU;P[J?A/Z3
MA^M6AP]@XQH8..(JX^G2P\99AB:&*Q>!EF=2<E&C1P\J,(5,SC0P];$U*\JE
M:A'V'U=4H2J1\G-J=&>9U_:3J3HQP\JE24:-*2P^,5*G&E*FY24YKZOSSC34
M>2-3WK\Z2/ZV_!5CJVE>%_#.E:_>G4-=TWPWH]AK-X;FYOC>ZI:6%K;ZA>&]
MO4BN[T7-W'-(MY=PQ7-T6>:=1(S*O6URW@W6SXF\+^&O$GV7[$NO^'])UM;+
MSQ<_8QJUC;WZVIN1#;BX\A)Q$)OL\'F;2YB3=L3J>Y_+\>O]17YE44U5K*I&
M,)^UJ*4(6Y8R52:G%<ONZ34U[NEDK723?V-)15.FHN4H^SIVE)MSFG"-I3OJ
MI25FT]4[A1114&@4444 %%%% !1110!6N(4D0Y7)()Q@;C\I'&X@ G(^\"N
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M>O;'R)].90EN\,:(@_*O]FK_ ()V:;\7A_P4%U__ (*2?LS_  5^+%[^TO\
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M/A_I8LH]/\):YX&M[FYMO"]_HUM8OHMM(UI8K#;,5JMXB_9P^ _C+XR?#_\
M:(\4_!_X=^)?CM\*='U;P]\-?B[KOA71]1^(/@'0_$5MJ5IKFG>$?%-W8RZO
MH$6K6.MZS;WZV,UO)/!K&J6S,L.IW18 _ O_ ()T?L\?#[X6_P#!5CQS^SEX
M#NO%7BSP;_P24_X)S?!#]GN+7/%,XDM=4_:+_;D\=:Q^TI\</CL=#UKQ%XFN
M_P#A9/QKT[PAI6L^)_&GA ^'EWZOXS\!Z\NK:3:>#%M_K;_@JW/#\1OVA?\
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M[66H_M,_M[V/Q3USQ/\ '_XJ? CX9_ +01\>U\7^+?$_B.7PWH'C[X@2>*?
M^F_"_4/"7PWA\+?!O699O%/P]T#PQ<^$="T'5P#^O)9 Q(QRN"1D$C+%1D#D
M9*L,GCY6SQ3/.S]U<C.T$$'+<\ 9!)P"_&?D^?[I!K^0[Q%X"^!W_!)/_@I/
M^VM\1_V,/A[KOPU^&W[/G_!$CQK^TA\=?AI:^/\ Q'XP\)?&_P".L7QEUL_
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MTY8(_+%IM>16_%*Z_P""#W[3?[&_Q'N/CM_P2G_;0C\"^.=/^'O_  J[P_X
M_:A\,Z9XM\/GP+J.LZ7K>N>"YOB%HWA+Q1;Z?X/.LZ;:>*=%T2Q^"IO=+U[3
M3!!KT%MK,M[I?ZC@<^R2>"QV&RNM'A;$8G*JV$HT:F"C5A]>E]4OB/[=HQKY
M@E7]A7?LZM.G2I.MR1?*VSX_%Y=C_K%"MB:,LVI4\93JRE&M*DXT>:=HK!R<
M*-7V;E"7-=R:C=1;2/Z?M-LK/3;6VT^PM+:PL=/M(;*SLK."*VM+.TM8XXK:
MUM;>$)%;VUO"J16\$:)%'"B1QJ@0J-.L#PT=:?0M$E\0Q6MMKTFCZ>VMVU@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,8I*R2"BBBF:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $3 G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#],/\ @L%_
MP7%_:I_8J_;#U7]FSX#>$?A);>'?!7P]\$>*=?\ $_Q!TC7/%&L>(M8\<6-W
MJPBL[2PUC1[;2-+T6SMH+9$ O;N^NIKB9Y(HXX83\;^+O^"V_P#P6M\#0> Y
M->^"?P'EOOB1)):^&O#/A;P7_P )[X[@U2/PY;^,5T#QA\/O WQ,\1>-OA_X
MEG\'7=OXLM?#WC70=#U.X\..^II;B&&81^\_\%H?^"-O[<_[7'[<?B3]H/\
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MO7NV.,X[@9/3I@ TX2@]@>O1@>A]A1SQZNWK_P .#:7]/_(EHJ(2@]!G\_\
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MC%+F;E%Q2NFA/PUX-C)0<\[YFFXQ_P!>>-[M12<G_P E>[**:;;LM4^IL_\
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M^%/_ ,RM?='V>+^[W_O-TQT^]Z\_I2?9H_3MZMUSU^]Z<?K1_K?GW_/S*_\
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M +>CSSY(\_&W'7O.S=E;BMO1+FEHE%:MI:EP?LT_'[C_ (SD^-!( ''@KX4
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M49*,6^5K<GX:\&PBI2GGB4E%Q;XXXW?,IRC"+BH\7-R4IRC!.*DG*27<N_\
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M[I-<T;VNKM_X9H_: [?MR?&<_3P7\*NOI_R*U*?V9_V@.W[<GQH_\(KX5?\
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M/Q(_V3PS\0?!D\UM?^.H-'MU2RTWQ=X7ENM8O+."%-6TB6^S<S?14*,<\RG
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M98UG]G&;PM'?PZF);6/Q;>ZN_C"VNF$L.CPB?27M+N2X:]KZO_X;L_9NR?\
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M\%M5C?\ YAK/?UOHM=#[E9@1D@Y4 8R.QZX]3VY^GO\ G%^W5^P=??MD>(?
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M7Q-X<74=>U'3?#R^,O"7B"TO=/31[MF\.:I8ZKI-]?F7RKX=_P#!'CQ9\)]
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MCXE@TB^T"YMM:M-/\:>&+G2M2TZRMXOT2'[=G[-H.1XM\4]_^:3?%P]<=_\
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MKG_DDOQ>],?]"/T[_6D_X;K_ &</^AL\5=,?\DF^+WKG_H1NO;Z4?ZN\0_\
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M1_P3"EN_V5_C+\#O%?Q*T2U^(OQA^-7A+X_7_P 0?#&@>/O$GAF#X@_#C7/
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M><\?7J/2K]AQFI<W]EYJWJ_>RR5FW.51>[S*/N2E^[:C'D4*<?>A",2?]<.
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M^BJR+_POA_\ ,Q]D^9[?K_\ 6H\SV_7_ .M7QM_PW9^SA_T-?BD_]TE^+O\
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MS'_P3!^)=KXNT3Q%I'QM^&/AS1[7Q[\,_P!I75/!_ACX*W&B:#;_ +5WP7^
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MW*>8QDTG)\G)#ZDE3C"G)14(RFY3C&HY<O-&6IXL_P""KY^#GA;X_>+/BO\
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M6E.3ISCG_KWPYS4W_KEPYRPOS*6/C+VC<=)32P2;2=_=NI<R3C-)S3]CO/\
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M3/%GAGQQX-GT8I^UL^B>'/"WQ&\8VGQ$\7:)\/=)DC:P^&]GJ/Q#LK;QS"?
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M_A,JOI_'H:WN_P#GSOY[Z;L_UE_L[#L_7T;IW'7K[_I2^0V#P_\ WRW7^?X
MCZBO\F;_ (:C_:E)Q_PT]^T42<X_XO?\2^P&>OB7G R,=?TR?\-1_M2_]'._
MM%\ Y_XO?\2^!GD'/B7MQCMSSG/*_P"('9E:ZXAP"NGK]1QG3>U\1^7X#_UW
MPO7*ZJ[)UL/_ /*?ZVZG^LQ]G;T?\F_QH^SMZ/\ DW^-?Y-!_:B_:ES@?M._
MM%D]A_PN_P")A^]VX\2]@..@ QSWH/[4?[4Q'/[3G[1F[CK\;_B6 O.T\GQ,
M"3C&!Z^PI_\ $#LR:O\ ZPY?9WU_L_&::=_;6UZ:WU#_ %WPKT_LRKK=?QZ%
M]O\ KR?ZRK1%>=A [ED;"C(ZG SQQUQZ=C7-:F"/$_A1%9]CQ^(-Z!@ Q2PA
M92Z@X8J<E,E@F[@!F)/^7/\ !O\ X*-?MT?L[^,=+^(GP[_:@^,5WJ6@WL6K
MS^&_'GCWQ)X^\$>*8+)=UQH7BGPWXIO]4L[W2M3MD:SNG@6WOK02"]T^Z@OK
M>"9/]+OX(?%5/CM\,_V:/C5'I+:$OQ;^$VB_$<:*\HN&T>3QEX)T77Y=,$^3
MYZV,M^UNDQ(,J1JY +8'Q/%O F9<'2P=3$8O#8_"XR.*IT\1AU6HSA5HX=SG
M3JT*TG*+Y)<\)QE*$E&2NI)7]G*LZP>=1J0I4)4:U">'E.E45.2<)UE%3A.$
M$FE*+3YHQDF]$]&?0OD>Q&0.,XZ?CC\N ?RH\@_[7_?7Y=__ -?M5_ ]B.A[
M?-P !S@$_P"%+L7T_4_XU\)ROS_\"?\ \D?1>RC_ "Q_\!BO_<9G>0??_OK\
M_P"+_P#5[TOD'_:_[Z_^O6AM7T_GW^I_/O2%4'7Z]3_C2Y7_ %)__)![*/:/
M_@,?_D"AY'U_%L_ESP??M2>0?4_G_P#95HE5]!^)/^-&U>P^O)HY7_4G_P#)
M![*/:/\ X#'_ .0,[R#[_P#?9'^/]*<+?CN>2.OKDD<C)SP<C'I@<U?VKZ>W
M4]?\D4;5]/U/^-.S_J3_ ,V/V</Y(/\ [=7_ ,@<7XP0Q>%?$$D9>-AI=PRN
MC%70@#(RNT@\G!! QD#'6N@BC4QPDJ6WPQ'&"SEO*'8$CJ"3USR<BL;QR/\
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MX?\ \-]?_P":P_UVPO\ T+*G_@ZC_P#*3_7!\A_[OO\ ZQ/\?TZ4>0_]T_\
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M\9?3_DJOQ!Z>G_(PTO\ PN?XT_\ 1:OC-_X=7X@__-#3_P"('XK_ **3#_\
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M6E^-_(/]=L+TRRI\J]&__IG?R/\ 7!\B0\[?0_?4?^S>_P"?7FE\A_[IZ?\
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M.C7J0?W%#]W Z!AG&0,Y'J.OJ >.YR*_RX?^"I^#_P %)?VYLEL_\-(^/0O
M. )[0@X.>,9'<8!SUK_4<@XC)[9Y [D$'GCVX_ <\U_F*?\ !8CP%XF^'/\
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M?*!T)   X481+>WC<R1P0I(V072)%<@L6(+*H)RQ+')Y8D]: .7\<9_X17Q
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MH7A?PS9^ _VD#_PB'AW2?$7Q1M_#'B'7O!=F$\'V6@Z1YVG02:W;6F\ ]O\
MVA? G_!(W7?VO/@MX=^(7[0?A7X2_'[Q/\._@IHOP<^$7@?QAX9\!^%/$GA.
MP^,?B'XV_"S5=(T:U\)3^'5O?'WCY=:2UN5UBQ'B^T@&FZ9:M?N)YNX\5_\
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M*#@=,=>^?[W)%>S@O=X=SZ]E_MW#^_?VF=;_ -,^"S7_ )+_ ((\LGXY;_\
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M8RE%Q4Y1:;37,GH_8UO[4#_CXM_7_CXAZ=,XWYQ]!TI_VZS_ .?F#_O]%_\
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M]2>_8)_P^*_X)@=_&MQ[?\6D\7 COWT7(/Y>F.*^D6&XTT][C&W2TLRT[?\
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MS_ATS_P3 _Z,G_9L_P#"*TNC_ATS_P $P/\ HR?]FS_PBM+KQ/\ X?$?\$P
M?^1TN/\ PT?B[O\ ]P7U/].U+_P^)_X)?_\ 0Z3_ /AH_%O/T_XDO/X4?5^-
M/YN,_P#P+,?_ )N#_6C@?_H<<'?^%N _^5GM?_#IG_@F!_T9/^S9_P"$5I=
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MI/!)&JY:7\V)_P# *7_RT/W_ &H_^!5/_D3O?MUG_P _,'_?Z+_XNC[?9_\
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M_H7-"_\ !;!_\31RTOYL1M;2%*__ *<_4+UOY:/_ ('5_P#D#=-[9G_EYM^
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M#EYI.B:+\4M"\"_$2^\0:-<^+=$O=8_X2GPOOLI;AHXJ[SX3? +X ^&/C_\
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M^U'^S/H]_P#"_1]2TSX8IX+\/ZC^PSI6O0ZG\"]%UO58?"%A\-Y]!_;2CO\
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MF_L]+U^PMIM^GF_M8=2TA-1L&MTN[4QV<[1A8+N!'C,:KECV7W+_ ""[[O\
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M%9<\L5E*;2NU&Z2O&*2T344D?;D)(0-@D!^G?H3GKR#C\SC'I_%O_P %!?\
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MK2ISGB9X1TG0C"K0Q"JJ=+GG)1I\T%!5'.,;M_S/_#?]A_\ X*2?"3Q_X/\
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M\%'8Q4, X7QH,%E(.&[<CBHY/^#A_P#9(B\M9?A'^T-&9'"1A]#\$*7<X)1
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M8W\WZ'R;_P ->^!,X_X5Y^T1]?\ AGOXGX_30_?]*3_AK_P%CGX>?M$<\?\
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M"?Q#U.#P[H^HWSLS2:C??"?7M6/P^#W N);*ROOAUJY+Q: 0.5U']MSQ'/\
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M/S?"O_@G[X&\8_$\^,/VJ_BKK/B/1?BU^SI\&_CC;>+/"'AG4_"D/B[X>_\
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M+?B[_@IEX%\)_M\G]AV;P!J%[%:>!XI];^,D7B_0H-&T3XWZK\//%/QG\*?
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M3KJOB(U.7EC4J^TI0DZW/4J*$(Q7-.4?AH7,6WB2,\*00P(7?(8T#,/ECW2
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M6W_Q-'[OO7_\ H?_ "P=Z_\ +1_\"J__ "!T?VRU_P"?B#_O_#_\71]LM?\
MGX@_[_P__%US?_""^#_^A9T#T_Y!5MT]/NTO_""^$/\ H6=!_P#!7;?_ !-'
M[OO7_P# *'_RP+U_Y:/_ (%5_P#D#H_MEK_S\0?]_P"'_P"+I#>VN#_I-N.H
M_P!?#U_[^<8XKG/^$%\'_P#0L:!TQ_R"K;\ON]*0>!/!_P#T+&@?3^R[;I]2
MG7\#1^Z[U[=?W='\+5=0O7_EH_\ @57_ .0(/&MS ?"?B!5N(G<Z9<#Y98BY
M&T 8 <D\YX')YR<D5^!/_!;/]BC]H[]ISQ/^S]\0?@'X(A^)5CX&\(>,_!WB
MK0M+U[1;#Q%IUSXAU;PSJ^E:M#9ZQ>V$&H:2R:3=VMS):737-E<&!Y+=K>4R
M1_NSXO\ !WA>S\,Z[<6OAS1(+B'3KAH98=/MTDC<*/F5E0$'!QD<]\XXK<A\
M#^$7@A;_ (1C0LM#&23IEL>60-EB8R<9!))((SWR*];)LVGD6+PV9X2\J]"K
MB$HUJ,'":JX>-.<91A5BU>#T<6G%ZZ['S7$_#M#BO*\=D>82E2P^,IX:;JX:
MK*%:E/#XEUZ-2#J49P?+4BFXSBU--Q=M)+^#S_AUA_P4+QQ^R[XSZX(_M[P0
M<EAG/'B3I@C.>_IFD'_!*_\ X*%YR/V7/&6>1G^V_!'M_P!3+[9!Z=AQ7]Y@
M\#>$1U\,Z#QD9.FV_H#S\F,\^F2 >:/^$&\(_P#0L:!W_P"89;?E]WO_ /KK
M[A>*N:O_ )@L#Z^QJN__ )=GY0OH]\-V5\VSAO2[]KA5>W7_ '3?OZG\&?\
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M\0?]_P"'_P"+KF_^$%\'_P#0LZ!Z?\@JVZ>GW:7_ (07P?\ ]"SH'_@JMO\
MXFC]UWK_ /@%#_Y8%Z_\M'_P*K_\@=']LM?^?B#_ +_P_P#Q='VRU_Y^(/\
MO_#_ /%USG_""^$/^A9T'_P56W;I_#VH_P"$%\'_ /0LZ!W_ .85;=^O\/?O
M1^[[U_\ P"A_\L"]?^6C_P"!5?\ Y Z/[9:_\_$'_?\ A_\ BZ/MEK_S\0?]
M_P"'_P"+KF_^$%\'_P#0LZ!_X*K;MT_A[4O_  @OA#_H6=!_\%5MWZ_P]Z/W
M7>O_ . 4/_E@7K_RT?\ P*K_ /('1_;+7_GX@_[_ ,/_ ,71]LM?^?B#_O\
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M_P"6C_X%5_\ D#H_MEK_ ,_$'_?^'_XNC[9:_P#/Q!_W_A_^.5S?_""^#_\
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M$O\ WXMO_DRC_A(+C_H6_$O_ 'XMO_DRCEG_ "O_ ,"I?_+0]K#N_P#P&?\
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M7XFD=_\ B1?#WKC&/^1..,^@[\^](/\ @LQ_P5.R?^,U?B=CCDZ%\/>.Q/\
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M_P#G^T__ ,#;?_X]7^/G]D3_ )ZWO_@PU#_X]1]D3_GK>_\ @PU#_P"/4?\
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M"<=Y_P"(&+_HHTUIJLME\]\6MOE?<7^OD/\ H6RL^OUF/3?_ )=]]/PWT/\
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M6TLW=;K96/O@<?Y[=OTK\-?VH_\ @K1XY_9]_:)^/?P%T[X'ZAXK;X:?%O\
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M#FWN?A3HNG.VJ>,]!\8_!'QOX5^+7P?.+JY\0:AJ[>'+J6[?2M0"?M1\.?\
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M@#C'08]\&G Y[$?7BOY+6R/V)"T444P"BBB@ HHHH **** "BBB@ KB_'O\
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MC:G\0-0\1^3J^IZ-=R""+^S=%CM=,@;]:XKB-HM3(T]T2$R&6((";TA<D 8
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M>V#T_3UIP7'=C]37R'.NM&/R=7_Y8CVO9R>]6?RC2_\ D#FO[7U__H59N_\
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M?TW_ .8FC_B(MLO^C1]5_P##OZ;_ /,31_JKQU_T!XW_ ,/%;_YZ!_:61_\
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M^0OIO?D?Q4O]KZ__ -"K-W_YB^F]C@_Q5T]%'.O^?*^^K_\ + ]E+_G]4_\
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M%]-[G _BH.L:^/\ F59^_P#S%]-_AZ_Q5T]%'.O^?*^^K_\ + ]E+_G]4_\
M :7_ ,K.7_MC7_\ H59^W_,7TWN,C^*E_M?7_P#H59N__,7TWL<'^*NGH(SZ
MCZ=:.?M1C;UJ_P#R8O9/_G[/_P !I?\ R!RS:OKY'_(JW Y'W=8TPD\]/O\
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MG-DOB+6-3UM;-ID6-9VM%O\ [*TH51*T/FJB!\#^_O\ 9"_Y-K_8M./^;>O
MX'8?\DW\/'N<\ #L?45\;XF*K_9.1>WLZ_M,7[=I1BO:O+8.HE&#<8J,^=64
MFK)-.5[GL\-\GUO&\FE.V'4+W<N1XNT+MK5V4;75_>WT/LP,!P1R6P..3P!D
M^X'WCV'7BEWC)&2".V#R.QZ<@]L$9((YP:_.O_@J#\.?CI\4/V8+3P_\#K3Q
M7XCCL?C7\#?%/QR^&WP_\12>$_B+\9/V8O#/Q&T75_C]\(/A]XBAUCPY/I_B
MOQS\/[;4M-LH+?Q/X:N-9MA>>'[?6[2?58_,_*S3M(_X*3^ =0_9^\)_L?\
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MF\*ZTGAOP_KUC=K8W^C:SJS6BVVG:CIU](FGZC;W+*MA?.EG>M!<R"$]-:_
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M^O? 6KW/C;X6ZWHUCHWB&V\5SZ'KNL7>F_#S5-0U3X7V?]CQ>,!>)J+WEO\
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M_$#P]\/O$-A=3Z5XCT8>$]?OO#\M[/>:7=WDEGJ?#W_@N=\.OB=XJUJY\,_
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MB+0#@Y&=:TTX(],W'%'_  EGA@Y_XJ+0.>O_ !.M-Y^O^D<^V>E;_P!BM/\
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MIU=]7[/7R['\9'_#C/\ :Q_Z*K^R_P#^'&\1_P#S'T?\.,_VL?\ HJO[+_\
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M (#P?_&Z/L%E_P ^MM_X#P?_ !NC_B*'$O\ S]PG_A!AO_DP_P!5LM_Z?_\
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MM#$4J;=2G=P=6I4J*,ME)1M&/,DWRM_#=Z-ZK _X2OPQ_P!#%H/_ (.]/_\
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,Y?L_9^S_ "_9L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "_ G # 2(  A$! Q$!_\0
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M1? >P^$$W[5_Q,^'7PL'C?X.?LF:W\:DLY/#'AGXU^.(]?TR[M=4L(;^SO\
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MOBKX4\$Z1#JWAKRO%>@ZO!>[O$.IN_@\7/\ 9]]?Q7T$^H2J(FBC3Z5^,_\
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M/'P*_:\^!_ACX1?M(_'W]E3]G7PS\)/$W[+VF^+?$/@+5_CAIMII'B+QQ?\
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M%%% !1110 4444 %%%% !1110 4444 %%%%  ?\ /^?K7X??\'!5K\-O&?\
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MTG[->F7_ ,*[#P)X]\'?$*WMKR73='^+NE2-HEV+"Y4VLMNEQ7^@)L3^ZO\
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M-/9ZO?S&^;48H3)8^(WQL^$/[55S^UW\:_VQ?^"A_P "]4_:5^,'_!/?QO\
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M  H _A5^!GQ\^"TGC3]@'PO^V!_P4F^#_P 1?V</^"7EU%K'[-NG?!W]B/\
M;4\+_%KXP^)/"_@6;X<_"36?CCJ'B3X:WWASP[#\-?"TEM;R:=X&M@OBF\L1
M<:G))+</>1\/\ O%G[''PD^!O_!)#X7:Y^W/X*U76O\ @GO^VI\4/VF_B=J&
ME_LV_ME1Z7XS\)^//$OC?7;+P]X&6Y^!0N&U^S@\46]K=_VPEA8&;[3+%.\<
M8CG_ +XMB?W5_P"^1_A1L3^ZO_?(_P * /\ />^(NA_L*^*Y_BE\3;+]LOX,
M^)?C1:_\%./C7^W3\$O#7Q9_9._;:\3? WQ1\+?C3X"\->!?$WP4^-^CZ+\(
M](U^VU:^AT"#5(/$?A:YF.BWMG;BUED6ZDDMO0O%_C/]C'7OV._#/PB;]H'_
M ()U^+OB3J?QR\4?&GXV?![Q1_P2L_:F\.?LM^.H?$6D6&@:'X8\+^+_  1\
M,],^/WA+QC\.-+TZ"'2_C/8^(K;QGXYA>32/%\DVEQ1"Z_O?V)_=7_OD?X4;
M$_NK_P!\C_"@#\ ?^#?"#X8^$_V8OBE\,?A]^T]+^T)J&C?&35_B!K/A;0_!
M/[07@_X2_LYZ1\1[:.;PO\#O@E<_M)Z5:_$SQ!\.?#=KH-Y)9:CK&L:U>+=S
MW0NFM]\;77[_ (.>X_#TYQ^8Q_2@*JY*JH)ZD #/;G'7@ ?A2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444QVVJ2 2
M>P'5N^!C/)&<?TZT /\ \_Y_*D!R2#P0<<D<^XP?2OQ[^-7_  55.L_%?Q7^
MS-_P3P^ /B?]OC]H[P7J#^'_ (E7GA;Q%9^ ?V7_ (!:XJ,LUC\;/VC-4L=2
M\-6OB73':.6Y^''@FT\4>,IS'-I]S;Z+=!Y(>1TW]G7_ (+??&>(ZM\8/^"A
MO[-?[)5KJT$(N/AO^R+^RM:_%74?#J$6;2K9?%_]HGQ-J!O-30+>Q-,_PUET
M])I8I8H[B*+RY #]L_\ /Y45^/O_  [T_;T/(_X+;?MA@'D _L\_L)D@=LD?
MLY@$X[X'T'2C_AWG^WK_ -)M_P!L+_Q'C]A/_P"ATH _8*BOQ]_X=Y_MZ_\
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M,T:/!-!9Z[IEQB4.ETNPJX!^QV>XY^F**_$W4;/_ (+H_LT33>((?$W[(/\
MP4O\ 6;7-WJ/@D>$-7_8I_:$FL(?.FCLO!VMVNO_ !-^#6MZNT&V-4\06OAJ
M"]GB6.-K/[07A^JOV,O^"D7P+_;%U+Q/\-;+2_'GP+_:<^&D,+?%W]D[X^^'
MW\!_'3P &"H^KQ:#=2R67CCP//<EH=+^('@:_P!>\,:BGDNUY:RW$=O0!^A%
M%(#D X(R 0#@'GG!&>OK2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!YW\7O%>H^ OA1\3O'>D06EUJW@KX>^-/%NF6M^
M)38W6H>'/#>IZS96]Z('CG:SFNK.*.Y6&6.4PM((W5]K#^<+_@FA_P %,/\
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M?@UX0^/7P*\2W/BKX<^-DOAI=[?Z%K7A?6=/U'2;Z?2];\/^(O#7B2QTS7=
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M")\0OC]\2]%^'^BW]Y'I'AK3[E+S5_&/CCQ#<RV]M9>%_AWX#T*VU+QCX_\
M%-[<W=K%;>'_  EHFKZD?.6>6"*U26:/XMM/VB_^"C?[1WFS?LW_ +)_A/\
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M7HOB3_P55_:/A:Z^%?P8^"O[!?P]OBXT_P 2_M1:G=?'C]H>[TVXA$ECJR?
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M26YBNF\/1^&V@D-U=3V]Q;?#&O?\$??VJ?@)>_!S]G;X4^&(_C1X8U_XI?\
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MM8[:2Z /U@HKD? OC[P3\3_"/AWQ_P##CQ;X<\=^!?%VDVVN^%O&7A#6M/\
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MX(?M>?$'QMX!_9ET+XV_#OQ-\3],\%_&;XK>!]%UO1_"?A3Q;J'A+6M6GO\
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M'GA'QI%%X:US4;A_#>GWT?A'PIX=^'ECJ.B1ZSJ#VFGZ:^HV ,_F! 0#J?\
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MK_AC0OB9X(M->+:[:> ?BMH>CZ;\1O!%OK;RZG#X8\2Z8EU<73 74WVR>/\
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M9ZDBT_[7=_\ !/BU_:1TS4S\9=.@C\37;>%_C_97/PTT'48;G_A%M7BU"_\
M"^O:QK'B<Z3<:=\V_!GX\?ML?$K]I+PUXBG^,7QH^-1^)'CO]@+PUJWQ/O\
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MA[:XUM_!.L2W'C?5@GA^2V@UISJCW<-VUO"D7]M8C0#:% 4G)&.#R#G&0,Y
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MCX?:B(=<\.:OI6HPW5G;ZBUM+H&OQVSZAX>U/4K!EG/V>"#T(/TK\V?VK_\
M@EY^S[^TW\0+7X^:!JWQ(_9A_:TT?2TTC0?VL?V8_%1^&WQB.EPC_1]!\:O'
M;7GA;XI^%DPB-X>^(_A_Q):1PQ1PV+V0 9?GNT^$O_!=3X)WRZ/X"_:L_8<_
M;$\#6B6\-CJ/[3?P2^(GP-^+C0FV>+_B<:_\"?$.L^!M8FL)%MWEU!/">G76
MM,9YI+?3"RP* ?M517XZ_P#"0?\ !>__ *)]_P $H_\ PN_VJO\ YG:/^$@_
MX+W_ /1/O^"4?_A=_M5?_,[0!^Q5%?CK_P )!_P7O_Z)]_P2C_\ "[_:J_\
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MLF;R98=2\$_ ?X<:Q??"?PIJ\MNS1+_PL[XGZ]+IEQYPU#P5++ D<G!6-_\
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M#%'9ZQJ%Y<)9CE/[?_X+W?\ 1/?^"4?_ (7?[57_ ,SM-_MW_@O9D'_A7?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^$@TS_H*Z=_X,;+_ ./4?\)!IG_05T[_ ,&-E_\ 'J/8U_\ H'K_ /@BO_\
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M ./4?\)!IG_05T[_ ,&-E_\ 'J/8U_\ H'K_ /@BO_\ ,X?VKEW_ $,,N_\
M#A@/_FXZ.BN<_P"$@TS_ *"NG?\ @QLO_CU'_"0:9_T%=._\&-E_\>H]C7_Z
M!Z__ ((K_P#S.']JY=_T,,N_\.& _P#FXZ.BN<_X2#3/^@KIW_@QLO\ X]1_
MPD&F?]!73O\ P8V7_P >H]C7_P"@>O\ ^"*__P SA_:F7?\ 0PR[_P .& _^
M;CHZ*YS_ (2#3/\ H*Z=_P"#&R_^/4?\)!IG_05T[_P8V7_QZCV-?_H'K_\
M@BO_ /,X?VKEW_0PR[_PX8#_ .;CHZ3/U_(_X5SO_"0:9_T%=._\&-E_\>IW
M]OZ5VU?3@>_^GV?7W_?^GT_Q/8U_^?%?_P $8A_^ZXUFF6WUS'+DN_\ :& _
M^;C?)Z8!Z\\'@=STI2>G'<#]>OY5SS:_I'4ZOIW!SS?V?H1T\[GKQ2-XAT=0
MA;5K <KDC4+4XSQSB;\\\ =>]2Z=>]O85^G_ ##XC]<-;\= _M3+?^AEEW3_
M )F&!ZNRVQO?3NSH\\X_S]?I]>]%9HO(G=W60E1&K!T!9&!(&5<95ST^[GV
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M><8YZ8ZXSCM@T?ZQ\1+3_6+/._\ R.,QO^.,^?Z"_P"(?<#M_P#)&\)VZO\
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MH!SZCZ]:* "BBB@ HHI,CC'?GH>GK_G\*/T 6BBBBX!111G/^?Q_K0 4444
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M1Z1:2"75UTZ]N6TL),MZL,EO,D?P5X4_8T^+7@7QA\1;,:/:>*-)B_8!\.?
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M!1DO3J\1^+];QDP-)X/B7*^&:N:<'4*_#T,+_:F4TLFQN1YZ^)L3/.,'P_\
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M@5TG^&,/A6Y\-:'I&A>#;;X9ZA!9:SX1LM.TF6SMM6L;:6]@O+"-+!?VFHH
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M2G@G_@I7X)TOXE_&K0[7_@J+XZU+QS\=-6TG7]!MM8\*S:Y]L@UW0OAS<?\
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M,'N:>H7:!P<@#W/Y=OZ=:SOM0]3_ -\G_P"(I/M8[G]#_P#$T6:[6?\ >7_
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0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $6 G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **3<,9[>IX&<XP?Q]L57:;L"
M,X&5X. <]#WZ$'C&3^%2YQ6[2]6E^;0??VV;_),=.?EQG;QU]<Y !SA<9YY/
M;MGGYV_:._:7^&G[,7@1?'?Q*O;\6]WJ$>C:#H6AV\=]KWB/6I8);E;#3+62
M6"$+!;P27%[>W<]O964">9<3*7B27Z!GE C+,RHJ8)#8"[55B<D_*IQUXX .
M>!Q^"_\ P6ONH+[1OV8;NTN(+JTN-:^*<T%Q:S1W%K.IT+PKMDCEA:2*9%Y5
M9%9P,G:02P'W_A5PME_'7B%PKPMFE2O3RS.,S>'QE7!SC#$*C2P>.QDZ5*NX
MU(4IUU@XTE/EE.G&=2I3BYP37XO](3Q#S;PK\'./>/.'Z>"KY[P]DL,5EE#,
M82K83ZQB<SRS+(8FMA8U*-2O2PKS&5=P4H4JE6G1IUZL*<VI^J+_ ,%H/@<%
M4'X6_%120.#/X6+?-C@DZKR<@9QD<9R0>5/_  6?^!_?X7?%4=]WVCPL,'L/
M^0M[GK]/I_..@,AYW-\O.U2-JC!'5-JC)'.1P< Y-=J?!-__ ,*YG^(S.?[-
M@\4V_AMX_+4#,MC+<"\$K ;42\$=BZ$8\V52K @9_M_BSP*^C-P-_8?^MF98
M[(Y\2\2Y'P?DD<?QAB:-3,.).)*N-I9+E=*G*$)QJXZ>78R-*I4C3H7I>]47
M-34O\F>&?II_2^XS6;RX9I9!G$<AR#-N*,WEA. L#6IX+(LBAA:N:YA5J1KR
MC*&#ACL*ZD*<IUK5+JFW&7+_ $"#_@L_\#L'_BUWQ4Z'/[_PQP#@\YU7&>>_
MODGN?\/G_@<3_P DM^*9[_Z_PL W_E6RV/0'CK7\XKG 1AN"G##<I.X$YSD)
MC:#D'&<<#.1BO2/@QI.DZ_\ &#X3Z'KUM#?Z'K7Q-\ Z1KFGW9\NVOM'U#Q5
MI=CJ=G<OF'RX+JRGFBF8/'F-VPZGD>]C_HO>"6 RG'YR\NXBQ6%P.7XW,9+"
M\4XNK*M3P6%Q&*J0H3IT*E&<ZD</.G3:J2I^T:4I<L9N/EY/]/+Z3F<9]E/#
MT,ZX-PF+S;-<NRB$\7P3@*5/#5\QQN$P4*F)4L7"K"E1EBXU:JY%/DA+D3DX
MI_OD?^"S_P #^,?"WXJ8Y!(F\+<<]#G5<')Z_P!0#@_X?/\ P.P0/A;\5.__
M "V\+X_/^UN"1ZXX''<5^8>A?LJ^ O$NI>'HIO%/B'1K+Q)XA\+W#>*;+_A'
MSX)O(O&?CKQ!X<O/AAX.2YADU'_A/OA[8:=#?:M<ZI<SV,ZV]XDNGZ?9BQOK
MBE9_LQ?#CQ=I.DR^!];\=1^(=7\-^#?&=OIGBO7/ MMILUAK?Q)U3X>:MX=.
MI6^DV[6NLB'2G\1:?J<D-Q;VYF32?[(U2:2WGE_+(\ ?1?=.%2>7\?TX.E"I
M6G+$9XZ6%4X1G%XBJJ"45\2;C3E.GRWK4<.Y1IO]LJ>./TWXU:L*6;>%-><:
MU>CAJ<,#PS]9Q\L/4J4ZOU/#O&<\VN12BIU:<*G.E0KXJTIK]21_P6?^!^=O
M_"K?BF"<DYF\,''.>O\ :GL,]P"/K0/^"SWP.SS\*_BH0>A\WPNP]@3_ &MG
M)(&>3UZU^>^G_LJ_"]AXT\&.GB_5=_C'X"7&F>+]/N-#/B3P#HWC_P"'7B?6
MO%-QK?\ :NEZ7:W_ (0\-ZS;6SZ^S:'H>IRQVL27<ND2;W7$_9P^$'@)?!OB
M[6/$&G^ ?C'?+X\^%EG;R>%O#6O_ !:N]&\)ZQ>ZU;>)=-N_#NF:GX-O?#NK
MZG:VD$K7L=WK4>B[HF+7+/&3SU> OHV1RK,<TPN1<>XMX"MET*6$_MC,\/5Q
MU',E2]CB:-:I@JN&PT:?/45:CCZN$Q"=+]PL5&K"4>["^-7TT*N>Y/D>,XH\
M*L"\TPN;5ZN,?#^3XJCEV(R:5:&)P=>A1S"GBL5.?)2='$Y=0QV$_?J->>$G
M3G%_I'_P^?\ @<<_\6M^*F2.?WWACMZ_\3;'!XSS@D#- _X+/_ _&?\ A5OQ
M4P3U,_A<EL8/.=5P1^.>Q]OR%\-?"'2M6\4_MB>#=%\+6WB+6/ .A>(5^&>E
M:-J7_"32Z;=6'Q4TO2K4^'M3MVA;7IK7PU+<6<MR8I6>-;@RQEXY)3L:%^RW
MX8NOA[X-U[Q-XSUWPQXJ\1^)=%TC6EETN&?0/!5W??$>/P+J/A/Q1')IJ1Z)
MX@L='D7Q5;:CJGB6WCN'EM]/DT!;&4ZJ/H<9X1?1NRV$9YC@>,,,ZM3)84:5
M'.LTQ^)JK/,AI<18>M]5P6%GB*>'H86H\-7K3I<CQM.5"BJTO=7RN#^DG],S
M,V_[+S7P[QE.E#B*>(Q-;AO)<LP5"?#?%=?A'$8>6,S''T<-4Q6)QU*&+P^'
MIUG4AE]>GB<1["'[Q_K%_P /H/@=S_Q:[XI]>HG\+Y;ICG^UN1V.<8YQFD_X
M?/\ P/(_Y);\51SG_7^%P3ZY_P")J.HP?KQQ7XW?M*?#GPA\.=)^"MGX9\.:
M[X;O=5\._$^3Q''XMDL)O%^IW6A?$R[T31]2US^R8+33PTND1))IK06%D7TV
MX@+1386XD^5/F' )&,C(5CQDD 9CZ<\\YS7UO#/T;/ _BK(\'GN"RCBJAA,=
M+%?5Z>+XDQD,1R87&XC!<]2%*C5C#VKPTJL(JI-JG."E)S4K?!<:_3;^E%P)
MQ+C^%\TS_@3$9CEL,#+$U<!P=E]7"JICLOPN8>RIU*F)I2J.A'%*A4G[.,95
M:524%[.4'+^CP?\ !9_X'CK\+?BH<>MSX7/YC^U0.GX=NYH'_!9_X(9 _P"%
M6_%3+'C]]X6..W_03) YX !P>P[_ ,X>6_O-_P!\'_XW_GOQ1\QQEF[#[C _
MGL'Z\9Y->\OHE>#3VR[B%/6W_&2X^RT>NN&M^G?L?*_\5"OI)V:><<(/TX+R
MS_YM3^X_K*_9F_X*-?!']I;QN_PXT;3_ !9X)\97-K<WV@Z7XN@T_P"S>)HK
M*%I[Z#2=1TR\NX!J5C CW4NG7*V\LUFK3VKS^5,L?Z$P$YP6!/89)QW.>>>N
M!STZ<#%?QU_L! G]LK]GYB7R/&EP QW X_X1[6B"?E SC<"&XQDGC(']B,9*
MLWW0" 0!^.>@./E(X/.>E?Q3](CPVX?\+^-L#D_#57&QRO,,BP^;1P^88E8N
MMAJTL5BL'5I4\34A1J5*-3V$:T?:Q<Z<Y3@IR@XJ/^G_ -#7QNXO\<_#'-.(
M^-Z66/.\FXJQF12Q648-Y?A\;AHX' YA0K5<%"K7HT<12^M3H3E0FH581IS<
M(U.?FMY'\7&#@9."?H>.>_!/ZU4G8@AE(4C<#N) (/0XSC@]3D;1\PX',I<X
M^?;QV))Q@=<#G/4]><XZXKB_&6H6J:)XCL4O+=-27PEKU_'9)=11ZB+1+&ZA
M-]%:^8+DPQSLL7VF./REF*H7$N%K\*IP^LU:5"G-)U:E.FY1M/DC4JTJ3J-1
M;?+3]JI2>B5E=QT9_6&,Q,<)AL1B9)-4*%:M&,I*G[2=*C7K*C&4K+GJ^P<(
MI*4FW[L)\KB_SY^(_P#P5A_9;^''C'6_!J#XA>.KO0+VXTS4M<\#^'M,O_#P
MU.QE^S7MG8ZGJ^OZ.VH_8[A)()+JR@FL&EBD$-S*J[JX;_A\O^S'G'_"%?'$
M#@#/A?PF!Z?]#LO'?./IT(K^:"3<TDA+,<RS$G+,6+2L=S%E))/5]Q)8_P 1
MIN"> 7XX4A3D#&.I3. !DY!STSQ7^F>!^B!X51P.#6+Q7%N)Q3PN'EB<1#.J
M-"%:O*A1E6J0H4\LJ0H0G4E.4:4:E10CRQ4Y6<I?X8YQ^T9\?I9KF7]GX;@/
M X%8_&0P>#GPW4QD\-AH8FO"A0GBZV;TZF)G3I4Z<9UYTZ4JT^>;IP4E3C_3
M#_P^7_9BY_XHSXX#'7_BF/"?MG/_ !6Q(ZCN!Z4I_P""R_[,8&3X,^-Y!Y'_
M !3'A/GU(/\ PFP/&><G/Y<?SB>%/!GBWQM?SZ7X0\,ZWXHO[6S;4;VST.PG
MU">UT^*6.)[VXC@0M%:)+-"CS.%59)(T9LN#5G4/A]XZTF/79=3\&>*+"W\,
MZSIOA[Q#->Z-?6L>AZ[K+ Z1HNJ&6!39ZEJV4&G6LX62[5T> /O3=C4^BMX'
M4,1+!U<VX@I8RG"E.IA:O%F"I5X1KMQHN5*I@X5E[:7NTFZ255W4'*S;WH_3
MV^E/B<%2S+#Y/POB<!6E7A3QN'\/\?6PLY8:*GB5'$4L;4H3^KIIUW&K+V2=
MZG*K']&7_#Y;]F,<CP7\;_\ PF/"G?H,-XVYSQT]11_P^7_9C''_  AGQOP>
M0/\ A&/"?/X_\)MDG.3UR.<\=?Y\T^!OQG>+6)D^%7CQH_#]Q=VNO/\ \(YJ
M&S1+JQMX[NZMM4/D@6,]M:2Q7$B3["(WB;&&S7DX.1D,VUAD$ D%2 =V[RLG
M<.<Y(QC%/!?13\$<R]K_ &=FG$&/]A[-5_J7%F#Q:HRJ1<X1J/#8&NJ;G%*=
M-U'#VD/?I\\/>>>9?3[^E'DZP[S?*^%,L6*55X9YCP%C<!]85&:IU70^NX_"
MRJQI5&Z=1P4_9S3A/DDN4_IB_P"'S/[,.<?\(7\<,@'_ )E;PH,GKU_X37@D
M# .0".&.:^X/V<?VI?A)^U#X:U'Q%\+-9U"630KZ"T\2>'-?T]M)\2:!<7:-
M+9C4-/,D\<EI?1)*]E?V-S>:?=&">*.Y,T$R)_%^.2.3]2I[X&[_ %8'IGMC
ML.M?M9_P1=W?\+,^-F68A_!'AK>-S;7V>(IO++*  S(&<(<?+N<+@,V?SKQH
M^C5X?\$>'6>\5\/8KB*GF62K 8B%/,,RIX_"XBE7S##8*M0G1>!PTH-PQ7M(
M5H5+PG32<)1F^7]J^C']-GQ?\4/&3A7@+C+"\)8G)>)/[3PM2IE>2U,JQV#Q
M&%RO&9CA\51KT\QQ4*L5/!.C5P]:CR5*=;FC4A.FG+^C'/\ D_Y]Z*1>@]E'
MZ_\ ZJ6OX6/]:D[J_?7[[!1110,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH .E-8X4\XZ<_C_ %Z>OIS3J:_W3_GN*3V?]=4#.8\4
M7=U9>&M?NK:8PW%OH.L7,$BX)BG@TVZFAE4$?>CD1'4D8R.AZ5\!_ 'X -\3
M/@O\+/'_ (D^.G[33^(O&7@G0_$.MR6'QLU^PL6U/5+1;B[-I816WE6EOYS-
MY%O'E(8BL8SMR?O'QD5_X1'Q-E<9\-:[T_[!-Z,'I[X^IKQ']C_(_9C^ 748
M^%OA$C'8'31@$$<# QCL>E>SA<57P>28FKAJKH59YW@J,JD(474=+^R<=5]G
MS5,/6:@ZD8S<4XQE)*3NTK?G^;9?@\VXUR_"9EA_K>&I<)YEBH4*E7$QHQQ'
M^L>5X?VRIT,9A(NJJ$I4HU)<\XTY2A%Q4FGRMS^R)I#P2JGQR_:C<O'+$%D^
M.GB-D)E1D D0VIW(2?G7&70,/FY%?@]^WK^RK)^RK\.O@'X=G^)WB[XC77B/
MQ;\4M1GM]9N)8_"WAV1=*T"58/"&B3S7<^FM>"Y4:O>3WLLNJS1I,T%J%6$?
MU1L"8UVYST! YZ ].1GKC.?;YL5^2/\ P5A_9R^)_P ;_A[\-/%/PQT"]\6W
M_P +=?\ $=SK'A32H&N-?U'1O%>F:;9/J.BVFY9-1N-'N=+B>YTZ /=36MW)
M- CO;-$_ZUX$<;XW)_$KA/#9KGE+!</XS/,/4S6ICX9;1PWM*&79Q0R^57&U
M<#3GA(1Q6.C&4X8C"TY.K%5ZO(K+^?\ Z6/A#DN?>"?'N/X<X3Q.9\799PU7
MIY'1RJKG6(QCHXC.<@Q6:QH9;1S6M1Q]7ZCEU2JH5<)C:D*="J\-AW5:DOYL
M=#\0:QX8U2WUW0[N2SU2R<O!/Y$%RKYRKQ3V5Q#+;W<$BXCDM9X98YE/ELO0
MC]*9?B[X7M;:R^'5_JW@NW^,&I>$)+ZT\.SV3Q^$9/'!TMKJRT&[D)-E%?R:
MD887TM[V*[>0,D4JR%(Q\1C]GK]H)6!7X#_&M0&#9'PK\> [PQ(*L-$^5XRO
M!X /.3@&L^?]FKX[W%PUS/\  /XU33," TOPI\=.QRQ=G5FT-@K%^=Q);?\
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M>_V@^H^ WQIQTQ_PJKQWVP.,Z&>.AXXYX[X3_AGO]H3_ *(+\:?_  U?CO\
M^45?J,>*>$H)0AQ+PS""5E&&?9!"*U;]V,<WA&-[O116MWNVW^)3X"\0*LY5
M*O!?&M2I)IRG4X7XGJ3DU;>53(ZDY:62<IMV2M:UCQLELX"L?^_?X\>7VI06
M!'!!Z#A."1P#F+CC^?2O8_\ AGK]H3O\!OC3S_U2KQWR.G&-"Z^W'U%._P"&
M>OV@B5S\!?C2<L5R/A5X\ ''7)T7. >"!UYQVIKBSA9._P#K/PUIT?$.1+?T
MSC7\&1_Q#[CW_HB.,M_^B5XEV7_=!6B]=NIWG[%_AR'Q?^U+\%?#-QK'B+0H
M]9\47%I)K'A/5YM \1:>1H6K2B;2M9M4,UC/F)8WEC4M) \D1PLA:OZ>!^R+
MHS'CXZ?M3;2<$_\ "^/$9&<<#/V8$GOG/Y'BOPY_X)U_LF?':[_:5\!_$7Q+
M\.?&'@+P5\-K^^U_5M8\:>'=3\,OJ5W_ &7>6&GZ+I%CK4-G?ZA=74]Z)YYX
M+9K2SM87::?S'BB?^G^ ,'.X9# 9.&!).6)((  !([%ATSP2?\[/I9<587,/
M$3*Z?#^>X3'4L'PQA:&,GEN(P6.H4,7/'XZNJ,\12IXVC*NZ$J=25.GB)<D9
MPYXPG))_[*?L^O#G$Y?X/9]7XQX5QV78C,>-\;B<L6=83,\MQ6)R^CE.7865
M>EA:U?+*RPRQ<*]*G5GA(*I.%3DG4C#F7R0?V0M' )_X7I^U/C@9'QW\29)'
M(_Y=^O;\OP^<?BM_P3Y&M_$+PW\48/VA/CE9:9\/O WBJ&2"^\<:IKOC?5+R
M;S-0CL;#Q??%$T+PQ+'$PU?34T^^GU&=U:-[0)YK?J@WW3W_ "Y]NG?^?<"L
M/7--.JZ9J6F,[11ZEIM]ITDR*"\2WUM-;&10>&:,2EU!X.TY)'(_G+)^+.(,
MFQ]+'87-*E.;A5PU2<L+E]=+!8R-.AC8JG7RRK"\\*ZL(R]FZD&^:BXU%"4?
M[1XE\+^"N(LGQ668[A^AB:3=/&4*5/&9OA'+,, ZV*RV3K8;/:-11IXY8><H
M.I&G42Y:W-2YX3_A"EQYCX#<R2CD+D8E? )*$OG.=^68DY/8! 2.?F(YP !T
M8#N$Z>^?<BOLOX@_L!?M:>!?%^M^&K?X*^,O&%E87]ZNF>)_!MK;:WH.N:8;
MES8:A;W,5W%+;/<VS1R7%A>007=I*9(9$<(LK\8?V+_VN"3_ ,8Y?%C .!CP
MZ@!P>&&;X8  R!ZXZ=#_ +#8#Q'\/L3@,%B*?''";IU\%A:D.?B#)Z4^6>'H
MM*=.MF%"K3J)-J5.I1IU*<E*,X1G&45_SA9QX+^+N!S?-,)6\+^/XU<+F6/H
MU%3X1X@Q%)2I8S$Q?LZ^'RJO0KP=HNG5HUZU.I!QG&K4C-3E3_9Y^)/A#X>7
M'Q5M_&2J;/Q[\+-5\%::+WPM=>,]%34KW7_#VIP_\)!X>L-9T&^O-*,.E3B0
MVVI03),T!!9<@_1&K_M8?#:YU3QZJV?BW5M$\6^)/ 7B&6&XTB*SM[K6_AS\
M-X+'PWJ-AI-YJ6HC1= T_P"(NCZ+)I/AJ^N]4NK#PH;Q);RYF.P>"#]C#]K?
M))_9Q^+&&R3CPXG)SW'VW SSGZYYH/[&'[6W_1N'Q8Z@8_X1M>F6QS]MQSGD
M\$ ^U?G/$.2>"W$^>X[B'->.<H>,Q]# T*\,)QKDF%H1C@(TX4)4XTL7*M&7
M+2@Y/VUN>\XN,I-1_6^%L_\ I+<'\+97PCDWA?Q,LLRG$9G7PM3%^&_$N+Q4
MGFU2K6QE.K*KE\:-2DY5ZG(G0NH\L)744WH^*/CQI7B*P_:4\[4/%,^L?&-?
M@W<Z1=RQS0B;4?!=II*>+KG6'2\Q:M>7%K>/:;4F^V1&-9=BM@?*K8).T-CT
M 4@8XQRA(Z9 ., COFOID?L8?M;X&?V<?BP>2 #X;4=.,D_;3U'3(^G.24_X
M8Q_:X/3]G+XM\'&?^$<0=<Y_Y?LD'C).< =>U?6<,9OX5\)X.K@<FXSX7IX>
MJ\'S*OQ/D-2I;+\LP>58>/M%CJ4G%83 T$^;F<JJG4NG-Q/@^,N&O'GCS&X;
M'\0>&W'E;$82&81I/#\#\4TH?\*F<8_/,7)PEEM=*4\?F.(<>7D4:*ITES<B
M9\S+D$'D8())"D 9]HP1]?PK]J_^"+N!\2_C;[^!O#>00.!_PD4O4#&#UQG'
M))![5^=O_#&/[7'0_LX_%D\8/_%-\_+SR1>CH1Z^X%?M)_P2K_94^+OP7_X6
M)\2/BQX<N?!$_C/3=$\/^'?"FIO _B#[%IM]+J%_K&L6UI)<)ID4TSP6NG6L
MUP;R2..YGNH8 85/YG](OCK@W&^$'%>6X#BOA[,<?F5/+<)@L#E^<9?CL77K
M+-L#B9*%#!XK%55"%'#UJE2I*,*4(P7/43E",OW7Z&'A5XEY9](K@+.,UX!X
MPRC*LHJ9UCLRS+-^'<WRK 83#?V#F>$C*KBLQP&"H<]3$XS#T:-&%2I6JU*E
MJ=*2A4E#]GE[?[J_UIU(.@^G^>YI:_R\7_!/][ELO1?D@HHHIC"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M? $>OPM\(?\ IO7_ #^'US[EXT_Y%'Q1_P!BSKO_ *:;RO#?V0^?V9?@"/\
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MJ6(R_,J4+_'++\QP^!QCI:_QJ='$4>]6*:OV>?S]/ZT5 DJL< \X!W-CHQX
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M:V^'NOS6OBO5AHWAJ"-]+?6==OCJESH0DTWP]_:?]N76E-K=I>:.OB!-._L
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M)HTL11G&I1KTX5:4X.\9TZD(SA--=)*2:ZK5.THR26N$^(/_ "";+_L*P?\
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M[KFL745AI.D_VMJ^JWUP=D-EINFV(O+VZN"3\L=M:PR3.P^8+&<9/7PKX;^
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M'<Q%]>^-&L:#K7B:W(FFE L;&Y\/V<6E#)G6%YOM<TS%"OWY_P .=_VMN/\
MB9_";&<_\C5J>?U\/\=3^0[< '_!'C]K?'&J?"7D8.?%6IG/N/\ B0#&>A [
M=SSG7#YYX9X:K2KT.(>$Z5:BTZ559HW.$HPJ4U)2E0E=\E6HFY*3?M)-MMW6
M&*X=\:,;0KX?%<'^(E;#XF$J>(HRX=JJG4C*I2JRBX1J12BZF'H2Y8*"7LHJ
M*45RO\L1(@'7H .HZ#\?_P!=+YJ_3\1Z=\'IVXR?;U_4[_ASS^UO_P!!+X2_
M^%7J7_S.T@_X(\_M;8/_ !,OA*#GG/BS42/R_P"$>.._?\.*];_7?@G_ *+'
MAK_PZP_'_8_Q^1X'_$-O$JW_ ";KCG_Q',5^'^TZ_P!;GY7F4-P <^QZ]R>W
M0#VYKJ_A]S\1/AV0!S\1_A^=H!/!\8:'@#W( Q@\C(W8K])?^'/'[6JX_P")
MG\)><'_D;-2'&,?]"\>"/<<=B:]H_9\_X) ?%W3OBMX0\2?&CQ7X(L? _A37
M-)\37>F^$=2O]9USQ%>:'?PZCI^C1O/IVGVVEV$U[:P/J&H2/--]FC>WM8!)
M*)HLJW'W!&%H8C$2XKR.NJ.'Q$_8X/&/%XFL_JV)IPI8>A3PJG5K5*E2G"G%
M.$4Y.52I&$9-=&#\)_$[,L9A,!2X XLPU3%8O!4EB<QRBIE^!P\?KN"G4KXO
M&8C%*CA\/0HT:M:K4DI-*"A"E6JU*=.7]&4;8^7!&%![]\\>O3H#UZ@9S5M/
MNCKT[]?S_P .*K1H!(7^]N!&!D!3@8'M@9 )'T[M5H# QZ?Y_&OXAC>SNK7E
M)_>WOJ_PZ*_D?ZR13C%*][)+:RTC&.G_ (#_ ,!"T445104444 %-;H>,XYQ
MZXYQ^/2G4Q^C="=IP"./?Z]OI@>M)[/T8'D_Q@U#6]+^%OQ(U/PWHNJ>(=>L
M?!/B:YT;0="U--&UK5]332+LV=CI.K-'(NE:G--M2ROO+E-M<".8)(R@%WP@
MLKNQ^%GPXM;^/Q#;ZC'X)\,MJ5OXIU$:QXEM[^72;66^@\1:QY,(U76K>X>2
M#4=0,$+WMU&\YC1G(&9\>H[67X+?%=+^/2YK27P!XK%U!KND:_KFC2P_V/=^
M9'JVC>%F7Q+JNGL@VW.G^'Y!J]U%F"Q99V0UO_"U(D^&GP]BA6SC@3P+X3CB
MATW2]4T>PCC70[)8H['2=;EDUG2K-%(6WTW5Y9-4LH%2VOY'NXY6/H<R>1)<
MJ3><MN=WS.,,MO"+O^[:O)RV4^:3U<;,^647+C+F<Y.,.%4HTVJ3C&=3/_WE
M1:>V4I0A&$KR=*4(JUJBL_19)8[>*269T2*)&DEDD=42..-"[2.[D*(T12SL
M2 B@L2 ":\K\ _'KX)?%74M3TCX7?%_X6_$K5M%MX[O6-*\ ?$'PIXQU+2K2
MXN7M8;S4[#P_JNH75C:2W,;P)<W,4<33*T._S$91V_BNWFN_"WB.UMX9+F:Y
M\/:S;V\$2[I)Y9M,NHH88U/)DE=Q&B\DLZJ<\U_,+\"?^">'[2'PM_80\-?M
M%6&K:YX2_:@^%G[ _P 9OA3\$/@C\)O@1H7PA^+7A3QC\5)-)N-0F^(WCFQ\
M1^(/%7Q:\>Z+_P (OHP\'17MIX7TC1M5FO-=319M2OY9 \#@L'BJ,Y8C&O"U
M98O#X3#QY(2IWK0E/VM9.2J*A":4)SARJ"]YRTY)>[B*]:E4C&E0]I!4:M:H
M]5+W))*G3LK.I)-R497<FK6UNOZ>[;Q;X;OO$&J^$K+7M&N_%FA:?IFK:YX9
MMM5L9_$&B:9KCWL>BZCJVC13MJ&G:?K$FF:E'I5[>6\-MJ$FG7JVKRM:SA-M
MI"H4^4W52,\8+<$#GC&<;<?45_.[X[^#'[7^@?$'QQX+\#:M^U4_A+5?#_\
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M\5^(-.FTKQ?X4ALQ#JA:> SP1RQ_H3Y.0P). <@$#)&,<].X)ZY! [$5 ]N
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M:47\1 _>Q_7>G/OW_P#U=,UXJC_<J?\ @$^_I_70^I]KA+O]]AK[O]_A]_\
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MR%25Y:=OQ_\ ;?SOZ>9]BOZ^]A10?KBBG=#"BBBBZ[K[U_F 444477=?>O\
M, HHHHNNZ^]?Y@%%%%%UW7WK_, HHHHNNZ^]?Y@%%%%.X!129QP3R2<?3_\
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M^SE?ZT$]^E@_XCYQ1_T*,DNM_=S!_EB.VNI_7K_P\W_8@_Z+_HG_ ((/%?\
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M?BJMD>!QE?&X7ZGE^-I5<7"C#$06*IRDZ4G1_=2<)TY<LU&-XR2:4DW+]ZX
MXJQ7&'#,,XQ>%H87$_6L=A*E/#2JRH2^K3@HU8>UO.'-&JN:$I3M*+<96?*O
MESX)+O\ C5^U9&2P7_A97@P@ G )^&/A8$@ C.>-V>P_+USXD^'-!;P[XO\
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MQ-%9VFAZ+HGB36;JY;2KE8X=*\/^)63P]K-\S@)!I>NNNE7TA$-Z?(9Q6O\
M#,./AWX$61+F*2/P=X926&\T_2]&NXI$T6R$L5WI&AM)HFE72."MQINBROI=
ME,)+;3Y&M8XFKNT63)OWG_:LGHE?3+TK-I<R2U:3=M&TKJY\S'_DK9-.2?\
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M^!?!_BB.WANKCP]JFLH=4M(+B-9()+ZTM8[B:Q^T0LDT$=X(7DB83(C1D-7
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M6+_%2Q2.?7+3QQ!I.@:.UR-(Q#!K?@=Y?&5S?E2FFWT:^'V2:>3SUNW/C?\
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MFQ\8ZAXLTO5-'N?!OAR3P_+&3HVD:E:7<%\S?:89!)$\0S&Z,<$>2?%_6/\
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MT'5]6OWB^*?BJWBDO=1O+*:YN&C@CCA1I96*Q1)&N%08_0XL,#)!.X<CI][
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M@U*\TF/2G\*Q?%,7#^)%\#W$4:#4_#RP+:ZI;27-I*%CN7:O4/\ AJK4^/\
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M! S;\(&!)#*%R3@5_7]_P[$_85_Z(!HXX_Z&?QV?Y>*#S^HI1_P3$_86Y ^
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M>O3L"*=UT_R"Z[_YZ?U\RS15829Y '4YPPSD<<YSCKC@G!.>2,4N_/'EY/\
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M>WJ=8T?)NE0U^?L_O\S3ZE1_ZB.SMC,7MZ>VT]=3B/[ \5_]#N__ (3VD?\
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M%?I9Z@M[[_I/[,GPY^&?PV\,:)X;^+B?#CQCX"\8:]XTTOXM:39?#'P[<_\
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M:Y1[A5@EL(]*U..[25T,-WIU[9,?MMK/;K\(7G_!/;]GCQ!_PC[2?&S43O\
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M;4N5:_*_Q/HMKF52KR647#FYH1DI34;*;LM[^\U?ECO)Z=14A<W\\WVHD/$
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M8RO**Y4TWU=V[*_*M6M=D$,=ZIN/-G1@Y_T<XW>4?F .TJORKE05^8E@3G)
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4H?6HI4Y)JTJ<6W*$'[L9>\M3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I G # 2(  A$! Q$!_\0
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MX@U^^O&-S>^(8/ WB#2]%U6[EW/>)I5I>RS3W%U/(=*F%R_$8"OC\OA7P]3
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M:RC!4VW&(U<VY5S8>BYR4Y-J<6HR=N6FDYPNHMI75^:%Y-\R2?TUI'_!5?\
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M=\2ZCIO@[5;ZZ\)> _ TBZWXLO=%U2ZO]5\+:%8SZA7P+^T=\/OV4OV@M6\
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M%_#GBC7M!BCLIKS^V==MO$GBWPC;6VD.T0LXY[>\NIVO)XHOLP4F0?&VK_\
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MXHOYO$^FZO=,/AUXSN;_ $GX<ZOI7Q3AETO0;'4-,$IM_P!*&_:)5IY+IO\
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MFGQM6#P[J4,.H7\,=[I*6EPL5_>1;S'=3J_=)^V[\3DSC_@G9^W(<G))T'X
M>WI\>Q_+UYZ5R9KFCS&3=.@L/"<%&K3O&49RI8C$3HS4E!335&LJ;@VX4W'E
MH<M"2IPVPF"6&C9S=1J3<9.^BE3A&I'ENXJ\H<W,DI3YN:HW4O)_H0O!*G/
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MZ_[/GGG_ -2/RT\S]P-Z^N.,_P"<9Z=_3ZYI=Z\<XST)QUSC'U[_ $K\//\
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M&O=N.><\X'OQ3A_P5R_8VY_XGGQ#&<=?AQKQZ<^C#G@8/MP0":]I^$GBJO\
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M_P!G^1?^J,^%U?L WWO^!'^35^/_ /P32_Y.8_X*^?\ 9_D7_JC/A=7HY?\
M\B[B+_L#R[_U=4#DQ/\ O&7ZW_?UO_467]?F?L11117G':%%%% !1110 444
M4 %%%,9@.NX8/;OGT]>PQ[TF[ ,F. ."<=AW.5/&.>.<X'KZ5_,5_P %CQ_Q
MDWX,SR/^%0:+@,20!_PDOB!F.,\#/50,$C)!."/Z._B'\1?"/PN\'Z_X^\?:
M]8>&O"'ABQGU+6=:U&98H+:V@0OLC4@R7-Y<,H@L["W62ZO+B2.W@C>1U%?R
MA_\ !0+XL^+?CA\8/"_Q+\1?#V[^'&@Z_P" ;9_AEI6LSR#Q-K/PYCU_5QH_
MBOQ+ISA3HFH:Y<_:[FTTP*3'IIM7=GD+2/\ U+]$7*<=6\5,+G,:*IY;A<JS
M_!3Q=:I3I1JXW$9=3E'"8.-249XO$4Z4'B,13PL*LL+AK5\1*C"=-5?X!_:)
M<1910\"L9PU+%N>>8[B'A;,J> P]*K7J4,MP>9XF%3'YA4HQE3R_"5<14CA,
M'6QM2@L=C%/#8..)J4:SH<%\#_@AI_QB^'?BBSLOLNG>-'^+_P +_"^D>*-0
M>_DM-!\+ZQX3^)?B+Q<SZ992!M5EDMO"EK=6EK&AO)[FWCLK66$W$C5>TO\
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MG')X(Z-WZ9'ZI?\ !'Q7/[5VM81BJ?"7Q1YS(A,<0;6O#ZJK.H*HDDBE8R6
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MX6N+Z.R\??#/Q1K]M)/=Z-<.T;7T-H P6&TC(>5_U"_X<J?"(#'_  N+XC\
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MO$73GI_Q(>_M^%/^QLZ_Z$^:_P#ANQGR_P"8?KT#^V\E_P"AQE?_ (<<%_\
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MXJ^(O$VD^![VQ\1:S\)M4N/"VM7<'AN[AMO#.L1/)9W6BZ3K]WID.GRSQQ0
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M:\XJ$ZL9.<(R<HPE&I4@XIR49-+V>_*D]6E9H?1117&=17;[W_ C_)J_'_\
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M:/,VTE=CZ***_,3]<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH /I5&_MX[NRN[.4M&EU;7%L[I@,L=
MQ#)$[J3E0P5F*[L@$+G(XJ]3) "IW<@<_P!.G?@].])R<$Y1NY1M)6WO%J2M
MZ.*MYVN)Q4DXR2<9)QDGLU).+3\G&4D_)L_/?PA_P3\^&G@_6?A)K>G>,_'T
M]Q\'[?P1;Z'%=OHHBU7_ (0.Q^(MEILFJO#IT;9O(_B5JLE\+1H%+6&G&$1*
M+@3-F_8A^$/A/2/!U]KGQ!\5:=H_P^T#X*^%[74=9U+P]IEG+9_![QIXF\2^
M'&U&_N;.&""Y\0:MXSN-,U(Q/&KQI8QZ?'#=,[2?,_B7X&_MK:A<>.M1L->^
M,,%[?:-^U?J?AV'3_C%#8V,7BJ+Q]::A^S#;6>GQZS':6=A'H4^I7%K9,L.G
MQQ!;+Q:'BC@M4K^*OAU^WMXH\9_$&]O- \5V6@Z_X+&DPZ7%\0?#>K^&=3\4
M:/\ $/X.:OH6OV6E7WB&\@T6[N/"-A\1/M1MM#\.Z=87+7>@Q0ZG<366HR_H
M-:AF#J1<^.,NK1BG*4XUXPG&4;RC&G&<9.IS/$XGDFHJ,9\W.E&<7'\P5;+>
M245P-CJ;JU(<L)8:<X/VDDI5:O(TX<BH8>52%W*4;<CO3E&?TOIG_!/;X1Z!
M?^%-;U3Q;XDU*T\*>"])\":Q'XETWP+<P>(?"'A&?Q)-X0M[O5-0\-37?A>^
MT.P\47NE7^O^%[O2-4UJSM=/FN+FVOK?[6_L7P/_ &7= ^"&N:IXAL_''C;Q
MO<:G\._!?PHLXO%TFAM!HOP_^&]QK8\&:'8'1-*TMYYM.T[7)]/OM2OFN+S5
M?*2^N76X:0-^='Q0_9P_;)\;^#?&NC7B?$?Q3#XUO?VC5\1>%]4^+&G?V/?>
M'K#XLZ!X@_9_TS1K*?6X-/T=[GPC;:Q_9GV>6U>-Y_[/\374$;6\,'3>)?A3
M^WA>:C\;[CP_K/Q;TN'6K66#X:6%CXW\')I$7A"ZU_X>/X-TBUU"[\:W.L^'
MO'W@C0K#QC;ZS=0^'XH-0NI-4GU?Q%XABU;3&.%?!UZ]#V5;C/+ZJQ$E3KPG
M.,H*G&I04=5>HFIWG4Y%3C]7H4=9Q?LJ&U'%X3#XCVE'@G'4Y4;RHU*<'&;J
M2IUU*\96IRC[.T8<_M9>UKU[J$DZE?V3QG_P3TM;+PIH&E?##QSXE.J>%M;^
M#^@^!/\ A*M1TZ"'X7?![P%\9M"^*FL>'?"MUIN@&?4]7BN]-<:3J/B2+4+B
MXM[+2-&NYEMX;BZE[*;_ ()\?#E[K5;Z/Q_\1H]3\5Z%;:/X]U"X?P]<R^,]
M3MOC(_QUM_$DT9T:&WT?4CXUO-4CFMM(C@TV;1+VWT_[*KV$-PWSM\4_AG^W
M1;Z)?^$?AQ:_$/4-,TCXL?%G7O _BQ?B]9'Q1IGAJ/4?!M[\-;'4O[7\4:;+
MKGAS5;,>-6-QKTOB+4-(EC@T8>'775+>YMK6O_"?]NA7UO6/".O_ !%M]6\4
M/^T9%KMMJ7Q+TO\ L^+P]+\1_!NI?!_2O"EGJ&HRZ=X/UO4/ P\9V7AO5K*.
MVET6ZO!#KMY:?Z(\#A4S*I0H+_6_+Z7)4Q"I2O!5G"K/#U7/$S@I.G3<J<IT
MJ<H/V>(A4FUSXCZR1-99&O7?^I68U7*EAY5%*#=&$J4*])QPT9N,9349PA4G
M":]IAG"*Y88?ZL_H+5?^"?'PNUK1=8\,W7C/XAGP]'IFL:%X!TIKO0WB^%V@
M>)OB5H/Q6\4:5H$_]CI=:O'J_BGP_96L%UXDFU&ZTGP^JZ39R-Y?VMN?^*G[
M!?P3\2:IXD\2>+_BOXM\-PZ_XN\6>/=7AN]:\)6NCVEYXR\6^#M<\ZSBUS3W
MATLV6O\ AS1]&M]=MS%JU]INI7/AJ?4#%?1+7EWB?X:?MB:C??"%_ /_  O/
MP'X(L+G7W?1-:^*'@/QYX[\*:X_Q0T_5=+U7Q]?:CXPTS3->\(7_ ,.X]1TN
MQT6YU#QY?>&[">?1KFVO-;N+'48[O[:W[-WQ8^*/Q0^(.O\ @;P+JWBK3/&?
M[/'A#P!I6I6GBO2[+3K#Q+X?^.WA?QGJVGWVBZOK5HMNUSX5M)M2T?48-+NK
M4ZE8.[SV^HI;M)S866+EBZ%.OQ53HJMA<56E5@Z-25"5#%4Z;P]6-2;HK$5N
M>MBGR5)OFI3E&I7G4]J^G$4\'+!XFI2X0=6='$82E"E4]M3AB(UL/.K&O3E2
MC[9T*#C2PR=2C'W9PBZ="G35%>OZU_P3U^&FKW$EY_PG7Q L-1CTK6["TO+5
M]"/]GW6K?'RR_:&AU9K>;2Y8[F33_%UC#I,-I/FVGT%GCN UX5N!Z1\"?V?M
M6\!?&#]H#XR^)[71;+5_BCXEM8_"6AZ/J-SJUMX>\)65O9W&N:C+=36-@EIK
M'Q&\81W/C#Q!IUE#+;V4PL;87=W)"9*^.O$7PH_;DM_'FD66A^)OBFGPPT;X
MD?$N/PE>:7XU\+:UXETJPG^)?A?6/!?B3Q?+XI\7:$WB#P==_#Y/$VBP6VLW
M/B:\TA9KVRN?#+7FHZ5>V^;\0_A+^W(?A9J]IX._X67J_P 0O%WQ.^.FN7NK
M1_&>TTZ_\%:'I&M:U#\ +?PMIESXIT/0K?PQK>AW$=WJL3W6IW>E7<=@-4\/
MZI+*J:>_JN(KQJ8.MQ5E<Z6/^K4)SKR3A&E6Q4*\Y3JN25"--X>E4Q<6I3YH
MQP]+FYI2F0Q>'P\XXJEPAFE&IE\Z]6G"BE^\KTL,\-&4(14W7<UB*T,+4<81
MY)2KU%"RA#Z?U+]@CX?Z@/%C6?CSXD:!>?$#5/BZGC:_TBZT%9_$/@7XXZ]I
MWB/QS\.2;O1;R.RTPWFFPIHFN6:QZ]I<$]^GVBX-P&C^D?@G\%O#/P/TOQ7H
M'A6[U.XTOQ9X_P#$_P 0FMM1>!QH]WXC:R5]$TMH8HV.D:7#86]M8M=//>>6
MO^DW$KY:OS&\ Z;^T+\2?''QDNM2\=?$_P %> -$^(_[3'A#XD_$S5_B38V'
MA;PKX6A^'UC!X1T_PKX4GOUU#1/$'@3QW<IXGM_$%II=EI5IIME?JVNW5I<C
M31]G?L-W_P 3/&'PD;XJ_%'6]6O]?^)^KIK.E:9=W5Q)I>D^%O#>D:=X,TBZ
MT&SG6/[#8>,Y="O?'C^7'_I;>)([ESDK7/G.%S*A@\2L5GM+'4J53+E5PT&F
MZE;$TO;X>*T;E+#TN>IS<SG3HJFW"C'$0I/LR3%997Q^'>%X>JX&M568NGBY
M14(PI86HL/7E+52BJ]5PI6Y>2I757WJKH3JGVPH& >>,]3R<\9/KD<]?SI]-
M4$!0.F.<\GVYIU?*+:_?SO\ UNS[@_(G]O\ _P"3[/\ @CG_ -G*?'S_ -9G
M\;5^M\'3_@$?\FK\D/\ @H!_R?9_P1S_ .SE/CY_ZS/XVK];X.G_  "/^35[
M>:?\BSAS_L7X[_U>XLX,-_O./_["*'_J#2)Z***\4[Q,?U_7_#M7P)\?_P!@
MKX;?M%_M5_ ;]I'XEWEEXGT3X*_"OXU_"G4O@GXH\&^'O%G@3XDZ-\:;?1+>
M]NO$RZXETJ/X>;189[.T2QN8;N25C(T152?ORHC&"Q;CH !Z8P<_4<[1G'/3
MI6M'$8C"SE6PM65*K*E6HN<6U+V>(INE5A&2UCSP;7-%J4=XRC)1:SJ4J=:*
MA5A&I!3A/EDKQYZ<E.#:U3Y9*]FFNZ>QS'A+P;X5\$>&](\'^"O#>@^#O"7A
MZQBTWP_X7\+:1I_A_P /Z%I\.YHK'2=&TJWM=.TZTB9GVV]I;Q1AF9BA9F+8
MGQ-^#_PK^-7A2X\"_&'X<^"/BKX,N[NTU"Y\*?$/PKH?C'P_-?6#^98WKZ3K
M]E?61O+-\M;W7E"XA)81R*K,I]&  S@D\YY[9'0=./;^M+6$)5(U%5]I-5D^
M;VL:E15.?FE+G5135123;?/[3FNV^;5MVXQ:Y7&+BUR\KC%QY=N7E:<;6TMR
MV/,;3X+?"33O%/A3QQIOPU\":;XR\!^$;OX?^!_%.G^$]!L=>\'> [Z6SGO/
M!7A?4K6PBN="\*74VGV,D^@::]MIDCVENS6Q:*,K2^'_ ,!/@E\)]1\8ZO\
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MAZZ^L"^F:]O].UXZWINHZE:7E'Q7_P %"_VG_'</BQO&_B;POXJU7Q]X&L_
M7C/Q-JWA.UG\1>(-*LOVC+S]J5=4O;^.[AMX_$-Q\7;Z:ZN;ZVL[>S'AGR?#
MEMIMM!!'<+A"''J5.*EDR7*_:5*EIU&YU)S4%&"ITO<IV4I)J*Y(1I\[=6<N
MJH_#.<JU1O.U)M*E3I1J*G)1ITESRE4=2I><U.5FVVY.4E&\(KM&_P"":7Q]
M?Q3\+OAB9/"/A7XO_$A?CK;-X/\ B9XV\%>#=(CUC]GSXA:GX%\?:=X9\36N
MN^((]4BT2/1]0\0Z]J?B6P\(:?IVB6LNK6]S?:2/[0,O[/O_  3/^.?Q[T[X
M?>,H_%7PH\"_";Q]J'C/1/\ A:&L^,+/5-,\-:[X3^&7CSXIZ?H^MZ98"*X%
MUXST#X>ZY)H=S875Y86D,4MSKDVG36_V&4U?_@J!^T?XHN?&<WCCPQ\ ?'D'
MCWP_\5?"?B2Q\5?"RZ>W?PQ\;OBI+\8OBGH6DW>B^+M$UC1M/\9^,#:6FN1:
M?JD1U'PIIUAX7O3<:<ERMS/IW_!5']JW3/#G@+PG;P_!7_A'OAX/",.D:6/A
M+8Q6NJ:5X)\!^/\ X5Z#X?\ $<$&M10ZCHR_"_XE>*/ M]:V<6ESWVFR6>K3
MW1\50S^(+HF^/)4I0A_9,:DG9SE4I3C"#A5E.=)N"DW&HZ%.C"M!J$:<Y3]H
MIJ,8IOPWC4IU*CS2I!)WHQIXBGS2C*C"$*JU4ER1J5:DJ<DYRE&*491;?(P?
M\$^?CCX@D\$2>#(O#4ND^./A_P# ;Q-I?B/QWXU\!>!?#/B+QU^T39Z[<_"[
MX6_#_7YO$VIZ=XJ\2^.O^$=U&7P/:7TN@ZSJEBL5UK^D>&_M%HD_'?$+]A?]
MHGX7_"*Y^-?C'0/"&G^&=*\.?#OQAXG\.P?$#P[>_$OP3X3^*?B?Q!X'\$^(
M?&GPZMKC_A(O#>GZEXV\,:UX0N%OH%O+'7;5(+BTCMYXKD]5H?\ P40_:'\/
MIX>LX+/X.ZGH7@OPY\%-&\!>$O$_PGT;Q3X6\"^(/V<K?6[/X'_$SPKHVN7M
M['8?$GX?67B+4[#3]?N9[_2M6L396_B+0=773K/R.)\:?MK_ !\^(?@KQWX!
M\7ZOX=UO3/B5\,_@]\*/&FJW.@;_ !3K?AKX'?$'7_BCX+U&XU^7499CXLOO
M&?B75]2\6>(7AD?Q'%<+;O;6F&E;KPRXRC5PT:[RJ6&C.E]9FO?K3I.KS5>5
MQ4(PDZ4M9*#O4A"-)>QE-G-BWX?SI8J>%_M:.)E3K_5H<CAAX3Y%[!R4N9R7
M/!:2G;DE-U'[112^JO\ @AV0?^"K_P"Q?@<GX@:Z0<8)'_"!^*\GIG@^H! /
M/>O]2J+)!)&,GCZ=N<8]>F>,9YS7^7?_ ,$'O#NN^)?^"L7[(D.@:5<ZJV@^
M(O&?BK6FMTW'2?#>B^ /$0U/6+UAB.WL+:6\M+<RR%1)=WEG:1;[BYBC?_41
MB&U54G+;02<=1V). ,^PQCL,5^0>+LE+B3 J+4G#*J*FDU>-\17:<DF[<R5U
M>UUJKI7/V3P7A*'"V*E*,HQGF^(<')-*25"A%N+:5TGH[72:LW?0DHHHK\O/
MUX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ IDAPI_#GTYZ]#3Z1@&&#_\ 7X_S]?2D[V=M'9V?9M.W
MXV?R ^&?VK_VG+[]G35_AO=V^CWNN:=JOA']H3Q=JFBQ:MH^D6NJQ_"3X73^
M.+;3KVYO]%U._3[9- 8K:[TF[TXV4["?44U"S7[&>5/[6?B[Q/\ L[_M5^.;
M+PMIOP]^(?P'\.:U+8B/7[;QSH,E]=_"_1_B5X5U;[5<Z1H0E:#3_$-C;ZQI
ME[8);I?6MR+>YNK*6.4_;OB?X=> _&WV/_A,O!OA?Q6=/M-;L+'_ (2/0=,U
MLV=CXFTXZ/XCLK4ZC;7!AM=>TEGTS68(]L6IZ>[6EXDL#%*A7X9_#V+3?$NC
M1^"/"B:1XTB6#Q?I4?A[2UT[Q3"NE6V@K%XBLA;"VUF)=#L[31@FH1SJ-+MK
M>Q %M#'&OJ4<5ED,'AZ5;+95<;1Q-"K/%^U7)4H4L;3KU<.Z#DH2C6PJJX:3
MJ1E=RA+FC"+3\"OE^<5,7B:E/-(4\'6H5:=/#>Q;E3JU,%4H0KJJESQG2Q+I
MUX>SDK1C.-I2DFOS/UC_ (*1WO@_PKK'B?5OA=!X@TCPV=?\%#4+?QOIVD^)
M_$?Q*\ _#+2OB+XLNM0\&G1+G_A%/ &JVM]+9:#XFEU&[F2Z%C=WVCV^D:QI
MEQ)TL7_!0'6/#WBO4]"^)7PG\->$M'T'QO\ $7X:ZYXGL?BS'J]EIOBCP/\
M!R[^.-K<RQW7@O2FC\,W7A.U&DZIJ[N;S3M<F$UKI-]I<3RG[TO/@G\(-0N]
M4O=0^%WP]O;O7/#L/A'6;JZ\&^'YY]5\+6\,-M#X<U*6:PD>]T6.VM[:V339
MV:V%M:V\!1HK>%$L7/P@^%=]<SW=Y\-_ MW=7>JZAKMY<7?A+0KB:ZUO5O#[
M>$]4UBY>6Q=I]3U/PL[^&[Z]F+W%WH3/I4TDEBQ@KOECN&I*JGP_63J*KR3C
MC9*5%S;<'3BJBIMTXREK*')4?LW*E3C#DEP1RKBA.G?B##M4E22@L$G"JX1M
M4E5YZ;J?OFH7C"I%TDIQC4FZCJ1_+V7_ (*"_$SQ'=_"K4?#'@KP?H;-XO\
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M&(I.-6E4:<X4OYX_^(8#_@EH ,:-\?2?7_A=VK\?GI@/KQG'/(/%)_Q# ?\
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MK];X.G_ (_Y-7Y(?\% /^3[/^".?_9RGQ\_]9G\;5^M\'3_@$?\ )J]K-/\
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MV&S$WC/^RK'PKH]\VF3V4<.@W6JZ-;1:EJNLR7+ ^LS_ ,'(MES_ ,8=ZYP
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MNY/C3H+#<N05S_PAOWACIZ$$9!J0_P#!R+9#.?V.]<XP/^2S:#U/3_F3>_\
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MFCFM[FWDCG@E0E9(I$=20:_R]];1?[%UD]!_8VJ@\GD&PN/?OT([\ $9.?\
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MP%4;0,* . .*=_:UA_S^6?\ X%14 7U15!P",MN.69F)Y/4DG Z!<D* H4
M ?J%_P $AOAM\4_BM^U?K?ACX0?'KQ#^SEXMA^#GBC5)?'_AKP=X5\<7]UI%
MOXB\,077AF71_&$$^E16E[/<VU[)?1Q_;89M/ABA=4D<C\KO[4T_)'VVS!R,
MYNHL#DX[C/()//7Z\_O_ /\ !O3\-O&NN?M0?$7XQ6&AW3?#7PK\)-6\&:EX
MMDAN(M(N?%?B;Q#H%_IV@Z1>-#]FU2_@T_1;V^U.*VF8:;;FV^TLLMW#&X!^
MW@_8F_;Q5E8_\%8/BW@.I(_X9V^!)R-PPN#IA4CH.5()Z\9%?Q/_ !JT_4](
M^-7QBTG6]=N/%.M:7\5/B!IVK^)[NSM-.N_$NJ6/BG4[:_U^[T^Q5+&RNM7N
MHY;^:SLU6TMI)VBMU6-% _TM6Z?\"7OC^(5_F\?M6:#K/A7]J?\ :3\-Z_IT
MVF:WI/QR^)27UA<(?.B6_P#%6I:E8S*PPLMM?:=>6M]9W"$Q7-K<1SPNZ.&(
M!X112X/H?R-&#Z'\J /I7]D+XD6OPC^.=I\0Y_&$/@&\T'X9_&I?#7BR9[A/
M[,\<:A\+_$MCX&6V>V@N91>WGBF73+2T4Q"&2>5(KF2.!W<?8GB+]H_]F?2?
M GP,\86-AI_BF[\:^,_CU\7OBC\#]!\)^ ]<U'X+_$KXJ>%/@AI7BG39])^+
M_A'Q3X(/AS6/'7P_\8^)/!>H:''<ZA%X>URQL!+9+9S1W7Y2E3S\K'T'../;
M'?\ ^O30AX.&)Q@DCGWX[9[XYP ..P!^T/PP_:J_9D\4:)I.AWMK\+?A'X:T
M']H+2_B-\1[7XI^$K?POX\UKX6R?"^\\+ZKJO[.^H?LV^&/#.A:)\;=!U6U^
MQ>'[[[%I7BCR]:M9;/6'L9M:*^7VWQ\_9(?_ ()]?''X >#-8^+'@?Q=/X<^
M$NM:;X%\6Z+X.^S_ !1^,]M\7)/$/B/QY%X@TK4+W6-7FM/#-MH.B:]:ZRFD
MP>%?!>@VR>%;*]U*ZU!)_P K1$<G@@>P^][GCJ,D#TZT[R_]GOD@+U.#P>.<
M_P#ZSC-  .@X(Z\8QW/..O/7MC."*6EVD=C^1HP?0_D: &D9!^GZ]L?C@_AB
MOZ2_^".W[/'[3'Q;_9?\5>(O@U^V_P".?V;?"]I\:_&FDWG@+PS\*/AKXYTZ
M_P!;MM(\+RWOB=]7\96=QJT%UJD-Q:036$4HLH$L8VB0-(Y/\V;*W(((S@X
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MPL^.&B?$+Q=H_BR[-RGV'1/$'@VSU/0987AO(-834)])GC2&X+U]'>-/VZ_
M'@GQNK?LT^$M?;X8M\,/A5X4L]%\9^/_ (K?"O5_#%]X*B\52W?AZ&V^$OCW
MPSI_B/1](E\4/IFC:]JBWLTMAI\#:>;2*>XCE /E[X1^%?VE?$&B>,?%?PCU
M'QSHFA?LG:%K_P 7-=U>Q\3W_@VR^$R^(&M-'U_4=!$LUI]F\;^+H;2"UN-%
MT^)=:UK3-,E%TG]G6)(\$FN[J_NKN_O[R[U#4-0N[K4=0U#4+J>]U#4=0O[F
M6[OM0O[VZDENKV]O;J:6YN[NYEDN+B>5Y9I'D9C7Z9_#C]OWX.6'PG^,GPW^
M)/P$(U?Q_P##K]H%1XO\+?%3XAZ@WCOXH?&?5=-N+"Z^(6F:GJ5U-<Q^']&T
M_3_#ND^.=:U;7=;T32-%-I;I_P 5'J[R?EY;SP)%&KW5N[K&BN_G1*'<* [A
M=^%#ME@HR$)*YXY +M%0_:;;_GYM_P#O_%_\71]IMO\ GYM_^_\ %_\ %T ?
M0/[*&B>(?$W[57[-GAKPEXPOOAWXJU_XV>!=(\-_$#3=,T_6M0\$ZU>W\D=C
MXGL='U:.72M4N])E EBL-2C>SN&;;,I45_9<?V)OV\LG'_!6#XM8R3S^SK\"
M<\GVTX#\  !T%?R/_P#!.#PGK_Q"_;V_92T?PC82ZO>Z'\8O#?CO6A:K)/'I
M/A3P4+O6=?UG4I;>.86=G;6T(ACN)Q'#+?3VMH'$DZU_H; Y (Z'D9]#R/\
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M ()M?]&[0?\ APOB?_\ -E1_PY:_X)M?]&[0?^'"^)__ ,V5?J;10!^6D?\
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ME*%"-&I2G*$*GLZB<(SCSJ,:D)/D;E%Q/W#IK*"#C[V#@GG![''L?3%?CO\
M\/MOV1@1CX8?MX?^("_M6=/3/_"LP1U.:/\ A]O^R+_T2[]O#_Q 7]JS_P"=
MI7$\ESKIEE?YU,*M/_"XZ7C,-TK0?_@:_P#<)^BNN?LO_LW^*-6U#Q!XF^ 7
MP8\0:]JT[7>JZUJ_PR\&ZAJFI7;\O=7U]=:/+<W=Q(>9)YI'D<Y+LQ.:R?\
MAD#]E'_HVKX$?^&G\#?_ "CKX _X?;_LB_\ 1+OV\/\ Q 7]JS_YVE'_  ^W
M_9%_Z)=^WA_X@+^U9_\ .TH_L7._^A96_P#!N%_^;A?7<-_S]A_Y/_\ *3[_
M /\ AD#]E'_HVKX$?^&G\#?_ "CH_P"&0/V4?^C:O@1_X:?P-_\ *.O@#_A]
MO^R+_P!$N_;P_P#$!?VK/_G:4?\ #[?]D7_HEW[>'_B O[5G_P [2C^Q<[_Z
M%E7_ ,&X7_YN#Z[AO^?L/_)__E)]_P#_  R!^RC_ -&U? CT_P"23^!OK_T
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M )N']<PO_/\ A]U3_P"4L_8< * "V2.ISC)]P2<_B>O-9EU=3020".W:59)
MIQDB/+8R=G0G.\;L# R#GK^0LW_!;+]DIU_<?#+]NR)P069OV /VJ9,HO4;3
M\-(QR<9.<XR .F&R_P#!;+]D_P#<&+X:_MTQ@$^<K?L ?M5ON  ( '_"MP4&
M0>FYB<?-@'-1R7-N9.>7U.6TDX2J8=J]OM<N,_\  4F[MZV,JF.PUFHUO>3A
MK",VVG)74;T;;7YNJ2;2;5G^NTEQ,M[%;K9[XY$!>ZXPK$ME1P5QD#<N<DD
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MB3XY?#3P=<Z_8^*?%6EZ1J7AR#4;N^TMYENM3FM=+T!/$MU)8:=8M<WUP_\
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MKX=O=2\76$NH^'M-COD%[J5M#]H,HBMVVO'<I]CO1]DF\NYD-C>F&.1;2X9
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M(8+:YT037T2M TNJP7MF]I#$\DSM=0(462:.-LJ3X\?"&+R<_$/PL1<R6L,
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M3Z9;02WIC@0QF.ZW*1)G..IV]&.U<G &0>!3;ZTLY9-.$U[)"T+ 6V9%S/\
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H=^!_RZI=[ZCC4<J\5[.A9YFXM^R][_=Y2YU+FNJVEG46\;QY;,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $6 G # 2(  A$! Q$!_\0
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MHHH **** "BC..M-5E<94@CU'3\#T/X4 .HHHH **** "BBB@ HHHH ****
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M$OCGP[X;US1] \/>+O T]YH7C/X:>#?B-X8U_4OAWXYU7Q#XA\(1ZC!XHO\
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M@ HHHH **** "BBB@ JM*I^4Y8 8')7G&[(8G).02!CO@FK!&>Y'TJ&4\#D
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M^]QVR..,9P20._3@D?/MM'\,Q^U%KDT%QKI^+K? GP_#J-HZ2_\ ",#X=?\
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MXU$]VD_FU]]A\R_JWY;_ (%BBH/,( 'S=N=ISZ>X^N/KWI?,;V]>5;IQ[_\
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M3BK5JT:,)1CJE3@TZ=!>PA28^BBBNL\0**** "JER00HP2-W.!C'4G.>N>@
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M-X0OO$UKXOLM?86NCRWLMGJ>L273Z-)]MMYVLC[3XY^*'[>/P^M/CGXDTO\
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M'7D>+-5& >2>O\^?>LK6Y-;M="UN[@\8^.8I[;1]4N;65?%FILZ3VUA<2PR
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MVY^\0><G)P#TP215?VYC%O0P_3[-5=;=:C_+J0^&<%;_ 'C%]_CI?K2/D_\
MX0_XBXS_ ,(3+G&01XET0G(X.<R=!V/3CZBE;P?\1MP*^").&!!_X230\@KM
M((/F\\C@9P&Z<]?S_P#C5_P4^\;^"_\ @HEH?[&_@;3_ ($Z=X=T#QC\"/!7
MCYOB[KWQ"\.>./B#?_&ZRU76Y_\ A4'BG2/#]]\*_#VK^"=$LK)M)\+?$O6+
M#5OBSK]W=>'O!_E75BLTOT]^U/\ \%)?@O\ LD?$;6_A?XW\ _'+QOXD\,?
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M?^SM_P -A>)?VI_V=_V=_"M]9ZM\14_9WL]*_:+_ &?;W]IC2/%_B"WN&/Q
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M_M2^9[?K_P#6KRD)\:L9!^%/4#/E>+^>F.?,YZ]>GO2[/C7Z_"G_ +]^+_\
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MX\NWT75].\ 21))X:N_%TFJ6^I:5T7[+?_!4SX]#4K/PI\>/A!J_Q7M/B/\
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MV/TE/TZ;-/\ )O\ ,****H84444 %%%% !1110 4444 %%%% !1110 4444
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MS3;#Q)'9G2-2**]I<R)*A;\O/&/_  2"^.%I\5;/QMX!^#WP ?X>^"_VC/\
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M1Y7NO_?'_P!E3_XC)Q+=-<.>&B::::\-.%4TTTUK['2S2:\P_P")9N"TFO\
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M>CCO],4K?GYGXIC]FO\ X*N!AG]KCPICT%[)CW7/_"OL<9X.,].>> ?LU_\
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M^) _LG__ #WJ^ZZ* /SG\5_MC_M+^#'\+KKO_!.3X^,?&/C#1O VC#0OB_\
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M9I]E>7][_P $Z?B[;V=C:7-[=SCX_P#[*3F*VM87GGD5$^+K.[+%&Q50#N8
M' )(^]:^5_VH_P!I72/V;O"B^(_$?PB^+'Q3\+/I7B36O&UW\-] \-ZCI?@3
MP)X:L(+GQ1XF\9:AXM\4^%-+2V6RNS'I/AG2KO5?%_BR>.ZLO#F@:G<6\R*
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? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $) G # 2(  A$! Q$!_\0
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M_P"'@G[#_P#T=;\"/_#C^&__ ).KSC]C30="U'XA_P#!0B;4-%TB^F_X;O\
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M ,./X;_^3J/^'@G[#_\ T=;\"/\ PX_AO_Y.KZ@_X1'PI_T+'A[_ ,$NF_\
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MAO\ ^3J/^'@G[#__ $=;\"/_  X_AO\ ^3J^H/\ A$?"G_0L>'O_  2Z;_\
M(U'_  B/A3_H6/#W_@ETW_Y&H ^7_P#AX)^P_P#]'6_ C_PX_AO_ .3J/^'@
MG[#_ /T=;\"/_#C^&_\ Y.KZ@_X1'PI_T+'A[_P2Z;_\C4?\(CX4_P"A8\/?
M^"73?_D:@#Y?_P"'@G[#_P#T=;\"/_#C^&__ ).H_P"'@G[#_P#T=;\"/_#C
M^&__ ).KZ@_X1'PI_P!"QX>_\$NF_P#R-1_PB/A3_H6/#W_@ETW_ .1J /E_
M_AX)^P__ -'6_ C_ ,./X;_^3J/^'@G[#_\ T=;\"/\ PX_AO_Y.KZ@_X1'P
MI_T+'A[_ ,$NF_\ R-1_PB/A3_H6/#W_ ()=-_\ D:@#Y?\ ^'@G[#__ $=;
M\"/_  X_AO\ ^3J/^'@G[#__ $=;\"/_  X_AO\ ^3J^H/\ A$?"G_0L>'O_
M  2Z;_\ (U'_  B/A3_H6/#W_@ETW_Y&H ^7_P#AX)^P_P#]'6_ C_PX_AO_
M .3J/^'@G[#_ /T=;\"/_#C^&_\ Y.KZ@_X1'PI_T+'A[_P2Z;_\C4?\(CX4
M_P"A8\/?^"73?_D:@#Y?_P"'@G[#_P#T=;\"/_#C^&__ ).H_P"'@G[#_P#T
M=;\"/_#C^&__ ).KZ@_X1'PI_P!"QX>_\$NF_P#R-1_PB/A3_H6/#W_@ETW_
M .1J /E__AX)^P__ -'6_ C_ ,./X;_^3J/^'@G[#_\ T=;\"/\ PX_AO_Y.
MKZ@_X1'PI_T+'A[_ ,$NF_\ R-1_PB/A3_H6/#W_ ()=-_\ D:@#Y?\ ^'@G
M[#__ $=;\"/_  X_AO\ ^3J/^'@G[#__ $=;\"/_  X_AO\ ^3J^H/\ A$?"
MG_0L>'O_  2Z;_\ (U'_  B/A3_H6/#W_@ETW_Y&H ^7_P#AX)^P_P#]'6_
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MST_GD5]XK("%SGD9S@  $GD],#CKC%?EO^Q1\+8H-#_X*#_"C_A8?Q9N(_\
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MIIA"_:%-U;A[6ZFBV6\B1%\/(&.T#](Y>C'Z >G5>_/."<?08/I^<'Q>8?\
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MK-EX7U[2]8@O]4,<L4>H^%O$/AS4K"XL;K4])UBSBF5S!]!_&#X&^!_C+?\
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MI^*?%]OKNI7#PQQ1Q6B1W%X;:W@C:3%O#&S.9"]?I3I>/[-T_P!?L-F#_P"
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M]*QFX,2:?[7^JZW\.?VD?^"?'Q6L].TO7-#OOC?XZ_9O\0Z;<:E<Z7J^G/\
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M<#X1_%OC'"G[O3&2#P/?.34O@K'2Q4L;*GXN/%S^K\]>7#?"3G)8;G]A3?\
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M.,6K63/UL^.G[+OPO_:!O_"NH_$*X\2P7'@_PGXX\)>'FT'61HTMB_CJ_P#
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M4^51M>4GR3DFK2LXR4$G&S2YDI1:N?<_BG]B7P%?^,-)\:_"CQOXT_9UGL/
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MZBVE+6TK-JZOK;2Z\FKZWMZ:=TFTTVD[/=72=M.U[>J8M%%%,84444 %%%%
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M%47AW[-;F%?%MGXNN-:^U[7^UF671=1MK VN[R_LZI%Y@4/YK$XKS#XSZ/\
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MDFDNS2OZZN_W"U\OQ+>M?L6_%J]CCU;P[^TCX!\#:[J?B;PY<W7A?X?K\4/
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M_5>OD,^1?V]_@CKG[0_[+?Q%^%OAKP_+XL\0ZE<^#/$.C>'(?%NF^#'U?4_
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MZ=2G-Q2J4ITJL%R5(<W1;KNI)-.S6FUFKM75FGMKTNF/HHHIC"BBB@ HHHH
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MFORIR]G]F_FFE_\ !0C]GG5])\):[;#XJQ>'O$^C:5XLEUF\^%OBRVTKP=X
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MU"8V.JBTT_R[GS99HOTV'@_0\#Y-1Z ?\AO6CP,XP?M_3D_6NB\L$%26V@
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MZ]GTS2DU'Z1_9V_9+^,$'AW]HO5_C)XBL_@1XS_: \0?"26/2_V6/'5Y<3^
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M/$?6:T:L'7JXNGAYT*4)2496TM-N2N]7*T4XJ\NB2:2LK.R5[GZ(*0P# Y#
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M'4'OU!_KU&78!Z_Y_P XK.,FG"<&FX24DWJFXM/5+S6H-)IIK1II^C5OU/S
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M;J+3;VYDMXI9 4CDE54=P45BW%#V8'5;<#/)(R<'')QR.A//X_G7\O?[3_\
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MY8V(!*.N0#D"\QR,=PR9_P"^@:8'YH?ML?\ */']K?\ Z\OB1_ZG]?I'I?\
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MT6OYWO?U \H\GX[^>P:Y^$GV81 AA:^-S-]H#Y8&/^T?+$0BP5<2;_,.W8
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M:YILU_I\\^DW]JZ>W?$O]C/]G?XP?$%?B3\2? ;>+=;EL=/L=5T?5/$WBMO
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MRT19_B!XAO=+OM6T^[\-_P#"*ZYXEB32KZTTK46M[G6I-*G\RTE22",M'O\
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M_P#3II=?:^E_\@W3O^O&T_\ 2>.OBC_@I;_R8?\ M.?]DVN__3II=?:^E_\
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M1^TV5I<K>7%N\WGVL$F_=$A7+_X:_P#V3O\ HYW]GW_P\GP\_P#FBH_X:_\
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M?LX7.O?%#PY\)] N]6E^-'P>UC1[+3O@OX.G^'WA:\\'2V-W#_8]]?Z0\_\
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M 7[9_P"R/X=^+G[1\O@2?XV>,[?XS0W-YX]E^&>B7?ASP*^H6-]K-SI.G_\
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M0^9;(4TV.VCFN&5+F+/Z$03I<1I-"0T,L<<L; ,-R2HLB-A@I *,K8(##."
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MMKW[!J%O]I@6:58I_,C61PH8FX'Q_P"3_P %.O\ GK^P=_X#_M"__)E'E?\
M!3D8+3_L' 9 )%O^T*2,D#@?;1DY/'(Y[CK7WK10!^;G@S6O^"K'B33M5O/$
M7A3]ASP3=V7BWQ=H5AIU]>?'G5I-8\/Z#K]]I7A[QC#<6-Q"EI:>,M*M;;Q%
M::1/&;W1[6_AL;V::[BF*]=Y/_!3K_GM^P=_WX_:%_\ DROO15"C &!DG\R2
M?YTM 'P5Y/\ P4ZX/G?L'#!!_P!1^T+Z_P#7[_GT->1>+OB]_P %*O"/Q?\
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MM0C\<Z"WAS0-7/BVRMK6>.31;5=8U35/#)TJ^DN+O[7X=N]1\X65_8AOT@I
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M:OIMQ#8:E) %0M=6L,,+ER$3"!WZOR?^"G7_ #V_8._[\?M"_P#R97WH !C
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MOJG@_3OA6NJZ?XB\2K\07\+6']I2@'VH(?\ @IU_SV_8-_"#]H4_^WE'D_\
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M]OV#O^_'[0O_ ,F5]Z8&=V!G&,XYQ]?QI>E 'P5Y/_!3K_GM^P=_WX_:%_\
MDRO'/CG\8/\ @I/\"?!6G>-M5TO]AWQ!;ZA\0_A7\/4L--C_ &AXIXKCXI?$
M3PW\/+;5GD0:B3:Z'-XCCUF\A-NHN;.QN(!=6CNDZ_JLS!1DU^:OC?\ ;V3P
M)^U/XS^#'Q/\$Z#\+O@5X"LX;G4?C]\5;KQWX<\/^)]3L_AC+\5-3C\#:C/\
M-Y_ACJ;^'[&WEMY;2\^)-EK=S/H^NOING3WFF+9S '<&/_@IPS,5G_8/8;F
M)MOVA$)VDCE1?,%/'(#,!V9AR4\G_@IU_P ]OV#O^_'[0O\ \F5Z9^R!^T[:
M_M:?"6X^+-CX!\1_#6Q_X6#\0/!MEX6\8S6;>*TT[P=XCNM&TO6]>L+%GCT"
M^\3:;%:>(/\ A&[J234=#@U&#3]39=0AN8H_JF@#X*$/_!3G(S-^P< ""2+?
M]H7C'?'VT9^A(![UR/A#7?\ @JOXBM_$$OB'PK^PYX,FTKQCXET#2+>^N_CM
MJO\ PDGAS2+T6VB^-;66PNHA86GB>VS?VVC72/>Z;%B*YGEE+A/TC(S].X]?
M8T8H ^"O)_X*=?\ /;]@[_OQ^T+_ /)E'D_\%.O^>W[!W_?C]H7_ .3:^]:C
ME?RUW%@H )8L0 JJI9F.1T502>1P/6@#\L/%7Q:_X*4>%?C'\(O@W<:9^P[>
M:A\6]!^*6O66N0+^T,EAH2?#"U\*7-Q:WD ,HN)-;_X2J-+5VOK#[+_9]RPC
MO6D2-/7O)_X*=?\ /;]@[_OQ^T+_ /)E?)'PW_X*J^*?CIJ>BZ/\&_V>?#/B
M3QI\3M2FNO@#H?BGXL7?@_4-:^'=OHWC;Q-JGC3X@_VO\-M_A>SO?#?@1I-+
MF\ 2?$GPY-XBU_3?"6J^(;#4M+U%U_5#X"_%S2/CW\&OAI\9]"TV_P!%TOXE
M>#M%\66^BZH\$NHZ++J=HDEYHU[-:EK6XN-)O1<6$MU;,;>Z:W,\!,4B4 ?!
M_P </@U_P45_: ^%/CCX+>,-?_8F\/>%_B+I"^'=?USP]I?QZU#7=+TN>\MI
M[J\TBSU#4[6PN-2ABMV:RAO;B*U>?8+G=#O1OU!LD,-O#;EBWV>&"$,5VE@D
M:QAB 2!OV[]H^[NP>E6\?SS_ )_3\J/ICV^M !1110 4444 %%%% 'S7^T;^
MRE\)/VH].\.V/Q.@\76\OAA?$EGIVK^!?&WB3P#K\WAWQMI!\/>/?!6HZQX8
MOK&\OO!OCO0-ND>*M$GD:&^M8K>:![6]M;6[B]\T+0M)\,:/I/A_0--LM'T'
M0-*T_0]$T?3;:.UL-*T?2K6&QTS3;&VA58[>ST^R@@M;6"-1'%!#'&@"H!6Q
M10 4444 %%%% !7S!XO_ &1/@QXW^,NA_'37=+\0MXQTC4/"NNW>E6'BS7].
M\!^*_%/P_BOX?AUXO\;>";2\CT'Q1XI^'\>IWJ^$M8U.UDGT\-;>:+G^R])%
MC]/T4 -48&#U[]><<9Y^G3TQ3J** "BBB@ J.6-94:-ONLK*W!R592C $="5
M9AZC.0*DHH ^%H/^">OP*TKQ-\#/%?A76OB]X(OOV=O!C_#_ .&-AX4^*/B"
MQT33?"UYXD7Q/KEI>:3=_;[6YO\ Q/<I#I/B;7(EMM<UKPS!%X:NM2;1C):2
M?= !  .,X[<#Z#V'04M% !1110 4444 >??%/X8^$?C+X$UWX;>/+&?4O"7B
M1=.75[*VO;G3IYQI6KV&N67EWMG)%<P&+4M,LYF,;KYB(T391V!\;\*_L>_!
M;P9\:-2^.NAZ=XF3Q;?:UXS\5:=H=YXR\0ZA\/?"?C7XDPP0?$GQSX/\"75Z
M^@^'_%?Q 2WSXJU2S@!O)KK4KF"*VN=9U>:^^I:* &J-H"^@'I_3@?3\N!PZ
MBB@ HHHH *^2OB?^QI\+/BU\;O"_Q^\3:Y\2[/QSX2\(-\/]/M-#\<WUGX.N
M?!-WK)USQ#X;OO!]U;W^B_8?&TX@L/'DEE;V5[XQT*QT_P /Z_=WVBV-K91_
M6M% 'SM\#/V4/V>?V:=9^)VM_ ?X2>!_A//\7]<\/^(?'-CX#\.:3X6T2_U#
MPOX9L?">AK9:)HEG8:9I=E9:19 I8V%K%:M?W>I:DT?VW4;R6;Z)HHH ***_
M.;_@I1\8?VJ_V>O@C/\ '#]F[Q#\"-/TWP'=:+;^/O#WQF\!>./&-QXA'C3Q
MOX,\#^')/#%_X-\=^#O[!.C77B&]U+5?[0M=:_M.**VMK8:>5DG< _1C('?U
M_3K2$!N_*YQ['UQTR,=_>OR=U']NKQ_\ O&3? SXZZ1)\?OV@3_PHWP;IWA?
M]F_X7CP'X?\ $OQ)^.3?''5_"T]EKOQ1^,-_9:/X1_X1OX3R0^(KC5[V-_"5
MW93ZF]UKEMK-O8Z5P.C_ /!:[X#W7P_U/XD>)O@S\>?A]HM]\-?!/Q'^%EKX
MRL?AY9ZC\6H_&WQ=A_9]@\/:6=/\>:AI_@_5M,^,UQ#X9OKKQ]?>']%?0)!X
MW@U%]!222, ^M_&?_!.W]G'Q[XP\0>./$T'Q,O=?U/4=9\0^$9O^%L^.S;?!
MGQIXCUC1?$'B/QY\#;:;6)E^%GC'7M<\.Z'J-]JOALP1H;&2PL;6TTO4=6L=
M0^FOA!\)/!?P.\ :!\-/A_9WUGX9\/MJERDVK:I?:[KFL:QK^JWOB#Q'XC\1
MZ_JLUQJ>N>(_$OB#5=3UW7=7OYI;B_U34+F9BH947X[LO^"A_P .->_8@^)O
M[:/A[PKXJ33/AI;>--%U/X?:VVFQ:M<?$_PCK:^#D\%V7B'1KO5_#.O:1KOC
M&YTK3]$\<^&-3U;PWJ^CZK;:Q8W3IYL$7P#<_P#!6+]H;P%XT_X*$_"OXF?#
MKX17OQ!_9S\,>"-*_9I3PI/XHM-*^*7QLOO"7PAL?'/@GQ5#J&I7-W)I.D_$
M[X[?#B31)=":UU.X\"7>I7-Y$+ZU\\@']"=%?C;\#_\ @K!I/B3PE^SD/BI\
M)_'+ZSX[^'_[+=G\</BQ\.]-T>3X'_"_]H/]J+X;:+XV\ _#&VM=9\5GXAWU
MAXAN]2MM/BUK3]$UO2O"EQXC\&V'B75TFUBYN;'D[C_@LCIGBL?!$?"[]FGX
MPJ_QH^+_ .QMI.@CXEGP+H,VJ?L^?M;^-/%?@K3/C)I-IHOCS5);#4]&USP/
MXETA?"&O3VFK"X&E:I<6K:1J*S1 '[>Y!YSQ2U^%?PO_ ."S-C'\%_$'C;X[
M? 'XF:/XOT3P)XH^)7AV3P+9>'+KP1\4_!>@_M,W?[-=UXA\.7UYXRO+[P%H
M/ACQ1?\ A"\\9Z[\4!X:L=-\,ZG?^-!Y>C64EO']C_ /]M6\^,'QG\%>!]5\
M*6GA_P (?'3]G:7X_?!+4(-;\.>(=31_ GC"S\!?&'P/XEU_P1XG\7^!O$4N
MG:AKOA#Q5X*\3^$=;FTS5?#6M7D%VD5]IX28 ^]M?T/3/$VB:MX=UFW-YHVO
MZ7J&BZO9B:XM_M>EZK:36-_;"YLYK>[MC/:3RQ"XM+B&YA+B2"6.54=?@R7_
M ()D_LQW.F2V=\WQAU+6;Y+W1]?\>:C\;/B+>?$/Q7\.M3T+2O"VI?!GQ7XT
MFUMM;U[X07_AK0M&T6Z\$7UP]G-%IT6HO/\ VW<7FJ77Z$C   Z #&>N/?/-
M+0!GZ5IMCHNF:=H^E65OIVEZ38VFF:;I]G$L%I8Z?801VME9VL"?+#;VUM%'
M!#$N%CCC5%  %:%%% !1110 5P7Q&^%WPU^+WAT^$/BM\// WQ-\)G4++56\
M,?$/PCH/C7P^=3TYVDT[4QHWB.PU+3AJ.GR2/+8WHM_M-G(S/!)&Q.>]HH ^
M"/A)_P $X_V=/@-\0_"?Q%^#9^(WP[N/!?@SP]\/-&\'^'?'FI6_P^'@7PP^
MJ75CX1?PE+!-9VOA^_UG6;_Q-XBTO29--MO%'BEX?$/B%-1U:UM;J'[U12H
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M-*BBB@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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,O>BUS+7[+:=MC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #_ G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_?:N<[5S
MZX&:38O]U?R&?SZTZB@5E>]M>X444$XZT#"BC(]:,_Y[_B.U 'RC\1OVD/$W
MASXWQ_ 7X<_!;7OBIXR@^%.G_%_6;J#QGX/\%:+I?AK5O%VK^#=-MDNO$MVM
MQJ&JRZGHE_-/!!;+;VUGY#M<O+,84/\ A<7[3/\ T9YJG_A]?A5_\?K@; ?\
M;,_%1_ZL5\!#V_Y+]\1Z^[* /E'_ (7%^TS_ -&>:I_X?7X5?_'Z/^%Q?M,_
M]&>:I_X?7X5?_'Z^K<\X_P#U_E^=+0!\HGXP_M,GK^QWJA^OQU^%7_Q^D_X7
M!^TQ_P!&=ZG_ .'T^%/_ ,?KZOHH"R[+[D?*(^,/[3(&!^QWJ@'H/CK\*@/_
M $?1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_1_P +B_:9_P"C/-4_\/K\*O\ X_7U=10!\H_\+B_:9_Z,\U3_ ,/K\*O_
M (_2-\8/VEV&&_8[U,CW^.OPJ_\ C]?5]% 'R;_PMS]I7_HSG4O_  ^GPJ_^
M/T?\+<_:5_Z,YU+_ ,/I\*O_ (_7T7XSN/%=KX5UZX\"Z;H>L^,8=,N9/#6E
M>)M6O="\/W^L*A-E:ZQK.G:;K%]IMA+* MQ=VFEZA/"GS):RG"GY#3Q9_P %
M#"H)^"/[)VX#Y@O[0'Q/8!LY8 _\*0&<$GK@^W8%_/\ &WZA=]W][_S.Q_X6
MY^TK_P!&<ZE_X?3X5?\ Q^C_ (6Y^TK_ -&<ZE_X?3X5?_'ZY ^+/^"A8'_)
M$OV3\^A^/_Q/'_O$/>D_X2S_ (*%GD?!']D_!Z?\9 ?$_D?7_A2&/3\Z+^?X
M_P#!'=^?XG8?\+<_:5_Z,YU+_P /I\*O_C]'_"W/VE?^C.=2_P##Z_"G_P"/
MUR<'BK_@H*T]NMU\$_V4X[1KFV6ZDA^/OQ-DGCLS.BW<L,;?!.-);B.#S'MX
MGEBCEF58I)8U9I%YS]IWX^?%;X5_%'PCH/A2WU&/PW)X4MO$VCZ+I'PKUWXD
M:U\=/&@\6QZ1J7P:TG4]+OK*T^'M]!X<,>LIXIOVEATY;Y]?U&.XT+P]JEE=
M/F?\S^4G_F%WW?WO_,]/_P"%N?M*_P#1G.I?^'T^%7_Q^C_A;G[2O_1G.I?^
M'U^%/_Q^O@/5?^"A_P"U@=%T_7?#_P"R[X<NM$CET6PU7Q/Y_P 7M2TG5;J\
MU"/6=3U3POIZ_#[2=5'A:U\*V.L^$'U/64M-4L_B;+IL[Z/=^%4N+B3T/3OV
MY?VA8O&MKI'B[]G_ /L_2/#>F^,M9^(-OX)T[X@^*-0L#X9^%/B[Q+H7A5KK
M5_"GA^"#5?B9XNLO#DWP]U+1UUNWG\/G5+'Q#;:;K%Q9 %WW?WO_ #"[[O[W
M_F?7/_"W?VE/^C.=2_\ #Z_"G_X_1_PMS]I7_HSG4O\ P^OPI_\ C]?GYIW[
M=W[=/ASPM)IWC3]D.TU+X@^!)(=)^)#7#^+/#L>KZM?WGB+7-,OO!FD^$=-^
M)6ARZ._@&U\.+-(GC74G'BS5KBTN$L(;1X*_5WX'>./$OQ'^%GA+QAXR\*'P
M3XLU.UO[?Q'X:$M_-;6&LZ+K&HZ#J$VF3:K8Z;J<VB:I<Z6^KZ#+J6GV=_)H
MM_8/=P1W!D%%WW?WO_,+ON_O?^9Y+_PMS]I7_HSG4O\ P^GPJ_\ C]'_  MS
M]I7_ *,YU+_P^GPJ_P#C]?65%%WW?WO_ #"[[O[W_F?)O_"W/VE?^C.=2_\
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M;R/;;7$=N;NGXF_X+;>"[[X7^,?$?PX^!'CM_&$;?%:7X;CXC7UEX#\!>(=
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M>O-*M[;4/V;I#VYQZ].?;G^E0,_+[Q=^WA\5?"OQ2\!^%+']F?QWXK\&^+O
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M_0SIVFVS:7K.MZ1<3:5JVHV9AN[[3)7T^>5[1C%7Y=_$']H7]JWX5_$KPO\
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MF33+R>![G3GN(QLFDLY8C,GRR$]#M#:%VY7Y0"2 %S_M,.O3.>,@\YYKXJ\
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MJO\ '%?H-7Y\_L\_\G]_\%%O^P3^QO\ ^JO\<4 ?H-1110!YC\:/"WB7QO\
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MIGP_\*:;X*\*0A[^>X=6L?#NDV-G-,#YM]-&UW=O)<RR2'U-,$ ALCZY''!
M].?Y5YLIQG5E*G=QM%KVK;G=ZR=W=OWW+5OFDE%NSN=<4TDG:Z5O=5EIHM-E
MI;1*W;2PZBBBM"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OSY_9Y_P"3^_\ @HM_V"?V-_\
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M7XA"Q\;KX,T+QZVG6UG^R9^T/?7ML/#/B*:WTR]_M*VMVM3-)(LUJ',D +
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M4I.4HSE)IMJ\DD[NZ7367YZ->K):***I;:_U]X!1113 **** "BBB@ HHHH
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MQI\0/%_@/X=Z?XM/PN^#_C2Y\/:GX&\ ^+/B7X93PC\5O&EA);:#8ZWJU_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (R.,=OQQ^?H,YK@C4B]VE=)J_9J^ZNG;76]G:Z+)**0,&Z'MFEJ[@%%%%,
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M2>&O$^I?%7Q1XMU7XG1Z[X033K%/!VI67BRUNO"BVX_L)[$RSM)^BGF)P2<
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M%72K;Q3\6K73+'XD>+(_#GQ \<^(=#/BGQA9Z/IUKJVNM8F_:&U58)H=TF\
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M7<?=]Q8YPG"UU)NJL+*ZFK62I>X[R7-LQ)_S*]V[\M[WZ6YNGJ_Q/Q6_9_\
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MX9R3>"K\EK>S6-][FO\ %[3ZM=1M[O)RM/?F6QHE+;FUOI*SM:VUN:V_5O\
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MJ6D6D5U9->".\TWS=.E(M9I(V /=@01D<BBD Q^9/YDD_J:6@ HHHH ****
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MW\6M_P#":V.LZ ?C3$N@V_AV>U\/KHMU'>WIUR'5[YY4M&TY5F /NBBOD/\
MX0_]N'_HNW[._P#XCUXX_P#GZT?\(?\ MP_]%V_9W_\ $>O''_S]: /KRBO@
M3XK?\-[_  ^^&'Q&\=^'_B?\!/&VO^#/ _BCQ1H?@S3OV=_B$]_XLUC0M%O=
M3T[PW9)9?&ZZO7NM;NK6+3H%L[:XN3+<+Y,,CX4]%X7T;]NKQ!X8\-:]>_&+
M]G_1+[6_#VBZQ?:-=_L\>/4N=(O=2TVVO;O2[A9OCE%,LVGW$\EI(LT44P:$
MB6*.0,H /MFBOD/_ (0_]N'_ *+M^SO_ .(]>./_ )^M'_"'_MP_]%V_9W_\
M1Z\<_P#S]: /KRBOAVY\._\ !0M/&6B:9:?%C]F2X\$W7AGQ/?:_XGE^"7CJ
M#6-)\5V.J>%+?PGH5CX?_P"%U.FI:5KVDZAXPO\ 5-7:_MY-(N_#NE6B6URF
MM/+;=-_PA_[</_1=OV=__$>O''_S]: /KRBOD/\ X0_]N'_HNW[._P#XCUXX
M_P#GZTY/!_[;^]=_QV_9XV;EW[?V>O&^_;GYMN[X[ 9QG&<#/4X- 'UU17YQ
M? ;6/^"@OQ:^%^B^.O%_CGX$_#'Q!J6L^.M,N_!>K_L[_$>._P!/M?"OCWQ-
MX3T?49$U/XUV%\L7B71M$T_Q-;>;:K']EUB VSS6QBFD]A_X0_\ ;A_Z+M^S
MO_XCUXX_^?K0!]>45\A_\(?^W#_T7;]G?_Q'KQQ_\_6N1\6Z#_P43TT^%/\
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MBGPCX8^#WCWQ?X?T2_6_NXH(-)\2S_&72KC5;:73H[*[>:?3K5X[FXGM@C)
MLDG;_P#"'_MP_P#1=OV=_P#Q'KQQ_P#/UH ^O**^0_\ A#_VX?\ HNW[._\
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M[^-MI=BYT6[N9M.E%U:V]R)+9O/AC<E1W?\ PA_[</\ T7;]G?\ \1Z\<?\
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M!/[&_P#ZJ_QQ7I7_  A_[</?X[?L[G_NWKQQ_P#/UJ3]GS]G[Q]\,_BI\?\
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M-4TK3=;L;G2]8T^QU;3+V/R;S3=3M(+_ $^\A+*QBNK.ZCEM[B,E00DT;H&
M;&0" #\P?@O^V;\2?'?[<?Q!^!6NQ>&H_A;+)\6-%^'-S!I%K:ZI<ZO\%)O
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MI6CZ+H]E;:;I.DZ7I\"6MCINF:=9QPV=A86=M%'!:V=K#%;P1(L<4:H !J4
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MH^A:GXMUD&5AJOB:_P!,LK6YUS4 ]S=2_:]1DN9O-NKF4OYMQ,[]M0 4444
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MSGRBJF/;@4 ?S">(OV\O^"AWQ&\&_M'ZG=N/@??QZ)\:/A)H'PDT/X.:C?\
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M[.2_:Y_L[3Q:]O\ 7_/\Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC/3W./T)_I0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #A G # 2(  A$! Q$!_\0
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M:G&"E:]FU;5.UU9OY7$<;91'9-VV;6_W^>GSU/\ 4;W'^ZGZ>W^/Z?7!N/\
M=3_./\?T^N/\M[_AYO\ \% _^CQ?C_\ ^'(UJC_AYQ_P4#_Z/%^/_P#X<C6J
MZO\ B"N>?]#2A_X!5_\ DSG_ ->L)_T+*C\[K_Y$_P!2'<?[J?YQ_C^GUP;C
M_=3_ #C_ !_3ZX_RWO\ AYQ_P4#_ .CQ?C__ .'(UJC_ (><?\% _P#H\7X_
M_P#AR-:H_P"(*YW:_P#:F'MWY:MOOY[?B'^O6$_Z%E3_ ,"7_P B?ZD.X_W4
M_P X_P ?T^N#<?[J?YQ_C^GUQ_EO?\/./^"@?_1XOQ__ /#D:U1_P\X_X*!_
M]'B_'_\ \.1K5'_$%<[T_P"%3#Z[>[5U]/?U^5P_UZPO_0LJ?>O_ ) _U(=Q
M_NI_G'^/Z?7!N/\ =3_./\?T^N/\M[_AYQ_P4#_Z/%^/_P#X<C6J/^'G'_!0
M/_H\7X__ /AR-:H_X@IGG_0SH?\ @%7_ .2#_7K"_P#0LJ?>O_D3_4AW'^ZG
M^<?X_I]<&X_W4_SC_']/KC_+>_X><?\ !0/_ */%^/\ _P"'(UJC_AYQ_P %
M _\ H\7X_P#_ (<C6J/^(*9Y_P!#.A_X!5_^2#_7K"_]"RI]Z_\ D3_4AW'^
MZG^<?X_I]<&X_P!U/\X_Q_3ZX_RW?^'G'_!0.'_7_MB_'[M_S4C6O\_Y_"B'
M_@IQ_P % Y\^1^V)\?CTZ_$C6?R^OX>U+_B"V=WM_:N'OVM4O]WM+_@'^O.%
MW_LNI;O=6^_DM^)_J1;C_=3_ #C_ !_3ZX-Q_NI_G'^/Z?7'^6]_P\X_X*!_
M]'B_'_\ \.1K5'_#SC_@H'_T>+\?_P#PY&M4_P#B"F>?]#.A_P" 5?\ Y(/]
M>L+_ -"RI]Z_^1/]2'<?[J?YQ_C^GUP;C_=3_./\?T^N/\M[_AYQ_P % _\
MH\7X_P#_ (<C6J/^'G'_  4#_P"CQ?C_ /\ AR-:H_X@KG>W]J4+]N6K?[N>
M_P" ?Z]87_H65/O7_P B?ZD.X_W4_P X_P ?T^N#<?[J?YQ_C^GUQ_EO?\/.
M/^"@?_1XOQ__ /#D:U1_P\X_X*!_]'B_'_\ \.1K5'_$%<\_Z&E#_P  J_\
MR8?Z]87_ *%E3[U_\B?ZD.X_W4_SC_']/K@W'^ZG^<?X_I]<?Y;W_#SC_@H'
M_P!'B_'_ /\ #D:U72^&_P#@K-_P4=\(74%_I?[7?QBNOLO6TU?Q&/$NF?CH
M?B'.1SW[?G2EX*Y];W<SP[ET4HUDOO4F[WLMK N.L)?7+*B7>Z_^1/\ 3\#$
M X'?KV'_ -?IU/X4IR54GMG/Y\>GZ5_&!^PU_P '*?C:W\1:7\/_ -N;PMIW
MB/PM>W+6(^-7P\T@Z1XDT"0ALS>-?!<(30-;T0Y51/X0E$D04&#_ (2YR7/]
MA/@CQQX0^(WA'P]X]\!^(=*\6>$/%^DV.N^&_$F@7J7VE:UI.JJ'@U73)D+J
MT4J/Y@<9(!*R 2*ZU^<<0\*9SPMBW#-Z;AHU"<5S4I+;FC.*LG9IN$U&:3;]
MY:KZG+LXP6:+_9)7>]FTI*ZVLW=VUU2\CL7C5BK$8 S@=>_/OR1WZ_A2 $,V
M"O.>,@\\X/ ]>HY'L:=PQ5QT8' QT)R.,^YR/?@9[?&'[4G[8'PY_99T".Z\
M17#ZWXLU2-CH?A33)D?4[O *'4;]2671M'BD7$UY.OE)DHJ32!TBY,ER+-N)
MLVR_)<FRVIG.;5FH4J5&GS3BY?'-64E3BE[\YS<(0@G*4XIJ_F<7<8<.\#\/
MYCQ-Q;FU+),FRF$I3K59QCSJ*<E"$7)2JU)-<L:5-2DVTG%)MK['6&13N++C
M.>8H5SSZAN0<]>^?PJP9  !N&?\ =)'XA5Q^1SS[5_*9\4/^"G/[4/Q"N[B+
M0O%-O\.])-P$M].\+6D4KR@ Y,FME4U]-QY98XXHR3PG0#Y]G_;"_:9>7S;C
MXW_$$#N/^$KU7&1_P$#M^?K7]395]#OQ#QN#CC,=FG"V2.44W3KUZM6<;I-*
M3H4H1;UM))-)WLWHS^"<]_:4^$6!Q<L'DO#'%F?Q4Y1]K_PC9'"7+)KF7MZL
MG9VYHJ5FTU=)W1_9KY@]1_WS_P#6H\P>H_[Y'^%?QE_\-?\ [37_ $7#X@_^
M%5JWM_L^X_,4O_#7_P"TU_T7'XA?^%5JW^'N/SKTO^),.,_^BMX5^[.O_F<\
MC_BIMX=?]&]XI_\ #YD'_P D?V9^8/4?]\C_  H\P>H_[Y'^%?QF?\-?_M-?
M]%Q^(7_A5:M_A[C\Z3_AK_\ ::_Z+C\0?_"JU;_#W'YT?\28<9_]%9PK_P"
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ML[\P>H_[Y'^%'F#U'_?(_P *_C#_ .&O_P!IH]/CC\03_P!S5JW^%6/^&O\
M]IG_ *+C\0?_  J]6_PH_P"),>,;<W^MW"G+_-_PL\O_ (%[#E_\F!_M-/#M
M-Q?AYQ4I+>+SO(4UZIM-?-(_LT\P>H_[Y'^%'F#U'_?(_P *_C,_X:__ &FO
M^BX?$+CK_P 55JW'_CM'_#7_ .TUU_X7A\0L>O\ PE6K_P#Q--_0PXS6_%G"
MJ]8YTOSPR%_Q4V\.O^C>\4_^'S(.NWVNI_9GY@]1_P!\C_"CS!ZC_OD?X5_&
M;_PU]^TW_P!%O^(?/3_BJM7Y_P#':;_PU_\ M-?]%Q^(/_A5:M_A1_Q)AQE_
MT5O"OW9U_P#,X?\ %3;PZ_Z-[Q3_ .'S(/\ Y(_LT\P>H_[Y'^%'F#U'_?(_
MPK^,S_AK_P#::_Z+C\0O_"JU;_#W'YTG_#7_ .TU_P!%Q^(/_A5:M_A[C\Z/
M^),.,O\ HK.%?_ <Z_\ F</^*FWAU_T;WBG_ ,/F0/\ #FU].NQ_9AYH)XD3
MKCGRCWQUSDXZ>_O3L9.=RMR.BJ<^PV_TZ5_&</VP?VFAT^.7Q"'T\5ZL/Z5K
M:5^VY^U1I4GG6GQJ\<NHYVWNJ)J@_+Q"N.O/7Z>^,OH9<::\G%?"\G9VC?.U
MS/6R36'T;=DO-HUP_P"TS\-7)+%< \71BVKOVF22T>[5JBO9.^^OS1_8M\Y9
M$CSA3RS@C.3GH1^&">><^@D,2 L&3Y&VDCD$D8Z8]#V],#I7\\?[.?\ P5J\
M5Z7J5AH'[0.CQ:]H%X19_P#"9^'[=['6[$JI4+J^@.SKJG4Y>R$1#$M(DC9%
M?O/X0\7>'?&WAG3O$_A'Q!8:[H.MVT-YI6K:?,D]C<V,JAE:.2)I4=74X5@.
M-I#!#E:_G_CWPOXN\.,=_9W$V52P_,_W&)@G5PV(NV[PKQBXQFDN=4ZJA4Y7
M>#J6DU_8'@_](+PQ\<<KEC."<XC+-<N4I8CAG$2IT>(*$5%*3EAY23J4DWRR
MJ474IQM:;@W&_>/L"@'.!D#'UP?U]/PQ297;GD<]>".W4\?@!_6@[=B@G/&3
MC!'8G/3\*^1?VIOVM_AA^RWX9AU3QG?'4?$.J"6/PIX+TF1&\1:[+^]C9P@1
MSH^CQ.J1W.OW(%M =P!>2,HWPV R[%YOBU@,IIRKYE5E&G"G"$JDFWJN9*UH
MI)N4Y.,81O*4DEK^OYEF>$RG!O&XZ7LX03;NXINR;:3;7O=+*]Y72/K8?,3L
M/3J-O!.<')(_^MQ363<<,BL<CY@<']",^N ..U?RB?%7_@JK^U-X^O)T\+Z]
MI_PUT JJV^F>&+./^U)&48+MK&MI'X@5WQEO*AB0DY" <#YUF_;0_:FFE$\_
MQV^(_P#X5^L8]..E?NF5?1QXQQ6%53%YKPWDKE%2Y:M6<FFTG:U.*BV[V>]F
MVE<_%L7X]<-X;%.%'*N(JUFUS*$5%V=KI.4K+1VUO:SLGH?VD[#_ '1_WS]?
M_K?Y/!L/]T?]\_7_ .M^OKQ_%A_PV5^U/_T7?XG_ /A7:S_C1_PV5^U/_P!%
MW^)__A7:S_C7H_\ $MW%'_15<+_^!USG_P")@^&O^A1Q%_X!'_,_M/V'^Z/^
M^?K_ /6_7UX-A_NC_OGZ_P#UOU]>/XL/^&ROVI_^B[_$_P#\*[6?\:/^&ROV
MI_\ HN_Q/_\ "NUG_&C_ (ENXH_Z*GA?_P #K"_XF#X9_P"A1Q%_X!'_ #/[
M3]A_NC_OGZ__ %OU]>#8?[H_[Y^O_P!;]?7C^+#_ (;*_:G_ .B[_$__ ,*[
M6?\ &C_ALK]J?_HN_P 3_P#PKM9_QH_XENXH_P"BJX7T5W[];;OZ>>VJUU0_
M^)@N&K7_ +'XCMT?LU9_.]OQ/[3]A_NC_OGZ_P#UOU]>#8?[H_[Y^O\ ];]?
M7C^+#_ALK]J?_HN_Q/\ _"NUG_&C_ALK]J?_ *+O\3__  KM9_QH_P");N*%
MOQ3PO_X'6%_Q,'PSTRCB+_P"/^9_:?L/]T?]\_7_ .M^OKP;#_='_?/U_P#K
M?KZ\?Q8?\-E?M3_]%W^)_P#X5VL_XT?\-E?M3_\ 1=_B?_X5VL_XT/Z-W%"5
MWQ5PNEW<ZR7WO3\0_P")A.&;V64<17[<D+_=S7_ _M/V'^Z/^^?K_P#6_7UX
M-A_NC_OGZ_\ UOU]>/XL/^&ROVI_^B[_ !/_ /"NUG_&C_ALK]J?_HN_Q/\
M_"NUG_&C_B6[BBZ7^M7"]WLN>M=^BW?R3'_Q,'PU9O\ L?B.RW?LXV7J[V7S
M:/[3]A_NC_OGZ_\ UOU]>#8?[H_[Y^O_ -;]?7C^+#_ALK]J?_HN_P 3_P#P
MKM9_QH_X;*_:G_Z+O\3_ /PKM9_QH_XENXH_Z*GA?_P.L+_B83AG_H4<1?\
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M8DT/&'_!0SX[^._@B?@[XQT/X)ZW<'X<>%_@Q>_&[5OA9HVI?'&_^%_@4?\
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MV/\ #'_@D;?^-?%/P@\#^)/B9XC\->-]4_9!\3_MG?M&^"-)\"Z-J?B?X3>
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MRG3=VFTN=)/5>[*70]'),3+"9OE>)3>MXRBF^MUJE;>^ET?Z;_Q0\?:#\+_
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M<;Q@B:V[Z-H7RJ! H0DDA'9@JOPWP_\ V-M,\>_!;6?B-%XO\8:?XCTKX?\
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MW<3?]%9GW_@RN']C8'_H54__ "3_ .2/R"_XA[?^"7O_ $1OQC_X>7XF>_\
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M_P#+#R?^)=O WKX,>&?G?AG)+^=_W>_?YGQ)_P .N?V//^A#UO\ \+?Q7_\
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M#BZ_\))XZQZ_\)AJO_Q='_$3_$3_ *.)Q9_X<,9WO_S\[Z^NN^H?\2[>!O\
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M\/2HT:<;I*T:-&G!;)*\E)O2\F>@[^,8_/GU]^>WZ^U(2K#:54@Y&"!CG/\
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M5UG9RZ.45RM[.,=[/7^67NRU3M_4G//!9PS7$\D-O;P*;BYN)CA57!)8G<H
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MQVNGRJR^Y?G=?KZ %4=%'Y#GZ\4N >H!_"N \[XE#C^S_ YQQG^V=<.<<?\
M0O4>?\2O^@?X'_\ !QKG_P SU0Z5^L7V=_RNKZ_(V591T22]$E^31Z!17G_G
M_$K_ *!_@?\ \'&N?_,]1Y_Q*_Z!_@?_ ,'&N?\ S/4>Q7>'X?Y![=>7X?\
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MV7G'[Q>VBK*T5V5HK[E=?@=,-'TF,:>(=,T\#2@?[-_T2'-DOEC_ )!H\O\
M=G:O'EE<=,[<"MNO/_/^)7_0/\#_ /@XUS_YGJ//^)7_ $#_  /_ .#C7/\
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M.U_6R5Q.LGO%/M=)_==O\#OP .@ ^@ HVK_=7\A7 >?\2O\ H'^!O_!SK?\
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MBN\/P_R#V_E^'_!/0**\_P#/^)7_ $#_  /_ .#C7/\ YGJ//^)7_0/\#_\
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M_;Q\0_ B;PQ\)/@O\0O"O@CXCVVM?#'Q[\6?$6LZWI%AJ>@?"K6_B=X>\/\
M]C^'M"\0,ZZYK_C'9K;.\;;?"_@WP]XENF^_"J>ADV4XS/<RCEN$BE.4;\TK
MJ,4HRG*4G=6BE&VFKDXI7N[>1G&;X7),+];Q=[.2C9+5MM)+1/K)=.[9^W>1
MD@%>O3(Q^IYZ\=_3%(%5265<'IEFX![=< '_ #BOQA\;_%O]HSP-^W5\%-8D
M_:%T;Q)^S!\:/BEK7PE'A_0-%\$:K\-?"DA^&#:]X&^'.I:QHUS<?$R+X_\
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MO&U81J"Q%EKZ//CC1R2?LGBGV_XH3QK^7_(O4#QQHP.?LGBG_P (3QKS[?\
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MOK7F^PQ';\O\ST/K.'_F7W?\ [>BN(_X3S1?^?3Q9_X0WC7_ .9_Z?KZT?\
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M^GZ^M'L,1V_+_,/K.'_F7W?\ [>BN(_X3S1?^?3Q9_X0WC7_ .9_Z?KZT?\
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MMFPF1>/UO_@FY^QWXI'PM;Q=\*KCQ=<?![2AX9\&W7BGQY\1?$E]>>&3XO\
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M_P#S/_3]?6C_ (3S1?\ GT\6?^$-XU_^9_Z?KZT>PQ';\O\ ,/K.'_F7W?\
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MZ1JZZL?AI\/_  3#X$^)_P +M7U>/Q L<L?C2$RRB:+9'%Y2HT:LS+#=T?\
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MK[U_F%%%% 77=?>O\PHHHH"Z[K[U_F%%%% 77=?>O\PHHHH"Z[K[U_F%%%%
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M2/Q=):E/!TUT]F@E3/\ CY^R3^W)\:O$7P&UC6/C=^S%J5G\+='FU_Q1\/\
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M-[-Q;T:3NG;2]T9>QPE[7C=/5<T7^IPO_"L_ /\ T*FB?^ B8_G[C]?3E/\
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M)Q.5X9K"8ITXMZI.U^][<R=DNRMY;GUM_P *R\ ?]"MHO_@''[^_^<?7*?\
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M">AZ$Q\,Z_X<^*GB'7]8\(B/Q8=GB]- CAC1(TC1?3?@GX*\87G[5'C/QO\
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MS2]MYP^Y?YA]6?9_C_D?0?\ PCWC+_H?)O\ PF]$_P#B:/\ A'O&7_0^3?\
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MW+_,/JS[/\?\CV/_ (1[QE_T/DW_ (3>B?\ Q-'_  CWC+_H?)O_  F]$_\
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M+2!CVWG'[E_F'U9]G^/^1Z5_PCWC+_H?)O\ PF]$_P#B:/\ A'O&7_0^3?\
MA-Z)_P#$U\^R?M >*I?"6@^+['P.UO;:KK7CXWHUF\U@'0?#?@?73I$.J:O_
M ,(UX=\4*J>)T5S-XE,;>$O"D30F>=U1A+TT/[47PLU'4M;TK1&\2>)-0T/5
M['1FMO#^@2Z@=;U*0DJN@.KAM:55 R8BI78"N&Y#]MYQ^Y?YA]6?9_C_ )'K
MG_"/>,O^A\F_\)O1/_B:/^$>\9?]#Y-_X3>B?_$UY%!^TY\-;Z^U#2]-GUG[
M5I-CX<UFZ6\\-ZPJZAIFNX$4>A.(V;6M;7:,I$K;>#^\*G?UV@_&#0_&OPNU
M;XE>!;#4]:MK:TU<6F@ZF3X;U2ZU+1HVW:2YF,BZ1(SJ%W2(Q&_<RX!W'MO.
M/W+_ ##ZL^S_ !_R.O\ ^$>\9?\ 0^3?^$WHG_Q-'_"/>,O^A\F_\)O1/_B:
M\$L/VG/"&DS^'=%\>RMHOC#6]8U+11I&@V6NZBMDB'0@-4UV/5]!M/$.A1[=
M?T8!)HY1N<,^]45%O7'[4'@Y;S2;&T\.^-H4U07]XFJ:OX;DT[3K#2XAKN->
ME=G8R:&3H.LCS2 ^(U.>N#VWG'[E_F'U9]G^/^1[;_PCWC+_ *'R;_PF]$_^
M)H_X1[QE_P!#Y-_X3>B?_$UYUJWQ:DO/!%WXK\%>$O$6H7/]JVFCZ9!K6C:S
MI;WUG.8BVO:3$D9UOQ!H022-T/AU)99LEUC,:S,_(:/^TUX9WM;^(]+U.VSI
M-C?KK/AVRU;Q%X;N]6E)W>#TUM$5?^$F4L=OAME,HW.6=MS!CVWG'[E_F'U9
M]G^/^1[I_P (]XR_Z'R;_P )O1/_ (FC_A'O&7_0^3?^$WHG_P 37D.H_M'^
M$X=!\4:II&B>*[F7PAX;\2ZWXCM;OP\VGV7A,Z FO_\ $J\;2NS-H3EM U4+
MNW#9%N+,6VKW.N_$NWA^$^J_%/PII<_B*)?#;:WX>TNX T\ZZS8DTA S!C&)
M&="?XBAR-AVLI[;SC]R_S#ZO_7](Z7_A'O&7_0^3?^$WHG_Q-'_"/>,O^A\F
M_P#";T3_ .)KPBW_ &L_A>FMKH6J3ZC;RW/B$Z)I'V739-0:RDCTKP^VM/KV
MR)1H;>&_$&OR>&;DN2!(B($E#.XZ'6OVCO!^GZ[H.D6^B^*]:&NZ3IVH+=Z9
MHHG6R?7M;\.Z+X=TN16"GS/$D^M(8OWC )&,,"R^4>V\X_<O\P^K/L_Q_P C
MU;_A'O&7_0^3?^$WHG_Q-'_"/>,O^A\F_P#";T3_ .)KRG_AI7P'Y8:#1/'=
MS=7)']DVEKX1F;4-=TP?VV4UK1HS*!-H:_V!K.+B3:X"@JB[SBA%^U?\*+R[
M\06&A'Q5XDO]"N[*R^S:!X9UC4FUIY0-IT-%0+,HRP;+1YP-Q<DD'MO./W+_
M ##ZL^S_ !_R/9?^$>\9?]#Y-_X3>B?_ !-'_"/>,O\ H?)O_";T3_XFN'\'
M_&WPKXQU>WT70=/\1:DUY\S7]CX<U8:9HUBVYM*_MV1U0:*\R9"^8L:DH&;8
M"6CX+5/VA+/PEJGBX^/-+M/#GAG33>/X;2&XU74?$?B@PZU!HJ'01]FC\,>(
M7\32:LLT9\,^)WE\$NK1^-S:!P8CVWG'[E_F'U9]G^/^1[K_ ,(]XR_Z'R;_
M ,)O1/\ XFC_ (1[QE_T/DW_ (3>B?\ Q->1M^T[\-'MAJL4'C*YTE='_MM=
M8MO!VM/IP_XDVN^(#H^[ (U_^P= U=S&-HRBY?!55H1_M4_#//AZ>;^VCIOB
MBY\,Z?I-Y;Z0[FRU/7O[>"KKR[Q_8:[=$?\ UA8@D8'S,0>V\X_<O\P^K/L_
MQ_R/:_\ A'O&7_0^3?\ A-Z)_P#$T?\ "/>,O^A\F_\ ";T3_P")KS31OC!9
MZG\;-?\ A.;*&WBTW1HKZQ\0R7\J+KFJK*TFN:+HD18C7)?#9?;?>6L?_",?
M<G7:0B\2G[3=GX<3Q#J/Q&TI_#]C#=[O#.E:;#JM[XGUI6UF/1%A2-HE\,ZW
M$'7/_"3^'/%EQX43<5DE+(-I[;SC]R_S#ZL^S_'_ "/H'_A'_&7_ $/DW_A-
MZ)_A1_PC_C+_ *'R;_PF]$_PKQ74OVH? \5@]UH&A^,/$4-U=:19Z3<VF@2V
M.DZYJ>O0Z'K0T;1]6+*)==?P]K(\1"(^4'1'82B0!4Z[P[\:]!\4:3K]YH>E
MZW=C1/#;:Y>:B=):P\./J9T:/67T8:R[D?VT@E7S55 B;E?.\C*]M_@^Z(_J
M[\_Q_P CO/\ A'O&/_0]S?\ A-Z)_P#$T?\ "/>,O^A\F_\ ";T3_P")KP3P
MK^T>B^$!XI\::!J"6VHW2KI]CX2\-^,M1OX_+T3^W-9.KKXA\,^%(XO+7<%\
MM,$'!# #&Q#^TOX/_MF>&_T7Q;HOA^UM =6UW5?#>L(F@:JVMZYH3Z3KHVM_
M83[]#>1=V1N?!"GYZ?MO./W+_,7U9]G^/^1['_PCWC+_ *'R;_PF]$_^)H_X
M1[QE_P!#Y-_X3>B?_$UY/I?[07A?4O$>GZ*^E>(=%:[M03:^(-(;3]5LK]@9
M-#C.DL/,QXGT5Y)+<H5V*L<:A"7:NC\$_'3P7\0M=U?PYX:M_$-QJ6A+I;7P
MN]*DL%&GZUM\K5D9@/W(;=O(5&[J@W':O;><?N7^8?5GV?X_Y':_\(]XR_Z'
MR;_PF]$_^)H_X1[QE_T/DW_A-Z)_\37EVE?%76?[=U[2-<T&PBT[2O&'AOP\
M-7\/ZO'JR6+:_KS:5#H^L[E<C7;21M#;Q2BN5@37$ +%%</\9_&G4/ 7BG1M
M+\2^$);#0M;F\2?9?$#ZUI.P#0]*\.R:/E%9F$OB?7M</AN!6 ,<PB.57<:?
MMO./W+_,/JS[/\?\CT[_ (1[QE_T/DW_ (3>B?\ Q-'_  CWC+_H?)O_  F]
M$_\ B:\BT+]HGPIJ7A'0/$VIZ7K=KK6JC3;!_"NE6C:GJC^)9-%AUM]'T0+L
M_MU_*U1 AC(4-R5+9SK:U^T+X,\.KJ,NJZ1XYMK?3-+^W7=VWA#6BBZG_8__
M  D(\)[?*^;Q-_88$GDEPA(_UXQ1[;SC_P" K_,/JS[/\?\ (]'_ .$>\9?]
M#Y-_X3>B?_$T?\(]XR_Z'R;_ ,)O1/\ XFO#+;]J+PG=ZQI%CI>EZ[=:1JVC
MKK+>(/[)D":>5&@ Z-K"%SY6O-_;8_=JQ7 '4DD]_P" ?BS;_%>WTG7O!&E7
M-WX0N;S5;#5]4U\#3-4T75-&(58SHS[CEY"OS!E&2"VT TO;></N7^8?5GV?
MX_Y':?\ "/>,O^A\F_\ ";T3_P")H_X1[QE_T/DW_A-Z)_\ $UWE%'MG_<^Y
M"]@N_P"/_ .#_P"$>\9?]#Y-_P"$WHG_ ,31_P (]XR_Z'R;_P )O1/_ (FN
M\HH]L_[GW(/8+O\ C_P#G-=UO3]$L6U#4IDM[-+O2[$W+3D*'UK5H='3D'^%
MYXW'!()(7#(2?&IOB9^S_P"-HA./$GA/Q"/&#_\ "&\.'_M,:(C:V=$?<H.U
M#KXDP,$MK2 ,=S >N>*_#^E^+M'FT/5FF%A<WNE73FWN&5FDT76(-;C4%3A<
MRZ2@8E6P"5 RN:\OA^ _@[3=5TG5=*O?$VAW]A::;H]RVF:PT)U[PSHVCZ%H
M::'K"%7,NB&'0M(:5%='W(Q8(LORP=)Q43?LO0^'M0\7WVD^"M-L?&-E-K>K
MVNJ62K>WX;=_:HET5]TF\#QL XA5P&\0!F4(R T-/U[]D^7PG:PF#P3I_A_2
M? VI:T='U*S51HOA3Q[_ &#KFN[UE)V+XG#Z'(_E/YDIC3:P4M">F3]F3P):
MR&6QUKQSI\EM9LOAX0>(I2/"^I%-&!U;1!L*QZ]NT2$F8F9&0R+Y:_(QP;']
MD3X/6M[K5_IUIJ\&I:GX4_X1>[O3/I&I7SQ-#'I2ZT)-<T"94\0B+28U>[8M
M%O5R(BI3(!3\23_ CP1X6\/:=IOP\BU_PQXHT/5?$AM]+N?#^F:?'X;T98I-
M:UN9O'GB7PRC7$ UUE9K>9_%3>8QV-L4C8U+5OV7O&?B70M4U6X\&Z]XJMW;
MPQHUWJ5KJ7]IQC2-.8MI*-)&N3!'XAW%71@RZSM59)&)?OM)^!?P]TJQ\$:;
M+HRZS;?#G1M1TCPP/%&WQ#):_P!K/HAGU9WN8R&U@C18D$T:J^7D9&3<IK U
M_P#9P^&/B3Q+X7\4ZI87UQJWA#5=3UC3V-SI^;R;6]9;Q!+YH\L Q_V[MDCR
MT)9U>/<0RR* >?\ @3Q-^RGJ7AO3[_3;/PGHMBWAOQGXF>TUNU":@OAC6@VA
M>(-<U9'.0OBO0M%#RAVD,EL#&%D90C[VDS?LJW6FQ>"-)F\'/I^O?\2A='LS
MJ2K?\?VUY0W$/C/[_<QSDA=X'[NK[?LN_">3Q;_PF0TV_.K?V+8Z.0;]T^:$
M>6=5,Q0Z\OB0Z+F/S'G4!< (26*ZOB/]FKX6^*?$/A;Q)KNF7MYJ/A:\U*ZM
MOM=Z]Z-0DUO6%\0S'5U</YBKKI:5 I((4J7P2Z 'GNE>(_V?]%T_QI\2_A7\
M/K;Q/)\.[#3?#WB*?P3::'I^?#:Z-&RII U[Q%X2\-211:"P#F&:(LI"-O#%
MJW]-F_9\\&10:)?^'?"GPVU;PRTGQ'N_".J+HKZCX1U#^Q!H+^()1H,OB'P^
MDBZ#K#PQFWN)%VR)+Y;;C)!W.@_!7PQH'ACQGX5.K>)]2T[QU8OHNJ7.K:ZV
MHZC9Z7#HH\/Z7I.DR&(F&.+0&\L!0YP"YR& 3"\0?LZ_#?Q'\2=5^)6HZ;?-
MXFU2SL+2]%NVEID)#%H*:HLRVYUM9FT72HX1NN"I17,7FR),D(!S7AK6?V2=
M(FN_#?AZ]^'VF3W-R#=:4A&GEG);7>0P4#8-!5NN&.B[/^6>YKVGS?LMZ%8:
M+\4+(^"M-L==MM3\->'/$D; ?;DUL[M8T72,@,?-*!9%C3'+J,(/F]!O/@SX
M(NWU!+E=04ZM>_:[G-ZV7;^VYM?P,*?^8[JS28.?O!<CDGC+/]FSP3IOA'3?
M"6DZIXST^TTK5_$FLQZI8ZEI-EJUX_B)@-?T:1%T#^P&T#Q&IWS0&V@9@R!9
M5(D\L YNT^)_PCTC1[O6?#?A&YN=-TGQ;XF^%$HL4T32-/OY-#1=<UM?[;\0
M>(_#'AE?#Q;[0ZS>)+N&3Q8R0JK3*[253\S]DO5AHGA;4++P[#=:'XH7POI6
MD:Y::KINHZ=XF_LO0#_8V)0@$2Q-H@DV[_"9 4*SLNYO6];^#/AR_P##K:!I
M^H^+?#]O:ZMJ6LVUQH&M"._0:TTC:WI"+K4%QHQT2=9$S \3HH0!'CD#FYYV
M3]F[P"LMMY%[XSL+%1]DO-)M/$DBZ=J&E[-$SHNK1A)#)H>WP_I(\A7#X!RR
MAB: .:O-?_9/\4W%M#/=^ =3NO#!U#6;10R Z<?!,BB1@6 7%NI+X!)D5< ,
M^,^>Z7J_[&VB^&X= AN?#6O:2S>%OME_]CU;45N]2UP^'UT/689 N6;']B2!
MO#((\(.54K:*S>7[SK?[/'P^US0#X=N/[?MK?_B4?Z5;ZR\>I+_86D'0M'/F
MX8$1P#*_( [J<E V%Y[3?V7/AYH]EI]C8:IXVM[;2K<?8E'B)-]G?#5QK9UU
M#_8G_(P^<0WFLH_=_NA%DB>@#1\(Z/\ L\>*4G\$>%=-\)7_ /PC%IIUY=^'
MM+^==#&M#1&0%5VE-PT31&8AB<0Q@\LRCS#0W_9H\1_";Q_XZLOA=:OX'\)^
M(_%FLZO;0:&@U#4]2T,%M7?2HM#E::0L$EC7PZC+$T@56M5!+5[3X8_9_P#
M7@_Q)K/BC23K7VC7/#*^$+VSNM6:33VT@'E1'@$,V, Y8@G[A[97A7]G7P%X
M1TSQKI=I>^)[^W\>VVDV'B!M6UEYS(-#@_L?1P@"1E2$#!'^<.%R5&Y5H S-
M1\0? KQ]JFO^&-?L=)N!I>C>&]0N]1U6R&FHU@^C:WK^B'2=4&QR?#6AS7$Y
M:*51'_;2_-^]=6L77BK]FNRTK5Y;F^\$V^C:7K/_  B^L,;5!IXU+6U;_B4,
M%C"$R'002$ "G1#MVB,%G2?LQ_#TVUQ8V,_BG1/MEYJ=_<7>E>))H]1=-?.N
M#6M%,K1%1H;?V[(1 J,V"@W#:6=\G[/WA:72ET2'Q-XXTZQMKV6?2%L_$,:R
M^&+#6D.DZSH&@,=';RO#_B.+SQ<1RJY8L)D:% P< XF6S_8\T.UUB_N;?X>V
M>G> _$M@-8G !T[0?$V0(R7RZAQ_81+ !DQHAX8I\_5:Q+\$=8NO#_Q"U[1;
M4EO$>H^&[7Q%=_+I-A'X%7QWK4VJ:JZS+H(T)#H6NRK/(A7=,JA\C"<[KO[(
M7PHUYO$HFN?%5@OBD:;]OM](U'2HTLVT71=<T: 6[MH#B8?9M<F#_P#"1_:L
MRA6S$$,3>MI\&/!)\*Z/X+_XF/\ 9&B:OJVLV.W5&^WG4=;TCQ#HFJNT^./,
MA\0:R2H#!7=L9VN" ?-G]K?LGZEXC;0AINF>,I_B=<ZIX_U/Q6;(RZ59,?&6
MO?O)-=++)H2KXD_MM0@>)CM=F=MZ>7U%[J7[%M[H5M]MG^&]QHVMP?;;0-L(
MFAT502P(.Y/*;1< ':SF$YRK@GUO6O@'X"U[^UA>CQ$3JO\ Q^?9]99,G'\(
MPW.>QSZ>]9?@G]FWX?> K&*QTR;Q!<A;P7XN-2UAY9&OS_;>&  7#'^V[@;0
MK9PA#'# @&-=^)?V8+S4['PI/J?P^N-0&H:1]ATHE"3J&M>0-&4@87?+_P 2
MHQDL O[LMMR0M7P5\1OV;_"5Y;>&/AWJGA;3'U2\U,O!I6=.TYM8&L>&]$UL
MZOJ^P@:[YNMZ,&660RD<HP^4UVD7P ^'4&E'1(8=7&GBUU.QP=7<_+K7]A><
M,C'S8T#2/+PHSM&<[B!Q>A_LF?#'0K9[&TNO%MQ:7-V+VYMKS5XF&IMMT3']
ML;=$0N"^APD*RQY&Y0VYLQ@&UIWQ)^ 5YK7@[4])\;>&6GN]9\56OAVWL[Q0
M+_Q+KCQG7-3VE\^8Z.ZB3[G_ !.BS[#(NV+XBW7PLE\5?#/5?&'@@>(+CQ/K
M6G:+X<\5MI ETZTU+7%/]@Z7JVZ3;JPE8$I&XECC"C,8)<'2T?X ^"M*^U37
M&H^*-;U*ZL=,M+K7-?UDW^IWMAH>M:%KF@J\CX)'AR;0](6&40H&VL2&:3:.
ME\0?#*S\47'AF[UGQ!XINQX;;1GO-+CU<Z;I/BV\T.:/6=(GU[2PAC=TUD"9
M4.& 01DL@#T >)>*?"_[.>G^'_"7BZ\\(6MMX?U[Q=]J_LG2='C8W6KZP[Z%
MKLGB#15Y_L+P]%)JS^,T\CRX!'(S%\K$_2+;_ &6\^*^JMX%TTWWA@9\7W9T
M.(/>MN\1Z%MT@ABK J^LK^Z"$'622Y$@V]7J/[/WPZ\5:/H>F^/=$M/&L&B6
MOB@QVFL6:#3&O_&FL_V[K>L'1U$BKKDDN[$C!BHF?:H=P4U-)^"?@_1M+\4:
M7#-X@N8?%]G8VFM7E_J[W]_>K$67/FLF%.& 9@K @N5^6@#F%\;?LX>'/"^K
M> SK7@C3/#'A"\%EK/AXG&FZ;J)US(1TY^8>("3D,W[[CB/&,6[\4_LP:E=>
M']7N=0^']S?MK&I:)X;N%*[KO5-$T2(-I*LR$,T7A\Z2^UMRNNP* 05/6P_
M/P7;:Y+K3WGB&Y$-YJ-YH>EW&L,-/\+2>(-<;7]>_L2%@&C'B37%$L^]FR&"
M*05P>;U_]E;X:^)-6T;5[R7Q1!)H/]D?9;2UULQV-W_8/]B'2&="K ^6-$@
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M#C6E+:ZX92DBK_;8<(2[;S6/V6OAOXCM_"$'B2[U_7!X#O\ =X;_ +6N-&U
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M1<;S@>$&-L&>6,&;2NO@!X;FT];*'Q'XYT^VMM5U2]TS['KZ(="L-=:)=?\
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $# G # 2(  A$! Q$!_\0
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M_P 8M*U/5?#5Q?VCZ%JAT?Q!H>N::^EZ_P"']12)A)I>NZ1*/,M9ERI WNC
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M/\T?_ H__)#J*;O3^\O_ 'T/\:-Z?WE_[Z'^-%GV?W/_ "#FC_-'_P "C_\
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MX2Z7XN3Q9?&WTG6M5L[KPGX#M_%6M^,;+P5ID4,D;01:SX@6.XE+2L) (D*
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M.?[M'U[,O^AC/[ZG_P L%_967?\ 0OC_ %\SSG_A57P^_P"A4T3_ , 8O?\
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MY'W]O<?3G^[1AO[Q_(^_M[CZ<_W:/KV9?]#&?WU/_E@?V5EW_0OC_7S/.?\
MA57P^_Z%31/_  !B]_\ 9_SGZX/^%4_#[_H5-$_\ 8O_ (G_ #GZX]&PW]X_
MD??V]Q].?[M #9^]^A_SW'Z_W:/KV9?]#&?I>I]W\0/[*R[_ *%\?Z_[>..T
MCP;X8\/7,UYH^CZ;IMU< 6[W%G:K&[KGA6* 83<,'& >A/IV!Q@+GISGCO\
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MV\<ZYI6HZKHG@BXUO2XO$^L:5I&PZOK&CZ&)FUV\BMQ-MEEB5XX\-G8T<C
M[NBF_P '_ ?Z5^-W@S_@K-X-\6?L1_M _M<:K\&_$FA^(O@/XC\5>#[CX&/X
MNT#5/$WCK4P\'_""/X>U,*MN^B_$O^U8_LMQ+;.+0Z'XD&V<^%YU8 _9.BOS
MTT+_ (*,?LR0>#O@MJ_Q3\>>'_A3XS^,?PW^#_Q*O/!.JW>L^(5\!)\7M/B/
MA'2?&_C;0O#<OASPZ3KY;PV/$7BU_"EO-+!$S>6=E=!K/[>'[.WPXT_7K[XP
M_%?X:^%O[.^+/Q(^%.E6_A_7-=\:ZC?ZK\+9&?Q -7TB'PK#K^AZ]X63)\;K
M##XG\'>#C#$UUXU=;D&, ^ZZ*^$?B=^W]^S%X&2_T+2OC-\+]6\:CX5:9\:=
M%TS4_$FL:=X?_P"%9:^+@:'XQUOQOH'AKQ;!H/A?Q%_9.KFU\33P2JKQ$O&6
M"R')^"?_  41^ OQG^*OQ8^#UKJ-QX8\7?#'XZQ?L]:0OB&RUC3['XE^.?\
MA6&C_%C/@N6;0XEFA7P]+K#B.1PP&@3LID:1%C /T$HKXL^.7[;OP8^!O[+/
MQ?\ VMFU&;Q[\.?@ZWB.SUT^"\:E-J'B3P]XP'@76=#TID\Q))H_$N(R1(R%
M=SJY/R5C1?\ !0?]D*"]\0Z7J_QG\-:9J_@?P=X5^(/Q!TNZL]=B;P3I/CC2
M]#USPQ'KH_L79'KWB./7M%?PQX7\H^,+K>S0VNZ0V] 'W917PE=_\%&_V+['
MP5;^/+[XY>&M.\.7?Q%_X5/;6][HWBT>)&^*AT+_ (3<>"6\$CPX/$Y\0?\
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MI95/ATS1SL&"I'*%"_-7QZ_X*</X.^(NG:M\-?"OQD@\)>#OV3_VK?C3XO\
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M8_;;^"GP[L? 7A5?V5/%?_":?L%Z;^Q)XXU35_&7Q+TH>"M6'C'X@R:Y\2M
M+?#?Q:WQ#\.CPUXR:4_"WQ./!_F>+HRY\<&$MNVM7_X)1?&CPOXVTOXE_#[Q
M;HWC74?AM\8?$NK>&_!;?'#XI? &^\7?#7QQ^S)\"?@3_:NL_%;X?^&/%?B/
MP+\1O"7B7X5Z[XC=(?"?C/P=XO\ "6N_9I DQ$9];T[_ (+-_".T^,>B?!^_
MMO"6KV&G?$GX7_ #QAKVG_%32$^+_P#PMSQUH^A>9JNA_L\CPXGBKQ!\/?#7
MB/7=&\/>,_%T?BZ.>TGE<1>#IHEVO]0_MG?\% +7]C6?QG!K'PE\2^/#X?\
MV=_$WQT\#VV@^(-,T_4_B=XF\/>-?#O@63X,:%HLNAM,?$DP\9Z-XCCG,TJI
M YC:)]NZ@#U;]D?X*>,OV<OA1\.O@[)X+\"Z'H&E^'/$OB;Q/<>$OB/XV\61
MV/Q/\9>,KCQ%K6CZ+#\0/#K>)-?\/!]?UB4>*_$7BN"\=XH8CX0"F,1=!XC_
M &+/V5?&'C32OB=K7P+\!7'CW2/$:^-8O%UOHB:9XEU/Q,=2765U;Q)J^AM
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MU '#3_L&_'/1_$6I_ #PWJ/PNG_9&\3?M+_#/]I76/&NJ>(_%\_QMT]?!#^
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M_P"$)U_19K9]!\/^(?AWX>T?PS<^$XU/A1K=6;[$C.C1@'I?[*/QF\1?M ?
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M\8O %G\3O!'B.WN/!^H>)/%GA:TU;5$.@>9XB\#^+];\#Z[I7E:N$D,B^)-
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M&FA?&;6O!VHWFO\ Q%\=G]K'Q1X?TGQ_J=S_ ,(,OCC]JG0OA9HFO2:O)H,
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MG%X'_P""87[/'@#X?_!+X:^']2\;R>%/@IJ7[15[I$5UK@?5/$(_:=\*>//
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MG.@?'CQU_;^/^+J?\S!\._\ B>:YXH_X1;O[\5]8?L3_ +.OC+]DO]GWPO\
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MT35?"-S\1? ND:[>>$]>(75?"G]L^#E\0_V#KI8%?[?\,;?*D!QF-V&5SN4
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M"'PB^(WP0\&?"_0OBK??M;_LH^!O@5XT\;:;XPT?3?#/P/\ B8NH_$,^//\
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M-@F/GKX@?\%8_P!G3X>?#KPC\:Y_"7QOUKX,>*O!GA/Q]J_Q-M/!^CZ=X:\
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MM"^$7C#X+M\7_A[8>&=5^%VC_"3P=XA\$_LH?"CX=?$;3/#NC>*O#6O0ZO\
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MX/?QO\*=(:0>)3XCD^(/BY%7PQ;>&?LBR)XK*Q@X=B?H7]F_]K_P'^TMKWQ
M\':9X6\>_#3X@_#*T\,:CXQ^&WQ+L-$T[Q+8^'?'273>"=>TL^'?$'BKP]J_
MASQ-'H.JB"ZBO?,+_NBL.U7F^0?#_P#P26\ 6?P"^,OP#\<?$W7_ !SH/QA_
M9\_90^!MSJS^$]#T[4M!;]D_P2?#_@3QDNDJ&CUF1M=TC0_$\GAJ1EB6315M
M5DE\XRK]-_LB?LA7O[,\WCK5]1\1?"7Q!KOCD^';28?"+]F_X<?LV^&K#3M#
M@D$6='\-3^+?$FO:YND#-+XK\77:#"A4C=!+$ ?E;IO_  5?_:!TKPC^US\6
MO%'PW\26NH>!K?\ ;?U#]G_]G-OA=I&G2:]IG['#-H>O:UK?Q6D^)$C$'Q&W
M_"0>,T_X1!?(MV,5L8D1(Z_?+X3>,-2^(7PR\ ^-];\.:AX/UGQ?X/\ #?B7
M5O">KE?[2T*_UO1XI9=*U95!&Z%W\LC!/F1_-]W!_-/6_P#@E3H'B#2O%^DW
M?QC\2B'QCH'_  4#T2]$7@_1!]AC_P""@4J_V\T8'B1E:3X6(#) "P'C %6N
M6@D5HA^E/PN\,>*?!7P[\&^$/&GB>P\;>)O#'AO2-"U3Q;IGAS_A#],UR_TC
M24B.JKH UWQ,-!$^S=)&+N8B0ICS(_*4@'J5%%% !1110 4444 %%%!Y!'K0
M]GZ/\@.%\>B3_A$/%0@),IT#7"A&1S_9<FWWSG YXS[5_"Y*N7<@<AAQW )_
M7%?WB:M:+>Z=?6DH)6:SFB..^^%QQVZM@#U'X5_#5XY\.CPCXZ\8^%1P/#7B
M/Q/HN#Z:%K7]A#@^X'X\$U_>7T(<;!5?$'+TTJDJ7#M6W65.-:K!M=91B][7
MBFTF?Y&?M1<MQ4H>%.;)-TH/B>D[7LI-91+ETNE)12;5[M7=M+G'9_#C'Z<_
MG6_#XM\4VDNDSV/BCQ%;7'ABS^Q>'+JUUC6/^)&#Q_Q(P3_Q(2?8'IZ5S]/W
M,./YCD?Y]Z_O2I@X8[W:D*=11YTHU(0FDIQ=.HE&<9)<]-NG.RM.#<)\\&XO
M_)7!XS&8)MX2=2FY)-N,Y0D[.\7[LHMJ,O?BTVHR5TXOWCJ-)\;>-]!MI['0
M_&/BO1M/N[O[8;/2?$FKZ=IW]J=]8*@L2>I(S[D]"*__  E?C"XBN83XJ\1_
M9[G1_P#A&KJU_MC5\'PP/^8(#GC0!G@=<]ZYT=?3WZ4$8_Q'2L7DN67<I9)0
M<I-2E-T*'-*2:]Z4G2O)^ZO>E)RTB[^['E[O[9SKE6%_M;$*"UBOK%;D23;Y
M8^_:R=W:-DG>RU9[-X*^.GQ,\%>-- \=V_B'4?$FO^&=)U/1]''C6_U?Q#IU
MCINLZ.NC#'S*225!/7<,CFN$O/&/C'4;J^OM0\7>)+C4-4T@:-J]U=^(]7)O
M]+)VG1M9PP!T#YCA1Z<FN6#/&>,C/8@C]/H:/FD/7IZG '?_ !_SBN2/#7#V
M$QT\PCD>%4JE.%&4HTJ-W3IRJ3IP:4'#DA4JU)Q2A&TIMN[:MUUN*^)L3A(X
M+$YSBI9:I7LJU1KFLE?2HIW:BE9R>BM>QVTWQ*^(MW+833^/O&MS_9EY]MLQ
M=>+]8/V+IQ[\$]<CJ*HV?C'QAITMA/8^+_$>G3:99ZI9Z3]D\1ZQI_\ 9^EZ
MYC^V]'T;!(49(P23C%<ICM_+FEP?0_D:ZWDN5J/*LBPZ@[^[[##J#4FVUR^Q
M4=>9W5K-MW3N[\G^L&=)W>;XEM;-UJW-HK)\SG=Z)*]T[=;G<?\ "Q/B-Y5A
M!_PGWC/[/I@TS[):'Q)JX%C_ &'@Z)SG!QGYNQP23Q5>[\<>.+N_@U2]\;>+
M+C4+6S_L>SU6Y\2:P-2L=+X)T?(.#ZYY)]>#7'[3Z?YX_P 11@_Y_#_$5SK)
M<K3O'(\.G[R35##IKF?O6:HIVD]9)-<UO>Y@?$6>/?.<2[M2=Z]=WDKVD[U'
M>2^S)^\NC1OW?B;Q5J.D6/AR^\4>(M1\-:8 -)T"[UC5]1TVP[ :+HIQP/<\
M8ZU@ X/(!^O/^32[V_R*;79@\%2R^+C3ITJ4&YS<*4(4X\TFYSDU3A3BY2=Y
M2DXN3E[TI2?O''B\;CL?.,L94JU9OW(SJ3G4E;2*BG.<W:-U=<Z2VY8H_J-_
MX)(/*/V7 &/!\>>(,#GH=/T89R??OZ9[U^I(&TJ,X(+DG\ !_G/'/X_G;_P3
M&\*CPQ^R/X%>X;,GB+5=?\0-C^%YM9N0@/;)730<\]?7I^B1P2O^T&Y/'&.W
M'MCOFO\ %_Q@Q$,9XG\?XO"M2A/BK/[-:J35>48V>TO>@[O75/5G_35]&[+\
M5E?@+X483&)J<>#N'ERM--<U'G4;/96G'332VG<FB\Z*:$]P/?.0"./?I]>]
M?C?\/O\ @FU\0O"/A[X$Z'-\2?!LT_PE_8V_::_9KO);71=75+_Q/\===T+6
MM#\6Z)YBDC0/"AA,4L;()E\S:A5P3'^Q%[]N^RW'V+[/_:'V4_9/M&[[#]MP
MVW=C][C?C&.=OONK\&_V3/VY/VW/B5\)?A;X(;X?_"3XO_M,>+K?]IWXO^)M
M7U#QSK'@7X:6/P8^$_Q\\1_"?0M!^U1^%!<)X_\ %OB*4^&/ TT?A=?!\?A7
M0!XU\:S1S,T;_G2V7HOR1^XD?PT_8T\8)^VY^RIX:C?6YOA3^RS^RS\+[#]I
M?5/^$/UOP_\ #KXL?M$?!'P;#X"_9PU?P=K.NH3K+^$-#\<_%+Q)<JK2I$$\
M,222 ;MG,?#_ /X([>._ _@_Q/\ "5]:^!UQX6T?X/?M"_#+X/?%6]N_CWXD
M^+,;?%GP?XA\!>']:USP;KOQ$_X5=\/9O#?A_P 0)%XT7X6>%BOC<QQK;Q^#
M7:1I,ZY_X*[7>A>+?'OCZRM]2U+P_P#'7PS^Q/8_LY_#;QK;ZVN@?#?Q3\5?
M!'Q?\:?%/6?',WP^\->+O%IT#PG%X-D/C>?PCX6\6S))X?7;D2.*^@_A?_P4
ML^+OQM\<? CX9_#SX$^%-.U[QG-\<K_XI^*?B#X@^)/P[\#:'I7P)UOP(^K>
M,/A<_B/X:>%O%OC[PU\4-&\=_:_ ;>)O"7@EK21$?QN\48E$C KQ_P#!.;X[
M6=AJ/P,T_P")7PO;]E_XC_&7X1_'[XDW-UH/BT?&NP\3^!=+^&HU_P '^"I9
M0/#AT'Q1K_PMT:6'Q-XDF;Q=X4@URZ=8[J6*WV>%6/\ P23_ &D=4^)&@^-_
MB!\6_@UKFL^&/"O[7W@R\^)5POQ@\<_$WXJ1?M*?#/QUX!T+7-?'CWQ(?#'P
MZM_"1UK26D^&?POV^#ALN/+.%A%<[\7/^"N'Q5\3^ ?VH?!'@K1/!>B^,M,_
M9:^,?QT^"GQ#^#OB/QAXU30]5^%/B[PWH#>#=7UKQ[\./"7PR\>Z^S^--#;_
M (2?X6>,O&7@\/Y@&4*&O8/B7^WA^T?X5U7X-?"CXPZ1HGP5^)^G_&?]B[Q[
MXDUCX;^*!XS\/^//V=OBQXC\0Z)XWT376USPU;C0-:M_$/@K7_"?C%50/-'M
MF\#7,TA\UP"W_P .T/VEOB9I?PLF^-OQ4^!EMXK^!7P[_9V^#GPU7X9^&?%D
M/AC7/!/PO^,WPD^+GC_Q=XUBU]8Y_P#A)?%A^%.C:'X/\+>&U/@_P<URTD<D
MBGRXN>\'_P#!+/\ :!D_: ^&_P 5?B/\4OA#XB7X<^*OVG!JOQ#:X^,?BCXN
M_$OPQ^T5\-_B#X!T,:W_ ,)YXDF\+?#O_A$F\8:,7\+?"WR_"'BL:$HF$,P
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M<7C?]L;P8_AZ[BF\0M\$_#Z>&?C9\5?&%V?#?C7Q!\8M7\0:U-H>C^#? _\
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MX[<YX_.OUQKX\_:3^'C7<-OXWTR#FU_T/5QM "JS';J^02#L7Y21C. <9)H
M^*J***/Q\@^=O/MY_+?Y!117R7^T7^UI:_!O6[GX;_#O2-$\3?$C2UW>,?$/
MB#_B8^&/"&I8YTC1M&R!KNOC/WF*A>[ '%?;<!\"<0^)&;2X>X=RM)0UG4D[
M0II-7G5F](03=VY-/6R3;2/S#Q7\8."?!GA:'%?'&8RRC+9MPI8>DN:OQ5/6
MU.C3CS3<VURQ48Z/5\JC)Q^M**_(K0OV\?V@]-U**YUC4O!?B[3L 7GA[6/
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MX7?QFT2@_:A$HKYZL/\ @GI^QGXM\/\ CWQ+\$_!FG^ O%7C'PM\>?AIX?\
MB%;Z?K'B&P\ 1_%B;6_#WQ3TKP7\+_';/X,'AY=?-PTWA4>%(O!LKPL;: (&
M"@'YW_M+?M&_MXVGB.?X">)?B!\"QX^\*?&'_@ECX[\!^-?A-:^+_!FE7_\
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M3P\)R4?;5J]*K2HT5>2;=3$5:<=+M14Y+X-/U?P=\.LS\5/$?A'@?*:=2?\
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M6V@?$)OAW>^(M#\3:IX/MO'7[#OB1$\(:/IL6N_\%)]?\:^(?$?PED6-28]
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M_@IW+KNB7BZ3KW[6/@:[LFU71PFEZUI0_9'^ &DLVEOM8:U"?LPCD<JRY=4
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M_@/XD:7X+^._@GPG\(/&7_%M#_8O_$^UKX6:W_PD?_%?_P#")Y_X1?QL0?"
M(SD# !^S_A)^RE\)/V7OVVO!^B?"SX^^+/CK<:%^S[X\^)GQ?_M_X0:Q\.=,
MT+P'XY^#7]N>!<Z[_P )'XM_M\^*SXWT0%0#M((SGBN ^+_@K_@H[^U'X3G^
M'7Q%_8]^#?POU'7=7\,:S\4_V@[OP)X,^&_CCXEZIH./[$UKXJ?%3_A),$Y
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M#-#SG_A'P,#_ (34  C&2>@'\TG[)/Q;_::^%GBK_@GQX/\ &UMX]^,&C?\
M"K/VL/VI_@IJMSK&N%?'>F:W\%?'BZ_^S_XX+LQU_P 1>%_B/H9D\%@'8/!W
MB#PT(U1 J)_3K\9OVG/ 'PQ_:E^%_P"SUXX%MHFK_&[PA\8_&>C>-_$.L:-X
M<\#:#I?PI_L#&BZY_P ) ./$/BS^W#U] >:^)_!__!2SP/\ $[PE\(-5^ /[
M+WQ(^,?Q(\=^'/BAXS\-_"?P0?AIINI^!/A?\*/&>O\ @37?&FM^./$'B/\
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M\%@?"KP;K?Q4^('Q(\6^)_V@/B$/$;:R/!7Q27_BBAN7)!(R ?U:?$']GO\
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MOB7XI?LY?&C]J#X.+^S-XI\.?!?P=\'O^$O9O"?[3(\;_P!MG6M:U;PVZ-X
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M/*<+DKF[REA:%&A)ZM_%1ITVU[SLN:R4G9:L?1116)ZX4444 %%%% !1110
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MK)X;%NWBJ>47"*6B$0C*^1^'/V5?VGOC3\6_VS/A[XCL/!G@']F3QG_P44\
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M*&^-VOL/#/Q2_P"$+\&^#O!T7ACQO_PGC1>$Y/!4@!^XJ_\ !13]DY_BW;_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX_&WQ<^)/QB\>_&5]>\"?LQ_#!?C+X=7^P?$'A?P]H6N0[$65VDF4>6(S(Z
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MH^"N@C1-"\$Z#X9^'?B^&3P]\5/VBSXW'@GQ./"$D?\ PAWAR+P4I8^*(60
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M%O4OVEO!7@CQ-^TC\4? 'QV_::\/?!%?BSXFT_PQX)^#@\1^"-<_9RT'P_\
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M%G2M!T?^VY9-<T?72)=#<Q[O*<R,C':ZXSYE 'T517R+>?M6>&--T^_UR_\
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MCU'3[#23HC.(7;0?.7:GA\[2\:,0@4+]TNV1X=A_9TN['Q?KFI^ ;+X7VO\
M;&DWWB2Z^)NB'X=/J&JXF.BZO_Q4,D*@?\A98G/</O&&#+L^#/V>SX=\,_$3
MP_K7BNSU$_$&QTG2C=^'/"FC^"QHT.B:(F@Z2\:>;XECDUN-70K<R%U5P=L#
M-L!76O@I\1O$]G;W'B7XL:-K.N:9K/\ :/AQ=2^%VFZCX(L!)HVM:(#J_@>3
MQ,[ZSKD<>N2C^WF\5Q%6C$:PQ1CD Z!+#]GWP9J^KS0WGPX\/:IX@\-V6BZN
MT^OZ-IDE[X901:-"AS*J>6P73(2Q50Q\@;T)+29*^ ?V9;2PUK0X].^&-M;^
M'[/5;WQ':#5=$5=#T[7 IUO5=?9V8^6QT,!IO$Z,H_L/.Z,PR;L"/]E3P=;Z
M7]@N+V#4ISIGB73?[7U3P[H6HZD!X@\$:%X&A<-+L!7PXVAIKR8Q^_?RD;*L
MX\_/[)%[XJTSQ'9>)?$]OI*W&K>*KWPW_P (]X;.D:I;2:[XOB\2Q:OXNUW1
MO$D7B#Q0LJ:1HA;P['-X/B1XVB9MZN(0#UI_%7[-O@6Q$5E?>!K.S\,:)X8\
M:[-,O-((TWPW_P 3\:'XP^7:#&C#6]LV6+#<R@JPKIH='^"/B_3/"E]<6?A"
M[LO!]Q#_ ,(D+FXTKR=/*.%TMD8N=A==(4P(S,<1,</AL>,1?L@VEOH-MX=/
MC(_93HXLM7O+KP[_ &MJE]JV?'8.K2:SK7B&5_[!7_A.9B?"R+)$/)&9@9"(
M]Z7]E?2+VRMK35O%5_\ 9[O2/&]AXDL='T:+0-/U[5O$#:XNC:P!!+(-"/@I
MM?U\>$3"TBH-9E*EPJ;P#L8/"W[/-OH5_P"*M"\/^#-7T'Q/X@TNTOM2\*1+
MXATV_P!5EU=="C)DT!9XVDB?69%<1DH Y+*VV,OUFL:-\'1XSM[CQ ?!,'C3
M^P#86=MJ>I:0FIWWA>.PUU&C.B23"0Z (]:UX,?)$)(?+[?E/F7A3]G"_P#
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M+.C>)!X:UWP[X<'A\/;^&D\(^%8Y2)$\T.(3<:^G_LB647C;PAXWG\<W8N=
MU;^VM?TNTTO5?#NEZIJY\7GQ(L&A:#HGBB'0O#NC?VV!*T=Q!XK !.92/GH
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M/\)6^GSV,^KV=W<2:'XVT==5NO"V@_V@'U_1_ >@1ZMR58R>'!X*)@P2LO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $I G # 2(  A$! Q$!_\0
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ML+0KU,;CY8J=#XK_ .%/?M>_]'@Z;P<?\D&\*CIW_P"0Z3@GC'TZC%*?@_\
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M%#>%_P O^0]^/]>U?:I50F[#8W<DG XZD$#) XY.">N">:4J@(41N"<'ER,
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M_P F4_\ A@R'_P"=(_\ B'60?\_>)?\ Q-N,?_HB/C#_ (45^T=_T>9XT_\
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MOT6;5])T;PKH&H LFH0Z1J-U9R?9;C,WWW;*54G'." 3G)YSD@\@'MCL,$G
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M\.!^87_!6HZZO[&UV?#\OB"+4)/VD?V*87/AF35H=6&G2_M@?!./545]$(U
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M<%S)_92ZUJZ:7O9_WG_(.^R^6S_.5VD\G-0?M??$G4XO#5A\ /AS=QW/QO\
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MR5< D].WM@CN2,9Z4?VADO\ T3&#_P##QG__ ,M#_5KB_P#Z./FG_B*\&_\
MR@^-?^&G/BA_T9E^TA_X$?";T_[*'T__ %>U'_#3OQ0_Z,R_:1Z?\]_A-_\
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M .)I?7\D_P"B7P?_ (>,_P#_ ):'^K/&'_1QLS_\1;@W_P"4'QE_PTY\4/\
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MZ4?\-._%#_HS+]I#_O\ _";^?_"P_P!?RK[.^S#T'_?1_P#B:/LP]!_WT?\
MXFC^T,E6W"^#_P##QG__ ,M#_5KC'_HX^9_^(MP;T_[@'QE_PT[\4/\ HS+]
MI#Z^?\)L\^O_ !</M^F:3_AIWXH?]&9?M(_]_P#X3=O^ZA__ *^U?9WV8>@_
M[Z/_ ,31]F'H/^^C_P#$T?7\D_Z)?!_^'C/_ /Y:'^K/&'_1QLS_ /$6X-_^
M4'QC_P -.?%#_HS+]I#_ +__  F[_P#=0_S].]+_ ,-.?%#_ *,R_:0_[_\
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M/^&E_P!H3_HQSXT?^%S\&_\ YL*/^&E_VA/^C'/C1_X7/P;_ /FPK[5^RH,
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M"ZE2>TN',=K<Q7#9'HGY(>+/V(_^"A3>/_V6;[PQ?^3IOPC^,"^,=6\1:?\
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M>EZ;X<\,Z-IUDLO@C]O3]JCQ;>?'+3_''AGX)?LSZ[X4\&>./BY\*O#GQ_\
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M9H5IXDU_PQX*@T?3M6U)Y([U)=/AL;&R]^^,?[.OPD^/MIH>E_%GPR_BW0-
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M?C5^SIIWCGX#Z_'H<WAV3X1:SJ'POT?XC^"O$GBE)KC5_!7B&:#;-<VT%].
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MC.< _P"?;-1ATY7@;G)'. "<<\X!.1QSU([5\<?\+S_:2X'_  Q;XW&0>?\
MA:WPI'T/.L#Z\8_E7*>./VK/C/\ #/PIK?CSQS^R#XWT/PCX9MDU'7]77XG?
M#*_:PL#=06SW LK+5)[NY,;SQGR;>)Y&'"@D44^$\ZQ%6G1HO)ZU:M4A2HT:
M?$G#M2K4J3DH0ITJ<<VYIU*DI*,(1BY3E)1C=M)U7\2N&,-1K8G$QXCP^&P]
M.I7Q&(K\%\8TJ%##THN=:M7JU.'U"E1ITXSJ5:DVHTX0E.4E&+:^^08R  ZG
MW^4#(XYP2<XY/.,<G!H/EEMWFH 5Q]Y2><#GMQCMR.I/K2T^[%Y9VMW'')&E
MU;6]R%9?F5;B!)=K'@%EWA&(XW+P,$@6PSG (8<YSM&2<G@G!X]!CYL 9.37
MSTERR<))\T6X235^64&XR3MI=3C)73:T>Y]]3E3JTX5(2BX3A"I3DG;FA.$9
MPDKV?O0J0:T5N9;:V4K&5(,B$GCJ,$D]< X/7TP#[#%/'E=?,7KG[X!_4\<@
M<#CO4@:/ .5P>G3/Z4[Y,9^7'KQCUHY4O3HM;6[6T_K7<NRZV?K;IM]Q PC+
M ^8@ [;E_+ X(]/R&.M(JQAF;S8_F(/W@?F  S@GI[9YPIS4X*$X&TGKVZ>M
M+\G^STSVZ=,_G0TO+O?^OU%RJ_GNONM_P"!W!X1U.!D;<$Y+  8!]\DCTSQ5
MFDP!S@#WP*6FM"B)^67.,9'0\YW#]./SR.U?,W[.=G9ZI\!=$TC4 KVFIM\0
M-/O(R4_>6FH>,O%5M.I5QL/F03/@,&!R"RE2<_2\V2"%Z@QOQD'ANN1SV'KP
M",5\YW'[+OP,N;R]O)?AGX=\^^O;V_N'_LNS!EN]0GDN[RX?_1\M)/=2R32,
M3N>21V8Y)-=%"IAU"M2Q$L1!3G2G&6'HTJS7)[124E5K45%/VD;-.3NG[MM3
MQ\QHXYXK!XO 0P=25"EBZ52GBZ^(P\9+$+#.$Z=3#T,0VXN@U*,HI-33C+W9
M(\ET;]@GX%>'H]$BT#4?&NE1Z7IL^F7AC\1)<2ZW;RZMX3U:WDOENK6>SM)]
M.D\'Z?;Z9<:39Z?<6L%UJ'[UY+G>F7;_ + _PZTZU_LW1OC+\?M&TMI[FYET
M^Q\?P) \NI7/AZ361N;1#+'%J^G>%="T"\BC8!=#AU*SMC"^M:G/<^TC]EKX
M%@8'PU\/=?\ H&6?<<#/V<8/0=.#D9)%+_PRW\#/^B:>'_7_ )!EGUZ?\^_3
M_..]6HY;K_M.8)+;_8,-Y_\ 489_6,__ .@/);Z[9CF>G_F-U_KS.*\._L>^
M#-!U+2=0F^+7QT\0P:9J5A>7&A^(/B-<7N@:Y8Z;I46FVNB:SI(LH;:XT^26
M"+5KZ6W6VO[[5E^TSWIC)@/NOQ8\#R?$[P7J/A"U^(/Q!^&DVHW.GSKXP^%N
MOV7AKQE8"RO(KQK>QU:]TK6[>VM[_P LVFHJVG3-/:221*\);S5\_P#^&6?@
M6>#\-?#_ #@<Z99]/?\ <>Y_GUI#^RQ\"CU^&?AW/?\ XEED?Q'^C]?IU[FE
M*&623C+$9A)-6:^I8>.CT:O'&PDK]XRB[;26Y4,7Q'3G"K2PF21G3DIPD\PQ
MTN647=-PK936IRL^DZ52/\T)+0\1'[%.KC.?VVOVY3R<'_A=?A?!YR,@_#?/
MUQ]._*?\,4:ODX_;:_;E'N?C9X8SR,#C_A6Y[XS@<D<<9KW#_AEGX%?]$U\/
M=/\ H%V7;I_RPZ@=P?\ ZP/V6?@5Q_Q;3P\.G_,,L^W/7[,<?7N>#QQ63PF3
MV^/,>C_W=]-+?\C?R^??77T?]8^-D[_\(=NOO85].B_U/>SZV_4YWXN>%SX%
M_9!^)O@Z?Q?XM\=SZ#\'_&%G)XO\?ZO:Z[XSU]AI&H3&_P!?U>UL-*MK^]Q(
M8?.ATZT4P0Q)Y19"S?5-KAH@01UXP0><MGTXXQD]/3/(^<Y/V5/@-*P2?X8^
M&9X?ES%+I-E)%+LD1P)$-OATW %E?Y' VG()%?2D,8$:@C' !R.2 3USDY/<
MYR>ISU)66&4*-/#3Q$U"=63>(HPI-*<:4(J')7KN22IMN4Y*6L5[VK.3!K,:
MV)Q6*S&&"A.M&A"*P=:M6C)PJ8BK4G5]KA,'&FY2K6C"C3Y%9V4(J,%,O0<8
MQC\>!S3J**S6W;R/4"C\<?YZT44 ,V#)/9A@CGKDY.<^YZ>I]:#&, 9( QCU
M&.GX#MC!'8\FGT4 <SIW@SPEHZ/%I/ACP]I<4NM3^(Y(M-T32[")_$-T'%UK
MTB6MI$K:U<!W$^JD-J$OF2!KC#MFUJ/AS0M9@U&UUC1=)U6WU>R@TW58=3TV
MROX=4TZVDN9[;3]1BNX)H[VQMY[R[F@M+I9;>*6ZN)8XDDGE9]RB@#FM<\&^
M$_$\5A;^)O"_AWQ#;Z3=)>Z3;ZYHFF:Q#I=Y'&8H[O3HM1M+A+*ZCB9HTN+8
M12I&QC5@G%,C\%^$H=:_X22'PMX;B\1"QATP:^FAZ6FM#3+>*2"#31JJ6@O_
M +!!;RR00V?VC[/%#))$D:QNRGJ** .;E\'>%)[W0-2G\->'I=0\*1W,?A>^
MDT33'O?#<=Y;K:7<?A^[>U:XT:.ZMD6WN$TV2U6>!5BE#(-M1W'@CP?>3Z!=
M7?A7PW=77A2>>Z\+7-QH.DS3^&;JY""YN?#TTMH\FBSW BC\^736MI)2B%V)
M45U%% &%HWA?PWX<&HCP]H&BZ"-7U.YUK5AHNE6&E#5-8O2#>:MJ/V"WM_MN
MIW;*K7-_=>;=3D#S96KRC7_V;OA!XC\6_"WQ??\ A6&WN/@[XL\0^/\ P1X?
MT>>;0_!5O\0?$FBW7AZY\?:SX-TEK/P]XB\8Z9I.HZM!X>U[7+"_O= GU?4=
M0TQ[?49ENX_=** .3;P%X';5[?Q"W@[PJ^OV>I7FLVNN/X=T=M8M]8U"SM=.
MO]6@U,V1OH=2OK"QL;&\OXITNKJSL[6VFE>&WB1/FWX1?L,?LV_!;7?B'XB\
M+^"KO6]4^)=O<Z7XDF^(GB#6?B0B^&[K7[CQ5)X3T]/&=WK(M_#?_"07 U/[
M!<&Z=I;;3H9;F2VTK3(+3Z^HR#_GW(_H: ,2/PYH$'E"'1=)A6W.GO (M,L4
M\E](B\C27A"6X\M]+M\P:<R!38PGRK3RD)6LB+X=^ H=.ETB'P3X1ATFXUEO
M$=QI<?AG1(].G\1/(LS:]-8I8+;2ZR9E68ZI)$;XR@.9]PS7944 <?=?#[P)
M?R>();[P7X2O)?%EE9:;XIENO#>BW$GB73].A6WT^Q\0/+8NVM65C B0V5IJ
M1N8+6)$C@CC55 B\/_#GP-X3UK6O$7AGPMHV@ZWXATGPOH.LZAI-E#8R7NB>
M"K:^L_">DF*W6.WM]/\ #]KJ=_!I=I:PP06L=U*L: -QVM% 'GMS\)?A;>Z:
M=&O/AMX N]';4+_5SI-UX,\-W&F'5=4,9U+4S82Z:]J=1U Q1&_O?*^TWGE1
M_:))"B%=X>#O"@TYM(_X1KP__9+:*/#C:7_8NF?V<WAX(R#038BU^RG1%5W
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M^S\RRO$QKX^K2GF-2ABL/4QM2=.OA:F$Q[Q%!*5*T'.":A)/W'RNTHKE?V^
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M'JWY^G3MVI<#&.H]_P Z6BG9=E]R"R[?G_F)M'IV /N!TS]/SI:**!A1110
M4444 (2 "3VKX6_:L_;S\"?LK>)]*\':A\*OCG\8O$A^'OB/XS^-M-^"?@W3
M?%$GPQ^"'@[4K;2_%'Q3\9/K/B#P[$^E6%Y</#I_A[PX=>\9:\UAJ0TC0+M;
M.0G[I/KP,=SV'?TK\@?^"C.D_P#!-G7KF^\;_M<_M&GX2^(_A'X*MO"WQ-T7
MX9_'_5?AK\0O&/P(^+/BKPYI%U\(/B_X*\":RGC'Q1\&?B-XFU/P['>:?=:9
M9"/[8]]I_B#1[&[U2ZE /+;_ /X+]_L;67B7XZ^'[7PW\6]<M?@=X+^(/CZ?
MQ!H$?PRU33O&GASX<:CX1T_5=0T[38/B3_PE'@;3M<7QQHFH>#=;^+>@_#_0
M?$]DFI?V=JC7%BT+_07AK_@K5^SGXE_8;^*?[>\7A_XD67PE^#OBW6? _C31
MY;;P3JFM+X@T7Q!H/ARYN] \3>'O&FL?#'Q+X16Z\3:5=R>-]"\=:AX9M+%-
M5-[?V]YHNI6=MX5\4?V2?^"1&F>"O'?B/Q'\5_AAX(\,6>F_&+4?B1JOA+XX
M^ = N->\#?$3XD:)?>)O 'BMK&X:7Q!X(\-_%GX>Z'I'PX\*WZW$O@[QKH3^
M$_#DL%[?:OI5[I^%O!/_  3(_:-_9K\0_#K2_B?-\/?@O\</CWJGQ=^&GA;Q
M+\1=#^%>H>$OBW::5X8^*>KZG^S[X0\5.A\/Z1:W?B.'X@ZEX&N=!U70M+U[
MQ5K]_>^&;*#4!:T ?4/Q%_X*1_!?X7?L[_LO_M+>+/"OQ5L/ W[57Q!^#?PZ
M\)Z1<^&M.L_%O@:_^,QDDT_7?B;IM]K5M:^&/#/@^R@NM4\<:FE]>_V)I5K<
M7XAGMXG*_$<G_!PK^QJ?B5;_  UMO 7[0EQ>S?%'5?A='J3^%/!NGW&ISZ;\
M2[#X76GB;P=X*U3QS8_$;XDZ3K>LZG;:WI&D?#OPCXI\83^$7_X2&3PW%9O"
M9?4[/]EG_@F?I_[%_P #_@SX*\82>//V3_A]\:=2TOX<ZG\._C:/B/IJ?$+X
MTQ^/O!/B"PU?XA6NO:J]YI4\GQE\7:G?VAU=1X?EU&VO[%+:VT^PMD\(U_\
M90_X(M?"7X._%O\ :IC^,_AB3X8>%U^!]CJ?QI^'_P =-(\=R_!WQM\.-;\
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M/@7P)XWNM"L?A?I'CWXW>%8O%?A?59;'?XWF\-:!<^&]3O='LK:*OI#]J?\
M8Z_X)M?&7X_ZUKW[3/Q2\*P?%G]H/X.6OPWT/X9^(?CQX5\#GQ3X4M]6T?5]
M(\9>"O 1O=,UCQ?KVDZUX-T:_P##^M:D/%FAZ-J.B//I&EVD]SJINP#WC_AZ
M5_P3[_L[4-5/[4_PU73](^'-[\5M7N'EUM!I'@_2[B:VU==6C?1UETOQ?HIM
MKNXUOX;7R0?$?1=.M+O5-4\*6NFVMQ=1]5J/_!1']BK1_ACX?^,NM_M"^"-!
M^&7BBU^+%SHWBS7TUS0[.5_@7::C??%S3K^SU?2++5=&USP+::1JL^M>'M9L
M+#7$33;T6^GW#6\BK^=O@'_@FI_P2,\?:I%I7PS^)_@WQSXB^,/P8U#PU-;^
M _CC\,=?\0?%K0=#OIM$U?XQZ='X9LI+ZY\7Z>FGWGA36?&_@5-)T)K2"^LM
M4TV6]AFG3LV\$?\ !)+XZ>";W]G34OCG\-M;T7P#^W!\7OBAJ/@;Q7\:O#NC
M>)=4_:3\-^*O%'B+XP^&#I_B.]L]4\4^"XKGQOXETKQ'X=M+*ZT6\\.7=S8/
M=RV$+24 >J?$O_@LA^Q?\-M?\9:#_P )1XL^(+>#[FXT^?4/A;X7OO'&FW6J
MV/PH^)WQ@U"SGO=+4V^AVMKX:^%.OV4.LZ[+8:)?ZS<0PVFH-8V&O7VE?1/A
MO_@H-^R=XA^ *_M+1_%-;/X7+XC@\$WTU]X4\:)XMTWX@265GJ,WP];X>6_A
MR?Q[J/C.TL;Z+49=&T;PWJ,\VBK+XAL_M&@1-J0_-CPO^P'_ ,$<CX3T?X7?
M#W]H;PG8VOB;X=^'WT"#P;^UOX0D\2>(_AMX)\ ?M!^ M2UK3)X-8N[G7_#G
MB'P/\7_C/:^.]>6"^LM3MK*?4#>6;^&YIT]2OM-_X)8>*/#WQ#^ >D?M4^'/
M#=SH&I^ OVTY?BMX0_:$T3P_KGPCUS5]!M_@'X(^*7@'XSI>_P#",Z)>SZ+X
M"NO"K6,ESJT7D:OJ']K61B\1V23 'V#>_P#!2[]A:Q;Q6DG[1G@^Y;P9;>"[
MK6QI>G>+-9\S_A8&K>'-!\,V>@'2/#M\/%^KRZ[XO\*Z'K.B>$CK>L>%-9\1
M:+I?BNQT2^U*TMY6#_@II^P>= M_%'_#2G@0:'=Z5/K5K>F#Q(K76GV_@K3/
MB$SV]F="%]-<R^%]:TJ:TTZ.V;4;[6=0M?"EE:7'BN5=$/Q1I/[-/_!+RX_:
MCOOAMH_Q7\1^*OC5X5T:T_:NN/"UG\<]5\7^%O@[+X&^)OP8^)?Q!^)U^D5_
MJ6B_#OQA\=/'6C_##Q[\6;O7Y+;6_BG;PWGB.T,%C>:U=W'A7P5^!'_!$C]I
MO1?$O@GX=_%*W\2:;)^R[H7PE:/Q-\5[GPT-:^$,/BVW_:5L?B+X0@\12:7:
M^(O%O@/6-'T2]\4?$'3["_E\)>'O#VD>$/&<<6C02Z?<@'Z ?$__ (+!_P#!
M/KX8>$?%'BR\^.T7BM?"_@D>/)M#\ ^#O&OB;7-7TU]!@\3IHFB"'P_#I%UX
MV&@SG5+OP-<:M:>*]+L[/5IM7TFP71M6-EW_ (:_X*4_LA:SXMF\"ZQ\6-*\
M(>+Y/'WC#X>Z7X?\26^H0WEWJO@NST^[O9M7:TL;FW\"RZL^H?V7X>T7Q]<>
M&M>U[Q#9W_AK2-.OM?M9M.C^!=?_ &,?^"-]]\/M0\(>)/VDOAO%X3UWPI9>
M.M0OD_:J^&WAHW>@ZC\*?$?[--A\4(IM OM$TVRM=0T_5M;^R^)]/M;+1KSX
MDVTVH1^9>V]Y8-V6G?L:_P#!*#4/B?KS-^T7X9\5?$+Q%\1]&^)_Q6\%7G[6
M7A>_E^*WQ#\9ZKX7_P"%2:U\7/ ]AKD*>*K_ ,/_ !%UKPYXR^"<6H:;"+?X
MC>+M/O-,CU,ZUI6FL ?6UC_P52_8"UKPGH7C?2/VD_"USX:\1^+].\"Z5JS:
M!XYLK<>)M:TWPUJ^@6FM'4?"UF?"VF>(]/\ &?A6X\.>)_%2Z-X5UP:_IHTO
M6KMI\+TUG_P4-_9?L/@#\%OVE/B)XWO?A-\-_CT;"#P-+X\T'65O[:\O[U].
M2'Q2OAJR\0V/A>U@NQ##?Z[K=]9>&].DN[)+W5X)+N 2?"GBO_@FC_P2UUS1
M_AY%KOQFOK/0?$^MZ!\-O X'[4&DVVB_$GQ;\)/#OPY^%&C^$],M[F^DTCQ9
MXX\&7?P1\*VLD6BP2>+-*\5Z9KVE3S0VFL:UH-SU?C+]E7_@EQ^TUX"_9M_9
M+C_:-\,^*M-^"%WXZTOX1?#OX>?M5^&9_%?BF5[#5M'\:Z1KOAW2-<OW^(-U
MX=^R:A<DSZ)/K'@[4]&O+FPO-*EM]6$H!]53?\%1OV!+>#Q%<S?M*^#$M_#-
M]IEE?S?V7XQ:/4(M7U;Q9HMAK?A1U\-,OCCPE+>^ O&\LOC7P6=?\(6FE^$/
M$NNWFN6^B:+J.H6_#>,_^"O/[ _A.^TW3[;XU-XQN[KXM^'O@Y?#P/X.\9:]
M:Z#KVO\ B3Q;X1F\2ZGJ*Z%!IUW\/O#7B'P+XJTGQ=XTT"ZUK1= O-+D@O)U
MDDA#?CW\$/V#/^"7WBNW^//B7XO?MNZ3XF\*?"+Q];_"/PCX?\<^,]%^"&K?
MLGZ;\#_C#\?_  A+X8L[/XI>(=>DLO!OB3Q3\1OB-X(T"XFT73O 'B/0H!J?
M@RW?5+MM5M_OC4?V,?\ @E%X2-OXDG_:&\,>![WP-XW;X@:5XC3]JCPEH,W@
M7Q38_'Z?]H2[N+.>XU5=/TVV7QS\8TT.\TR_MYK!/!?Q!T;PV;>+^U-"NR ?
M==Q^WG^SQ?? ;3/VE_ OB36OB+\(=<^(/PY^'&C^)/#?AC7],@U?5OB;XV\+
M^!O#VM:,/&.G>&AK/A,ZAXNTG4I/$^E&]T2[T0S:AI-YJ"H%;Q?X<?\ !7#]
MB[QS%XUDU/XAS>!6\#:7X/UZ]AU^REUA]9T#QQX)^&WC'0-8\.)X-7Q)/JUG
MJES\5?"?@O0+>.!-5\7>.KBY\.>$-/UR\M74<]I7[*G_  3Z_9_^$]C^RYK?
MQATCPMH/QS^-_A[]H#PUHOQ!^/7AK1/%_P 0?B-:?$'P?XK\-R?#C3KV[T:Q
ME\.7'B[1_"VG6GA_P%X=M]*U2:\6)H[G6M=N+R]^,9OV!O\ @BBGC;PM\$M+
M^*>DZM\5/CG=1_ G08O"GQVTOQ-XKUG6?V8O _@"]T7X>:[=Z4=3TJWUOX0R
M?#_PGX]\/>&O&%H]S9>/[V_NXM-NAXAOM*N0#]+?C%_P43^$'P^M?@XOPN\%
M?%C]K'7?CIX'\0?%GP+X4_9A\-Z1X\UV[^#?@\Z)'XM^)\RZMXA\,Z>VBZ1>
M>)-!T2WT2TO[GQAK?B75+3P[HWAZ\U/[1#;V]<_X*"_!GP]^SC^T5^TS?:)\
M21X-_9L\?^+_ (7>*O#(\+[?'_BCQ[X6U'P]H-GX5\%^&)+Y)KW7?%OBCQ5H
M'A;PUIFJ3:7<OK]^NGZG'IK1SR1?$$_PT_X)5_M%?"@?#O2_V@KWX/6W[!.I
M?%#]FKQOXH\'_'M?V:/BOX0\,:=XS_X5M\8? /Q0U;2=0\):B_PI^+OC;0(H
M-2U2YTS2-%\9:W!::WX*U2SU"2UO#%XM_8?_ ."65GK/Q*C^)'[5T\WPEO?B
M7\./C=\1_P!F7Q]^V/X;3]F[1_&>KW^@^(OAEK6N_#;4M5MWT^S\8:AH&@:K
MH4&L:UY7C5K6WE235HKAQ, >]:I_P5T_9^35?AM;^$OA_P#'#XA^'O&?A7X,
M^*?&_CGPAX>\&MX5^"+?'W4+[3?AOX2^)-SKWCC1+V\^(=W-I6LWFM^!/A_9
M^-/$>@:'I-QK=[8BQFLGNM#]IK_@K3^SC^RO\4/C!\)?&^@?%7Q-XD^#W[-$
M/[3FH7?@/P[I/B#1/%FA7/BO5/"5O\.?!VH?V]:MJ'Q4GN-'U/5H?#%Y#8PR
MZ+87MY'?L;2YBB\%\2_\$W/^"3OABT^#PU3XEZ5\.?A]XLN;CQCX%^']O^TY
M9>$?A1\>O"/@KQ#K'Q@\*:0/#EUKL.F?$3P)\$I?&^K:QX$U+PM.NK^#/!6O
MKHMWXEN?"%Q;:>.7^)'[*/\ P1*L+[7?'8\9?!'P[>:S\-M2^+6D_#[X,?&K
MPI!?>(O#/AG0/VA=5USXA_##X8>%-7N]9\6:KXDM?B-\7[_4[_PYI^K1^+-9
MT&UD$%S?>&&$8!]XZI_P4B_9D\*Q?#^^\?>*M3\#Z=\1_@5\*/CWX;;4M&U#
M7=;NO#_QFU"\T_P/X<7P=X,M?$OBV\\47\^GWT;V^E:1?V7FV5S##=R2(17I
M/B#]NO\ 9'\,6'P2U+6OCSX(LM/_ &C=%TOQ-\&=02;4;VR\7^%=;GT"RTGQ
M=+<V&GW4/ACPC>:GXK\,:&GBKQ@_A_P^OB/Q!HWAR34DUO4[.PF^"?ASX&_X
M)D_&#6OV:OB?I7Q7?P[XE^'G@?X2?![X :7X\^*VD> ?$WC+PM^S9IA^('A%
M].\&:]>6FM^*;S1=.\>M?>+;N.PMM1C#O!K%CIDEBP'"W?@#_@C;XJN_V>O@
MC%^TGX$U*S_9Y_9KBM='?0?VDM)7P3X\_9?^&?Q"\%VY\#_';QAI.M)X.\<^
M#M-^*6D^$M;N/#6JWUGJS:SIEQ)(!HEWKME?@'TUH_\ P5[_ &--1U+X0:+?
M^,=;\,:O\5]'\2>(KVS\2:)+IMG\)]!\,^#?%_CN6_\ BSXC+R>%?#5[J_A[
MP;=WFA^&H-<U#Q=J,&K:!=QZ ;'5K:[;Z=^"G[<'[+'[1GBZ+P+\$?BWIOQ&
M\5-X,;Q_>Z5H6@>,%.A>&D\3Z[X+DD\57E_X>LM/\(ZW#XK\,^(- G\(^)KK
M2?%\&HZ/J$,^AQBTF9/RC\5?L/\ _!(S5OCC\(OV8-7^(WBCQYXV^-G@CQL?
M#?P$T'XW7_C/P=X@2R^"&N0W?QK\>^$= FO;/P]XHOO@YJ=II_@KXBZN-)TS
MQ#;>'O"JZ0FHZC9&:\^H?^">OA+_ ()^_"/^QI_V:?BW97/COXT?#K0+%/ G
MCSXH^")?BKXJ\.>"?%'Q1\3V'B67X::--ILPU2[O_$WC?4=0UO2-#CAU71[.
M*ZD!33KB:@#]::*13N4'&,C/4'K[CC\J6@ HHHH **** "BBB@ HHHH ****
M "BBB@!GEIDDJ"2<DGGG^6.G&/SS6/K"A=+U8#&/[,U#CJ?^/24 DY.3C(SU
M[&OA;]IW]M\_LT_M&_LU?!S6?AMJFK>!OCA)XK?Q=\5S>W=CHGPWL- LY95U
M.55TJZTN[LM*F2&\\7RZGJVC?V/HFH6-[9_VA/+]FKLOV3OVE;_]J3X3_$WQ
MU=:-X9TNV\+?%3XO?"[2K[PCXBO/$6A^)],\ ZE-I$?B.V.K:9HFO:6UQ<+=
M6+VFM:1I\UZ;#^W=,MVT+5M+GE3WC_BC^:)G\$_\$_\ TF1]/>%O^1-\+#_J
M :3^0L8LY]<]/Q],U^??[.^/^'C?_!0P$9!\'?L@\'H?^*"\9^O'7U[^]?H)
MX6./!OA;@_\ ( TGGCC_ $"+^N,#'/;)%?GY^SN?^-C7_!0T=3_PAW[(&!W_
M .1"\:8X.,\]NN<8YXKAQVE?*K?]#2KKV_V',M;]#ZCA>SROCM?]451WMI_Q
ME/!_K^I[K\4?V7==\:?%B?XR?#3X]>/?@+XNUCP)HGP]\73>!/"GPKUZ+Q=I
M'AC6M;UKPY<:Q)X]\%^);L7VCS>(M6MK:2UFBC^R7"Q%-L:UYC^R;^V3\-O%
M?@OP1\+OC)\>_A;_ ,-3:5XE\4_"CQGX&U3QW\/]+^(7B7Q[X(\5Z]X8>ZM/
M!6DW6E3?:O%=EHL'B'3],TW0K026=ZC6MD(P"?T#+-@J5884DD$8&[Y220>^
M2>>I!]*^=_VD?@UJOQ:^%FNZ)X&O-/\ "GQ.TS4=%\:_#3Q;*HLET3XB^#M4
MMM;\,:IJMW;Z;J-Q-IGVVU6WU2)K&\^TV%S/$T3%P1[%+$4:\%A<6Y)-X>&&
MQ<84%/"PI*K#DJRG3]I5P[56+DN9U**@W3V43Y&4)0?M*7:I*=-N7+4<Y1DY
M))M*:Y&XNRB^;WMVSZ/23+$'H?N]P2#SCDG(.>W&!CC%2Y'ZX_$U\!7?[77B
M'X->/8_!G[67A/P_\.;+6?!:^+/"/C#X86_Q<^*WA_5+RSUH:/K/AW59M)^%
ML::)JULDMIJMM%-*7NK*=G1#Y4CCI3_P4._9(3(?XD^(!C'!^#GQP!&<8)!^
M&N26SGG/MUIO+<QBHNG@Z^)ISBI4J^%I5,3AZD7S:PK4J;A-IQDI1CK!JTDF
M..(HM>]-4VW)<E6U*:L[6<)M2UW3M[RU5U8^V![XS^G/3K2U\0R_\%$_V0X(
MY)YOB9K44,$;SRR2?!_XW(D<4*L\LLCGX; (D489W<G:JAF8A0<?8.A>(=)\
M3Z'H_B/0KM-1T+Q!I6G:[HNI0&00:CI&JVL-_IE_ )4CF$-[:7$-Q%YL<;B-
MP)$1LJN-:ABL,HRQ.%Q&&C-N,)5Z%6DI2C'F:BYPBFU%IM)MJ+4K6U+C5IS;
M4*E.;23:C.,FDVTFTI72;32ON]+W1NT5&K#O@<+U([YQC& ?KQV&.*?D>H_,
M5DF7==U]XIYXZTF/3 ].,X]?3&?;T]Z-R_WA^8HW+ZC\Q0VN_P"/^077=?>@
M'3ICVI:0LHZLH^I%(74=6'IUH37<=UW7W_\ !'4TJ"".F00< =_P]>:-Z^OO
M_/\ PHW#GGI['C\/QHTTU7W_ .3^\"F;($D^80,DXVC)X[GZY/XGUI/L _YZ
MMCGC:/\ &K]%3[.':ZW[_/\ $CV<>VO?^F4/L _YZM_WR/\ &D^P#_GJW_?*
M_P"-:%%/DCM;3U8>SCV_K[S/^PXSB0^V5'8=LD]^W'3T-2P0>7G(SE2">/O;
MCD]\$C'MQ5NBA0BG=*S?77H-02VTTM\OO$ QQDGZTM%%44%%%% !1110 444
M4 %%%% $<KK&A9SA1][Z'@Y/8 <DG  !)(&2/Q\_:)_X)S_LL?M3_&/XN_&;
M6_V@]?\ #.L_%+X3Z1X.\4Z%\./%7PKL-":3X6:KX+\7>&OB)XH6;0]1O_&.
MI_#?4?"?AO4K+_A+[S4='T:QN9[&[C&BW\5I'^NNLZ>-6TG4]+\UK?\ M+3[
MW3_M"+O:#[;:RVIG";DWF(2[PN]-Q4#<N=P_G9NO^#=[X:)I?AF#0/V@M2\+
M:WX8T[X*0QZSHWP@\-QP>(;SX._!JZ^&E]8>-]('B6.#QAX"^+_B(:1XR^,W
M@+4KB/3_ ![8:;-X6U.^W75MKVF@'L?B/_@DE^RE>>)?'?CR;]J;Q_HNL^+-
M0U_XQ^&KZ?7_ (&7ND^ +7QY\4O'7Q;\7>)-#TO7_ ^H:5KOA'Q-XK^+WC14
MN_%]OK^G:99Z[I<>A7UE<Z3I-RG.3?\ !"C]A;1=6^%<FO?$SQQ=W?A#_A);
MNQTGQOK_ ,.]3L?'GA>:7X:>);VPO_#VK^'5TJ\LM UGX7Z+XCDUO3--CNOL
M>I:MINL7%UHATZWT]-;_ ."$OA35_"/Q!TM?VB-;T_Q7XXC^!5Y9:WIGPWM=
M-\.>%;GX0_%GXM_%S7/A]HOAC3_&MKJ5A^SMXVU3XKMH>G_!+2O%6EVG@K1_
M!7@PVWB;7+K25E;WKXN?\$D/"7Q9^'/PR\ 7/QJ\6^'+GX4_L<>+OV3?"7C#
M2])OM5\4:1<^*?%OPE\4M\1]-U[Q1XRUWQ3:R"V^%G_"(ZQX<G\37MYKW@[Q
M1K.B77BV%")Y #=^''_!/?\ 9U\%_LYZ!^S%!\>_%OBGP@WQ=T?]J;PK<W7B
MGX>0W=CIOAC5-(UC2]'\"Z+HVCVFA:1\'M/;2H'2/2-.DL[-K[4);;5;.WFM
M;:S\JTS_ ()P?L)_!K]CKXY?L]77Q[N] ^#WQ4^"'P4F\4>.+_QM\+K#4_#W
M@/\ 98\ >'['PM\4])N[?1(=$N;6#2O UAXI\5ZY?Z5J>BWS6][(!;:?(8H^
M!M/^"&>F6W@7QWX$MOVCY]*A^*'P?U_X;>*?%^F?"47WQ)\':GJ-QXYN+&;X
M$?$/QG\2O%WBOX/_  UN7\;RGQK\)],U+5M*\6"SO+73]9\*Z5KEQIEGR6I_
M\&_?@+Q)H)TOQ)\?[S^TKZ>=-7U?1?AE(TT>BZW\-OVD/ 'C#PCX9D\;?$?Q
MSJ_ASPCXFN/V@QXFN/#2ZU>^%[74/!&F65GX?@L+](], -KXJ?\ !(+]@3XD
M^"=(\?\ BW]H7Q)IVG^*M.@^*?AGXC'Q5\,-+TGQ+;6WB_XZ?&O5_&1L;CP[
M;Z+XST*\T']HSQ[;7<%W;7]AI?A<:#?VIM;C2A=3^A^+O^"?OP'_ &G_ (K_
M  3^+^E?'SP[<?LK>$?V//@G\+?!&F> ->\$3ZUXWL_A#XYG^,7A'7-0\3:G
MX=UC^S/!%GH=YX/\1-=>"=5\,:U,;9X=5D/AR^\F3T#XP_\ !)VP^,2?LF-=
M_%S0O!FH?LX_ T_L_P#BC6O"'P>M1=?$CX>W'A^VT+5/#6DZ!XA\=:Y\/? _
MA[53;_:S!=^!O&GB+0IF,OA;Q5H=PHN*^9[3_@@LT.F>%?#S_M826/A;P9X>
MTF/1?#WA?X$:;X=LKCQEI/P>^!7P:-[KRQ_$V]AUCX:>(-#_ &?O"EYXO^%8
MM[(>(3XC\=:?-XQ@L]:M/[, +WP^_P""<G_!+SXL^/\ PS\5O"7QKU3QQH_P
MP^!WPZ_9]\16>F>-X_"?A75;3X2:7X\_96\,^(;7Q[X?LO"NM>"_&<VJZ?XR
M\):P?AQXLT%-<\364Y6S OY1J7?_ !%_X([?LI?%'Q+XJNM2_:*^)MOX7\._
M%&_^(]Q\-[/Q'\*+_0?AKXSUWQ+H'BMI9M2U+PC?>,-/U:?4]+NK0ZCXI\07
M.N:CHNMSZ1<W-S%%;M7CE[_P;]V=WX972(_VM_$&GWOVG4;J?3-!^%)\*_#&
M^/B/X@_M*^-O$5A>?#WPQ\4=*NET.RB_:1U*P\ Z98>+["7P3?>#= UF+4-4
MFEEMX/K_ .#'_!)_PE\*/ 7[9/PKN_B8FN?#?]K3PM+X<3PII_@F_L5^'NHW
M5AXF2^\;KXC\9>/_ (C>,O%GBN^USQ!#XCG6[\2:5X=CUK2AJEEH-IJ&KZE<
MR@'Y]_'7_@EC\%9OVB_A)X&\>?M"_"7P3^R)X]\(6WPSL_"MSXKM=*^.OQ#^
M*WPS_9%\4_LR7B:%JEOX7@T'0KJT\!:?:Z]KU];>*[3PW;ZSX<FT9_AP=<\2
MW>I77NFI_P#!$/\ 8MM/!NM> KSX]^,M$N8)/!$7BBY36/A+I4J?$JS\=_$G
MXA>$/%6O:*?#D5M#KOB*V^+/C31;GPW>!-'\7Z9<Z;JT^FW6LZ;'J4OF/AC_
M (((_!R2V\3>"=;_ &N[_P"+NKZKH?B0-;>-_!'@?Q5K_A[7O$7PP^+_ ( ^
M,OBZQTV#Q!'-:2>,?VA?C!<_'O6K=K:)/#WCKPUX>\*17B165C=V?LOP]_X(
M7^%_!WQ@A^)WB/\ :.\7_$>PM_C-IOQB&C^+O"]_?:W>74%IX@DG\/:IJUY\
M0K_PE?VVA>(=:M-<^&6O'X>P>)_A]#H6D:3:ZOJ5O#/-< 'T)^R9_P $UOV7
M?V-/'^M?%KX7_%77[CPAX<\'_$GX3)X-U_5_AK_P@/@.;XB>)?A[K?Q,BGU[
M2/#FE^(QJMWXN\ Z4UKH/BSQ/J%AX.34KGPWH&F:3I@LK&#YD\6_\$IO^"?/
M@KX/ZOI_Q7_:4UNV\ Z/X,GUZ_\ %^M^-OA/X=O-'^%9^!7CO]FG1[Q=9T;P
MY8A/"^G>%OB/+-%KRP20ZOXNL=+O=0N;R2XO+>[S-5_X([^*_@K_ ,$\?VDO
MV8/AQ\:[#XG^+OBUXO\ V;/$:^./BSI>I:=HMEX>^!GQ<^&WBG7-?^(6G>*/
MB!XQ\*>)->N_!/A36-5\97MA9^!M-\?:E;I::Q:6QNEO[7)U?_@A!X?^(VG>
M';H?M6:7KW@M?"GC^;0[./X!>$=7\/\ V[XM:)\0!?IX5GLOB"EB?@A8ZIX[
MTOQ-X&^%VH+XD3P_!X4T'3-%\;P:6D'V< [7P!_P26_8JN?AEXY\,^ _VD/'
MUI!\5]%\-^$_%?B+2-1^&.BS>*]-_9N^,/QA\7^-D_L'5O!ITS5/#FI^)?BI
MXET7XC/:V$VAW-MI>@ZQ:WEM?&?5=2^6K'_@EE\'_A]X3_:&^$/@G]K+X,ZK
M\7?$WPU\<WG[)7AWQIXX\.:5HOPD^$4GA[]FSX+_ /#2/C;5O"7AFT\<^(OB
M-\,/&'P/\/Z[I*Z?KL/PXB\<>']%L;2UT.YOM<O+'V'XH_\ !&+X97GC*&^\
M=?MOV_A37=?^'GQ3\/7?A/4M,B\)Z/9-\0_B+\=_&L>O_"OPK9_&+P\?#6@V
M=Y\==6\.>)?#/B%/B'X9\7Z=X3\-6U];VMQ:$Q]7K'_!"/X9^)KGX@>*?!OQ
MG\(1Z=\3A\0M3\+I<_!:WU/1? >D^//BE\/?C/X.?X::IX$^*G@+5=+M_"7B
M'P?=W%N]GK4WAGQ9:>)IY-1\/26_VV'5P#U;XO\ _!-']ASQ9;_L$?"SXC?%
M6YT/QE\%? OB/0_A08=6T""S^/6@0>)/A)XL^+.H:QI&NVFK^'[W6/%?Q)A\
M$^+;O5](N;775U;Q9<PZ7<WBWBM:[W@;_@EU^R9X0^*'[-_Q5T#X\^*KT?LG
M:C<2>!_"\WBCX67'A@^,O"_B'XN^(/%&KZY-:>'(M9M_$#VOQX\2:3XVAL]7
ML?,M+7PG>:I!%>:<)KV]\>_^">_PM_:=^#G[/GP4\5?M-^'M6\4?!3X._$']
MFOPSX\;PK\-K[Q'K/Q2!^">J:MXZT+PKH6I:'HOACXD> [?X%W\LOA;PQ:P7
M.@V7B+59)VL8=+9KGQGPG_P0NT;3=6\6:[XR_:9UCQ7JOC7X_P#PU^+OB"XT
MCX0^&?!=IJ?@?POX5\3^ _B3\([C2+'Q)J6E6=G\;/".L:!;^,O%6A6NB7=M
MK/@[1-5TW1T2,6,8!V7C+_@CE^R9XU'Q"UR'XZ?$S05U/Q3\94^)&HZ'XC^%
MMQ8,?C%\>=:_:!\?^!?&[:KX1U2T?38-8\83^';+2-::*\TSP[+I.]I+U%NK
MCR_XB_\ !'G_ ()W#PEX>M]:^-GC32FOM(_9-\'_  TU.P\6^$/$ L];^$6B
M:3^SQX;\1^'_  U9^'M2M=8/QL6Y\*:#\6YI;*YT#6/$&BZ!J22Z%)I<D@35
M_P#@D%K/PU_9._;N_9T^$_QU'Q=^*?[3WA3PY:>'+;XB7&J:/J>D>'+/XH^(
M?%5EJOQ M+WQWXG\,>*-4<:_XCTF?QCI_@;P/%XMBT2#1=7BN(1%;Z7Z39?\
M$@/A]X/\+>,)O&?[0EEI>O>.]:^%L;^.]%^&WA;X46G@6^TW]KZY_:/U3PM\
M%[&U\2W$/PQT;QWK^K:3X&\.^'-(U>\NM)URUL/$T-SX@UJXCL% /8OB[_P3
MA_9#^-UC\$=(U_XC7=E9?";X1>$?V7OA[:^'_$7@",7VE_"WXP_!?XKII]AY
MVEW<T'C&/Q%\#?#OA_6;3PVUC<6&D:AK-C!96%X;&XL\'X*?\$P_V9/V=OC)
MX)^+7A+X[>,CX[^"'B33-,T2S\2:Y\*Y;70/A7%\-_'WA?PI\$_$>F1>%]/N
MI;6R\.>-/%'B"V\?:Q)_PMO79(([O5O%VIZ5IB6\53]E_P#X) >#?V=/B[\&
MOBU=_%:+QW/\%[GQE+X?\(K\+-#\*>$I+C6OA9X%^$^@>,H]*AU[6H[#XO\
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MC#\=++2O'P^#GPV\/:WX3M?".J^/?!7@CXD> (M(%A_PB\,OC_PIX5UGX9W
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M?I8-9TQ1C^T=.SCG_3K4_KYPS] .N<9ZEK:KI;$%=3T]<9(Q>VH8<]SYPZ]
M.<>H/-7A\3/#PJ4O91KX>M*#K8>M1E.$G34^2<)-<]*K#G?)6IM2BO=<:D6X
MGB3A&;C+G4:D%)1G&<4TG9M64M8MI<T):-J^CU?QZ/VV?# R!^SS^VD>V[_A
ME+XL9.#P2W]CC).0!GKCZX4_MN>& ,_\,\?MIG"YX_91^+!)!QS_ ,@?D_J.
M>*^PAJNF\'^U=/(ZG_3[<8R,8/[XY'/&<$$>]']K:=_T%-/!ST^WVOY?ZP\C
M\<^U97PVWU&K;O\ 6L0]WKOA[_EY;D\M5_\ ,13[_P *GI?_ +C?\/N?'O\
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M"\JJ/O!""!EMH!SVPQ'4'(QS^HI/.0?\M(O09=02>>V[].#_ $3=MT_DI/\
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M1?;C&[OGO^/6F-,-P*NA.,'#J<8Z<!NA)Z\\YSC%/Y2[_#+UZQ7]6'SKNO\
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MII%O)%:B"2Z@N/T$48&#R<DD^Y.?0#OV'7WS0[O[4_\ P.?_ ,F'LZ?\D/\
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M/SSB"4EFN)2E-*-+"Z*4DM:5]$I)=^E[O6XWRSR=[\\'YG_^*]J7:W_/1_\
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MIJ[?9,(U)\JM4J)V_GF^E]^?SZ_J1Y/3=)G ;EVY QG^(XYZ<>N>:=A\GYI
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MR[Z-===.P/B7+5>_UC_P3OY+W]>GEJM3Z*I =PSTZ\'KP2,_CBOE'Q3\=)O
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MY8\J<8NSYI:WDO+S..^+/_'CI/\ V$9__24UXLO\7^\:]I^+'-EI ]=1G_\
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M)_B?X!^'7@_5K;Q/\(O$>D>&O#D/ASXDR>-?!EQIFF_!?0-)TP>(;OP1\'_
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MI=/UK4+K3]*_M>[T?PI%X7UJUTWQK'J_B'0)[G0H--U6UNW_ $ 'AGP^=O\
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MT*#Q!_P@GAGP7X&UGQZMAJ*MXZ\2^$/"/ASP_KWB![O4;'3(S++++^J \,:
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M$-+^''A'PKX4^$.N0>+OA]\6--_:!\-ZIXO^-6LC0O"/P-O;S0/!?@JY\/\
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M@/%MS^TW^T]X<UWXZ> ?$OPNT6\TCQEX?G;X+>!/B)XM\+>+OBOX<^&-U?\
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M<?#KQ)X\T_X5ZE\0=+N[&?5FB\*>)FU6_P# ]UI]C_8TWBZ1+6\_<_0_A?\
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MN\])M&<^Y)]_K].WOS2T5@EHEOH;B8 Z>N>O?\<_B>N*JR<-SUP !GID 8!
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MG@[QEI/AS4_B'XYN/ 6N6G@+5?B3X;;X9_"G]HC2_P!G#2_V@/%^H6&DO;>
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M:;<:YX8U+QWXPUF[L/"?Q$\;Z#JWCR+X9VMY\(?$%IX,BTB/QT;?4?NK3/\
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M]770?%6C7FB:NN@Z[J_AC6);"]C,=S;V.OZ#=Z?K&E2746ZW>[TZ]M;E899
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M !:T:3X7> =,\<_#[Q)-JW@AM/\ C<NM?$7PE\'_  ]9Z39VNM75_P"!M/\
M%_Q+\9:?H?@O7/&$=M%KVGZ)XOUR>RTNST-!?<+X>_X*]_#7Q#JFA^&T^#?C
MK2O%6L>"WGFT37/$OA:P70_C)IGQPU_X"^)?@[JVM^=+HEO8^%/&'A/Q->:W
M\51?GP/::-I;WEQ/#'(3']5#%Y[["E*&"IO#0A1=E6E5IU*-+!\JA4Y\543I
M\DYUZD(\LHUY.+</9QPU+Q:M+ 2G.$Z[C4;E>T.2<)RJR:E%QI)J:DE&#?,I
M0UY6YNI+]1/@_J7Q UGX5?#75_BSHNG>'?BEJ?@7PGJ'Q'T'1V+Z7HWCB\T.
MQN?%.E:>3=7^+33]:DO+:%1J%\L4:");Z["B>3TJJMI/!/;P36\L<]O/%'+!
M<02+)!<0RJ'CG@EC+)+#,K!XI48H\95T.UA5JOEDTW)I*-VW9)I+F;?*EV3T
M5];+J>RE9)7;LDKO5NR2NWW=KOS;MH%%%%4,**** "BBB@ HHHH KRJY/RKD
M%3R""<D8]L8Z^^3TZ5^)O[7O[+OQ4\4_M1_%'XC7'[(?A#]MCPG\6_@_\$OA
MY\&3XU^(7A_P-H?[,7B[P!XW\1:OXXU36=0U2]M_&?A30/$YUS0/'@\8_!NT
MU;QM>:IX*'AR:QA9]*N3^W1SVQGWKF/%.H:UI6@:WJ?AW0)/%6NV.E7UUHGA
MB+4[+17\0ZK!;NVGZ/\ VSJ6;#25O[E8X'U"[#064<C7$B2!"C;87%5<%5E.
MC&G-UH.C-3E."493IRNJE*I3JP?-2AS2A5A>/-";]G*:>->E"K&*FVE"7.K)
M25U&2LXRC-234FE%Q;YN5KWDC^;OP]_P3;_:V\)_M#77Q_TOPUX4::\_;;_:
MR^)?A[2(+3X5Z;XM\ W_ ,0O#WB33O@'^T1J7Q4M]/;X@?$?X-V6I:E)'\2?
M@!KNO1:M)%?Z/KECI5S%HFH^&KSZ]^'GP'_:=US_ ()\?M@_!OQUX-^/4_QR
M^)O[/?B;P/::?^T!\?\ P?\ %O3_ (A_&CQ!\$M1\-^-M4^'%[8ZSJL7P]^&
M_B[XA7<S6NEZ_J^FZ7*EY_:&F>&?">E1O926/A;_ ,%7;W_A4/[,OBGX\_!V
MYT7Q_P#M'?%7X]?#5C\/]6LK3X-^ M4^#GQLU'X36N@ZW\5/B#J&C:"?%?B%
M$L;G0=,O;W2IO&TFG>)KOP]:0+:VFES<?HO_  4\^.WQ$^ NF?%+PI\-?@I\
M+=9B\._M"^._B#JOQ@\7^(]1^'_P[^&GPK_:,U+X%^$?&1/@Y?\ A)O%>KZ^
MN@>)Y+3X>Z;:V7B#QOXJT231/"\]E#=V4L_T>-EGV,4*.)HX*$J6(I4Z5>%2
ME#WZ6(DH1ISA*I*I3C7I6E*$/>G[*HXU)RI.?FT%@:%W3JUI*I3J3E3:J2NI
MQYI2FI*+C-PF]&[J-XI))V^#OC%_P2K_ &M]?\$>-O"FC?#:QUF#0/@'K/[*
M'P41?&G@:YN=+^!'ACXW_L[?$[X=:;?1:[<0:9]IN+6W^)=O<Z;J%M=6'E?#
MRQM=4$UOK&EPW7H%M_P3Q^.7PE^,OAK7_&_[)NE_M=>!/!O[5GQK^(WBVW\(
MVO[.W@OP'\8/AY\1/V4V^%?PHUOP[\!]8O?!'@#X=:_X)UM;7PS\3M-6T>;7
M/$E@_P 2-*U#4+._@L-'^\/#G_!6$>$]'^#.D?M*?L[_ !%^&OQ$\4^$?V6M
M4^-#:*NE7/A7X0>(_P!K/Q/XG\$?#/3+[2==U:S\=RS3^(O#1E\1Z$=&N-7\
M%:=J<<>LR7%YIMXI[_\ 97_X*#^(_P!I[]H'Q_X2M?A9+\/?@I9?L??!;]JC
MX4Z]XTOM/L_''CC1/BS\0?C/X:LO$&JOINNZMX<T#P7JOASX;Z+J^CVFH0V?
MB#2)[_59->*P+;P0;U<TXCHT*D:V&PL:%*G)3JQ<8W524Z?M*5>CB%4<INO.
MK%TN5N-7ZU:,>23SAA,MG*'LZE1S;DU&5Y/X8N4:D*E-QLE3C'WT^7D]DKW:
M/F?7/^">/Q[\9_L"_L'?LP^*;K^R/'?P@^,MA\0O$7B'0?%%K?S_ +/T.A:5
M\6O$GPBN-$U>XO+5_&#?!#Q)K/PV\++!I1FCUVRT*YBMH7T:0RCPCP-^S?\
M\%7[+Q%\$?$,Z>)?@KIVO?'/XL_%3XM>#OA+XL\$>*+30/B1XZ_:CT_Q=XE\
M5>,+:_\ B=X$\.^,?A5X]^#S>([+3[#4K3XBZIX<TK5KNRMO >D^.SIVLP?2
MOP1_X*H_$9]&^+-_^U%\//A]X$\7:!X4\!^// 7P7T&[\2^#/B-J6C^/O'>I
M^!])@T?7OB(\_P -OCIX-NYH]#F\/_&+X,>*M1TKQ'JE_>Z##X-L9X]+FU3;
M^&/_  6(\!^.O&UAXGUCP;JOAK]F'QA\&/V<?B-X?\?ZCILEGXN^'FI_&W_A
MHJ+4T^,=G)J\^G6'ANQUGX&6_A+1+OP_;W,X\0:];?;99K._M)+?.5?/H4\3
M3G@<!7@JE>JJGLZ=6"JXEO$U8X.4K0FY2Q$9PC&E54G3;IRE-3YDH8"4J<EB
ML12FH0C;VCC+DIIT8^VC:3CR^SES7E%^]><4DN7\Z?AUXS_;I^)7Q+_:!^$7
M@3Q/\8OB]\0[#X56=K\95C^._B&T\!:?XUU;]M:_L_$?C/X0QZ-XI^'5UX!U
M/2O@3I-GI_A_X1W'B_X1:OJWABSU2T9K#RI;WQ%Z=X"_8J_X*&'QAX1\=?$O
M2?BGK7Q%\3?"[_@G?X3^(WCB;XY^'KSRE^!WQ[^(%S^T'8ZY9IXIEL?^$EE^
M'6K^%_$^B:]H&G7QU22?7Y[#5$\2ZAJ,5Y]PW7_!:']G?PQ-*WQ!^'/Q,\"1
M)^SEXE_:0UIE7PAXEU/0(/!_@OP9X[U7X<>,M-\.:W>7'ASXDMX8\=^%I++1
M=8DCN/M%Z]MJ":=#%'<S'B/_ (+,?"3P5XEU?X>>,O@!^T%I/Q8\*^//$_@[
MQE\,M&T7PYXT\2:+8^"?!OP>\8^*_$VF?\(AK>LV_BFTL+7XX>"++3])T0S:
MQJETNL-':PQ:<3-:K9TIU/J^1X:G[6E#VGM*=%SG'V<H2E\5&$*//0DTHQC&
M#A"%2<FX.2:P/*E6S"<N67*N6<XQBU-32LE*\Y1FO><I.2;E"R;M\>_$?]F7
M_@KO=^"9(+'XJ_%V>U\#^,)/@7:Z9X(^*6FS?$7XE?![X9>$?'\GPK_:=TZX
MO/BC\.-.B\?>//B)XI\+W_CW3?$_CS2M3N(/!^EOXKT#Q)X9BNO#%Q]*?M^^
M!OVE=:/['6E^'-1\0:_\5(OV=/VR/!?A?Q1I+:?X0OH/VW/$'[*$VG?![Q=/
MJ.FW\GAOP7KM]>67Q-BT35QJK^'=$U;4+B&TOMD]G*_TC^U__P %#](_9,^(
MWA[0M2\%:EXN\%Z;\!?$'Q[^(T^AP[_&CZ+=_%?X8?!+X<Z!X*TW4K_1]*EU
M77/''Q(6\UUM<NH4L-&TB2.%%N[I'C\EUW_@L/\ "_0-;T#PMJGP:\;Z7XHN
M_BEXZ^#OC#0->\:?#71[WP;X\^'/CRT\#:_: S:]-;^)M,\V_M=6L-6\.RW$
M%U:O+:;$O(GB/#2J9M46$Q<<MP;I4:=:=-4Z="G%QQ$)TG*NYSA*2O1JM*<I
M7YW2]QSIQ.B4<+S5:3Q5=5*DH1:E4J2LZ4HS:A:+4>93BG9QLESO2,SRS2_V
M%?VX/'!\9>%-9_:/^)?P^\(^$O'OAOQ!\,]5\>?&#XW^,O$GB;3/%/P0^$1^
M)5O)K_P;^._PGUP:9IGQITGX@R:=HWC@^(+'3DU*1O!]II&BW)2]^&_VF_V'
M/VFO!OC[]O#XSP>']?T/P=XG\&?%G3O =_/JW@?Q;K_QJ^-'QF\7_L[V_P #
M+WPSK_AQD^*MSI/@CQW\/%\2:/X6^+,,T?P:N"FC^"=:U_3=>UW5(/T(_:7_
M ."K?C;]ESQ3^W'H7Q+^%WPX\,S_  2\*? ^V_94\/ZO\1K:/5_CQ\1OCC-\
M8+/PW#XUUIY;+P]X-T"X?X8_V_+I5O*^L:'X4M=7FU+49-4N]/TZ#Z;_ &/_
M -MS4_VC/B'HG@77=/\  5Q!XS_8T_9S_:U\$>)_AYJ-[JFCW\?Q+N/$OA'X
MI^%KN2ZO+^&/_A"OB)X=2VT">"Z:YFTO4GLM20:GI%S-/NIYY@(3S6>$PDL+
M6IT^=05)PE3A1P.-JN$:5XRDJ=7#NM-JU*M5K0BO;0FHY2CE^(=/!^UK>UI3
MJ<JDZBFI.5>@E)R=W!RC44$])0A"[Y'&_P"A^A0ZC%INFKJTD<VJIIEA'JDT
M8 CFU)+6-+^5 H5 LEV)678 NTC'! K:'  ]*AB!!?I_#C'0<$$#V!'_ -<X
MXFKY2.MYNUYMRLE9*\I.R79-M+R2MH>TE9)=DEO>]DE=OJW:[?5MOJ%(3P<'
M'7GZ'_ZU+2$X';\>GXU3O;\>EGY.XSRWXR^&]4\8?"3XK>$]$TVSUC6/%7PV
M\<>'='TG4=9U'P[IVK:KKOA75=*L-.OM?T9TU;0;*^N[J&TNM9TN2/4=+@ED
MO;%TN8$:OY']$_X)0?MLO\ ? ?A*R^!%YX/\>IX^\8:;IUW=>-?@+/HG@6+Q
M'\&O@?X&/Q$\5_#*RN;WP1HDVB^(OAOK%KX$^.?PBU9OC[I&C:;'XBU_P[KO
MBCXD>)KRT_KI^+7CZU^%?PR^)?Q.OM-NM8L_AO\ #_QG\0+K1[.1(+S5;;P;
MX<U#Q'<:9:S2+)'%<ZA%ISVT,KI(D<LB.4*@@_AWX6_X*O?M(Z_^QUKG[0T7
MP4^%&I^-/#OQK^#'A+QOH$]]\0O %M\'/AI\;H/A/JWAO5?&W@KQM:Q>,/%?
MBR]T[XGV6G>#Y_!NH'PMXRM)M/\ '4UQH&D-<Z(OO9#5S:E3K/+*.%G">.P<
M92Q,U%1KRC7C0@KRC'V4U*7M7.+BW*%.\G.,'Y68PP52<%BIU8M4*THQIJ3O
M"+I.I*\4W[2/N.%GS)<TE[L6UHZI^R3^T;^SY^UR/BI^SIX.UOXC^%/$/Q_\
M*^+?&=U\0D\/WFG?\)1\6] ?3OBSXW\,6FEZOX/GL?"7@CP-8KX2L?B%XF_X
M3'X@V7B+QSXJL)M.U_1-(T![/]^D ' Z8R!Z@  $^N1CDX.1WYK\@M&_X*#_
M !+\+_M4ZK^S_P#M!^!/"/P9\/7GQR\1^'? /B[7++Q3#<^+/@Y):+X;^&FI
M64*7VIQ7&M_$'XF31VVG>/KB'2? ;Z'I'B[3S9V>I^&I[V;]?D)P 1@@#(]#
MCI^?<<>A->=CY8F7U3ZS"DFJ/[NO2E*?UBFVG%2FDJ4O9.\%""7L[N,VVHWZ
ML+&E'VRHRE;VGO4WI[.5G=J+]^//\3<V^9KFCNQU%%%<9UA1110 4444GZVT
M?]:Z?U<"M,>F5)&</MZ;2/7C)[#N.HK^7K]I[_@GK_P4+^(/QZ_;?^)>N>&?
MA3\;-#^/GPG\!>'?"-YX6\::EI6IZ5X3^%W[5_@;XB?#/X7>%_ ?Q(GLO T?
MBSP3\./#6J>+?$NE>)[D_"OXK^+[EM.\3WMW8:_JNC0?U"RG#C'))X"G!)
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M55E-S46US7T=GK9/JB6BBBN4Z0/OT[_2JDJ9;*G.1D@D8!3& 1TZXSP01D#
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MM=02ATN+:XA9X9X)$9)87>-E*L0?E3PS^PM^RAX+^#OB#X >%?@=X1T7X/\
MBOQ=IWCOQ%X)MI]=-GK/BO1=?T/Q-H>K7^IRZM+KLO\ 8>L>&_#[:'8#5%TW
M1]-T73-"TVSM-#LX--7ZZI" >OT_E_4>].G.I235*M5IIRA-JG4G!.=-MTYV
MC)+FIMMP>\6VU9ZJ)0A/XHQEI))RC&5E))2C[T7HTM5L^MSYJ\>?LE_ #XG^
M+4\=^/\ X;Z?XE\8)XO\$^.QKMUK?B>VNCX@^'.FW>D^#8W73]9M(9_#>DVN
MH:C._@R:*3PCJ6J7UYK.K:)?:K<2WK?2:C ![D#)P 3[GN3^0&< =:=TZ?X>
MF.U+3<ZDHPC.I.<:::IJ<G)04K-J$6^6*=E=12O97O8:A&+E*,8J4K.322<K
M7MS-)-VNTKMV3"BBBI*"BBB@ HHHH KS1EV4CT(R#@@XX/0@GTZGL.IKY2^)
M7[#G[)GQ@U'QIJWQ(^ 'PW\3ZO\ $/P9'\/O&>J3:.VF7^N>%+?Q?!\0+:WE
MO-%FTVXM-7M/&]G8^*K/Q3826GBFTUJQL+ZVUJ.:QM##]:T<_P"3V_+]/UHI
M2J49N=&K5I2E'E<J=2=-\J:DHWA.#LIQC*SNKQB[.RM,H1FDIQC))W2E%22=
MFKJZ=G9M:6T;[L^7O$?['W[.7BWP+X3^&NM?"CP^_@+P)X,\3> /!7AC3+W7
M-!T[PGX:\8Z?:Z5XA_L Z%J6FW>F:]?6%G''%XMMKB+Q58/-?W&GZS;W6IW\
M]Q[KX.\)>'/A]X2\.>!O".EP:)X8\)Z-IOA_PYHUM)<31:;HNDVL5GI]HMQ>
M33WEPT%O$BR75[<7%Y=2;Y[F>:>621NED<(&)PI )9\X"+SAB<>P'3OCC.*S
M[UX+FUD8W*QPN5!E#@J-IP5],$GD9!)P1QU<I5:O+"=2M.'.V[RJ3BIRO>;3
ME)3J2YGS7]Z5V[O4SDH4W*<8TU4Y'97A"3C&VCDTK06EF_=5NA+<I+*Z>5.U
MOMD#.%1',B@!<-D%AC##:N"00>W+##.;J.47#+ @96M]L>V3(8YW#YAAB"&7
M[FT#!YS2NK>U=+%9+YHA'(@BD$H0W)^38 2,,6 ^\"!EL#J*2:"V;5K:4WOE
MW"12>7:>8!YB_-N^4@$+R7*D'>%/H,6HZ?%>T*O_ "Y<KV=K::._5_8V;6K,
MIR=Y>XM:E"W[^,;MJ[T33BX[J#O[9*Z318A@N4N;B26ZDDB<8BB*(8HF(/SJ
M5 <\  ACAPP.00*K_9=12PN+<7BR73H?LMQ(JKY;EGQNV*5"E3A4",8U4Y!R
M:CL[:V74M0EBU S3R*OGVGF*?LX<Y# #+*5  7(^0$@=15"SL;"/2=3@36))
M;>=IC<7RS)BV.!O!.XJ/60G;OSV')M15M&U;ZO[KP[LTWU5K-+91VJK5<R6N
M+;U3BU=8U:8R-TU9>[J^5R3YKO\ W;:25[':GH>WTKQKXK>*O@KX0D\$2_&/
M5?AYHS>,?'.B_#;X?S^/H]$!U[Q]XFCN;K0/!OAN;689!/XBUI=*NYK#3;1A
M<79L9&C0O%\OLIZ''7''UK\]?^"AW[+OCO\ :G\#_!KPYX"/AR/5_AG\;)/B
M_'>>(]2N]+@TW5_#?P5^,.B> -3LYK*WFNI;FP^*'B3P1-=QV[V\D>CC4[I9
M)#!]EN)PU.A4Q5*&(KRPU&?M%4KP?+*E^ZJ2A*_:52-*#_NRFTFU%';6<HTY
MRA!5))7C![2=UIL];7MIO;O==SXW_;9_8?\ AY-K$WCO]H;X$>'+O2?B%XB\
M$:X=6\3Z!'=V7Q.^'.FZ3?>)] OU199T\6>"](U31YM2BD#7NBV=Y9[VAC=,
M>>_%GXC?\$\_C7J/AG]G3QY\9_@^OB?XCR>$O&W@KPOX1^+"_#_Q;XIE\;VM
MYJW@C6?#>N>"M<T&]U<^.;/4[R[\/QQ:C<#Q0;Z6:P@O;N2.1?RKTO\ X) _
MM47?Q&TW5X?C(/@?<S:C\<?&=_\ &KX.>,HD\>6/Q.^+O[-_P'\+:GX@ET35
MO"MQ!XB\.>(_C=X2^(=WXL\/2W6G7%]X4ETF6#5+.>Z6*S33/^":W[7%WX+\
M6? RW^"GP ^%WP^^-'@/_@G]X9UOQUI'QBU;Q?=?L[7W[(%ZEWXQU#X<Z%JG
M@R7Q1XZU;Q#<Z>NI^ =6U+Q5HNHVE[KCR>)=0:YM;J>Y^AA@,DAR5*&>UX5J
M=Y\WM:-!QY9Q5.I%23<VDJE54J;E5J1C"$>2K4I.7E/$9A)2C5R^FX2LE%*=
M534HMRBTI+EN^6FY22A%N4O?A%V_H8\ ?";X<_"SPMX'\&?#SP3X>\*^%_AM
MX9M_!W@33=,TR-G\+^&;2&&WBT;3+^=9]3AMI$MXFO2]X\E_,IN+YYYV>1NO
ML=$TG2XIK;2]$TK3HKA3YT-AIMI90W &\'SHK:*..=?WT@Q(K ":3/#ON_'G
M]M/]B;]ICXV_M)>)_C5\*?$D>CV^B_#S]E2S^#UT?C!XU\'3^%/B%\./VH(O
M''QDUV+PUHL@\/+-KOP2GU7PO'J.IV6JKXBAOKGPS>VT%C<M./A[QI^Q;^UO
M\"O#OQ)^(7Q?\7>/?BMX0E_:"\">)_B5X7\._$[XJ^(=%_:6\!VWQ.^+'BJ+
M5]?\.?#+P?JGQ!^%=UX:TKQ=X)LM5N8+C6=%UBV\*6'A#4M)7PWH^A7R\-'+
M<-BH4ZLL\H*OB%3G*A45:57VU2<INFY2J*#E=V<ZDH*-24G+EIJ51=$\55HR
MG'ZC4=.GSVJ0<.7V<8I745#F2<4O=2=X*T6Y)4S^F"+1/#^CK#?PZ/H>DC2-
M(ETV"^BT[3]/_LS0D;[5+I\5U%!%]ATE'C%Q-;))#91M'Y[QY0D<!X/\4?!K
MXCZ]/KO@B\\">,M>TW1O#'B,^)]"LM-U2Z&A>,]/NYO">M6'BB*SD6_T[Q!I
M=G=R:7?:9J5S#=6,;%)%A>,M_.!^S=^P5^WI\2?#W[&_B_X@VT?AKP-HGP8/
MACQ_I/C_ .)OQ"TWXKZGX9^(7AS]HC2/'7@SXK:'K-SJFH>)+22^\>?#;7=%
MTRXNM$OH=&LIU\1I)XJTFRCM/1?A=_P35_;R^%WP;LXO GB?POX!^+OPR^$O
M[&G@?X0>&[/XT^+KWX=/JW@#X1_$WX&_M0P:I!#IJZ=8:+XJTOQ]:_$WPE N
MBR_:_%GA_0H[B#3)].CGC=?*<)0E.F\\PM2MSRIWA)JG&*JU:25249R;3E!3
MG%.4(PFW+G:A[2:6+K5ES?4:M.%HR7.HJ<FX1FG"+BDM_9W:4N9>ZDK-?T!:
M?X\^$=UXAM_!]GKW@J/Q./$^K^%K#PVYTVQUF[\5^#])@\8ZWINB:7=06]SJ
ME_X9TC5K;Q!J,VDQW46E6VI)=R7$+W:N_IEI9VMD\@M;.VM!=W,]Y="WMX[?
M[1>7)+7-U,(419[N=@&GN'W32$#S'8@8_G)UC_@EO\2O"'Q(\*>,_'&J7OB'
MX$?"+QC^V!I</B&#XH_$KQ'\9?!_P"^+'[(?P5^%/@SQQX2@M(M2\1ZCX[T'
MQW\,_&7B#5/!^@WBZS>ZCXGMM4TV[OKJ:6S7]%?^"5_@#XQZ#^S@?BC^T-?^
M,[CXS?M!>*7^(WB#2_&XUBSUCPIX1T/PQX>^&7PM\--H&K>5<>%Y;GP!X'T?
MQIKVBRV=I?P>+_&?B.35HSJ4L^,,7E^%IX26)H9E#$J%2A1=)Q:G4G6=2?-!
M>TD^6C"GS5>>*E"<X1BY)J3VHXBK*K&E/#3I\\*DU)VM!4W&-IM1^*;DO9M.
MTDF[)IH_308QQR.1Q[''Z4M(,=1[]^.#C@=.<9_&EKS$[KL=H57DC=V!R% Z
MD#).>.AXQCUR.WM5BBB2YE8/Z_K[S#;1--FCU9)],TZ4:XOEZRDFG6C)JZ?9
M19!=55H674D-HJVA6\6<"W @!$0"BIJ/A30-6@EM]5T+0]3M[C3_ .R)H+_1
M].O8)M(\R.8Z3)#<V\T<NF&>""?[!(IM!-!%-Y7F1QLO3T4K2_FENGI*:MT?
M+[UUHDO\*2T20N5=ELULNORU[Z]6WNR&&-842) JA!A5"A51!\H5%4!44  *
MJ@*HX50H $U%%-)+;[];OU?484444P&L=HW>@/'0'ZD].G7_ /4?GCXU_M7_
M +-_[.%[X8T_X]_&[X9_"&]\:_;CX0M/B!XLT[PY<>(AILEI!J!TB._DC:]^
MQS7]E%-Y.XI)=0(<-*N?H9_NMW)4X ZDX[#VKXE_:G^ WC'X]?$+]E+1UL?"
M]Y\$/ OQFF^*GQ^L]7>#^V?$.G^ /#6HZ]\'_"&FV+Z?<G5=$N/C7#X*\8>*
M-/-Y9V<]OX*LK>^@U"UNIK8ZX>%">(BL3.<*')4E-PE",ER4ZDX).<9QYISC
M&G&+C[SDDI)ZK.JZB@W22<[Q4%)2:;<HI\RBU+E2?,VGLF=AJW[8W[(S77Q2
M\-:O\?O@S)=_"2_\.:#\7M(U+QAH<Q\":EXPUJT\.^&=*\8V=S(\>FW>N:[?
M6>DV%E>+OGOYXX3&&!Q[?X?\1>"_&TU[?^'=5\/^))O!^O:UX1O-0TQK74)/
M#OB.PBM8_$6A)>Q*S6-_;QRVD&IV]K*NT[;>XRT1C3\.?!G_  3-^-4.I_MF
MZ9\2(=)U?X5?$?6=8^)WPO\ A[HOQO\ '6J7'Q!_:./Q<\5_%+PY\;9]>\0:
M=8ZE\";>7P]K>D?"_P =_#_P_J&LZ!XHM;?5]4?$1L1+]S_\$_/@I^TU\ -,
M^*WPT^-^K^$M7^'6B^*--N/@;<>'$T<W-W9ZO;ZEK7Q UN^-AI5CKL<>O>(]
M1M[^YB\=ZEXD\4R^*F\67UOK*^%[OP]I6G=F,PF I4JCPF/5:5/V#Y93I_O8
M5J=%U/9*G9RJ4YRJ0K4W;V<%'FE.2JQ7/1JUY2@JM!P4^?WE?W)4YRY5-/7E
ME'EE":;4I;**Y6_OJ'PQH$%Y9:A'H>BQW^GOJTUC?1:181WUC+KTHN-:DM+V
M.!9[:;6;C$VJO#)&^I2YEO#/(=U;Z1A#D,2 ",'U)!SG_P"L<=,]J>.G_P!;
M'TS[CBEKRTE*TG=Z)6;;MOT;:3U>VEV^QUI6OYN^W]:^844452V6M_,85"T9
M+,=Q&<8XR" #D'TR3[$#@=L344-)[@9<>EV45_=:E%9V<.I7<-M;76H16D,=
M]=6UF93:V]S>K&+FX@MGFE:WAFE>.'SI#&J^8Q.;<>%/#UW:MIMSH&AW&G/I
MEYHSZ?<Z/ITUF='U+8-1TO[++;-;#3;_ ,M#?6'E&UO-B?:(),*1TU%1RR6T
MYK:UI2T2VMK?W;+EUTNTK+05EU2>_1=7?MKY]^I6MK:&S@M[6U@AM[:VBCMX
M+>")((;>WA01PPV\,06*"&&,"..*-5C2-%5 JA15FBBM%_P_F^K^^_WC"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC2TNO$/]KPR"!(3HMG:VITG3DL6M=\>J:H^K32:5DK\4_P!M2ZO[>VL?@?\
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M1:FTM^1.SK4Y*]9^]2W/8K9M9_M#4/M:VYT\_P#'BZL"S2#[N_:2P38/WPD
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M%M9-0@M96;1ECO;6W73)A-"EEH>BV1,EM:,DGUU37^XW^ZW\C0!\/^%OV&/
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MA"UMH]9@\A/#US<>);G[&BM:M(LUN/$][:V%\96GM+%#:KN6>5C]B-T/T/\
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MJ*VOYGTR220ZC<><XE@)4!%C.P8 "KL(1_M#$EO,W<4])_Y&WQ+_ ->^H_\
MHVWK'TG_ )$WQ1_UT3^4-;_5Y2YV\17T_L?9QNW6BVG?DWHVM2TT3?-SZ6Y/
BKD%."^IX?6/$+O\ O/\ F&5Y+6I;_:7;VUT]OW?)=W__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282417484976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Actinium Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,409,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">275 Madison Avenue, 7th&#160;Fl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282416701920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 94,522<span></span>
</td>
<td class="nump">$ 108,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">98,546<span></span>
</td>
<td class="nump">110,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $536 and $487</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long term</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">102,026<span></span>
</td>
<td class="nump">114,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">7,358<span></span>
</td>
<td class="nump">10,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">7,864<span></span>
</td>
<td class="nump">10,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LongtermOperatingLeaseObligationsNoncurrent', window );">Long-term operating lease obligations</a></td>
<td class="nump">1,954<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">44,818<span></span>
</td>
<td class="nump">47,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 25,729,370 and 25,674,823 shares issued and outstanding, respectively</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">356,984<span></span>
</td>
<td class="nump">355,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(299,802)<span></span>
</td>
<td class="num">(288,765)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">57,208<span></span>
</td>
<td class="nump">66,481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 102,026<span></span>
</td>
<td class="nump">$ 114,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermOperatingLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term operating lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermOperatingLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282416714816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation (in Dollars)</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,729,370<span></span>
</td>
<td class="nump">25,674,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">25,729,370<span></span>
</td>
<td class="nump">25,674,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282417403296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Other revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">7,849<span></span>
</td>
<td class="nump">4,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,735<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,584<span></span>
</td>
<td class="nump">6,104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(11,584)<span></span>
</td>
<td class="num">(5,164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income - net</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,037)<span></span>
</td>
<td class="num">$ (5,129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock &#8211; basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic and diluted (in Shares)</a></td>
<td class="nump">25,696,623<span></span>
</td>
<td class="nump">22,143,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282416713712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share &#8211; basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</a></td>
<td class="nump">25,696,623<span></span>
</td>
<td class="nump">22,143,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282417584784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 329,271<span></span>
</td>
<td class="num">$ (255,748)<span></span>
</td>
<td class="nump">$ 73,545<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,129)<span></span>
</td>
<td class="num">(5,129)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,692<span></span>
</td>
<td class="num">(260,877)<span></span>
</td>
<td class="nump">68,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">355,220<span></span>
</td>
<td class="num">(288,765)<span></span>
</td>
<td class="nump">66,481<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">25,674,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of issuance costs (in Shares)</a></td>
<td class="nump">54,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,037)<span></span>
</td>
<td class="num">(11,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 356,984<span></span>
</td>
<td class="num">$ (299,802)<span></span>
</td>
<td class="nump">$ 57,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">25,729,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414688272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows Used In Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,037)<span></span>
</td>
<td class="num">$ (5,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation &amp; amortization expenses</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,989)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(2,770)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Other liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Operating lease right-of-use assets</a></td>
<td class="num">(336)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(15,077)<span></span>
</td>
<td class="num">(5,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Used In Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Provided By / Used In Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SalesOfSharesOfCommonStockNetOfCosts', window );">Sales of shares of common stock, net of costs</a></td>
<td class="nump">770<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By / Used In Financing Activities</a></td>
<td class="nump">770<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(14,383)<span></span>
</td>
<td class="num">(5,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">109,608<span></span>
</td>
<td class="nump">78,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">95,225<span></span>
</td>
<td class="nump">72,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SalesOfSharesOfCommonStockNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales of shares of common stock, net of costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SalesOfSharesOfCommonStockNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282419715152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b>
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with
cellular level precision to treat patients with high unmet medical needs.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2023 and December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases of corporate office
spaces.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
March 31, 2023 and 2022, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,324</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,052</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,092</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,385</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance</i>, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, FASB issued
ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers</i>,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, FASB issued ASU
2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock
Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282420879520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282418353696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a
lease for corporate office space effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration date on July 30,
2027 and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such as insurance, utilities and
maintenance. At March 31, 2023, for capitalization purposes under ASC842, the Company has this operating lease and a finance lease for
office equipment. During the three months ended March 31, 2023, the Company spent $0.3 million in improvements at its corporate office
space, which has been included in the value of the operating right-to-use asset as of March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">162</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">93</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Cash flow information:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.8 year</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/>
Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/>
Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%">2023 (excluding three months ended March 31, 2023)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">456</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,728</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(271</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,457</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414655728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueLineItems', window );"><strong>Other Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueTextBlock', window );">Other revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 &#8211; Other revenue </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#8217;s ability to terminate
the module. The consideration is recognized as revenue over each module and revenue of $0.8 million was recognized during the three months
ended March 31, 2022. There was no other revenue recognized from a collaboration during the three months ended March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had a grant
from a government-sponsored entity for research and development related activities that provides payments for reimbursed costs,
which included overhead and general and administrative costs, as well as an administrative fee. The Company recognized revenue from
grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and development
expense. Other revenue recognized from this grant for the three months ended March 31, 2022 was $0.1 million. There was no
corresponding revenue for the three months ended March 31,
2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $35 million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#8217;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#8211; current liability at March
31, 2023 and December 31, 2022. Long-term license revenue deferred was $35.0 million at March 31, 2023 and December 31, 2022; this deferred
revenue will be recognized upon European Union regulatory approval of Iomab-B.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282420860288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5  - Equity&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company
entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which
the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. Shares of
common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. On June 28, 2022,
the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales Agreement&#8221;)
with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley Securities&#8221;). The A&amp;R Sales Agreement modifies the original
Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three months ended
March 31, 2023, the Company sold 0.1 million shares of common stock, resulting in gross proceeds and net proceeds of $0.8 million. For
the three months ended March 31, 2022, there were no sales of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the three months ended March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; vertical-align: bottom">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,204</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: bottom">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: bottom">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(82</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,324</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.07</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">11,114</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: bottom">Exercisable, March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,304</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
March 31, 2023, the Company granted new employees options to purchase 11 thousand shares of common stock with an exercise price ranging
from $10.20 to $11.60 per share, a term of 10 years, and a vesting period of 4 years.&#160;The options have an aggregated fair value of
$82 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 3.59% to 4.21% (2) expected life of 6 years, (3) expected volatility range from 81.3% to 81.4%,
and (4) zero expected dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2023
was $9.0 million related to unvested options, which is expected to be expensed over a weighted average of 3.1 years. During the three
months ended March 31, 2023 and 2022, the Company recorded compensation expense related to stock options of $0.8 million and $0.4 million,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit activity for the three months ended March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%; vertical-align: bottom">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt; vertical-align: bottom">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; vertical-align: bottom">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">325</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.96</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.9 million, was determined based on the stock
prices on the dates of the grants and is being recognized over three years. The unrecognized compensation expense at December 31, 2022
of $1.6 million is expected to be expensed over 2.4 years. During the three months ended March 31, 2023, the Company recorded compensation
expense related to RSUs of $0.2 million. There was no compensation expense related to RSUs for the three months ended March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the three months ended March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,443</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">16.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.08</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,440</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">15.94</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.08</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282419437232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6  - Subsequent Event</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since March 31, 2023, the
Company has sold 0.6 million shares of common stock under its A&amp;R Capital on Demand Sales Agreement, resulting in net proceeds of
$5.6 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282416680672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NatureOfBusinessPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b>
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with
cellular level precision to treat patients with high unmet medical needs.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2023 and December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases of corporate office
spaces.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_GrantRevenuePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LicenseRevenueTextBlock', window );">License Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
March 31, 2023 and 2022, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,324</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,052</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,092</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,385</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance</i>, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, FASB issued
ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers</i>,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, FASB issued ASU
2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock
Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LicenseRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LicenseRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NatureOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of Business policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NatureOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282419459648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents and restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of diluted net loss per share anti-dilutive</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,324</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,052</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,092</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,385</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414800032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">162</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">93</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Cash flow information:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm', window );">Schedule of weighted average remaining lease terms</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.8 year</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfWeightedAverageDiscountRate', window );">Schedule of weighted average discount rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/>
Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/>
Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%">2023 (excluding three months ended March 31, 2023)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">456</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,728</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(271</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,457</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOrDescriptionOfWeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282416686416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; vertical-align: bottom">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,204</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: bottom">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: bottom">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(82</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,324</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.07</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">11,114</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: bottom">Exercisable, March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,304</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of summary of restricted stock unit activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%; vertical-align: bottom">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt; vertical-align: bottom">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; vertical-align: bottom">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">325</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.96</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,443</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">16.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.08</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,440</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">15.94</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.08</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282417392992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems', window );"><strong>Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 94,522<span></span>
</td>
<td class="nump">$ 108,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Restricted cash &#8211; long-term</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 95,225<span></span>
</td>
<td class="nump">$ 109,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282417575472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,092<span></span>
</td>
<td class="nump">3,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,324<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">325<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282417984368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 15, 2012 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNetAssetsPercentage', window );">Net sales percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetAssetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of value of derivative contract to net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetAssetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414416624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease description</a></td>
<td class="text">5 years 2 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Jul. 30,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Current annual rate</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember', window );">Corporate Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandImprovements', window );">Landlord assets</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282416017888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of components of lease expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems', window );"><strong>Schedule Of Components Of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_FinanceLeaseCostAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414850064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information related to leases - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems', window );"><strong>Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance Leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282419244720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average remaining lease terms<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Leases</a></td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282419305040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average discount rates<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageDiscountRatesAbstract', window );"><strong>Weighted average discount rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageDiscountRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageDiscountRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282416666704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems', window );"><strong>Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">$ 456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2026</a></td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">2027</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="num">(271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems', window );"><strong>Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2026</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of present value of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentWithImputedInterestPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment with imputed interest premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PaymentWithImputedInterestPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414895328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LongtermLicenseRevenueDeferred', window );">Long-term license revenue deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermLicenseRevenueDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term license revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermLicenseRevenueDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282415722928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Expected term year</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_GrantOfStockOptionsToEmployees', window );">Grant of stock options to employees (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_DescriptionOfExercisePriceRange', window );">Exercise price ranging, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$10.20 to $11.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_StockOptionTerm', window );">Stock option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_VestingPeriodOfStockOption', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AggregateFairValue', window );">Aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_StockOptionDescription', window );">Stock option, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 3.59% to 4.21% (2) expected life of 6 years, (3) expected volatility range from 81.3% to 81.4%,
and (4) zero expected dividends.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageTerm', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_CompensationExpenseRelatedToStockOptions', window );">Compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember', window );">Capital on Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CompensationExpenseRelatedToStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation expense related to stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CompensationExpenseRelatedToStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfExercisePriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfExercisePriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrantOfStockOptionsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant of stock options to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrantOfStockOptionsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockOptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option, Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockOptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_VestingPeriodOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting period of stock option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_VestingPeriodOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414673200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of summary of stock option activity<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfSummaryOfStockOptionActivityAbstract', window );"><strong>Schedule of Summary of Stock Option Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning balance | shares</a></td>
<td class="nump">3,396,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning balance | $ / shares</a></td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Outstanding, Beginning balance</a></td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Beginning balance | $</a></td>
<td class="nump">$ 15,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 10.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Exercised | shares</a></td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled | shares</a></td>
<td class="num">(82,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending balance | shares</a></td>
<td class="nump">3,324,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance | $ / shares</a></td>
<td class="nump">$ 8.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Ending balance | $</a></td>
<td class="nump">$ 11,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable | shares</a></td>
<td class="nump">975,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 13.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">7 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 2,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfSummaryOfStockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfSummaryOfStockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414427264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of summary of restricted stock unit activity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract', window );"><strong>Schedule of Summary of Restricted Stock Unit Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RSUsOutstandingBeginningBalance', window );">RSUs Outstanding, Beginning balance | shares</a></td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share Outstanding, Beginning | $ / shares</a></td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">RSUs, Vested | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RSUsOutstandingEndingBalance', window );">RSUs Outstanding, Ending balance | shares</a></td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance | $ / shares</a></td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RSUsOutstandingBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs Outstanding, Beginning balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RSUsOutstandingBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RSUsOutstandingEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs Outstanding, Ending balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RSUsOutstandingEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282414862208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of warrant activities - Warrant [Member]<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NumberOfWarrantsOutstandings', window );">Number of Shares, Outstanding Beginning | shares</a></td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Outstanding Beginning | $ / shares</a></td>
<td class="nump">$ 16.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding beginning</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Beginning | $</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NumberOfWarrantsOutstandings', window );">Number of Shares, Outstanding Ending | shares</a></td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price,Outstanding Ending | $ / shares</a></td>
<td class="nump">$ 16.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Outstanding Ending</a></td>
<td class="text">1 year 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value,Outstanding Ending | $</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable Ending | shares</a></td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable Ending | $ / shares</a></td>
<td class="nump">$ 15.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Exercisable Ending</a></td>
<td class="text">1 year 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable Ending | $</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled/Expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/Expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfWarrantsOutstandings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares, outstanding beginning.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberOfWarrantsOutstandings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140282420776000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharesOfCommonStockValue', window );">Shares of common stock value | shares</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NetProceeds', window );">Net proceeds | $</a></td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharesOfCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharesOfCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>f10q0323_actiniumphar_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnm="http://actiniumpharmaceuticals.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnm-20230331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2012-05-16</startDate>
            <endDate>2012-06-15</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2012-06-15</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-36374</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="c0">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">677-3870</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">275 Madison Avenue, 7th&#160;Fl</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">10016</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="c0">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">26409826</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">94522000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">108910000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="-3" unitRef="usd">399000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c3" decimals="-3" unitRef="usd">396000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">3625000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">98546000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">110942000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">536000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">487000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">604000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" unitRef="usd">304000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" unitRef="usd">302000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">2544000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">2341000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">3000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">102026000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">114192000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">7358000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">10130000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">503000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">494000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">3000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">4000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">7864000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">10628000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="c2" decimals="-3" unitRef="usd">35000000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="c3" decimals="-3" unitRef="usd">35000000</us-gaap:DeferredRevenue>
    <atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">1954000</atnm:LongtermOperatingLeaseObligationsNoncurrent>
    <atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">2083000</atnm:LongtermOperatingLeaseObligationsNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" unitRef="usd">44818000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" unitRef="usd">47711000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">25729370</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">25729370</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">25674823</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">25674823</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">26000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">26000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">356984000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">355220000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-299802000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-288765000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">57208000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">66481000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">102026000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">114192000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SubleaseIncome contextRef="c4" decimals="-3" unitRef="usd">940000</us-gaap:SubleaseIncome>
    <us-gaap:Revenues contextRef="c4" decimals="-3" unitRef="usd">940000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">7849000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">4369000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">3735000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">1735000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" unitRef="usd">11584000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="-3" unitRef="usd">6104000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-11584000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-5164000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="-3" unitRef="usd">547000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c4" decimals="-3" unitRef="usd">35000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">547000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">35000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-11037000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-5129000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">25696623</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="0" unitRef="shares">22143974</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c5" decimals="0" unitRef="shares">25674823</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="-3" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c6" decimals="-3" unitRef="usd">355220000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c7" decimals="-3" unitRef="usd">-288765000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="-3" unitRef="usd">66481000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c9" decimals="-3" unitRef="usd">993000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c0" decimals="-3" unitRef="usd">993000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c8" decimals="0" unitRef="shares">54414</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c9" decimals="-3" unitRef="usd">770000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="-3" unitRef="usd">770000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c8" decimals="0" unitRef="shares">133</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c9" decimals="-3" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" unitRef="usd">-11037000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-11037000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c11" decimals="0" unitRef="shares">25729370</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="-3" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="-3" unitRef="usd">356984000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="-3" unitRef="usd">-299802000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" unitRef="usd">57208000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c14" decimals="0" unitRef="shares">22143974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="-3" unitRef="usd">22000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="-3" unitRef="usd">329271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c16" decimals="-3" unitRef="usd">-255748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c17" decimals="-3" unitRef="usd">73545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c19" decimals="-3" unitRef="usd">421000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c4" decimals="-3" unitRef="usd">421000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c20" decimals="-3" unitRef="usd">-5129000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-5129000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c21" decimals="0" unitRef="shares">22143974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c21" decimals="-3" unitRef="usd">22000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c22" decimals="-3" unitRef="usd">329692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c23" decimals="-3" unitRef="usd">-260877000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c24" decimals="-3" unitRef="usd">68837000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-11037000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-5129000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">993000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">421000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" unitRef="usd">182000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c4" decimals="-3" unitRef="usd">137000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">1989000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="-3" unitRef="usd">114000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">-2770000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="-3" unitRef="usd">-275000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c4" decimals="-3" unitRef="usd">-731000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="-3" unitRef="usd">-336000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c0" decimals="-3" unitRef="usd">-120000</atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
    <atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c4" decimals="-3" unitRef="usd">-90000</atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-15077000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">-5781000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">76000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">-76000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="-3" unitRef="usd">-7000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c4" decimals="-3" unitRef="usd">22000</us-gaap:FinanceLeasePrincipalPayments>
    <atnm:SalesOfSharesOfCommonStockNetOfCosts contextRef="c0" decimals="-3" unitRef="usd">770000</atnm:SalesOfSharesOfCommonStockNetOfCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">770000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">-22000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-14383000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="-3" unitRef="usd">-5810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">109608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c17" decimals="-3" unitRef="usd">78221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">95225000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c24" decimals="-3" unitRef="usd">72411000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1 - Description of Business and Summary
of Significant Accounting Policies&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business -&lt;/b&gt;
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with
cellular level precision to treat patients with high unmet medical needs.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2023 and December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;94,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash - current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#x2019;s leases of corporate office
spaces.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers&lt;/i&gt;
(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements&lt;/b&gt;
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -&lt;/b&gt;
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share&lt;/b&gt;
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
March 31, 2023 and 2022, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,052&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,092&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,385&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Recently Adopted Accounting
Pronouncements &#x2013; &lt;/b&gt;In November 2021, the FASB issued ASU 2021-10, &lt;i&gt;Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance&lt;/i&gt;, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In October 2021, FASB issued
ASU 2021-08, &lt;i&gt;Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/i&gt;,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#x2019;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2021, FASB issued ASU
2021-04, &lt;i&gt;Earnings Per Share (topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock
Compensation (Topic 718) and Derivatives and Hedging &#x2013; Contracts in an Entity&#x2019;s Own Equity (Subtopic 815-40) &#x2013; Issuer&#x2019;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/i&gt;, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <atnm:NatureOfBusinessPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business -&lt;/b&gt;
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with
cellular level precision to treat patients with high unmet medical needs.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</atnm:NatureOfBusinessPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2023 and December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;94,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash - current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#x2019;s leases of corporate office
spaces.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;94,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash - current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">94522000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">108910000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="-3" unitRef="usd">399000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c3" decimals="-3" unitRef="usd">396000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">304000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">302000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c2" decimals="-3" unitRef="usd">95225000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">109608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers&lt;/i&gt;
(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements&lt;/b&gt;
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <atnm:GrantRevenuePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</atnm:GrantRevenuePolicyTextBlock>
    <atnm:LicenseRevenueTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</atnm:LicenseRevenueTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -&lt;/b&gt;
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share&lt;/b&gt;
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
March 31, 2023 and 2022, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,052&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,092&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,385&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,052&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,092&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,385&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c25" decimals="0" unitRef="shares">3324</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c26" decimals="0" unitRef="shares">1333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c27" decimals="0" unitRef="shares">325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c29" decimals="0" unitRef="shares">1443</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c30" decimals="0" unitRef="shares">2052</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="0" unitRef="shares">5092</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c4" decimals="0" unitRef="shares">3385</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Recently Adopted Accounting
Pronouncements &#x2013; &lt;/b&gt;In November 2021, the FASB issued ASU 2021-10, &lt;i&gt;Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance&lt;/i&gt;, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In October 2021, FASB issued
ASU 2021-08, &lt;i&gt;Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/i&gt;,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#x2019;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2021, FASB issued ASU
2021-04, &lt;i&gt;Earnings Per Share (topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock
Compensation (Topic 718) and Derivatives and Hedging &#x2013; Contracts in an Entity&#x2019;s Own Equity (Subtopic 815-40) &#x2013; Issuer&#x2019;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/i&gt;, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:MilestonePayment contextRef="c31" decimals="-6" unitRef="usd">1000000</atnm:MilestonePayment>
    <us-gaap:DerivativeNetAssetsPercentage contextRef="c32" decimals="2" unitRef="pure">0.02</us-gaap:DerivativeNetAssetsPercentage>
    <atnm:LeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 3 - Leases &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#x2019;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The lease term for all of
the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company entered into a
lease for corporate office space effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration date on July 30,
2027 and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such as insurance, utilities and
maintenance. At March 31, 2023, for capitalization purposes under ASC842, the Company has this operating lease and a finance lease for
office equipment. During the three months ended March 31, 2023, the Company spent $0.3 million in improvements at its corporate office
space, which has been included in the value of the operating right-to-use asset as of March 31, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;162&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;93&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Supplemental cash flow information related to leases
are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;Cash flow information:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at March 31, 2023:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.8 year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#x2019;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities
are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt;
Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt;
Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 76%"&gt;2023 (excluding three months ended March 31, 2023)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;456&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,728&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(271&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,457&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:LeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c0">5 years 2 months</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseExpirationDate1 contextRef="c0">2027-07-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseCost contextRef="c0" decimals="-5" unitRef="usd">600000</us-gaap:LeaseCost>
    <us-gaap:LandImprovements contextRef="c33" decimals="-5" unitRef="usd">300000</us-gaap:LandImprovements>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;162&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;93&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" unitRef="usd">162000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c4" decimals="-3" unitRef="usd">93000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c4" decimals="-3" unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c4" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="-3" unitRef="usd">21000</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;Cash flow information:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" unitRef="usd">150000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c4" decimals="-3" unitRef="usd">94000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c4" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c4" decimals="-3" unitRef="usd">22000</us-gaap:FinanceLeasePrincipalPayments>
    <atnm:ScheduleOrDescriptionOfWeightedAverageTerm contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.8 year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</atnm:ScheduleOrDescriptionOfWeightedAverageTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P4Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P0Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <atnm:ScheduleOfWeightedAverageDiscountRate contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;</atnm:ScheduleOfWeightedAverageDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="2" unitRef="pure">0.08</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt;
Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt;
Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 76%"&gt;2023 (excluding three months ended March 31, 2023)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;456&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,728&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(271&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,457&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c34" decimals="-3" unitRef="usd">456000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c35" decimals="-3" unitRef="usd">3000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree contextRef="c34" decimals="-3" unitRef="usd">618000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour contextRef="c34" decimals="-3" unitRef="usd">631000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive contextRef="c34" decimals="-3" unitRef="usd">643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive contextRef="c34" decimals="-3" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c34" decimals="-3" unitRef="usd">2728000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c35" decimals="-3" unitRef="usd">3000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <atnm:PaymentWithImputedInterestPremium contextRef="c34" decimals="-3" unitRef="usd">-271000</atnm:PaymentWithImputedInterestPremium>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="c34" decimals="-3" unitRef="usd">2457000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="c35" decimals="-3" unitRef="usd">3000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:OtherRevenueTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 4 &#x2013; Other revenue &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#x2019;s ability to terminate
the module. The consideration is recognized as revenue over each module and revenue of $0.8 million was recognized during the three months
ended March 31, 2022. There was no other revenue recognized from a collaboration during the three months ended March 31, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company had a grant
from a government-sponsored entity for research and development related activities that provides payments for reimbursed costs,
which included overhead and general and administrative costs, as well as an administrative fee. The Company recognized revenue from
grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and development
expense. Other revenue recognized from this grant for the three months ended March 31, 2022 was $0.1 million. There was no
corresponding revenue for the three months ended March 31,
2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 7, 2022, the Company
entered into a license and supply agreement (the &#x201c;License Agreement&#x201d;) with Immedica Pharma AB (&#x201c;Immedica&#x201d;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $35 million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s contract
liabilities are recorded within Other revenue deferred &#x2013; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#x2019;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#x2013; current liability at March
31, 2023 and December 31, 2022. Long-term license revenue deferred was $35.0 million at March 31, 2023 and December 31, 2022; this deferred
revenue will be recognized upon European Union regulatory approval of Iomab-B.&lt;/p&gt;</atnm:OtherRevenueTextBlock>
    <atnm:RevenueRecognized contextRef="c4" decimals="-5" unitRef="usd">800000</atnm:RevenueRecognized>
    <us-gaap:DeferredRevenueCurrent contextRef="c24" decimals="-5" unitRef="usd">100000</us-gaap:DeferredRevenueCurrent>
    <atnm:UpfrontPayment contextRef="c36" decimals="-6" unitRef="usd">35000000</atnm:UpfrontPayment>
    <atnm:LongtermLicenseRevenueDeferred contextRef="c2" decimals="-5" unitRef="usd">35000000</atnm:LongtermLicenseRevenueDeferred>
    <atnm:LongtermLicenseRevenueDeferred contextRef="c3" decimals="-5" unitRef="usd">35000000</atnm:LongtermLicenseRevenueDeferred>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5  - Equity&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the Company
entered into the Capital on Demand&#x2122; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which
the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. Shares of
common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. On June 28, 2022,
the Company entered into an Amended and Restated Capital on Demand&#x2122; Sales Agreement (the &#x201c;A&amp;amp;R Sales Agreement&#x201d;)
with JonesTrading and B. Riley Securities, Inc. (&#x201c;B. Riley Securities&#x201d;). The A&amp;amp;R Sales Agreement modifies the original
Capital on Demand&#x2122; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the three months ended
March 31, 2023, the Company sold 0.1 million shares of common stock, resulting in gross proceeds and net proceeds of $0.8 million. For
the three months ended March 31, 2022, there were no sales of common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of stock option activity for the three months ended March 31, 2023:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%; vertical-align: bottom"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom"&gt;Outstanding, March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,324&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.07&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;11,114&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;Exercisable, March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three months ended
March 31, 2023, the Company granted new employees options to purchase 11 thousand shares of common stock with an exercise price ranging
from $10.20 to $11.60 per share, a term of 10 years, and a vesting period of 4 years.&#160;The options have an aggregated fair value of
$82 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 3.59% to 4.21% (2) expected life of 6 years, (3) expected volatility range from 81.3% to 81.4%,
and (4) zero expected dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2023
was $9.0 million related to unvested options, which is expected to be expensed over a weighted average of 3.1 years. During the three
months ended March 31, 2023 and 2022, the Company recorded compensation expense related to stock options of $0.8 million and $0.4 million,
respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of restricted stock unit activity for the three months ended March 31, 2023:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 76%; vertical-align: bottom"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt; vertical-align: bottom"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; vertical-align: bottom"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom"&gt;Outstanding, March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;325&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#x2019;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.9 million, was determined based on the stock
prices on the dates of the grants and is being recognized over three years. The unrecognized compensation expense at December 31, 2022
of $1.6 million is expected to be expensed over 2.4 years. During the three months ended March 31, 2023, the Company recorded compensation
expense related to RSUs of $0.2 million. There was no compensation expense related to RSUs for the three months ended March 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activity for the three months ended March 31, 2023:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.08&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,440&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15.94&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.08&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c37" decimals="-6" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c38" decimals="-5" unitRef="shares">100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c38" decimals="-5" unitRef="usd">800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%; vertical-align: bottom"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom"&gt;Outstanding, March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,324&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.07&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;11,114&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;Exercisable, March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">3396000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0">P8Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c3" decimals="-3" unitRef="usd">15204000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c0" decimals="INF" unitRef="shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">10.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="c0" decimals="INF" unitRef="shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c0" decimals="INF" unitRef="shares">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">5.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="INF" unitRef="shares">3324000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">8.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c0">P8Y6M</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c2" decimals="-3" unitRef="usd">11114000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c2" decimals="INF" unitRef="shares">975000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">13.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted contextRef="c0">P7Y2M15D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c2" decimals="-3" unitRef="usd">2304000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <atnm:GrantOfStockOptionsToEmployees contextRef="c39" decimals="-3" unitRef="shares">11000</atnm:GrantOfStockOptionsToEmployees>
    <atnm:DescriptionOfExercisePriceRange contextRef="c39">$10.20 to $11.60</atnm:DescriptionOfExercisePriceRange>
    <atnm:StockOptionTerm contextRef="c39">P10Y</atnm:StockOptionTerm>
    <atnm:VestingPeriodOfStockOption contextRef="c39">P4Y</atnm:VestingPeriodOfStockOption>
    <atnm:AggregateFairValue contextRef="c39" decimals="-3" unitRef="usd">82000</atnm:AggregateFairValue>
    <atnm:StockOptionDescription contextRef="c39">Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 3.59% to 4.21% (2) expected life of 6 years, (3) expected volatility range from 81.3% to 81.4%,
and (4) zero expected dividends.</atnm:StockOptionDescription>
    <atnm:UnrecognizedCompensationExpense contextRef="c39" decimals="-5" unitRef="usd">9000000</atnm:UnrecognizedCompensationExpense>
    <atnm:WeightedAverageTerm contextRef="c39">P3Y1M6D</atnm:WeightedAverageTerm>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="c39" decimals="-5" unitRef="usd">800000</atnm:CompensationExpenseRelatedToStockOptions>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="c40" decimals="-5" unitRef="usd">400000</atnm:CompensationExpenseRelatedToStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid; vertical-align: bottom"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 76%; vertical-align: bottom"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt; vertical-align: bottom"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; vertical-align: bottom"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; vertical-align: bottom"&gt;Outstanding, March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;325&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <atnm:RSUsOutstandingBeginningBalance contextRef="c2" decimals="INF" unitRef="shares">325</atnm:RSUsOutstandingBeginningBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c2" decimals="INF" unitRef="usdPershares">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <atnm:RSUsOutstandingEndingBalance contextRef="c2" decimals="INF" unitRef="shares">325</atnm:RSUsOutstandingEndingBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c2" decimals="INF" unitRef="usdPershares">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c41" decimals="-5" unitRef="usd">1900000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c42">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <atnm:UnrecognizedCompensationExpense contextRef="c43" decimals="-5" unitRef="usd">1600000</atnm:UnrecognizedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c43">P2Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c42" decimals="-5" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.08&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,440&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15.94&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.08&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <atnm:NumberOfWarrantsOutstandings contextRef="c44" decimals="-3" unitRef="shares">1443000</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c44" decimals="2" unitRef="usdPershares">16.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c45">P1Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c44" decimals="-3" unitRef="usd">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <atnm:NumberOfWarrantsOutstandings contextRef="c46" decimals="-3" unitRef="shares">1443000</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c46" decimals="2" unitRef="usdPershares">16.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c45">P1Y29D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c46" decimals="-3" unitRef="usd">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c46" decimals="-3" unitRef="shares">1440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c46" decimals="2" unitRef="usdPershares">15.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c45">P1Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c46" decimals="-3" unitRef="usd">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 6  - Subsequent Event&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Since March 31, 2023, the
Company has sold 0.6 million shares of common stock under its A&amp;amp;R Capital on Demand Sales Agreement, resulting in net proceeds of
$5.6 million.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <atnm:SharesOfCommonStockValue contextRef="c2" decimals="-5" unitRef="shares">600000</atnm:SharesOfCommonStockValue>
    <atnm:NetProceeds contextRef="c2" decimals="-5" unitRef="usd">5600000</atnm:NetProceeds>
    <dei:EntityRegistrantName contextRef="c0" id="hidden-fact-0">Actinium Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c0"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SubleaseIncome
      contextRef="c0"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c0"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="hidden-fact-9"
      unitRef="usdPershares">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-10"
      unitRef="usdPershares">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="hidden-fact-11"
      unitRef="shares">22143974</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-12"
      unitRef="shares">25696623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c8"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c10"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c8"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c10"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c8"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c10"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c8"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c9"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c18"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c0"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c4"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:SalesOfSharesOfCommonStockNetOfCosts
      contextRef="c4"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c4"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c4"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c4"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c28"
      id="hidden-fact-33"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c4"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c0"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c4"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="c35"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="c35"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="c35"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="c35"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:PaymentWithImputedInterestPremium
      contextRef="c35"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      id="hidden-fact-43"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c0"
      id="hidden-fact-45"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c45"
      id="hidden-fact-47"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c45"
      id="hidden-fact-48"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c45"
      id="hidden-fact-49"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c45"
      id="hidden-fact-50"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001388320</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M77_SN>1P@-.1Y<<M(^+G4>(G3F]XP35G;E[$KTJ,KV6MZW1+C7B:&R^R3-1
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M1I5]DRGED+0&]8VZ_X*^)DZ@XZ@$O%U,?6=F;PWL8<<>CK)_9Y+D8^RC[K_
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M:&5E=#8N>&ULK5EM<YLX$/XK&MKI)#-U0.(]M3W3V'2N'^XFTS1WGQ608TT
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MY+T="+8JO^D^,2%85MXN"4Y(H03D^P5CXGV@/A/7?SQ,_P=02P,$%     @
M%XBO5DT3/7'K!0  R1D  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RM
M66USFS@0_BL:7Z?3SL0!A%]3QS.)>YWV0Z^9^G+W60'9U@40E60GN5]_*T'
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M=;CW[J 7TD;] C#X*_3">#@+/ZXQ.BI+!["_-,;7+\2@^;?$V?\!4$L#!!0
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MRD-PM*LH+\R7MJI4H"X'#\+DL+0F*%.@D0K]- U$P8&I[."N6KCL.W 3^$@
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MC/>FY,L<5* L;<#SS!C?W= !_=?BA_\#4$L#!!0    ( !>(KU:[VA$)H0<
M "T2   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;)58:V_<-A;]KE]!
M3(LB <;SM),@?@!CU\5Z&R?9N.YBL=@/')$S(D*1*DEY,OGU>RY%::34=E/
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MP]!D\/DT M?ZMYV0K1K/K"VQ YMAR2T/70C@_8WE.G>3<$#?1+._4$L#!!0
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ME_5]4'>T*-V1NA3:'-"NF9LK%*0M,/,K(?1SQY[2[:6<_@902P,$%     @
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MUZ W,I4NZQN@GFA1NJZ[%-KT<#=<FTL3I34PWW,A]'YB S37</(#4$L#!!0
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MV=D_P ,G74'C&EH4MB:8"8T5AOU,L08$:0)P/!%"KQMF@JJJ#/\ 4$L#!!0
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M4.\#TVE@E0>U(HC#<!FTC$M:9'YOHXM,]59P"1M-3-^V3/]=@U!#3B/ZLO'
M]XUU&T&1=6P/6["_NHW&*)A9*MZ"-%Q)HJ'.Z==HM4Y=OD_XS6$P1VOB*MDI
M]>2"[U5.0V<(!)36,3!\'> &A'!$:.//Q$EG20<\7K^PW_G:L98=,W"CQ".O
M;)/3:THJJ%DO[(,:OL%4SY7C*Y4P_DF&,7>94%+VQJIV J.#ELOQS9ZG[W $
MB-(S@'@"Q-[W*.1=WC++BDRK@6B7C6QNX4OU:#3'I6O*UFH\Y8BSQ3U@28:\
MNP7+N##OR4>RQ<97O0"B:C+XJJ B[  :FT0J;DK52TLTLV"RP*('QQ24D]YZ
MU(O/Z/U@>D&2Z .)PSAY#0_0^NP_GOW'GB\YP_=XV>#JE,.1,3W-Z&[!RG2L
MA)SBF!O0!Z#%VS?1,OQRP6\R^TTNL1<_.[1IN=P3X;_\*7\C0S2VS-VJ0Q$N
MPO0Z"PXGE--9.;VH?,<EDR60^[.Z(_[S:]G_58.C67/7%ANZY])@.37"PL6G
M*TKT>!7&P*K.C]].61QFOVSP[P':)>!YK91]"=Q$S_^CXA]02P,$%     @
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M]8H6[/ /][97J;XZ4J>^4K?8+6^_@51Z J Y",;C]=34& >?4G/L%2W8X>S
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MH9+.)IP=$-=/JVQZ8%HUT0I<F.A964JN[H8J3LYN?Z2A?$;HX@8D#2/Q'GU
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M-7E$WU&20L9J81YD^QGZ?&XL7B*%[KZD=;Y+9$QJ;631!Z-=\-+]V7-?AU%
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M$&;^B/?F'UYOU(EVJ/'"#[S41$"&4?[T[0TER@V*,XRLNN;<2X.MWBUS?%M
M60<\SZ0T)\/V^_!:Q7\ 4$L#!!0    ( !>(KU9U_U8T0@,  "84   -
M>&PO<W1Y;&5S+GAM;-U876_:,!3]*Y&[3JTT-4!&("L@;4B5)FU3I?9A;Y4A
M#EARG,PQ'?37S]<.X:.^B/5A+0MJ8]_C<^ZQ?4/<#BJ]$NQNSI@.EKF0U9#,
MM2X_A6$UG;.<5E=%R:1!LD+E5)NNFH55J1A-*R#E(NRT6G&84R[):" 7^4VN
MJV!:+*0>DEX3"MSM:SHD[?@C"9S<N$C9D#Q<O/^U*/3UN\#=SSZ<G;4>+J_W
MXQ<6N"2A5[1[A.A5JX4+ XB)Q\>)']+&I'N[TG;XN1%RQ'.,UC_*T0%#F'#B
M\6/L;RQ!!R'W6E[R%M42P[I,1H.LD)MJB8@+&&6:L^"1BB$94\$GB@,KHSD7
M*Q?N0&!:B$(%VI2I2=6&2/7DX+;K0077.CF7A;*Y70;W>U(/WP/6/3#(A6@,
M=H@+C 8EU9HI>6,Z=K -/H."NGV_*HW#F:*K=J=+-@1[,TDFA4J9:M*TR3HT
M&@B6@1W%9W.XZZ(, =2ZR$TCY7162&H]K!EUP\A.F1!W\'C_S':TE]G6GMD=
MDTW3&*J;3L9U0'];S6EORT8OT@U*_ECH+PLS'6G[4*'L5K&,+VU_F34&,/4V
MKD[+4JP^"SZ3.7.3/SKA:$#7O&!>*/YDLD&I3$V *1(\,J7Y=#OR6]'RGBWU
MNIR6&>ZY<X*>_^TZSYADBHIMTZ;VW_(JO]AQU'LMR_9;9=^PUV/]SG[K)KNG
M8#(^!9,G49/]4S"9G(#)WJM]:QXT&=:GC*VCS,Y!IHD&<& <DA]P]!2;I,%D
MP87FLN[->9HR^>P\8^0UG9@_@G;TS?B4970A]'T##LFF_9VE?)$GS:A;6(AZ
MU*;]#:;7CIO3JLG%9<J6+!W7736;V&9@&B9K?0%A'[FQEQ_!. [S(X!A>3 '
M&,>QL#S_TWSZZ'P<AGGK>Y$^RNFC',?R(6/[P?+X.8FY_#--DBB*8VQ%QV.O
M@S&V;G$,/WXUS!LPL#R0Z>_6&M]MO$(.UP&VIX<J!)LI7HG83/&U!L2_;L!(
M$O]N8WF @>T"5CN0WY\':LK/B2+85<P;]@3C2))@"-2BOT;C&%F=&#[^_<&>
MDBA*$C\"F-]!%&$(/(TX@CD #Q@21?8]N/<^"M?OJ7#SG\'1'U!+ P04
M"  7B*]6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
M4$L#!!0    ( !>(KU;ASR-9 P,  ,45   /    >&PO=V]R:V)O;VLN>&UL
MQ9A;3]LP%(#_BI4G)FU+[;3E(HH$E&U(:" Z\3JYR2FU<.QB.S#X];.317-8
M=[07KT^-+W4_G]KG<WS\K,W#4NL'\J.6RLZRM7.;HSRWY1IJ;C_J#2C?LM*F
MYLX7S7UN-P9X9=< KI8Y&XVF><V%RDZ.^[%N3!X7M(/2":U\9:BX$_!L?[>'
M(GD25BR%%.YEEK7/$C)2"R5J\0K5+!MEQ*[U\Q=MQ*M6CLM%:;24LXQV#7=@
MG"C_J%X$R&]\:=L:QY>WW(/,LNG(#[@2QKJV1SL^]XQ/X#MWI<;I3T(Z,'/N
MX+/1S4:H^S",GT4>3:.-0__9!?'(_$L8]6HE2ICKLJE!N2Z.!F0 5'8M-C8C
MBM<PR_HNY%15Y$(Y'R1RJ;JA?-\P4__3EU4W:^=QHQB:(^$;S&75@J>#/->J
M F6A(O[):BDJSU&1,RZY*H%$D R!9#N$_,XBR *!+'8"N0@X_JL1Y!B!'.\0
M<A#)"0(YV25D$4%.$<CI+B''$>0^ KF?%G(.MC1B$^J)7I&SQ@H%UA+N,]*B
MJ2/( P3R('4DZUJXT*D#\_%T/F>#*@78"/$003Q,BW@%W Y8Z A+V:.T--=N
M#8;<PA.H!F(HU".)17+QV'C!Q328,&AB8RR:I87')MCWPH?)Q5R8(VAB29R6
MI6[:Y4UN?,X(*_P]6;YTA9=8MQ2S!$VL"31O##1!,4_0Q*+HMB79\X<_"?9=
MC(69@2960[<5MF)A+J"[E,% JQ2S 4VL QPS%BO%C$ 3*P&U%MF+#\Z8*UAB
M5_1;9 Z."SE8C S3!4NLB[=<Y -9^&&K1D+XUV-,],4CL4=0S$$B9)A66&*M
MX)CQUF:85EABK>"8\=9FF%;8?]+*=LQ)C(EIAB76S. 8N'V'8[IAB7736W ;
M%^87EM@OO[C^EGIB3,PO++%?4,SAG0?FER*Q7W#,./,4F&Z*Q+IY^SZP=5D6
MF&F*UC1Y?VU8P<H?2ZJO?G3KZTLNRQM#PD?W[C.>A-/)JI'RW-==JRO-J_X6
MLK]!/?D)4$L#!!0    ( !>(KU:*$X-D8P$  +<3   :    >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'/-V,V.@C 4AN%;(;T RSE5U(FXFHW;B3= L("1
MO]!.1N]^""[P([.8C>E9D99P^B8D3PB'+UMG_MJUKKKV+KHW=>M257G??VCM
M\LHVF5MUO6W'.T4W-)D?ET.I^RR_9:75',>)'EYGJ./A=69T?O3V/Q.[HKCF
M]K/+OQO;^C\&ZY]NN+G*6J^B<S:4UJ=*W^MYV^GI0JMQLHI.EU0-IPLI'3J(
M(8C#!QD(,N&#UA"T#A^T@:!-^* $@I+P05L(VH8/VD'0+GS0'H+VX8,H1AEC
M 4D+K 5H3<@U"?":$&P2(#8AV23 ;$*T28#:A&R3 +<)X28!<A/230+L)L2;
M!.C-J#<+T)M1;Q:@-R\^M@7HS:@W"]";46\6H#>CWBQ ;T:]68#>C'JS +T9
M]68!>C/JS0+T-JBW$:"W0;V- +T-ZFW>J;?SC]JZN>>YQO/?2;4?G[7S\=/R
MN;EX+Q/.&O[3'7\!4$L#!!0    ( !>(KU95*9*/B0$  %X4   3    6T-O
M;G1E;G1?5'EP97-=+GAM;,V8S6[",!"$7R7*%1%CIZ4_ BYMKRV'OH";;(A%
M$ENVH?#V=<*/U(I&("IU+K$2[\Z,O=)WR.1]:\A%F[IJW#0NO3>/C+FLI%JZ
M1!MJPDZA;2U]>+4+9F2VE MB8C0:LTPWGAH_]*U&/)L\4R%7E8]>-N&S4[J9
MQI8J%T=/N\+6:QI+8RJ521_VV;K)?[@,]PY)Z.QJ7*F,&X2"F)UT:'=^-]CW
MO:W)6I53-)?6O\HZ5+%-Q9S?5N22?HD3&751J(QRG:WJT)(X8TGFKB3R=97L
M1 ?]SC[<,.V>_&K_3J;/,%3.K38N3,S2Y7:'D;3=0Q.$R'K5?\2C8Y"^^GS4
M3CNG_$SO<+V?VBZ[>3C6+=??\?<9'_4OS"% <J0@.6Y <MR"Y!B#Y+@#R7$/
MDN,!) <?H01!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M (6N*0M84A:SI?Y+U0^OE7__Q:M>DEJHY^+/N
MM^+L"U!+ 0(4 Q0    ( !>(KU8'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ %XBO5F,Q1N[N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ %XBO5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  7B*]6SHYR5^,%  #Y'@  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ %XBO5GO<?(:Z!0  5A<  !@              ("!)@X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !>(KU:]P,B330,   4+
M   8              " @184  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  7B*]6&' ?<R@$  "G#P  &               @(&9%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ %XBO5B2FK%##
M @  X 8  !@              ("!]QL  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( !>(KU9]PAC'K 0  (08   8              "
M@? >  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  7B*]6
M31,]<>L%  #)&0  &               @('2(P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ %XBO5C5=J_BL"0  HA@  !@
M     ("!\RD  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M !>(KU9$3P6Y?0,  +$'   8              " @=4S  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  7B*]6K]][AE4(   Y%@  &0
M            @(&(-P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( !>(KU:[VA$)H0<  "T2   9              " @11   !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ %XBO5M]FL!NH!P
MTA,  !D              ("![$<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  7B*]67IOTCVD"  !0!0  &0              @('+
M3P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !>(KU8H
M#D"&L0H  *,@   9              " @6M2  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ %XBO5B_,*:D% P  3P<  !D
M     ("!4UT  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !>(KU;4^D3'4 (  #L%   9              "
M@?=N  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ %XBO
M5N(. 5FC @  D@<  !D              ("!?G$  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  7B*]6QBL>8? "  "R"   &0
M        @(%8=   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( !>(KU8&E!E?(P,  &$*   9              " @7]W  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ %XBO5I.N-&83 @  Z 0
M !D              ("!V7H  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  7B*]6QE(Q4PT"  ";!   &0              @($C?0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !>(KU; BA]4
M/ ,  !P.   9              " @6=_  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ %XBO5H/ Z _J @  ] L  !D
M ("!VH(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  7
MB*]6<(7HG4<&  "'*   &0              @('[A0  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !>(KU;*B26#) 0  &D0   9
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M;',O+G)E;'-02P$"% ,4    "  7B*]6X<\C60,#  #%%0  #P
M    @ 'HG@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %XBO5HH3@V1C
M 0  MQ,  !H              ( !&*(  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ %XBO5E4IDH^) 0  7A0  !,
M ( !LZ,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "@ * #/"@  ;:4
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>47</ContextCount>
  <ElementCount>209</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>13</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/OtherRevenue</Role>
      <ShortName>Other Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Leases</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Equity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Leases (Details) - Schedule of components of lease expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable</Role>
      <ShortName>Leases (Details) - Schedule of components of lease expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information related to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average remaining lease terms</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Leases (Details) - Schedule of weighted average discount rates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average discount rates</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/OtherRevenueDetails</Role>
      <ShortName>Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/OtherRevenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Equity  (Details) - Schedule of summary of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable</Role>
      <ShortName>Equity  (Details) - Schedule of summary of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Equity  (Details) - Schedule of summary of restricted stock unit activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable</Role>
      <ShortName>Equity  (Details) - Schedule of summary of restricted stock unit activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Equity  (Details) - Schedule of warrant activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable</Role>
      <ShortName>Equity  (Details) - Schedule of warrant activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10q0323_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/SubsequentEvent</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f10q0323_actiniumphar.htm 6578, 6587, 6588, 6589, 6590</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="f10q0323_actiniumphar.htm">f10q0323_actiniumphar.htm</File>
    <File>atnm-20230331.xsd</File>
    <File>atnm-20230331_cal.xml</File>
    <File>atnm-20230331_def.xml</File>
    <File>atnm-20230331_lab.xml</File>
    <File>atnm-20230331_pre.xml</File>
    <File>f10q0323ex31-1_actiniumphar.htm</File>
    <File>f10q0323ex31-2_actiniumphar.htm</File>
    <File>f10q0323ex32-1_actiniumphar.htm</File>
    <File>f10q0323ex32-2_actiniumphar.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img_001.jpg</File>
    <File>img_002.jpg</File>
    <File>img_003.jpg</File>
    <File>img_004.jpg</File>
    <File>img_005.jpg</File>
    <File>img_006.jpg</File>
    <File>img_007.jpg</File>
    <File>img_008.jpg</File>
    <File>img_009.jpg</File>
    <File>img_010.jpg</File>
    <File>img_011.jpg</File>
    <File>img_012.jpg</File>
    <File>img_013.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="293">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10q0323_actiniumphar.htm": {
   "axisCustom": 2,
   "axisStandard": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 293,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 47,
   "dts": {
    "calculationLink": {
     "local": [
      "atnm-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atnm-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10q0323_actiniumphar.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atnm-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    }
   },
   "elementCount": 300,
   "entityCount": 1,
   "hidden": {
    "http://actiniumpharmaceuticals.com/20230331": 2,
    "http://fasb.org/us-gaap/2023": 48,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 55
   },
   "keyCustom": 33,
   "keyStandard": 176,
   "memberCustom": 3,
   "memberStandard": 8,
   "nsprefix": "atnm",
   "nsuri": "http://actiniumpharmaceuticals.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:TradingSymbol",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:TradingSymbol",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:LeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://actiniumpharmaceuticals.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:LeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:OtherRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Other Revenue",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://actiniumpharmaceuticals.com/role/OtherRevenue",
     "shortName": "Other Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:OtherRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://actiniumpharmaceuticals.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Subsequent Event",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://actiniumpharmaceuticals.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "14",
     "role": "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://actiniumpharmaceuticals.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://actiniumpharmaceuticals.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash",
     "menuCat": "Details",
     "order": "18",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive",
     "menuCat": "Details",
     "order": "19",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atnm:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atnm:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://actiniumpharmaceuticals.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Leases (Details) - Schedule of components of lease expense",
     "menuCat": "Details",
     "order": "22",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable",
     "shortName": "Leases (Details) - Schedule of components of lease expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases",
     "menuCat": "Details",
     "order": "23",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable",
     "shortName": "Leases (Details) - Schedule of supplemental cash flow information related to leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "atnm:ScheduleOrDescriptionOfWeightedAverageTerm",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms",
     "menuCat": "Details",
     "order": "24",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable",
     "shortName": "Leases (Details) - Schedule of weighted average remaining lease terms",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "atnm:ScheduleOrDescriptionOfWeightedAverageTerm",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageDiscountRate",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Leases (Details) - Schedule of weighted average discount rates",
     "menuCat": "Details",
     "order": "25",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable",
     "shortName": "Leases (Details) - Schedule of weighted average discount rates",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageDiscountRate",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c34",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities",
     "menuCat": "Details",
     "order": "26",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c34",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:RevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Other Revenue (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails",
     "shortName": "Other Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:RevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c43",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:UnrecognizedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Equity (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://actiniumpharmaceuticals.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c43",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:UnrecognizedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Equity  (Details) - Schedule of summary of stock option activity",
     "menuCat": "Details",
     "order": "29",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
     "shortName": "Equity  (Details) - Schedule of summary of stock option activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "atnm:RSUsOutstandingBeginningBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Equity  (Details) - Schedule of summary of restricted stock unit activity",
     "menuCat": "Details",
     "order": "30",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable",
     "shortName": "Equity  (Details) - Schedule of summary of restricted stock unit activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "atnm:RSUsOutstandingBeginningBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c44",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfWarrantsOutstandings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Equity  (Details) - Schedule of warrant activities",
     "menuCat": "Details",
     "order": "31",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
     "shortName": "Equity  (Details) - Schedule of warrant activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c44",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfWarrantsOutstandings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:SharesOfCommonStockValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Subsequent Event (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:SharesOfCommonStockValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c14",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c14",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0323_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 13,
   "tag": {
    "atnm_AggregateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of aggregate fair value.",
        "label": "Aggregate Fair Value",
        "terseLabel": "Aggregate fair value"
       }
      }
     },
     "localname": "AggregateFairValue",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement Axis",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_CapitalOnDemandSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital On Demand Sales Agreement Member",
        "terseLabel": "Capital on Demand Sales Agreement [Member]"
       }
      }
     },
     "localname": "CapitalOnDemandSalesAgreementMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_CompensationExpenseRelatedToStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation expense related to stock options.",
        "label": "Compensation Expense Related To Stock Options",
        "terseLabel": "Compensation expense related to stock options"
       }
      }
     },
     "localname": "CompensationExpenseRelatedToStockOptions",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_DescriptionOfExercisePriceRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of exercise price range.",
        "label": "Description Of Exercise Price Range",
        "terseLabel": "Exercise price ranging, description"
       }
      }
     },
     "localname": "DescriptionOfExercisePriceRange",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash [Table]"
       }
      }
     },
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsScheduleofcashcashequivalentsandrestrictedcashTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Descriptionof Businessand Summaryof Significant Accounting Policies Tables Line Items",
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies (Tables) [Table]"
       }
      }
     },
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTablesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "EquityDetailsLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "localname": "EquityDetailsTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_FinanceLeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Cost Abstract",
        "terseLabel": "Finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCostAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_FinanceLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liabilities Member",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_GrantOfStockOptionsToEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant of stock options to employees.",
        "label": "Grant Of Stock Options To Employees",
        "terseLabel": "Grant of stock options to employees (in Shares)"
       }
      }
     },
     "localname": "GrantOfStockOptionsToEmployees",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_GrantRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Revenue Policy Text Block",
        "terseLabel": "Grant Revenue"
       }
      }
     },
     "localname": "GrantRevenuePolicyTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_LeaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Axis",
        "terseLabel": "Lease [Axis]"
       }
      }
     },
     "localname": "LeaseAxis",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Details Scheduleofcomponentsofleaseexpense Line Items",
        "terseLabel": "Schedule Of Components Of Lease Expense [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Lease Expense [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofcomponentsofleaseexpenseTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of maturities of lease liabilities [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of maturities of lease liabilities [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Details Scheduleofsupplementalcashflowinformationrelatedtoleases Line Items",
        "terseLabel": "Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "localname": "LeasesDetailsTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Text Block",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_LicenseRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Revenue Text Block",
        "terseLabel": "License Revenue"
       }
      }
     },
     "localname": "LicenseRevenueTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_LongtermLicenseRevenueDeferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of long-term license revenue deferred.",
        "label": "Longterm License Revenue Deferred",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "LongtermLicenseRevenueDeferred",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_LongtermOperatingLeaseObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term operating lease obligations.",
        "label": "Longterm Operating Lease Obligations Noncurrent",
        "terseLabel": "Long-term operating lease obligations"
       }
      }
     },
     "localname": "LongtermOperatingLeaseObligationsNoncurrent",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_MaturitiesOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of present value of lease liabilities.",
        "label": "Maturities Of Lease Liabilities",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "MaturitiesOfLeaseLiabilities",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_NatureOfBusinessPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of Business policy text block.",
        "label": "Nature Of Business Policy Text Block",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfBusinessPolicyTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_NetProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net proceeds.",
        "label": "Net Proceeds",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "NetProceeds",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_NumberOfWarrantsOutstandings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares, outstanding beginning.",
        "label": "Number Of Warrants Outstandings",
        "periodEndLabel": "Number of Shares, Outstanding Ending",
        "periodStartLabel": "Number of Shares, Outstanding Beginning"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandings",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of lease liabilities.",
        "label": "Operating And Finance Lease Liability Maturity Table Text Block",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_OperatingLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Member",
        "terseLabel": "Operating Leases [Member]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_OtherRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue [Abstract]"
       }
      }
     },
     "localname": "OtherRevenueAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_OtherRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Revenue [Abstract]"
       }
      }
     },
     "localname": "OtherRevenueLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenue"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_OtherRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Revenue [Table]"
       }
      }
     },
     "localname": "OtherRevenueTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenue"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_OtherRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Revenue Text Block",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherRevenueTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_PaymentWithImputedInterestPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment with imputed interest premium.",
        "label": "Payment With Imputed Interest Premium",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "PaymentWithImputedInterestPremium",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_RSUsOutstandingBeginningBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RSUs Outstanding, Beginning balance.",
        "label": "RSUs Outstanding Beginning Balance",
        "terseLabel": "RSUs Outstanding, Beginning balance"
       }
      }
     },
     "localname": "RSUsOutstandingBeginningBalance",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_RSUsOutstandingEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RSUs Outstanding, Ending balance.",
        "label": "RSUs Outstanding Ending Balance",
        "terseLabel": "RSUs Outstanding, Ending balance"
       }
      }
     },
     "localname": "RSUsOutstandingEndingBalance",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_RevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue recognized.",
        "label": "Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueRecognized",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_SalesOfSharesOfCommonStockNetOfCosts": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sales of shares of common stock, net of costs.",
        "label": "Sales Of Shares Of Common Stock Net Of Costs",
        "terseLabel": "Sales of shares of common stock, net of costs"
       }
      }
     },
     "localname": "SalesOfSharesOfCommonStockNetOfCosts",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Abstract"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfComponentsOfLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Lease Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfLeaseExpenseAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Anti Dilutive Abstract"
       }
      }
     },
     "localname": "ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Lease Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summary of Restricted Stock Unit Activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfSummaryOfStockOptionActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summary of Stock Option Activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSummaryOfStockOptionActivityAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Abstract"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWarrantActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activities Abstract"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWeightedAverageDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Discount Rate",
        "terseLabel": "Schedule of weighted average discount rates"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRate",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_ScheduleOfWeightedAverageDiscountRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Discount Rates Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Remaining Lease Terms Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOrDescriptionOfWeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Or Description Of Weighted Average Term",
        "terseLabel": "Schedule of weighted average remaining lease terms"
       }
      }
     },
     "localname": "ScheduleOrDescriptionOfWeightedAverageTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Granted",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance",
        "verboseLabel": "Weighted average remaining contractual term (in years), Outstanding Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_SharesOfCommonStockValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock value.",
        "label": "Shares Of Common Stock Value",
        "terseLabel": "Shares of common stock value"
       }
      }
     },
     "localname": "SharesOfCommonStockValue",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_StockOptionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option, Description",
        "label": "Stock Option Description",
        "terseLabel": "Stock option, description"
       }
      }
     },
     "localname": "StockOptionDescription",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_StockOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option term.",
        "label": "Stock Option Term",
        "terseLabel": "Stock option term"
       }
      }
     },
     "localname": "StockOptionTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_UnrecognizedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized compensation expense.",
        "label": "Unrecognized Compensation Expense",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "UnrecognizedCompensationExpense",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_VestingPeriodOfStockOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of stock option.",
        "label": "Vesting Period Of Stock Option",
        "terseLabel": "Vesting period of stock option"
       }
      }
     },
     "localname": "VestingPeriodOfStockOption",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_WeightedAverageDiscountRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Discount Rates Abstract",
        "terseLabel": "Weighted average discount rates:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Lease Term Abstract",
        "terseLabel": "Weighted average remaining lease term:"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_WeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average term",
        "label": "Weighted Average Term",
        "terseLabel": "Weighted average term"
       }
      }
     },
     "localname": "WeightedAverageTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20230331",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r114",
      "r193",
      "r391",
      "r406"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r114",
      "r193",
      "r391",
      "r392",
      "r406"
     ],
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r84",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net of accumulated depreciation (in Dollars)"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r45",
      "r373",
      "r424"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r291",
      "r403",
      "r404",
      "r405",
      "r412",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r6",
      "r27",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r67",
      "r85",
      "r100",
      "r126",
      "r140",
      "r146",
      "r151",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r212",
      "r214",
      "r226",
      "r262",
      "r318",
      "r373",
      "r384",
      "r410",
      "r411",
      "r417"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r81",
      "r86",
      "r100",
      "r151",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r212",
      "r214",
      "r226",
      "r373",
      "r410",
      "r411",
      "r417"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r17",
      "r83",
      "r362"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r18",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r17",
      "r55",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "auth_ref": [
      "r17",
      "r55",
      "r98"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r55"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r394",
      "r420"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r40",
      "r263",
      "r305"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r166",
      "r167",
      "r359",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r403",
      "r404",
      "r412",
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r44",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r44",
      "r306",
      "r324",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r44",
      "r265",
      "r373"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 1,000,000,000 shares authorized; 25,729,370 and 25,674,823 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateAndOtherMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate and Other [Member]",
        "terseLabel": "Corporate Office Space [Member]"
       }
      }
     },
     "localname": "CorporateAndOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r4",
      "r25"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation &amp; amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [
      "r296",
      "r297",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r350",
      "r351",
      "r352",
      "r353",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r39",
      "r296",
      "r297",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r350",
      "r351",
      "r352",
      "r353",
      "r363",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNetAssetsPercentage": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r376",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of value of derivative contract to net assets.",
        "label": "Derivative, Net Assets, Percentage",
        "terseLabel": "Net sales percentage"
       }
      }
     },
     "localname": "DerivativeNetAssetsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r93",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r115",
      "r117",
      "r119",
      "r120",
      "r121",
      "r123",
      "r224",
      "r225",
      "r259",
      "r271",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock \u2013 basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r93",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r117",
      "r119",
      "r120",
      "r121",
      "r123",
      "r224",
      "r225",
      "r259",
      "r271",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share \u2013 basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r20",
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r6",
      "r77",
      "r89",
      "r90",
      "r91",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r124",
      "r152",
      "r153",
      "r190",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r254",
      "r283",
      "r284",
      "r285",
      "r291",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r239",
      "r246",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r241",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flow use from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance leases current liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r240",
      "r249"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Financing cash flow use from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance leases right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r239",
      "r246",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-to-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r252",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r251",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52",
      "r328"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r16",
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Other liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income - net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r94",
      "r96",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots.",
        "label": "Land Improvements",
        "terseLabel": "Landlord assets"
       }
      }
     },
     "localname": "LandImprovements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r245",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Current annual rate"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r100",
      "r151",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r213",
      "r214",
      "r215",
      "r226",
      "r304",
      "r367",
      "r384",
      "r410",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r49",
      "r68",
      "r267",
      "r373",
      "r402",
      "r408",
      "r413"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r82",
      "r100",
      "r151",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r213",
      "r214",
      "r215",
      "r226",
      "r373",
      "r410",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided By / Used In Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided By / Used In Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used In Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r51",
      "r57",
      "r69",
      "r80",
      "r87",
      "r88",
      "r91",
      "r100",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r118",
      "r126",
      "r139",
      "r145",
      "r147",
      "r151",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r225",
      "r226",
      "r270",
      "r326",
      "r341",
      "r342",
      "r368",
      "r382",
      "r410"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r126",
      "r139",
      "r145",
      "r147",
      "r368"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r247",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating leases current liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r242",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flow use from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating leases right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r252",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r251",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42",
      "r58",
      "r59",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r1",
      "r50",
      "r227",
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestrictedAssetsCurrent": {
     "auth_ref": [
      "r357",
      "r358",
      "r398"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.",
        "label": "Other Restricted Assets, Current",
        "terseLabel": "Restricted cash \u2013 long-term"
       }
      }
     },
     "localname": "OtherRestrictedAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r43",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r43",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r43",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r43",
      "r306",
      "r324",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r43",
      "r264",
      "r373"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r10"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r261",
      "r269",
      "r373"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $536 and $487"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r41",
      "r209",
      "r419"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, net of reimbursements"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r394",
      "r401"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash - current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r71",
      "r395",
      "r401"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash \u2013 long term"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "auth_ref": [
      "r348",
      "r349",
      "r354",
      "r357",
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of all restricted investments.",
        "label": "Restricted Investments, at Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "RestrictedInvestmentsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r46",
      "r63",
      "r266",
      "r286",
      "r287",
      "r289",
      "r307",
      "r373"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r77",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r152",
      "r153",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r216",
      "r218",
      "r219",
      "r221",
      "r223",
      "r283",
      "r285",
      "r291",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r138",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150",
      "r191",
      "r192",
      "r258"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r327",
      "r361",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r92",
      "r100",
      "r127",
      "r128",
      "r138",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150",
      "r151",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r226",
      "r260",
      "r410"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r250",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r250",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate value of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock, shares (in Shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of diluted net loss per share anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of summary of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r8",
      "r9",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r369",
      "r393",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Expected term year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Exercise Price,Outstanding Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning",
        "terseLabel": "Weighted Average Grant date Fair Value Per Share Outstanding, Beginning",
        "verboseLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Number of Shares, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable",
        "verboseLabel": "Number of Shares, Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable",
        "terseLabel": "Weighted Average Exercise Price, Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Cancelled",
        "terseLabel": "Number of Shares, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "RSUs, Granted",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value,Outstanding Ending",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning balance",
        "terseLabel": "Weighted Average Exercise Price Outstanding, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "verboseLabel": "Weighted Average Exercise Price, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, Beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Grant year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Exercisable Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding, Beginning balance",
        "verboseLabel": "Weighted average remaining contractual term (in years), Outstanding beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "RSUs, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r79",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r369",
      "r393",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r6",
      "r15",
      "r77",
      "r89",
      "r90",
      "r91",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r124",
      "r152",
      "r153",
      "r190",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r254",
      "r283",
      "r284",
      "r285",
      "r291",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r124",
      "r258",
      "r288",
      "r292",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r124",
      "r258",
      "r288",
      "r292",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Sale of common stock, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r43",
      "r44",
      "r63",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Sale of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r15",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r60",
      "r308",
      "r324",
      "r344",
      "r345",
      "r373",
      "r384",
      "r402",
      "r408",
      "r413",
      "r425"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r32",
      "r33",
      "r35",
      "r77",
      "r78",
      "r90",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r152",
      "r153",
      "r190",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r230",
      "r231",
      "r235",
      "r254",
      "r284",
      "r285",
      "r290",
      "r308",
      "r324",
      "r344",
      "r345",
      "r355",
      "r383",
      "r402",
      "r408",
      "r413",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r99",
      "r177",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r222",
      "r346",
      "r347",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r248",
      "r372"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [
      "r236",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEvent"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r236",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEvent"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r255",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r72",
      "r73",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares of common stock outstanding \u2013 basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(4)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r388": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r389": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(3)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001213900-23-039902-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-039902-xbrl.zip
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MK3L#ZT[T::.W:,(1T9"V[*_4%X/CKI0+];H)-U3J<I";=*E1!SVD7^1LEA\
M8'VM,(8XJ]F4.LZYSH*TB@FSG.'>!ZSGC/G%%U5)CXITSI9/',(<LMQEJ]&-
ME)Y4(8Y#7?]@HL)K@-*I"/U=H-LH9N/WT[ET[4W:*W2S=X#"I77BXP;GN_%T
MT4)EMF$XTO)8#/;E]_O4- +8XV9HY$RJ(2KFTYPR1G@PY/+C/!B&YJJ]&AQ2
M:3*.Y:YC97 FF?# 98%\:0OYJ".E19$%L'8]L1!A2##?Y$-$DQSD^VA4+Y5L
M#Y.]8%M05=ZE*GK@323B9F$DN*'LCN=VT(GN^J:%*)^VQ+S(!84RWEDR27I
M\?N\CZJ-+F2+ '^(8@Y%FP'OP23P#>:"-36+U#AS)'CCXA%@HH#?M.2R5TSP
M=TBLRMI26K/_)$*;-"MF!OQU996& (067/P> Q=U3&2F_@9,^&G*1*;J1H0O
M/ L:CN*9<^\PZ&$=<XP22H9<%!P001],CE@+3.4",QE[W32D.V"]*5KW&5=D
M//.)PP/HTJII,C0$*$L[?=Z/DR#$O-.+0X-JPNSXJDH]V]N/''^XO%8V!\;8
MY()KNBL<ERZN8^W&2,QKG2O41T*RUD8C1&(O?6U+SU#\<<-[!PRO2!,&::?@
M?&>2 4?4V QMS9Z.!X[-S&M5XU' #B,O2X%E'?7PP,0973K<A-^'IBXD,KEZ
MY=.8?=]%P6'EN+EO.F*3*%.[:4@W@_.F:*OBMHM,K!E<S30,DR0&_([X5*>D
M_4#?A23FFD]%T["T%.@M@+4&J0$+<Z#'7>7TT))ZR-R/!4^0X@R4;<0!)DB[
M!I2(^,PJ$-J&Q -I8K[$$,=?APM4^![BTCZX>=2&#LZ7*T1+?'X+5)=RG6A?
M.#P2;K],.^HD@KGA;)H2K682F>P@ N-?W?AI>H><^ (7..N\EUZZM?*NXI^K
M6T=#+M_PO,CVR:&H\6JQRHK;_5=B#]IQ<F34!:W2X:C YPOFPYK-N.@Z%0CH
MMCPI*&O+XI_V"";)]"*4!:GFC=ML;DZ%$>",N=#1L7NZ7%K.O3?NM=ZF<'5U
M:O3/+_?=H[_^?(:6/7DA1Z?:['@T>)F2IRM[?'-,3X]O2]^>'J=,/Q[!64'_
MS%7>09]GQ^7ODR*\XX77>KW4N55'DVKMI3#2.K1W1-CC:[TXG+!&H]SA]1*Y
M!W6,2E^^V;U'@NZ'#5X=FP_VK=7]7OV&+/OJYO7SJ&!77D1'BL4KW)[4QYW;
MDT;WR&@/1C?]3V.]:@VA5NBHIQ#@T4>$M4'[&;R>SBK/VK>'_NMOF'V:%+NS
M[NO),9H.FS-S $NMYY)6?'X]&>N_7=6[U6I3;Y6>F[7NL7'R2'N5<5F%$\-X
M(K,;//O4YB^&=5J=_&Z(\#*^'0X^]=L?87_0U+HS_=F>3*_YM?[<);46[<VF
M]>'=\?#C_?CBXB^EUFG/S\QFT[.WO<IS/CIHYV!QFB3N2+DK/[*I;<20P%2>
M$+L2<.FF<QA@(3?^?7H?7>DN#3PIV]JW]P/+*_!%X65^:ET7FBJ:(:9XQJ5Y
M(Y0,,T':4IV@]J(F$*^@O:?,]NR0.7@M \T?- FO+)W'RSN3)1;3UC1D)"3L
M]MF%'[]U9^;[X.*(N^,E?\",^& 2<].49 *9MY[H!8 &X4B>]]^0%_^)0D\U
MZ8Z"0.;6_<@;JI@7!4)F8I%H4W;J10G7KKH.WO5F&8Q%@1WQ<37?V3O5HLKJ
MBE.TDX$"%"FA1<T1%O94IT],%FI6G%:$+:,DCE*$4!P]ZO^C1FE('C<\?Q.H
M&._B=(0/HZI8Z&KRZJL83$Y'XJZBN"M)/]X<0(D7<#%OEUXABR*(Y\B(Q8MA
M4HYG29#DI^E=,^4+H?>-G8BY(*2R;'2%YC\;I *A:1.^/(HJ#8"0VDA+[A1<
M1"-2SB,/XC@J[E[[M+%QOZ5Q>6_LQZFHM_6",.;\=/X0B@NO:P7Q>$:RIS.#
M];WS?&@/0!?\?3P@1W+.,>ZJ<C_%OC. /0YXAI'W3ED*C]N"K.-8=E=V-2_N
M[BY]Q/4.;^)#<"\C?JZ8NQ_N"_)/8JHDNO>A04:(I;%@=E,<N7,BF7'.RSR:
M%?BWC2GRO*X;<^="*,[F6L&'_XTSQR$ WEV%YR,OPSVLGM_)2<%KW12']EIG
M'N@ ';%FWUDNBY]KYXN%:OD[VXZ]'A/G7H)2W8@,3^)JMMP/I1CK/L)(B)#&
MY+:AHZ=I.;<RKB>(0LQ^5#[C>Q]"@+ZL)CL!](4 U*,T=.C=QA;%PCY+GA6?
M!Z^8J?/7E<F,94_. E#TWB2/^H:JK9<L;;[G0<PNFP_66K80Q::VFV$M]O:O
M)W (R "U 4?7_3Z"<<__;VQ\V@<OTN%JJ^*_=RJ>P;V\S +HF@<&'.[[%\"@
MT.I914]C]S7*NQDC%O8.8ND*,\MD0+^AIFVMR!%/H7,5PD;:8K2++")+X3R4
MW0?<JWGK5SD&O</QO4:#*'ZV_8+(?]\,^=/2&_*MDY%.A\IRWP\]2;YKTE=5
MZDO,5(GV9\'WU95N<_CYZL7?TBO^#U!+ P04    "  7B*]6W7P1;Y@G  !3
M80( %0   &%T;FTM,C R,S S,S%?9&5F+GAM;.U=;7/<-I+^OK]"I_MR5UN*
M+#E>QZYXMT9OCA);H]-(=N*MK11%8D9(..0$)"6-?_T!?)GA*P"":(*4575[
ML641W7BZT6@TNAL__NMQZ>[<(Q)@WWNW>_#=B]T=Y-F^@[W%N]V;V=YD=GQ^
MOONO?^[L_.W'_]K;VWF//$2L$#D[M^N=8W^YFMEXYYI87C#WR7+G?\+E_^[L
M[=R%X>KM_O[#P\-W-OV=P,8$!7Y$;!2P'^SL[=$!LR&/"6(#OMWYZ'L['ZWU
MSL&KG8,W;U\<OGWQ<N?F^GCG\,7AR^23O_WH8N_/6RM .Y1O+WBWFZ/T>$O<
M[WRRV#]\\>+E?O:+N\EOOGUD/RC\_L/+^+</WKQYLQ__Z^97 USWBW38@_U?
M/WZ8V7=H:>UA+P@MSV8$ OPVB'_XP;>M,$92R-=.XV^PO^UEO[;'?K1W<+CW
M\N"[Q\#9L$A_QPDW9/(#O-I/_G&7X;6S\R/Q772%YCOQ%-^&ZQ5ZMQO@Y<IE
MG,<_NR-H_F[7"KWE'H/ZQ<N$UG^SG_Q.?C_VO<!WL<.$=&2Y;,ZS.X3"W1TV
M],W5^88-RPZQAZ/EZLXB2\M&48AMRXU%OL]^=[]QJ/U_PO+Z^Z5%D!?>H80C
MC:R71X:8R3E=D4LT"^F?EY161^[+H^U#*$J)B%[\!8-KF]",,H/N?->A]O'T
MKPB'ZVLZR*%/7BI,@#/8?FP-]0OAV KNSES_H2/<FV%B/K5P>8("F^ 5LY7^
M_"@*L(>"P/*<6;1<6F3MSV=XX>$Y9<H+)[;M1Q[E=W%).;(Q4E&?C@0UKI'E
M$H=,:QEUBC(C0W=<M5GQ1M/&\@=$]R$5[M(/=6KWE*YR<H7ND1<A!8X*GVL#
M*%G-"NRD'^H$:!;=!NBOB&K$Z;W:5E$>0=^BKZZKHW7\)Q7L.(/IQ+.;W;BV
M;ET#YBHEF^"@T08H3Z?PN>9UI\Q4X7-]/@,]"#B1B_RY3;=-]C^ZF/"]Y:9&
MFAZ$0H)MNJVR?XNIJRQ2!2I:S<R&OH/=B)+Q4.CZ0;"BS@WS<ZA:XOA?\#WJ
M/D=9&KI\[QRZ]/3J>PQ4?^XR)4:/*^0%&N;$'UG_3()H13]CKH+E,IV84X<.
M>^S0'I]8"7*9JQ?Z[G:I=IJ?"CT8#7U >'%':5GWB%@+1.@YG4["6\240T26
M&F8K2T._7$N4'1S$NP&+T>B?5\WH&C>9+5FJ(Q'!(=W*TL7A8NL6N_%/ND]*
M/#K(I()L[PY"W_[3CS=WQO5]M@MU7&^BT6$GM=UQ8@8B#X< DQ-2 3(A%B%T
MNTE):5'"AB'[.&B>H-#"BD$8X:"Z+%SB,JJS6OQ>H^[GSY#J[-6-H@NZQ+%5
MYZWXO4ZS43Q:JG/8,%#WQ7/BVQ%3[XGGG%+E#M?G6Y=%Y1C'&R[CUB*V+,,-
M=P99R)]=%KR*Y^%@2I;=Z>PY:&Y%;KB[DY+)\[\9 WOA/OUD/_V=_>KGJ6X"
M\^HSMTF9U>3KK;Y",'M'AR!V=(OV-H3;\5LW0&[3 @$X!F9OB9:WB+1$M_#I
M)A0$P:7ENNUX8Q]L.*)Z2I<B6U<?*.T"5^@Q1)Z#G(PO]K&&*ZM,S2AQU[<+
M%%UV#>B3C*!KW2+WW6X4["TL:_7[YMYB.C_#'AT06^ZE'\3,3VZI?T-YJF(8
M9%#,K> VQB,=;Y\9L'WDAD'VD]BDQ9BV(IDL\=;3F03TA!,<1X3=P0#Q7T]C
MP_!6^!-29)WJ2L9*JC9M=3[]>D[\I9H(0U^(E4\<1-[MOJ"?Q(OBK>WZ 7+>
M[88DRKNTK67#;F[HWL/^<[J-#TW"8^I\KJGK]LERHYKUVDE6<C2SA6M">ER-
MS8M+$CZA^%1$=[4YZ3#R*;.:155/P]RRDA9, SBI( ZTKZ-+@E86=DZ3$!U5
MB=A]+["K630R%/=S6]!P926%72JY0Y[D.F].D)M24;MZET8+!6W<CX ,V27Q
MJ<<;KB]=*SD(44NZ8GOG!=*_:#BDS I(U6/@HR<V>-VWG@O?LWO8?7)DMGR/
M1DS-D$E8-A4935<L#9/Z('&<ZXI%Z:?S&[KTV8K6+"@^K1%*2P!>*K*7FD66
ML(AZ$!B/DDG'6U5>7.12:7VO==-*-D80AV&TQ]8-U*^T^]<?MA=PL($$#J'Q
MB86'6BJJ?V@7U84?HN#26K/;*AB_NHZ"P4U&K)MYF=3"(Q'?Z>X#9'RN8:0B
M(&;T+-I.1"+89*((7?=_8&%Q29D]"+63%1\SL6^M9S,"WX0,RT1&,_D;CUP,
M6T4:)VB.* EGD_2M513ET4=DQBK 2!Q;6DD@OK3_X'L+EK]6-)K36Q<OXEOL
MH"D\T) $T&:\,1BJ]B )SRO=?6@X>S5N+WD#_FO]-VW;S*A)I:Y'[_T:A](8
M#_=<Y%)Y_:#U<#]CJ8.%2CRP:_=&0N-;1SS44C&]@;AX2W:YF#K$=74=!:,A
M39%NEN[6JO  G3;9.O4],#E4AC>Y0MK(H(H+V#7TQ'%B'.B"M;!S[AU;*QQ:
MKNXP90,5TQ=H;832B!3,D?&*):!ZR#FU"*OZ"":V'2VCN,*%NNG8QOKOSH0$
M1V/$9, #NI*I,@KN 1A>1O*:RM_[ 9/6<@X[=0C!120D-T:G6HQAMDEQY,?R
M:O>+B;7;1.7>$V[+73Z>\V_3K2Z_@E<$T;'9L/3/+HK']YS)TB<A_AK_O#&A
M1+<7H8NM,2X_?3(!2LG*'QOHNIJ2>*9.[,!>(A+WJ@$]:#42->UEJJ9IR2$*
MD[!5I!Z3"B91>.<3_'5KAD'D6"%F-(*N1WQ5 *'24^OHG@=!U(O04D+CBT3Q
M4).Y!-$FJFD4LAZ K%EB#_+*4WL:0BO@)W,OTC5PU=-6)T-QE'92"DJ9++&.
M<@3>XGB4QNB.<I$39HIID17(KM9$99P^9"-FXDM++2*"V\VXI)Z(L.KVLN9K
MRP'$5LIM8!75J#0,4 "EB4H'MR#-FPF .*X,;\YE$XBH&(LO@R(.\W8 _XSR
MR6[\&:G/.+P[CH*0LDHHQV[$EA++/*?_YUQ;CS#R:<6!.1$V*6N-[-IA"A;%
MGT6W<6^M1/ETQU.+@QN\ZI(13!D*B?OA+@8-R) 9O[B27@$!U#7O)K\OK;.%
MVCN:Z1@]-;;81SA(";5?L605T9FP;@TG5 E</PZ?I\2U+P@>+8.V2*B>I8I5
M'F(PVW[R>HC+KC^<)06'L<?:M\((2D3-W';>2E)"T* *5BI<0ILYH\&55C*I
M@4;FCJ";&!+[^\$/P 21HV#0CJGL,WELP"1QX7M^D6#6< /&#Q#3,^N3M1"4
M!'2ZZU>V7(:(]8TMD-7??*21C,&5)*VP>5$UXP5V6&SDLZ\%9=:Q5A(3!S,0
M%YMJ -@&5!Q[/$:M" E495>6JYE=L1U9 ;8U2Z">QBABE@WPB*\A563Q.6V(
M/TD:XE]$; K3>>4. $)&[6B/)530$E&9Z\IAW:S4)*Y^4Q<MY?5YDKSF FS
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M%H1-+E[UE5!HH=T"9;A6#=)3,;:8GX*=KL53(@-&HTC3?KCF[#2/@:=@I[D
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MN\V%;J-,-9/KUQ6N<M%JX=9_V?\NHPIY*Z_,T"I.FL$I=^0N=Y6[\$,HCTM
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M1L*X(*QIS1L T'6C.73(Y_G"6B+Y*&+G!9LC9RBPV*/I$VM,'GVHS H19;G
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M9;!1&/TJ!!G,^O+RMZMFXCB$'MG2_S"F>)FXLO:D;M31&/A:2#(9<.]J.XF
M+:TIN?8?>*T36@H@-^88'/Q&/#+TM5_3IK3B;7Q*+HE_CSWN2[ M!5 >>'12
MJ""3B4+C.;= \-(/0LO]@E>:O,[:84>Q$?!@R:3 +1-O+8@9LB-":1X<WE[C
ML&/.7V6P48!>A2"#6E^A>)[.Z:-]QXHT.J?SU0XX@CVW'H@,=.XY5_68&R*6
MG8SOT8D56N(7/^3/M[4#C\?D-R&3"8-_<=N0I_WC/J/$2M38K_T_4$L#!!0
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M87!X1AV.^1ZF?M>>>ZW7.,U!%^>,=Z[ILA7FJ+^1K>#=U2H!0IV_SK]$.>\
M\>_/OWW^_ !M@PS=TW&_1R^?[SU_SOZ/<MX>(M@5=VD6_8K#/53],,ISZIYE
M^>_R]A% J>\JAG=2W:4$&Y42W9SR(LC.,]99.62S7^",]::85?J4B\*D2=N
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MJ7.7L@7(6(?-.BEKTL=92?T)TU[EY'"\)XKP+?ZTV]S@['S=2W>;XXP;MC:
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MB<V!0W[ "[MD%K5L:A!A"N4FQD*KE?$!X#?L3+(UI2-*2=JQQ6VC80*Y6SU
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MB,I._2$D\FN"ED^0BGUYK.^75'Y=GD![Z+C;+0FFV8,,"1DC=.CZW#-M&\=
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M'CHJBBRZV16LKVJ1$KTDZSS7"W5)M-!07@H29/W>UQ=9NL(XS&GKU4&9!N5
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M;W&UW[\!4^(=R=#C\2ARBNTIB/"!3"R4/?(3\@^JO-,O_C]02P,$%     @
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MC]I*1(,-=QE\V\4-)I%'P\WV$LWFDLL5CEB:UQP'5)-)%]"R%SJ7D^O\N?V
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MP@XV@"<]"_0J"W0G0(8Y$- "%:G<AP=ZB'YERQR6A]STR]S-0L@[FNC2M;[
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M<6'GATU699<<X0H'*8 H4'Q@V+7J/?OJO7"?IOO ,&]<@.S&0T#8*:>U>I-
MM'>RS^-DI_^8S+9^/5 .0KKHJUV1]!N6IWD,-^L9'H%+O5"X$ RN'R^_P<V3
MN7PQ(*C#W[?+F\<5=?E;5]3!U)BVQQ[E@8G(0I&.X1+]P307(XZE#;1[DO7,
M9R[2YP<^'YB^J 2 <6XR0)$43OB>1:X9638,5 'YBY[P!K8KRE##BI5CJT2E
M!DP+%RJF.!0U9&RJY<<-SW6&S$7Y#2L2@!)$F<J)%XZ8RSL\"$Q_B-&\L*X
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M[;]'V"'HTMKR;0RW/+%VM=+Y\5ZT63F)*.[ ZJ7JV6L)%)F+A @=9Z_;S"=
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M?3;;._3:\'TQ0.60F':,\BON+RN@C+#T(. @#9BNQ1S;;-O.GKUO+66[\_G
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MR"3,AG?^&[D=S3=I5C7%S $)5:1%!E@T!P1%.FJ"2* OYH6@)(C1M=,/> .
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M$Z75*_SQ;U$(<CP\B:0?4YWC),(+(;JI3LQ7?[NXOU!]F*GV0V2#I!W!/,8
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MKP" S1YW<RZ>I#<GEES07D@!@R.A-*MH43#-X+\YO4GU59RB;!_/-I1MIM-
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MJ,R^$JJ-OHE";! YH1(&,W:;EGE?;*UM1[3?-JG:*.,3!.B*J]E ^4<_1DK
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MFOO:3:D4FTD=<%,UG4KH+.8#$7PT@ %)2%7M<'>HD;20VU%0%)+[VZGFI&N
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M[KAC=ZD@Q8E"NL-&XM=G#R BRB8EQCNK51HT'OS1_*5D(!P/FT?L3^Y[\;M
M^K%&O!54QIG'FTS@.EN8;9UN('U/7V,BUEA87EYZPZ9,?*).7FP.HCH?;4Y_
M]3U02/^4-:<1EVTJ<XV(@77\TA1-]A6(W$35IDY"0E,%H,>+0QFSRV^-4)@Y
M*EY]3ZPG*3!>BM5,SKX_SZAXI0L/)#HM1"[" 8$DX%J2A42Q^*&Z0Z*VF@2
M!*?)7E0>C2DS: KB"2-:A&!/C<J8IB#9 1L5;XPI69N$+F.U7..*>)DGGH!6
M,FDT3^F%A<\]XZSOQ3(>O:0TM&!' 03#C*8'U4TN?5Q;44LO&?$5=H9OM;S+
M^<)$_&R%I=#L3UC"".XFWA:1+H^%;U><++\UAU*K+GPJY]N4&>_'ARCH'=[.
M?8I\?CRH+5X!K[K2)/GX>M+2Z'*2<6F?,;^BC/D=2IB_?_B^3Y(7G\CLQ+!0
M,4/-7B0UJXQY$'[I=A67-;^A1.?3DU><Z+R0>T]T[8)[D-C]9PZ\"+T8GT7%
MZDR7D8[PJL_VU.U<%NPV^4]G1HS<>%*A'5$CZ4I_R33538L3+C(#?<5MZS>>
MI)FW77-C8KOF33G[\JZ\N>#*-QTU+-G0'"CS3[I#.Y^6DOMDCXMM(;X38?&Y
M@7.R<_W5]Q'RJQ"%+H5 5) <])8#;-^RO%1 '_=]\$EMB2X+&V@\CH2$'&[H
M/J..=*;OV/ 9[8TFZ_1$SZRN:-#C.0Q;J<BV7JK[LRTJ_N-7/MR2@2VKV^O&
M/@!/[!DNN[HR+*8?B19WPL=C!C@"->H)84+6'J9:/E"C+#.2/?SBMM0F:']P
M)P)4@.7\ENR?@']3C(QP'J:"#NA'W'=IEJ>EMD1][MBB=TWWF.YX*QR_M&-.
MEEIEO.2%=K)0+$*B2SQ%H^G.3(AR!H7&!.H[A$B0 HGNH2:\L0FW*OD/IUDY
MF_5,3^$+,,: N\5E'_P<V*+A@\P*_B1,VN17'+WM<[B'QQH%&;-;C"_<$FEA
M!W&M,DZJM7]PEO=WZNDUYBN0M0A;H_^D@H> J-4KDT*&QGS$T]P6.5S#1H9K
MF$C<[(->I!.7 A?Q;ER8SWLP/5"E:Q>6Q:\\'YBW*]HR=X:)W@0MUZ)/#BW[
M-]-VOWI!T/)MC"T20!'@N^'A;??1_#G-*9L1P)39TWFF%YU E;NY]0I]O-2^
M27'X]I;4\9^W9O_)VZG9W]S7[%\<L5<KCR[><*:VLHXS%)+PN^F3.++6BOWU
M4V'F68Z\%'Y(BW=1J*VY]_959G0"QO*^B//<ZG@$=?P%!20L>F;-HH(),J=6
M%^O6OZ>>OZ\@;&"!((%]^?PW%1FP+Y]?:/E\L?A]#?T=K:$?5\S?_8"19G/1
M+"#5(5 SQ!@2,U+42LUF8TOC18HLUIT&[9H2P=?K^:B=5(['X^VWXRB7N"K9
M!K[C^0Q\ZZZ 7ZLT&N/.FFTXB=5=JD6RT(NIG)7.0I^<_UA@8-PR 01C,3!;
M%QYUNK/A46?;MO)]#9^IXEO>,#&LX3.P_;<4#W:^CP>;")SCZAL$SKYF[D;B
M_3+CO-YD%%_S9$OUTVV,XQL3M L)X4L?P1O68[?QR%=7R3:'OKNY4K:U2O5L
MEK*[C<>UCANZ_4KQ_*TF"BU/.X_2L+U*TGXQ.[&8PL7 '(5E]V+@!LO6HO@X
MNW'56V5..UL/][AR_H:;6&S:(S)_N=W:7DC<(A(J$FM;+F8?4'S]HX=?)8YU
M0L^##0F1*N5JSN2G9:/L\@2P3HEK&XF4C-H!Q0J'EYA6%$>JQ:%R,T+A)@VP
MPLC5]B<,LF,GC)59/#^C!6B0;$<BW+R1C#F.8ZU;>[ QBCPC"\1062 ],T"O
M@C6]SO$BN1VQY2"X[5Y0,6(*MYR<O:48<75: L^$ L>@Z7&?V6' 6G\U^X,/
M]^S"'-BAZ6 >UQ=@(*[%'DPL]-H"(D3TK(3UP"*'2F7:+G-YR :^U^'<"F:7
MUET8(C<\O).S3$Y).9X"@4J>J-O-7)]-+6&^M)+3MY-6<KQ/*UD%:M-_3*+Y
MYG^J5<P@>&=^6GG:R_7CY3=6KS"QK&^MF]9OE]\N;QYEKO #^W+]</']X>'Z
M]L9HW7QA\,#7?S]</[#;*W9U?=.ZN;AN?647MS=?KA_A&8;/W%\^?/_Z2(_<
MWEW>M_"';+EDV7V)_R)@9Q>[7%,>T=7M_>^M^R_EK[>W_WM]\QM[>&P]$D39
MS>WC]<7E"@%1TV!0.%=6Q&RZ>+C6_'8[8%? UV"6\C^(_X$>%@#=\O$/S"M'
M^;_L>-X/9**8ER[ZWE;P-<PR#["1PL +L,P_2!OQ$VHT58X]-1,5C<?L M<+
MD^\ TX<'0\]'VQI#ESWL;6BT.?!B>$1E]$Y;EP#M[S;F-83,L?MVJ/)GD<@]
M>>1ZI81L%D0@-H%\A/>K7OT 4Y7HS]H']=4+L&3UG2&_$^G%HT^VN6/S9S[Z
MM0D<O&,/8'VCOV *, @47'T-\)2_*!4@\0OFI9H^ZC.&R&SW'.]I2""T@<=0
MRA# !NO%XW'G@-!CCP<\"7M14\#V09;!AL4P[K/G/,,C(/.&N TX$=\.?E!V
MO!&Y$DE"FZM."R)87LA< 1X<L^QN%Z0VW*8/[SOP#0?-D\J=8RUG]FSZ-@^I
M.@&>MH<%]/N(2/"%J.:ML 0;7  B>9&O*BVD=F+(UYFLZ,_:48QAA 4"0AQ>
M]OI"[[)L40S[B;O<I]51WK\H"P!7)<("!1R'E&MYX;0K. EUJ!]$QG!((\DU
M&K3&'MP)5XTR+,EUX<:3;U [@#ZBH0-WF/OZ1]@*WME.CTZ:KH-I/6/U&E&=
MH&O:#IX25O:..O!MT(T$?)^YXPU@^P'<O2 P*'D9M]FS!T%E[<1N_30_T1@"
ML>BS!,3&B>T6B-%8*]>UH[YQ!SI6W^SPB)P8,/"UVZFP0TE_U&.2_AR)1,:V
M[0U2KPFBY&J<(S*+6(Q7S3<MFPJ6@)+&J>&.!03RF?M&!Y'8+_] 90>K:\"#
MIKX]E&@7P5U@#@X*^AIH6 '^"B.$(*R""@=/$\&BYWOV4P]TJS[H=L ?:%DN
MJEX5=@NW\%F\:],"VI$-:K!I8 UV($8A7$JXI$*'['H=[!Q22JZ;MAGH71+/
MDEL5=Q".X0='2H<3(Y)1ZAQ>N &5F\"_NS[1I2$3VS;BU?<\HD^T*7AZX ,W
M\&VXPD!NB!BP/R*DFZY);\.C:K6!*O-B8]F7L--# HZ#F;#MWQ5'P"TC$"G'
M"2E:!^"- #(L,S3Q:B"=<KB)<WM6!+RV@RY@JH<"& &(URY_IJD0(?!3JT1,
MI@_/ V, _HHE'(@^I@]E @C,3A1RHS\$"-H6S!S]X'W;U&CGO_-9Z]M7C77
MD!P3^$R/$.O%2YX-()T?/06Z/P8<^D^0)&B[CBB=@4LU+0O842!JO\#]L+L
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MKP<'+/ [OQ[ Y_]4J[7*?P=/!^]>V::G"SC?OI*P(ANJ!5AH"+@\5@/S\);
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M7 S31>P0E$"0%4!FPUV5DN@2DMT:S0'RTAB)2Y/&I4B*1X.!YX?H?Q\**Q*
M'YWYDO$J75\((R7&I7U(6&)$S5XI\^&F$T)?P)^$E0"E!</G@#V!<&.@5>*X
M^LNH@/-V>/9DBX + AFA"0#W%N"(I9JHTBPAIR(P2.#HBI)5;(A%T0#5Q"E9
M$3E"J,ZI ZB/I7N$**;-!-;%O383B,[8PE!H<8P-P4'0\6$'PHX96X8ZW#@<
M_-4)/U0K55"@CA0&#.QG#\V$BIX\X!W 831!=-DE%AD#I+E/: CW"ED$:L4N
MGH?KR_O[EJ!+%>7GN7;9%6_[6'[&$($\+TF H8%_U-H07V0DBVD"EI <)2U+
MD;#9YKMW,:X;M'[Z581_LUJ9%!RR@P(G B+BD?$M5ECT:=P^Z,,0?BRA9FCJ
M#E=1WQ F_%)DR'G!PJSR4A&?,O LJ!GJ(\S+^^P;Y[AQV-D/DP[J,::M1&XH
M5(A=**/RHZ21^CW)Z%H4#@9[> #EA4MV,#H6;E6-9*B1M&'JX?%"6_ET&>X+
MD@!IM&N7;+F2V'TF*Y-8W3=A.(RG [0!_H<A76KTBVO@0!JEDQS/$/0PQ?=P
MYB2"":>5)(HC%+'$[*ZV6>&YPL%X;=)QKKX BQG@>Z9#AE_09N 1.^C%4@QR
M()>_&*18F3YU5T=;]5NG=(^]B6=BB#,AY,;;2B)" LN%YM^)@D#(9D+F ^8K
M7+Y*[,/GW,@7MDC/)6L'3_9 [G%'N&0\D,8\$Y9'BS!?X'C(,Y@@7R90D2<8
M&A,C@KA4O<.?$1V34P8=FUS,Y$'M]Q&';%+[$8E@%P.R%: M0\FO]!R&" /<
M_I2QE +E.CW"X"2>5=BMRUI ]1U6/TT6M9Z.X 1,,KD&/>^E8TK0X7.7D0_R
MZ<C5%M</]S-V^81!5EV\RX3MGC7//P;1X%/8^_@._V4MUT6'MR0F"="_ )4H
MFZ'TR\MB_7HA:8V>0#A,[OM,[?L%;42*^A-[)+''"T(\)>F/@JOJ8(UO)3IV
M;9$>/0%2@8URTAAEI0>;9YG[NY6H9]Q(=%.0U/3])B;P%Q(54U*Y6#OZ8,:Q
M1^,^KH(",JB! @K>W@\4G;6-)/9S&Z;5A^T*OB?<O#$C[D8!>?5A.&791_%=
M*./Z@E"7 -0A7F2DB.UVT(&6=DGRGP.J4"H#'Y0/$A^2=P\I7[=+Q_<-J&RM
M%A\>&SV\%*6.41:9\R"44K3GD_A/$)%L9P2/_\;[9BAH04L:VU(8^[>6/@QB
ME7\;HC*F#T:&T !U(!'L"I#Q!_IE2NPW[HO0"Y?]/0+(G)75;MXZ-9=*F'+G
MA![&U@12QT9L('4HB-I].R3D0,_J9UM$;@3L*VAR6$>^-=#FN]@W^#4^+A(3
M)!XCJL&I?Z\\8*B5)%9?_.B)M=*XKP8"*JH&,J34&F"P"QJ;T9S8C;O( _D5
M]!8=WB])?W&25/.D<*O6LD<$8:/NXTG+>#1L18 XD#@Z+4\_.5Y;1Q8E<8A$
MZ>N^8*VL]5F?H_I.'6:)D$G=_A+[9EL6B&F7)G:D@4%O0)+KL587Y5<]R.7W
M;Y<W,3Z@4<=%/5H5G [BK P1Q$ NB@@HH:]XM)F!K-]:,;(F:*[6Z36-^J8C
M(EI/V-<A7M@W/4+%$(^SA.)LRLB'& _E^E)*O-#H$(-_4@0=@/?_L_>N36VD
M6=;H]_P5&3[E>>T82<75V%7=%4%A7&;*MP'<'>?3B9240+8EI5HI&:L_O+_]
M[+4OSR4SA<%E,#9$3-<8D#*?Z[ZNO?;\7!, +,&\AJW 9 QG7QQ.?6/HA:!6
MXOYD_^:C2LW87B*U%^>UP)TH$L[_2*C+H=VZ0)6$2?(N!XTLLYTNY@4)&(-E
MBJ5(NG!ZEH6ZUX1I495S&D9BL*3NQL9V@%7"C[&S[VPA]B*+2>VLK&^O!2$Q
MA=]PR.9)+:LO[J@-$(ED\OR0M3_5,P9P8ZZB@,P\&0Q'V"9E^F%2GD^@[PMX
M1W0\QSFZ1175N)=>M-P2-!OWK7,4STG "4%R"8U<1F4Q=T^=DU%5+3&X0C&"
M$?IGO!![HILAQ8@/N^$([L(L*9V$N]1E_U_Y@#.+]$?G O+&T*952<9<# R!
ML1 D38#C!5&&TV5A89%IA/>.P6'LYD"B^Q/PW\G>J]T_NJ]#H%%T **83QCI
M-Y^>'"<$0%V;,220<>3)PS)[ERWKR/:LF_])(PA"SPJ,31_I>!D:F!LU-TB#
M&ONPG 7C6DQ\7RGNBJ-AM/6F4^<S(O^=ZJ(T%P(N'HV: WKTA&G)/7HX_LO1
M*+K!8UFO8HB!66[>:;'#YVX"$Y2K<C.&CMSHD5CWR/2Z0%;2ISN/0#HMR/;F
M0W[+YL9#K!MG(6 [D6,FJ+,HFF88O^440H4N0=B:"G!(_B*043@2T@""A(,Z
M2]D8,L.<RSSARKBA6SV6;E@,$:3J)X3KQ;?9';.4_*I\7@Y&V2=V?]A+I<W-
M9SY=;^M9A8#EK"74ZOR-(-+*-HZ@HV7]96L* T\!^\3%JH)(IJ&2O3&ONXJY
M@JS,[PM\)@%?ZZ?.,_;E$TTFT!A)>"H&P@70V&H.\A&N-M"'U@YWO>7<"7RV
MTD=CTR<N%%$Z)(A?61M%E$N(0ZJXK1B+B/$SNU60PBP[2#]\:^C6+1"1QV7*
M6FV6!X9!P?#<&?0,A[%F48*I81?&LM5AZ33$R79(;'C@^0LY;8%6GDAJ/YTO
MQF0S(Z:BN O:Z1E#2O"B0Q9VS]/\Y$1.\M[SS<TNS8&Q1PBI*9"1AEU(WG#*
M?T-)!UJ*>*'T_&BO>O"8!VD!$043\='B88R+P:S,)Q^+63G![-GMS#_E,S*]
M$$TI[?&X S0F$C55$%E:#R)+@?A'SB"RF%22!-$%=APT0=<(3N_N>AF0U)2!
M!JFF GURZ^N:7\Y*R8"NGB,'I,F.0:ZB/DL:V!#KR@TQ>05KH7%(Z,7,Q\3F
M9VBKF<U8;+8,QY\(U%7D(S%\I&R%Y1^_A!':"PA&SDOCO Z0'1+0:&C<(;Z3
M1,E6&CNZULWTB2JESQ9C>$W\\- Y>;T<E4CP O#%1\ME>U&0TR^'RRYPT @
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M$6?JMQ4<2JE68M7=+_</-[N[AWL=_&L#_P(0A\TI_%N$XQEB=4!K(ZXEJMX
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M]M+?EZ2%23\[5N)P@!Z@ZWCR\JBBA=ZSL94:.V) 2RQC<$R8:=:'7;$I :/
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M#Q*A%@T?C20OG$](7Y]P2(3Q+_,(]ZWUS55$=.P(G1-'0!NP.G.BDP52W 6
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M+ N^["<+/K;]?'[.CXZ;F)QXTCXFK7,45O@UOQ&G00Y?(@#!3M"/AJX>[=Y
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MCP"$#/VPN:W)K.VU+HVIXMIJ'[^9G683?4(OO;%;>GO#8=A)[X('*V4QK/"
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M$<<Z@3_AR;@CL?M\3S58//3TD?7O6W_<\2EH#WLVN-V2'+'R4S$P>E&W_4D
M>@T;CM:J+_P@)]D'SKQSA06T+FS0YWMT,?U%7/2+?R^*>;EPM:(.%J[C#F\[
MUZ6;+58M^O"R^&3Z8L;04"@D6A39'[. CRRL 5V@[CVX 3B(?&V@45NO0Q+9
MU!WPE89\\69EM5,\X+=<EN"GUU% ?A,(:JXX4NLL73%VI2K' O"]2K1R==FV
M"E8!04;5X(,4TSO DA)U2HO2/P6UZ+_I+:MP^\?E,)/:VPC)SU(Z:4CI']8A
MNU*N?^/.Y/HWU^YS_;?UR'Y1 >+JR,&/M#HK>HU[,Y1Q>%I!N+F9N-I!6K(/
MBD)W"H)4_/1L5:G6[J"[L;$=&@2BORM6Y@Z86@5E?21FR6(R%YY$M*L>U"*^
M1MH1T06QD4;*X!7"3AD6:PQE8N5JF5\X_J"Z3I23E/BQXYT59+S4ZE(2%Q4U
MI*X,CJ/#;14('"YEXC%7BX T4HZZE[F/N\A@.% QP!A=59.L9&H+.\W(,,J&
M8L\.,G@2"B64<"\-W(/V0\,SC;99('DSFUZH^<+V+>:EX^-2B=DDCT<&31QU
ML@A&I!%=91B#Z?(9&Q-LS#=K.33^8K9=4*> ^155:X"8:R.Y$9%8<3WPNR9<
MQ11:0D'1RW!&6\?FNB2 ^R"U@.G"/%DP9#Z96;.^O18SO-*Q>V(A)@ZB1T8M
MG7S4/YX&S!I+L> $KF@Q:L8M=M+^8LYY#.GT5 O_TS# 3H,.5KZC'MVAR&$W
M-]R@Y%4Q9.83G@6Y2 B*G&*V#$CWO7I<D&Y$DZ@&M-M*??%K>@;=U4DE?TFO
MP(U<C(,-B[(=2LSR$16EIXC,=:4[L"20Z_G7Q.5?)7BOM"U=#>;!GF_/_S!*
MP'-,L:'N;C_^YE  '#6)( 8W9H[54&PW6L=W646W%](OOM#JKW=R-WRJ]+H
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MD?]><)Q H;OJ\4\7,U=ES&R[QH9,ONU9.:R4NCBH+W6$B5R<:\AWP&>B[H^
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M&EM4>SH)H@M6#8P]&I758I8G+)QY&1CBS$_@SX4/*2ZY R'K2CMZ%6$/^K
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MJ.#V\@Z55UZMN$D-.NX3B[5/,-PXV*E?FFX6'$F-RHYE/3"J/J:-#5>50FO
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M\F(6<P1,/R1V)?& O/L^/O),#(7 .:"@</</M_=/4,WI6'Y@JNH3./4^@4<
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M0TNOQ4@_3E;U+EOUU:/X%L=>KH6*;=Q%J1Q2+ [-5A<,S$Y9]PR@9_KI^/H
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M0GKR6PX]IN6J8C)58Z.P42<$*W^PLBZ.]C"D!2%#R?VOUB:YJ?Q)T:Z]\KP
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M2A ;.W'RZ>!Q*SNKE+'0V]R84(0?T),/&GGE]J'^]_GGE^O&YQO?\7+Q,U?
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MI\C.Y;Y(I./\5T%UUSWW5\<QV50]+ZA^6/BKT<0P!H4%0>#P\T7D>P-=!27
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MME^\2=@J)&_ 4!)7V<=^FO^J;1@^<O*1;_[7BC<PLG4T#GL>!]%U@R&!VZ0
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MT-MC54GK.7?D2+Z5/,;*UQ$!C1/+C+!:T5VR@-@AG%\YM"*#JDR*0Z<$E93
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MX3=CE)@#F8O]LTSSK'W,F@@T=7S%8\&6H^ZC:[VO9#>P(C,C:LI%](??5IV
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M_W][7]K<-I)L^QV_ N$7<Z/[74H6*<GKC"-DR>[6M+>1[%[FQHL;$ &*:),
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M*X@UZU+&0?V2,H4CC (G V VH&A423157@O_O:<$Q^/&N:PHR"5SA5*BPVN
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MU3:*9GQ=Q,5]/L)]<AZ<I PL=VO0$^8K/8#4=A.= 2,KH20@/C&> %PM]FO
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M8;75":FZC#,A@?+E5YK<@<=D%_U%A%L2\H[@A>N+5I(JF7'!"E"VDIK3[8-
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M02\=J/V4ERDBD/EH@#; 6&'X%%) @- !%HZ/,8>@SB/+H,*VS<41%E*=JJ"
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M\9N#^.P[02Q8*!.@A "W H4#!$,<KP&;E8!,0I0TGDDHDHFO\@!* ;TU"#B
MK4S5@DT!' (]98-2*U27>#(;MI$Y@23%#DGD"@* L@;<K#E3KY%'/D<W#)6>
MFPKHJ9A(DZ4<EC@-%I[#36<-KJ;RYHF[>\2^.6)_VK6C\MB"!<&78R4HIDP
MHF,E343EB0(=H]I2Q:7G0!I?:9.G*+I4B%.MC!6:IMH7 <8-.P1( @'8%4AP
M'_R()Q-!W9D-<P6)UAD_;IT?BB,[M74>%$_%HR3&FA1P)?V,RN :B@M0D3,P
M5*_]F:5C:RI\9"J$*5KJ)K@A013C8@_8[P"L!>4K,,N/=L)L3Q@,(."VQZ[P
MR+X!1X?ZO\]SU&;PA-WF4",>"X"X-&5[.]-Y"J.H=C-I;!&%E$BL'CHNK,KO
M>@E/A>(6K&5O7\$-I+2H[_16HA;#&:.5#'AF5S<V,I \E;0$67 0VU824I4;
MH@6V>1C+(6S)U4; HPPUGB9-.<4Q5YQ:!=9EO5C1"\RP9*5>6Z=9^&LL2!+5
M' I$L*_>[Y$,X]<DP\Z5$]!;)L4+I^Z>&DBGF0P(\=SHA%-[X0;90G29TH"G
MA'Q"'STJR<=2R6Q!I&.;7<I0BUZ+RR*Y'HFNT6W;QA[*%4WS=(K$,)8E^;Y.
M ^N!)=X3D8#\*+4 ]?%],:7,(QF<*XH<0(;**1K)/@O>(PO\W;+ G7&5VZI)
M !%A".XK9PBMV4)A/Z3F:Z[;9B<J4SQNI[46])B($DZ8A_!8Y]FW7=BA50&%
M2W%!AX/PS\^#;%P=.VPBBV(OX%";M.]A^PZP#78LW@4@G@*+;C9*)FO?;(,O
MD8>=2S:Q$^W[>4KP66,"6[(BUB;#.-T;0Y?!YK&O.8@$5!]^RY,0F8!BNB%>
MNH[CI+"W,G1CD^1+QXX*MR)NEL0)-(7;S!&!96UV1\KFL6!*W@M57M%LR-MS
M:+VV93D[;](^6][EH'K^HJO?H,H89U7UJ JO@W95 (&Z%V2)\Y2A+U'$0=(S
MG9HE";$#4!G',LN$>*;+C#5X#NA6".?AH=5R"&RCIAMJ&OBDPT*5D>)K+K$
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MO.$QW6C^FWVL3^KM.IMTVW8+F]<W#>>8+KD3YG:&(Z_;83N;5*V4#EXWKA#
M8WKH?>BRB3M^< ?=R<7PO_WN)X#+JU: OJM&XY5\_)YL+U/L+]7;PXM4+ 4;
M_I28SYEN]74VFRN)>;Y(4AFN63KGZ>U?:/)9J?#<AWZ7M;O]_LCM=)"8O]8:
M-?L\&;GM\OD;C;X9QA9;R2"=D[[&O[#%WK@TLZ2E^UR5*(*6%MN%U?\R0WM#
M]?W.ZY33"G4-&=>HA73N][RK7]W(^&ME2H2 5+/^?,I>@STVYPA7(I92K$2
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M9FQ?U?HL"2#@*E\;\&FX32AESD[P3V,'+:G<J*("2_]BP8[U9SAY'M&^O_:
M_S/ S\6%LDOP8T_0O!0VW/&^DX_XN>L&%UQ=W,]%/#<BDE$/%D1;Y_3X,?XV
M\>,<E&Y+5?3SQZIR=H^+#EL_;VU*D8R</N]M&WLSB9T:C9/R^@9X-2#&+AH'
MWAQ!\3^<.:QV3@/^^H7E:[-\^2,Y2Q9S%_B0E6<&C;DK,?M,@(M411Z^6/DN
M"_G#F1;Q2Y[XHX/Y*8X'NPWUB^!*<>+^#H^PJI$ZGT^'IP^DR%_]8=Y$A,0C
MSBY!.NTS]\+'8>^L[=RLW!<CN(M<9*/U,P#3XGZ*=YKFP9E_$-97 X_2T;QJ
MVBUP"0[/:0\,]'K^Z;/%"X:7=$IFGO=*V2LZV?4Q<(&#%$@6L4WCM7#VR+L"
M2ZYS5Y.!$-8LA VQ)\P!)_S($2[QKD"3V[1,&D# 9QY.9\&3FK)V#6*XT"J4
MN!O6 %2R17$KG[)810TOC4]'\F0;4Y=[W3Y'H+FBX(ZZ$L%^()H%_\';F=84
M87JAA^"CE8 NGX^K4#K=ZY;$P"/?]%.5W'#ZZZ2Y6H<2[],F,\W0RF&)/0##
M;N"XX,*+:4NOYZY>WSQ#JLH^3Z?:9_H=ZE"SM5?CK>SY%=/:-7O9XXDMKO,4
MOK5KQL;[9USYV%%Z8R!N<2@O+]F6.W_O\!EYK$^#7:IV;!%8\J7L<HWK--+:
MLL7A5FR2U<F$@M=IB )(I$.2Q'7CG^'0\E\ $L,H5 [.LU.N'EW[)>/V0^0O
M6A]-WAG6F#9^-#3".:P85$4+@GD2%_MOC/_8LB]=G8^49NA(U;]SEY=.9'3:
M/T[V+QU L?0/X<AR#+E6^>G= >]O(E5)F7B;<RI]0?INGY8X6:^G/FUREUW[
M3'_E6L:^L>8\G9\^+A4W]]6NV>I4/SHEX)$/.^[28FH458D2?5</L;LC\$+T
MJ=A LX*T!'-'\\#[9?A%U6U5-E8# G# #Z$&,K1D8RJ0\MA<CL-LDQ*]HBH.
MR3H1,HC0P$F49MG?!Z7$_/<TB Y3#^",>I]VUQI[O*0C(8)66FM6R,KU\0WP
M1O!ZM5Y6[+.P/-_"%FL_.X/UOT'QO6967/+RJXK4L*O+N]_RWKNZU%CL??#N
ME>G!FC''7RM+<Z>&!IX6>M;4Y5.S\[T'' RL\J_<CC.J^)KY?+@5$^H5L#?V
MLJ=J9=;%L80F]=S'-^[?_S8X:W9XO:I!C+!MY'-'&$(:6&&'-"88?!T;<B)#
M>+J#"RCVQ,N;'7EDYO%T=E$NB"^;=GWAR&EZVXO?*PJ.EVO'9U7ZV"0KA):X
MQ#5<"53X$&;WQ^*"QI$KBI=N/JGY$*8SV9UX)8K^R_254MW)GIS2)V%]/@YY
M/#OO_N: ,;MCW*J]5ZI]Q!\T#[+>S:N_"U@]+2O[@!)?]/MU>0TNZD3[S2<O
M[9V!%T]/G]GTY'W+Z!_5&29'G*YKB\4VLHH8FQ[D1C=%1!KO=>@D94?J/'QT
M:MNFF>&[7:/:603SX .PAW-=.$(TGC/5$_T'7 +L6:%P2>S4^JXAY\5WAN*C
MJSA+;A'[\ZQUDLS=46+,M\F9/*#K9\G<LU[N<KR4N)PCA=K()/)46,=R_K&'
MWA_X5D-L?4Z4XZ%8+";>8A?W[2.ZH<U1K$>LW6%EM1^*<K./3;:UF3^TURV6
M-1\LKS,U'BCG&Z$A3'X-6D>9]Q6SZGJ7U,4^9(F]41\^^V1D9'I@7!9;$'4-
M^UDIN4'4%^>0)]B__HR :9))YB. :&A6VT.5:-!XY$40I6I-UY0D48 ]'3&_
M3Y(D\*H?'6>T.U@?Q$(-3*-Q5_+<$Y0_B(5'!,[^T7"#=@$U'=J)OMMH3V>]
M$C#5R;8[(@L3"X_)XS&I=LWV=-ML#8RFXR^EP,X/\<8&$M+;?^$],6_;3=TG
M%65%FZA^,.YZ.'-\-7]7F5+F3>8/@]E/K^^]E1;0<GU5.12UXX)6,WMJ+*M7
MPD6[3=OUN,16ESU_Z*H^&5M-E+&_++OO?HL>"U\*9'-GFI"RU'VX'P$4YVQX
M.D44BK1#+%49J.QI^>J+6)YI<C_UGE)K5.+R<5IF#%-:DWZIS^_JO6]2$R[F
MK3H_&6B&#L8*8==)D2.G %\NF77Z->9E^RCSOO(1X"Q;"-L\[.(3,E 3F57%
M5;7O#B9&!WHK//9?3C#?I[XN8A5AOJ/SLZ/I03>/Z[C5MP"=?YES@_9JR\&?
M'?6K@-51)\T/A2I!>RQR&]2;Z_U,L =O%D<G7*P7;8$/E8$)6_!(9<.MZSKO
M["X<Z/#2XQM>1^TVJ_G]"QMW][!U;[*6U[[K.PK-,_*WS>'-=.9>G,&%_M[Y
MU<E?INKH48OTNWJ-7W>Z"AZA/PR;>"%<WIBAW?9]$\*4"0W:A.LT:2;.>D!S
M,<)+"W^@B7?5M==0FDW;BZ6UT#8;RO(P'&1T,&4W=H:]',E%K#3?1DA7\J(?
MS"U]MER*2T!$G,#8#7S5.0,-X\7>!B]!%?YQ0H-&,5[19RB52//TCPFAR2$.
M,'AQH^@6+5'F9-I@\^*K]X87^&<%^CQ"$W+SR/00HQD2/1=XJ3%9*R:\3JJN
MTLX%YRIN9Z;O[CA,@==(<.8X^?DZ#G\"WX]!\AZ(/8(&92W")DP\1Y2OE5@M
MA,V\1T#WKM[E[R<6 KQ1C<1/A.8_EJ?<BD2:S2-=D<LIUL>"<[=;=L5@\8$_
M1Z8>.F;8E)9Q+1?NU8IQ2$'TV(Y=HO-(XJ\;<]NPE#3Q5MWZVE^2A\.J7SY5
MT[W-B3@X/!:/VET%C08F^);+J5DJ-570].?(XNTF<1+D@\A $>=LQ[ZF$64@
MAK>O$2Y3Z_ ,<+'HTQ5[X[L/U8<_@%7]B2?F:O)JFC\086!IXZ8Z6RE#,P%0
MR_K @5%F3(TI_;.8Y6 NKP1Z.X=!5Q=[0Y3TECVMSIX?,I'8/2RPJ4ZR>DCM
M.IR2#8\,NIOG-;O%0-U8^^-"P/X;2, 56?$+0_#K]J_(+[58,5H@5)N=GPLE
M(,S\ 5WOPI\<%.$P[@0,&I4WO*U?XO!>DI,GEF0U+W6I9[BZG<ZGZXNM#\?%
M15*I27%Q 5Y?T^N&?3]AF='[AZ/LZ0%^YI:,.]4-[F;D=T(82_YS01(JU^)5
MU8>NE7WKO;U38* K'LFNJ1?"LLV$L,4%.'H&K2L1CZYPM!7"Y.[L$,)>0<D@
M_6RZC#&\)IF5<5D.J.*C(%EO?IS >H0:;KDW((1=A>;$F5&EED&^V2&?S FK
MT1WWFBKN?/FR*WY@+Q!XTIM :]4HM \+4)6@_NZF+6'45LA855GVGS9T+K:1
M<-_&V3M2L<<"E R)J*4*8=6O)$8)SJNV'-59+RZ24Y6(@7(B9C$X;V@9/#H/
MP^YQ6F1*3BM84@0JS%V@MB=!6:"Z<\CYCYCCQ7@5;(@%M:96I*.N]VKJQ?33
M9=4OX8 KH<)1"$O_427C#MX0*_$,.@*C,BB$#9H*CB.'*&""2#7RF[OAUB41
M\%RFD5K/VS)O;?NC[&_>NGN\K$A27R0?H5)FTO1CO1#VP8/)Z"OMQ%L[XU)"
M0V0ZU0H>5TO%.]=\+/_FXG9Z;F$UM*H9#AQFSI)XZJ"4Z6 0+4;!?K"9\ /N
M1C^X?QHA#I1Q*%N\W4^_%\(\P]?/. *E7$[S2I9<?_GK"F(40F6PW$C6';7-
M72?%P+TPGWX\\W"M;%AFW7(4-.UNZ5E_LO0:T^?[*Y#-@N^ETGPI'[$+]4B9
M6M]1E)(G';\'4!F]79$S":IR6_(+F,Y8?SI-G*J,1?_$LXKJT,W*#20S2LY7
MAGVZ/!1)"\*?PO>3%C& $%8S/WJ< 38\60/+X?&D"C0*@/+IOZJE+/*V:[TI
M;"VD)#(U8&=L;,>M3D?!22',^=5N=-2)?L-P&]<_?@N]1E9V;#EV[%@+>J9*
M/%"?<"T I=W?OGZ.LV7^]C!M6;/7MW)HS+=R/@*E^IXV^IA62HZJ#<(%Y& O
MM*0<<@?2?XYNF.-=8#B 6^[-,^!BNLC[>/UT4++8UHD:^Y5#![?T8WHK?#Z;
ML]= L2<]*\8U/9@L_EP --1PS;L^8IIJ?-.P8?,<J_L<)9EA5CXEDJHQR53
M^1?@W+AA.#7 _R7N +=+H()'E%&C+Y=&S;.BWCP'U)O3@H2P&SV&YW+%I/LT
M#KWI*6\O0KI!.&[EVT\@N6^5:)-0+2I/B%P2=)FC %=TQ764X-=-7X2P;BQ7
M=A"\FT4B5ZAY?#)6#[S^^EJ:N9I%[#?YPW(%N?LLE'MCWUAIZK6Z65JQ77V:
MU&_DQMJO5,%X]P8M@UHOOVCK<&II3VZ>T*"-9B!?93W,GL;+0E+HOBY1 @BQ
M[\9O\I150"2Q.VZI>[Q:3T<<FB;(@/LNE;FY?F9VO:A*7,I$N?+P%>$A(2^
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ML$ IS:7";\F]O+N*-!<A9?FZM[0!3;C"+T&H"12VCJ<($2H\T?;G*%"+/?R
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M"&-)*@[&8 E8#0D_1%V<I@C$BH2(CUU;?@CF!49 <^I_AW1>B&#:;<P+?V$
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M?09@-FR6\#8%4Y.O#\),9T__<L,Q8YFR91>?>>9#]_1Z9#N^)A-6G^VP"*?
MM$=)\.D-2ASJY-9EM1CA8C JJ*$:MBL%U887#2%.M N.\0NO-T*GP("VQLU5
M<4P@EF=<!-6T$_7B6DW;B"J5/=?Z=?3BO+/,?*F6@#=JJ*2)425$S/)!<6X0
M*'C'HDB$V+*T&^_)YE&@?1.FE:!5FC^3)'/#]5CW?.7]>I.\D+@_CIN4A@1;
M>3[KU[.T^C@]2*_.[6<_9K-T58$F5.-F0D!OO4(^L9<AC3DEZ#9RO(L^!=;1
M! H]]:8LG A!MZ?T&K3\,B38!+Q##7Y)I#>*0&97BKUK@^,"%7A8YFJ0>'BR
ML1YE%_1TT+EW^>VR?$RAR..0>>X;&-NPD'4N$\;I.@.N1V_>A.2Q_.(%QT*"
MN=Y]1/V0Q":4"-J2R9 A6('!L[0B:(0V+)UQ 6)?@%K#F986XZC4>E/F;^ W
MN.FD1NJM1P 7.=7DTJ&OTU(=NI.HEM2O'MQKT,-QU$Y(#!>3NXMSTXA/2IZS
M;2'NX)"C9GF6SW'@/C_1S^QUOBS[$N=777XI/6GD?>[.Q-8+TV&8(C*4,DA;
M<W]9X1[NYZVHNVU="V@RI'HPADS;,+I0#G,&)@=^;4C%D9#?VFV@7I!(;\H]
M"%6XD7G&T*EQ(#*,F/4"FFYO#CM1]W)J>#Z&MZ7 R_7 Z\A9I^DQ#>I %6[?
M]F7DFS,K[^7EEUAW,3[\QU3WU%AL.:/Y3Z(DX8!@F$2;8\TKAZPX]J//[$\*
M2@YNP^XBX JAFM:P_M&:V$K<#@A_WKG!T3;]\%+J#BC@])?*3GF?5[.!7QWV
M>ZR9)QS8),K])8+-C> W\+T7=05BEQB[!P6BG]>=J,T*/+P/&RX$NR4.3;R_
M[>4?\D9)BFUQE*6@%UIYK/:3C6Y<EIW<[:E7-??)2FW1D>+(WM/'4Z^*\HX+
M ,7O:&W5F[IU$RVJ:O,TH.7G8M3[\8D=>85=OTX:7SQ\_M;?V1@=N^<N5_S_
M1N->%_&,/L;X>4UU3;O.G94T_641V.=^/57+\'VG7B>X>LU?YM;M3\=F:=N4
MW<7#;QXNO^CT)3G,[*-<CJ9CKE:N<I>.CO5/F]35&9X!3,@C"XE=&#$.8\YD
M7,61&\V9N(N.('MC1>JUV*=&2#+0\(A=[\_*$YYDH%F%):H_,HKID7OR$@IB
MA2>KCLD.+JWF<QKFAU^->O W>*,; 0?_3A>T4JOFFRE###:5ADO$J$,1ZSC7
MR4LO&YAXY=$9@2ZIV8&H<>]7)DL0Q9H@7:KHUM?>K*?&RHRI4CFMNU?1(N+J
M&*WEQ$#F;L =<SI&;._Y [\7;EYU\S@Z=WZKM=+MOU&:VVYY=LI>EC59B*,I
M^VZ*_V"#<9=(_=L#F9IU4F;E76;\@T^<K[/[U6+>N"L':O64.)",C4 S@PPK
M?<_NZ,<+0U;Y:9<?4@XZ%?O;)%&E/]1+M-X28 ]^.N*ZUU^IY/'5(_)/I;UZ
MR([B!]_I+B=(/;=%72*]H4^=3M<4/92X33$XH51#] Q':]QC[N#ZY8L\?8[O
M?::?#'1ARE6EGI_#TP)"P5/,^61",(L/V/-?8O0)#AQ7,LN"OIN2''C0880Y
M6I:8-SU\)V/M9F>XGQS7MZ1P:L#&).#_8NR]HYK:WJ[1>"RH""@*2(T%I0E8
M*$I)+ <1$'( %04A1Q$I$2("$B%DJT@O46D*2E2:""%*E1HAE*,(* $B((0$
ME2X[E+ A[6[.^[OO]]WWNW>,.P9_P(#LM9XRYS/G9F4'B0\7^)"^E?432NQU
MISCZ5%:3*EIF?%C/E+[)PBO4GZ?5;-8VX\N=[2^-"#]SAG@';QBY\$^=>;ZO
MAZ6X):[.YD HK^-:R-Y<K'0[_CMRSX&_K7>J75MW?MT?M@MJ"III5SX]/M-J
M;_A(]M!/+?H_=2._U[]G;&6;[A*R33UP\RQ7U'SP;BV]VDJF_4?3?%:IGZ5\
M2N4_(MY)VV%A<8W[9%JW:UC14F5-)4F&> :N\WUQ'VEMC[]P:S 0K84%VQ+$
MQP@'B"?ZZ@P:E$'O5MI.H1[TTG>D2P8R^<1L0<LO: O7AG -9=U/E.!B& -M
MS>X1FO45M2#_7GC>I4G99]XS2($C\0J/E1#\?&]S&#M&J$,CHJ%Y7I;=>]&S
M8'TIKL'ST5E9 KX16V;8NBPT'44J"ZW I=CB&:(]!Q/KPO;N6>B:GI*1=DC7
MFY5MYZ@'+'DP#?97BJ,R!S8,J&A_TTS0E;+Z^_'K76>?2MWXIGDG1WX+)?-M
MR- &?^QT'/[U9=_8#.E]TY57%"?GAG9G&I7?N;S]IU3JNP,7'_AN,\GXQ[;X
M?&:.*LV\"M#*KYK#Y6><T+;)K\ZN<<N?&BLM9=5WM=8B![U'76(L#HU>\2R$
MUCKP@*;9Z)J_H7"!P1123GB'*Q='43"2EKL_O(-W#:T\(UR]#7MM)6\I*L6I
M-R3"(<+0X8MQ>W\Y<K.?B@(\>U5;6<Y/4%6B)+0/387HQZ.WSDKC@*UB=:$'
MF,%X;LY19T>*=8BFH%:LA50.5 FHC=>(\[@7?Y3V$4]Q<6[T:;L9%!L3[:[J
M]+XR:D=C^,%>)_$ :UI;*&?DK=6BH?EW95]?^@_WII3!4S=>9WG6)&N^OW)P
MRW49P\[.SA,/]9(ZI(^G6.$>A[B?<DSVF>9&JS+7)'?H[SF$+(N]&AL9_#G
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M#[R\O-I:,XCKD^N>L?A5LOO,VX<=1QUD$](*=.P-?,I3!U(<:VV7 )^VE9_
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M0X S;7- E.*K@J,U02LMQIL=4PKNA%V\C-_1EW._68+PNH:72VQL5XV\&*^
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M/S6<(_:C\91-)H4\9#,>/'6.W()"D[G9%%25'#FX.B?"D!O:)+.6X^CNP;H
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M^G9\P*,]XH@S?:X!@+QY01_,K!F6>B-+K9AHE:H6Y!J"&_=Y6RMZ4R.'K%;
M&+K.;EYIBU[ ;((&&2J+/X95>18J5?>($2\)WHSTL!K7Q@)"PO$(_9)R=6O2
MRT"51\UCP^U;"QXD>F&VG3::9!:<S+O$>>/>EV9A>?::S_GG>B=T'"HU)G.[
M'Q2</O(:L[XID'8_N&S3N:@;BOM#P,7)JZ^_Y"4^>/661XU_>;<PGM%-57+)
M-'I]]4<!1D;PZ2^JTPY(3X)X@%4(KI=J:="O@4*YRQ9*(QAYOX:M/._DA2&5
M>1=P?Q)MO.;)UT7S8Q9>^=8AG*E:7,2)EY5F%6FBSH>MO[[V@?MZ#@A4:-,"
MGN DDU81@1\);>G8:\,TLK1K7LDN?"U$\8SS*5<X0WO&+TT._!SZ/A#6LB$K
M__+#C)3:-5NN7383I3YMJW<EL<*\8B++GZ/M(8<!9$*=.N@YJC6]"/[NLN*)
M<RGK@Y%1@+(Q6W&RRG%*@I">72@:G-T!T1K#0A,7W>5.]M(LSJMI['G,:!K6
MY%TS#6-%36\93BF!)\Y)0V- 'DK (N6$?]Y8I"4@RY6:?WP9@Z*,>QP9/#K?
M[:THJSAX$['CJ.MG\;9P+=Y5]XKW]^?,,[K]9XK9(?.?WWT_F>?S\RCI3&>G
M,PV/^]3WT)&F6?VJ6I0WBLG,?;ESWXE.:IO>R)B]PQV^OD/NU5ZSBQX^W:DI
M]/*TLQ9>/A_GS.PR:?I'^T(T>;II<ND6QH)#Q#">P;L1?UU,-$D'S*,U%V6U
MH]=#16UF&A4<\GJ<\P !\Q?O?3R[F:427&G/ER!D?$--5^Q.EQKDJQB6*N_U
M]8J.N8OVQB8#VT/P#VK0421%0A>^S?*ZC#0GH)HZ;I8?Q<$J#'>L6RJU]^::
M#YZXPI>V/]PIN%!;+[/').-*>(1/U<T/B_S?58( X3%0*V':6"X&I<!S(0,5
M*$52Q[ T;S;6&(@URR4IU2"E2)L[.%)O(6#$/:@IO8R@UZR(TNT+H!I'D.Q$
M3I_<3:T:JL#.0?0.C^^TO7EPRD^$J!N+MTUZ<WZ]R&3=L[ 6F$V*C9@+[!V0
MMQWHDE@^V\^PL9=CO)NX;4*72VFI0145?].K,:%R9_ V(+5YB>?#=W&]71#H
MK604I*']YEGAM9[=FQ_Z42JH[;K.B8?DG8ILSZ?ACIU.]4=9:?8LZYBQJV?2
M[3XL:+YTBPUT+CR9ZT[@3.B^H]KT-+8P<SQVNL3\2M2*+>QP.)+J8J$V%>&Z
MV*#+0S;))6C(?C4D8KCT: _S+Q9Z5[C/71I=//1Z+0R+^PE>%N=?39JZGLYY
M95 1Z*N>XLXHO.C>K_OTO&9U57H_9L#S\7IQJ01Q;<Y:N'U6O G=IL5_!&X]
MIE$FQ&N5W"1H[1J;;P',D=OH-_ZQP(&1SI#[*PC9[+'S\3R''2V6V9]CFD!$
MOO%US6#(21%^C;4.JP$[!@H8;H;RDPV'CU3DNM;U>1Q@UJ%#J8-VW"DW:3?!
M8-8F]"N@WP(>'0T2Q$C*-RDDV(U:JS87R"<G2U%(PT-W6H@45>Z1S<LH]P-M
MF]04?'XMOG1XIAOT)C7=GDSJ]ECH<4O-+/=JK_G:.B]2:GJV'Q/%O3RI;'+%
MHDT&I=YT[KEM:GUJ82_1)I7F2;(E?G_G& #>JJ]?ULG#+(4=W+3KQXC.CY&Y
M%_/)U>B'W+JJ459,!5:!N 7ZR@'D)DIQ*K-QI.U"JR]&[GN47U5EG>NM($M-
MF=U^GM\2&'C@X(E]BS\_FQ0:,:VV^&O?N?:G$Z/GB[#?\E#CT@?$EG#OUROG
MJC4DB$<2Q&:AI>O'98.I5_/B6F3?;;?^B/:N?\075H_.60C]P8+IYZ!YFUGB
M1YX=/XLIU)$@UGV#W(- <A-%6KR5N!6<9>"CL5)T/TS_V*A+2SA2N8.C;VL'
M)#0<!/<0D)<"1ZE LXO+MHDPA^(&A:\.!5SSL1YB6PMV'7JD5,,0*N15.8)5
M,>@;<E$D!:B14YO.*TE%^^J;>U2!Y.;Z(WPV9%@\C@&QK37DUJ3KTC):9T1/
MV=P'-;>KP7D.OA&]R1T*.#&2A&LB'>PM3\ -LJ<&JY"PTIND=> '54=#9XZ\
M(#$EB'?LZ7;!44(M!\L8[!I08D@0Y>0X"\PH$ </]8K9^(>^A: SPV,#R\C?
MT!X4Q_"V<\J.UWP7:]55]1@K5R1$5YZA#D@?P^K^;E]9M<0/ZX?*%YA"\D<V
MDM1" 1TMK\[#RG]3,#8669E4T-@5!?,(Z*Q*OR?6_$KWHP;9\-AQ>,,%P_O9
M!J*X\M6G=YW2.(95@[BMZ+B]W',H68R*1]?^I/P)!B-;MYK<%& DPG0(<:"T
M6)K"E8O'[B!Z<;"Q$H2*4(<7WIR]Z;[A@X%BCSU@!7MZ_@K(Q_23SU300:7X
MA4%ZL@EI+8AMN40R YHN]J'V5(J>63AR14BN.CN&> G93#W%2315N4[A*S49
M0H92,2%9<I$-.Z L4+7%M:!%NA:]<8)=3GH)>CLRC6GKA"8\I032,:B+3_RR
M2(O)5N+)B*I@%Q<GEN\CVHWH>[;5I*+4OAK;S2*$)K7E/2'MH@N_NT$7*B%'
M+!T()C0UR*0TN[#7D;1,:GVO@ *&RM@#.D<3"MPBWBEZ1=(F?0&VT;TIFTF=
M&KJL MZ><0\-7FI86Q,R3N,H3Y%>.#0(X4]  .>;<7IU337+"*?:1E^$N_"V
MW2LANOWW-'%1H$Y4%5'1WOY[Q9L+>.&<JNDA@4,_U,;%-U'Z:;:BE+HC F>A
M-VC=@DD"MHKW"M&0Z2BP$6O'I<3>(I[A%?=EJX%=S91MKD.=XH,\O>$3+PWR
MWHR#)EFA^>/IP$$B6G0/9H!\":(4WS0;RR[K@KMGG>\*OHD<AP9;D8JD@U ,
MWP)J#\\E'H?N&3* ;1-8&0D";Z_4*-;G#=&;:#N@O?PD42%)O9%#B;\],!OU
MVTA=8=%^;9NBF0O9B+9CBE_:SO>.H8]4==&(SMG=S!'OI!(AFD8\ IWBH&.
MM>EMMDS4$8C,_P"E".R)'M!6E,:)T21<\P6DM"%):6B"+DNM<W]%=*SLL8ZD
M$0\OD7:7LPS3.-TQA3@*>&G\P*(=>3T!QS\,+8UB$CPV?$'[V@.C$@1#'PFW
M[8;I$,S]0/$G4_&Z!&X2E14;0E'Y1L"VT0K'*=N(A[C(F,.0Z;GZA%;%S#3J
ML[%3/:[<X>]5B[3E9#9K@7RW81NIA0TZ&JXC&I5^:=@.A?.C(=-\<3>E CN3
M -:.KB<GBLU\:L@MZ$@)HBRFK2NY01JJ!6?YU7T526NY&K17A,A1EP="*8Z<
MNA!-Y\DFO9FB[* 9(^,';+%^H=*<VMH:&H\YTB54H,&=5RXUHT\E[@>!&4]P
MB>%Q&/(4W(!DN^T,!PZSW<'@JO9\*(#)1[/$"L.3$H1RQEFPKRI4-LZD/N<[
MX=1(%2/IU >SI-]Y+X4G>6/-ZJ<NT:NQY2$TR( ==2W+O0>E*FZC(TDZ!!4I
M:$+JGC BAU [TA833(L]+.ZD;R::\EC<!WV9+O'"H+PIL?I;)DD>RAQT8^(M
M3A2XJKLT5\X14 -K[V@J=8=644 W]GT<S]D5-$@"O4>E8BV47@Q8Y4VBMR^,
M@8F5Z=BMO^G>@\" R6!33<']77TE1'P.Y&ZA ^1#=HY08:&OR?"F;O$>K-NX
MDM+IQNAR.\/:E5G:YPM8EO 0+Z99KC^<+P*1+7+Q*$0Z!M+V;L5_(\.]J5#G
M62(\R$3)BUEA'E$"!YS' 1XP/02Z7 +)<0$H?4)M&TF59P]KAR%I?E3,Z(7G
MA@^,D=LN^31LXITN>S6YA-K,0S(L#=B8\GE#F!_+JH1*&R2(4:4VN!N.08\$
MQPFXMDPJ+>% PPX/I 9DW4Q9-P9MA$%A%(%F8&7Q%?76HP8)(U@987@9+/I^
MF&#EC?#]=RS.*[5NDTO&"T/"P3:GS$$'@:U +&W-V]OJ"C1E(1^PW\7 8-"
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M:D'+^U&D49:7B,90U4B'\P@M<A$?2]D8#!L7:,D%LN':21 Q*AV+,7?KG-]
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MP]%>HM&IH>DP/T::6FW[UIGQQ=+R8;AAV8C4F2I:<(:4L^MEP[H^8V&[#/^
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MNHY./*YE19][I(]M5MP.)][+>B@]AQ=C$;<4N7%B4@0"0C6P:X]6%$G?K"&
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M\*YQ))Z@P?E ""NF"0=VX%MQ2+-3&T=\C'2K:JMS?,E<F38(QRH[G"G1XOK
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MALBX(D0@7Q?4\X7K&:TDSQ3;#-NN8H]='TX6;L_?<V[L31>)VL7@O1*NKXM
M>!'HQC\#"/I$(-= &I+1UV?I*TA0[?/[K$<$S/LL+;Y:VP5DU V'I?-5F=O?
MYD@<Z']=U([UG1A,TVVZI/4C)[!4:6ON85+PV?AXL],G^)09$L=$(\GMU"<9
MS FQC<_0-[G;Z%Y.V.@#2TY $'?WC1H<N<:N_#9+3<<D^A>[-0EZ(1USM.]A
M?3"DO%V:[+/N$9U[9G&$WOJ'"TWLW[^QBG4.&58 0;@+P?5L\0TWC.ID#@CE
M4;Q%TWFM>G<S[MZ7Q]+X-K]:SJ OYWK5S-5=Z-ZSN\Q;'U/<6[GRT0)!/?G/
M6;7^-=$ O])MX%)5<GG$XNJ9O3;S#/L.,3=WFQOVH]/"JH;@S<(#Z/9Q;I(%
MP6!"3T#X*]6%QF/4?ZUP&1ET4E6366R'\/?=I[IQ7W!-6K##RBTY*J[.+0S.
M,Q1K'?*DYH?;:2YTU2EV0+L]N3R\9*SU$/'=R!&+,:)A]DB<X0AM[#J5Z;QN
M\)X+B='JWO_]JI_Z&ZT9\/:F?.?[O4&4++5\_NE=4$]+*=*\DBMM^SDY6,>G
M<[O=:NQ]<JYM(7293%!61"#9'\E8IKZ$,FY'@T%BMH]1V-+4,CLQD/QB8BWZ
MH9A1> \6Q3JX&'K='L_>=8YPI%@=_2$WFJ!0U.I*^/H\T=J,0GS&B39M)CD(
MR4U]31T0MZCK'I;W[/[(#[4.^BQ??(<;-.%5DW;"0R,L,/773V7_S:E'#]BK
MZQDDOHWP*!NVNGN%E2&4(N[]UV#)G0O[Q$3H7<W(PPYYX1:^P&MS>H1[-5.<
M0@MN&MH::RM6(M#(0Y+^F?7[3@L^'\RKWXM?%2B?P5=VD__7 !.IL6,BT$]7
M""<;%?C/; PX*D8$2@NBN0ORUD/X,(%K(67#8AT;)=]/FNB$\R$0H;7\"]R:
M ,S?+^9WR2;_9@T.L*S3^]<@3.6ZRR+0UYJ98'&"CV6; )AZ;W]AKP#6G.R#
M6/I%$()Q(M#IO==-^,(8X0X1:)XBIJ([:3&P?R:I/%V-Q:[9F_R;J4&UXD)A
MF<>'N55\VHPJ."<O,X._5B0"1;+%NUU.$=L%$\NH)["-SS^-5+G)4:$%PZU[
M:/],O'QK^L;W[Z)D22P\$Y'CJBV=92(G'7M@\>Q.V?*/N7Q[\:N>8YO.OB/Y
M(9)J="C@&+R<E@CT^W1>4Z;]$[X)DWB$K\_-(19T*T:%%XY,938D%'E]H(_0
M.X_KIU;1>#)5U?N_W(K^-39]R/LVK$91<X]6@O61:.A%YAU+N(3P@*$&B0"[
MGNQ;HIKUHUKYZ'VH8MBM?1)*4S.M82_O^L6WE]QH^]F7O>>*43G\Y==LAT\W
M>2K^62I6_JD>'7)3O8YER''/$;T,?V.P=*KGS4%E"6L'LZY]O$^A;960>U,W
M"791'M8'<%I5 19F5OXA=D(C$_X^&$L$@G"?XW>#Q2BVO@<*+S:M#,W0GL.9
MF3!F$^,P;/*GT2'WQR+0<3*+>)$*^&Y(J(3-WX*--0INXBU%($&@MW C9&$-
M@RB+4.9?23Z%6)(R&X4-/<#S\];7(&*L]UU^A)U$Q"^)0%%GR")0QCJ>TB3&
M<3L?88CUAD>]%($^WN:*D8U;Q^;$\'5UQ 8)Y/'-Y;CU?!%(&K;EZ\KJS +B
MNQ%9P)N; H38?#GPZC"A&H$05D*X!W3SA$^\L4QU*1'H91, :00+/;X3^7IW
M(?Q/0J-_3J")!\3;X(%[1BJ/5]K&&F+*()QQ1H((M!R WZT_(32-:7438&/J
ML;?EX*NOB,1[#_EK@M,7( O5\/N?9];\UWM%H/U*\;#)DQG" TS8&EXH#V-)
M<"0$NS\@@(!OAMB)I6DL1+SF0H)8;(FW(E!A>XQ4LC"^:\N=_V4K&#@:(FWR
M3E^<=<19B!BUH)4Y<4F@Y=T6;CR4WUB%X:9,-@$4@5YG8@&+IR+0KP<B4.RQ
M1MBR>BN6V7%6'-R,9WPT!#B*;!6!UO7@4=FD7R_0MK/G!'0X\.!_78P43L6T
M(H0G2>^38C;F&%0.G^2T>9K[;*ZA@3 5VW*-A5O?L3D:[1-<Z"G#_U,($H%R
M@U5%H+V.XM36@.&PFXO-/F)4D)K[[8Y"(YF(5N_XW\D/GQSM68N2Z/SY\LX!
M]UO/H0N0OH79:LY&HPA4+M$(CD+\IH7<[RL\^1[P8'II2;$43)K7?U;^JL2>
M&.C*+Y[V\]Z;Q76\&EZ,<.WVO?/\^IDYI]T(H\ C:<*2X>E."LDM 'QQW7\%
MVB,C41)A?B#"/]&=R$X6E+1UH0C:W5-6N2\'@@I["J>I4;J]N=*VE)0<R[2M
M/T_(M>GTGAS%$9AX\*? I_Z'2]TN1Z7+227DR1OZ#,S<\0]\Z&Y#W]#'C)'4
M=+^^L<&?L4DQ6_Q8_D,$8NIS)OBKFX-Z<KA@$4AE<V#P#!G_SS"?YO 6&+_D
M7<5I(5=<+5S$[+E(7)E6YH00@AE'KPC;78P'#+&+*;-Z_I"E=1AP#)/V__-2
M]T5\J"!F]S^3M)B&+(C0MO??=G -AM%A!*0X2VECB=B*48&!$")\UQ]H+:8B
MVC .&KMV+> .;&(9QC$1@8+U(/]V/-@_F/+^$].9LO_2<LQQ/-P4@R,&,_B_
MM?/#_]1.))5_^L+_!M/KESB@C7RPXX 8][]_M&"[)['C..%\ .+_:%P/L?_'
MZC373:N$!U_]![TT$;?%)7$$2%!$H-28DTI"K/AD6[&K[L__+3SR_KW3SF(K
M(L*Q,5-]8OBPE@SQCL3Z_^B,I_X_>_C;/WU6'(!43#8)W$VK_W_NM5W_'H"?
M$8=0M1=KJ;//=RYT4(BH,&;=*-@E+OABB?,UP+MB<F#XS@>'_I?'E>[Y='TE
M#/ VB;:8=#I]6I ]H-6Q1]-=> "Q)V0",GSA*>8U1G?!R3H-YKW;!M^:/Z/<
MYRR<0BQJELB.=1&T'2K%5,W(.ISB.9?=P)1(KC/(>KER]/P#+!/"W='=^87"
M<PO;DS-DZ&/%)DKF7%G_SP/>>GZM??H[Y3#HV=2D[NK"\VL8&/W^YSFA@B%)
MO]TLC10%XRMFW,]I7<]<I T.W"IE\#^3<DCU)O]C]#:=NAEY1"1'H&_S7^/D
MV7\&<\C_*)C?_8OJ;'+6)0412'S-WF>S&&3B 2,8_ZW>.7$M@ !BRVJS_J<4
M*ECLVHA)\;H,*FGS^:-S_VW\/?N?Q-_HYJRQS1G?_XPM^^>PQ=AQ<;%;W?'/
M8;'_.NP6-G&O/$8$LMXLWE_J68HOOU#XYF+>2H;*3M3IL"5W#7;-Z]TE=<QD
M+G>47Z;=W:Y7Z5ND=+RUH*;H+X^1IS%Q"<?CY?<9P@[/AZU/1%(3PWA-"[1J
M#>9Y2WQ$.A05V8).H>D/C/]8;80]G@[L^977;KT\4:]=AA!#3,V?P/SX1)L@
MA'V@%S2TJC\C\>M#1H,FKT"#F*2UA2(\'"#47<*NRIC_>^)[(X+Y7,H/;'?8
M?^:^]S_UR1;&"4-L1*5UQ(I_Z!'KS=UBKO$_9+(%XCK\[PG[_YG*,EXL -CU
M6FNV>&$## 1/#/MO@@3W;]9)4-SD(8L,&P@"_'^S+@59B\$*?.2+A@%;&0$%
M/L'?9]7BO3%I&"2@6-9L>*[ME%N+?R?Q9?H(_.C']U].7-OS-MGL_9[Z'5U_
M1FBI[]2#IK0%Z/$HD!B6A7ZY_2"O&@YH$#N^34K!)B16EOD^,G='FY1 OW^"
MIM1"SLISSNO!8DZ^TMQV+&'V-],[#D>W$+L"&UWN*RL<?&+Y@($/<P*6>-\&
M^1=+B4E0>PZ5Y\P1DHH 9/,@YO>!>:@.&Y=,3W\<[I\_TW"ZGW_[3D<)@&2^
MU<^O[\IF=AJ0JP\Y$6*%'>IE(457;_&J^M9?WG=< 5@?M+DW/_)K?Y.U;F//
MV!0Y/[?]J7O[_?=[:B=+V.=>%%&+"V]/F67>R'/>[]8  1L'>2PYBMFE".3>
MWWCK;&@$>@+:.1&;;)_*++$BZU=P4J<&*.X?OH^8I<NI?>4<G+F!*O7SLLNH
M;+G]_L5U=0VYV/Q+,&Q9S]^I)MO:+'^S_E-"0O=>\JO'2H]"OTSY.TA+O&X+
M-:Q9,6JQ;PV!O2<U>I7QNW?2@0UF=^SM&_20).A^[F7*NF?<\L:G^+H0A'<=
M=YL@_>T36\>)BL$SR.69M7URPZ8]'^48VS!_H*]P""U^SCP_@%W2Q$(>]AZ3
MQQY!JP%Y_Q=M;QX/9?OVCT^W2K),RJY,BRP)V25,RXT04]:RC9(L$Y)D,&8J
M(>L415&F0D.62<AN[-)"64.,F4G6R4P8%[/]+O?]^3[/_7R>S^O[Q^_U^_TQ
M_UQSG>=YG,=QG._C_9ZYKO,,NI1]!B=CKC0ZWO5JSL^C__G%BSZL72T1_1?<
M@=?B1D&9!;Y% 7535565$7HG&Z&'6BY=>_S4Q>Z)4Y=3<U_N =E;'9->0HJ[
M]QP]::!3XROF922>_.)4[M-R)ZI+IH:X#4KRD/,;5JD#/L<JL>*JA,^MYE#[
M4Z?4\W(NJ4^^_4[1[-GW="KLTUQGR8PO>M5Q4R9==\%%5S^P39OD$']@4UJ[
M8Z:$<8JAU@WU2^;OY4S3EIV.3UEOYO6G7</.S,[BD=@H5V/WCI:< .97N\\5
MH8,10:I3XW&=C!K-E-21KMW#\57D1FG?Z.[??-,R 23A!3N=H-DX<FPER0[#
MFPIIGU,K0^)2S$SU!)"8.0K70F51#C=0,094!5.8L"6*/D, 0:ACID-X;PC^
M LCT=Q"'8?SO<_YE[A$I\+D+L_C&8@&$!>?AHCSY(#DN\B.M5H6<P86!>,_(
M]:_FF>:!_$)6 -FK!#*(WEH!9!+.JQTXY_'NKW'Z.:/D,EP]2'56NZ1"6 D\
M6S,!)-E% *%!UV;3?E&6?V?QQ9#<>]%6W P!I!G'"7N5\<NHKW:3 '+@RS((
M2'9XODM>+RSNO&KG9G 1MQHLB<4P7%DSL;, P>TGE*L,VOM$3!SBB6O55K%G
M(-YSX.R&2+HWSNB3J7>0^M,?M+*G(;V<#\$#KV.:YD37Y)]9U_?SQA&T_NJZ
M^EY^[DU^G5*>Q74.]R*(T[TAM,'ZZ*OTI?6?&;B-V2]RW:IQ@/ :(ZD'-#5I
MD0.R__<*_VULT<O:H(F_O%+-"N21)^'33?[C=.AZ9A0,[&GCGK*8;2_!IOB-
M6=[ZGPW_=F<9EETJ@+3C5AH+_VZ)BW9=Z5W%K?,!6C*N_P,<T,']WL2 _08!
M$?0*H^=5TE0UT,8OR*WEC%:#H@FL0^R\B!1C >3!AA7CH!6]K,\R=@8,M7DP
MMO\>&FBJO7XR\A0-*@HBKE.4JQ>%(#T<2Y@S,RO^9.J"0?"R@M@$P(HM'M'F
M?D;54?MG*L[^]VV)' S9*"0'G_-!;(?L=@WB.(T?NG$JF0<^QV5%  D#Z[32
M2EZ24T#T\OB<RS#!BFO>\$P *8O7*>*LOXNSY9B87">M1_(X*]RTETE3J^CF
M924%LRC#4@I_TY@ ,ICVT*\3/LZD\%:*07IT"[?.&7#G@/%G'@.G'#_1AUSZ
MA0.$!) ?/2^3?NK18;\ %'_]+P]O_#;2FX*KIY*0C<4X%J@<7/@\[;_VGH &
M:*^M@G4<@N,^Z?_JT83QX5'$!1"*&QETFRU!#JS1;<C<#>^?"UGL^_N=K>-L
MD($2PN%,80&D^YF9],?IO^PB3@P*( !^N%3KKTYP?_=A02:#U?,/T$2A45M^
M#,AAFF$"B,J-95>=?_6^.@12\TT;M-SZ[RNXU2$29>/*'./OUD+_WCI<ZA^M
M26#KM?75/',=_F(\>;'4G<P%&PR.)N.P67_MC2%<F<7E@#3[%IQ_9G:F#/G7
MC0+(8BFR>N-.4&$ 79PFQ65P'8(&KZ^\I%! NG(;Q[[-.+AQ:C5N$O14ADF2
MQN/_Z<0S?S430)JJ<,A5.'+V'\;F@L$@;LC9-;W"E[4Q$T=ZMC&'29[G!9"%
MQUWO8F;$Z7^8H%'&>U8P/O/5>U=65X@?P.K[+W--R?\%,6K_@IB_%ED,N7\V
MK3+X+X0@)[N J+1I$73;9XW_ZQ(00#J*(S;R)?=;WE]],;ANY!  NK:8K0GF
M/JCR)S=6K' E;B-_P)D&A^N[:M9WPE8.+\/_;BJ >*Q+6@H@&V@U#(_>@";X
M^L2 .S_W'$AOD@60^]#_B(L\!G(8/@Z:R*$G_;]"1EBTZ\96(NO\Y>#_@XNN
MBW]-T*S<(HO+_6=KY?\>'?>O:5:'@+BTF&V$_J<?P+6S<NF?J,'E$/A@T,:>
MV85B#6$LS?XNU8W#PV/L#9(1O42ZR^I?S2D=Q2"CN@5;&C;XA'X#/)X=NK+(
ME^01F/?1$1=O5VFVAC"BD:HWEV%UE.K/8UF_VQABWZ0+U"9*X1,.0"FHW6\B
MO^N6.BP3?SD!N*P>.,5,!Z%J7@:'C CAN^8=7#4)LM-XP+(N(V6N(>.7["MK
MTRB"E_C?P/F"K^E."MO NY7LU"R6.FXR.HC8C&(H-4W9@=R2^PJ,F#9Y(V(K
M?';I+/X7B)05GU7^W8?_UWB!M4^WU_$O+(<N=SW_5R'Z.\W /#9;LB#/3L&X
M<N0U"!O/C^G]1YK]EWM7_\J5?^09&  H3@#Q^O=(_WNL_KN&&/T?9[/_[FOM
MGY4!7(S3?UUF3Y^-W!LVG-MT%S\LW0V<]4,T=<)_>+/DY4 X@+]??5\DBB9'
M<#^>(FZI\A8>N-K<>S47,>6Q&K]QGB5'>GJ$3%7Z+8!4&_ Z'8M^+9&K?C70
MZAU_B41$1K9=U2"+G2YF1Q =*<3H/@XVC#\]_BK?AKBX#XQ<H-=7]U%1V]Y/
MRT_QN/>$@>UN4\GH-CD8,R7M^>ZY//+SX[K;NH;-E^NY%V>I!,[\QE(YI%E-
MMA% Z&3^-V1EC/K &JBGJD$TR:30Q7"?*K[%,,Z#ZP&SNKR;&6EVOYM&'0 N
M1W#6JX_2.80LY,7OQ]P9_P6\>*SUWVMD\)Q'859'UVVPP'2#6!7(PW,("4N]
M-F?Y1PZ :22AEZ[HTC732.:=SW_$"'Q8-4:A@&[_"^WA7#!RO_T<K1_PH_B>
MJ*QQ^L:N+BEL,,FJN<(@!)+TXQHN]O/5G]+3PH._S9V,'<YM9/6ZW7RW5$#B
MF8)1W^2$ZP;78E8(]^E<82']NV3$9*U\4/Y#\5ON6VH[PZK-RG/#;'YXIZPS
M):"GP-FZXPN%##3'UBG]ZZ<'J$TJMIK5;;U*'NX-]WN%[V#<]?4L&;OO?Y2)
MQ7ZU5BSZ_O9 W&5OR[X7\=OD?A-&#%O;K'F/S2'N%\:Z?/T)PN:PB8:S+R1+
MJIMDWPQH%VS7M?7P[#5K?WSPV8^;0D]=7W//R0$HEC"_'2D;"W(C]HLQ(A+Q
M0\<KA*,M ZNP6@"U#?$Q?;*Z[5(2[,JJDEC?!5GLMN.?ZB/NGYS>:RAA]KZ:
M7SR8.D[812W+L'W2M:_=C3%&=<AQ_>KE8,.@T ZID269UT.3TR?%/JL;1%K8
MINA.'82IJUD]T40>#AY_1)8(!XN@EFL7<BNPBQK12=ZU<60@= K8P[I)H9$2
M,;*T$ GL$%]JP-2O%)"=;"*4 3F=ZR7F6QJ8FJD_LVA&3*OX%9*DOY+"L/8-
MX-=BT'[FN^K70'1[UCKV6=CZ&.OF>J\KL,*! KDM*O=07GN!S'?]GZ$CI+18
M$O< >9!RIM[RHX5T>V;VC=7,%!O>VP_C:5[CI[G;!) [40C.46XHK_!&(ZK+
MI'=!Y"++D=Y3Q3*$)E/>9MW!>>,41]#QT:5_+'4H'<AHC4)VD7>B3 AMG'I%
M<9_642-\PRE:T+'CE?WF:HB\THZ!B&'7(5>06YW [;&$^^.^M8M!S/=R[2%B
M6R 89=:V[7]PGZO)0;RUCIB$+8?[>U^+'#35$MVR<NA!-W#G?(((;;>&8^F#
M*X%2 I!\6%B>?7C0*_F&CLZYHLT#Z<0IE@=+NN:Z-&K(F<ZON.912%2P<2(B
MDG\K]BPO3/YX]3V@V[)4\8.$Z\\PCL3.%] 3W3ZS*9L(+[J*?A:/ST5A"0JV
MN!B_BV+ID3K=T6%;7EKO=0G;'6+Z(._-GU>^W7TW<+-3*KM\QX<=QIOOQV#G
M8F-S]7K-BKG%N!#8:!AMFH'D.'&#@0R6;:>7RI 8;!<WDMJ[!0B."3L+RF&A
M%B]%E@OI)3JZ-5?N*^.7JUW_X07],37^<&B([.@*:JUL98_-W-SOG]:HA#O&
MAM7R/CJ/_7W4O?V]_1U+O2IG/C1:SCL_.N0TZ^!PU_WZW>\%1PL[=4;MS]G.
MAS7\DE=1BK,^F[G_U?[K=_>^*NI0L["__G0TXZO-(9VDAIQQ,+L<>P&;#:ER
M2B8.A-08N "2KK:Q=6\;?%G''PD8]8.L8S_Y_>8G6XT\*2GW=4=S7YI?45:3
M?[K3WA+28ST3Y5ANA*RD7)Z.+0K<3=\CG&LRO;9JL.[&- CAOR5Q#8M7Q^;W
MD%W?$3^!4(#GQX':9CM! %'G-_2N</_70/C_98P&]]:]A\NUY"[DFLB<TG<<
M:0'W>':\-F.?^#C[9[>SR3/^>;6/N(^=UX0]P'*TXZA93?HQ)-^BB'\^$S9/
M1RYIN@6"+,@KN9&7CDRK5\:1!!#N025Y >1%\DFP?#6!MG1+X5K/40GK<I7:
M7,59\/L'R!^0!59J;V14\5/?%;L3KN:W<A[DFBVMG97_OM7]XT\'B>US68"J
MV1._Z<)?6XV5\@60>XHQ-0]NUGW<Y3I'6HG/\ Q!1<W 5Y90OD5@Q=/17!SZ
MD'&SVK/.0P#QK@]RM!MPN-(?+@JR/57_QR.>+>$_UFX_,>T/_AT9W:KC.16Q
MY1)T:VWS"=:'1_*]=SWPIP20787=+7OPFU=)OV\ \BPZ;75AC'6J10"1Q8IR
MC[.0MQN"J/ =_J./JGX]H.WQ$C5S&QH[5Y6^U-:DW(\=9&OBVJ+&GV>=&=*/
ML1=-MLW1>'+<XJ'5?EPQ.:%*)-PS[,0@,<WXRJ#Y[MGUE#=MY.XD]_F/MD\.
MW#NJ.:6<_@8?IL> Z2C_),/IYL*DED?,I//KD7%B;>+)-UY;IKQ9V6=Z[(7"
M_2(;QR+Y )>=<:?MU%&R4H,4<H9?Y5*-$PIZV,S# &/R=(^%BVXJ,I!JW&TI
M?J&CR.)5_Z!1:>/^8L^)D6^GV,F<>I1&#*MK>KQ7NM+\<D^Y!2Q'[V5(IM5Y
MNMW8LY%S)RYMJD ^A3.=*"-^'>1WR(7Z$*9LJZ'NQ$>:=HH LKF*L./C5K)P
M_*\;.!' E;;U$0F5>Z!J@/A@4RUSV244M6/D9+6LZV<_=G2T;='N$ZHMI+GI
M/MCS+'-EYLK3GZ-+GE]+M2P&7%0FYIW*JY]Z(78[G@B8LC5YK_4J"7TPZ7MA
M]NF?B8/;W\=5*JQW:PTCHC\ZDZ,#M!W:>W<T1!M?3I,OZQO&Y0Y]M=,_9VW2
M><GZ8*I\FTDL-WH>QCQ#'MLG@/@; "LL#EOC*QGU@!7Q)Y!#UTXCB#/XFG_M
MGA0\1A\&>?,=$Z.[FK^X\% 6M#W;N>P1E1"_/I%< #A:LNQOHT)*@6B[?DV,
M%;5>]HDA[+D XD<"5,D,,E.47<)[B%5&]U/9!!;!BPF[3?8;UV;'\?(:?%D'
MVKP,O_Q:QM]%O@6%8ZL (C/.W9L[Q3W .<759#$6DQ85CV=0#7,$$%%A=C30
M=17105 X[V]N5->8-GB;=\ICPNW"?NO(\)" W14M0;NS]#K^,/L\4+REJLZT
M)*G_N_VLF*2ZKIU&26BQSA]/>'G$N(:P&/]=]IOG#@=?%"4R;@>[,SXA97*"
M1OQ"*N58HB*(]Z=<)Q%<*=RD+ .4TUNT 0N.Q@Q%V%PV@""T+(?=@UYBXUEE
M>-98UVC6W08+)H>=E-!R4P&V,$Z5RP<\0U_/X^F+\>:'6,A[YBJ\M_[0V_!*
MS(%7Y^<54F3#W"T\?B8RV]B,@08CL'--IFP*_#)4S@T=RUX'+AK6OT OG0:J
MF,'(36A1FF$11P2 4V]63'YVZ$$J$9-+3V(N,_GESV?7RS+RO (<1I$!=3^J
M,]E7?OTZ IU)W:/\9[K1A0/AKE:68FDIFUPL'9P?W=YR?N>VO;%)X=AH?C=9
MGF_R*HL)F\1W:'^;I@NW=!_&2H_/9%-23:WIL+M\;>9$7 R3! 8!JE^,8-B2
M$IJ.L$XI8\V:AJJB<:(-;T]%*#=)#2FQ/TS(:Q;@OH0U&R_ >4Z;W@.]PJ>K
M5(7XAZ"BZ?:Z<-K+/J9Y0K4]3M++G6.!'4!63"\\FT3S]_._XF0P,&9&R[#;
MW2CS9Z_1KWDOL\X/*2=9]ULS^?B /4,5I+G4S=<]#-+P%Z.O9;*Z0P\IJ_4T
MY='/B*M\VWW?8'%[VI,>C-4K.EB)I[ET '1B;([I15I,"'^[+%5;>"[[,V,Z
MKF$+QQQM3F]U$_VLUJ]O2Y&9GU!M8*GDH:Z4>"N\JF0K7#4:?8!G9(P$C(8G
M?QAZ=\V2<*'EJ9'$H9XCD19GSC!K(D_M22QU>>IC4I:II*\\^]5A5=HF_>E^
MHCY=;LDVTTXM5R;L20-1/+'3,KWX7(S;(V/K*F&3ID%U^QYN^;F,RO"@@R_K
MX84A #:+N_/^)L*8: N=Q 6YZRY+],PFIO7>&UUS 7#J.HYI U\WA6_#4?>Q
MP+KR.$D ,2 ]?AIDBFM<?]:0BZV\*(#4@V4(R.85\_<2Q$EK3_R.J;*\C^&^
M'65!T_04R6R/7;-5./X%X@O^0S*3!P<.PGA*L+MPYGW@B0#RR0+V'Z[ALH=@
M'#(H:A+SH#P**#+:096RPS&>/./[E = ^5>@*Q0= >3Y&=F-_9<R8;.@T(>"
M]>\.6,&^4@$0[D6@B01N^[G_?-EUK?2_S 85W3@?Q[6#L;88H_CQ%WKY6T!%
M\]-; /%<@JUO;HD9!,OJQ?]O3 >UPOG_WXP/8CSQ W--!M3.3V)Y$9]P,[NV
M;.QW-96P[B" M"V#@S_$+:.Q.T (.T7S XNJ%.X_797FHY"&Q_=*//<[0.1N
M]ON^U(DP+J-8 Q=9MNU*T@/<".HBR"UVFIZ:#))E$,:4#)B@X#%U+D-;6?-[
MG&*L.+;M45X9$?G?0'0]D)^=,!K\DB-V5;GN=]ZQ8I-<,6:55(&[T6>UC@]'
M'(K=-0MDC\YN*W(JL-=]F)NDDY$19:DYXX3NU\N9BA<5,<QXE"?V)^&PR]M*
M/Y679225A\XKZ?"O]7P8$2Q8H(+-:V,F\'?"=L'7[N7]IXND);^!&Y\=K;(G
MQES[0RIS<CX;MEVHK!Y8^'55I>YKE7MX?5]5\OFR%TFVJ=I.E;[U_57;G!G:
MI1>T-*]DJHA?F @,$E/2S;]?HBQW6.^^Q$2TDNZUJ(C2 Y-$<6MU*[V>@S)E
M!?+>RME#GXVI!;(5(^0X]DU$:H7R O/Q0<V8H6*B[X\YY+M4U=<W*^P$D ($
M%X[@BX"RV2J!"N4JFZO@EB2M_L,UY,_R&AGU1UK/=[ZX[0T]ZKW5B@8_-!!K
M,:Q54EJEX0EUJ^O7#F^A1HO;#UL/J/:'<.V_GKC6)%\^L*\JVI8BJ1A=?$$
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MI&LO_&PDM*UW$B6RPHES#FYS,A0++LBITU$LT8T?M@60.7BA:S;_8XDKVP^
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M:^Y#7^]OC^KMTO1KSHZ>"0V0*8W !E<R=+\NO!CP3GZ/4>7XX5KLM,S-,:;
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M>\1-$]]X,ATA,AOEBX\WU2&AC<X-OF1>53B?X,+T2BT9/U'451@=G,'JXHN
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M'*X,D4-[6QGPLA)Q_L\BFIE M,O7&^1M .(T"Y:0?_<\(,TYBS&&04!=%9)
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M,BVO>Y;^>V@35?/8J#ZXBJ ,/Q+&G9==28;R/S=!8,*X@+&QQ7MD\883],M
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M^4K6 NO#_43;#^5YQ_PH=(\7N^]8__#1N'\DDMN\=[H4IXB4)T]6X]XM83R
M1RCFD@<0,8G[(T#)B&5XFXH0_XXYUH\Y47C!GP\;"KF!NF 0%.(XH$HX.TCJ
MZV)4][6^N="E_U/4'4V]IP>8&MW_N3:%^5,WLJ_ 4=1F5ZE;V7ZTG]Q@3L&V
MUAO#E1F%=&5:-OXPTC 5R:@X?!.ZQ08_+#6]_6UHRCX)K)_<DI$R;\S"X,I*
MO<L _PF.&D_V;6!Q=/@?VL;X\HO-9&ZJ%??(\,*[*/XGW-M: :0^FJFZ4F7
M)8(4]Q=\\N5N7$?GAMR,3VXC#O?]$$"\$IAP*JA5F.<DA+F'0Q)@2,#):T_G
M,=S'7@'$?3</V\8[00^NS93$C;O*57EJQV#=<_5Z?A\$B?3*C6IN6PNYS:MK
M96.O?@..)NYK^<:/H@ ^=[,Y87E^ 6X#W["0M&X('P&7I.12,X&;B/R XYI3
M^-OW"2 6,&J71R@3WT9\%]K1>[';[*@4@<G! VJ1 D@VGDD?YEO+)N#65++6
M;W<6\Z^<1^2B4G#/6OR>[!1 'D>1 03TU'HY.!EY7B9YYIL XHOC6O7^@?M]
M\"CN(F$$=8"OD\QVI?-+EYJ?^O''=99725-&?%@HJ$V@ LA+<(!7N!\/T!$#
M^+4U <0LX344T"1SI>#I6&7,T2Y[<TET6!IY>8E W'PM#,$[3G<FL3-E&S.#
M4I#AHYZ5W^'5NIJ\.*_UB[-\5W@90@C[40#9RI=%E0,D*K&E]Q8!:GI.NF'H
M+)#1@MS:H$DMC5*TK?0O*[TT6/F8$?+RSB]#G>\=4G,55H]_BA&#HM3>L;:Q
MDEX&KOO7*,E>/ZAPZAX7S[BQ==^. 1'H3\S8ZF2:X<Y34'K]QLF6/["4.OOZ
MO$"%WD2^+%!\NG+P, R4V:MM>X[95 \M+U:U:A^6*,H/E%E/RSG,9NP?HXR9
MIJ)TTES?U5H<@;/A^1,"2 ! L!U(P2+8^%M!VBDGN"TB]0-!9:;/.:YHA)'W
M]>)Z^=&CTDOR_!-/?QBHVQH5@3I.-J$]6N%-&2MXP"S]V=&>UV%X[<J4/%FT
M^95!@L[,9&C-X2B4,".@\U&@!S.@S[IWU+BF\-BQW_5C$R[UC;^N)L.EEU)1
M-I,@1NRTKUT=2  SK%%[Q/2" '*B41O4S&]O"B U60((J2I<3NE.AM 7[,DF
M9#9N>1&,F*, <N ;VW9M#C<Y2OAY70"YS/+C;5T&PW_-&K[F"Y:5Q23S;EKO
MND1 Y#Q^X8+>&BX M\ZYTB#+SN$55L)'ZL:HP>FY$!:EHS>1L+MI/[%U\2YL
M.U:Q@SK%TDXQ1810\3L NF=N#+)383$>LX^*ET#[M&!WL83O@>IX!Y#EU5_)
M\3_\XLWMLBH[*T1%S1JY"\ET7(PCB('V73;;15-MA8Z*-C>I\$I6Y$I^<55I
MO5MF1N&)<#]%1?QNP)9JD94(]_?4PNW4SY5AEA6Q4%U-XD!T'CJVK9>6JGU^
MT-2"&.ABI.>OF^I T"?/4O@B1/Z)A:REC6)1!?U_BGOS<*C?]F]\6E62RE;$
M5)0DE$C6J80D)B19YU,JR\1DGQC>E>Q;I2ADDF4(36$HVV1/DAA,1ADSLF\S
MEO'&+,];?>[[>W_OW_T]?L]Q/,]Q/'\8CFM<UUSG>;W.U_DZCYFYSF_D8FP)
M/RP(Q=]\70 ;2KDU&Q3<P4%* M\P9M _*)"YD&#4#_)%/:,+"6 #18!0C3J_
M>VI%T8TL$KIWK%\IB4EO;K]?5K/?0!$\SM1\QXZ<9,N]TXI=@+2N+BNRH2B8
M2:]O7X]^.VH[6)NAR2;?*W42<JH,T6E\HZ)*"M%6#6D]QR-I5EMS>JD"V+5D
M7FJH:B\Z8P\8DL-U[@H]\@/$#U3BM##A]@)8%,X4.F91L*[G<Q]3K]_@V7C_
M$599498 5J>'VUNS]UWOMLR0&QOB[OMKYPA@%A#_F"-F1:^34PE\D;R0Q+_-
M6NU<? 3/+>8%6?Z+H2\$L.D#^ DGHWT#\,RL5-0J/-93_C'Y3F*L2M6Y5,]R
MFG_(B4LZ(Q&GKLQ'QB<;LS>F[_-IXBWN-R/U'UWC=_EB:Z5\[HIBC._3GM(W
MZL=YT8J[M?7]58]WS85UW:.)_NY;0BV#3EY8+$$'3+RP\%4WU 9L7OTT,A2
M66 K1X^M%A&Z"2?<4:4+L%$-<G*Q3:$*;$SL)*%'0W0=Z#/.F4%V3-[R$W:H
MUIN0.]B3^[:J\G)-=2RRL_3[_E2SD#.>I^7+YF=_E,-?V-8-+85(VWAKND:A
M4S48%MMS\\_[>UA8>A,VY:8%>);O:CQO=8[18%L_D'RP9G_..2N"]&:2E9?/
MDP^#NXP4[YSH,W7R#U+H73FG@KLDI#/\) CX(HT<R\,[\X)O)I9@"R#87 8F
M1=2<Z7,0=>I_&D,U0BQX_P=0:_CD+]PYT.\[[#IW/XNA2% H^F05<EM\]1LK
MJQ]-@T*TPP3T_ITPZ-PDE L4":W19/Q!)Y6%!S][%LU$,J$D4OC<UC;!&9D!
M";'#8Z. !^(FVQ:*33Q7S P4P+X@N9QV>X,V)G%99 P!'DPA8I:B\:Q%665P
M]<Z@U4T(8*-9W)-0CC)BS/!-L_X;1PM@(E*19"@)< U5#PI@^.=:?.B9F8L"
MF)T/<;A) /M%YY;RNVK:F'AH?11X,(W WQH"P&_YFG)0$A!H3"'0:%0#+-<Q
M,'@DAJ],9BS"6=#TY4,"V#8$JP,;#*E3M_]A)_M2Q(#V+VD"&!13BWD 9.F<
M"S"+X=L#'JB;;"1D)1&RDE+.;4@$5[:5AJ0UHN9E.J$,^Y=[T"*4I9(1CD%B
MJ$8,UV"0OP7^)^7QI=5$@5ES^.]4!_#$@4@XZ%:E#TDV#:!!G8E96DH"H.CA
M+X@N)!WFW\+PS06P5N24R63_80'L97_2:E<T0'0I6@#+ "?,.!AQB% QYU>M
M)"=R&\CMM^:)S/+_Z,-$,*092G#\&$1](E?#60YR7BK WOH^C1]ZG0XB!+!J
M0][US^0T&0$,>I59RHK5BE8,>50K>]44#7(DMR%R<'DJ^_>@9H[?5%8+SU^M
ME=I/CEG]F/YOP."7\O[%K2%Y?_QZ%A*D=9#R:$>"I<ZR(_J(H0GRR$2,5(3>
M!8C+AJ&X#H?S)HC#F@W/;7'H\B=X_A"")/H'N2C,4ABTM2/!B_.<K+]]D$+A
MWX4$2JM<#3T'D(#H8P7XIVK +V>'RHZ,\1_?65[QIBC^]KR<#M<$O"U*X!Y&
M;$MW+9?2XP4%6_[&<@JWJH7,"N%/7/7G5PHMMSQ=A" UH+YZFP$GDX.! (0V
M@W!]*G"5<Y% 3V(Q"-GT!6/&]0M<$,#>1HV43T"@$L#^5E%DUCO^'O]F[F.U
M;3Q@9*3SWC\<,P)??284OHFKS>5W!07^QA:F_?=1I_#61BZW/@ULXG62^2^^
M\;L,6IED",VNY=)'TN'UEO/+B_.-BKUZ-@^!LM(J=CM'X67Z.@',$FZ8V+Z[
MA<C\"-1Z(08REQRABL8G]*]SB$U5N@G; AYQ2 <LCO;9.:R_^_&I_&(B?_-J
M=[0C;,4IDE""P1Z< XL?ELF]!F)RW&OD0ZSK+CK9@:Y-?-$NKX1D6E60T50;
ME[:M/!N]5MG)HE93IE7YF=KD=*'TWI2CS4.N>T0;=JMNR;T:0[A7%)%U*-C]
MJJM%85Z3CZ7-C<T=!#77MD--5K$IRD\P,KIO"N5\4US0S:+G<P]** ::V_C+
M[^X],;A;J<6YA235&JRKY;)02L.6E)%R!M-=C))>KLJ H0F3?Y4&@:MC(V/]
M%:%@\ZX)WC$SE%R.VC(T>C\?T2'77HQJ@Q3"QBYMX+^RY)0 Y@W-17D@_XRY
M\C<KS/P9LPT:=R.T_9GO#F69X /<;@3+TS!E13$6,:H%Y:2!9"3?SO+_DXAL
M+8WV= I@!  \^.P?DY+_3,H%!AY#<ZQXB8UDB ,@-)@I0K MR'N5X Y0R%PQ
M)#>L5VUX]4I4CSWE?]MVG,H_]1B8;9W_I[7'(6L?_Y<0TK#\_]DFE#P7(5)?
M",R:S#CR.S;H_+_^14F)_W.!R'\Z"?.WDR#=OM=.5P#[ 05@=_^'1$E[,-IO
M1<RWP+TSGRT:>;\PR*RI[G+WU%F+YJGI+?*,YT>%[]KZ3&^L/O/[*TPG/@)=
MK0P\3\]>NL+G<8&($CF8'V)MP2T>3YI3)YH'*ZUTGX 8.RGXY'S%M#V4;*,'
M[3M+\,MK/XG^\M\?XML>BA4G_]%Q7Y]#YBG@(?Z*'.(N4\^_URW>&*@UZDUG
M+5,F-)4T21I$PO3+9=6)#T3(BLM\?]<)"G7H7>N_.3O_MP04&<L@SZZ'&"P9
M1;#_EX.._$\H@>+Z*?S/)LC<G2UT/A/%?[/096GR1X+ERK4 FDBNS,6AFC]+
MXT&%I')> YD7DA_Z9P0 #R21H1&$Q7]-^Q?EM@WUCX.!]F"G"ZPZFTI+^GOP
M^6H_G7\>047JH>$4GNXJET,"1/\QWP,/GLALC45*I(L5C5UWY=\ESNL![JZS
M$Y1JWXP]Y>S=Q96SFB$G%/@_J/7*H[.F%98%/Z/W:''N>]J&?(DFQ>0+5Y?]
M6C9;TXRLILB:#L[-.%_C*U%PNP=XF :=5*=VC"M3).#0$0W0O(?P>EPK8V]&
MZX5.C4JG,4Z1F0TY0UCFD/VYP>,61+UWIQY_CK=P3.I\NGJI;VM>8 ;'_OGG
M5$XI5=/!IQNBL)(0I<4@P$'V9"D;PO&S_B>^M0)8M (>2AH?!B>:%<5[CU19
MC+);"]UW&G^V.D<_&V!LO,%.UL'JL,V]>J7U1P\@=TO,A30WTA.3^?N[_*(,
MX+A=/0M%BF=*V0$$%L8$;#\&4ET9(L;CTZT6W8/WH81R.4,$;UE=_:[J;5EI
M97<I7L31(X#26SMH&R\YC7S%%1HT%V8J/BC%[ +]I_M,J2JI;G]U>1Z@+)@;
M#/??\=24A5^A# L;O"@<I3VM[D\I&)N[Z:!O_'7\9V_<C;A\9.#DB@"V)0,?
M.?@A*[N(?2F4Y$K[Z50T\6WI06B] +9&H:9C87.H+&C,F:AOR3_]4O8"MM(F
MS+"X6YXR13?O/+( W^5D[TZSP+ODN-.<[^78G]Z&9U3+?551/$.BS/,X4P0&
M\+U]@'!_X:=00\8N,&3@A9H#*_OR;:SS@E];P"0VB&[>_;4RBS;*H?(/?"!1
MIOQ43@_S/Y:519STTU5.>Z%L9N:D.AYLLCQR;>3D;@(\%VBO]F"?3,EZ/>7E
MX.<=6*42LG]ZNBPPT(&N&?X*KZ62$^IUG:ZE^;AZ*KC ?H5&&RUB-^6O2'&%
MR%TJI!>NC)G[FL*M(M:7N_U:-&40.YQH;G/H67.#@MQ16DA[#,JBHTHK,,_\
M1(D MNG-<[0GX[WFHF= GUGDI49:&P/U?6X =0_GD FVUR%$:^3 P$;[??%<
M1'ZO6U!FBL7C;LS.S84JTWJG-7.J6(UY'D=K]0+X'J?S/;8W3<A.?39=^,)Y
M^R.W)27HUYZ=)O(GM:T(^7JNZW<>B[NF?<0S.WEW_]'K86L/MLC .#_$5W9F
M$Z_:[C'W<K H,COY53WNUN!-_&'3SU]5)A2ZR]U/_)Q+WJGWHX-@/OMYF[IO
MZ@O*8M]CV\OQ'XXL]G\:DB]CP_'J:M'S97Z)HEX:OE$V[$B8QYI[ YXW54J/
MB2Q&' =*2(F3!<^HC<MW2N<<6P-Y:4IN45<_K*?3KH<'P+87:GF=9,3[FW$V
M+3B,)O?VC!4]6#Q^.&G/VY:'+JAG^*-3,@\WB)9NM[NWKME?+9Y>PHG<6/0*
MC1+C[QX-I/E/)J<2(Q82HT)W4#0K=4>OQYEB0J[>(9[V=_&5O*A9_>U^,.[6
M8PV$BN.! ZTWE'T9"PGPK0+8\U&\#<9G&5'VQM<FSCYU.)?WY9K'E?2;';_,
MM23\RCAM3LW(ZVF5SEG!&)GFEYB>?OJG5/C!T_OSN](/[UE'1N^&R?A<=WJL
M<_79=+YDOQIH>O"#3D.&[Y5P'>U' ?MA"%Q+U9 ZKO;)$86;NISKMH]:V2,<
MO^K$"U="C^"4NRY_EJS>[,*6KRT7S?I.*U3Q!H ]TG.[;A7VOD(71-+7'ZZY
M]>5U3F)^LW^6&?..O(,VW,93SXSW4DNSI*_*X[.D48"5],ZTFY=HGW&E#S/,
M0CNLDWX5N9I(S:P<=BRWN?1BZ,;U)Z_&?5HNA7=FI]O7>%UZBC5)$VU;2-^0
M-<7&C57I+=F'ISNFQEYZ)8#Y6RJ9;?]Y)>\ASG*$06A0 ]:"9$@*\<Y443E.
M/X";^%YNYFE%KA(JHN:*S^?PYC"-5_=Z#=5S![2.;K@_XG4E9AX?@YHUK]DK
MA_AEQ(Z$M+$X_V50X*Y/"&=MXA%>&F9ROKT7/7 S!PAQR?E^!;<9# D.S!OW
M-<(0W#D]-4*=(^]KNE0/)N]2F?24CVOWUZ#4BU]LFIY]M=;$QY81$VM6HUA/
M8P]35S86D\IQ?6YIU+,_'S&Z /:[M\D=JK O0<3E([>E.9=_.O<@UI('4N6.
ME%$1'C/;N(90$=F&^ C 0]4G$.)%!D>Y4BP$=R>#OP-KW:!E?U9.Y0/_(XGW
M9EI/PC//PUF28A&?BRTQ9QM!-!O:P=XR85$2L72]JF?G5[4^<@*!KP[GJ*^[
MMWJ5"3-2%JI()-,:%&9]C$7S1XI"SX36PX4%,/3J>RO?R5L/L&O25@Q'Y;0[
MH;036W.(5UZCS$7R\C028U!0M$\9,N [^L9[X!M)^%[*0(/<\6YDA$8E2L(1
MZWN)U53.F(FDBY32(VLD.OV):\ (I(3'<K:6^_(2FXI@?1/ WCW4-VF 1R_)
MO@?-F6L6]F1$XGW[1I57M!J\GQSN*-A]?7=U=?QY_WT6QUI*GM7M>'J2^).F
M](U3\L+_-(7S54(\O[Z5F8!9L$]]JFV-CL%:C'NG.Z8Q^;)>/M8TSY;7,4J&
M--]@ S>?-E[D9EWDRG?N$V A'$A+)N>H5K/+&U+7E[2@1:-"3V(C3R6/[QI,
M1I\DM4>G+%^BWFY6FLU)IBF7I1X:6JOX:,?U?791 MBY[P9C AA6 -O'!]KA
MPZV#(L83Y\#RP9";M1V8>50L7ZW';TDA_D:,+D^Q>3DWZX;"HW?"&FA_S#I3
ML>W%N;\4UU/+&;:Z#=Y;W4M?FZG5'_;L.Y_1)]:BXE7=^UZ+8)Y1S@'?]+>J
M59;:>"38.[,MLW\5%M(\QK)[EDM##K#AG$/@O8%V<9SAMU+43A!QY3VKFMHH
M M36;.Q> (^$:F 7!]KK9G9-R.WLJ5'MPRHB*;F=*O-YQI&OT=;N:D4TM"WM
MX//7Z*"-\7GN)UHTDO4L5S9P75A/4V*\U' N+%W+"M9]G#VI:UY%C'DA99G7
M'AVZ$7N&SE1KA&]TUPD&0WO5JDP9F$AJ<HU*Q?YQ%8F!#%E)6:<J(X4@!V^Y
M?;QW!CK@J_:&'6CIY@>Y/55&\'B_<G8W^9Z>+IH-/\L*;,"(H;#U4!FU3>_X
M8-1+?E]'C1PVTJE;4ZN"M6RNQZ'=S )>CM&>9D3[ZX?5%H;V"& RI)^&CET+
M*B[UQ4Y@9 ,@JV>7_PRGYH(1GD"58NI_ZC* 1NV_$I2$>J<61#>Y!URNT'P-
M5SM3'4^<BDN8C)Q/]7M??/0^-H[T><MAVP<W)\X?,^UW?'B;H)"EBC[\V;=
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MV<MKNNH LUKQ4@=7\P8B4G-F8ZL7IUPGO0*(NC60T5#Z0[]\*F3%U 3#N+*
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MW%HG\(GX$F1C+!"K$_&<+<.)* 9K!^$;P<'36BAQ%82'K"77E*TU@)S:[$(
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M8MB*-JRIPD6M$Q4;\P<QF]SEY*%D'!S[W7/F9J195=?-=_$S>^^//89Y[4O
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M'64^]H7*O).)9>S*P4.O5C1$_5RZ#SSN=U>3D':$FTQH7+9!;?GU^E*1O<1
MCD56^(9(@E7ZZ\YTM0/1#:\_)U9[;,\T7B!:7;(QD)XO0*K777.1?C)F99EE
M22F(C"NHNO#T7&?^EGBZ<"3'JS!+E!/-]*"%^=G8(LZ!2>NI>%&NKRM:K,T_
M<( LX>!P*L:L56]98O[VV;#X=H6XO )\U:EV0U0J(%$C@B5R2@2P^Q:CP":^
MF+,;+3&ZRH9E,C#RO0K!%#$.@=?1=UQC;<P:X 4WXH6X3@6GMW:.94B".5<9
MGJZ,Q&CB@^,F[CE@Q+0=,[GW@.%R]9&;%]:4OMFD^V']4?GU?T58;=Z%&$2M
MK75E*W,0;*&HHBK] >1.G /O.<Z:.!YZF#*?N*8O-Y\M->!<0G1L!9@BAYOK
MBMNV9JB +M"1^!>.=;C%\\H9[D2U*2ED#:6F>8_^'?D,M34HM;JN>DK;[:4R
M8=U6-^9KZQR3HT^WJMS:IKAF"VG\6^8>E,+HM=M='M3Z0GN;4<NB/><SI?''
M&KKE3!OL,#N9K.^OET0N1!YG%(Z(W:^G-MJV\$N>,8[';?.,JF>X7SMF_?GG
M+0/Y=0G$R#HF(>4#P_OIJ-EZMN91 >PP3H<5V$RDZ7*^\))KM"> =QO)*SM&
MX<4I#VH.@-9-!AIL8H-HA XYID81Z]K WU+%(D0"KHCU;N0MFC]]Z(Z@828V
MS;H,3%X6P*)_430<S%%UTE+<_<OV]'Y4BV@??<]!4[([XCL5&?T@I0-;PNS_
MH/+ZKS;)6 )7O4MC9<K"Z*O5U[Z+W:65IC=/6GH#:'C_T].1%WDDOE2KNWBH
M,,NV631*3K'ZC$;[)C!X@-P@B[A<^>%8Y/8?=!!O^&U>5NZH1>^TOZ<%;=>Q
M@\PO-0YN.#'P*EO*#@Q_P^] R1TIK99G'BQ_20CCKF&-G.NR>)?#E0/]%EVL
MJCI5-:,^%5-QWLP0(T^,GFO1E;HCMBL(9*=&RXVWQ7,WY^4CFFY,E[FG7Y4T
M-Q%^,JP=:IMB4] 6W\QD=QW#7FF*E_Y>>%D=&R3A_;W064W&SK+^8I9QLHSH
MX>Z)0W+&-S)NX.QGI^&,6]?:QZGMZGI4[;:W?J];E5J*?Z0=K;VY0(AI+I03
M6U^R]5KK[6=;*Y7KVW?$%]F*.4A%Y8377?6P 9P)F[XW"^W->+X&:=#\QI?R
M4A,482/XFVZL:(&+3*T$/?\<+)ESEV5.C,.9%X(OJI0RKV#5H7*E0XU4.4:2
MM: :ON^:Q%]T4EH0CGT^Z>DUG&IV[J"#MT9,#'IQP5@\SG]^%+M.GB@T/T:[
M2]BE=Q\V(K1K+ .FQY?[WH;KL4V[::=YGN3SP^G6D0E*_.&O3UX]86P./I=O
M?&D\WZ>]/[;8V[.WMS04'U-[L>F,.%L\R]+:R]+'UIWDBK80<;+3/?&"9#+W
M&#%P5P"#F:QC-D\IKS:?CR0(8+<.08EB/6[-5X!Q*[3SPPC_+T TF 4,P]L
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M#">_[,<"F#B>W\</)02NDJC:/TC4^@^)PDA04"PC&/O3^.%$,<AE&U;7I]I
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M+FIP9[R[=U13W=LM&@1$%(CT3E1ZEZ:4D(A*$P$! :7E54":@(!(P) HO4=
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MQKG0 SKP7$+:;R*]\+,_J;C81U241">7TS E03( P(JBXCHY72FZR&9.R<_
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MY!7 N <E /*:@#O%8/Z6;2=@D4C$<V.N@+9D',^ZB.43##M%CP0=$.</]G6
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M%#F'Z$<D2+AQQ&K\UK\'+#J$.MY.!+-NJ%0U/*:%+7/@5#].M<E73"9V*%A
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M!#_XB-P'XZ&%$%69T/?&0IS!R+YL:@9Q6%VESX'LD"D7]"OB\M>5U&Q:):6
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M39#.8X$35]O?S16![] /_<T"^#[$@;+V*JTF-(P>S)^F@7WG2?6$0'"/Z.*
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M:\6-6E2 -6?00Q'DJ:W"!R(9/)/K2*Y8AZ6A$R^OPSXO4U^1NOJ[2_0[1!U
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ME(?HI:A!=BX FC$\1-.!,!S<HOR3W-JPPZ-=ZS#(.9)*0 ,5:5<(1SBDS5!
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MN\Y=>@U[;2RE+1Q4S:%:P=[-"C5@49)-FR<PI;UXA#";)5,F"1HOQ@R.DNP
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MT)6O]4"R[G$ID-_YV!)D%VRS!]DDZN-$UH?:IYU"B3"]@9R4N;6U\@"ZPGQ
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M%X6836?TM5H3=?N>06$:\[%^J,NPEO-%KO5KE/!#^S.HX7=1WSK$^^Z):J%
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M9+KDJ,A\X-G91SFZ^9JRN*T0!;4KT7:FP<R-YVPPJT]0<VJ?+;+B$;(P+59
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MVN* OMY\543EJ*VM6/7F,][)W@<]!3<$#DI&TK3F7&-@0@=#;=N6:*L3*;0
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M[?V<.,Y6(O_;D:0$E@3>V18L2,#??9]S /STWGOF&SP!Z40EP=S%4<I@070
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M\I&:=1(5$X77GR7S0>F=*;AQ.!N/30::^!;KQ9\TP=UYZZOK.)+:<V1&\0[
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MW!/SND/=[Q\TOI13ZQ@R\)GM2CS-OF#\]?%;5#^7$+5",T#Z:%A3U5ZA;BQ
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MU_H>,6E1;$B4<@\0F<,CI_XDS%5KP,7+QMAN5LPMH[U@,\X6&^1@@[S6(_9
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M!9[)[\[B/1%5CTGSI.@(.38\_04PW<RHMKZ"S63[PN5;B38!YHNN?^I_AW#
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M9Q6EF4:![99*=<7-O%9L>M;,OFC<B))J)LKC3QX00ZN)Y>C^>XBI8IM2$IC
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M2Q51VEY5N5UD6>4E7?:NVCO";]=L<9O[^3L/J>.P=F7CSWZA?@K-CZM<;UT
M^)S:J$G,:^3K'F=BY/F%,H[S=R#/3@VV*+D^HFBUMZK.;GGM!6!PK7BH6S1#
M,9MKM3V;$+&V45V,XXLQZ9D2QL\GXL#7;*/DD7A2L= R?!)'(=U7U5ON-G#T
MK'^!RZA?4D"SCY8S0]O!X$J>\T'X[- <3#/1RC3?V\PLX]FV)<SBC'6M+5.?
M[4DIF$(M4XM7_9_FT80ZLT2/%+@9 \QKO*;V83TBFJ^KHOOGS)H6A.78-_GX
MG_/+"O)471+'2&(7.%X_?RM*["" [3%1/.MTDRD:DL1X?/9P_RU\3'+EG!#>
M8Y@G,B:K7[AS^O <LJTTO655Z$@_'Z6A2!<)";4Y/(MT"><XDO=-N!J8R'7K
M)H=/1A)M>J*%$,=RW/";=#F'-V1'I'-,X@4 [[\P> %8*L:"4F+<8E)/K=)
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M-]DX-=QBJG_5;053U+I&95"<6#\SO_E <I*2\16_KME!H"F7\9,"]0<?38/
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M[0(P<"DQO4#\6I'52DA"V' R=M >%>@3$'0*?7O*&,>A!_F]TK98W=$\V^N
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M)LN6,&3\"F_NLY!]<Q;.2W6CE<[2IA0R5ZN*Z&]\D;^Y/[U)KEO?9P>"L4T
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M3^$\&6URT(O=@NG8JB/P[N\T6+>/ER58WVP=94$S=B"[PIY@H@]<$Q[Q=+S
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MDJ4+-+_F@C]PS1E*A7.F/#903F@7PYN"5.&7Y'BS"8$!W//3W&PJOR&H)&J
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MQ/L)G-WJ,<(FK>*Y>+3772V)L@Y*?QAK<;"Z=R;VXI=YW+=LK&JO6S.6BH[
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MCSX$B\NT1%V?[>]B/'Y[7O.\&K04\GU7^:[($/6TO#M<&O H4AZA]XV?T/N
MK0XLDP>PNH]M;-E^CWGVZZE7)\)*HP^>*-"[]_C/K?<JPLX9Y17\=FSCAKK
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M1AQX$T&%!\-1/2LE-?TX8(Z:HN^&K>$DL%,NG-P)I@1 QTJ0/>#(9!ODIV9
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M.91)AJJ.0"U#,%O9X PC4_CN^5SIE- 9DN1T4[;B:O 9$.809IA4)[W,I<,
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M0J6V'-H?MTL@/P8)/E9/3S<AR$\OY!\%XEWR?6S^"')\>%/KDV=;<YLPR?Z
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MR(-L6R7Z>\<M7?LO;85_UKX.4I.[VS6/^ LL@YUY#A/CP=@[?M)GNU>V\OX
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MO5H__$OXC/3JJOHK%'4M%5%+Z=B!I7N) _/Q[0ILPV']:L$N[6I20N#*S0_
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MTM+C"!//#X6O?43,M'(%-'9@@IF;=$[I#LP;(8H=A3?LP)836.K8_A9D%T$
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MIQJ W W9=F*/CF(G 299)C(5JP"E6@]C-/R8J$>*5X&U1+814^0P]&J-8JX
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MI.%3>!@3F42Z#4_&$R<["$D(&;8/KXL#YD1Q0EZ+YB<@/];Y1;S =?#F,YP
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M3$KF?7B] 1D^G41[W<KH%_\ W.'=%BOICGY&_O<=>%M&)5FE<>09M2<ZL3K
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M6/R:NU&VZV-5N[LO74IZ6#"1"DVRV41H@=L.)@)R;$.1&J:[V))*3-.#(32
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M'LM<%X%6B"5D)CLWK4%2AJ6:;R"S/K++<!BG<H4L*_F(43J-)0:.Q;ZZGOK
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MV19)T$@<G!B(>,4WMW#M)&O5Q>#<>8=^!#MUL',:2AE#R$4ML9;L-8/Z#F^
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MWVM183K9YM5DK:/FZ[N.6CVG+G\Y:]P(_^O=@<VQ.;W7K(:B0\T>ZV[[?.?
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MR"C*N!PNQ "M_);[0)&H6OI8MA9G@LI:@0"GX:#I<C8AFJ0N,99O,HM7QLU
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M*H@R89HEA/ A$IQS??H425_%8T.P0(_0LCUO%D[J)RN.7>I;=3WKI?D4TM1
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M^L4J9B)>%ZUMN(XTMNE^BWZ_N]QTZ/$%E9N;RK<W;](QK;I3TP$8V)!;*88
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M<EP<ZAPSEXR41Y_YE7^@5Q_Y&%Q BZCO)0N-YTB7 BDS,+M\G0!1UV]A6(L
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M(>G7ZT\DYO;7A]G8]ZA_S6[VKU#*& $ 6$MD7BQ)<HW"244F4K,X\1.J_R>
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M)G/,-Z3*DYA@"&'_\I0 I@/W1K&%V;2?!1#\LFCBD%WW^ W7B3\=[:"$O22
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M3<^RX9G-2SD\@5244JW,UBVI^PD&S>/N3V6$3=N)Q=C9?0'KBH1WJI!J;-7
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M[+K^E=;LLS"U6NU'B\1,+JPBBL@5FY7G88SZ.L(AM=-(5-F-7&P^ES*GN6X
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M%,* ?;AU,1F]"Y:*/1+$SR<KXCXR8$:%;M8+5S!+2W%B"<+ZSY6;_VLTL K
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M'0>Z(BR&_ZQ%?P4<X)M(B>TT4^LQ4[++<T/Y]\DM/ PG"R*W!6/$JEAETN.
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MA1<HME/E+D-V $!(:OGS8 %+@7D;6VZZ<G;S1#5:Z54P3G;2;4!5U)X31A)
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M>1N]M\]MN(R8=VPYQCS=6N]B;^G)#<@\(AX^R .@M=_*5D*'\!.(Y6(TB$[
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M=V!$K&:C&3XMPE)^L=5C*OKE@\?NPQ.A/I[%']^1<#]_F#?,SI)_D;8%2A"
M&WDHKJ56L]E1F6],(?NQD\QP'?@D3/G9=OPF4K\R;CT1'P+D"(\#F&D=H(;'
M2%FH/\S33*Q":MR&'/<6\;&)'K:W+.3XE(V$>TT-FWH7\-M$U+80O/;8Z8G-
M1%_X5)Z**N>1:6A%(.N6A28@S?M%#>%@XFJ9<75F!C"TY=Z)WG# FUSZIB#2
M(4''U%*@@-I:BVD=UM"5=NV9"B=+@V%' 62KH[%K?YGA<=:"R-Q^@&A,8K]
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M[1B52J8"J-\RLA4TY.)OHS982!41703237AU-M$&J&EF*Q ] =M;X?1!XY/
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M5#:/*J/47+GKP*@BL->&;ERL69!4@@RBW1L)4/0HE_[!8>=#'+XQ8D/<$0=
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M8,,QYO2[%0?/$+?1Q?5(NFOB/^0!(571UJ%+%Y_YI_AUK^$S5E&Q_=K'6P]
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M<'.D5O6T5VJ+S5IC,'[I8\_]^UH%FAWVTZI3M*:B.&OW;J&Y4V 4>?9J&\L
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MX^^>16))'#24"/[F$&X0F,;3PE%PRF 0)YUN_<4TO 3\V($SZS4U\2EQF7#
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MH015!",I^9.'7I5%V./3+/$3H\LAX?;X(/P^TT+RFYQ[I#E((L5_PC<[Z!!
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M][?BEGSCA\1UY<68K&1S'T9)?<=Z!T?5YXJ?#GC[G#WC4Q0\.^>WM9V2[OR
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MAN-]%[?6PPW-W]Y7=</J,RH2$/[\T(7?^"X766$JNY1XX NZ4RMPLAYI;WX
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MT44P:1<.XD0%6-X]69>1:+J=IST.ARJ('\X()*2GTPQL\_O!$G0O-DJZNNI
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ME)T9$3S$^Z@A6A<'2"WXU: G2[$5KHZ)1U76U=4 =HVL3V[-PNU =3XK+-J
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MOK&Z9T *538O)X+)(11'A3&?L[(CKD2@T![DK@82TWNJC&>*W<2A$H2[L7M
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MM+0_NC'"9'$L6P^N)V)*<,09F-IP="FL@3=S#K\1X#NSEAL!?N/)'>CK^;<
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M:K*^&EG#NC&5B7!75X/7LOK9);)"R'R)AL/>"G/OMZ*- L'&<[]K!L2A"H;
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MLM5 FVL$J),R#$I8N$GL,\%>5!9 YD"!.CH^00B1Y#F)S01/:/[0A^\4]$]
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MN>]ER[Z@Z<H")('DD.^%IG= <$OMP/OT1[X?$%?GG#25OPNR\R>NGE%/F5L
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MC,0,O/!@[N$4'O+^'MJ/N-J=QE:RQ@@YAVO@1TV$80%/J?,A<YF,P4D;@K>
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MTBN)X\E&S'!!WLQ=P,7ALMWA?P!02P,$%     @ %XBO5F@M'9D8R0  _=4
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M\O*J2W2G*S^;Z&-#V7M8/V!)EZ+=(DOR*D)AKE<!)17/S7U7#.*W&FZ2O=*
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MWB"RXU'&^8/7%[!"Z80S&*&9R]_&N;_C':J1[=LW-BK;;#&5[@@;])]T_8_
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M%Y^G6N<?N6/$7>[\CXH,\U[1]']_*LG\L4 N:CD+Q7R)]?2O3*!3#N[11+L
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MA:%,_?8I$;B'7RAJ"CM%2>EA)!B. >G$T3R,61'[#\K>:4V>*M\4M>46)1)
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M9N\E@\1,AXM(\QE 4<5KXG:FLBPANIJK88!=*HLN^7%>(Y?#)B'NX +8.^^
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M:_H%[4E69G8.VZ_R8.,3XG<- Z^/-\#)^B#,I*P"4FBE%#MT84 GXPS/&=W
MM*.:3U1A]9%R1R-T/$XLU)BX#DY2 J4>2UZPG&^DT9P0BA%G/:\K'#ZDTMJ\
MS7DD*LP:?0S@1Q,\+_)7!CS;M_;HD;DVC#W#3J(.S ;=EY"Y".H5"]??-50(
M",/;]3%]&>REK_S8&PCW>J>GH ^*HLMWZZ_4RD.2O$IF*:?+@>+&\(SO'C'P
M8<JF@I#L[.!6:7.'ZQQB.Z>[!5OF@9FZPYBN.HGZ,9-H<#6&]D8<U"OAE317
MF8.'+R@)-F+]6O9S]AJXI&X?'-89(+(MD\H7-7833.E;WZ+X5I!X\CJT0TA
M;7UVR8AV]+O?HO4UT\'80G%]+!)YV2BL%LMH13\*^+8IMO ;RJA6G2 L.:BB
M+9"UCA?/G,R>,UR)C^0F@CWG!+JZ_5[ZPY?2[-Z_67)E^:YG_4;<]Z)APC:P
MK-0?."$'OP)D%DIBH=!^7THY1T)8C'RZV' 6[H\%YSI&6[/";J<&L+=@_6K$
M=0E)X--?6 G.9U<NALM[?&:[]R^_6SSP.AIGJ'?_^/VYK1;G@O.2CZZ?^'SC
M[C^,.$KWE(9V_F/.]*0^'X[8=1^B33_!@-.[C[V)F;RGH7F@)5C)EXTJ^$>%
M7C!-DIO]_-S;P3S*:8+).ZPJU7Y3C\.5\<&[K8EVWCO.)MQ/+(5V)0+B;<*-
M[)Z?7V(NP&RAX5=2))C9=GC!&ZVNSE#ECW&[+$!':VAL#DQY.(CD>URZG$)S
M1:U25W\\?6R6ZH;XM8 72ILNW$Y,2]S0(#@CB[B,'[3R/@L2N2WV$*6=[(Y!
M2@?7"<[L8IM!A\^GU\/QG8F+!S%HMV4F2^*"5=JF%UD)C%T/'O7/NFV)"4H6
M/#B[P>J<R[>+'OWK]AS7/]V.__$.O_WSO/PCFH]6R)1!].DVRC%GP_V6+4JJ
M&S-"FB.:!_R(/Q83D[C6<!%(XYDOE\'CRN33WZR\P*+44Y=^B7X.!ZM=#D_2
M[-BN4\L_;(.<2K-_;N\+WN4=?].("[U5>^68Q0?ULMD_YBQX=3AV)C8BFT0_
M]MJC@R(K5CSFKZL6'U?F:([I-S+[&,?D@KGVG5]T)RD9):YD7GH>78VW<.,<
MR<87 LZDX. R";$HKNV(YAT2?-MPSKM[,FNR_K7!Q:6M-Q%Y([)#/T]9H\<4
MO3@-."@OK2*<L_$6&W'@'F(!S8YRD%=Z4;B_Z?Z T!?MC5O*<T)-X,X)QV\S
M2'L.*?Y LL'W8S%).8>NBVMDV^O,BJWU!VT]':H>C/_^WM)]]\:M^/_^->C7
M2+K*#\PYWA*CFDRO;CW>+G0;(H4'_VZW<N-8R)74G-SK36<C5Z\/\?DS[K>D
MBZ$IZIR%BIO+CF8[Q"@('0!,U+813O' R&XYO)IS@FP/OWE'M&8QX#P0KXII
M"^JUG8BN(H'X4O(*5BA85M 8RQ<\]-E]_N9D@*M%*2M(W;-!9_UMTL!,WIM[
MQ9=;FA^^-^)H+8 ^ZM/&M"4I3\DHI#E24J@%HD6H%W-XE+N :=%%L&_Y;\R]
M:5 3:]0N&D2-@! $! $A*B@J @X,RI X(2)B'$% B(K*)$:4(4!(5&0>(K(5
M124@(J(B*I,R!0B#;C>$>0A")A49(AV!T)).YS;[.U]]]]Q[SJVZ=>O6.3^:
M(JG*VV^_ZUEK/<\[K-;ADW3)CT?.K"]XT&EO4SSAYED.UM9D;)FDL@,%DI^R
MG/ZVK$V[#66.E%&QB80I^PNG&N@>9=/,Y'CQ+%AFOH2^,I):H*T3'6<&8AJS
MWSPI(2=_#C-#._=8BDC>[VO>U?59]GGO.U)9%6]2_=8T<EETN(;[:["RQ9,6
M7Z,@H"5N+92,9/*YRX)\MB=9?OFP*LA:#Y=VO?CIV%SNY\"Q%T-#-P-"WT@F
MUZ<?;=-M0X6'NO^8FRQ"? 8GRV;Z$P;F> FB2#&Z941!]C#4(HVI!KF*\8<!
M8@LI>03=&5:+;:1JB:_D\<V"W'+DJ&-UG;D]9:\,]G;U> >&A[\*#MA0Z'MQ
MEU?1,6P+_@H=W)(U.25=]Q/[7C3*&J3H2X^2&9(&<3U0V!!L4L_$PLM!;$,6
M9XMU5F8@7KUFG]BEI6Y#2J,GYN;DE,A]KVM41-;A3)](RX\EP5=X_@?1DXXK
MI^^G24]2T)D"S&UX"5@HF&NDH>$N).C7T06[:'ZN+H*2&U-U6\9(1?YCK[X&
MQ++TJ!\WY+^J8^AP)-RQ\%*/\?#[Q\>KKK<5KGP,EHCL%J(%J KH\!E--'7R
MCE;\,JHUA0@<21'(7 [(&*%X#IJ'A#W[ZT(5;D)5W;T"RNZN-8A6%'AY&['Z
M<4OA;AW<YDROW^X'U!]YE:7_)J^]BJG]6?*H)ECJ ;<ST64E\?UX0W@GQ1#4
M>06=?-?UB[(VEW(,+.*1E+E![E5/RA^7//]Y/4BO-Q6WQEK'YMWIMA<!N)C;
MF65FJ_/,UPZ7"A<FJR5!H%=T< '%59:+4X$<>DDG&M\/!.1L!Y_PF&J![AGD
MB>./#@"GFI_$%Q=[>@_O$]2ZC8P2@!F)V%F[.()D;VUA>>>3NN((GOU'CK*7
MM.G*=I:T!A-A%1, S2?=@G7!!,G]3CS?D9PE=!?=%""B5A/YOA L! I;2UZ/
MXS!B2UNU?+%[4YTIP$[J9N'0(.WYX!G.>)V%GNQ;%#MV0UW7C-GQAMEBOT-E
MU3+="ED!S2\)0N.;5^'L*095H%^P().7!*]M$%LT3(/F6-TG;@:J]FM-DH1]
MV .&&X,OD4,S<F,JI2>DA_Q?QQ5]S# ZB[GZ-%M_%^]FRXY4V$/XHGYB@JTU
M_F^UF\U&&W4_K?FEK+#FRF6_P&]06_KN,W=ME>](PT<GTKGT0] G62V-EX55
M9O+RLA'KS9:D,/28 7)40I\<M;QFQYO3D$UGW2+H4E^=UEB.)ACW.K!/+ZVR
M)6-IRN*D-Y C\/UYCJ6%JFM)ZPO_*K>,%Q/*V1>RLKY$7%:8P -'+89\67+4
M6_=)41'E6B^L0W$$NXN_@I6--(R] I#/I^98V)\2,K$@]QC<!DB2#";?LL_Q
M95L_E;)?DA-.I(DL)\BZQ_6K!XLO_\)OATP1"$K!"#[W-J.2D<(,H@VZ"YTF
M,\7YL)(TCV(CUFG&#XXV94_%46@"K-8 %&A=16OX0%$2XM72\*RH]#PA?05Q
M8,Q"*[DBVZ%@MN*CU6Q[=A;[XM]0="_.AM:@AC]/2N?JZ@@C1 A=7G)$]AQG
M-@XK@@$ 80]8FC_N8_<>N#<57U:RDJZ\#:AD#1O^<%5IS#%XWQLVI04YB8TK
ME5Y">WHG:_ %M>T,6DCP=2S?L!A ^* 05EHX):KW'C3E,8;PPBE(R[T%9RU#
MACR(S6$+2*TE@Z5-M*4DJJT/65%@D#;)4)&C_-K01P-^/&K$JU!V/ ?3H$T\
MJ1=)%/#:[*EU%9%!R_?71F'KZI8C9I/Y5]!4F9>?$"59LA2J%?4+=C5"44B#
ME7MDK[PD-'%6"L5,4.PNJ&Q@KCKC\3-'78R.IYS+&Y-4A=/73Z6$N>JS.+-U
M105E.7J(F]I<BIRT"L83QBA&2*<SP*0(J17E<A_BJ#O!ZX=EY50=:B]6E79^
M:BE% : W57,U(3NP6<P6QL?RZ 84BX2&.GP-T)+T9D_N$,*DRW(VBOD]D-62
MJ011S4I!=:)GT#:_3:"I1(/![X=6YL/*@]+]\( GNI%A$,1X9T:'-$T:B.\B
MZ">$>)8WJ;'.$,P4Z[?@UGN[(Y1E^;KN&I<@WPTEF+C09WV6)5KLLUG;/ +O
MA]BV+;?-R8BX7D_M--0#6AM429(:4(HH"%QGG3YE893< JL(+'I"CL.C?7UU
MYAXVHB]21S*#7WAK8<F=4^E=*:; QKVX38'8=W.3U=;W> :;A2TV59),OHQX
M4AR7EKVGT-\S[@4*_ERL6E]:8=.X(OK;'DE/68!AK[EDTT<OWXT:Y57_K-Y[
MX=C:1'/>J@P?);S(6[K522@RY;M0.VA+T4TBOU:]!);9#CY$6U&S/D3HQ4B,
M.O (5_J2O):R;>FK#278I#*9^4C01)MAT.FIM?'6%LL$=89(WVVH/5A=9A!F
MD(B(?W7J=K#OBT#&C,,'$CDF?)N&$H[1$806\TPQ2'9T8I48M.5#-N!P$)^)
M\0R =2M3B.5!,G5O,+"1[83PJ=LA)4;I+D46)HP_,G E8-% 7%*W$^$HK8C3
M<G7AOWW6B.DB4T!%D@F6"O #7UIM"QOE*/W NDW(;[.:#;%@9B[H.<<W^"M\
MF=4C,[^6^5]_97,3:RR"7QRJ.OQTWJ6W+'[DN(),G?HWPG5.T0>[);&@NX"=
MRE"O<4'D91 05]A,X^@W8%7=!24MF*6#@8R5=0;4=JII#4!*H>X8TXN9_ZDQ
M0#X?$W2H[U09>.0MQ[OV5EM$D9VW\:9YHP+*?D GD6HX )WJL/?FB_SX%47\
M"^*61\)BBV.5/?;;:+PQ2[:H26R67A(X[>D3H!%@*LM?.;/=7H,#S^K>F8;V
M0XX+!4K\3U#[:4 P8[)(S.*9UXHC>.R;B.?(44GJU YK3W:<O6\)60V;B#/N
MF*I;'Q3.76'UZ77;FR>2J:2Y[#0Y2D)*+%<Y^.N*Y#1;*^/(6U?I$\1C6L4D
M.FX1,IQ;I^2HBW+4P"B_,M%+H"/2C^!A!O)YC#B<+IE(K.G&&9*=6C(<^<77
MCWV@J8[-=8).2#@!(WU?_,R8L(WE!,P'C5NCV#\6+U9$B,<M JWA<IT:TJX[
M%"S=1]:OQRK7^ ())\'UYDDEX%%ROT=%SQN<.;1>;/ZNY&>V3K.9<KL!]F"F
M<_<5\YG3&M-'M@>*.817'D.J/C_VWZWA2A:FK:8I>-E[1 $3.!B)29WLB?U%
MX/P<+X;1.B&R$# 2[:\_)]-9#(VSLB?P^D'(5ORAH^P5<;E_E\?AYZ*PL769
M)YG1^OX%Y1^V\"^16IGQW/?]D%8"K.0J#44Z:H;#0R2 /CDJQ-^,<K^YL-MX
M<9WX);7)9S$H+ KDD!I5?;@G>Z&52.ZF:U.-Z#XN8S-X[!EF2CE>[[33LX".
MKT/CVI7:X6+BZ19&-EX7ITGM9:#@590KLG>P"D4#9+Z&?$#:P@%5Y%F*X'8Z
M?QB+:.YT?,7"5DU&!;TQYCK+&F?UMJRTP^]CO_VF9T'AP27^>N.#1/":0V39
M'U%)\*S2NCLH*@ AO8M]66<('0)=I8&0=S?M/"G)T^VF% M9 S;-04'>1,%(
M7$"(.*AA! <.\Z=B/7'Y3TO!E32^(0*%2CF*OSG=0]AWOKK\'<,U?M^6CN'*
MV3V(Q@X!I?4XM/B;V_: #')_HZ&^.-3S0G=!#R>4NK[S<OE?;^^/6Z;;)5WN
M [QJFT(.9%I><MSOIHQO-Y7$RI)A,PH:8$#:ICR+^#IURLF^8/OUR"@B,O"6
M/[0!*/^1!DRU1/46IE$"^$0#N,T]Q^H=4#Z;GA&Y,!WB>G'VB^B4Y:.TO5X;
M1;,J*=W+W6S2T+/-4B7$.N=IE^2HM&P&PCPW@R3>J*B CX0CQLV:7;RF?IPQ
M]6^L)H0&1H_T40P R#OP2S$XZO4^Y5"7V6I_F[X^F\J<,SI9)0$!FG_Z[X_S
ML!_*CB_/(>B*QN"HF8*%!8=_+\P#6O"#P@^R5"33I41?N.OR<&%7/OWJ4+,V
M9= DD^^>HF&<LAB[[=O%DYP]PZEZOS'@>H>1C&CD$3\M[-H^XV\6.!\@2\%?
M.FT4M-&U]NV',M".;^J]Q\UHM>,%^O'X7W:QI197C3/-]:-CA"\\/ +=;++#
M"_R"7@1PXHJ;T_,*N5ZLB(O1OA&:7L.<$<^OQG?.<+YZ?3:VT9X^ +0MIZ]^
M\>F?0K$[O.R=0)]YFZ%6YT!KL(2"(Z.Q36S0Q*:%K479UA$\ZWNEJC 947")
MV16OQ$:2,V"&SJ#H]9(?C%<0OL^KL3+BG4=CK#>07F@XT/TY$44=<O^!$2$\
M:G$Y:"8E4?OP*#G*G\CQ.HY=6:<-LXFJ."/0KI'QGID"F>0%X96M2/J0Z_U5
MY>QDZIJJ:M\7XWK#=2GG\@(\+]VS*NNSI509/"^XZ%#>W#S_%68<VXV]7;=P
MHAL-?VDKH@[J81H9VN1*21BH+[U(60MZ\QB:%'50\]PYGID.G]N,CXV:#QI9
M#,X"<V>Z2=K>-LUO7;"#8<,:,1N\39K"*W7>CM\]E'58Y_'"!.P6*%A<V(17
MHQ!ES_&\YS0]FC\I!;L$H2,EJ=A%M(L$72YE)7B*IXM3'&?JUFB& '-->#T+
MD;W5CH7S5,4E\6\NNC@0F_L_DZZ_= IZ&=@9N-WKM=.<)%6AX_P-/(.Q H'>
M!QI D-(')AJXI1$W[#5S*>;@$ ^O!IDGL/ 5W+@:)7Z3+&\+=0UEAU@M3D $
M/=YS_]SOF_.4HY*M5#?,AJ4X6RS)'@K2;%!HOI>1,*,C"9?%SLA1-_ 5)J(,
MJ:]-,TT=Y#;+417AL5+K )]MP/-\_K".8P?%] 6U78Y2R0,##,OSS@RP0UYX
MMPG#DETC3I8R22;.U0\&3[N8U02ME2D\O:'W4DM]ZRZ3]&^/O]UU-ND991P*
MTSJJ0+2'>YEE)O',BQ:#7(3_BU8(ADW=Q6HI */!EI&,CH-PBF!LBU[7GRA:
M7(TF'QST\/(1%R9-A=)5?C;<ZRTW<_NZT@'3T2MF0EHJDF@Q4>0B-8#"0"Q/
M]<3A3IP1N;"Q(HK-,G#W<HM1ZQ9DL:96_&2N@'4KF!KV!(N$;^+^VS.KK 98
M:9R3_3=>+=J#$I,&N))M_37X$CF*1:0.:/ICM?%7II*R'6M'J@4!KUVYMVF7
M:,KC%9W>7M1V9NFE1T6UH]#:.C1 .?[$IJG.[+WUB"F2Z!?V30B&6M*GCW2&
MTKJ&8S/+KIR]=E#7I$+8OR;D<2CT2KAP9E92!Y!$,<!3@E9 57@!CY1BN+A7
M!PFYHI7 CN:K;QZ)=7@F+4\VMRL*F DCEIT7?"TW9KENR.?C5^PU[JCQXP?5
M6C2-8*NKNJ<R,B</S\SE8EC,H2%8Z94X0O)6]G*&GJ)GQ64IP=I89;C)4$?L
ME$ Y]S(H(U!OY!&@*.GH@7&4DUV_0K^HJOUNGS@D1K.B!RW--HS$[#EQNO?-
M+\O:(W:JEI_)<E3.@O<9R5[J\'\5\9X8+<QV03H",X)D8?W_)K3 7!EJ$X8;
MB"L@@PX<CMI316AEW(S"WTXA.UIHUF^'[+K+IVX9V@"_4HK\VW@$-?)TDQD_
MB*810+?.C)S/1]ISE551S>!/MMS)"3XAH0K!-2$V1P]LUFF-(;30RK@B+']J
M%9C/8[."F+'$Y1?%<[=A@W&.^ZURINIXL("6ZIGL'>"YNG-"8SR@\*?M.)G$
MHIJ(%0<"6+_91Q?2%Y6#+<UJH7-<FN\3<JE=7!7*":D;Y3H8P\/?JHPB-#G7
MA!2,RU$8.8KW*$=/]JK&YCEEC7A+Q(4Q'U0_Q9LO;=-W!52Y+-F^IOZM8(7T
M6#;<>N9VP''4T6JD>0Q$%=O$EZSK*2NY5760-/A((@$(L1!&0$PUW (6%4+6
M(%?J^!6RJ07Q I+R1 9%'UQ8\,4$^.@@.:&(G"8$:#<L3?$)\\7#]Q!F6"9R
M<HNN=8S9)RR$5E1+_@8+Q*7"UI0Z X@ 7@3B,70L*HP07[<+1/CN:#-7 PIX
M%>0"Z","I\8<7O2N!V<XYH,#-5^>(<<>[.6!]!B>')6*^#R+JPEN$)BVX?D%
M]!22A:&%(6 ":=-A907Q#D=P5[Z_HL2^K ]G%$ L;TU^0UW[,_M2@=C%,1C-
MPTS& :.2_*X9YYI-@%3H5O@<]&IQL^U/G&4F<)YGO23/':UB=A1VEHN<#@.5
M29?+,6IMX[B%+4&-5$Z66Y1)/!2&GF3SE6"3GPNG])F)).D^%QXMT8VVE'F1
ME,"H8+(LDG.L>]>#E?E!6/7\1\U709<FQO(9A@)(;*[,V0K&/!W'K0,3"DP2
M\[N+7V>4W,"?QO.0T7K'I<M1OOA;C!447;':E\,=Y7@L=+8/-AX"]^T!RU]2
M?("YA+4]]C9\$J8]M/;(%)_4,*S)\O6L KY5U<!:0,3-,K9JP(\?IO>BBP/G
M/*H9,\+SL7=0$_6K1OO3$UZ8=/0W8P$"AN.$,,\@Z5HD+TC%A'I$UV-J_(2/
M+%842QX]]PJLH.J)K1(2:H@EH.]>\"$OQ95<41W PR9S#.G/H0. 8UW%[_&K
MH&]3U7GO,]Y;=4[$O$><RX'ZEP(BKBY"Z%[FA12N(:W!B>G+4#L-7A?@;Y8%
ML77A/NPB"OYRMOL-_&5\; [6Y(2XO*4V;^P'E]"%]V<HD,/-B,U$%=A\K \C
M,'#[U2ZL]]E*5 =)Q(.A[ )FX!3GQQ3?;[*43T_%+[;T(B0R5E = O'*.$/J
M/X:&O=KC!BK-> VFOTJMC2OH]X+\V.L+*1)SNTS?P8VPFMRYYF,Y@O#;1!:G
MMK9\N*#G'0'+^(]C\OY###2TDS!X@M=!;V94.(F2^.R5D"FH /SZ^^OXM9^>
MU.KGG_- H7"JZ>#Y^%_XY10]<-O3P"S<>C$^:?:!)J%G]K0E?6D [7(_9=_%
MP$C2$$;B*Y:C$O"^I,%?7)YV4HAXAV .TI0V<16HEI2- .6\?@Q1P('9\WJ@
M;PL-4Y9D_L:QF)%$W4@QJQ,7QD,[^Z^Y!.LD606;ZZZO= KZL-NA6[)7EF"/
MEFYU%%A@R0F>=>"P]!1T8MLX#=&"@26&@YZ?Q2:"2]6FNC^ZRL(.Y'#YS,:T
M14[P/R -2&GX/;BP#PY;VBW:[WG_95;5L!PU)#WII[SKVRW;G/S,;O'4SZ!I
M#$(N/]0<0Q(8N('1C!_"PDJBIR:M>$,O\JI PT7 ,QC;:V6A3@[R26CB."74
M&0V"K?R":@[Y%:R-KJ_=,-H<-9=,Q0P[G1.\XJX S84-QX>:8\@WF5M@,W@$
M7X%P:=PJ: M658X*(*E#3F#$"P]J;]1;6=D5&H^!,^\N1W(Y40=6#\A1[:U;
M!'^QP2[.[PHN&_*V$ZX?*10&F\&;R81&V(#>>A0\C\5 =KTU=H)7#ON.]^S&
M'T0:90[0)"_Z: &TU=0>YCL+D3[0S\,W$=.XI76Q4AO*V0]@*<#P %^I93PC
M&S6-K!5C6(QDAE)^%\67?[",D>BC0= #Z_[VUF\^.D%5[<^)T8#EJ",>H1_S
M:_\0!4[0"B<$8+ YY218]!J*!+XBX;T9RWG$UVDU( B.@=># \3)%FBRBD2E
M%^_+U/8_2GYT(&8SZXA8)]F>\-)5?*2+>[#\+1"36CTS:!FYWO_7FC^>TTC(
M0O+&C2[[?264_;'U[B-K>LV8_G0=2+$;[[N+Z5>TKAONCT 2%U@N>Q;:=ABZ
MV)U+;^H/YM/H$G>\JJ7! 7T&Z%A.+E=!2,P$I^6=X/JSKP%<:T@7%$LO4P[)
MGM58"3;!VRC^8 _5F#PE603T%8MQB% -$',;N6IDG2;;RLD):6"0'*553#$%
M^H]U;UD(N^O BV)#$II,;*HS?]=I9IGR!^&"RJ![2\<XSKC[5[G9?D61Q> 4
MK KWXS3&::7-4\GV$0#>NQ(T$1MV-QMN*"4H0^YB[X1F,PL6XSTCE>E'4 KD
MY,2)G03HE!HK/F.EYWC.^E*Q^X"]U3-/_RC<PT*G7*^VEVU!A8%N=T$G>)GJ
MPG&,W]2V$6.@I)EX,TU@,5C-(TR>X[VHT7Q!6=OS%,2+JP6,2:: 0+>!UXDQ
M+0RU $Z3#F*8^!J_9Y3+.CFKJS)F,5H@H076[*0X7K]>[#649@]Y2;?"/<S*
M.1;Q)K?T^0O**;&O5[_5U,"HY&0G$A"X'!,!K9ZX"IQHY99>X*KC@PBI/CJR
M7"CD-=E6>K@\2V"1 BO]E&0O95@]9Q9,].N=]'Q,U*@A%9)3&O6N%%P,&8\:
MA;1VP,H3T20!1L/?,Z>X "3RT9/BYQ1?8)(M-2 ^DZ/*B],SI=>'H65 89*5
M@;[[^TQOT(=J14'W7*8BG*^!JK<5I.]-<7DG)MR^7(/-'=>Y/X?"=CI-:DHW
M.TMUJ%]@E"SG%^5LG4V/_8XB) 8WS5>4^#YC)M18^+V&#H,W!<0DO?YXJB'H
M_6L6#62Q"$KC/INK@'[6U/+/+XC.3\$3+EV3SZKNGW[R:G)7</"OM=DC@E6%
MMWYL6O,AWK_KM%_\Q4U;=CBNN7!_D_I?=W>MS.BX=_7D'5KJE#[,H0$GF2CH
M@.P]Y  <$#9QU: =/(N%8E:$.BO_:>R@^PDP18Y2DG$GI4+BC>T4+<#UR6AR
ML/GI >AP1XV3H%BU'*_R>0M'0@^.B>2;+@N3'IRMMB@M)X(;&:*/ 0L%]$ 3
M(+K9QR*%7\AB)"%J>C^VM)99;S<U^$N@@EE!95OCWW^A7 #F6O$82G2_:!5W
M@JM9$_$BL$J[@%^\XW@.06T -.>ZEG:'!A_"J'L'[<:>H_B!%X,17ZH&,YY1
M>^6HTN>,(#YA$"V(:*8KD7TE MGCR0UW67SNK6=@H<  6T_5DQ7#RWZNR.J"
M]4%ZP\B.OM#%X"C?0NWT(.@EL+E1KNK4'*&MYY=2LZ&JKE#J8AA.;S6\'16;
M>2?J5N2:_F]X2"NHM0)?%O^.3P/7]S<^(+9@5^)V(@Q-K<9+ZD0<Z_@<F0>W
M,=_3XBFD9V16BX\=F%+44#6T3TQHUJ<I.P/=/':<N4GL&;%)(F5?B"":G-MA
M;_&"Z#[1=.Z4UIK&.(7=D[FH_**?*-W/[?]M_2]7&N)H-;#F\VR]X;,9Q:\=
M:*$.M!+G8B/+I_'2/"E*1F"V$%;VSB<&7!K9IS61.\8L9;?J4KR-J/-K)*]\
M';)'\IQC\Y3*M!68?O';6OL!^W0[6@[Z$.3:4YY$"V* 9H38,H9J9%1E(QY<
MSZB?6C4.V_:++J3';(3[N.7Q](#<GWA,SL7DT^:SM$60<O<L5G-"NV\Z)4UY
MKL73,J+.L2=I,:-BQ9M>Q=C6,[[T43KABMU1Q9]/DU&F;74[3A,#F<MPF\>B
M+CZ;CR\H@FS$[8S"TYYY]\?GX3F67D'YDR=E^QY>,7^S/GV9[^J:NYO37:-<
ML:._QW9C&R)$%HAYVV6EE&W2I=0&HL9"S>98K+H538-R#720JE,4$2873VVW
MAG479CU9+KUX/U(2#H/DZX82>B9X2<GW0YF8QI*Z*OJ 'L*@C[P[<E3C-H&J
MAF#2.#S['G_>2-(FNT/%_:1IX'EE6!7[Z\@-OX,WI5?^W2-[+W ^>'3RF/0X
MZ,2J4Q2;Q-;I^1?6A_OH ^ZW<6L0!>K9=K\<6(N_%!,X@M4)L'EWX+Z/56U'
ML:#;VS Z.I%6EI:KL1N54_@1BIH9&W-^MWO-QH951JM7="\.M0_9C6UVK(0T
M;83^2#*]]=6#$B;+":-S%(5+N)#&*\D%T )P$?HE40U9@A1V*D,?4I$:!=FB
M4T?!7:_&P_LUQW&F<E3<$SY7.:NG+&]I&:?O8:ZKY/:]=2NE*X 3DG.R#PR)
MI>S.MRYFP)0V9 !8W&">I<=1EX"ETI6!S-)*%DT+I+?ZV'?B5,^,44TZPXC)
M(^O_@IR 2Q^+1[X&5&G-7TI5ZGPS<ZOO44'M!\4Y^\VI9S%_G2./#0B[C=)W
M%=3#-2'L$NRH?0=:? (9-DAV [=E&$(X6"PEF.9?,FC:;#.B+&/0?(E#7@?
MVG-B%SZ+")+XI"9O6FM4VQQ+BC$8F__^ND_O4G71D'=,-<LMJJWZ\Z:J6[^[
MOKJNNHLQ!9$TN)@+%@:'+)BED^(A71GDRL?'8P$O[M"^IKIU7?;.P*WV*4?
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MXJ9J],4'VO]VYAF:5]W8%X#-&:+V([*:4+^?3I"5X,\N')$ZW%7\IOBUWT+
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MCG(._ Q@B0F/@EPP>H%U.) 6LWU+VVK<&@!#?S/[165H=;N4_[:Z^WGBMNB
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M\ <T6S/!?V(7S2CZ!=1)[=/T>\!<";+7X!CDPF)0_P4H!R2YL !N!_*(JPV
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M2?Z[/DWAVQ'3 U!<M"R ]*,R]Z/X$;Y46W+   RO2(8.F'%[1^@G!C NT!\
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MLT05;^JRP/MSE@+,@.U_ U!+ P04    "  7B*]60QF/F39F 0!Y; $ "P
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MRJ\N\-Q-*ZKK8A97,27R/O$;O\@GH8J_1OH7VG^0_<\!B_Q?0O;?P/X'K@4
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M>MF9G#90+S+)DN:[*[\BZS)6&DV=&R(>^$[Y7S.<(SR;J8BLBL7J(K5U;%/
MM=R7"A2_R9F[=YOL=I.G]\>J"M>.Q%0203)?.B99\JRJDL(@&83R'W-)N19%
M"5VS17HW4(F]QF&9!2+&#O=$HT^/DX/Q4L:^B!($\8@&>(6#D#PB9)Q3$.'X
ME.\8TDT<4])>Y.UAAG\O)$20!HBQ(YF=.U AVV?W<9R=2KW50MSB'WXL[$)
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MVZQOE:)SP99?%7 \AP*V.W02266D>)\A=>HN.&953VX=%=76 1*/$/-)OC3
M!=<^BMA9HHEVZ@ZC0HAYSOEK!U_708'4L,D5[[Z@U];OP+QP4C'QM'>IMN/L
MD*6X"ZL:5@G#=W=K&N^MO7+2;BRIL[^?\>NJ>D)=['"PAJ8@ZZ*U\R5FQOM,
M+W[+2OFL:XH+](+XQZ%=(H,+-(#KT_P[J8=BPU;'.7R/2.Y)E3HCG.7$.:&M
MO'S3 G43[,*]9=0H1_#ZNW P-3-8"]NQ+(M_4/<DRRHV.)7.R0=H;?ZT8CH
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MO("IC\_MC&:^[H#2//)3UP3N<&X7K@ ?%.[OI/_1C[ *DDBZ<:1[6Z"_2U!
M8[6HZ(D?U;G0SK)_B0;HCC$R1?Q?3+U[/-/]'_^_ZU+IA)Q#K'+*<2EGLUWQ
M00@AY+A*<EA(3I/9*J><BW Y+L0<8I53.6RQH2,QAQ!V2$+8PKRQS6_7[7?[
M?F_?/_;/>]MMK[U>S^?C\;B_]WJ_=QCK%FKFZS<3'I;<!3XV*3BZ*@WSA=.%
M1,=^;[9STHE-II[PZ.6UX/7YB14MVK16F?5DEQ8[QE.?RCXR%(](GM5ZFX(
MW(>]'9H43*Z_O-GA<-F70I0X6Z"DD1^0<='HG#7-MYU7!3T5B=:6)<.EQF,G
M],OV^X6GS)Y)F5[Q&DI<8%>WOB_[38%/7@Z.&?$,D<_> [W^MKPFDQQQ.L3E
MA?J,'<SQ2/2[3^W['5WGC@P> AW=-#Z=]5H)YE^:B::LG,Q[/SWV=BUO0EVJ
M7%UW,J UK'$-&W3E=3A_WI0X6W;A&I#<'?G=()\W]IC>ZJ#6"%E1J&E:Y70N
M^B\L(Z9<>]H+ID(9* 3CL]Z2NY+0Z#5O7#)?ZV'0-2"MP7=17C_VU0=_XN"R
MP]OF7*R4]Z4&2,H+E7;2F,SL+.K;<">OKDLDP#\."TG"G+,5R<YAF-^E76 5
M]GL8B032PV4M:9]^-=)2'8/#(&&;&E:<'/_#W8.$9]H=\[D.UR4_(6R>/MU4
MX5$??S8V?O_.&/18*'K@CHW4[1+A7-3,0V_E?=EBBAVBQH/&!@C/3Q*A\_GM
M#I 5S32#A*:765M9*S790\[V^RFQ6ZC$PX5:3GR]WV9;!4-\:_N/GYK:9Y=[
M\+RJ+G!X?+2_>BI,LTC' ')\,?<2201ZF9-E]!!J+IS6:LMX8R]YHLV#(WLH
ME+[<JB/37?]\RKWX5G<60](+,ZPDT=W=^C*'C)"J+.:L]\@XFP^0<R2]IU7*
M85\A4*OGMN:4 HQ;-[$L($"G/0V?_P1J5/\AO":$%-CY)MMPRS?W1\+OW L]
MRO.@$S$G;M)H=QW/3W:J#9UZ.&^4\/M:-FKU@"C_>*X-\3KCW$IH_KA+:PE_
MI)$=:[]4T)X_0HT/>4\#,DI\=H\R/\]!. <4@Z=+=JU(Q4Y?MS]@0[ IXP4R
MQ=6K:6S[2]2U%MR19?'O<UP(^ZF6/-#>EPL87:0&/@J^.W2@+3KJW)*\=[]N
M"T^#/A8VKF!2F=\]0/8S9N$R-[8WPP^A$FW9NB6A]2%>JGV<-&QH[=1_N]=?
M+TZUE6B/_S&U2:A!7#!H7.D45Y'L4[FK^?J8X>=S"R>/BN=UY9Z[&F9LW+.8
M>73C9+;6_-PCTB$X7:[K+=#,2G7"BJ$O#.O_:!W=<!);'$9XHM9Z8KRX? A;
M^$%+SN&992](HGZ.#$!UHUQ&_8FW;/"<<?1:8EQ5^5?QV>OO-[NS3*/_+*V'
M.C=Z2+Q"V8X^;70L5RY.EA^5:JI8631]G%0:X%*<^+0NDA'"5G(3SJQS%2Z_
MME@-=5=*.> 9$V"7='HFY WLDKN62$:9?IE3_7B6W%A2@+PT[[G_X3F/0U4J
M]VUWWS";5O]2HK!Q?IJ7UC.5)A?[$^+XGDWJ/43U5^R<U!:$Q%6#]B=UDV3]
M-LY..:Y^#Q3H)ZV!?3Y4&^QA9(K>*K9:&JI!*)BE5=IW!C._&T[</JY4=CYS
M=P^TV<WVBZIP*;.EULE91,V?<91PCRA5/?-1=]&LIC@>'W"F74Z-GR?F5Z"6
MI6TEUU\MOT%W?TI;DZ/6'1R4=(C*S476CYG9G;-%)@&)>Z"3)9#=PSU[H.<3
M^3,31]A"_ LR@?S*\3W0CGT<7SH*/LL2?.(?^-.^M#U0;&/[NZUI_.:R_SP\
M&RQ/5. /D@YW^;)QC)]O(^AKJ?S#B0X)-S@#=J/1/#_.KN]XE"#I N'D6246
MYXE(?R,#+(FJHA03\^E[(+&@XML2ODM>316A?V\'W2R&_\L_@>VQ(8+0SD W
M#7&?>&R8"+5G%_;+PH]M8,6! [LT?N?U!JYT)V!5A\)> AZ$LW\R=RT<C.AC
M.:FK: ^ZR>]-U]@7OXBGJ5SG9R%$>=)8(Z3@(A\/D%E8^L# 7 I1"[C CB1?
M1I'H:UF-VBO1/%%DPZ=#7@Y:5UY/1#EX7!K37UR)UI'U9?&[:X([?B8V+K:?
M#9%W)^ G9Z<^$F2H#+CP'NB&V.0TS8GB"V=LW8?"&7. E\R.+(4GY@D\8*R!
M427],'7V*$X.ZDH?DD/;L&TH#O8^G6^PQU%4[_&N4_3:1JYEG=AYBZ\;\4YB
M004[F"='8QI6QZZFND!+RS]^*F8GQN^NU#1MV'WP=OH?JF7>0G]A2*XCF]O5
M6/NK>[IEO&[.O63# 8>;PG)EQ/H[4E<^,."3>C IKLKXQI (?]QT#_2;6K_H
MIP@,,9=)4V'D=WQY5C^.,2?%ITZE]B[/)0]S#<#[N<+26QP\Q2P?J%!JKEP\
MUCW67=U?%WT](*Z500!T\._V0.*_P$=;$9/>O;-G@95:%)-3"+BQL%<= NW'
MN\3Q@+=@$2EK1[F6[)H\]E+?R00;MPE]'2P9=P0=+/:PI>I 8=-WY)1/&^P\
MM4N->*%S)\>)5XR]@4C#BO/5 2/RGP_UW&N V>Z515+K$*66:\0D'/N&6J>G
M#N#2,0=?9GLV19?$/ERV9PGWB:7*VRWZG07\I<<F'G!MZ06C^D/'KFH\*9#L
MQ;$N#7W;[>$KLDA):".ZD[P5W>D UVX$IL4U9U'F9-&^=4'$0Q-0#7J.'("T
M_,H]4O.ISE8Q]3[71##^1[-:QP"OKS-3O5/593^KHN$<3/'PW3\W<HNS[!S/
MY37_3 R.-/@D9USSHN6UXY=)\[#H^$M:=^[BW8S[-:KESK0Q/\_K)"QOA1J%
MWKY3C.5*0SC&XTW8@#G%Y8[ OJ$#7OSQ(\+)1"&T-5#!NKO<6[/6.PL9"Z7V
M3$QE3A40X.E0. V<;IK?VKV6NND M^JF_FQK;1N'>LBF;JS[1ZBI->^!]M\&
M+%7V0,V.>!H\&=<"3L,H\4?FP-Q3K"HRXCC7DS7M#02POO#E48GOX.)\Y45L
M"R(1ZL"(N0B-ITD*OF.*W^FQJ.EXUZKEMG+PJU&TTXO@'0<\1Y78_1G5S-'?
M SV\%HR0(P4*.!>F0N5Z"/<1)O/H1N^<#J--OJZ@/=FQSM0N,Q:)=JN" 09S
MC[P!VE\$M\D21=[Z'@LJAW2G[($&.OIQ\$<;&@:U!D%KC:LZAS=P?^V!;B(
M]1P*83^@=170@U.&CJ&- %<VDC[0)Y844ZX*9+ )=BPG<I:WM< LHIQ2B0<
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M8)!@XIW_5*H4:XWU=WI$U &^[*IAOI!DT GQ!_!,;!IB'T8!H/;M9#45'<A
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MSVS"DXJT'L+I6J/LN1HT? ?W_K&M&%><R6E55G<%; 5VZ_Y<6,!A3\J+>O9
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M4KO'J'YM"?>4#+3UE_H<)1^V%(=X.'B-!S?N_.)LMVR3TA$O/5;$:;C]W%M
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MLL%K9VHZM(;WND#M[)5I<CL,M3[CG6]SJZW#6W]F-\0+6-B5!P88.2MZL>S
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MK2<,0.C+;[)W@YB+3R! H4N,;OGKA![V]B,HPLOYQGK_#>A]BUC.3::?:6
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MH0NYSAUMTN1J)-&+JD-7#=[J5)E*:Z[:'9^P/T.3)^)C^1)1W9J*(:?^C,K
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MHQZ77OR>^=)D5F5'*^O/3%<.WS&T3W_%3>/$[8=0W.Y]HD+:(77,\70%;&(
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M\S.YS,LI:_,[M+0UIB@,/GL[8_GI%=I==*B[\%7%T*J_Q*.;&8=AT,USOLR
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MY(T_;ZK7ZJ5(,E<-V_2!EAA"=6O)":9'/*$/6,W\B_TT2C.FC*RW6Z7E"P3
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MYOED%F_@6QO77!]GP:6/-WXT(A,4!/YQ=G'Z"83S8BY)!UK'5;SI6W_Z+>[
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M0Z=%_)6_IHDW\UG&\HW&6H82+_-ZI<FF@2ZK9!K_&%O*$53RYI?4AL5(05[
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M2 <L.ARE,=,!M\%DRUB[XX_9$ 98__,]@B)>E423"/\,_P^( H$K E0A2%J
M$',1%=+Z[IKJ?-T5?V%"$VBF8*H*031EH"C8F$$RC"!DRSB&V"X.OW]L]/?6
MM64->( >5950+>L<IJ3W10[>V>KFU>-DC66[-289.U>OK=F<ZRGH"7MO^3E
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MR/3,S*\QKB#\A9,H+4-9]D''LP+D]^77=Z46&]_-XTR2R7?VKO#^,Y'E/F3
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M7EB">]_D6!57GSD#=F4_S$[D!I6C(34 OA@@.HUS[8.,\1"'(%2\^^A[ULQ
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M/CNSU!^"^,NOH*$9IUK^. F:'>P_F3QW\ET5UXYUH4UR&YGW",U?Y>U^B;5
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M:E7]NB/>3WY[];HB6^NT!*P.^F #%/$[\B?%;]<(YG8N?W!H:=:\=-#_W>\
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M 3[A'9LR#1ZDZ#X?J4[SO)VPUTW'J"NBSS+>0=&G<*7C RF>:VV$7+CK)UB
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M]>BV\6;D@;O.KO,DGL*,.W& ]*\'@$KZ/W6*D<J) ;GQ"8EYD&3%W(Z;YM]
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M/H=PJ(^;J##$Y P_OAFR %VYB$036@\7L5VX$: D1*(?DS2JVRWO*:KY(/>
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MV_'<,\[;F "=,: ;:HJ?POYP[C ?MK.>F(RQCIZ8!.N@*8$9J?.2C05([K1
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MTU?=T\QX<DT7# \^)1]\6I"[[ZKZ:T>/[]F3K2Z'@S"S_.4M__8_*H"N(G0
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M$;;QI,6PT$52D/;Y:^+@E77?SK]L3#EDQ7F_VI+:X+QKQ]2-/4,N'U7GS _
MGWGG[#UQSSW-ZDD+<J]Z4L]P5A!G*ON"-<4JR/N6:6'D]Y+]=E:1OV1]% M5
MY3*KU-T]:%E3^H8GWGA#E[WRCMY28QY.:2PGOJW: DM_%#;9'!U[(+CUN/*=
M<[Q].S?((G+DE5*O5O0Z!M^^@UIG\P=NG9C#:%^/_-Z*'36L9RW'9KBNBVE1
MJB4W+V=@U&?TU-_^;:C7;!LV5BJ,%9">DYZ/7CWXIV_0P*O?]S"6LILR)RMT
MV9K[U@UK"W.(I/$B$G8<^UJX)GI)"B5I$+9 [Z2BGQW%($W,B2WP]%Z6K%A?
M&%3X7<##,:@/\W3C.1D)5LN/;% 5$\@Z<+-#FIA:B<7WH6/VY\2XGC-FM[ZA
MM34W/3S/HP \L5R*0!N_W$EJ8"6ODI- H<V(!!8$EQ':@M0X&WVN2.]<YIE/
MEZ&2:C0G8_/<M 6X(YX2+-X!/)_6!^/3BSDXN2DHKELS-#%EU?5DH?;K$9_
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M6[,Q@:4E_U"78RJ=5W4UI75')O8IS9%EB\'Q7NHF"-Z'4I/Z?-?>9EV%$%%
M=W.T.;5O2M?6E5/"P@^[ E^1.BG_ =TF74OP,3W,1J9!4M5\U1:RUN2\VEV^
MZ;JJOM9#=ESZV8S\]!.+CG8Z,;<M5: ,J6GLU(_L1[!)&4C%EMXE$RY)0_R1
M!:#A]Q>XII#==X_+J,5C-7U5\YC=3P>;$IY^1SQ>TOU@:V+]>" 1J_3A>-%;
M'O]#^#:9I4M'[Q0%:"".&-YGG&!? ^\[&;QND#N/T1F\=W=OS:T 3_..QJ?.
M^L[#V>:+<S][WIPMYQQP]RTMG;GWF06W.?M;7.=BMA2PXWRX90CRVE!6<W)J
MYI!PK+XN',41DZP.[GL"_S"L6P0G/C.T'>APO7" TK J7/]M%FE\,GE_N>Q7
MIR51WY)416\*WQ0N@2D8@<",>*FD3X/'LM%E+&!K=^[\SRJ34G[D^7/%R<DW
MG2CL.SBT7U9(#A J#H@_>O%FQ VHM*I5V@XRL%4"R_1M>%9:/ZT5ZX/-$(;_
MXQ>U3/]ZFT.?#I=E*=I+8&>"E,8[Z<V^2R0N:B*SF]6P_)"@!WSHHN\4NDE'
M<3?-!N#GA_/H*>N(3O06R,\4!IG@-%G!FJR4R"DXIN7)JA9>D^$^S&GRST\9
M2]K[2^/A^+0W2%TZ(M BV(@JQ7KBCQ@3B!+"82E#UFS9).(>Z*F $Y J5"B2
M#G>$XE>0]> 602T45\W$)PXT#+,87A?*.RA3)OD5KOI?C+;Z1QI<GF%C=JE7
MN.JHV1P*NG*!LQPSBJ3ZSR]\R;8T7R5?C:"HX-)=M/]A[:IR2<W1*?-^G^<9
M:G).<"[&D:IA])*P%%,_-N:+)$*&$MAF;V@;Z-I)WL[J-D+=1QX3^N#2CQ,U
M(%>%T>5N8SVO$50 61%JZ$(IFA<@N/3[C6Z^G=&Y#*V+5[NB[LQ)Z:TL%SV(
MJS8U^[TWJ?;'TI+^R!"*78VHF\[FD!-]6<KB_4$T&1"51E,7[H5JJH*L;J3Q
MEC7QV"Y=#6@R0.HA=S1=]._3]'UX>=@X J46HAD[GD P?[EP.+ ^A+A7@,S8
M_##88MM-6UPWJB[WT;+87!I366A4<QXO8S=(OX9((M4CDZ3'(X8/F4DMUFPT
MO!NE!OGVA$'D4_[;JD,74:_@\2^&:VR.!95W7@Y7&"RH91\^A /'TJ3UE##8
M2-JZ\.]?FO$2&%?KT3AQD[1ED$39@5BI^]7-E+>7750 G?R@_!(HBTE]K&N=
MDI&T9O4A2+/PKQ][@<;#\I-&->[.VXWFAB4P'\-_Y@<T$F?.5&HJDANS]#V]
M.\KVCV8?$/]XR#>V=+Q5G?4T+ZG'(L^A;/-)0DW/R-,@ER-?@]WEPES"U\;F
M',Z_7K@Z-X45R\4(U )9.U9PR18DI=5W-H95P2C%B(5.BM 8JGFY0%/$/5([
M<U[H\P9*Y*19=[9(/?H]BM#JZ8\AK,HTU(<>+!I>JJWYX5V6<"U\<$!ZP.JB
MC%!A&!>>R./^HZ:[&Z!1 2\'4*6?DD#PC^2D&4A@_.168#2CTRZ*=R+B./"R
M!]R"4X-P@EU_C+(B:36AX7>:^9/?L/'B8Z1.'7-4RE&A7_TK476[,T<"VT((
M!ON6T#RXNA YAE2=0QX&+I;-+-E6S+4,+ZSO>(!*C8@](#806M4/#R0*C7@#
M2N>@G&GCO=^=I=);87;]GY#*YK4>U&=Y+.0E0(@_DW>(M2>@%GXZN+:TC;W\
M@*8#H.-7PMD26*)5QB.;>T  NX6!C4/!"??4D@BNU+2#1@HR/:@=-M9@R+G6
M-_=,S1H3%DX/FRW=<@WT63J98(<\UZ>8Q&\*Z2HX82DX,13O]U?D4LC'&KFS
M2XF/ZBQ<[E97]$:5?WTQ6?57S_39B@K'7>%Y[K=N*59>W^I8\I3_]&QU]1?+
MZ;GC- @<6,(!RT[0!H$S(1;8FLO%/!.8,<!,=] ]Y?*^]=VC-F& X_N?:'7(
M&CUFKJ5W<SGHY7G7%^]J_#I)90[$S&K/+UK.'L0_( WIF;@ %JEB!'Z!9]@[
MF3$QSLGMDEH&5\Y,4I-4_Q .BBH)E@*7D&G-5BB[YG,@!C%D$\-FP? G!_P
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M=_W\@C5[ON;EU)!TXAM]PC#S>:FL#OK(CZ>*MJ+%(N>HB%\73BCHR4UID\@
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M5FU$I2CJZ8>7>><K)%9>ENW_[PKC+7'?PFQ0I>9M[JOHW*Y[!E\/5%Q[@\Y
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M0CY)A2[KV9+"#^MZ&H 8+*<7N,IG9, KH6?9?$,@Z"[U]9,%<%+G2->12'0
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MJF)B*#)N[/%,6779I<3A^KJ)@CL93Q2N1*-=N_]9?W%!1DD(J;&$RFOM6O0
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MJI%]Z\BE]!.0=7L+9;W?(-?]@YR[GLN53*J":^\;:#V51WK8'4P.;#T!<3T
M, (%=[L(/*)AVD05,Y5*3@NSWPKL9<Z)U<YJ=ROM:FWY4FK-LLGF>2/D[<M$
MSM58^'-"5]7!Y0+L\SX*X<+]%NC?KT9ZQ_K:.T+KYFZ\+#4K.Y_&>0)2+BEX
M\'Y/!5=)_.GN[:ZD%=F88[H+?P/5T*"H?B%<##3]G< CQF(,7UH:)4\'K:MF
M#0=U=JZSIQ?N[PF>>0^68/7N/[-(.:NEM82.TM 5;4\-U?[2*=6DO8%F=8N,
MPXOA_LLTM\R?.=A=, J/H46'?D(M/=H\>CI1V[^VU  +,CL!!=:-<ZL6B/PH
M3C<] 1F]3F<C?RL7 I'!*[AFW/1: 8,?VGG?5!)Q#4"8BPT&(ZZ4QG)HV@<0
M=X8MD+R"%L(S+O5QESF<FW+N;#U*=?[J(GL"XE!SSW&N4#W]+>38D"X!>/XY
ME=@&V%*&=[LP#2>@SB*);DT#$"6>D+A7;;C8?M#\\5&*QO/[,ZYIR^OK,O[;
M?G).'!';R=B9*TE+[!5?6:D.8[(RW2OW8*>,.\(SERK2/3&6?,,RY'?X<\O/
M/F.%>4[G/K()QOK[)-=^2'M;*/KC-W*,9[H-0_JE<)EJ _>_0'*3@J>F)%S2
M<=$UE*VU92]?!;\HL>6OO[TA]<)[8B6P5$:E5O-:OQD_T4M1B]FA1EF@?\><
M,W[H:0R4/NU35'J1?XLN6Q'A/-Z<.UA0X/LA]R;^T;<AS.J5B?!7_)P0P]10
M,IIMG4?BW9G]VFD"((V*P_D$<-*5@; 0Z@[YS_O&(P4(*(7+(VH+9^FZ69U3
M'Y_6=$!PF>8;*5-M'P7M,1[G.VEWW@VI99BV/?G'@<S+.OCDE\F9Y\^SLF+_
M?:6<WL[W+6,49W8HM_AX>9YWN242G.N:WZ6]<,Z"]*N<5.$N)4U^W-]IU[OX
M7J#4/M^,;_7?<:<&*2WU 0 _UJW1XP6Y);<!3NJO+XPM(:)YL<<%&)M.:_Q8
MFEXEK]!$Z"_Z@'JWC%:BE$U6NH*EJ9DMUBP\-2O@]A8!TKVP*XZK-;L-<F!G
M$<ED&<,?F%P4G]8+9E&QT%*2.'.XUR\E1B@6;Q%331^?/)TNB&[5.BW4*04&
M(</%@*6_D"41!1::?J/1U<UNF"D/8%A^P7E_P9'Q<:>TO;%U/V^S6C-.<HIN
MY4DFQ(NS4 _B]-2)J/-T&VI3,^GU?K_ZL4B7 >?8I2.'1+K:C'U]F9/\3I)Z
M9;6$:9WO:X5!A\C"YN$/3M\'N"*Q<:%6L087@;O8;JGN3^)3O=2?XM> ,:JV
M>@ ;G#1FTP@X!U"%9^;)YH 5.27MT<#U"+HNT32F\^V;O32G;K<VW\IK^R\;
MM6Y++0\I$G?ZBE0&NFCY!BDD>5V+XW_IZM&L"9FC48^K.B3@'N8=KC</.Q_Q
MG76;&3XRC_U%ZEK;6C5.9ANT$$V&9*!(B2A(%^MG7F 5%G#FBP:&@\L=5W_;
MF!K&TJ"Q^<\:5OVP>L/;5V=M"%[V<R9B.A-WAB3.5=T;,>S^FG("$A[MBO92
M[U?FZUZFF^>_&^GR_#:H0N\*4VIY$NW$USLU-*F1'=@"OQ\X/R;??;/M+B5L
MS8&!)4+/O:.8<"^#3?B!L.2^8Q,)DIY.STKAI4RS:L2C, >Y(9671"I0]2%!
M <V28&1[R@D^>'M7SZ1N*"A,B7K8!.6"<=$$4PTX -\^-VXJ)+6##^[<+6C8
M._+3!F[C?74" 7'WP (:!*< H77QORFK22[K4TZ)J,9/5T] M[Y5[8S.2U?3
M^<CRQJ.W+J$GM6/8KAF/-0C(@!W/&?J[;M1SAJ=AM;>QM5]#MG>!/%H\)1U%
M3//W,^QUTLBBAGQN0K-3W--GIL1E*9KQVUX46EX9$&*9_&/[<O+\JEU;W5C
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M:WW?DC^_2(=1PFHQO*?B&X\'FP0S1$&(M@+ME<:<0 X3V5BE'LR6 C3CY9E
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MOH9W.;\S*X!Q9G)2R/&Y$]#+E()US O&-47H)H._XP1$<X'MZV%HQY=P_AA
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M7J2K=Y_U3& S%C_(N0FFM"34<(BD.2)&<U5R/6)[/23KQOJZX/E@-T%6.<E
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MKU4PX 983%=RFDV9YK!+UT-( 2_R^K+,-N'ZOQ39-75MIMD4T^<I1>"/1$Y
M_96,X;=H'*O>F5N;4)*AQQ2FFZ(W->9]8$*F#R%?S!D*B%\B";U[5XI933*2
MS'Y07SAM)%F5:2K)_&-^7&%JC2BOE (GD<W,TB://;"G5%KSZK*"V)<"OZ99
MO_59OZ;MV;GXC@/ZV1/0U5H\,^^OYM$+\72!70;AE^*Q-8:CDG;J_S@LBF,8
MS1G]V=P*9]2\$Y^7.B:?.@'!-I#K<KA:5=KEY&NU6EO_^V7W/Y?A9ZBAN85\
M:N'#],^IBV'Z40]1;N.X:CJN=O 4"KQ_ I*,D=!CW/U,OPFD$"'Q\SQ45E1[
M5*WWO# %%;\I.1Y6[67[QCUV<EY TOC-[QJ%[8?2 9Y>9R-V%"23SUK/7V_8
M>8GD;8=0FCL9EZD[J'9#+-RCRT"PKL!ZLK'(S)WK4W6#"?O+LPM!X4&7;LEM
M;DV:%PR\D6AN-I4,8]VM_VQPFHK9&B'[\9 Q>/G3=RF8S06BA84ZZAGFU'[+
M_,P.7O/I<*TGU9=4AG;$!W%]_HO<A1;\:)\^/^LY2(G/66H_O)UXN015"M,>
MKE-7F0</5/2A-<%GNQRK8A2L5TLR'S:L.VE5S0H([)ABXP>4/J ]7MO%RX0J
M 81G9&[%GF5XJA178-_YW# \>$AZ?"!X)JLP$&S,HBX@3+?J^9ZLB3Y]Z;-%
MXUE9C_KV4.EEL)',Z^3OA?9NA%, :Q^L&98:"DW'B.Y9&'8MU'LEA%UKQ#W#
MG6J,CXJ@1X3YK[BJD@B]15JO)$T#FPT$*>U'U<5-CU=:TF^AC=OI$TPZ[;L(
MFPGH]!&0, *TB^/OWCC'KF=*XK]KQ%[^0>FOBMHO[8H#SV0/ \P]SV9@OU0\
MD_GOQ=V[I^X*W'QQ]Y]3 G8R%<\J*D#6OP2W'([X$3+'57M;9^#S%E[7J9KQ
M:5]_BBM1!G/?K^<V::9FNJX)T@Y>67E5>*M^C27ZU5@[S?Q4HXW=),CT'^+B
M#>0]Z5(D?Z.>>\/GFTZ_^%"%4^]_KVUI#29)9-X/T>&-[>E+Q9J5>:94NN7H
M6?JEEE]!#<K:E=_[JE0<WWF'$4,] ?W<*8(_7TSDHP1PKC@^F>WA/-#^HE6@
M09)C5"F%P0N4^^O49<S_EJ'$FX$U8(G=#WP6?W%^R$;6JU3)L\-C3$G*6G-X
M7GH(,?&,Z-Z2-#DN*Z$O\GZHT.*#HH;8&_UKN^Z1Z)"#NC[+LZ!"=D9J(IW7
M@<AV*K$/FB3*3.$DK_C?BYQ!OO@SXL^BJ.8G(&Y;P&B!#.D)>.(= X9@#J6@
MJ_F,!:1Y  OTIQ_ZYV'@L.>/@XJ]65PYPPW9JQ^3^2.8^P*S![FJ1,,8;'3"
M:H!IOFZTK6G^*L??'>5E<X/ 1<D[;IURZ1$/_GF<J7RV:E %)/47SE@O@'I$
M1";[(1__7YR]!TR37_P^6D5EB""R9U5 9(. [-:O?-E2-LCL%Q!9LD$+%*K(
M7E6FLBHRRD8$!%F5500$9$^!M@Q9TB*C0FEO_>67F]S<Y)^;FZ9)DY,W/>>\
MS_-YGB?O.>>5YUDD9QLOB]AMV3BS$K5\'N\[PLW([KQ8>6;XO\2.'=N3VIQR
MK^D3U(L:9<15SPKV1!F)9I1NV_>QZE^Z^1\&3K@0*TD()CU%4@9>#? 2^Q:7
M\BA$:VXU]"1\'$F^V=RM=1',1Q7;O?!I>:>.]>* V27]V8$;8?-W]$%OZJ()
M[$)1R$7?Y*'ZSV61?;/A<[XJ>LC).ZR^W%)WO@6\C9.*69,TBAKB%^+6NG53
MT>?8,<MK'U]N5L4^V<+XL^"@F7@L/_QQ$14+8^>.&[FU[6H#3@X:'"F4XO=3
MDNMR+<=RQ%C#6Q\.MBS*E)04A%F5.JLH9&V/H5;OHDG^=./+TQY(;-,GM=MO
MQ+4SH\E+(Z?8UNS*I4N2\K&S);DU^2;$O2\B[%-6WG>GL5C;0I\UZ[8[.OY<
MB1OL5F2?TWMD<.]QX:TV<EX-3-4P8G2>ASU9Y":"'W;_N!=91Y%!]C2+\*"^
M8-CD#MH<DD=98&WWO^,;)]J!$4]"JE)!4[MQ&=5>>DN'$F=B0*(N-,8Q@Y2,
M-QBA!Z-KF,N'%^ ]/"@YP/6K3U<(TW0GR&9#UF,6)4CTYK^J!.-M<<$I")XH
M+"3@;N$]!B!R]#%(_$P@\(_W(*X@,(WWBOX54_;H]*_UL]5ZE^8*X#.<SEEP
MGP*OJ;Z9.C[KDSZC5VA3YA?9 @H5<2G>D8]-5H 3II+#$GE6N$Y /QW3@^3V
M06ZU*IEN7(.*I7CWZILG*G YQO18C8=2?% ?75R%194Z_C?33'Y12CF.LNN-
M=)$KK30MTWEVZ2VHJL*TI"M",OU(^%:DT;K3K?D3F[ KPX>U;\5+.W[T&&!]
MWJ#S(OZTI07<5XTX K '1S\,I(RZJ@''ZBCJ#CAF4:H\L/>YXB -\)CLF!XX
M0]5FF]9B98>GC/T//>Z'4QZ1D0M4ET)^,;</-,"_/V%\JVSO7LP<IH#'>[J>
M@$3B1/C[KTZFLBB78T-ASQ0K[ .+]5*YI::$=26G<M^C;4IS&BO4A[%R)L 8
M MAC;]R--ZD7O]&3+VH$JX:(<FJ$P/IOE=[/K^?>=A6'I*H8&17<-FHL-LK-
MS-(P*[TH>=N'LLZ1D<(9#6#P,QQ@"<X/@HD6/]M\?5)*=X%P6W#3TZ88UPIB
M3I](\$U.H7^:ZM@KJS2BR],-2MW$GWM87/6[ &P1I#)5$1/^HXLZ@?P:&]C\
M@/A%5!O[Y 2Y-M^Y<9:)<$7&T  ?'Z-JFJ,7;$CL212C&_%.)'2B;DGN\'2!
M-];81*!/9B5NYL'XC3S5*UY^;;5R"87K=O9J_R+R83T';XD32>UJ^#0^W/S<
MB%N>!YEI+?,&5++7??*V7JWH98M:J2:XB2V;D3)Q-#OSAE26-T0R"'LG_2SG
MY^:!,*GY1;O[BI\*04B5S9V?G>4Q9N%AZZS?C>['Y&JK#V1'7RD^H;N<%_7N
M'+U):BE'.S<9F!=#"@Q'"R%<:X=O=6)=#?X0!.]A]6@ R$9:!ZDEA03M5>W7
M30>G0GG=0D.SV1,[-6+QD4-B?IVW)G7^)75.VUH$X+Z(BI8I0A>57S,RKFEW
MY*6%O^B'.IYN</\I/M5%=,F#F"D(<F(%Q83Z@V3[]SS5^*&<WDU<Z/C&N,J9
MD=C^@GUNC\6GG)W<CD5C%JBIAW+ DDKKHJ'_44ZA%P+5F1HE%; <"S=!N<+>
M\Y'=/R^9QW7U\+_H&1+4NB5Q,:50BJ7V6O[F5(&0KD:39/!X?JE1R7]KD)#U
M1? '4"X5$%B71N'N?@.ZD&UKJXY+N]&WSAVT,\'/^JD0?/&M^X>AK<$XC1J-
M3,F9;DBL5&V69Y]ML7IEJ*@%BQ+5^OXG=<*+= 4#B;*PZQL+S8&&V0=GC#0
M+W0LAZ)NBF,#K]93]!F%#S"LU$?)YG^BVL=I@)Y,ZE7$F"L925?:958:8%_X
M[T/XW@688A5U:K2.!G@T[9I#+4!44#TQ<YL'633 >T0LZFSIK2H-($D#*/T9
M=AHTOB%E(!5P[^N32R-,?"Y=PNH20KFJ:O]"ESY8]'&7_.%JR':M%/3F49>S
MUMM759!-HJ9@<(,(I@BX&SF5O%G(#S[UTO_;0?8S'G "W<W)$D=I@!N30YL>
M*^TE);\?[+U5V4-4DH_%Q@-;\W)4)AV2O+!C&4EC \:ZIZ#.#/,RG%!&G)58
M;I8*]H]1LDF%\GAT2D:FZWR@5TM?XZ(K@;*^2MEXW6%_U]I556_VBE",PC7)
M>56QO-?UOQD*A5$_^GF6LU7# &K= U(OQ))?/M\'7+O/_4RJ7'T!.H;XVS%>
M1 J*8]3T3QS,0QN@=9:Q(#HQGD,5*B6^;,:"$_[TGYVG*.TM[W2>!?[2EH+2
M2X.^N,2;#38C\QS5DQKD^GI2IINJA(2$FIZ%&7PFVD\QTW71^?49O= :_NR9
MJT;%<ZLR3X3,"*T5CLY-9GI8""7>#H($I*R)0.P@4A8I)9G%E+4LL7,#6,B.
MO&7:ZN\77S8;?1FTC6*O$]$2+[^,,**_:6Z0ML<QQ6!R$*I;_D0&P8&YHM2C
M4P?]$X+/H JAB<GT4B?1&SBJ-DZY SNBE[(5I',!LC-YTW=E$+%_=]3W[XUV
M)Y\>3PS^T.2CRSTHO8[Z2.OO$6)EIC3 8!0B"[FAZ"83=.XZSW5XB^"+Z^FC
M*5?0$NJGBZM)U+>8E50CP2,74AC_' UP.:./X2GSXE ).>3.QBL#,3] OA!#
M]#FM<$07=R<[8\H0Z27>\75)PKZ^2 $.]H/ N*Z;L>.[EFUF_8CC@YY@@M^Y
M,W.R(M'CR_)YD# L H?LJ;F]&<5/I%@PQ4Z<H2TFZ^3<507BZJJ6LFP[)@\%
MX[UJ:]]RBJ??'E<335.AL&_R$X[/P5*_S$;QX#0^UVKR.V@._18R>?+8SD&V
M!Z<P%]0[C);1M9NLL^6PY."[S[52#%&@9[IG*<##YN\+/Q/QHR\[I5S5MI$_
M5^T>V\7B\I<ENUT^4O:NY+N29MM_K/RLTF?4XR).!C1^:*BQJ0G[;)6Y:5'*
M>#K0CP7[63T]RP![<B7:>_'BL!]..8SKK6#"/Z)37B55_S+\8Z8HX?F5JIH@
M8\G(9]W_P^_^:A#3@.@>0-/MW3 B3&/I92DLV6A*6=:O>\%JK*D M&TXI3PT
M>PU/5RA(9^QNW9/:HM=VCYH_1]N)9K&SI@4$IT3=A[VD,G41;]( ]I/R<&T2
M$ ^.4XZH>EO[A )"_SM]?=S"PX/')N<D]6UG.G;*]+5GCJD6J;?RXZB2^^A(
M)#_%=V7Y\G[MK8&6CO6'GNMAA9S*7P@?'K)\CI74@$E$U\16Z:4:6)>JS7-7
M6 462/:-@%;QGZG]FVT'CB3Y?KD;*VGBQ"-U.?75M[=<7C\.>^R>:S&P/7$T
ME_[MP^P6-\EJRZ6>JP1MR6Z#5-&8K-3COEEI62'O09E;ZP#? Q^Y&:>$'HL]
M5V 7!<,V1$5^G/F<*-+]B6G,A4?TXI 2I)&JU"-Q<"H2C(0?%__%<3P&*Y]
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MR!6\,,#UM19SLYG""3VZ+7..+%@2;:R Q>#? 1[+-ND?X>;?NKU2,SN?C^]
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MWCPQ:5AVUB=9]@CTUNNDNXXWJC^>4O&9BZZ8NY*5R6FJ]/&/-Y>D^V/NLW<
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MOQI0/2WB%?DM[H=6=R$G;TQ,/3^4V[:LPLUKO-1)PZ*4;]BJU' LWUMRO$"
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MB8.<W-6ZGHK?8_(.]NR4)=96N.#9+_M<[?=1/M%/"*F*Q8R%JHEV1J^/&->
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M*$*MHN915SNOP:W.2BC/"'O1MDM2DU% 6%Q/5\W%O10M]2*8I54[238^IK%
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M@_1N_^S7P=!VX[ZU&@,Y#UI5L;I!(@Q*"G<+T,Q"IL+A_CAI,'ZJ'"_OW]1
M, N=DI!AU%-@*8M5RR_B.G'R<#7@5Y9A8N)T^L2MNO*KI95CV9=R\IK 058Y
MY4$VON;R;_]RH*F')4]F]TU.FJL=KIMF_ZICB"%%4+:&C#M]JM#-K=TC.JLG
M M1CESRG+E<?%%T.\V=O"SSH+K?KJT?1_(0SU:?>56O8D=IZ/M0Y?]^L31<<
M?==NO6H%^8=3A]N3+2^9+EFK[_1QO]6=NUUU=D:.KR8/Z(;>*=V=7Y=CU)9?
M-:?Q@M[/5Q,BT"W^@-IA=@,5FI![#K'K-FX?UQ=T9\!2?;8#!*[.\FY[IC)]
M._=LG,T[ ,KYDG-MN$%(JEK0\C5!NFDD3((Y_&#L*&?9N:7_UI2"M/O?6<8\
M6%U5W2N,J=O7%O4IRAX4V">4N*57IRIEF/BXX!9\H3],I<6:C#%ED)-;KC+V
MORZ>B<?JEV-(':/\E*CR^;O6DH\//3.?^%V2R_;Y^!)8Y^_VVW3&ZK&?3)H
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M$__ OG02@5M&7.FO1Y-S-7NF%BL38$IK$8>G'89VAWW=Y63Q\):ZRHX_-G*
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M0HWKK(G0D6_^%G7 S*A"Y'A[XBWZ_Q!)E;J#YC5CL?@> 81\63L%4RJ _"N
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MZ! F7B9P=*+SI(E:VL&?FSIFEI(O7\]'7/3N\O,],F:[\"\&RH2F4ZY,A%J
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M HC5#'LQ_X'H*%\E0ECS97TYA:L2OVF\3VAY/UJZ3?-!NWF\^-=CXNY'>ID
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M6#PCGR^4'E,H:DSF=S^^]"2I#J\QYOXWK[N2Q7H"[WS5.E$A_?2!XK^Q)X]
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M\F]0&TH!_TP;H!:Z.1Y/3SW93W\W]_Y7[K=WH6Y#E.DYKOCM=)Z,/>_0=@K
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M0NS2U+/-IF3FX,4O75;^\4_U7&L$&R]H)@A[Z189WOC%IY!W%=N R&%D'>
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MI<>OCZ/O#C0Y%.TDM>N%A[;4J^0]'"PDXQS*'PRY4C08V!>V8W#-48A<VTI
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M4[G'X:&FA?3/VK*-#. LM,(*X0RZ"A$;MW MOH?OW1" OWN++R.3IM;84T7
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MF&O/ZLY""(2=RY+:5$_=!B-RVCGM%\L;%7/G]8%?0_=9;V$/:UGJLJZO9WO
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M#&I9[^_9S*V!M"%&]8V5O[#"2+&K,DMVH*EQTZ <Q1IO#&;+IOEKOQH<$R.
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M"'CVG[O_J?*?1OYGVR"[[  P4I&Q7?,D)[L+N,9(1LY(=MD#X < R*[_GQ4
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M%Z,!NRK2Q[OT#'7<?7N-BNBIIGZXPC'GT4ZO0]T?M=CO C0!0U_)WGMV?N[
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M\$#53^67E/2< B6N7R6"_2+P^EG2A'Y-:&+3$_0*9[^-$D8!S==Z9(T&[//
M5IZ-\X7DY.B*1/1/Z(M=TQNE)QNE'E )#%:Z&8C3UY2;E(PT>!2  >([6#)G
MQ.1#5N;6/=NN+ E\>R$M=&!@,X#%^,6:X.NOB/MB85K(6Y(ME'Q9?FB^PR@R
M;S._/CWX:Z]X/6!H_-'9(MRZ-CCGFW#(65GEIQ0CNTX0^/71"3J+'UYQXS&]
M_$.%49^<PP0+4XN /:+M13^T(RDF=N 1O5'X)A08TCBVH\7#ET\O!5@CAN1@
MM@\J(H+?J\9\ 2MR]^M2C08(\T;O!NNQS+WWY&!Z?%O:OE'Q&!V_A.MSMCV[
M!-QNOD>IN!=..!9040J6CB?D@<8:$/"7?IC)4LZP]>HB87=-L8%1LJ/%6%AF
M-)HB49-G_=O].YX=C(,[X:&'S%F,1VNOR9]]V#P_$ULXJ&Z'M5T?KOOWX70!
M;_-A=G'1 *EX]D$5@8JQB/Z%>7A#DV.0X[9//#%8V6=PLZ##6#GJMK?/F*[/
MW X,RF7?),3*\7J>.PK )YWU&G.A,=4F?R6J:</G2M "E=)+ZIJ4*E$J5[U;
M<6TSX^LM=0V!XI.+JSOU8;+U_MNLW7Y[4X72?_DM[ =0_G2MP?N:Y/"7]L*5
MNE[''3\O :#';8@*(O4A,2A^96IN,JTXOS?:X,FN%GGB5S-8HUN/7Y_BJ+3I
M+>SC36KR6*_0G:TL1X2M"W-;ZR4 A:#,VSUZG>%?=_0O&'XX<<2KQF+(H:_&
M C VU_":YM/UF8^DY.^@UZ @>HK.F&;_(N,E4SSSYF[DM-&D^ <6J/KNDC%[
MH,,+:W8BOF^VP3<O"3><7@*ZX:-+1P],,6,7+-">V:^D49@<]MX/K(<.H<4-
M37>W-RXJ7I6Y$P=%N?R=)Z [+=P*4RL(FA=^6'RP1U]# ]=N8'_W" T#LS.3
MK4LS7>^J2WW25E6G_QD-M#MW+) @3*(QK;1QXJ^6B%_F!VRNW*H-]NBQ98!(
MHKGI_)$V->?:?P@>G7Q"N.7P?'!1?QZ2/>I-IC6A) @9)[5O>\N9Q#5E."9?
M[[GM+66Q=9CX3(&!(-3PL<XVBO]:JR%JQ.+*>'<W-=K&*+6M<7GLA>;F4*^
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MT!CY&/D=SWC,N5HD!.5TGU;Y1J(1X\";Y\T>3$I"WQ,R%ER>@S)@)PG-K6*
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M%?XJTL8L\*.Z 63&>TZD]MAO: =F$DOFZVA1)UHY]"_%,:]9H;9NTZ+#MYZ
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MRB <*%,P!,1IQN,X$MT?>0RM39N+0\MSUM#P-@>9C#,44K0(UP3CACN&O'\
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MY[G:K75ABCPK6@P,SV-8@CQEH RU+9&+/-$)O?!H=>J?O<!DC> 1&ZL>LJQ
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M4]L+?YP1.ZMH=HJ1-^B;]$5T(K([",<^P9H()?1%DF'@W78$IR*V'G9!HG9
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M+()\$8!W<1@8 E#\Q>0XJZ@";^"4_+E)Y.H%&ZMWBO&H2W7U3W]="!MHHYF
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M;7VHWF)UZ>> Y;OG)\VRPWO4RB^ZBAQI7WK6;4YP<X9^SX[Y<]LDHGZ"/I^
M4JUAC#ZU5A) P6X>C*-]CZ*/6>9(QS?Y/A=]&I<5YE=05"?5]:M!KU4C?XE\
M-$%(@UM.@?:KEMA] P9PK3+0Y_CK >RIG,Y:GY!R3,:6U;*4(M+/W'E0FSE[
MLA3?*E/#_ QM1TJX<P>BYH3U>M"77=?[8_AY'URZV!WCP=6.$P2$L\-YY9;7
M6X>XO0+# O^M'9R(&H<C%3A!9[:2Z;G3UU$O.GBV?G-V4([V]K:B,_V;CI<(
MKKO-'=AQ:QWP$)-ZP3_Z3D;[BZM%VBIOSSWV.]:7N=Y"QZXG,0&[IL<$L1E<
MWV;NGRFAU@/C2L53'$6_ Q<TLQP1OI&;]1M/&YQS=-3L7QVS%V;C643+I?&'
M/OF8+7S\$!E^+*1B!(SLMN?))96.!X13=@92-&MZ9\N7NGX,S-5(KPDKB]I.
M]-*G>"S%I!\8%74Q 60GH:/:#F"RSG>PCE"K,#].#B[F$[<T_SK!O,8+2;M<
MDE#9E*&EM-)]Z?W6LG5[XER_U;V5A,H#,+,$>PFD<:GQ)!F<M,#T[1">)6'C
MU60Z-,[Z()!06@!&M5-E$;XH:8%*/UR-Y]BDEX-.N/RH+:>'D39V@;=.!.D+
MNES#^Y:1.QON'%&I>>&7 PG4A,U>"0$4.,HT?2A;#&F!)N(,>_$L$E5%#+D6
MB&H7*8))+^RU9QD25@Y-%EB58]!<9$=CDD!+D9E0OG@):_$"4RDAN?0,L)X.
M8!H[5XH?!43L2_3A-WZ R?LB1VHYB0IV.4X*+B%-O-,YSC2')T5Y)N87,OT'
MGCW[+:Q3"CM@]_FC3  -"0U#M@6MI>KW$3;=;G2=*%54&C]:L>_QOJ]O][XT
MQ\N;(MPH.AAET:;S0!"C-9RZ-11Z+_(DN=TPU1+6@MRTQ6,LT&L)F1(Y.SI"
M9_VVS2SU,G@:52@8QFGG7@@X@I3Y?&(XY\N0L[&MO6@MUDC"RF^(^AIP]1%
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M1)3H]$_6TBZI])?0[?\R(;V _/EID?J/8JVSZBZ&_.]98#IA&!]('56@X<P
M&*W"5[2)Q\L9EE *A:N\:^-;^O-![JKN%P]_9Q#F6#TH.#WLRA-X'9SL\;V"
M]]-JZ&F<S3C5NZ]?Q5^XY\[QO#!S%:L-F*Y%J5)R-WX'OO6HM?PQ7H($X:J$
M&3IONET,J4'2CDS.2FBA/+T-)8NF:(!EM/%#-3S5 '4=(,03>RIYF"W*+,?@
M6]S'R0:/> [.()Y#V(9Q[[<;"'TJ?2[.Y;4MA _]5WZP^Y=!07Y!V2IP ?!T
M:(+W.I *+#A'>[10Y;':ST%&6WV_>\^5< ,"V<TN*D!-&/^^? 57<.NU2>7S
M*^8*;JACP0$'79/B(QW_#^L15M] 1^"D/PA;J+0[):RB^J6A.W &@ OA3\:?
M"J"L3Z29J0HD,E=9#+D1B#A&-%0:0?FK'@>CVL/QBCZ2G*E?8ZJ\J9)6U*UQ
M,]S1#QV1U4A %,@TQJQ[2.22V7_A$L?VYO]Z,ZIRK_7;KPW<=[O6T $N1$;F
MZCUK541-R9\7^DGFV8"?8_W?"A*Y:,]'.<M/TFU40$(LRR[#),RQHV43S$CX
M#'\=FBVLM#9X1/=>8WUO$:Y-(XRA^??!"C8)/(.52.YURV!W&29:0HN4,=>^
M>@E"A9DUD]D>@&%R+6D=F#,V4RWP,OSNCB$<'0P,G+/90:YXGK BO_M-.J50
M6&1M/2+J8<HLX9-6R/>P$3QIVT]]G'FWU\ .(+I\5"FQQ&\YAU+-P6^=IECS
MT+%8#;90^E1_S>J3&TV#V&.!6E_'1B9SPIJ_"K\=K.\10UXS9\M6K;#>8%(I
M%BHDB6 @V?[3XNS:9<YVBF;B"0"?(-B;,YRL;,<;3@I=%4,VDI,)[<W2WF\I
MO)EP56(U!PJ9I.P:Q)Y=F7OJ1QZ?NOM:LT4-\2_CI> ?+HA8^&-(PNQ_!%'#
MA8FZC=-+NW?A)"IUFN@WL.;W,!<U*H;P\P#H?:PSE[H-WVJ.@_<\PQRAK5"3
M:G/Q,H)KPFR!,T<EM'ES9^!IOKXTS=*N(ZG6$>^6-3[NTE\3;6UA&+:S0*WH
M=<W"B<2B%'ZFL/Q;FA82U$9T*KGYV*$.2P13?JKB)\OO, [GM?5&>=V7F9?M
M>E+KOZ+EWW;I07>,?FZ5ME 7-1."3U?=UXRUAS^EPU=6U>EJF,7_"Q,D_5<F
M6-P8>,[.,[@S8GF2SCT*RZ$@A&]$"*P16LHP#<\BX55J"G@[.<H)(D70;H:Y
M4R+RGMK-BLQX5_WE;[I',T<H^F]>O7KC:+ P:_FXL:!N;,>O:X=D*7'_4E5,
MU=/QH]6L&TF\1XY"4A@JP=H*7.!5MU+D4O@/ ,8]BCHH1^^H=S<M>X;)IHD4
M@%?50TL]2%N F4C9RPCC8FH#]4WT44A':.MD.::^734A[5FA<C;>1L1@JL'-
M5D]@S?I%FAA?6YYVPNS$$-:9G>9!\S:H[:\0'&,S%#$:[9:)\7#7YTSD\ZF&
MY403Y$Q/N$-379P;,-18<5.U<)/:>/9+K['WE1"X]'_+IO[KM-*BAT]"<"'V
MJSZB?ACPM /X3F7EX6&)23> ^R(S^T<<"1'NED3FBT\52R^,-^E_XZ$%^E<*
MM)/DGH?)? *#*S<\-\W2&NAU;))?,PP=/<^O@RVD(U*:0L60U'_OV/6KK&K]
MBV^P;*F'S!+49(?U/>OM_QTYQ0V5B(*[>*'1B)L2SR,2!5[S"XL]T<.>U%3!
M%39A#0;9[FW*2W][A<W8C'$]11G&GJR<NK.C/+19PS%F#EU9J6)SZL3MSM6]
M29K$B-/'UIWKT0M^(]V"VRJ4V.,F2LU_'-$+-_PG2_3@2P5&O'#![O'#L5PN
M::;B1@X^"?\J%"4OS/CH1C%</Z"/KQ+8%#D9:FQ,\/M>/T89/WZ$]*\RN+<)
M@!=M1JP:8*HYV6WH=0(X&,S;28N<F WT?2:PJ1E>,ER/P=/,7"V74T*A.Q#Q
M*#I1\0U/#[7MQV M=(M 8Y@S#+<KQMBX Q,Q.\_TA4+5 BBP08.]52E+\#L;
M(EF^:OO_FR+N^(C_M["\(-U>HE]B0[#>ISAIW^ZB",S7CU/E30S&- @<;B-E
MS6AR8?5EN=KEP#V06*C-\*0(?P BF (0LTFKCH*C "$1&\QF@-I0^KL:F.*D
M:>30(^EDG!'N@[42;[N2Z\/??]'+0;0K6+6A)-__0&%TB5-SJJ<'=>[;FABI
MLG\MMH\7?_G+R4.EB[';QZ(3"9&Y;5[RZ1_A^5_TW!MH$K5N>78-@&]M*&E'
M/$ !2$*:*N)^34#%VNYS [<H%KCW*X4 DH/:YN>MU#NH%T@Q3/IN7]N,1L:R
M!V+0ZUY[JG4IZ CWA]3:M\#3H<6V^*V'CLZ=Q.&Q#L)*T88 4DT/8\:"BTY<
M ,N<H[?0B :\A#+.4Q3;^@DP;U^C>K> M^4$,5"ATQK>APWDO*W9WZ2-KD0Y
MLE$; NZN;,]O^\7A:-8UY7R0NBR25*,7VB*3;MYMUL-?(@F;29"3DY)E*F]G
MQ62^DPXR.U!W(0CCRF7,FI!!$JU!^X$8<@6:[+WADTG@C?<T#QZQ@$?EWQPR
MGM\\F7THL&&8O$B2$YP=6!(Z]3O9_.CVR?<;;DB=,AWS./T%=EZ81[U)3J36
M0FG3S"3F%L*#(B":G"[:C=D@D5GMH^LG$N9-TFS8C!03I+3_RM#3HJF=:'K"
M4K3-::)$AJG&?U-ZY+^RBV^9/WIR_;?=J^7)*L=TB;8V\M9SP<,JWZ+"M(MO
MOHXTP6?@GWYZ6CY?[YT3-D4UF4*>W'[VX'^L)Y(S$7[4D2-MJ!H.YERT+UT,
M4<3MF*8H].'V8"XR);QHDPE#[N;*> D+D6*I2$JTU@05+B&50-=.=Y/..$ZC
MFN&)MU&-7GO[VT<-*IY-NI<DF@CW3FU*HP^&GI5&L-&R/T5RP'RB0(L]IMF/
MM6)'2Y\"?L27V/:]RU(U3;R"+O:[Z-Q]V%XO*>!*P+HUW\(?QFZX>T.3&/N_
M7F;W3L/<BN"I3E?DH=M@GU%LPU9\NK<F.,NV"J$?GEKI('=L<91JS2D:OI_=
MJKX.IMH4P&8^("D6 :,WQ[?V"E ONR0Y;@?H83_XCK><TN2KG'BJN1HHC%2+
M%P[64/UZCVY$D"OQ,/2SHG]?(=61=+GR4$!E1+KOEVK''1#( <L=>'F!-N]&
M526&?'S86@8D=:@?!!R9\?.AC5>4J!R)90Q!'ZL?91O*"J:W,O=EYF/ZSP\L
M/G"Y?*IVVLMR:F$VZRRCY&LPZC5]IO7*JKXDS5EOZ[?6$3B"U="D)L=PKJQ#
M.UYI-^AKF(K&GBPM-FGV=><ITQB)>.B<P*TBX-'&XH$PAG+EV[*9VNI7U<VU
M?;/Z,P4KZ?]S75>G_'G,^8=_V=HYYX5:$4JX3G^642AZ^-;#E$T"-X*;US\O
M)(,?,7M@O5<0P!/5A[.%YUN4D5A2C6)B8LU\DO?V^EH>GL90]&NP)02CV8%[
M!$8<1U6&$_B$U?U@[@8P3 CMC[CS&G?_YXI794KQY.C)V/=9JDZDZ\67"ON_
M>'VHNZCT:72T?#C[#B,L_)#-9KULY</VP4?FLOPT'SY)+_J?^PU<W^-KF#/-
M@:L.I,2S4S!ED9[@<+](#5.*]=N0 OR"Q8]F)S3YDD>C,Y#0+]BC +/#,(&Z
M;1&MX ':\AFK'C3WJ)$Q-_> 0Y5E8>N7!HDY?/Q%YZ,P%:RT\#["ES%2S5EN
M1Z8R-X8BMH*^DB!6$.PIQ#ATC%X@:E$'FO:$#JG_C];.+:JI*P_C4110!.2B
M(!!2L124DFB1HA@2+8(H8E K" JI4@="@)220(28U I$ IBV*HQ0."!@J@BI
M @8!DV)"4ND 0@@H%'+!5;E(<T[5<$9.#Q/6FC4S3[/F81[^[WOMM2_?;W_[
MO[Z/(4"1<%QA<K.=OL$<<(;%/>B>T3:J<V+\:95HLA>\4'Q8_7,[';@_^GN)
M![A;&6 4YKX6"Z8,/X$;I5J+.IA%Z'&PE2!>@YS82L6/[!7-W.<9!/O+WF"^
MB^?FDX45^-+;ZIJ<Q<\D<9DKKO.G8A_SX&V\GE(KG;%;+,0]L"L"0[NEUO O
MYQ8/PHW[GTI7T60N2)9! U)?]>D #SH:8,EP&*,%)\B*O(>)'J,=Z7=[3;FW
M2IG,3IK7""+YPGZB]Z,0^A^R0^9[H9FSGNJ46F$E1#>B3ZE6.\U"@%VN(JV%
M<DJD[YOA]D&U,R@NZ=H$AC/&#A'6S>;$6Y6PQF>,G$@PN-^H[$A07A=I9TRQ
MF83"P,9'08HO56<2)<O^9:@4PQU:PMB1 I!#8(/J,I'<@%BJ_8EAD)>*ZHG5
MX%O%5G3/561'),#0B(WM-G.( -EQY^3<Y-HX<654ZRB."J*-9V[#>3UN1X1W
MGSU)T^%R!ZE?H]CE+"1VO\I@)7@C+":O[MJA,UJ07VVB+9Y%@C1O9,ZS"^@6
M#9)LL,$FJ[B.L*W!SZ;1.LT A3> ]ZDVJ4Z3,U>?K)/Z7U7D1N5GQ3T;GR#?
MY?8O8<"8$)P26"==/ZOU)#G"HF[<^K=T@@5-UEJP(*^,, -7EHD&C?90!"1?
M.!*4R\TKX4C3;=KDY@K")E@L=SQYX(>4,<^'R?J7,C6!>#"S8>9=594:PU5]
M],+INX@7=C7?['(EKJ=,5>^SE 410\U"8Q0,*I*^1X&^I(PYF8 A%#_3DKH=
M"88KSQC$A<E*W-HN\MV$N9:Y1&=P_O<ZL!I5*X-#4,!@([0;IR)G[\/E!H8]
MG'-DD"FV@2_MC]H521!.\+H3."N6PR&8 X6 !3>0'JO=*-V&]B>Z#9KE\_;!
MG53KGBPPSY0/,:X@-B).VE"MYV991[K+7O,.!IS9W"7,7HUAB+C76R _MFA!
M<RMM&\_4KEO"Z%JTMF+2ZAF> _HQYP.X%)Q3Y4RZFN$IC1-T+KTF3&=T2P$<
MN%MAB0Z]:!BP@5\KI+[JG60;MI=6F>C0:4;M2(@>#:Z^!:3GU*?R65=:1$]\
MK>9BNP?R45MX ]CY$\Z*ZQGWZPQJ!=/T6/MNKFO+H\XR%*$%VUZ+B1EU*ZO=
MY33K5J4M6\B]CM0FFM"\XO+HH<]RSW'HBR14XP\5&T1"DNL<R;F\>ZR +Z?D
MR["H1]B%K%4=DB*2+>>4^NV>/>Y]W)'^!3.L&#? 5*5T$^3#9TTSTY-BGS;/
M7^'?F0FNFI#6Q)%Z_Q4\8F\'OP9/(E^ '*XCI0APY&YHS>6/NR?"M*"O7TB'
M_;U_?*1NL[>?>V>O8%AR]H&$HJ[=M^,3=[</(:%Z;-291X6_'+U7UH_V3NI)
MJ<O.[ZI)V&9Q%Q(.+@<2NTD4!0]@GMZLVU*J5X(?R)IAWC%07-!F[S%=[?24
M<][0JCD+-@$*BA/[4L^(U$[=S+@)B:YT1>K[ H[*-$9.4$V*F)7Q@%<S'+W2
M%X/9LV)4?"1 NTN9%?G/,_,X-G(KIL"GSN'[7-WGO. +SBO^/@@QT#57S?Q)
M@>NF<*4H;I2$1^Q@U931&G[YV',;+ 1/*<'IW/XF%\6W.G?"!KI8!'>&00!?
M!P4.\$G8E$G'-DTZ,R6,SV>P3J;KHCZ)Q(;+YXQ?X]:FH=;(#A!X/!&DB)<(
M=HHM::J(P;<A]%#0A\^(/2A(IML2:63;KBTZAM78^,R#5V79+Z- 38G$(1S/
M6D,(7)/!\'E;\6_C4KP#?@AFZ64JWHHYP ;U9\</* %[)!(O)#W4-RY6A0^I
MHROWCJ010^N>?/CNQ'S!'^ZVC$AUVZYU04=Y]6/[3T<\C'\SZVOQ&J=/1AP!
M$PO>9Y 53&X&DP7H1[=N@"+JTZZ$!C8E#J+R _O("1"_H)ESCJ4WKJ=+_:1@
M$A+UH+"OBW$;7ZLGK(47Y%P+*.@9\P8Q5I^>D?)V:R!9_=5VS!O7__!)Z<TZ
MRX@7'L(DX/7/II<8) KZQ>0"GU@,@TWC"L"5>!3RZZE>F4"12]\;1E?V-<(9
M6KWE(X-LS70%>E%O=)R-9.@C4._XB;B3<.%OI_I<0N'2>O;Q>.D]-?YME24R
M_JOWP+A9)?4#+917<K#%% TRBJ2>"*X56FT&P2C(1ZEUQJ<1PPQFKG5\(IJ3
M[AG>(AMF]GDM'*/AY[MV-QQ8W0S4S+1$9@56%=P]F'G^_)>O)R+?'#U=8M;H
MY)=+F)&&FU^U_=^2>\QE_?[93=8ORS!.2K85T3'X^Z3Q+0)D#J(@3BZF> AX
MS,C76K(J"9=]NLF6G!#(*">MN:)6CG[<T9I+G=]2"Y?+ <?1$\-E@_6R]JM'
MH)BF/R_MB.C_]HOTOY0<2G]\+PS#0KV6'_2Y?9-X3=>^.^RZ_1#^H8M ZI<*
MN'+"ZJCLZOG6J*2>8.VK*=:BWVRV2_:W<@\ O)+(\6ZO'DG ;ZT[!UF49OCE
M_]5:=0Z\9 J!D\$\/4]!+=AJH!29IY&S PH*9]C -ZD";B"@&,OGVE"L>G3^
M =VYSMG9\21A;4HPM2"_3,#LVZ;]5"/^W=@F6S\;K[S'\IYWCK;J3<29QW>8
M8S/2Y0)6'H87+QCLBQ*#X'W-W'Y)16PQ,R3O4_"1J(BI?8Y%3M0B]A((7^Q^
MI$75Q'91;!P[H$S?A*\?Y)S_(?[@;L'(W^09U1>7FV=D?]Y@3IS:U_EC.]R8
M?I,V)N8':EUA-\+EV'NPW]3&-AVCJ-H;EH#CQV!)O?<WY3T!G"#(6,SR3WH\
M*,\1[87BISNR99X2T?1(S."U:,MK5#"*_+RYGUSX'>T[SJ&A-D(^"0M[ZX&5
M].SJP&P-LQ/W%=4)28#H/Y4[/<D241@\7J:!X@G?4BFN3ISZN4)Y\8<E3+)K
M#7OSPXCE#OY4SLK!-U2[&:XU=$ IY.=,VL)A=8@3N' 9V0RM/C/B+\5-+\<:
M07BLS_&VD9T)5#GJ4VB&F$1?C6XDC1-5ESH6+JH/K/K^769%[]AO7@+,K.SS
M@6=YW>3[0#'G:!,[YK?=K;ZH.Q((NX.7/EG"1+6W@[ANH%!U&G(QQ8CN:"GO
M=ZB*B$F0N[)Z.U1>1$C7W1\RY#7Y'1[Z\,.[K2\$4N/_\/?AO]72\W\ 4$L#
M!!0    ( !>(KU8D.,C7&R,! /8R 0 +    :6UG7S P.2YJ<&?LNW=04VO?
M+APW*BHBTCM1$9$:E=Z2C0@("!%0$!"B(EV("$B$D"B]9PL""@(B74I4""@E
M$4)1$) N((0D"M)D12E+",F7?<X[Y\P\S_[C^<XY?[XK<\^L=>=NOVO]RG5E
M)MS/W%G(86L+*PO(KEV[(-=X'PAW"F+V]]/_U?7W(O^W:^SBOH,([]NU_X_;
M?+N.0?X0WL4GO(O; 8%"(+OV_,\!D/^Z=OW!MWO/7OY]^P\(\ :0#D/^V,7'
M]\=NOCU[=N_F?1O%^QZR6WB/R-'3IGM%[:_S'PL6._/@8=$^Q;.OVL0=!H'C
M6C?N1.\_("$I)2VC=$+YI(JJMHZNGKZ!H=DY<PO+\U;6CI<N.SE?<7'UO.GE
M[>/KYQ\2&G8W'',O(B8V+CXA,2DY(_-15G;.XR>YSXM+2LO**RI?O*ZK)S4T
MOGG;U$[MZ.SJ?O^A9VAX9'1L_//$))W!_/IM;O[[PB+KYZ^U]8U-\/?6WW;M
M@O#]+]/_T2YAGEU_[-[-MYO_;[MV_1'^]P#AW7N.GMXK8FK/?SU8]-B9!_O$
MSCXL>M6V7U'+ 1"_<6?P@,1Q;;H2ZV_3_H=E_YEAT?]'EOTOP_ZW79.0@WR[
M>"^/3QB"@' X)Y\G0_YG^RLU6NCL/O9WOCF\#&>""WF-HA+$EPKVL.979(&0
M=MP9H*^O-2>QY70M9ILZ)C,3=R^\?&)Q;"RB(5_GYY>%S1"_B+CX(GG2D+F1
MR\SDE^6?Y4E3.5Q(0C2.RH6LA5'^0 !,$,V%9%;U(SQM^<^.X(YR(6UG3XQH
MNQ_;0H-!7(AHC,Y<GE?(:;X-],Z3ES(NS^Y)G:2'GYY\<[G]OMH//'@.J\*%
MG.U.H  V95S(3QT(EL*%".W>2>!"OB_A=N/IW0"-"U&V_Z=.YQ$HD @Z<N((
M0OC9'%LNY*L_@BX,E.\(*"CPCJ&9QX6\']GUDPMA&XMN0+F0XAI0F'=X*!7/
MSK?\AS[417R[(AVY)6%LPH5$N^MQ(0\KN)!8R_;"-75,)!>RNXEGJN)%_EXN
M! "0G_&<],992XX<7I!W\##HOW=%F7(A^PAQB.]7@$W._E :QZ*8(PP]@/_T
MBK[*%EF@L-/^A,*X$&H;XCH7LF5(>P %@]F\73^,X/^];W2=GWT,+L:%%'E2
M::#2,/ZW#.&_T?N/T5O[A4&V6^]''P1#=W$A%]WURFOA?1<1\<;'"W]I@*$
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MJI-UJ>&;Q!?I*,=+=/M/14D=3:Q2"ZO>K-RFNW>=72=::^M?M^;H3-J6]OS
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M"JCOX"=Y]<\/NE=[=9=?@?0X6XT)DY@"QSWT7"T36Z ,(S=W[TV/9)NBVH4
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MP#<5F?F_G7_/0.70;3>XHA,PU)$LFC?N5:NB'T1W%,63D_,!J4SOA1Y'J%L
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MXVPWV2E+IN,)2VIU>L\8\+<9KJK:&A";]3/<RB/T8V@Q1F1G+-W=V;F%99[
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M0R YI8)J.HLJH^,&@:?JT05L+^8EFFJ'6$%U"@0,/.QP0LD36"IY);"HU*P
M2'*V9_*3X9$.JO=,\B+GW0=84T/\^-I2U^XX?<HO\[)AA5WWAXG)J>[R2":6
MABHH= >"YVE_7@K%Q0B5P(-*.M_#ZNH*-=TLZP;#KM=;N2&LWXZ&NAFYJZQ6
M"@@&X=U,8:=]%1W%7"L-,Y9'R>TEQ\4J[1U]^XO*SSF6&!B&3CMEU3Z-39:C
MV@1J6:M0]<C#939Q,HA7?U=[B)=U$7Q''!E.%5[2H^4R,,)A U5EWMDS?FK-
M[FP"73O%=1:#NH3T!B("F!^ FG;/8Y CJIT[[&LT["O#XE:-T; ]8$O-6)W9
MQ6C/SI64O Q1834AT!T1AA(='HJ-+XPT#8<9MU,/?:1^_$WZ8K[J0@-3T^CR
MY^ 8U&DFA#@C-DZT4@I!Y'1*93KTTCQE#CR$@_>3W<ZL>,*L^JVQQR,R_?/V
M0T\\V.X>2N&?DT0W. /1<]##?E=7_""BS&GFJ.RM&//5[,NX8&K20MUO5]_5
M#[7C:Y1]T$1X6F\ GE/1MWU7.?-LN%)5Y0!";VZ6+(QI*O2;X6/:/*<9O356
MQR/.M&ORV,9:?AIFJY;X1:428 4PUX#LSH>E=^NJRSW]]((F)MLIE+3B/]:7
MK@EGX71([SB_V)]76AD_/8&SX^G>Q=PV'.&XBW*[QJQ0X*.@H.C(J,DL^^%!
M"?^>>=\VD/?#<\6_S2*KFS8'=HXLLN<YQT=PGE/F?4C; Y76W >E"W/PT)4<
M]WW0XHA5-6&3=-!K=HMQL,Z*6<-3/M\\ZYU3=. @;N\^2)1PT!"_YVG.&!5/
M?@#= 17764]B(8^.0^074*JL^%@:QZTK2KACD7B!(;UI'4T>=TUNRDRY/P-N
MW@>]3+]='TM^X ]>]:R;W >90)FV\,1\R7$2;&""1+.>7S5G#&#'4?SC6[Y$
MA=;S!YFN=F%6FM(AU:K Q"4^"45+>Z(&6J4Y><:"00Q!2WFM7VX)R LQ#,IP
MK7F#3-[PDMC".)U4BL9NSXCC:*DU00QL@NM!O 5@4EPYEF0YO86G8U<X=OTX
M(J0CRJ.1#Z,\3K0]W)402CHY]=V49N)CV7HWOK'$7RKJNIY3A-3KJ4XV'46>
ME32V_<@=W@=]H73*1V_GL+H[P/'0VO448@",F3-'P:#GWD.. A3&[)%;7"$6
M-LFK%MAB0@;FYN.>:",OT?KTS!M'C*VDR"3I*2LFO@-C.D)XIUL>HC-ZB&-W
M^K#XC]RJX"B<Y_QPFMW;[V%*3TULS/BJ?U[W#(IFM2E^WIV;VUI<3+U@'^/+
MP]S;IAX$Y2G2CX,G^7J* \UD#R4F*FX.I[ P*T1+ZJ1BDHP='LT<V@?%A="@
M"2CYYA%C<^8EZ\&?S/JN&'C'"((+(/3H*C4,8>%E,/^3]2VGD=KEB<T^-5UP
M,=H'/J'-X%60YQ1NH9/SS]0 (@PHE:<#?$P9:\7)- Z+#((^"\7&@OF)LLSV
MKCTKUCXHD<A?F%3IW,W3'N*7'?>!Z1BT,"-+'";J4*AY/U_NIJ.R6*L#?+-U
MT#S3X$!1:GC-S9+&$]\"BAK"4_ERS6:N]BG!%(M5;K^P$#605]3XEOI5#<2>
M_^^'!X2])X\G=]I#-*<S_P)K-%MUM8^^'$*?33 DU#4S-!]9[T&X_5))*HWE
M5-CNG9:5S,2G36%)YOC)HZ&]1NKAHD1K8UQ15?-VRO<VWKF094K]J?O;BB1+
M]H&/?8&X!XRO.W*:UR"*,(C4(!&NNCK&$*M>A B,$Z BP.-ANSTHJE_MODZ?
M_]UA'7G+/P/#:>UTX!Y,\@'%/O-W_^%,ZHS:3XYL4(9BE=F%Y/E1X6"C[67J
M,Z@Z^P(3^Q5]A#17.7.6A8\E2L *EV8)\RL1=&%QY'66=7QUB,E  C&"R4_O
M?A9Z%!XV?68WLN.(+1_29G!S^LRZA9N;?OJ-UGIB;73B_0;HAR]7+P=;@$#D
M:J/F4-6"]7SB1C;7#W*)??;@7;S' IKS7]<E$&C&P,K/(H2Z.R<##6L6CH_J
M_[QG@MBS8W(SF$G6P Z3WYT%;Q=$3B+=ZS =8-G 6BNLX!(UHD/][J:)F,WP
MYK29 ?MT&6$ED#3,'1SZ6'4UKX$!U0KI-V(T]@O?^^UO^+>]4]"O<)CZXL<Q
MD_%FC^E=HTO5.V <].0^Z!-*Q)1%O@*DX@0@@MQ_<?(5F\!]@%!H0>>OEM\'
MD:^Q;;+W3%FWN/K,UX-AFD<"H*Z$3\R^\41Z_-B3)X7--4W#A-[KJ;^&F3$A
MS$IDM ]-/W0?E!"5F5Z)P%J/A;5 3'S,/]>-:&[%_$5QR(0*+&6YWLF8WJK+
M*//P??S-GV.H7B9)I4U<N7T5>[6AWCR1V&%Q8N[MCT0E/MCA",47>%Z>W*>1
M//J*]-D)IPWRKEZG]J0YS2-=-2$P#'V<.X1C?M;M(427YTPJ0V79_#3LR0FJ
MK\/4]10AW*/Q/W^;O+2W@GOI^Q9X)Q3[3]M5H&1:PBPKC1_S"<<ARD90P_'G
MDC^+GQ=G243.GZN]<"*IX/B8N^4FZXZRJ1V9=MJR9/XF59,=C/PX#BO^1<_^
M\G/F&U5]NGEJ+P&=/SO/*LS&5]_;.I6[M?C]$,[TZ_H+:\-&,3>/?1!SFQUQ
M]K\JY^)V-T#_-0F!B<F,N7A>9//S?O,KP3;Z91^)\V>O?N)[:O#PV7L?U>\"
MH8KYJ$)O?YWAF">;UN&-%R=V3:(CV?64^A[V"*...\,I.,#PX'MOC57?'[!*
M%L1-A%._$H5^OAF>9\KXQ5+X.)3)\\OL>W *+IZ BP770CMFDZ.D5AV88!?
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M)FA.3-EKG]Y;:3:7THX:[XG>[#9-SQ6*+#O+\WMVNX=3AO;5GIBDY\61R/.
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M(S7#B\5CFTW.UNY044Z>;F_Y;"Q.>+,R4BMT71[ATP8Y-HPZ#;@YCFN&#8@
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M> 'ZL+_%,Y0J8CGDT;E]4*>&]-^'3OUW \W;U5ZOX*LONH\?J[:M3H/Z@U]
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M=\3M*+8[$CFI/O_M*5STG99_::^6N'-7<.DWOWR<>I9HV]7[#KJWK4\*SN+
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MF:'%W(F-Z![HCX^ /13,@3I&B]PBQ>**&?>I>BEE&HFJH:97BT[ 6ZUV(_3
M,TATC_KSY9#MML9]A:.+H4D#5T]$)*P7WK)*"Z)[4]TV',M0[ "L#!CJ)W(%
MF+F94X-B%#:V.VZ2<N(5 P]X;D9UV?$UU<6A'"8+-1)^Z3B7.G:C$>]6ZZ]T
M5CED#,!9#"4'ZFAI=!=  =P%2<LN%*.JE\X'AU_(0XNBC"?"CP./-'J(PG G
MP<DG[8]DWX\U_A@D)NA :P@>&;;2C19-A/*#<G_6X%P_^ ^L.,.7&M0#!6ZM
M8_O)=2S(_KY" 1HX)0 ="^%A:%0AN<B>@&57ZZ_,8G@(H61^XSZG25<_=*)I
MX^3<SY:+]^'"J*I"QZ[T&:=\^!M@5EKX=W2]9K5UW/L[J<+BWPOEOH[3[A?-
M;N%[#*[DJ%9;E)J\D^?>4!8MDU4H>UW0V##2UIA=K?8:%I8QYDB,;B6F!,).
M7-.3G/' .ZDW3+0;5JYF[WF5>CS=%7Y:1#9S,:/26\33U4NJ'5;HA',C3][N
MW)?,_?6 3,K5.'F#R[*NX'1:W3*ZL9.F7Q>I6-<N1R'&M"K%J$%%5H*$[U;$
MD;F.K3DI3FXHH"P>;/+7ZQ:65\*5IY9;&T\$>B&08/."!QK<NF&\IZ_M?-+<
MFY0(,J[USMS_RI_>PI8?,.2M,JA@>$[*QT?S\_<30C^9+$7?XYKI&VMC-)8A
MK!RR$'*, :'5)2X^O_ 7)\3H7'][3DKIE7I!V=R0E[B/@6O+_5(+S*+;'0$I
MET6E*70W>HH@,9%.[BGBTOO7$/,!P993@/YSFILVE'SB21%1S*9'/<6'-V7T
ME+IZ59WQ0669*2ZN%1$M9>V./8?<^E1XNFVF,;V4B$P<LYA\N02Z,!Q0>^NS
ML8C+D"2KQ;ZRW9= ZF^HD+$0YB-01!X21!D@71U,5 ]!9^ -E7&2#X-=H[KP
M=JH^OR&!3==.'JDK+EZ()7US-.U3Z:=(QD4]]>HZ^4+6#=XW7HT?I9D9?Y'9
M1'S;8FV <O]^JW2I'"KQ]1#4>+&LK 5NE2W3Q'\ =!*:4%?,;I0F%Y/7RUYM
MY^N_Y!QXIOW(97M9NY"-Y0?-TE*2]0+KK[4O:\E4"-?6^MZ?[;?I>W;_T$/7
M?PJ!Z]),C/WW/5!RV2)A^O.CX2=1QK&KR\N6@Q52>\U-Q0,/A^%=>/?:G]P_
MG+J#3K0TQK<WJR^\>]R2RKM_\GG:S[!^G26Q[X9;.\5<;$!_!>/J>"7@@T+3
M6&R <"^=(.= DL8H R8;;=.K)ZT^U@\GM?V1G&Z=R/JF(-WMGJEIO(A)I1ZE
MF]!^H4Z":9XH44+ )-MZ:^*?K573MX.7A?$5K!FK5<I51G\&G$[+[!^LA,L2
MW/%L74$A==UBEF0+&._4](\4^5NC.]4,:?_@9AZR7,FX6Z(]W&BB_97B^JBM
M18&D+^]9G9+PXRFXDPR)FE/XK\W3SWXK/E'8;BFQJ/5\<%.QP-.L*;D^Y0W^
M?::H-*I)U@L4,G=>B-6E;F>^:(!Q84AH(WF)L65:B!W/;66V16RA>W'/N&@L
M4)H/M:AG2(0!I@DDEU*W6],24%Q>I*29^!T$!_&Z;P4REM#=*RQ>[P&O_5*I
M?PAB9Y973269#FQP?6V&QR\U-K1$=3$E@$WZ'E6\;1Y]"A"97^I$)T_+X,J)
MAN2AQ%%@R)$:+<Z*W]XP4TPM(7.!]"OF//?HF35(C_+ZT4OM8K[!U94)YVXB
MS_8Y+FV?>A;R+"0U;&_\[+G/(-<DVO/+E:F&%4>^7SFQ)VIC+2#X/K42\VF^
MP82G-*'L_0^ ['!AO.=.UDED*Y_/RWR%D/OY4K/*JF!=N[.U)AP\L3T6YGFO
M#/9-[@2ES"H\S>S(S?"H?!/B-+@6JO8;VD6<!I-M$IH.0?S+$&[<8QR8H?T7
MOSRVE1@+M.=TN4YKUY.*V3$S$=/>4744O[^S<53!\CIF%'7SZ"I]O;G?.O-6
M6Z&"_>V6&&PJ-2U5!T()T]T!<\VI#B#\@YRK?CAV*J0VE*Y::YR=)GA,]Z7[
M58=5.ME#>:32'7HBQLN&&Y\/\*;.^7>*B]'$UH/VWA6T622.[6OKWOW^>]=T
M/,=\_Y' 4.6[DHI9NSD1.:4'B613R_,)/V&OC*3$'Z(CB:==\4KM_^9C_WK=
M*O2JI_9&-N:=QUXO(PC\F L17&WK><;184IVRFN:\#U8"M/DWC\U>FZH[=6!
M5:5FZWAFHE]D7--"=>45R\!S2VSMCRA"9>.B7B)?<94'GB$M#U4BLL6.LX-W
M\9?-=?=HUQ]33H;4Z?5K[?%M.NE6HX2IM:O7%':X!-T'$6@X:FR%H$I3>N77
MO"Y6JWAVZVYKPKKW\;-D::.YG .'JBF7WVZ)AZ"'8:%F1:3SP%6:H=7H \"%
M0N0&*B" 7;@T4$^I&9CCZJ]]<PCJ\B#]^?5W7XK7/F7W]>5.4A5#@BF!&<_L
MZO2*R=7X4?MUXT:J"/<7L\>\/J-%:JLN)4XIPI[*^9.ZGJHTO_8_]YP][Q[\
M))W0?.<A-0-S[6BT1DS:NV-"MB'Z5;*B1;2U?L\_I;: ')IN=L?#KLKC]@>]
M B_9>!VTAXIM;:;2#WM+<?D6_NEH3)M4U/U]SAYKWWELD<^9.#.9)7H&=5M#
M^R$2_0FK5H_1/KN\-YF@@U"/J_OBXEMIUU\S[3F\C.5J?]_:,J+&_JZ0:!'?
MMW?PEJ:3;OL]]?1%#8>OS2*#VK3HK(P&WVIAKSZ[J5YC)Q6S=X[03+V7GP]!
M.S1]%%/'>%^_H0],*NIJLM2K%-%@*'!Z?'M*KV<;^_64ZRAGOU7FY9<L+!6'
MH+>YQITS#LTU%*7IBDE;:D=%'E6%Y%13MHIO+2-(X]/ZUM98J043365^*\UQ
MT#P2(R=D>4(Q:5JD5M,@.^+V5I_DN8ZNZ%4-/M@1 3XMC*587#F'9?0;S:WQ
MC*3\\6 /R]' R@N6%?E+O','X<:X3CC3U'(U]W;4<-IW[!/(6::,[5] _PYI
MV:7-]RMC;$CM8RN-WL")?R4V;MV<VUQ4Y4[@+"2L7EWZ:)#:I[.JOK*HV]O:
MSYO:@KT(]%)@IP!$K]U.7\[\(HS3H[6IAU:>TYO7,9FM+4VH8Y4_GC,O/[-6
MX_&PF4-UVK6)$ME'$%SH4)XQPH-Y%X1]2[0S,Y-=UG-TW"ZF7LRMO("UW6KI
ME2G<")QR5)BVGNL0(([OY9W;UGJ-/0\X[YL -?VM]R,=);O4"^5'VL7FB6>1
M^#[B38#D57+?C$SDO$Y6C>J>[L-1QXR]PMEK?Z:?NC/3_V;:I-H%[>R%QLZ%
MXK@9[C1(3#ND#IEG5T_]X"$N/(+#[,35CX9?6LVIKN 0"CPOG?JJ$N G'X(L
MV]6?7^74ZSM19QW6_*%7]%?5=Z1.5Q:L9OP3^7R\7[1N<O&$C7;JQ1?W1(*R
MS-W]I X6[G*BKN7;F1FKTN'WF$%ZKS^O%+JSBO[6E!(/<:G[LUN7SP0C:RB;
MB8VA!>B[U,JN, WS"36M.L89+QTS2E30&^31O=&N_6YM+*YRM9![K$X5S$VX
MZ:]!Q\0M1%J/_DS5="(M7)'PLD,YQG7OY<1O(Q+>VP%PB^'I[XOX+8,FFGG+
M:\]I77IN3A]39*18]@6=IWPA:]NUP!GN^O#S._[ZW4S?%PYN0B8\2:-W\D5+
M-;_HE@OU663@ORLX3B7O:L,#P)NRS-@F0^CXAIKI506#KD>M[\=KO3;?*IU_
M,.QH.]>5PX\YHW<<J(PT6DB)9RU]=TWKZ)9H<M"I5X<@;$0%VV+<_Y'BXS0@
M7FE_#-,V$(<@)]A9R ZD;E3W?[B=''!D_A#4I+'!,[\Y93^?EH15 XAF-/Z.
M"N I[/1RB&R,CIB'!YK")8I<ZR^4'6&<H/X%3#P-N(\-[_-ZPE5HN/AM\&D/
MSBJ"[4KV;DBBH^=?+GG9X791'.ZDWCEXR- &A1K7310/O\2< ?,QA9"2]#A:
M4%=1#%.#]KUF7VD%?'P[;2;3&)![!PSUP(XSKA<S1 $TJ2@QI#EM'A97>)X6
M%-.8)C0'Q&Z1EA+T))?M"N/\G<-59W2M*?1N.O8O^SJ@"=##:)O1$$\P[_+?
MOZ7TIOLU)!Z%('.)VZ(4XSKM"*_(NF!KJD;2-B(^:#HU4R"*X4@J$KT/A-I1
MO9MS1ASLD(5#IN[\;A($V-#FU"X)S. 1!Z> CZAQQ:*;H9',JPPCP(1X9@<1
M@SZ]PS4]2<+UB@R=17D#I1J)@9 D<&-A!ZF X]X_Q20R=(.;8B;04R@YJ@85
M@*MXY@;%,93]@[U(8$[ UZQW !0^8)BFH#S&(LX\:-U9EH-)&[%(I1YHKH=W
ML+&M& L=XTU^$)$LFAR&+NK0>P;AQ<V7%-6C-W+V#5'^@!<%'8/5!*R4NNO8
M[@,-UZA%<4UY16"D?2_NI#?*GZI"$8C4":4=U[UI2!.BXI)VT@0\G62HE=';
M VUU7"F6G<+7/;9?_HS<[<'P[&FLQ^VKH8*IE1&'( _[-*YE?MC[E*'>.D&4
M3!O@-F_& 07<:+<95V%QX!,,MGFP&+("QK&\*U!T2H>8,+T4VV1,MC=-4)/O
M4+O4;O&NO"X^\$2MPB'(5ECMH>EI9'? .?]/NKZ3DB5#)K4!FUYP'SI^P_?*
M3<E.[PPI3M^+!H.\1SU\>8^[<9S)N*W/[?/[3,3[(W]&_IVN#3-L26U#,Z4W
M:9.ICX%7Y(VK] 7:$[NE-$4=Y=?(*S!NAR_[>N&#NV>^$P2I%/64\MJ4?/R>
M ]H%LE(_I5CB5Q,<Z%.ZG8K31,\7[ TEH&Y6,^>F)Y-1 K[4S9[=0Q &F@RV
MH5H1XU6A? [N=[O_R0?QX[_(X$C].0;CD,9+Q<T3SVT'SC>D'ESRCF]KSN<:
M6?WOO3INJ.SM[(*7)I-3=ZB&&US4('I)ZT$)DS]\&-9@P[@@9K??A6/'2C$D
M:9 X/:W50Q!W([O>%PJ,'^#HM=;>C=T!@]QS_Q0N3C%$](K0+C6VW2(WP\1Z
MRS^E"W)A+RQK,HZ!4'7[YU"NM+I^8L0>(BU<$H!W$7AI&Y4IV$LH'5IX^GP*
MW&:2(:Z&BX'QM-M3"6MWJ=^KR6+R^OC%T< H4MJ&O?N.F3K^]P1"&&_UO'L1
M6]<'94=^A9YA* )1U+I. CL^7 (9VJ_-%KUS".)%YA*X:]W!((95W8H&3N@2
M2@TMA=^J**FR!4)OM377QQK'+)96V'YLRK[_D(5\E<B""CE(#)=@#H4(1&$A
M'DQE0( V0Q^C(6)V$-%8*4"--. 5=&M,3W/E$"2JIPZ'NM)N&M%$A6LG)N,8
M]I7<Y7-S[J?<1F;V]9A:MOP[:%MA<*:D+RI6*FR#E* P"?IY6KE34TTUK_OA
M^<1*01/?&).[T9D+-3<:+]YH%J^4JOY^S]-_RR2SJD3N[NLEH3>H#^(U.:;J
M18["$U??$7)6 E!K<#*,@SD*.]8(2T!SM =2!KA.K]D];GN'A-I2O19+2+HP
MJ\(N71=]?KN4E(,D)VU[3[Q_5V[@W%MO1.W#YY&7:U=A)Y1T;E:A+@%>8>3.
M<!W+X'DPNP.0N6\W]78'MO&' :G\4O-WU=CI^#0U_1GG_-(6]35IH.C;=>$C
MB50%GKZ0HDY<TG1_-T)T[>XJ5AAHHL!-#T%3D]WAK,!-<D0I0YO:5!3-@+B0
M$:>0:[WB0M1M+/<HYU*:PM\)X5EIQ794_?BB5M%._[[>[(')H.:DHF NY*$D
MY@GJ;L_,S!HZ5OP<#9K,,,%>.2@*EW.8[2]9"YD[!"7*#K?+4K1V0CDY^G][
M6.=8>FA?"N<V,T%(<&BZU#_O>X\Q>\)Y_U[UCB<R\8>3"3)9UVW0UI3#:C3Z
MWIKF\%+UC0YHU63UND??_:^!]R16/M[S*VMMS&V%Z[N).>4\;;?1-FZ[7ADF
MK+=RY4@JEWQ;LBB79=30S>&_)-VJU;GIM)%#O>9W<]_Q6,%9\^/^:XF,QH/2
MG;1I#GHL%=&5!@X?W.O/HN*7*$J=^R]UU,B(*"*/CA)-UA"/TJ4 QTO_@@">
MWAIX. \NAU21MM!;A<RYU4)=:,QM3C@VR[^76]8Y-(TH#A^^BY*A&235H*X#
M8?ZTT#LC=;4,77(=%U+IWC!#J=S3S[;QCJEB2A60XX#-RJ;XV\^I%_./?S"6
M;OK:]47Q3KD2 LKAY-LUGBTA&/*AI_JZL\.;KORE1 MZ9K2[@5^-?9:)28'<
MQVK5S&X!IWN77^:;:?/Y^I7$UL7'"G!]7B.7&Z38#7</+V5I>S?+W"N]$:=#
M$K!NTO.XKB%-(C9MQK^[M$A-?56AE7>_<5@GK':EN:TH="T7F^E!G>S:E[3\
M./L.0XGP]30PSAC/NFB^L,_3F7L,%Z.C1")R3MO'>^GH%KOOB17+*BQXV(5U
M9(2<,>E,_R2DM:0&B.TKH%@.WNOH[E\#S,<H-8[NK:>;R%D=X_:]T]/([KLT
M>Y3>Q\R^NP3 STA-JVRLL24PH#[;T6H:/QWZ:CW;3-LL0O*@DK88MW^3B&V0
M[0;'XSA0V@U-><CPF3X(Y\[FF;QCL(:#ID#3#I6^/4E8XU>,S'%,Y'#/HQ@'
M;-?@GD!\.R2"=,G<JKL%<?9GNTU,>52J\R6*5/Z;!_(3O5\J3:YDYFSZ;.#+
M*$/RT@)R!I99%R$Q2,E>+4P\;,U09 DEU*/#EESSJE^JO+L=:L+;<%OMU#%M
M_\ %ULQ[]<JI_&6R@F,Q5C(E0@;Y<.O=F/0@UFZ67^R26I*ZABX9V@&::@KA
MWLQ>YK&#VG8M:N0AZ#9M,PDE5 )52D#!(#';16<9>C3]H2355XM )ME^T/L0
MY-B"HWUDCH_HW*P<Y%N*VJC-[MUVO+C8)Y_0Q!I]\> $E4B/'/768T=2R#D]
M'6YF#=!HIW- -0F7,-V<\!K.W^I4 .G"\<#MK&N#7<O,IPO+_L8G5P]ZSMA-
M+_77I[;,^-H_L++C"HIP8*B%;>OC2K<:C^GP&A?YP;_[^O2JNHJJGZ291RB"
M;["Q0HO/Z;S4E5+!LEOI',Y9]N<\[AS1Y_U/&=MY"COCP;2#X:<M]S-P%ZM1
MJ0P8=W>H8N[TE57^?L<8ZTZ\;ZAB-H;#Y;R,VD?7N=323TP^4YHVT6"" 2;-
MN<P?[."Z-WD\"[E;]M5RTB8V-B7/K/Z><3(,#N1._<WS1M5/H:/WH%1"JAZF
M]8H4MUIQIYOU44C(?IA>I=A%P=KBZ#;]4Q:-'QJW5'W+'MN^LCKUX<7)1R]>
MOQ8"^_/IL\Z? @5?-*0154Z\"^=^^]"ARZ6)UJ!B_^*&^,/IR$O^0LG=#X7N
MW*IO_FV;KE7$A6P@XQ("H0(>(4Y-5+]?:YVYVT[B>&=,(VTEM]LBTZ1^XE@M
MM247+_WQMQK[(UC]8)CW<"N/SX><6$C)R^."DE&3:5LSNEALK%2DX"N"9JE!
M5M2W->&:;ZLE? L/VLH"K4X*)5PL/O7OHRY9H)!$2)XO];GAX@6,\@QRHH#\
M>Z2@PF:<SZ)G\<YK]?3;UP4_/G[DI-)-T ;RR&@> -?5ZH2A1J[=I[H.Y@LW
MY:N#SX2/N&-\M?LFBSPRI@ERPGN3%K'L&]Y*=T/AR#I^*]MHC^T"Z]3O>+G%
MUE0":\O'^]FAT8FJA8'/-&/<7MTSOM(CA;Y@\EV"P'2:Z\LT_I6YLW\(NJ:3
MJXG5CLO_ NE2B[XB\M04)MR86NZOD9^"JA&R128;_&:#%C0K7]1,$2!S]82%
M]C$5 ;1K'4.TJ*>0JW%4:4=740%"%NQHK)\8[+D\2^#(;JZ_ETT?)8NX?L#A
MKN@+SYK]9$L168D\PBH>6V+O?C;HX_WSQC_U4XVS+_1\>'WV<]T%"\E+3[Y9
MV"96/SYWU/W#.EMZ&40LN>$/!GSBV'ONI*?V,)$_W]I 1=\-</>BGD2=B2>8
MK<0^3/9UD$FB<9'Y.RAU?(RK[VFRG? Z'D![S*P#KXI4"#^G7NK"7R*L;18J
M.MKMRLLZ:YL4K+#YB^ O56%4VUZ/6QD](JC+5:=["!H:J[5*[/M^XG$AAZG[
MXY;,P9;<"R[&WH_8ZQ,4I>[9Y%X7ECB>GA]S2ZCK DNRTTK8P"2F;L='I]R+
M>57H\5DH->DS!]?S 0^*I8KZ7UQ>XWG$ZM[&;Q.CA0@OTLEDJK!;#R)>>Z@'
MP<>X_('&U?FEW9[$"=;'-X6)_<N6%"$:/DQTNO]23([E5+5O'7SH93=VMSW;
M4J?KOD+R*:X@FN4M8+(*6N+$$*6E1;5K*<2/9SJ.ZB!(?W8&11P%(KL4],BF
M*=KV89Y]9L*:.W+DR*[?TPH&Y%#W.BE^FA[*T(&*V?CB*QM=IZ-+49JJ,YBH
M7<(/I97G?&(JMK^G*>8&NC^BSA7FZ.06XU7;9APE?G16F^KD//6;]10X:]\O
M8FOWIR9+,>D7 T3?CJ+4YSH,4>/MV5\K0Z9TGCR^DJE4^,%@=TW4]V*PC*RQ
M8T&NX_(S.>^3_?]TF)020C:[DM#<**&\/JPH=3&'7&MXPPQ"!M-CL.EO9LT0
MG-NQ!FFWX4&9G^^;-5<&^HT:7QR$'^T26P;@1@<-7B@;9TBRCBV5S8;J.!1_
MR=YJ#*5%0@BN:!->D3YN_(#UEL,\A3LV.C8V>K\<>]0>R\-N-*U38RQ\8"R6
MU6BI-CKS">-WP=@[FSWF6U69E[',O;-&54=)MO%_#(Y?.U^6W0SS&QM[+P[]
MR7AJFR^2%IWTI+XDH1>3\@T;?.5$%F4?F?+P/@.G@'_\V$5"U9W/U.=I$3=3
MPHEA,A'./PVDS?<PY4?:KSK7$5?.=%)V)Y[,=Z3GRK0W;_%_%=&JE6XJQ >.
M+^3:9-PO'%46-I8=ZSG*KA/U/&1W=Q5RNN!-U?L& 8C7OL)'++>(;\BY>,>#
M_-:6J T1U*9T =\W_:\"5GYM+YPU*T?@?PB[.RQ?=8I2F:''6P!CNO.9\S%U
M*=^([ES9QR$;X$NW)#IMSB*V3L\] _4/<?6"1=%=8Q"VR=ZB8T.I<3'VO1ND
M>CB->R=ZI'=ZYJ"E"T-_9/WD79N4=G%[MN/G9CV[/Y6KL"VFKU5,P?N7#@>%
M+'[UC:8^#Y-GV>V%XLWO?95\>,3U%._S$VR\?H8?6+Y$@\6P8SW_4LF?\3__
MX%QIF.GP45=6V6P$H\%[V#47JF,D<Q)K 7L9/#C4DR:"ZXD%K@:1(7_#)36;
M"#AYH9!^<*7XA"J"1V8C;4#U3+VPU\2SYLB-.K>D>P+\F2)(\>&\Z!=AT$^@
MTU$@%\:VV,&;^@]-*B)%#=WTC$A)WP4#-^6CWR14^*[\"2V(OT:Z+NLNI.5A
M_T#/ 0BCHLG@;DZ;7@T"9]XGJCWPU4Q\\UXCOMV"%MJ#%T8QQ4:]&CDEAKJF
M_[)SPZH?2#<3,\59D0&S4S\Z@\.8.?X(G5&ANQ-#?T<G/HVZ,Z;'[8#,FY\&
MB%;4B<E$!56>2H:!=G)KX-OU)+\8TY4;X_V(\%%3Q1J^KZ9/GB?)"K!35J4%
M!?4.099#;+I^!KH'JRV-S?"L]E!X4%N*G>:[9&Z1EQ3G+8GO-H/WO)/?=$)]
M\2_!!6B,6UP3^I^*FP[.4T3LZ=+MU@F$#IA<X$TW$^=H\U*6F=2Q\:H^*/RN
M<&-Q=>MKLWW$B0QR4+"CW6V)K.M[YRO0GS6@_0Q@&KT<OT9& W+>$%(TY#^T
MX&![ :/[N_^30O,P6S1SG,CA HQ09<ELW5\8'J'4WS/6H_/CB@QGYWG$4911
MV^@EQM5J6V3B2@G5I@=W"L!UYO[,N>-QUXY=#7%Z]<K-I8,:J%$@NY>W!-,=
M\@"=P#,;/HD[LCD4HZ=U'Q#H*90?5B5R 9O]V".'H,B'2--N 7H1?S@O<HW,
MUB6RX:04 >9Z  R2VHH2"OFH.?&NU,7,TE6\<+0P,[,::=.38QUD;1>3B;83
M_O"75X7R"J14#BFD_/0A%L>4O<\U#>:_.F&:%7H7GVJ-<BC]=/O![13Q>?2K
MM!\B/7IG: (;DM3C0U: [U\FWT<K2F8*K!7Q,=E7P(T:7=#$(MXG>G) 5 ]3
M;"1020RYN/D)=WKIH! E24USH#77>E#@.'['=Q$4.=5!B"D-DN;-%%\=71Y9
ML[[%LA>4=OX,3V;CHXAGQ@S:KZLAPPN1&:7I*=B?\P]H$?GS;AU2-]G;75+S
MD]TR.W?69@J[R[7&KSP/W?VEV_]GJ1P4[A(^3<14IJ ?'H+$D,);O9 3C8BS
MC%,TCXD ?9IZ'MDL'"*,26PDLJUAY?/G, P)*)72F:LC(.R=1BI0'.L+5Q]#
M&5(V$#UR'O->*G?'59?&E$**HB&8<TE=$/% I6FB"57C4RV<_G0R7,0.N65#
M'4IH^J?EEW,3Z)Y'< "[GX)RGU;[DCKD>SBJKR/(+]N5R2)"VRHGX;E/)O=0
M6RL:]'>%<S0ENLI! ?,RZCHL 7(6=9R@@%^H'UL/= 3?HVDDSGP*E_;B'[ <
M^^LA0 /IF]TW)W::>@<I5-?-*J[;CEY?XNC9>KY]:]W[]<>F^NR9-P#GOCKJ
M_$&N#J06""(IQ6UNAR)XX'?@!*F)0"(/4-3'E*.=KG0M\R"(CHK8TF#)36'^
M/<(QS5&D6K !E1BW+CLN/F0PO-VFH&$>R2[9"?H#99[X0N/Y= CB?P?Q1L03
M.=N-G<G_.F?5T!=H88L19%UE)<GZ\9*F@R*<&^>5[:[<F-HLLFYAI4MHY>PE
M_ B9/ J[](4K1YZ9:=-)K+=XSKCVUTVC_L0D<<U@>B*"(MF3PP>+&F1?')_7
MNR[D^%+DJ0MK*I2@^C]>O#M"F]R@4*,Z<0*0QXCX4:"ZW<SE#4.6NI2DIXK2
MH"E%,F!D* NRH1-WEG%B'L*/B6VW+ 9RNJ9C\][8.DWI5Z]:IW$7VE\=N+I?
M8S]@_U+:?<AB7P[E3(WKP47@6,,':)"N0AW:X%(G)-;N+Z^VO$V+C2&#N:'H
MT/F-HV8N]R<VMM?V\SJE^VH"-D*#5"^D!&F=[OQY,CRKM0G3@2D<_<7N[>7M
MG,V1!X_/" W-"Z:X5V(^1NJ[+T6Z%Y1F"_&59@F6ULB=8YJBO,>P1\._P)J)
MZWDT$Z[8:;8N*&@.Q77PEB%$AO$RE $-]$&>(JX:#FLHK"8YLO2D4/N[-!K*
M>S<JDLCR<\<5G&:OGQ_;@=9?SG*U!AVX(:^C7[R?#3X2STH];:/#:-]A*Q9[
M+QCQ^ F6Q4TDE8WU:.GKC;5^/48^BD*-HV,/"IE7@:^'(-(AJ.LO&F)SH+W+
M(451['&G/ O/TC#1:OXDOHGY86D:7Q8N&:55+&9X&X/_Y;7=EI?'U:30M-!S
M&;J@6F6_DM@Y'*>A<4FK)3_3PGB-C0,65KC7YNA5_&L#OH*AH+_]$: 8=FV*
M+-N(ZP!S5!6'\5]8;0>DF\'(-A<GPPC(HP@RCZ>H]SL.N])8'(!SJU"2&<?=
MC]2.[%HQ7/S&=GE;TMULN<6LD5_6T&K60D\$RT^4INO3P.E^R=,MUJRBI5%Q
M=]FOFL.+@(1Y,"?C+E4I14\4Z,*'$D\B_X[L[QQ&,LP\X*&!%7.SRWK28XJ-
M*=8<CC?ZC!!/%!]]:"MXT-&8*Y]GFSB$D#")B/N* SL#KE06$T"-!NMER@,S
MSJ2BF+VA9^$"/U:PO#0"%LN;.^"$;:3^RB-#DL3!J:M780(KK9I&%7@UKWL.
M<R^#-+(NI46M.OM,^+L]&RC5T4=UKP5>!H1Y+YMWH/2%7YI8=,Z7:*O)F53N
M6PF1J!^#S+>=)&K=['DN#G>_>V(M$7LZ5E8@OL:0*[:;M/I063!?W\H\5CQ5
MG,]SLL[NKF^*]KVJ+BNXU8N,9#D-F5(!Z66[1_5 *3V7=NS3BXZ<KJ&87+UD
M;JP/]AR04C.WNOM8.5FJ>8\K3G4AD[4^[DYTH:C;RKV$(Q DE4V*PB::&@*Z
MOGP93D7T0:@VN"DWNALUJ$<IB2D_\7I\YQ"4 &FLC$*IN)+"X-8-5.L:2*2.
MV1LD_!._WI6QNIVK\+6K&Y*DW:@G9;2BA,87W*MG?G0&>M=P]E0-[952$7]]
M+ ?GKK1N!4CO7T=) N6^=5/PZ=BD2J1*OS!_W=M5:W&!]BAS&M].<PSG$KUM
MQCT'HX[?*^L;?%B?O7A$)4)5G]F=I'.5QA9W&7E[1G.^\,+ [PL6P5ZB1.[T
M1=^!\H2O[S^*&CPN3X@]V22LNHP?I%A,U-G%R/59OH";W7F[S%"*91AWS]JD
MCP_]%EV2_WYY"N];X$)*&*A_H7QO.KA"EN5&4H'VJ'G3*46;F/*[&8W5+==_
MZULG%6&02YWB8D "2>D,(-O[-,@N+@YE43%4!E=_FEM16>KH<-]A@T?_>$VI
MXP_/YM.=UP7X!9HGY:,^6 V&/^8"I-VZ1J@-9&+T-'T=6.O3)O:T_;M$IR!^
M$<@\2)O?4.K5"+H"J'?;4R<9TH>@*<+%C]3>]N?7:YQ6LR=Y@!AR<!W!+2O^
MP";5X+%%G\HGT7D^J9_;E&3?Y8M^-X^RW:;HE8D_.ZNKJ;4&*S)X^Z@Q*&@%
M3V]P,E\^8 ?&YB?CPD'AWT*P;=0<PXE2ZN-:@1@=+G)*^%H?C%LM-$4$]G$<
MTMR8'D::@8D E19ANGC*S7;F2)Q)+!ZO^4X5R#<:Z:L/TZI&7:.J9[J6KX84
MI;2?K_!H'>?T+UT53DM0A<N+.1V[E;XT^NL70B+J3HQDAH:'UZ-L-4.#2RSO
M @)A)P 7A]RK!?#NUM-UOKP&[$L3 6%7+5Z=(WP_;URG4)$N<?H;6?I!7H+F
M%YE7@?.'H)/$F:DI(A+>O8L/>?)80?W[EOZ8=VW \BLK87F.X-I"><TI;JO2
M9J/TR&>&1QO-#T%II&(^'0AEZ!CR]2\XUVGD0%>X!#:2N.%ONRPN,:J65.5U
M*XG#8<"KDN!@)O8Q:U3R:G':M\#D]P^+=SY%C:6O:O%MX?J&.+I)F['BLN/A
MXDC+=;WSL0B.[]!G* BON'3;Z%N&<PG1$X^W<,^FKFI\6LG>]3-S.9&YP2U9
MG##@I3O L*5V8'/FYYR82F?<\>%7:6IU40S(Z0926-!MG/#!/J'7V:/FA^.4
M86!);YAT<M?W3<M$PK07?09V('%N7KQ$7\WXG!N(DEZ8?PC*WQ.7&___0IQQ
M?MCZJ?E3Z5\D*_^L73NWO<VV-50Y^HS_/U/A\[\QKEC<?#GNM_,AJ''I(!..
M.]#V"*1C<PY!Y^:N,MN](-N%VD I\Z3](4@&O&^.GE+_Z\)C%3DP^ KZ-^<8
M;JUO[!!D3"EF5\OC\+(Q&U=M6WO47C^^KA2P/V L1DE=Q=.G3>%)'E+)"9*F
M\>5(IUM_2FUFBR[7+8K0KU%MNKBB81B;;N@4A1Y/V]TPINZ34U^1LVE+ZU/[
M<LC%W7E8SV8,#QS&H<<'8RA3#1/2^M*>A? 2M"8;A^)@Q^N\__+WHRM$L76F
M<+L_3&0.QN2!\'3SC4-:T)BT#;&WS*_H!H%4IC(2UMT*2VQW/5Y-_1OH-I]M
MIW$[$5;"SQR"HG<IX![8288,U:F24@N#6G>,ZIPH 3+[[+R;*&(&PX9!"-(^
MQR'H@QGG@+Y$N ^*'7"D23)/9-)VZ0% ,%GCX"7V/,!#)])VXYD"0,X]0&O_
MZ@KN"%,!*4\YG4[=["WB4\6=F86/( ?ZQ?])*1/VNCL)$L.HFS6HZQ/>[:XD
M+3?J8H-B2V#E(-I%D.T7P\&@ &DQ_I,IVU*9&5'$Q"R&Z7IJ_KDE&9%:X*.<
M''9]<[))JG)!LG!*\[.DI&1JX8'RJO;P42&#^=(C\8H\*=_C[QE9^'$\<;O3
M>QW4&MOI_/*7<RR=0![UZ>.(+\>\O)3&\W+!(-'5^&% MOITK\[G M>$[Q;I
MX]R Q2'HV#% A,9&T=@0;+7I_+LE42BR<>'GNN=-=5UN'C2V*_E@KNJXNO[+
M 82S 9+S:3P:/6;JN_,YW7D#!P9D=)JX?!-US!Z9.&;?.'9N9*? P#XEZ 8=
M\J-T?J@??9RA<U#.U86(J]T77\9JTNJZ9OX+:>\9U<07_7O'B@H8Z44(* C2
M59JT1$6I0@0%!(2HB! 00B=(2%"D-P4!!2'2I48@@%(2(!05 >G225"1GBB$
M$4)R\WON_SYK/:_NB^?%9,V:F<R:<_;>W_/99^:<0WZ"XV-K_]8A:0VS3@93
M4='0@W1R-USH#LN F_D8NQ7?QEQBD))I)Z=$AUGN'L$T*_,SP)-RQ[T*Q!O7
MR' P2ZBGW54:""YGST)YZ;FM>Z6Q0; I0K?-4N9D23,!G<T^0]K#<T >TK:_
M[WB3%$?J(T(XH."MK=XNYIK)C\FVP0EGK9!,NK',[S6L#S<'-*@R#"R>P\[H
M( 1;+E/G1-'K,E/XKL\TV G DA*:!Z;/%OO-U6VLTIBH8@!E,VYH&5YRIB%S
M3#3T?D3@#>_FE? *8/9LM>"DS& /_N [6S.#@"/]@4N?VZ4'I.ORE.]4;C4Y
M!;5.;:YYA-9>WL-&)RB#M6N/VH+Z3<33] ]3S23D-Q6-=FS_46KQG>>X!L -
M5&D-3R&R!JJ:XYN#4(.(/PH%;_^2OZ,ZH;BKL/[4B[C@6-8A,CQK)^2WTL8>
MKEU,]R69+@J_9KP(7F_<^\,!L:P@?C_6?(UR\*6]5\91*XSCJ/7>=?(/*QOA
M8UU1Y^92,Z[\>)$7GA:FUS/^5OS@6P[H*.L53KM$ KT;G6*R[V#PVK?G5_(^
M2!LMNY\1)D3XU!,(/KYLLU!G+WRV]\9OTB/6!D!U8Y"IBVME\XC) VT($,:#
M,=5&IO?F703TRHWGX:(LW6];>#! M@-JYA&2WWLC2EE7&*AG!1^&-8)\#F\=
M8N;XAPRZM$NW=AZ33[B\Q@&!<,@*0A+[/%!*7^@D\T!/8P2!*'K:5)M35ISA
M><;A[;:=C^1O;+E)[RSHR5%B!*(-HLQP33=\-"LU6D6H4O>M(CQ:?&I$)P;*
MQRY?V_?\#5_#Y<64EN/Z(6W2:,-?I'V,K/;4R9X.!+&TBY",JV.2=_5F?LN(
M8P3HZ92F_FA&)H7FM.*D4$&OP2 ?-4K:S3WU[8J>S:ET1M<JN:A3$];'EC^_
M<#+[85NE-3KVU>.W* ^4)3/.L@IPU:4_C&+P=.2=HCO$KW874^>$?V_OB#;>
MO]W%K-*U;?0.?S7D^2GMZ)5/$-ZXA,\'R]-,OGPY N1T.I%9PA3*K,SXUK_4
M524M)TAB^8K@I??8;\?^EF3=\\=\X]&%G7IY^6?LY*ZNV)'=$-UA<AVALW<N
M&;:/?1QS9V0SQXK'!LBB][9C]4>(5M!?WGT&YF0&](E[^>SMVR[3\KIB.IGC
M8A>NH8PZ;?I4CZ4JJT:_1%H47S=RNIT@HFQ#N%*EO^EM\Z9LM-@IV<RNV/[-
M_,+96Z6V;Y2O^'O9O)$[4VXB_D:;[^%)@:@NF]+X#MIO>\I]OZU\R9?>5(9P
M.??_]7JEQUY6V%389S@%6&N6VOJE^:?#](/G #G8ZN=J##=PZ0T+7631M0V6
M.P'0[<Q6[/RDG7K,:H$0,]E((0@YHYO;0Z'\$:8=C[-B_4M7,D/^+E=4_Y8D
ML^1#WA>GU#$K##OFDCB@.A3K1 ]SX;\>AD,B#'AW52@S VBE;U!O-96NB845
ML\+H/,E0'G 2Y#21$9IDJ%@.V/,'4@18FA_HS%P?ANT O'D$>LH9"1&K9?<U
M#ZNN$>.U1%ZW#*R:+SR4$I$VD_[(@@W\C'MV7._?Y<4#4FY2&E(I 8%XN-=>
M12PV+>\\O=^EV_':<07V1)M_OVGBISJTOXE+%D.H@\K@@&QOMUA;_S4D"]>N
M^MQV_WYVY.4]!QZ8V['TWD67"'<, 8S&M;<HOOPY(<-+9Q^(#4BJ$' 0>=H;
M\#B@C:HT1G"J/DW\:9WKJ)]6X=1JD:&H]Z7HS<N(@F?WCK H=%P73HRE$3BO
M$843Q2@NP*70C59T_OJ-9)QGE88U?32KP\>CD]XC=^?VU<3*"2#;R'9>RT_5
M'[ X*711OD_\3(4W!4>$YAA,&G/S=U<HH!1* R?H_!?QO!Z,T[U7'=FRZ)AM
M2](H<9?,S\V:5*K1F?)#A"JMJFM5Z\%E6F6L7G-;,SDU" >4C\GL/VYT>5%O
M80."[@X7A.LM:O_"BV(.Z2:S1*H=D4??7EY(-K@^MJ41G7=FG!AN=5]C'\8"
M!UZ>1#QC^;N)S%11ZT>T>&<L^\1"_'+R/;?M5W[)#YEP0$G=#6)"\0&=U%,Q
MM\M*[1LD6YVT?MN5V5=4Q''%?58R0^RF@(6=W^92N!14,OKV?%G9AVL1$=GF
MBK7V5JY+SB9LE0G/+9_U-7*I_+/GY\#2,>>P1=N?/K/"&4:8/JI,'$2?SH57
M7,R<2) 9KG83'H4#;T68,I\VC6WV:71 +@+Y1EWCL2PWJH'/A75^(V*K)[Q$
M(V$MXV%PRW"PWXM)I]8*GNTR0_-"TW+C?/,*I,U*Z(V3S2ZRRR&6Y=-39Q]Z
MQVG]>N5J!3KV]6'*X42O&K5([[P@[QLO[]D.V[E)$KUL6[V"S]X*CLAUY485
M\G,Y9E3)+FB9^G*ITDY?\,VM;&3)1H&/04GE**&5T%3G "]>[:-=./)90OH#
M[(9W#_8\VL&58=1(*7SKU!7&;9S5@0-=3<2;KL8/W;X1#?X5C?K>1<9,Q:_-
MO[R>Z74URT#B].DKFC,]- Z(W^IX6;!8G):23Y">JYK7+S5OZS3^TYX4T5B[
MU^K9:GKC?,=<#<]P)<U\08.OQZ?$U9+&OU_%*, NUJ0IW6E8<.IVIK6@FCIU
M_9E^>MV)?-79A_*1(+>$:*4BPK&4[>'O#JW#X_![$:TKSCEIHU(1^(W#]:W9
MPQ%N'-!GK '":O.BS G6)2"WV/MQ#+X  QYCV11-F26Z$R:!N7:G1Y)O? X&
MF&LY88O?&>,>U7S]X_RR*5DZ^_0RR5FI2F@!$2?7WEN=^LRI#OUV^?Y70!C=
MV(%'N1A^N;E[9R5F>Y>/\A-\T2FB<.T!IEEW/P]*)H[H,?+SV_"MH3FG^@;G
MYESI8!6%T;M$GR(7J])_OYCBQW^Z9YN)*AQ_IO=)^[*A#]5<J[DU "8(^&]Z
M*_75SQ(@'XM(64@_@A3V6G^1>E]&:T=+36FZUF>%?S8A/R/E\IA),_6XC]6;
MNR=M<)!O_K;,9)C[VJ-_+CE3.ZQP[Y]C/6#JG S+:C2X0AKF IRJ0CM;? P3
M_>O:Q&A\6F\9H2>H&)3F+*UY(WMGWORLF9U:82B_[,-]M[++REDF0)5[V;)H
M-JI-+=1IN KEJ[9:GXB#H 7[I6W'E(Y1</S%OXJE9XBA%H9=3Y<$T4^FE&,.
MM^H@1- A1XD5R/HJT9/)P:&_WUM6(!F]E;*W/V591*\?;$KPR3PM^5GAH/[=
MW-[7:BS3 E<OL2:KO++BF>7'?L9ER,RFC#<[F3DMZMVM-3$.'^OX/_HSXPH^
MN_]8WY\24K4.C\ %.ZH@*WQ3E1-0F;8!-K9W4KQ0+]2SAJ;6R0.?R58A(S1"
MBS=C_US'I$Z=!SW5;J3%&!<HKU\:5<! 1:L1@LX*K>WS+1U=U[AI2C;G\[NO
M(O$C SJ4$[O^8PH<;1C($',>NS_,,J<'.M#M7S*W!7L)LP"E0[*O1:B[_&Z#
M-[\DF[8WN11_->.T9X'<A>=%'B-I]W*; Y.2DAAI%Y?2COS(TW^0\I+D]0.4
M:PZ:#^#!1M+-%E:V"B=-*Y:'2*FFU3E+?UK'_3B@)\#:-O[-7(/BFO;N%6Z[
MY%BU0A( 3M%@QWH/UU!S/+'R?31\C-.OQ,*NX 4RV),VMGN%-.+>G D7_3[[
MN0C9WQ#0D!M<9NP?,/9K(A=;,LQ69-FWTG$Q+9?FZL;C5[EL/U!QK0HX_;>;
M?3#5CEZD(X8ZC/>/*%.O4$A]5UV_/[$W:&B]U-OSNVF([9TGJTT9*3F5CO4I
M5:7?ET,"6C34,@N1A[:*4E$7IB_]<;[3HVK]#2X<*J I)UZ<HG>CHKQV)L4F
MX\I1WX#':=-2B\\UOZ\O0MINVLFN(=5<,BM8PRS07]@18)AV^&,XCB<>*[!,
M.E;?,.S>4D<B<2VA_6I+!?B1+#=T/^I:ZX?L2<<"C]>^U79J)TSL\.'OJJU(
MBBRW[XZXAQR00)W/_7+H:9;!R;C^;T='_73]GS[V^"7E0+X7@):ZZ^>?5Y0"
MEOM.#^-)&LSH]C,(.4 8W_$@%T/1'-"%R=VJAG6>3*"B&W]"RZT(?)PE/]IR
M7X/XHWFD#Y]HJ%B8>_Q?0@72X<#MULC9KZ\#F<VGSA3^0SL8Q#A0L%H,=A62
M *_&R(VVJ 26?(^H,*EM8GA$:SLPSOSZ/+>K,^FCO(,.FN#MX<-YC3BI/)H^
M/-.@*S<2=R?EL%]86YO$NN9TWNSFAX.+!Q3EY"1Z2DR-ZK9V;/H@*^2M[2<_
M\'QL12]7_5%#)'4/US;9&,FZ-A]>=9C?\OK(E@_8R3(.<ZTH&0%O(I*^55?[
MO+X*?:#9=2K%[&=JY._VU&J'F)72+I( (Y-<!?!0I5PU\-VBD]H]\<'_L+)+
M)*D+LYXA?Y'ZP:^&@BTM&VP\2A_!O.L%N@(>G*)8Y*0P7]#(\5E-&G&HX-3H
M%YY.8SE2*.K:(4QX@9=;YQ#Q^@#O<@/SO+/G4[W]IJ0_2IUY=X/WV47;M6U9
MJ'2LL<(8#8YKM@OS:JU5+8TZ@RYW4A,ADOC5D*'K+V9<PI2**NY$I,G)TPZY
MA['(2L?JGNH86G&%/T'?OM[?G9KZ[ 6Z^6K*R= HUW2::#25^2%W6/=$K@*[
M@[:\#Z5PLR_,[!7F=[[G@?&S*ZYP)/<Y0R%BH_66<]$W)H""(<;IH199PX@"
M%X4:3^P :8MU323A]E(!3&>^JJJ+6&NF%G-$LWIZ1J-[3KQZRTI_W $X<SBQ
M>-KUVO'"2HW.C>/+'I9U]V=]Z,-OAVAY0 ?H])B$H&/HW7/M;\%>!2V!K@Q\
M5ROL-KGF&Y2/0K."3%ZUY/<GR0,X$Q\+T1A=S5SU%:OL7[V/JN05](H>0A&O
MBBHB-1H32&=2CY:\)_/>1XGFPE=KT8ILH3X!6Z.+S1K,,H;B=ZNHM(1:WGV/
MU"_L6B87/0??*F@)O\1([4HV=:S][U. 3YCSA=8/Q29W,*;?M$N&1T][),=D
M($O:@\,6+<J.?R^^DL/J_G1'\G%J"O3"E)=^-"F'KL_O8-78^B$6/GJ2EA6K
M:EWL+I74L/WKBX^ZXR/2\ G!O4Q'B%EHF._/)UK[UH@>.]CZGPZS:L!KGABB
M%1P.V!TOI#DO_4B]0\]G,.,?DF2>7&5;?5GY\]THK]+C?!O)BBA@^' ^T^WG
M.4_6>:X-=AIJI+,2V$+&\WL25=4/(H*QLIYYISVKY8XRPU&KS=+0V5^7@SK+
M7C^8..+2?YP:"78L:(&@9# H<U]1<&3(]KD>U:6#/;3QF-.[5VT^K?#-WD2J
MWM45*+=P"W"2_BF>5I27?H<![^SEUZ1L/Y;I^-1B7+:L4^*",T-)_\[6![Q^
MF_(FGAE1?_0PUGEOH5?B(S%%O"TQ[(Y9Q25(V8L=#WI!2T4'6P7(JIA!4&CX
MZ/=H_;$YJ\Q%> L<\COO-'MX9,C.C)B.<K^'.O,\6TZ>C'KYF<]91\O]E4#[
M"DX(YGE26GEYX_K>ZV'$R.DC=P?7V)K A2_>K4-%OH+KVU8)8Z(I.A?2Y=[)
M^O"W/+DD8[8?? 7\[5<F61OW0&92B/F6F_!\L7+KPAU\P @9$&-9UC8R?HYW
MSNW[C7RGD\I0Z9+4<A5/I3#U$9,^.>T-8P( LMZ\X'9]71'.J_./VO*G.>_?
M$.[3OW,$GJ).8%02*0[9$9'X2S4(B&?3 $N^\9?> -._B5CSU$A,4%X@HF%-
M(7%/+LSJ?<,E(TNY$6Q0_?P@5^T6XKV#L^8/M5C*==9^ !JI\7P"=;*95N2)
ML^[GY317K1],$4_<=C"FX419UD/U-AY41+0 NL=2]/F7R:]YT$'#B[UA<F;J
MJK@Z5*6Z[Y$&7@FQ*W!EG.8/&V+:OA5AAPPD217(\*?.X&Q&H:+7BH"$MFXM
M&3XPY'?34W2RA5(ZME'DJ>-ODG.=QLZ="_^:+_Z,ON^(7EDPW&[PF\,<BX*_
MSUX^0@C>Q[A)"?5Q\_JK?,>5UXQ(3%M9'13-61TT2[-J_'*ED@*"4*^%\<0;
MWF,X6(UIJ+;HTK%@8<_GJC)NXU,TG:A\[75 T+Q]:"-H)3$'<?K^-RSSX=^G
M1QV\WMO0-SHU)DV9-8,XY$8T]N PSJ/Y$]'(HP,OM&'ZY#1 H"^;D>1*$MBB
M?PP=Q.+6M1@:,0X=I]GV[$]-:'7MU#4I>133)A(\(JG2K0679+FTC&E-J7G/
M$R5%4P-#7BSK#[&LZ,S*29\*N<QFR4>200ZZ77=,92:H&2Z-Z_8=\]D]R5B-
MB>6=Y+Q$NCU_N'E]$YJXAR0IH,,M]'/+YWM"@CYO3E2K8OI-)Q9?%%F1-4\$
M@(SP1D:_"2H?&(C.=RRE>Q53+-6G*UV!<Y]1$?.#"S/'A8>#-K.#7,S0R:M6
MR7.O^?RLF!>KW%Y#!W]J_E(X Q7%7"4!T=ZT] KT0Q3/BNMQ1DSA?*OWU73'
MFG&:\RZ_IMGHV/+XS>'"F*-W/]2-55EWQR@59+BG7/MG]^K J.?_?$O^?S;
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M>KNAB@\-_GVA"RNZEX$U]-PA%=,+J>"U:_2_S%K&]FK7KJHWZ1PPJ"HC"54
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M:65HQP;X2T:P>VQ ^MN,##$E?=?/#5,_4__T$*Y59'7.9G^43U]/:V7J3W%
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M!-.JJE%DU4RKC-OOT=?GCHC/I*!W[K[36R#[Z2T>CM+GBW$]<$B.("_X<?.
MYT&\VTKJ\9$-G&=&"V"W]X(*C](5%?/VA.I8O0,6N\<:L=(HY>]S,M'?IM""
MZS)BJ@':\T242!^5)]>M$=EYV%%41@Z@$K#332:)#/N%^50*?**P<UO4/%_F
MV0M@A5;:6;5_VYF8N<236,(8D32E+*UA8,'WBG)R4L&$V'J?T+7)9WZ7'S^Z
M_V(Q$0-QCN^FO?]@YA;@)=0U7GQ%I.9C@\S1Z$+E#^^HPHS;V1]"X?Q'^K$3
M7PK\4X[#G'R,M[W<M444%FS>E:P=T3/_4^WQ);VE.MU<[6?)XD3>XQ=/WV[*
M2X7VW)D7>@/)12]&P?_>NG<E_?D1Q$L^J<?S^R_.2_W-9BEQ0$_M,2;<WUST
M%%."[DMF>+1Q0(?J!\2MW'DQ>@R>+GP"!R2F9ABZ8&4(;'>/S9YK CH4@-!*
M+ZST6!#:9[,7P>.T-/;XC5/>\\P-G%&D62/[(V*&%0R!THT:<KA1>H%U+L<D
M#1XOV9V_("/F#&R8,L0R3HF2CM*WR%&^AK#JWR4_U49F5TBGOVE<U=#"W_.X
M&H-P3D [BW5@KN']?LGI4EN&&HRS'^KY/**<Z?=T^S/]X,_DFWJ5NPSA=]JV
MXG'$]YL;>E^(7M0WHTZV;PJ2/<>*+2J18\^\N@5MRJQOO+DU.J[E6I%EV3AC
MI/YB->_^XC[P'7!S4GJ2AZ&NU&/F5EE#U(A'XT5#C]2?W6&L0-?S=&<:.($M
MAY8PM%F Q39E4=1\6#8+K7R PZT/V;\VD:[BC))FZ@RO"])7E?CO$#F!Z*/>
MV]D0I]9@BBSKDM*<[DST5R2$+4C-[XN:SNOT RV\\3N_X]!OMTBQKXJM4O8M
M@?AFF!XCEAMG*Q_WS76R4[8M$UXV4;[QIC"(-G<A+65&J&[<):^? PJ9P23*
M[OMV/^GX!XF5?UOL8)[L)Q_U#OHHC@^3 DS J/[T :D ,]D%N?2HN8L+XM!2
M?+M^67""*_,/PEUALZDAV777=_704^&M X2W*QS0^,:R_I#/';>W/- W.XLK
M QR04_[?&VOS\^&!/3Y%/Q88_<<UGRK'E%8B)TWP[[RRBV=(N<5+]J%.F<6X
ML-/.$]]O.SJWCO[\^6/]JM^4TY2IVM<_=0=3SDY,/"T3;BV>M/GYLOCLE7-6
M>M:!R"L"%E9?;KXL%#=1^N)K8Y/TIN#5)(*0A9\I>SS4W]\M4_=]<LIQZE_:
M5UGB4Q7TP;HO?P?.I@A?G=,:,M<B) ]9;,AE/I2?:-L4^03 NDE"C.UH+?!)
M0*Y3'Y:(D:;UG:9T0B08L%C"VI85V/7;ED%0\W"]C^(-8IIE^!IT9W0A;W*9
M!UT23^E>C;:Z16_LA.\'QF\PL%GS7&]&AW=.9D4:FFM$L5!N^<L-V1ESSUKL
M#B7G%>O&8BX?(J:9%Z\(W/82U4U;VC:7[G!VF?KR2=!.8:XQL=/DEI?);?.S
M;J>7;OUJ[Z.=>6;3I6Y)+6+<R)0P/?'.G":G?%1_,$/>Q=& $$X-';+,RF9L
MK.].(F:V&T;6CU6XR4I))3&U[GI<7&2E<K%NK+S[+J\_!61ZYT\8LQ\\<_!-
MU'"DL?ZA&T8#T!ZY:=^U'GA__JCEFC'!;L@>YUWJ4/O80/?N+GMCY8=CV^*3
M =BK=E9;X0'QMIY2U)<*K=]'9),>[(<;YZ$EY"$@Z<]2@5U*KTW"MCXI/C\B
M+HL5E^CY-AQ\/]VGR_$SXK5C0-'6-G'.)6*V,@3U8*X M:EZHO0IC^+%MA^,
M ;+7.Z9HP#0E3*V*F)598\Y?OT 1<G'N@<X130^U&ZN>[[?A^WPR.NO^!I_P
ML076-<;)-I+@.$:"2A!&-U)F(0QPIX_3]B4Z)+%B.3-3$I]4WV=@\7$<M9G*
M/S%PP:K"2\?)*&.V+!#IF68IDM&RK5YP,3>KP7$P7BI)NFA^'C*]RTA1)MB>
M+[4MUKN2Z]D?I&QQ(5F?7FI_2]GZV?0M%>ZQ+TF+%G:GC@UF*'W1%BK)3%G2
MFD2:J]$F?UE8%B)G%!^.YO7_^" Q\&^Q;&?W&T@:)-RR6"J^LK&4H-R63"?K
M? N3>SO0UP[]M]W>;?KX#S?)8"M Y4>ABFU!$0;F$&$@JPRX;5E:\EF[SILZ
MP+=LZCAZO!-<9K57QC27N2!T*+=QX^)W4A%%3IS'4(HI;CB>[4GFW90Y#B3V
MN,H/;K3 4:&,8P];&?R1#)WR'4FOVN\3R/05)VBJ:I]'@;?@Q-*8?^O64U.Y
MO=S;K*[7D48:H1<I$7[^_S9+'9YHK') 1:J7<=0'K.#I!#'%!9[$;).)R.)<
MPKFOWP\E\J59!V9'V9!&B>1)#6I_K$_UBN*U4=()]+]Z-<$%V^P%B]96^EQ<
MBV"3=8W:R^:L75_Q^N0K1[?L5(R^"L5Y3)=!0-!G!<\]DK8VV!'LE\3_=] G
M?9PEW,B^#F.^X8!J?4(YH%(K==+X$ ?TXV0I;CRYE)W>@Q#&M5OB?E"XN>E_
M0[!Q.T%#*VL1_Y\)[Q[_G[$O^X"/NSH818!*@_,"J33[Z'#:49;B?&HB&:Q*
M'!W=XN6'['8@I V-2M .-)VL"L<)2UY7[HU_9U\KKL\=@A\:>]6-K"Q)0.JF
M>#-Q>R_8PNP!;M3'QFZ:L[P9QS=HAUN+5V;U&+AN@J@+ZP8#G_"+SHPJ1L,[
M="2[ZZL[;'T4VTDBWS91QP%O>$+_V=75H,V/'[Q;75=NC&Q \V?ZP3P2/:X_
M<#%&_?JCWI_LEV>]C55K>./<8_L:7U+\97).=CYXZOXO/\^HBYH!]2R^&BQQ
MYP9/.^+]7D9>S@(,.'L<7SKAA!RSYX :40EN];7OZY]^&3J4SO3;RWZ@PE_?
MXG]9_,7,SXBXYA\O?MX?,M#$(G#M-TBZ&,A>'FS^/8)NBDJ4D<:> 72INA0X
M/UJ3.>,2W@,U&*LB@OF1 <MS_$$1&A8)?V^VN#\]&JQFNSP%KQ,4<?1=3)#^
MTO^6G?K?F/H6.?"3>HTI<L<Y=%0W1"GVVEX3ZYXD.JK'5:Z%$9JX)1=&/\ ,
M&'D0@>AT>EK\Z^TW\\?,S--V'-"EH?G:89I'S* TJ1G(WX5BC@+3DZIX"1(O
M1A5HU(C-9&@=Q<IC8/3&Y >#@JQ.5)8%2F#I<=3M,XS&1N\BHN?8/$4@"Y?Y
M[+$>% ;._*5.4L\\W2!9#99^6B6ENG2%K&# @^!7&LI ?TG5AGD6(TMRLS=[
M!*R++4)*YDLEALL@6%_[I=[72@&[8X_GLERJW&@B7 X9^>_MXCXU#@C,NY<1
MU\/#%B7'3DF3%\D8J;]I_K^1==SS2/)\6AU%7I"[>X7L[I%P>U+O!LN!OK.1
M<.W\IZ+$-Y&?OE[0^_Q)-M+[=RIP%_;=O0G;C:C]!DVF"U%#I0YP0%=ZC,+!
M+W]  I X:B3N'GE'$S:!X(#X%#LVV ]5RJ G:NLA"DWV0R0K5-:NP>Y7P:]B
M=T1:S^NR!GI@@A@G#BC*H\5Q]P)&;R\U>&#R %,3S\0"L&IS&BH:(E@/[%4O
M<:^A( 3AY5Z/NWKB,/P,#0M&<E87F-?;P6%RMM*WWNADMTYHJ'U3='^NX=!W
M,Y]8)'WEOZB+"B )+,O4/2RE]S+3]A(Q0J&[IY%X 2)A@DH$)VM^;Z?O@!,S
M#U@#KX,>#7?&#'1E]R3+\BM\K 8F90160D.'[RSC)GG?35L%<$ 5,O0VV/NY
M/0G\*H$K;]RR<T":PC@*B$W!;3[$U9+9XO#H.=97NT!ZEI,A?-'K'XQ[ 9@M
M;#!/6C7]A]\/\+"/G>> #BH!" 9N(;2'O \[P14&6"Q6'3OX!Q#$)>=I-@)]
M_'V+J>Z 1X$+$-A&>'=[SEM7WQK_WPP:R1&A;J#!1UKM^M9#B(CRNVD:S]#C
MS"1N*<.PI]&:M/$H0^==3VR_?@++"]A"[5H!<UUC<T1232'+7.;D9H6/IA6=
MD&*HR1 S84#P- [HZ!W@Y)7!S3D^M.)U.K/"K1 (I(CV&-?4N$"7=T[BQV6
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M-<./LD=EZCTH_(@>29&O^HB8EGT, \H.SY,J#9^6\Z'%SFC?N>LM=.OBP!+
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M%JWB>&&RX,GDGD^C4U&+J7!8&?Y6S&%EFQ:[2_3HLY%J!NDCAM/4'S?[?V"
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M"1-NO;=MRW[85MDMVV2W"-M@"!ALB]A_!,#^\[9EZ[;M8CO$=^Z2D!0%5,O
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M9VE4;WX^@.;+X^P;(4E0DHN)I\C-\FJ#, O)Y91/"*E&;38MVGB[+RGMH>#
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M"P3[BH%7F1RMAOI(O7[XE!// !!OQC%QO*+4#FSD"RXK@EI=5A3(12H2!*>
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M8_)G9[O_+E M.JUK;A1L^>+$TBC!GTSSV#A/:4;)NMV=8+78X2G;ABD*_--
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M2B$N8;8+87>\!<; 5*WZYYJ:?E+H<IMCK2(.3ZPJ961#:)X9)#5Y#?4;'H4
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MMFE%6IA>87&%$-EYI6 -I)/H;Y''\UG?FZ )ZI#+@.Q5:EY!Q8(O2W"D36F
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M\O3K#$-J=VS"GMH)<%R\W^*@+#WT+FL&L*+J=#I:X5Y]CFS2QL8AE8IG@0Q
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M^UP'7Z>\=0VMA%M":)]<-S 6%TX.%@X.6KM-U3D1$JK'S;)"5WM%13JU_!<
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M4-?DE%2S3/]^WOFPY?1FW]M^E[N'BH9^W;=71D 0CET=;._(S=IXRZHAX'1
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MRO"KJJ'!MZQP4]7'D^^9H4634U9>$D6'/B,=_7]4J]_/>R?^:C!_4D7>_S\
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M!F\E%E.1^U*K;6R(0J,PO31!>2V8K.>#%0L1A3[A D.&\C@+>G@>G='F=F"
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MC]S%W)]YXHK$"QW.MRVJ7<Y6%!?#C9MK'5P9[Q_'\E"(22RE\(&M_.8>!.[
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MZ,0$?:YA0G304D3VGA[FP?&1#.D0<"]K5(8E$+&\<E^;U".Q&K"O2.]"^]7
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M;RA.%/3*%O[R"RPG-!7+6_AJULALERO7C4-F)1>ZA'P^*%P[]#*)6Q&M!9F
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MWCP.S-3MA988?["^CHG1/6/77.49DC9(@3I15M\8KS3,G9A6-2@V(-03JV]
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M1Y&_W;E%JS/0GAD9?$+5$7J3DG-HE[#[/BX=J8BV<^'EC?A&3M^_,AJ97C*
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MI+OA3^7/\3!UAK309*O^_(+KD?Y^7>GMS?B] D28'U<# !_)[5ZD+1?%3 ]
M+Y8&^']I<]0_#_V%V@N8>!5H[U/@VV=.(714'0<LK))_WOX/'.V\UK6081A6
M-^;=\.IF?R9?D@]_\F?3/X^LX/\Y>H&_C+8P_GZ@M8Y-@S0=,4N_ W4?03BC
M#!SI&,C@))9O]7^21-$"Q'\RBV #3P!'</_&O\!,-6Q>7ZXJ/[+Q"0!&WJ1
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MP/MJ%"ZOU$TS>JT LLH89EXI6 IJJSP%%U6SEX5P+X(;#_([@Q_V%1X)9D8
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MY^^#RVX06%0[L ]\A:(W?".I@R\,2T 1]JIE?;X3&]O#(DF6%KVR(ZC6D.1
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MA\.")&VT8H/#]=G8$G$AG+6[:ND--%&B_BN06=.K$7V3RP&!LZ ^BT!9>WY
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M[[6Q.!N28[4@@@&/H"(@@(=A9].QFXFRO$-E#]6J@ 4R:/D2LF[-([H$!K(
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M?_N!>,PYHNYW^00+=I*9\F>3^(9+)5-)\7/8-W/\1_?$3AH$1AW8J'EP=;,
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M5;8TLS BJHT!@4<#>B^\ZCTT6CWH>3_ZT/6[?WB_B""^Z5Z\\7/@O='!^+X
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MY!O0KLC+]"W0N*2I=.2+4[8.5D_%XVTA:4S.Y_>96K-A 4 !8ZH=LA_K1"6
M]:F]NM<(3D.P,S@_EP!X3>W/S>RF<KF=:J*&(]6^8%/J(/VU>B40XW I]5#R
MSET\YNA!!BN)<P5>/K5-!=!/ F#8Z+Y=VJ]3@.D\@6T*H2=@>KCX;A(]8P !
MI-,;^B@]U)M:2\J=:U9OAQHURA;3#:-6R[5#;0739?78&L6>=A<"YC/:TX7H
MC"/OOX4%[CZ ;CK#S *\BN;O+#TUKXA%-2@&UY#&-.6,L;4C'RM?*CS<)IFT
M6DO=C>ERA:M5V ^QXT'D5>0WB'4H889K6+HM@[,S&IL0Y>T'OI>V0+3?E]2%
M="+7X:;;#R:CMT#MHP],6$Y8!('\^XYV.#(7QA#!N1,Y!<\ ]+*]TR5./L[E
MS+L[];^X7<.9!J^LM62C2I<4GJ]M)ZES6!C@1Y/C:9M43[4>@@KB3$*=*5^]
M1)!>-<+J215+ @%!N>@!O5;JBDM-KDM^W%'/']\4F9-W6:F_\,,$C^VI(W$>
M\><2(:CRC%0.. E'U<W%,: SUHCJM0B%*L;9G[':)&'@*!91[,W$N8YHUXE:
MI9KUFZW8V.JY^B0J6#H<%S$ /1)_?=%F.T$2 :<MT)Z-KI@;;QAEG1DH-'/"
MDP)8!H;N1ZS@EC4#,E]_5Y(\,./_HOW%ZJYEJY7&F9\'-ZN6MT"0[V=KN<)K
M![9 _3]UN:+!*EL@4<-MA9W<5MCJ/Q36.$[&52/;MG^#J?S9N@G/P0:4J($P
M,8M!Z]V* X,#ZV^)Y/B;W)4TM0W,YY?]/'M%8+SP6XC([70+>2Q_9-#!;E"#
MZ%9H',IT,&P:>)(]^C4+C!B3Z?XQVCU2MM'?7AIYZ-"7M^<@-3\2OI ^P$M9
MB"YV@LM_:]OO6];^C"/-8W]?9=8DN@6*KA 9Q*',([@'A]!0]'ZPE+=.K23.
M77FTM;Y')ZN0L'PP8,+614)M5SS.4/F.B=SL93?>&MANE@%@TEF+SMD"N0 9
M9/B16KHWT/G#:'2]VTKTLM4Q ;WF'_*O#3">%ZKN&2L-_"Z5Q@]P";R/L6V#
MP[CM=B5PP'Y_;Y?V=F@&NBK8*O?F1KG"?S^F4_3"+AP_4#-D(WTKF29!ZF<?
M+0%RTI<,0[4NC[H-'- O>8DO>=:M*.A[^_@<SQV1YZ=OWS-AV;!AQ 'LR1(@
M]A*#@$>VC]8[)QRHIR_7NG9='UEWXG-Z<EHI/C.9OV*>FI#RWD1U3_,5T?&@
MKK\)_SNW>68"]R<=:>/^L@M0[PYQ7H5)]P50QV5B-:2]_ !"^]&<!?X2S!F[
MU^"F6J_TGIUOPJF_[N2;V8K8Q5[*EUOWP7E#^.RJ1;IS,#5#YFC%:R-K!H4O
MC L74RG.6CG>E/U/6B'.YJ+OS)^Y?J?GW'EE\JBI-C/L]T6N'F-<Q-<0W[^
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MUZP;M#'DCCNYCK=2AA;(7"7*6M3^A 90/([%=V[X2Z=.7.XLW<HZ D<T)\.
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MC;FPN[R[\%0T"ACBQ!/V<&%S>[DPV=7*P_S_OZG_3YH*=+2"(N?2A=:/HBV
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M1[^C_NG)S)$7_Q!JBW^DQ>:Z-Q=F)K.UAOISF0NK75G>A&$(/%4?.?0?"84
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M>?4Y_[+<;.*WYDFR@YUCM5MI7O#O:N>@QIG9"]ZM/Y=J"K;OBS2)8MWZM=-
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M/J+@GT+-M&:P*[YQJ1K#V64.EG1S]$8YA]BF8' ZT\.2WM2'$/LQ*P>XXVY
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MQ9@R**RG0P4TZ8_O4()F>A]\9*/!W+0:I'FUW^81U%ZDT:SR)!N)P$P<4M0
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M7@!-5=E4CM</G XA0$HU @1[T$+D< A:>3=.;06' ;_;S@LS0+R4@<%?(N*
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M,B@SS.)2)7*B(1GNY4$F[(0[<6'8/)H3L$::VXO3B\$9@OO*ANT6-; 1=[>
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MQRU2S4,/:Z"\#=TD_=LS(J23:BD\53N@W(2^D9!S!N>AT;?C:&[=1*MO9+A
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MLMNUYU'_5.=6KR8]A%)(EJ K,BEM3*<M!79N6G*U*8HCZ\N@GHGP-YM7<_=
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MU_DRVV[JRZO_\ 5-JB+%$]5-;@QI@*2XH[I9!M/SCJ ;X,,2["7.(G 7R;"
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M+)$U_%U1#E-%?X_ XIW9E:29C5')J%5-MD\X_LLF21?.E4B6'KZ"@N\4.=5
MW]!5;.5)I.WG M.PY_1FTE0B&:1$/H8IX/3V/EP(9!<</;H60A<09+%2QJ*D
M V/;^YJ/9-V;D!-.%N5^[5@:-O(W=MXQ=*%5\Z.,_./-%[RJ@C9LOA(2D_;7
M3(Y)^M&0C4?*D^V^H\V0/R7,A=2(I6$"JY*'):W)79<PYS^QND,'WWU^R_#\
M=R3JP>XR1MB+&D=LHQ/K6:.^ E)=F_FPPZ4J=@](*FZ>U#HIG8KMB-AV^2"
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MHZ_M0IV=ZE:'5909Y7M5\PCYKY'(IS;)23].>34,?/UQ9 Y%\?IR]U>#5_Q
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MD]Z=A<6&J$R&/7::G28<[6TY2YQ**X^DCZ!5NBFN+161KE>8U"&<5LO3^)
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ME(J4Q0:MV4MRT?QOFMX\W8K,8"R8P>3@;5THR^,!AFAC'XMB\Y/;$W<=93[
MTOV7T58?<]9E-1K#PZ&O-=R E_7^XV1RH\PL=6TW^C*D)ZF>JE<<A;H[O;=
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MB%%'5K32@&!\ 1NM+*8NIOP+=+8 HRKS)OZ[1*DSW:,[,\SQ+!IV(:F#I]U
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M5[E+Q+L\EO3O.O;>,^7#'^$_RIM4+6B?LI%D 'L!]])JGC@>4Z%[W&N]]NU
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M>;>!/EQ%BYLN*D,,SB%BB;K4]T2@A)+0CW536[CN@GNP7ILW,HMJ#[&ML1O
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MY-<1=K3I9//6V.NGK_L\HASP>"(Q*:G+^;.>CM(?$NIK+K+3,K78WCDIOPN
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M;@CCGDWP@;T<+%TR?Y]IO&F3HH(?<)FV1U"O:U&_%!"'DT8^.DL;W"C3^W5
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M.AR03A_RV6UQ3;F<09U=4%]HQ]26S]R[:B@CH61^:Z,Z[]?.?@?F<OX#=;G
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MZ+\6RO%UZG;6Y$"B(HQY/044P3F \&91H/JD<B'4V+E(G/@!I^_-KCN&XBV
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M#&Z(V%8\4J>-BAG4XZJ3O''H! ,5*@H=@$YJ/_5AQH +5MQ/4R0;X\$QJ/H
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MC81R'G_P'?*XK#G[(_]!]L?8H=SD#TH9(6?&MQ!CI&Y?3U+-6(N+N)-[Z*@
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M'J3+A@X@_FPW^E3QM(=<?<EWI*H)U3>*$)3C0 C>O(PO#QSHLJ+^3/B9-W/
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M0]E[^/"W$ZU^.(2&2-7* OQ''?YYB5R=HSR0\88%>KLYTX:UWR$F2KW@!?_
MOM03VXYNV/!;;O87HG-?P2EET%WS/=C@GS:6@BP'4@4]H+F\[4HLK2T8/C8Y
MAYAF*33 >=IA6]*NB#,:<>54!E>!G%7Q"?B$^3N7#F^"#(;SX3HZ$EUR?,!;
M^*+9]?!6LPFSOW0DK<)W_XJ3,"?]7JV#4F?&!EDE<!ZY<]JQM#VNX-'93Z2?
MCSQE-N'1(F)!WMC5S-L6O7=:4PI.+H (-GYYZO+'>Y0U/IFI=.Z!SNM2I3T&
MS=?UAL_!#M0Z,-BP*'I_U""\+U/'@['[?8)/O]W!L;85*J/*$F'O(DEJQ0JZ
M.103L.CJ?"NZX+V0TTB78I,@6WPG-FRF"<_V7'[XX^\HHV_ BB0*Y'A\)ISW
M]H<$NCKP'7/Y3)ZF$E:]C(]_$:-^O['QT^Q1T[.7;[2JR2:8=XQ;;=76CL^[
MNZD@O'D=%/S3DJ[PF80DBHG--7/2":%/+HI3'3B-V!%FE2VZY;,_EO%'7N G
M_<;)?G75>P5F"J&0Y[9BQUF8D^D+.,!!(N<W%,_?.--3^]-.6N6&:Z?OKX,.
M60F+!L$::+55_)\\2RS4SPHY6[7GNL'Q ?WTQ[6!PZA)U%2/U91?JLG0;_R+
M1V#=>XXJB^JWXQJU"U0[WA&1MPL<)ZMAVL&W5L=]HJH'?-K!TLJ*8_"TA.#8
M=="UV_X-AN*4T,ODRJ36@.5L<2%VDD4W4L?V+@G"JZ2GNC>)_WB('.3X_TQ&
MJ7R]7P<]G!B;@$U(=,&26FI<Q?+9 _GWTO-$+"OX2$>XJ%-].Z*J)#H]/,^_
M WNI4\-QZHJX^OGL>^O#,4.2\VCK4+%[E$R3Z%*=4"GY8'?GH;'F-9^9 []A
M1_[O&D%)RUHJTO<_001Y:#5ILN#ZXK_^)<3_,-_RI."V4Q0P(<6T5.DI8!@+
M9@-LAI_CGW'X/$-"A?SO-?A<7K4D15V*I7)H:RGN[\=6J#NO@ZQED^&"KD8Z
M?O' 7*'0^N\4WK8..F\NE&XHBXN7ZL&OV\M%_TO=_K=5=#8R)+=TY[!51-$"
M9(6S#O+ _8_5N;S:_]G.OG70%:!(DJDH!>W$S!U2_=S_?S:#C\>*!IUP;&D;
M4GG>82[$;TJ?8,&WL,A2:9'9. 03;5]SG46*6T2=P#>]@;6TV2B%!Y;\O+'E
M3^N@S>+JK 9XGSKQ_VW0L)F\Y)DR(!KVD@;TI[<CEY:D6W$[4\%STNJ)D)Z$
M&M UC <J,7*@5\O*PGLZ>3\B]Q7$]*E (]="1.>SURR9B$T83='&M_54'#8#
M<Q@E&> =^D 4O]H3%C &WGAJ;W%=_JLA+>MRU!-+F5L'GOBK>/X*K2J$5L;!
MPO/B.[4+IUA5XP4U9??>Y%U73_P1? #GDZ31B>YQ']V>3TCB_I?XW*V^%97S
M8=3?WK;]"/20J;&;1Z9<CRWEJ/,=&]MG?!1M^C8F-C6M""<$IP5Q":&!=AOM
M$M]Y]&DOOZK>4;T?-7WT4HA\EBIA^_ [FFYW3CI_(: 1_+V3R=E*7EH'*2,U
M]P_ #HJN"M^$@=5%;L+'M=G-,5]-" 4#9[J#]7L#)7L%F=G:3PF W]G$T5;Y
M5L_XJ#L>?HN]5T%FK"]).II)1!_&P#\O?]Q3J[39M,L!9=ZI\<=L8XV,3O$T
M"+1# )H@:Q+[:;2[<)67U\K]CB]-I#1?OI26]TQ;V9FX=[O1X4N$[9>/ 3%[
MNHEG=I[.4-T3*'W/5RN+<[![_#//*KOKR^_T@U#%[>GEER^/35\I<Z$&?JG4
MWIO:[%KFJ9#>>JW\RY4JMZ\^VKM3F_N?E0^0S,U*]<].-PM^!*1O_),7,,ZO
M71@GE)BK9YZ,SUO:N!I0M51I_0>YX*E93<U?ACJ? _PJ;G)41*%"!VQ*@7F_
M$4X)A62.:E8#B%+O?R5;!/D=B6[#R (-ZH7^V#AG#QVEWU]F57[D_8JX^41S
MGF5Q;IDZYJA\L\[-M7<)NQV59M/C%$U[D2-5J*[Y6V^Z S_YIVJ'04^-[\\Z
MT);?&%U@N!NX.^/3BS9%DF^N:&IWDTA2E&76K)*>L4?S_= =-4KLS,=[YDK=
MW7V@3JS \,C0/4IZF?L>?[IJ%)EQK8>YJDFLY&S;F8DC!*E2.<\*)TSJ@O-6
M!K0.?^^)>*U\?6M"MF%"P$6[G55[A<;33EGZQA9N7@::N#7H8>R[2X3/">\2
MMF]_?3FW1NM2F5.M4">9;!@7_2<$;-CHW'+&("QB9MQ,Y'.0I>2JL@[:KDP[
M3<)Y+56Y?;B$W)5M(J]09+=]'13IN"TA;=GQ#P[P7@=M>B/^0-L]%GK?1[%[
M*30))MO'\)<*[_>;C&IL\BVHNV)AF*#"%:A?LT"?0; 5?!(/+S[>%V?([QM@
M<F11YR)R/V5P'@93,X*#]7-L5)$GL8T6V)#H=5! +#D1<[0;&B<\T\1^SF@=
MLMHXEC$_YQPF^#W!G6@.51;I"1SN"U;X4E9)6\3N!8I1;4VJIAEO8#J<:88<
MM5,-R-)-D>P[Q[\B: JRB>66PJ_0I7[?>)EQ Y*FJ2G.@%IS!]%Q 0%KP=*T
MW/*4*U(=O5_BYBCXW<G%)E'C8EM,I?P\:H49[_QXMS2BE%*Q<\7CX8!'%JED
MXPX77%14X!S=0DQ;!_EU@D1JO1C+( 3%L3'?D=M2#>0Z=E%)8%[4?<-7PJ04
MT9'7H\BZ[ ?0_7<D^VJK!J W5N.*;)"O/$=ERYQB[9*.LX=;;G_73/FSG]<Y
MB)-LWS,*%V>%THYC?TPQMDJ.&:9'ANX.7 >IH\]MLH _G&?<TO=DP?2_(9JT
M6WTT!5\\9K#5";,PI>H<L Q*:LJ7J[*P22L"E*-USRW_#VLRR\IB',92TJ%I
M52>$I$/M>0V.#L*568ZOO] )(H\.$1*;*^S/+#^I!LA\>X\A[RX*62'(HYV8
MN"@^R:VD%@%WN]>:LM@^>757$G.+/I<,VQ1YMB-N LCE#V*\\0?:AN(9A()$
M$Z76BMUK[.UG X0+%EHXNZ$; _AXI?;BF3I\TI?)4<TJX4'Q2/N/U:SGD5=7
M;0V7:UZ26(:)D;&6$/DA[\"+RPQ9*? C[G%4Y]'V1+0ZP!+4\Z2@^L!P7X_(
MUU>PP,*H"1/F$T)#KK]/54/L\ICTR)AE0W\[!L0&_^0<V&$P:_CFA6R%Y8O7
M(,G-2,-[B!KX[,]"5'4+GGH()]1Q!O8*P7R=1K$?"[\-HX'Y!E>)K.C40*4Y
M=,.@E0U6K&:R#!*QFQ;+Q8'!N[W0ZL(X3DIDM&@#070VMRD&^]!8+,,T[0ZL
M<1TM6E.3M$ $%W>&ML+_H1\6718RFMO5FBPXC0RYP $R'Y*J2O\0+77=Q!Q.
MHY7KOW1 1RC+7&6ESM)<>>N@7>3FD;/ FD??4).'2S5/IO<-U:XS6:(B5,2)
M'P>N[11B)=O-UPZB#PO:\<FW8'J #"]AN4@X]!%;':&I#B"%2EQZ1=EWD3L0
M7VZ5B>>*,=(A%][%O4+Y1^3J6@7X# 0,&*=!W@7&;'E3T^43=/$07L=1"%G^
M)& U=::KNC+A\J(#P/=UT-:&B72)ALBDEV[I"5C;QH_]2A$J\'K*4>"FC++I
M JT>D3O/)G3B0W>$.-Q'X/J09L_%;P_*6<XH 7!N/;\(O=H]_\+UESJ!@P$M
M\PD>2LRU^>T \0HP.JH"W.=A=T]+%($S?(:RY"O=T@UM(\"[ 5@B$J,$) E-
M><36>/_2FQ;YTZ,^0U-U\_$^*V?I#,JSF;=QM6?[Q:%CY-F4-9M)+ 4^&\?#
M)D-D:1M>M:R9W<1H:9H!>,%\*V97EP2,OO"T%;*Q$JU$0F4.C2EF<#44W-^)
MBV\(O4=QW#9R*FC*1S&)2TRBG?(K8FZN32.)CA,D]Z?70378CUA9*27QDNZ+
MXO@0,/H$!8"7!=:99D"#A98M$AD!)'XN4C_T-!!*OOG9/YKGJ."&&'6;WB:T
M9EK8SFPCECP/YFU+3(F*DBN,)C"Q?9/K("I^MH&WC:[J.8F@&#9Z>_#Y!Y1<
M(=OF9F&'4+!Q/@]J(BT?UXRQ3WY]7POVF;"+3TXY6Q/?=!M4A(:5S*W=DO_X
M"G*Z\E]0YK\JJWQ\6R:V*8OFV,BAX&;%0D4F;TO9&#B#L9V&+$$?CBT46EX4
M$'&BXY5L--S.,G:M/A>G-!Q8]_RKQ^9B%[9+Q7%:K\]H7[9MGXD#RX&VZT\[
M:ZYO#6*:0!"&I*S9HS<(37(/55>@7*TE34";8/0G^@P_&&*7Y/Y><!X7K9-R
MK6=":#DU<%=IAF@7)7N.P&'/F.Y4?#0.@.+\SZ'_!*Y=QG3,'Z(2IQEJ, 44
MMIF^&P@FBKR%4JRE.J:,;OH;^#A)M77&E0V&:6C?X #RR+EBX!KS/SJEH4&H
M][0VB?>VKJI/R3GXY,6WM \"/ [R]]\]@^N@Y;@NNBH2I@M4O)[IE^HO6D8(
MYSDVD8$SD59*[DDLC!QPCMLBM$Y;R@<[YUYYUZU3+6F_6F<\,-124QWQCN5O
MR0H.-]H'07<AC*>P-::S^(I)'SGIY:[9BK8U?(/M1]6L?<1LZ=>GZP&J<2=;
MZ"8]!E>K>VD'N4.3D;4U?4LSLO7ULL@,BU;W"1NJ_I'3^#E[^)SQ+WBPX_?M
M/:Z2CQ_$1/H_9RK!:N!$4O%GH5_CD5*=9NW;-;BQ:'TU=P5K7KUG;6;/Q6_%
MYWHCVCX$ST7*Q@;^NFH-6KV3*I %L\G+_GVT4SS\MBD$14GJ%BT^6_IN&1FJ
M @$.0/;8VDA4XVH'@5>!W3@XA3G<'4P-#%U4F\&IC+JC[(.7+NA?U]S/J.KZ
M<9E!HR8B? 2<5)$Q7]8RWZZI3O*89V71YMI/D:T7@R]1^O1(2YURTU$>!HRB
MMDA_O6\&A,(91=<8G[) 1L?;7OV06[^<+).O9_QKH7KX];WM_S\7:  +HH'>
M+%CAX1MQ\1+M;&]<*UQS'AKK.[:W^INQ[MS.2I@:<&(=Q,(<5/W5L /Q/6>W
M)J3'H+AG'PT_YT'] G5Q^7W ] 2S3=*!I8*E^9'X<76@V?%A76)M)+==IH4]
M$6\, 2X867+ 04=*)P.#4=F"J17?DNQS Q0[L6%S@4;OAE9"85"-Z?G#AY[/
M\>9AA]![ %=AIH86.&5T:Q?T.AUBT7;S1)#@RX"%+I!F_5ZP7&^0'15L3!U)
MKZM)B(HJ1M@%0YT<B5[#'I;*-Y[[D._3=Z.- '.N57@3?!L4S,4GQ6PAEP/D
MEH$8>,+B^XA<6?(>H)(WXS1@_)E'N;)E[1(CGYCE\[BURG.HV$5P1M[.YGT)
MF_:D;N%9Z$_JREK_&Z>[Z3DCYYT0R].A"[825_,:,0&V0?QAL4=8S;4-^F=R
M4,T<HX6"6?Z@V4"SJ$\Z['U#Y+D'1Q2&H,C;3T,R^#8;-H[P7QQSX<8G7&5N
M=E-@&I@U*N^;D"D=2Q7U5 && L/E!O'C.9&O@,@E,]=!6U#Q/-:#ZW0!X^^-
M TF:&N^$6UZ2W8.Z/=O+@Q8"7>9+6?KCQ&)OHQ67[#G4M^'<5^-1AXU@NB)'
M,96^%:TKQ#:+8QW%.=0,,'<BZ?I I+ZN738/:E%0Y$](=D)Z'OGU75_K0]:)
M3?+M:Z6#O]]L()=FGKO'TK/:03:^?-+FQMX[P^?=F\W2Y;94ES]7]B7>+Y !
MIQ ]C*N,CW+]51<(+OD>$7G%?:Z')8AD/DR+^_4\C+CW]L__?&SL](FYON'T
M'8TW7E8J)FR]TA(7DQAF=[+E*M)7EWL[0C XV,MT;OY&MB5%.D![_;9)GFSL
MY0],_SOUI[M?,1N]TJ\:N1:O-'3K5N5RZ(']'VHRL7H__N%"FVCW+JC=VY0S
M['1AT\HZ2'N1_*+/_%Q)GO]AAENM$M B9D-*>BI4WR9<L&PJWN\$1OY]E>OO
M%I8I!??-MKQ./9*SX^X092PO3SUB8V]Z^-P\0A,S"!?443D;OJ,M ;7BF8EF
M.K37X-8267FR;MA'";L%L+.E(,4>O('F7[7Z10#.*W<VQC2I.+%UW.4)\O.&
MAV?&R8-]+A>>C6T:*\ XG6JU6/@6GK#13#.Q_L0LLBT,\&HRNV5R F7QI0$*
M.W&B+*',*>=I\8Q3^NOIUGQK57K[Y_/A1'L'@<,)H1GNT#K([<Y_;0>B$^&Z
MQ)=<8CPIX\MT:Z*O-?A*RS5%I=V'.P>OD&Q/OJIH-2 =OE)QU,%8W1_\Q7->
M3<+.+OBG=U;?"*L)V#5;6,\N<>.Y<Q:LCS%**9$[8UE*&*5X1^&A!A*J_G+O
MCCK7]$5#^4\!U8)V0@9G:/96R"]"8K3A'(%2YOL&,YP5]<1]\B2 <^CV%_HD
M76-/I$@TIR3[>JD9<MYWX^06FG.>YX]7[[#P'R'>IQW72:XD+5*KJ75"F>3%
MY)]4]TJ#_4^7[EPM;WM4\>BCXM%73^]MNQ8.+'O]N*V[,'-)7"6R">% #M0
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M3Z!AU $K;K"L':U?KU+DR8-KHKU,?39T01U+XG*9W=Z3[.Z@&)\T6/[M;[-
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M.XWBM#14V6W-FL>Z)/N]44'!7C9AD44C0ZC3E^D/&X:2GR["EU6 #VNG1.'
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M5H8<B#PP]".BU?S/A<]C_'C$<=%U0"5TS7)2\["X$B:+1@@[&ZT<6WZ+9&@
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M;FT6W[X:>R B83'!>2J3YKZ@Z%H%>G<R&NHU(&N/05<IV'Y;NXO8!A8R\0<
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M)GV;P7M/I=/B"=X&_ZDD/@\O,RO\$8.]@4H)^/088+B"1!YU![9RS^MAL9I
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M0\YNN_!J);A*0Q9^53]MW\/C<?IR6H&RF1WG]W6R. /51V*_[ /( ::<P\=
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MD?@?D2:8MU&__Y(WN?RHR>SC]17SAM-/%+DU*,VB^&,14SAUAH;D'/<G:J>
MHR1QAD[EJ7 7* E,X!]H4^B]O-U0=+GD5'),M!/P/4MH6C("-;ZU<??Z@3X
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M9 @B=C$!LA^C\;K&/I6"$6U\%5)8I'@W,:(C[S#P_=$+B0'D8)C(O,J)E<.
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MS3VD=#E=M_V=7T0WK)/#2I,W=J7[H38[;F)VT]IZ/C3^@1R%7-BE _YD G_
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MW_/LGSR--Q=V'R^WWK7PM<?P]HO,^SZ<<QH$9+1'6<7(@_I$.[>,5WT>4%%
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M,9X&DY#J=HI33ITD'.;W$^K\"X& ;NFD0):0Y@8,CVC*IB&CYJO003T%@GN
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M;O2VR52OJ&QJ+#U[YKU^>*VYM+FSOLH4@5ISL#JS9Q+;0VCZ"RM5]Z;CYT9
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M3.F^\B&ZN/3P<JOWD&WN9NG3ZVNJMF9NENJNDS_+_Q?8ZLY- :S(@.6ZA88
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M8Z"!YC%AMY.H<-QJ%JYI,KA/!B[V IE.R9&K73,K\:Y=TT\S\3WC-&VJ'_I
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MEY$]K0=6_IG(:J2B@V[O,6 I[PP8R&X7IES$#O6QYHW_Q$X9*W&^;1(.DR0
M@^T>G+P6UO"+#Z(>\0SN6 &V43:EM@277K(1T6$I/4W3%_?>O^1:\91E1-$5
M-O'0%6:[^A6C8Y4/_.R)1^8$#X_8JY##\LVNYCL/.VKG_5VY5C:W-)%1:F5N
M>=W6CZW/E$C1_]O7_"B2[^I\E/M/N;42457]1VUUQI#S3^^M4(#,%_+;-L98
M@M=8Y&B8L Y2&OLQ#$5%2*%_YPF(A_1'-^LZQU8! E8<A>)*WQS52!+2%S@!
MD_F1S1=I'5LM' F9.N+MZT=,,1;1LK/(5PGOE4T.2$)QK,)7I1>D"6+K>V"$
MDH*' A<IC ,8[QE4+%8&?,DR.M'/U(T#D#U[]5?+W^>["Y'6;" ?05O)(\TM
M/;ND<?YCQG(_+DYB=%N F\*L))C0./HYB]P,RG+C<O?D# BG$&1)PNQ\6>X+
M$F!,V/Z+)S:BK17-WP<BF.K09P8!W?V'^%\0]=\;F40)WB5PL?!:,<\$T'T3
MQ!GMI9\82VG(MW4#Y/-'TP7C3>,;&(=,"[\X+5CW;U_^+6<Z.%'LV)C;,1 '
MC%T#2%O$KO9KW.L<? K_*$9WQ$^;(;. $C/6\((=@^]CPR2<P4M=?%@':.LW
MPQ!%V_X?3>\=U43^OG_'BHH0Z5*C@M($5J6)(5ED 8&%2)>:M2!-1*0%"(E*
M"9V5^EE:I$N-2E-* @3(*@M(C8!"BHJ P(Q"F(40?MGG?)\_DI.3G)G,F;GO
MZWI=R9S[[3G)-SO[M2RTK,2<7F BDM4:;=#9UCDAEC2<9VQ9&O(XM<I[8"<&
M(F!Y>8_LZR@:(]TV3O'550X&1QSH+M<?I/O:6-B\1D4OB'C7CMO]N%J.F>G8
M@W7R@O)/%/O^,QD=HCF9AE\;Q]+(AU"* >3#J!-X3<BLPMLVMA*O!86R:*28
MX-V^Z#"AB%VB=X20&M>K+;,QNK8M$_F1V M]^O,^7PV6?1E7G1<SCQQ\$,:D
MG"KM$6^%N#O7<4Q.]T(?%E*7^=)4 =HK9LGQ7<=T^;&A7#TQ#]PECOU+T-QB
MMXAZ'D=ANY$$:C@KZXE@?3M5QVF"T;=291-RPJT7\?0HJFKS>/@U[NN)M9M)
MBXOHQ ?"4WI'H H9PN$?\0X@@X3W^?_6HLQ*5:A)(YS%H5GM?9J-7;$@G.V6
MK ZM I1KA7,\/)12YG,#DF)$=IS*H6_YG"3U$Y2["F^&<<4LIY?T^W_<S,=(
MUJ34_^^/6ILJ_&_+(]WN5T>,:\=KT1$VRTZY=<;/?SZT%]>LGZN[\??[+U7'
M#<\$_E)U4DO_WX82C=<#-1HSSRN+NHO26V?W8.^_ K^>H@@)XN&UD7TCER97
M/[-BQ[7C7\O^GB[U!.5R\T?.3T3W"!S&8K(1JP: .B_Q]6X5S7<A&77FU6XU
M%?GM[8Z4@$D]!JT*53R1)D%*0IX-XEI ?@ =,]9"W+=,/=D"W2S'83A9@\H!
M_)LJ*=RTA'$#V[FA*[$A\+=L4]2@XA%^#D_C/56??QXJ$S;%-G!^7A%J9'E?
MW!FD 0X9%[I.@QA'9LL>3'I!\-81PPZ1YQLRN]R =9=IOAT1^ $7P_U8[_,0
M><S7I$!9_7)4I>8W><$&*:?!*S.]MEKI+]8ECD?(M]K.OM:VP!MO9]<,:S65
MY\H>0_TL+].XY=\YR']%:3)PN.JLI?:5'8L*6A#/?>/L$=!EGM:R5J)0J/^F
M8",<?N]):"FZ]"*.'Q!XY,)/E8M7LZWL;4,']UU^.^I$_OUNS(];:Y3=D"#E
MWFL/14[R8R(^DZ?SGW:HD)3^C$W%;/_P[OG2Y<;^A!X0*(%Z"9O$5J(OKL)L
MBG^YUC1C: 8K=L5KHDF_D^L;I^+;VB7+?+B;S]$K/?KDVE\7.#0M!E]BAQW&
MUY\4* SO_$887Q=)Q[NC&L%XKV80_7BC?C3=1XPH@K-E?\JB+\A_\T _;NA2
M#Q8GL49AD"/C*KB0M*$LQ_$I:)P-+#W7!CJN**Q5Z=-JL-(% Q?YEZ$4^!/D
M&-<:">=\XR,^5S4T$_N<]$BMTL!ZCLSJ5$EN=LG-!GYE5U=KJ]_I^_>#.3I:
M1.59O^]/=QX$()JM>D=%^"C(;L<R0* !M ]@DJUZ"V*V'A-.X=Q<0<K Z G^
M1>AJ!Y&QGN%A0&9DA#A ?N !-CFK93VY5$;X^I+#E,'H8^KI]Y;=E!7"B9?=
MT_JV:7NPLK\UW.J/_2@K<AH*3NVS&&SP?VZW<_YWMH]]0T&GY0.'P%_(M+.N
M-J@^LE'!_UP2C43.*[W$=M;[B6@/(C?*C"LKNB8ID1,M7BX?B] 561EHP)Y&
M6I GZ$!17+&MK"X7MFD8'64$.7"4%>CT&+^DU>^KR O T.IL"2,QL7\ZZ8=W
MT"!!BX:57"%*-)TE#P+GBLJ^1;8O7AN[=YJTX>N\&#IB_=E/M1K'4U]X?XM6
M.K2>M =KJ?G.V+EME-*ER::EHEO<Z!0YPIA 'J2EGGXSCG2OQMTV@TI 1M\X
M%.(VI?\V?*;+2I8FUS>:U$&H#L&'1L.34'*,>FB('J.S6YK8")E8AQ#+C$=A
M?E%;&'6M"^G%MZNO%"^:!@TSKG:IQCOU,V3,)HI?_$@OVVG5M)IURG6*4 T(
M[*8,1&BH58ZDGR_3=/OR[)OSHGU=6TZPP=&?:F7G. W_$A0?#CFG:)2G<J[\
MW_C>BFT!K1%&,7+XN^=@\>/2"YGV,7ZJJB)J,<RO\(%1Z)P1B7 >RN$] H-'
M5XUV,+@P;VB)A9#DZXZ%Z&?)XPB1D X+DURJ [2G4;6A,';&U!XLZ<NDTS5P
M"+)A6K2\ .WV8,G!74?+ JFGF@$ECY-3?KF$4OM+/2L,G7RO;..Y/S%*W#7>
M8-"_C= 6P.3(/@6W>'LPL"EM1Y/PL?0B%,>AQ!O)$@P!6A)5#9H>U\L2JD$X
M+0,-WT0GSA+[&F/M0$9R];1 B6\%5"S@L(.%Z@DMH_L_\B4ALW(<E]Z\Q,S&
M#232JK+I4D@+8AUG6K*\ROJ=4Z9":*V F?BYYM[O[(.?K.0KBW.[\^H?CMVW
M)2%,KM>(N&:UIA7GN-6](4:XO"-VI!?9&-DO!6@/_%0C+\$SB:S">2GH\0Z:
M_PMTE$-+5S&:NH>2PHD.S,/'D+ZA;'12FP*O*JIV*<H$_=C CH@!A"=F W[\
MTS>TZ,:NE1/)#%!NRPIBZ[BL/>N<;M0-N1>\9C5//()"S/#5(6]@BYU$K@^,
MV231]V"'H:A>7N'TJS'#^KI>]JHN\_>TZ]T_9'0XA4O!?'IPL(*G1ZUGK.^-
M,QE6/UV>"X876O0>$_8+1LC2?"GXJB)W0:;].Y>#.<BWA RXZ/UX*R#C*XF%
M)97^,D4]@VONW2YI$9P&K3+":8=6F.TF</IZ$@J69C.-T@@T.1\IT!SOLH[6
MS3F7A*Y"Q O.@8@,@AP>"6:E=6F'LK#24$4O50$42>;+/SSGSM=K6)ZUR)LO
M*[O6?GUNWF*W).S\G^?EVGA;[\\T&+4!WA;G;:,;M!U3%QD,1=N5&R3CP1,5
M6KAVK:;F<(JFQO!/XY$BGA1-_UZ5Z(AX^.)ES^/?G#.T B\2?I0<?L;*^RT7
MJ]=1[+OS]\RY;-.+J1H4C8W_"OGPGY?5YRZ_55+:V-Q8?W^L#SS$W_9Y6K_L
M.NL[3T$552TL_Q+@NL^.5ZN34<QT"&@S>[WCN_'T;!658U5R<9NUKB("$3<A
M_G)+ZHWBI-ECG[<.1?]]ZG-QHM:O?Z/R)%]][NAP2@OR=HP*7/%V#&BMLVNM
MNQID%:Q<4O@IFC<1:\I;)AHM[<$.R>^6E^_F=D7O6-ON.!/^V2[HQR@3!FF*
M1/^00X*A&"S].:E?[Y'@/!3%B5/]O;4U?Q.)(>JE(*^P(J8J >R 8D@*+T:E
M(@P\/*X/?&^+' LLM"MM[Z5 FEFKYNQ1*?ZO4 BH=^U]5QQW9S2-!B>(\5'
M(F,!<J.]6DC''^+44YX0C*%/W.X@SA9?^Y,GQR_Q.T$"(O65RKQ [^<'_\',
MP?\Z%;)I?"OOGGY1?3+ZX>E=,NJ0)Q9O/JE#/8(_$W\=>ITA,F!W%9%$$$O]
MR<'KCJK2P6-?].\4#%[OHIP?A2=[.J141I_U#3A[:QSJ9*GWPI,/N*%,H0M
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M?/O]X[_5:U?>/TX/_\SL)<L2;R_,%/$>014AX!4&2FW:@*+RC2Q)5?SHV53
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MPR;_3)Z)"]LQUW3[1HJ&93%;*[O6WF#)PS'!=&E'*]- 7<N>$'SH<5F4?6.
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M<#L^M_'H&UL)^;X+52[6$_>+JPQ0=\H>Y=:^O?52NKKLR-RL\5!V8?CMU8H
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M,U.QD.;S)A492L-T#(X[[GP;N< D<0>)M0,U=$PT5)JKB)SHR#/X4O>>W;Q
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M2-[.5TA"UDZ49JYXGVLCD3'2N+O 4L]\55:Y&Y7K&<P3C>(_3.;FX7V'S>8
M0_.1F[=]$J85\.RF,I0G5'*YJ@JIO6G&E,-2-8ZQY<($._JH:&'%.IYW&G@C
MQF8[D?$!">V4DV<J9M)6W3N7N?+1MKDOZ'7[UD<E=X7SL!,\1__:1Q/_;AT
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MB&G)8K-5I6-(6,&DNY717,<-GS-JF4XX"8E,.Y^\^5?8#'/IX@_M)Y1.75?
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MS+[#\UC6).6)EU]19G.$KT$]CBA"]&ZU?, H:A9L$SSU /G$GIE4I=BDQ:K
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M8EY#*^$R;M<['HG'4D'V5F1IFQ9R?=/%S6R@#'<"4FXEGL_PI\Y$1[:X3+E
MW9!Y!N,:J_G-+<E_YKL'.WU-8&7PR^8^?J+&E$QM+M!*JXN^;+_RP67IG]$)
M[\RZ(.)" X5 ^7,WV[P^%>:F.$P<Q%;AP#\_KKG3!"^9L9ZDY^9FO@38]*^%
MYA][F@.$/-;ZA??EWJOGVZL4<OU" 9SBU1LP4?Y[7[A^(8L]:,X,7LTO7V[$
M.K.ALS,"2YE9*TLNCT8U^UI:)6Y:/>/8T#ZMT"K^W;ZJR?,I-.Q4V+55''EL
M6%WS0Q@W]A=[\\%^?I4AG!;$</Q0!F6#QP9& [X]&<:?"=1;&_AX#%>[N+%,
MF00^KX]2KC&NFWGPH/H9,S)-7$>;WB$!TH+ ,QUX]JKK9S9!CE7^@?.A<.GG
M3V#^[MNRRR7#9=(*WTB.7IS8]>,50>FK^5LYH+*TEFLQM_(GQP'7CP1I&_Z0
MB3!\E*V487?%X=>*F95:&0\K[P^_**#G"S7*)GT^<O)*;@3_T3RB,=MNDQ69
MW<Y5KF>J0>ZZ7WG_Z]!,+&Y5B)-R3,"Q$C%V'M'.4F%%:JG+T1VLG9TK7F2A
M(ASYDRE+$N'],EQJBDMR(BBWU+*Q6"3:@G%"Z_,C=&%_2?;/\Z-T?3]\UAC+
M.4*#!X,H[A,=-*2X^D)7?-7S#8X-KWRLL(.-%ATRJ[)\6B#I-JGQ<TAOL?SH
M\)64LN\4ULS:=OV#.%B3'L%%N[+<A5J^*@6?"O8<)B.J(C[M23;"+&\%"KF^
ML*V7X/OR;NXI<>IXA_#KE["-7,\]Q_'S0F@/,<7@9W+/,_GUGPJ-\\U%.M[,
MCD\_)\6>;C\ L ;W;%Y;MQ0A'\\;N #Y>NEP%V647H%B2Z6EP,9*4*/^)SQ3
MD"66PW^A=43.0-;.')4MH&'ZKW;AJS">S\BW/HD;<#_H8F.S7.Y#@A@C?>*Y
M\."32JM#'Z'!450GZ PCME5;]B7=)_IF"VJ*9B9AC1D961$G[F4&B^QG'6L2
M=:#?T+)NQ=1FHX938;W;7BPLR,$H:_+C;=1J3>7$Q"/M3KLX<].R>MQOZX$&
M/=6Q\&W0X.-&A.>>R;T]R$2NX0&@)[[BG_YS>RVLE#9MP1E>P/DOR2]3'1!%
MS$O#V^+-+@XC'7<T1X]K"^G:[;GTK:$2?U^1O';\!,&3C:@,'YYAY#E3.->'
MJGJBM(X/5P7R138,G0]5C1S"0U^5+4L.;0N8(\Z)F,RR5Q\W>5SUNN:5A13N
M9JT;#V6$>&R%@+$(18*W4O.K+%G3![6_&@%A T_5BH2Z[\FB$CX @5>&-K1
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MR =)R]RNC>)N[/ZFG-L0O3$M[G.3F:)CIZ6<-- /PC79<U-MHV[H80"3V4E
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M4E;.Y7I;=S[L>TA0C/T?4$L! A0#%     @ %XBO5H6H^=XG#P  0)X  !$
M             ( !     &%T;FTM,C R,S S,S$N>'-D4$L! A0#%     @
M%XBO5FI7KF96"0  =UT  !4              ( !5@\  &%T;FTM,C R,S S
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( !>(KU;=?!%OF"<  %-A @ 5
M      "  =\8  !A=&YM+3(P,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    "  7
MB*]6U,C[:$1F  !!2@4 %0              @ &J0   871N;2TR,#(S,#,S
M,5]L86(N>&UL4$L! A0#%     @ %XBO5CRPSU[>*   &*(" !4
M     ( !(:<  &%T;FTM,C R,S S,S%?<')E+GAM;%!+ 0(4 Q0    ( !>(
MKU;BK:,8C+(! #>4"P 9              "  3+0  !F,3!Q,#,R,U]A8W1I
M;FEU;7!H87(N:'1M4$L! A0#%     @ %XBO5L)/X)5J!P  IR8  !\
M         ( !]8(" &8Q,'$P,S(S97@S,2TQ7V%C=&EN:75M<&AA<BYH=&U0
M2P$"% ,4    "  7B*]6C)\T.& '  "-)@  'P              @ &<B@(
M9C$P<3 S,C-E>#,Q+3)?86-T:6YI=6UP:&%R+FAT;5!+ 0(4 Q0    ( !>(
MKU;\5'"/^P,  .4.   ?              "  3F2 @!F,3!Q,#,R,V5X,S(M
M,5]A8W1I;FEU;7!H87(N:'1M4$L! A0#%     @ %XBO5E2=6AC] P  8@\
M !\              ( !<98" &8Q,'$P,S(S97@S,BTR7V%C=&EN:75M<&AA
M<BYH=&U02P$"% ,4    "  7B*]6P81;C96' 0"THP$ "P
M@ &KF@( :6UG7S P,2YJ<&=02P$"% ,4    "  7B*]6P_( [A$> 0  * $
M"P              @ %I(@0 :6UG7S P,BYJ<&=02P$"% ,4    "  7B*]6
MB_6JBP=V 0"LCP$ "P              @ &C0 4 :6UG7S P,RYJ<&=02P$"
M% ,4    "  7B*]6@?+.IRZ4 0![K0$ "P              @ '3M@8 :6UG
M7S P-"YJ<&=02P$"% ,4    "  7B*]6:"T=F1C)  #]U0  "P
M    @ $J2P@ :6UG7S P-2YJ<&=02P$"% ,4    "  7B*]60QF/F39F 0!Y
M; $ "P              @ %K% D :6UG7S P-BYJ<&=02P$"% ,4    "  7
MB*]6"N64SGD[ 0!Y1 $ "P              @ '*>@H :6UG7S P-RYJ<&=0
M2P$"% ,4    "  7B*]646S_@??+  #^U   "P              @ %LM@L
M:6UG7S P."YJ<&=02P$"% ,4    "  7B*]6)#C(UQLC 0#V,@$ "P
M        @ &,@@P :6UG7S P.2YJ<&=02P$"% ,4    "  7B*]6M,H7%1V?
M   SK@  "P              @ '0I0T :6UG7S Q,"YJ<&=02P$"% ,4
M"  7B*]6DB12GE_)  !_ZP  "P              @ $610X :6UG7S Q,2YJ
M<&=02P$"% ,4    "  7B*]6%1A*;8$E 0 ?-0$ "P              @ &>
M#@\ :6UG7S Q,BYJ<&=02P$"% ,4    "  7B*]6N35PA[O8 0!-X@$ "P
M            @ %(-!  :6UG7S Q,RYJ<&=02P4&     !< %P"K!0  + T2
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
